



EPA/635/R-22/191a
External Review Draft
www.epa.gov/iris

IRIS Toxicological Review of Hexavalent Chromium [Cr(VI)]

[CASRN 18540-29-9]

October 2022

Integrated Risk Information System
Center for Public Health and Environmental Assessment
Office of Research and Development
U.S. Environmental Protection Agency
Washington, DC

DISCLAIMER

This document is an external review draft for review purposes only. This information is distributed solely for the purpose of public comment. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

CONTENTS

AUTHORS CONTRIBUTORS REVIEWERS.....	xii
EXECUTIVE SUMMARY	xiv
1. INTRODUCTION	1-1
1.1. OVERVIEW.....	1-1
1.1.1. Background.....	1-2
1.1.2. Chemical Properties	1-2
1.1.3. Sources, Production, and Use.....	1-6
1.1.4. Environmental Occurrence.....	1-8
1.1.5. Potential for Human Exposure	1-10
1.2. SUMMARY OF ASSESSMENT METHODS	1-13
1.2.1. Literature Search and Screening	1-13
1.2.2. Evaluation of Individual Studies	1-15
1.2.3. Data Extraction	1-16
1.2.4. Evidence Synthesis and Integration	1-17
1.2.5. Dose-Response Analysis	1-21
2. LITERATURE SEARCH AND STUDY EVALUATION RESULTS.....	2-1
2.1. LITERATURE SEARCH AND SCREENING RESULTS	2-1
2.2. STUDY EVALUATION RESULTS.....	2-3
3. HAZARD IDENTIFICATION	3-1
3.1. OVERVIEW OF PHARMACOKINETICS	3-1
3.1.1. Pharmacokinetics	3-1
3.1.2. Description of Pharmacokinetic Models	3-15
3.2. SYNTHESIS AND INTEGRATION OF HEALTH HAZARD EVIDENCE BY ORGAN/SYSTEM	3-19
3.2.1. Respiratory Tract Effects Other Than Cancer	3-19
3.2.2. Gastrointestinal Tract Effects Other Than Cancer	3-46
3.2.3. Cancer.....	3-62
3.2.4. Hepatic effects.....	3-161
3.2.5. Hematologic effects.....	3-187
3.2.6. Immune effects	3-202

Toxicological Review of Hexavalent Chromium

3.2.7. Male Reproductive Effects 3-236

3.2.8. Female Reproductive Effects..... 3-263

3.2.9. Developmental Effects 3-283

3.3. SUMMARY OF HAZARD IDENTIFICATION AND CONSIDERATIONS FOR DOSE-RESPONSE ANALYSIS 3-307

3.3.1. Susceptible Populations and Life Stages 3-307

3.3.2. Effects Other Than Cancer..... 3-312

3.3.3. Cancer..... 3-318

4. DOSE-RESPONSE ANALYSIS 4-1

4.1. ORAL REFERENCE DOSE FOR EFFECTS OTHER THAN CANCER 4-1

4.1.1. Identification of Studies for Dose-Response Analysis of Selected Effects 4-1

4.1.2. Methods of Analysis 4-8

4.1.3. Derivation of Candidate Values..... 4-12

4.1.4. Derivation of Organ/System-Specific Reference Doses 4-18

4.1.5. Selection of the Overall Reference Dose..... 4-20

4.1.6. Uncertainties in the Derivation of Reference Dose..... 4-20

4.1.7. Confidence Statement..... 4-24

4.1.8. Previous IRIS Assessment: Oral Reference Dose 4-25

4.2. INHALATION REFERENCE CONCENTRATION FOR EFFECTS OTHER THAN CANCER..... 4-25

4.2.1. Identification of Studies for Dose-Response Analysis of Selected Effects 4-26

4.2.2. Methods of Analysis 4-36

4.2.3. Derivation of Candidate Values..... 4-41

4.2.4. Derivation of Organ/System-Specific Reference Concentrations 4-45

4.2.5. Selection of the Overall Reference Concentration..... 4-48

4.2.6. Uncertainties in the Derivation of Reference Concentration 4-48

4.2.7. Confidence Statement..... 4-49

4.2.8. Previous IRIS Assessment: Inhalation Reference Concentration 4-49

4.3. ORAL SLOPE FACTOR FOR CANCER 4-50

4.3.1. Analysis of Carcinogenicity Data 4-51

4.3.2. Dose-Response Analysis—Adjustments and Extrapolations Methods 4-51

4.3.3. Derivation of the Oral Slope Factor..... 4-53

4.3.4. Application of Age-Dependent Adjustment Factors 4-54

4.3.5. Uncertainties in the Derivation of the Oral Slope Factor 4-55

4.3.6. Previous IRIS Assessment: Oral Slope Factor 4-58

4.4. INHALATION UNIT RISK FOR CANCER 4-58

4.4.1. Analysis of Carcinogenicity Data 4-58

4.4.2. Dose-Response Analysis—Adjustments and Extrapolations Methods 4-66

4.4.3. Inhalation Unit Risk Derivation..... 4-70

4.4.4. Application of Age-Dependent Adjustment Factors 4-73

4.4.5. Uncertainties in the Derivation of the Inhalation Unit Risk 4-75

4.4.6. Previous IRIS Assessment: Inhalation Unit Risk..... 4-79

REFERENCES R-1

SUPPLEMENTAL INFORMATION (see Volume 2)

TABLES

Table ES-1. Organ/system-specific RfDs and overall RfD for Cr(VI) xvi

Table ES-2. Summary of reference dose (RfD) derivation xvii

Table ES-3. Organ/system-specific RfCs and overall RfC for Cr(VI)..... xix

Table ES-4. Summary of reference concentration (RfC) derivation..... xx

Table ES-5. Summary of oral slope factor (OSF) derivation..... xxii

Table ES-6. Summary of inhalation unit risk (IUR) derivation..... xxiii

Table 1-1. Chemical identity and physicochemical properties of Cr(VI)..... 1-4

Table 1-2. Major anthropogenic sources of atmospheric chromium in the United States 1-8

Table 1-3. Industries and occupations that may be sources of chromium exposure..... 1-13

Table 1-4. Endpoint grouping categories 1-18

Table 3-1. Overall findings by system and implications for the toxicological assessment 3-3

Table 3-2. Pharmacokinetic models for Cr(VI) 3-16

Table 3-3. Summary of human studies for Cr(VI) lower respiratory effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a 3-21

Table 3-4. Summary of results from human studies of effects of Cr(VI) exposure on pulmonary function..... 3-22

Table 3-5. Summary of results from Lindberg and Hedenstierna (1983) study of effects of Cr(VI) exposure on pulmonary function 3-23

Table 3-6. Summary of included studies for Cr(VI) respiratory effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a 3-26

Table 3-7. Evidence profile table for respiratory effects other than cancer 3-41

Table 3-8. Summary of included studies for Cr(VI) GI histopathological outcomes and overall confidence classification. 3-47

Table 3-9. Design features of studies that examined GI tract effects via the oral route of exposure 3-48

Table 3-10. Evidence profile table for effects in the GI tract other than cancer 3-59

Table 3-11. Summary of human studies for Cr(VI) cancer of the GI tract and overall confidence classification. 3-64

Toxicological Review of Hexavalent Chromium

Table 3-12. Associations between drinking water exposures to Cr(VI) and cancer in <i>low</i> confidence epidemiology studies	3-65
Table 3-13. Meta-analyses of GI tract cancers and Cr(VI) occupational exposure	3-67
Table 3-14. Summary effect estimates from random effects meta-analysis, by cancer site and type of effect estimate	3-70
Table 3-15. Data on neoplastic lesions in a <i>high</i> confidence study of rats and mice	3-73
Table 3-16. Summary of included human cross-sectional occupational studies for Cr(VI) mutagenic effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.	3-78
Table 3-17. Associations between Cr(VI) exposure and prioritized genotoxicity outcomes in epidemiology studies ^a	3-81
Table 3-18. Summary of prioritized animal studies for investigating Cr(VI)-induced mutagenicity and overall confidence classification [high (H), medium (M), low (L)] by endpoint ^a	3-94
Table 3-19. Prioritized genotoxicity studies in animals exposed to Cr(VI)	3-95
Table 3-20. Evidence for key events and key event relationships involved in Cr(VI)-induced carcinogenesis.....	3-114
Table 3-21. Evidence profile table for the carcinogenic mechanisms of inhaled or ingested Cr(VI).....	3-144
Table 3-22. Evidence profile table for cancer of the GI tract ^a	3-157
Table 3-23. Summary of human studies for Cr(VI) hepatic effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.	3-162
Table 3-24. Associations between Cr(VI) and liver clinical chemistries in epidemiology studies.....	3-163
Table 3-25. Summary of included animal studies for Cr(VI) liver effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. ^a	3-164
Table 3-26. Evidence profile table for hepatic effects	3-180
Table 3-27. Hematologic endpoints commonly evaluated in routine blood testing	3-187
Table 3-28. Summary of human studies for Cr(VI) hematologic effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.	3-189
Table 3-29. Associations between Cr(VI) and hematologic parameters in epidemiology studies	3-190
Table 3-30. Summary of included studies for Cr(VI) hematologic effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. ^a	3-191
Table 3-31. Evidence profile table for hematologic effects.....	3-199
Table 3-32. Summary of human studies for Cr(VI) immune effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.	3-203
Table 3-33. Associations between Cr(VI) exposure and <i>ex vivo</i> WBC function in epidemiology studies.....	3-205
Table 3-34. Associations between Cr(VI) exposure and immunoglobulin (Ig) levels in epidemiology studies.....	3-206
Table 3-35. Associations between Cr(VI) exposure and WBC counts in epidemiology studies.....	3-208
Table 3-36. Associations between Cr(VI) exposure and lymphocyte subpopulations in epidemiology studies.....	3-210
Table 3-37. Summary of included studies for Cr(VI) immunological effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. ^a	3-213
Table 3-38. Evidence profile table for immune effects.....	3-227
Table 3-39. Summary of human studies for Cr(VI) male reproductive effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. ^a	3-237
Table 3-40. Summary of results from human studies of Cr(VI) male reproductive effects.....	3-239

Toxicological Review of Hexavalent Chromium

Table 3-41. Summary of included animal studies for Cr(VI) male reproductive effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. ^a	3-243
Table 3-42. Evidence profile table for male reproductive outcomes	3-256
Table 3-43. Summary of included studies for Cr(VI) female reproductive effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.....	3-265
Table 3-44. Evidence profile table for female reproductive outcomes.....	3-277
Table 3-45. Summary of human studies for Cr(VI) developmental effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. ^a	3-284
Table 3-46. Summary of included studies for Cr(VI) developmental effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. ^a	3-288
Table 3-47. Evidence profile table for developmental effects of Cr(VI)	3-301
Table 3-48. Individual and social factors that may increase susceptibility to exposure-related health effects	3-307
Table 3-49. Dose response considerations and rationale for specific routes of exposure and health effects	3-313
Table 3-50. Available animal studies showing histopathological changes in the duodenum	3-314
Table 3-51. Available animal studies showing histopathological and clinical chemistry changes in the liver	3-315
Table 3-52. Available animal studies showing histopathological changes and cellular responses in the lung	3-316
Table 4-1. Design features of <i>high</i> confidence studies that examined GI tract effects (histopathology) via the oral route of exposure.....	4-4
Table 4-2. Design features of studies that examined hepatic effects (clinical chemistry and histopathology) via the oral route of exposure	4-6
Table 4-3. Summary of derivation of points of departure following oral exposure	4-12
Table 4-4. Effects and corresponding derivation of candidate values.....	4-16
Table 4-5. Organ/system-specific RfDs and proposed overall RfD for Cr(VI)	4-19
Table 4-6. Evaluation of epidemiology studies on Cr(VI) and nasal effects.	4-29
Table 4-7. Dose-response data for effects in the nasal cavity of humans (<i>medium</i> confidence studies).....	4-30
Table 4-8. Design features of inhalation studies that examined effects in animals	4-33
Table 4-9. Summary of derivation of points of departure following inhalation exposure to Cr(VI). Data for male Wistar rats from Glaser et al. (1990)	4-39
Table 4-10. Summary of derivation of points of departure following human inhalation exposure to Cr(VI).....	4-40
Table 4-11. Effects in the lower respiratory tract and corresponding derivation of candidate values for Cr(VI)	4-44
Table 4-12. Organ/system-specific reference concentrations (RfCs) and overall RfC for Cr(VI)	4-47
Table 4-13. Summary of the oral slope factor derivations	4-53
Table 4-14. Application of ADAFs for 70-year exposure to Cr(VI) from ages 0 to 70	4-55
Table 4-15. Summary of uncertainties in the derivation of oral slope factor values for Cr(VI).....	4-57
Table 4-16. Summary of included studies considered for the derivation of an inhalation unit risk for Cr(VI) and overall confidence classification.	4-61
Table 4-17. Details of rationale for selecting a principal study on Cr(VI) for IUR derivation.....	4-64
Table 4-18. Results of Cox proportional hazards modeling of cumulative chromium exposure (mg CrO ₃ /m ³ -years) by different lag periods	4-68
Table 4-19. Results for relative exponential exposure-response (R&L) model adjusted for age and smoking.	4-69

This document is a draft for review purposes only and does not constitute Agency policy.

Table 4-20. Calculation of lifetime cancer unit risk estimate not accounting for assumed increased early-life susceptibility 4-72

Table 4-21. Calculation of total cancer unit risk estimate from adult-only exposure 4-74

Table 4-22. Total cancer risk from exposure to constant Cr(VI) exposure level of 1 µg/m³ from ages 0–70 years, adjusted for potential increased early-life susceptibility..... 4-74

Table 4-23. Overview of air sampling program for the Baltimore cohort 4-76

Table 4-24. Variation in unit risks among the Cox Proportional Hazards model results by lag length 4-77

FIGURES

Figure ES-1. General assumptions regarding absorption and distribution of Cr(VI) ingested by rodents during *ad libitum* drinking water or dietary bioassays..... xxvi

Figure 1-1. Sources of Cr(VI) in soil and groundwater. 1-7

Figure 1-2. Drinking water chromium (VI) concentrations in the United States by EPA region..... 1-10

Figure 2-1. Literature search flow diagram for Cr(VI)..... 2-2

Figure 3-1. Overview of the absorption, distribution, metabolism, and excretion of Cr(VI), with focus on extracellular transport and metabolism at portals of entry. 3-2

Figure 3-2. Reduction of Cr(VI) in samples of human gastric juice (fasted subjects) using data from Proctor et al. (2012). For these experiments, stomach contents were diluted 10:1 to highlight the effect of pH. 3-6

Figure 3-3. GI tract pH values reported in McConnell et al. (2008) (rodents: female BALB/c mice and female Wistar rats) and Parrott et al. (2009) (humans). 3-6

Figure 3-4. Schematic of the rat oral cavity depicting the gradient of Cr(VI) concentration following ingestion of Cr(VI) in drinking water, both from anterior to posterior locations, as well as across the tissue depth. 3-9

Figure 3-5. Schematic of the mouse upper GI tract (stomach and small intestine) depicting the gradient of Cr(VI) concentration following ingestion of Cr(VI) in drinking water 3-10

Figure 3-6. Schematics of the human respiratory system 3-13

Figure 3-7. Intracellular reduction pathways of Cr(VI). 3-15

Figure 3-8. Relationship between ex vivo reduction models, in vivo gastric models, and whole-body PBPK models. 3-17

Figure 3-9. Lung cellular responses in BALF in male animals..... 3-29

Figure 3-10. Histopathological results and effects in macrophages in male rat lungs..... 3-31

Figure 3-11. Lung weight in male animals. 3-33

Figure 3-12. Diffuse epithelial hyperplasia in Cr(VI) treated mice in *high* confidence studies. 3-48

Figure 3-13. Diffuse epithelial hyperplasia in Cr(VI) treated rats in *high* confidence studies..... 3-49

Figure 3-14. Cr(VI)-induced degenerative changes in the small intestines of mice and rats in *high* confidence studies. 3-52

Figure 3-15. Fractional incidence of mice with adenomas or carcinomas in the small intestine (SI tumors), and fractional incidence of rats with squamous cell carcinomas or papillomas in the oral mucosa or tongue (oral tumors)..... 3-74

Figure 3-16. Key events and mechanistic pathways induced by Cr(VI) exposure that can lead to cancer..... 3-113

Figure 3-17. Reported tumors of the digestive tract tissues for all rodents exposed to Cr(VI). 3-121

Figure 3-18. Cellular processes involved in the mutagenic MOA of Cr(VI)..... 3-138

Toxicological Review of Hexavalent Chromium

Figure 3-19. Hepatic effects of oral Cr(VI) exposure in animals (histopathology).....	3-170
Figure 3-20. Hepatic effects of oral Cr(VI) exposure in animals (clinical chemistry).....	3-173
Figure 3-21. Hepatic effects of oral Cr(VI) exposure in animals (relative liver weight).	3-175
Figure 3-22. Hematology findings from NTP (2007) and NTP (2008) in rats and mice exposed by gavage to Cr(VI) for 90 days or 12 months	3-193
Figure 4-1. Evaluation of studies from the Cr(VI) hazard identification for derivation of toxicity values.	4-3
Figure 4-2. Process for calculating the human equivalent dose for Cr(VI).	4-10
Figure 4-3. Candidate values with corresponding POD and composite UF.	4-17
Figure 4-4. Evaluation of animal studies from the Cr(VI) hazard identification for derivation of toxicity values. <i>Low confidence studies were not considered.</i>	4-32
Figure 4-5. Dose-response relationship for lung histopathological in male rats.....	4-34
Figure 4-6. Dose-response relationship for selected endpoints in male rats using data from Glaser et al. (1990). Data (\pm 95% confidence interval) are for 90-day observation time immediately following exposure, and 120-day observation time (90 days of exposure followed by a 30-day period of no exposure).....	4-35
Figure 4-7. Candidate values with corresponding POD and composite UF.	4-45
Figure 4-8. BMDS 3.2 graphical output of selected models for dose-response of cancer data in male and female rats and mice).	4-52
Figure 4-9. Literature screening results for studies containing exposure-response data of Cr(VI) and lung cancer.....	4-60

ABBREVIATIONS

ADAF	age-dependent adjustment factors	HERO	Health and Environmental Research Online
ADME	absorption, distribution, metabolism, and excretion	i.p.	intraperitoneal
AIC	Akaike's information criterion	i.v.	intravenous
ALT	alanine aminotransferase	IRIS	Integrated Risk Information System
ALP	alkaline phosphatase	LC ₅₀	median lethal concentration
Asc	ascorbate	LD ₅₀	median lethal dose
AST	aspartate aminotransferase	LDH	lactate dehydrogenase
ATSDR	Agency for Toxic Substances and Disease Registry	LOAEL	lowest-observed-adverse-effect level
BAL	bronchoalveolar lavage	MCH	mean cell hemoglobin
BALF	bronchoalveolar lavage fluid	MCHC	mean cell hemoglobin concentration
BMD	benchmark dose	MCV	mean cell volume
BMDL	benchmark dose lower confidence limit	MEF	maximal expiratory flow
BMDS	Benchmark Dose Software	MMAD	mas median aerodynamic diameter
BMI	body mass index	MN	micronuclei
BMR	benchmark response	MOA	mode of action
BMDC	bone marrow-derived stem cell	MTD	maximum tolerated dose
BW	body weight	CPHEA	Center for Public Health and Environmental Assessment NCI National Cancer Institute
CA	chromosomal aberration	NOAEL	no-observed-adverse-effect level
CASRN	Chemical Abstracts Service Registry Number		
CHO	Chinese hamster ovary (cell line cells)	NTP	National Toxicology Program
CPHEA	Center for Public Health and Environmental Assessment	NZW	New Zealand White (rabbit breed)
CL	confidence limit	ORD	Office of Research and Development
CNS	central nervous system	OSHA	Occupational Safety and Health Administration
Cr(III)	trivalent chromium	PBPK	physiologically based pharmacokinetic
Cr(IV)	tetravalent chromium	PDC	potassium dichromate
Cr(V)	pentavalent chromium	PND	postnatal day
Cr(VI)	hexavalent chromium	POD	point of departure
DAF	dosimetric adjustment factor	POD _[ADJ]	duration-adjusted POD
DLCO	diffusing capacity of carbon monoxide	POD _[HED]	human equivalent dose POD
DNA	deoxyribonucleic acid	POD _[HEC]	human equivalent concentration POD
ELF	epithelial lining fluid		
EPA	Environmental Protection Agency	RBC	red blood cell, also known as erythrocyte
ER	extra risk	RD	relative deviation
FDA	Food and Drug Administration	RfC	inhalation reference concentration
FEV1.0	forced expiratory volume of 1 second	RfD	oral reference dose
FVC	forced vital capacity	RDDR	regional deposited dose ratio
GD	gestation day	RNA	ribonucleic acid
GGT	γ-glutamyl transferase	SCE	sister chromatid exchange
GI	gastrointestinal	SD	standard deviation
GLP	good laboratory practices	SDH	sorbitol dehydrogenase
GSD	geometric standard deviation	SE	standard error
GSH	glutathione	SDD	sodium dichromate dihydrate
GST	glutathione-S-transferase	PK	pharmacokinetics
Hgb	hemoglobin	TSCATS	Toxic Substances Control Act Test Submissions
HEC	human equivalent concentration		
HED	human equivalent dose		

Toxicological Review of Hexavalent Chromium

TWA	time-weighted average
UF	uncertainty factor
UF _A	animal-to-human uncertainty factor
UF _H	human variation uncertainty factor
UF _L	LOAEL-to-NOAEL uncertainty factor
UF _S	subchronic-to-chronic uncertainty factor
UF _D	database uncertainty factor
WOS	Web of Science

AUTHORS | CONTRIBUTORS | REVIEWERS

Assessment Managers (Lead Authors)

[Catherine Gibbons](#)
[Alan Sasso](#)

U.S. EPA/Office of Research and Development/Center
for Public Health and Environmental Assessment

Assessment Team (Authors)

[Michelle Angrish](#)
[Xabier Arzuaga](#)
Thomas Bateson
[Krista Christensen*](#)
Johanna Congleton
Barbara Glenn
Leonid Kopylev
David Lehmann
[Roman F. Mezencev](#)
Rebecca M. Nachman
[Kathleen Newhouse](#)
[Elizabeth Radke](#)
[Paul Reinhart](#)
Susan Rieth
[Paul Schlosser](#)
[Rachel Shaffer](#)
Andre Weaver
[Amina Wilkins](#)
[Erin Yost](#)

U.S. EPA/Office of Research and Development/Center
for Public Health and Environmental Assessment

Contributors

Nora Abdel-Gawad
Ted Berner
Todd Blessinger*
Christine Cai
Glinda Cooper
Kelly Garcia
Carolyn Gigot
Andrew Greenhalgh
Shahreen Hussain
Grace Kaupas
Stephanie Kim
Urmila Kodavanti
[Alexandra Larsen](#)
Cheng-Kuan (Calvin) Lin
Larissa Pardo
Keith Salazar
Sabah Tariq
[Todd Zurlinden*](#)
Stephanie Smith-Roe

U.S. EPA/Office of Research and Development/Center
for Public Health and Environmental Assessment

NIH/National Institute of Environmental Health
Sciences/Division of the National Toxicology Program

Production Team

Maureen Johnson
Ryan Jones
Dahnish Shams
Vicki Soto
Samuel Thacker
Ashlei Williams

U.S. EPA/Office of Research and Development/Center
for Public Health and Environmental Assessment

Contractor Support

Michelle Cawley
Ali Goldstone
Kim Osborn
Alessandria Schumacher
Nicole Vetter

ICF, Inc.

Executive Direction

Wayne Cascio
Samantha Jones
[Kristina Thayer*](#)
[Andrew Kraft*](#)
[J. Allen Davis, Jr.](#)
Barbara Glenn
Paul White*

CPHEA Center Director
CPHEA Associate Director for Assessment Science
CPAD Director
CPAD Associate Director
CPAD Senior Science Advisor, Acting
SAM Branch Chief
CPAD Senior Science Advisor

Internal Reviewers

Epidemiology Workgroup
General Toxicity/Immunotoxicity/Cancer
Workgroup
Inhalation Workgroup
Neurotoxicity Workgroup
Pharmacokinetics Workgroup
Reproductive and Developmental Toxicity
Workgroup
Scoping and Problem Formulation
Workgroup
Statistics Workgroup
Systematic Review Workgroup
Toxicity Pathways Workgroup

Ila Cote*
Alan Stern*

U.S. EPA (retired), Contractor
NJDEP (retired), Contractor

*EPA/ORD/CPHEA Executive Review Committee

EXECUTIVE SUMMARY

Summary of Occurrence and Health Effects

Chromium is a ubiquitous element present in soil, water, air, and food that can originate from both natural and anthropogenic sources. This toxicological review restricts its focus to hexavalent chromium compounds, which are a group of substances that contain chromium in the hexavalent (+6) oxidation state, denoted as Cr(VI). Cr(VI) compounds have many industrial applications, including pigment manufacturing, corrosion inhibition and metal finishing. Because many Cr(VI) compounds are water soluble, they are highly mobile in soil and may contaminate drinking water. Cr(VI) may be emitted into air by industries using Cr(VI) compounds, and by various other sources such as the burning of fossil fuels.

The systematic review (see Appendix A for methods) conducted to support this assessment evaluated all cancer outcomes, and noncancer effects for the following potential target systems: respiratory, gastrointestinal (GI) tract, hepatic, hematologic, immune, reproductive, and developmental. For cancer and nasal effects via the inhalation route (which are well established), the systematic review focused on data that may inform the quantitative dose-response analysis.

Evidence indicates that Cr(VI) is likely to cause GI tract, liver, developmental, and lower respiratory toxicity in humans. Evidence suggests that Cr(VI) may cause male reproductive effects, immune effects, and hematologic toxicity in humans. Evidence is inadequate to assess whether Cr(VI) causes female reproductive toxicity in humans. Organ/system-specific reference values were derived for GI tract, liver, developmental, hematological, lower respiratory, and nasal effects. The overall chronic RfD is 9×10^{-4} mg/kg-d, and the overall chronic RfC is 1×10^{-5} mg/m³.

For cancer via the oral route of exposure, Cr(VI) is *likely to be carcinogenic* to the human GI tract. Because a mutagenic mode-of-action (MOA) for Cr(VI) carcinogenicity is “sufficiently supported in (laboratory) animals” and “relevant to humans,” EPA used a linear low dose extrapolation from the POD in accordance with *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)). Furthermore, in the absence of chemical-specific data to evaluate differences in age-specific susceptibility, increased early-life susceptibility to Cr(VI) is assumed and EPA applied ADAFs in accordance with the *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)). The total lifetime oral slope factor (OSF) for Cr(VI) is 0.5 (per mg/kg-d).

For cancer via the inhalation route of exposure, quantitative exposure-response data were evaluated, and an inhalation unit risk (IUR) was developed for human lung cancer. Similar to the oral route of exposure, linear low dose extrapolation and application of ADAFs were performed for the inhalation route of exposure. The total lifetime IUR for Cr(VI) is 2×10^{-2} (per $\mu\text{g Cr(VI)/m}^3$).

1 **ES.1 EVIDENCE FOR HAZARDS OTHER THAN CANCER: ORAL EXPOSURE**

2 The evidence indicates that Cr(VI) is likely to cause gastrointestinal (GI) tract, hepatic, and
3 developmental toxicity in humans following oral ingestion (see Sections 3.2.2, 3.2.4, 3.2.9). The
4 determination that evidence indicates that Cr(VI) is likely to cause GI toxicity in humans was based
5 on toxicology studies in rodents reporting histological effects in the GI tract. For the determination
6 of hepatic toxicity, toxicology studies in rodents reported histological effects in the liver and serum
7 indicators of hepatotoxicity. The determination for developmental effects was based on the
8 observation of decreased offspring growth across most animal studies. For the hazards listed
9 above, mechanistic evidence supported the human relevance of the effects observed in animals.

10 The evidence suggests that Cr(VI) may cause immune, hematologic, and male reproductive
11 toxicity in humans (see Sections 3.2.5, 3.2.6, 3.2.7). Male reproductive effects on sperm parameters
12 and testosterone were observed in both human and animal studies, however most studies were
13 considered *low* confidence, and effects were inconsistent among the *high* confidence rodent studies.
14 For hematological effects, *high* confidence studies in rodents reported changes in hematological
15 parameters that suggested a pattern consistent with regenerative microcytic hypochromic anemia,
16 but the confidence in this judgment was diminished due to uncertainty regarding the apparent
17 transient nature of the effects. The conclusion for immune effects was primarily based on coherent
18 evidence of effects on 1) *ex vivo* WBC function across human and animal studies, 2) antibody
19 responses to T cell-dependent antigen measured in animals, and 3) reduction in host resistance to
20 bacterial infection reported in animal studies; however, confidence in the evidence was reduced
21 due to primarily *low* confidence studies reporting findings that were often inconsistent across
22 studies.

23 The evidence is inadequate to assess whether Cr(VI) causes female reproductive toxicity in
24 humans (see Section 3.2.8). Although an association with female reproductive toxicity was
25 demonstrated in a single *low* confidence epidemiology study and a series of *low* confidence animal
26 toxicology studies, effects were not observed in *medium* or *high* confidence studies aside from a
27 moderate decrease in maternal body weight.

28 **ES.1.1. Oral Reference Dose (RfD)**

29 Hyperplasia in the small intestine of female B6C3F1 mice was selected as the basis for the
30 overall chronic RfD of 9×10^{-4} mg/kg-d. A LOAEL analysis was used to derive an organ/system-
31 specific point of departure (POD) for GI tract effects. Human equivalent doses (HEDs) were
32 calculated using PBPK modeling to account for species differences and human variability in
33 detoxification of Cr(VI) in the stomach. A composite uncertainty factor of 100 was applied. This
34 uncertainty factor incorporated: an interspecies uncertainty (UF_A) of 3 to account for animal-to-
35 human extrapolation (pharmacodynamic differences); an intraspecies uncertainty (UF_H) of 3 to
36 account for variation in susceptibility across the human population, and the possibility that the
37 available data may not be representative of individuals who are most susceptible to the effects; and

1 a LOAEL-to-NOAEL uncertainty (UF_L) of 10 to account for extrapolation from the LOAEL. The
 2 remaining uncertainty factors were equal to 1.

3 The confidence in the overall chronic RfD is high. The RfD is based on a *high* confidence
 4 chronic 2-year drinking water study by [NTP \(2008\)](#) that exposed rats and mice of both sexes to
 5 Cr(VI) as sodium dichromate dihydrate (see Section 3.2.2). Multiple *high* confidence subchronic
 6 studies also support these data, and mechanistic studies support the involvement of oxidative
 7 stress in Cr(VI)-induced cytotoxicity in a variety of tissues, including the GI tract. The
 8 organ/system-specific RfD for the liver (hepatic system) is also supportive of the GI tract RfD,
 9 because the GI tract and liver are exposed on first-pass following oral ingestion (so both should get
 10 the highest internal dose). While the human database for Cr(VI) induced GI toxicity was
 11 *indeterminate*, this did not warrant changing the overall confidence from *high*. Organ/system-
 12 specific RfDs (osRfDs) are listed in Table ES-1.

Table ES-1. Organ/system-specific RfDs and overall RfD for Cr(VI)

Hazard	Basis	osRfD mg/kg-d	Study exposure description	Confidence
Gastrointestinal system (GI tract)	Hyperplasia in small intestine of female mice	9×10^{-4}	Chronic drinking water	High
Hepatic system	Chronic inflammation in female rats	7×10^{-4}	Chronic drinking water	High
Developmental toxicity	Decreased F1 offspring postnatal growth	0.07	Continuous breeding	Low
Hematological toxicity	Decreased Hgb (male rats)	0.01	Subchronic drinking water	High
Overall RfD	GI tract effects	9×10^{-4}	Chronic drinking water	High

13 The osRfD for hepatic effects was based on chronic inflammation in female F344 rats
 14 reported in [NTP \(2008\)](#). An osRfD of 7×10^{-4} mg/kg-d was derived using a LOAEL analysis. Human
 15 equivalent doses (HEDs) were calculated using pharmacokinetic modeling to account for species
 16 differences and human variability in detoxification of Cr(VI) in the stomach. A composite
 17 uncertainty factor of 100 was applied. This uncertainty factor incorporated: an interspecies
 18 uncertainty (UF_A) of 3 to account for animal-to-human extrapolation (pharmacodynamic
 19 differences); an intraspecies uncertainty (UF_H) of 3 to account for variation in susceptibility across
 20 the human population, and the possibility that the available data may not be representative of
 21 individuals who are most susceptible to the effects; and a LOAEL-to-NOAEL uncertainty (UF_L) of 10
 22 to account for extrapolation from the LOAEL. The remaining uncertainty factors were equal to 1.
 23 There is high confidence in this osRfD. It is based on a *high* confidence chronic study in rats and

1 there are other subchronic data and mechanistic evidence to support the liver endpoints (see
2 Section 3.2.4).

3 The osRfD for developmental toxicity was based on decreased F1 offspring postnatal
4 growth from the continuous breeding study in BALBC mice ([NTP, 1997](#)). The osRfD was 0.07
5 mg/kg-d and was based on extrapolation from a NOAEL. A human equivalent dose (HED) was
6 calculated using PBPK modeling to account for species differences and human variability in
7 detoxification of Cr(VI) in the stomach. A composite uncertainty factor of 10 was applied. This
8 uncertainty factor incorporated: an interspecies uncertainty (UF_A) of 3 to account for animal-to-
9 human extrapolation (pharmacodynamic differences); an intraspecies uncertainty (UF_H) of 3 to
10 account for variation in susceptibility across the human population, and the possibility that the
11 available data may not be representative of individuals who are most susceptible to the effects. The
12 remaining uncertainty factors were equal to 1. There is low confidence in this osRfD. While it is
13 based on a *high* confidence continuous breeding study and similar effects on decreased offspring
14 growth observed in multiple other studies (see Section 3.2.9), this effect only occurred in high dose
15 groups where other toxicological effects (as indicated by the lower points of departure in Table
16 ES-2) may be occurring. Lower confidence in this osRfD was assigned due to the possibility that
17 other toxicities could be affecting the animals in the high dose groups where developmental effects
18 were observed.

19 The osRfD for hematological toxicity was based on decreased Hgb in male F344 rats at 22
20 days reported in [NTP \(2008\)](#). Hematological effects were observed to have the highest magnitude
21 at short time periods, and ameliorate over time. As a result, short-term/low-dose data from [NTP](#)
22 [\(2008\)](#) were used, and a subchronic-to-chronic uncertainty factor was not applied. An osRfD of
23 0.01 mg/kg-d was derived using BMD analysis and PBPK modeling. A composite uncertainty factor
24 of 10 was applied. This uncertainty factor incorporated: an interspecies uncertainty (UF_A) of 3 to
25 account for animal-to-human extrapolation (pharmacodynamic differences); an intraspecies
26 uncertainty (UF_H) of 3 to account for variation in susceptibility across the human population, and
27 the possibility that the available data may not be representative of individuals who are most
28 susceptible to the effects. There is high confidence in this osRfD. It is based on a *high* confidence
29 study in rats and there are other subchronic data and mechanistic evidence to support the endpoint
30 (see Section 3.2.5).

Table ES-2. Summary of reference dose (RfD) derivation

Critical effect	Point of departure mg/kg-d	UF	Candidat Value (mg/kg-d)	osRfD (mg/kg-d)
GI TRACT TOXICITY				
Mice (M) diffuse epithelial hyperplasia of duodenum ^a (NTP, 2008)	BMDL _{10%ER-HED} : 0.0443	10	4.43×10^{-3}	9×10^{-4}

Toxicological Review of Hexavalent Chromium

Critical effect	Point of departure mg/kg-d	UF	Candidat Value (mg/kg-d)	osRfD (mg/kg-d)
Mice (F) diffuse epithelial hyperplasia of duodenum ^a (NTP, 2008)	LOAEL _{HED} : 0.0911	100	9.11×10^{-4}	
HEPATIC TOXICITY				
Rat (M) liver ALT (12 months) (NTP, 2008)	BMDL _{1RD-HED} : 0.204	10	0.0204	7×10^{-4}
Rat (M) liver ALT (3 months) (NTP, 2008)	NOAEL _{HED} : 0.191	30	6.37×10^{-3}	
Rat (M) liver ALT (90 days) (NTP, 2007)	LOAEL _{HED} : 0.203	300	6.77×10^{-4}	
Rat (F) liver ALT (90 days) (NTP, 2007)	LOAEL _{HED} : 0.190	300	6.33×10^{-4}	
Rat (F) liver chronic inflammation (2 years) (NTP, 2008)	LOAEL _{HED} : 0.0669	100	6.69×10^{-4}	
Mouse (F) liver chronic inflammation (2 years) (NTP, 2008)	BMDL _{10%ER HED} : 0.182	10	0.0182	
Rat (F) liver fatty change (2 years) (NTP, 2008)	NOAEL _{HED} : 0.0669	10	6.69×10^{-3}	
DEVELOPMENTAL TOXICITY				
Mouse (F) Decreased F1 postnatal growth (NTP, 1997)	NOAEL _{HED} : 0.700	10	0.0700	0.07
HEMATOLOGICAL TOXICITY				
Rat (M) decreased Hgb (22 days) (NTP, 2008)	BMDL _{1SD HED} : 0.126	10	0.0126	0.01

^aDuodenum: the most proximal subsection of the small intestine, immediately distal to the stomach.

1 **ES.2 EVIDENCE FOR HAZARDS OTHER THAN CANCER: INHALATION EXPOSURE**

2 As stated in the Cr(VI) IRIS Assessment Protocol (Appendix A), EPA did not re-evaluate the
3 qualitative evidence for an association between inhalation Cr(VI) exposure and nasal effects. Based
4 on EPA's 1998 evaluation of the literature and the determination that the effects of Cr(VI) on the
5 nasal cavity have been well established [e.g., [OSHA \(2006\)](#) and [U.S. EPA \(2014c\)](#)], hazard
6 identification was not performed for nasal effects. Rather, the review of the evidence for nasal
7 effects focused on identifying studies that might improve the quantitative dose-response analysis
8 for this outcome.

9 EPA evaluated qualitative evidence for an association between inhalation Cr(VI) exposure
10 and lower respiratory toxicity. EPA determined that Cr(VI) is likely to cause lower respiratory
11 toxicity, based on evidence in six *medium* confidence animal studies examining lung cellular
12 responses and/or histopathology. Because histopathological and cellular changes occurred

1 together, and in combination with serum biomarkers indicating an inflammatory response, these
 2 were considered indicators of adverse responses. The human evidence for Cr(VI)-induced lower
 3 respiratory effects is limited in terms of number and confidence of studies. However, three of the
 4 available five studies provide some indication of exposure-related decrements in lung function
 5 assessed using spirometry. Mechanistic evidence supports the respiratory tract effects observed in
 6 animals.

7 **ES-2.2 Inhalation Reference Concentration (RfC)**

8 The overall RfC was based on effects in the upper respiratory tract (ulceration of the nasal
 9 septum) reported by *medium* confidence [studies](#). Effects of Cr(VI) on the nasal cavity have been
 10 well established to occur in humans, and this was also the most sensitive effect. It is considered
 11 protective of the other noncancer effects. Organ/system-specific RfCs are listed in Table ES-3.

Table ES-3. Organ/system-specific RfCs and overall RfC for Cr(VI)

Hazard	Basis	osRfC mg/m ³	Study exposure description	Confidence
Respiratory (upper tract)	Ulcerated nasal septum in humans	1×10^{-5}	Occupational longitudinal study	Medium
Respiratory ^a (lower tract)	Lung cellular responses and histopathological changes in rats	1×10^{-4}	Subchronic study	Medium
Overall RfC	Respiratory effects	1×10^{-5}	Occupational longitudinal study	Medium

^aHuman equivalent concentrations were calculated using a dosimetric adjustment factor accounting for interspecies differences in particle deposition (the regional deposited dose ratio, or RDDR).

12 Effects in the nasal cavity included irritation/ulceration of the nasal mucosa or septum,
 13 perforation of the septum, and bleeding nasal septum. The osRfC (for upper respiratory tract) was
 14 derived using data of nasal septum ulceration in humans from [Gibb et al. \(2000a\)](#). LOAEL analyses
 15 were used to derive the upper respiratory tract related points of departure (POD). A composite
 16 uncertainty factor of 300 was applied. This uncertainty factor incorporated: an intraspecies
 17 uncertainty factor (UF_H) of 3 to account for variation in susceptibility across the human population
 18 and the possibility that the available data may not be representative of individuals who are most
 19 susceptible to the effect; a LOAEL-to-NOAEL uncertainty factor (UF_L) of 10 because this endpoint
 20 had a high incidence at the lowest concentration across multiple studies; and a subchronic-to-
 21 chronic uncertainty factor (UF_S) of 3 because data were not from chronic lifetime exposures
 22 (however the effects had a short onset time). A database uncertainty factor (UF_D) of 3 was applied
 23 because multi-generational inhalation studies were not available in animals, human prenatal
 24 studies were rated *low* confidence, and effects of Cr(VI) differ by route of exposure due to

1 pharmacokinetics¹ (thus, the oral database of multi-generational studies does not inform the
2 quantitative analysis for the inhalation route).

3 For the lower respiratory tract, the osRfC was derived using data of lung cellular responses
4 and histopathological changes in rats from [Glaser et al. \(1990\)](#). A LOAEL analysis was used to
5 derive most organ/system-specific points of departure (PODs). Human equivalent concentrations
6 were calculated using a dosimetric adjustment factor accounting for interspecies differences in
7 particle deposition (the regional deposited dose ratio, or RDDr). A composite uncertainty factor of
8 1000 was applied to the LOAEL-derived PODs (BMD-derived bronchioalveolar hyperplasia had a
9 composite UF was 300; see Section 4.2.4). The database uncertainty factor, UF_D, was 3 for the same
10 reasons specified above for the nasal osRfC. A subchronic-to-chronic uncertainty factor, UF_S, of 3
11 was incorporated to account for the less-than-lifetime exposure. There was some indication in
12 [Glaser et al. \(1990\)](#) that the effects were transient, and therefore a 10 was not applied; however,
13 there is still uncertainty due to the lack of long-term data for continuous chronic exposure. An
14 interspecies uncertainty factor, UF_A, of 3 was applied to account for residual uncertainty in the
15 extrapolation from laboratory animals to humans (an inhalation dosimetry factor was used to
16 estimate a human equivalent concentration from animal data, but some pharmacodynamic
17 uncertainty remained). A LOAEL-to-NOAEL uncertainty factor, UF_L, of 3 was applied to LOAELs
18 because characteristics of the lung histopathological and cellular responses supported a value less
19 than 10. UF_L of 1 was applied when BMD modeling was used (bronchioalveolar hyperplasia). An
20 intraspecies uncertainty factor, UF_H, of 10 was applied to account for variability and uncertainty in
21 pharmacokinetic and pharmacodynamic susceptibility within the human population (source data
22 were only available in male inbred rats). Table ES-4 summarizes the derivation of the osRfCs.

Table ES-4. Summary of reference concentration (RfC) derivation

Critical effect	Point of departure mg/m ³	UF	Candidate value mg/m ³	osRfC mg/m ³
UPPER RESPIRATORY TRACT TOXICITY				
Ulceration of the nasal septum (Gibb et al., 2000a)	LOAEL: 3.4×10^{-3}	300	1.1×10^{-5}	1×10^{-5}
Nasal mucosal pathology (Cohen et al., 1974)	LOAEL: 9.5×10^{-4}	300	3.2×10^{-6}	
Ulceration of the nasal septum (Lindberg and Hedenstierna, 1983)	LOAEL: 6.6×10^{-4}	300	2.2×10^{-6}	
LOWER RESPIRATORY TRACT TOXICITY				
Histopathology: histiocytosis in rats (Glaser et al., 1990)	LOAEL _{HEC} : 0.133	1000	1.3×10^{-4}	1×10^{-4}

¹Because Cr(VI) is detoxified in the gut on first-pass, it is possible that inhalation exposures may induce systemic effects not observed following ingestion.

Critical effect	Point of departure mg/m ³	UF	Candidate value mg/m ³	osRfC mg/m ³
UPPER RESPIRATORY TRACT TOXICITY				
Histopathology: bronchioalveolar hyperplasia in rats (Glaser et al., 1990)	BMDL _{1SD-HEC} : 0.0413	300	1.4 × 10 ⁻⁴	
Cell responses: LDH in BALF in rats (Glaser et al., 1990)	LOAEL _{HEC} : 0.133	1000	1.3 × 10 ⁻⁴	
Cell responses: Albumin in BALF in rats (Glaser et al., 1990)	LOAEL _{HEC} : 0.170	1000	1.7 × 10 ⁻⁴	
Cell responses: Total protein in BALF in rats (Glaser et al., 1990)	LOAEL _{HEC} : 0.133	1000	1.3 × 10 ⁻⁴	

1 **ES.3 EVIDENCE FOR HUMAN CARCINOGENICITY**

2 Under EPA’s Guidelines for Carcinogen Risk Assessment ([U.S. EPA, 2005a](#)), Cr(VI) is **likely**
3 **to be carcinogenic** to humans by the oral route of exposure. The evidence of carcinogenicity to the
4 GI tract from animal studies is *robust*, and the evidence of carcinogenicity from human studies is
5 *slight*. There is strong supporting mechanistic evidence for Cr(VI) involvement in biological
6 pathways contributing to carcinogenesis.

7 As noted in the Protocol (see Appendix A), this assessment maintains the previous
8 determination that Cr(VI) is **carcinogenic to humans** by the inhalation route of exposure based on
9 long-standing evidence of a causal relationship between inhalation of Cr(VI) and increased
10 incidence of lung cancer in humans in occupational settings.

11 **ES.4 QUANTITATIVE ESTIMATE OF CARCINOGENIC RISK: ORAL EXPOSURE**

12 The animal database for cancer by oral exposure consisted of a [high confidence](#) chronic
13 2-year drinking water bioassay which found “clear evidence of carcinogenic activity” of Cr(VI) in
14 male and female rats and mice ([NTP, 2008](#)). These results were based on increased incidences of
15 squamous cell neoplasms in the oral cavity of rats, and increased incidences of neoplasms in the
16 small intestine of mice. Using these data, benchmark dose (BMD) modeling was applied to derive
17 points of departure (PODs) for small intestinal tumors in mice and oral tumors in rats (See
18 Section 4.3). For mice, human equivalent doses (HEDs) were calculated using PBPK modeling to
19 account for species differences in detoxification of Cr(VI) in the stomach because tumors occurred
20 in the small intestine (after stomach reduction to Cr(III)). For rats, HEDs were calculated using
21 BW^{3/4} scaling in accordance with [U.S. EPA \(2011c\)](#), because tumors occurred in the oral cavity
22 (prior to stomach reduction to Cr(III)). In the absence of an adequately developed theory or
23 information to develop and characterize an oral portal-of-entry dosimetric adjustment factor,
24 application of BW^{3/4} scaling is recommended ([U.S. EPA, 2011c, 2005a](#)).

1 The lifetime oral cancer slope factor for humans is defined as the slope of the line from the
 2 lower 95% bound on the exposure at the POD to the control response (slope factor = 0.1/BMDL₁₀).
 3 Using linear extrapolation from the BMDL₁₀, human equivalent oral slope factors were derived for
 4 each sex/species/tumor site combination and are listed in Table ES-5. The adult-based oral slope
 5 factor for Cr(VI) is 0.3 (per mg/kg-d), based on tumors of the small intestine of male and female
 6 mice.

Table ES-5. Summary of oral slope factor (OSF) derivation

Critical effect	Point of departure mg/kg-d	Human equivalent dose mg/kg-d	OSF ^a (per mg/kg-d)	Confidence
Adenomas or carcinomas in the mouse small intestine of male mice (NTP, 2008)	BMDL _{10%ER} : 1.05	0.319 ^b	0.313	High
Adenomas or carcinomas in the mouse small intestine of female mice (NTP, 2008)	BMDL _{10%ER} : 1.03	0.316 ^b	0.317	High
Squamous cell carcinoma or squamous cell papilloma in oral mucosa or tongue of male rats (NTP, 2008)	BMDL _{10%ER} : 3.37	0.923 ^c	0.108	High
Squamous cell carcinoma or squamous cell papilloma in oral mucosa or tongue of female rats (NTP, 2008)	BMDL _{10%ER} : 2.70	0.645 ^c	0.155	High
Adult-based OSF: 0.3 (mg/kg-d)⁻¹ (rounded from either 0.313 or 0.317) Lifetime OSF for adenomas or carcinomas in the mouse small intestine, after application of the age-dependent adjustment factors: 0.5 (mg/kg-d)⁻¹ (see Section 4.3.4 for derivation)				

^aOSF prior to application of the age-dependent adjustment factors.

^bEstimated by PBPK modeling.

^cBW^{3/4} scaling adjustment (administered dose multiplied by (BW_A/BW_H)^{1/4}, where BW_H = 80kg (human body weight) and BW_A (animal body weight) is set to a study-specific value.

7 Because a mutagenic MOA for Cr(VI) carcinogenicity (see Section 3.2.3) is “sufficiently
 8 supported in (laboratory) animals” and “relevant to humans,” and as there are no chemical-specific
 9 data to evaluate the differences between adults and children, increased early-life susceptibility
 10 should be assumed. If there is early-life exposure, age-dependent adjustment factors (ADAFs)
 11 should be applied, as appropriate, in accordance with the EPA’s *Supplemental Guidance for Assessing*
 12 *Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)).

13 The total lifetime OSF for Cr(VI) is **0.5 (per mg/kg-d)**. Partial oral slope factors for
 14 different age groups are provided in Section 4.3.4.

1 ES.5 QUANTITATIVE ESTIMATE OF CARCINOGENIC RISK: INHALATION EXPOSURE

2 In 1998, the EPA IRIS Toxicological Review of Hexavalent Chromium classified Cr(VI) as a
 3 "known human carcinogen by the inhalation route of exposure" based on consistent evidence that
 4 inhaled Cr(VI) causes lung cancer in humans and supporting evidence of carcinogenicity in animals
 5 ([U.S. EPA, 1998c](#)). The same conclusion has since been reached by other authoritative federal and
 6 state health agencies and international organizations and the carcinogenicity of Cr(VI) is well
 7 established for inhalation exposures ([TCEQ, 2014](#); [IPCS, 2013](#); [NIOSH, 2013](#); [IARC, 2012](#); [CalEPA,](#)
 8 [2011](#); [NTP, 2011](#); [OSHA, 2006](#)). As stated in the 2014 preliminary packages ([U.S. EPA, 2014b, c](#))
 9 and the Systematic Review Protocol (Appendix A), the review of cancer by the inhalation route
 10 focused on data that may improve the quantitative exposure-response analysis conducted in EPA's
 11 1998 IRIS assessment. An overview of the literature screening for exposure-response data is
 12 contained in Section 4.4.1.

13 The IUR was based on an occupational cohort by Gibb et al., ([2020](#); [2015](#); [2000b](#)) of
 14 chromate production workers at a facility in Baltimore, MD. Details of the cohort are contained in
 15 Section 4.4.

16 Because a mutagenic MOA for Cr(VI) carcinogenicity is "sufficiently supported in
 17 (laboratory) animals" and "relevant to humans," and as there are no chemical-specific data to
 18 evaluate the differences between adults and children, increased early-life susceptibility should be
 19 assumed. If there is early-life exposure, age-dependent adjustment factors (ADAFs) should be
 20 applied, as appropriate, in accordance with the EPA's *Supplemental Guidance for Assessing*
 21 *Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)).

22 The total lifetime IUR for Cr(VI) is 2×10^{-2} (**per $\mu\text{g Cr(VI)/m}^3$**). Partial unit risks for
 23 different age groups are provided in Section 4.4.4. Table ES-6 summarizes the derivation of the
 24 IUR.

Table ES-6. Summary of inhalation unit risk (IUR) derivation

Critical effect	Basis	IUR ($\mu\text{g Cr(VI)/m}^3$) ⁻¹	Study exposure description	Confidence
Cancer	Lung cancer (Gibb et al., 2020)	2×10^{-2}	Occupational cohort	High

25 ES.6 SUSCEPTIBLE POPULATIONS AND LIFE STAGES

26 Susceptible populations and life stages refers to groups of people who may be at increased
 27 risk for negative health consequences following chemical exposures due to factors such as life stage,
 28 genetics, race/ethnicity, sex, health status and disease, lifestyle factors, and other co-exposures.
 29 Populations susceptible to increased risks for negative health consequences of Cr(VI) exposure
 30 include:

- 1 • Individuals with preexisting health effects that overlap with those caused by Cr(VI)
2 exposure may be at increased risk. Health conditions that may be exacerbated by Cr(VI)
3 exposure include gastrointestinal diseases, liver diseases, respiratory diseases, and anemia.

 - 4 • Individuals with chronically high stomach pH are expected to detoxify Cr(VI) less
5 effectively, leading to increased uptake of Cr(VI) in the gastrointestinal tract following oral
6 exposure. High stomach pH can be caused by a number of factors, such as low gastric acid
7 (hypochlorhydria), usage of medications to treat gastroesophageal reflux disease (GERD),
8 and population variability.

 - 9 • Individuals with genetic polymorphisms conveying deficiencies in DNA repair capacity may
10 have increased susceptibility to Cr(VI)-induced cancer.

 - 11 • Carriers of a mutated cystic fibrosis transmembrane conductance regulator (CFTR) allele
12 may be at higher risk of Cr(VI)-induced cancers of the gastrointestinal tract. Suppression of
13 the CFTR gene was shown to enhance intestinal tumorigenesis in animal models. CFTR was
14 shown to be inactivated in mice exposed to Cr(VI). Thus, individuals with an impaired CFTR
15 due to genetics may suffer an even further reduction in CFTR expression levels following
16 oral exposure to Cr(VI).
- 17 Life stages susceptible to increased risks for negative health consequences of Cr(VI) exposure
18 include:
- 19 • The developmental life stage (in utero) is considered susceptible because Cr(VI) was
20 determined to likely cause developmental toxicity in humans.

 - 21 • Neonates, infants, and young toddlers less than 30 months old, which exhibit elevated
22 stomach pH and therefore cannot effectively detoxify Cr(VI).

 - 23 • Elderly populations (aged 65 and older) may be at higher risk because they exhibit some
24 preexisting health conditions associated with aging that may be exacerbated by oral or
25 inhalation exposure to Cr(VI). This includes conditions that cause elevated stomach pH.

26 **ES.7 ORAL ABSORPTION UNCERTAINTIES AND ASSUMPTIONS APPLIED IN HAZARD**
27 **IDENTIFICATION AND MODE-OF-ACTION ANALYSES**

28 Even under controlled rodent pharmacokinetic studies, assessing the oral absorption and
29 whole-body distribution of orally administered Cr(VI) at low doses involves uncertainty. Only the
30 total chromium concentration, which includes the trivalent and hexavalent oxidation states, can be
31 reliably measured in tissues in vivo, and most total chromium is likely to be Cr(III). Total chromium
32 measured in tissues of animals orally exposed to Cr(VI) results from:

- 33 • Rapid cellular uptake of administered Cr(VI) that was absorbed into the body as Cr(VI), and
34 subsequently reduced to Cr(III) within that tissue.

- 35 • Slow cellular uptake of Cr(III) that was absorbed into the body as Cr(III), formed from
36 administered Cr(VI) that reduced to Cr(III) extracellularly and outside of systemic
37 circulation (e.g., gastric juices).

- 1 • Slow cellular uptake of Cr(III) that was absorbed into the body as administered Cr(VI) and
2 reduced by other components within systemic circulation (e.g., plasma, liver, red blood
3 cells). For example, plasma can reduce Cr(VI) extracellularly, and the resulting Cr(III)
4 absorbed into other tissues. RBCs can reduce Cr(VI) intracellularly, and the resulting Cr(III)
5 can be released to systemic circulation (to be absorbed by other tissues) after RBCs are
6 broken down.
- 7 • Background uptake and distribution of dietary and drinking water chromium (Cr(III)
8 and/or Cr(VI)) not administered or controlled in the bioassay.

9 Additional details are provided in Section 3.1 (Pharmacokinetics) and Appendix C.1.

10 Elevated chromium concentrations in red blood cells (RBCs) is a strong indicator that Cr(VI) was
11 absorbed in the GI tract unreduced and was not subsequently reduced by the liver during first-pass
12 metabolism. Uptake and reduction of Cr(VI) by RBCs is rapid, and the resulting Cr(III) in red blood
13 cells is bound to hemoglobin and/or diffuses out of the RBC slowly. Therefore, elevated RBC
14 chromium persists longer relative to plasma chromium levels following systemic Cr(VI) absorption.
15 Based on analyses of the RBC:plasma ratios of exposed and unexposed rodents from the NTP ([2008](#),
16 [2007](#)) studies (see Appendix C.1.2), general assumptions were made when interpreting animal
17 studies for hazard identification and MOA:

- 18 • At oral *ad libitum* doses below 1 mg/kg-d, Cr(VI) is absorbed by the GI tract, but most Cr(VI)
19 absorbed by the GI tract is reduced to Cr(III) by the liver (and to a lesser extent, plasma and
20 RBCs in the portal vein). At these low doses the GI tract and liver are exposed to Cr(VI), but
21 exposure to other systems may be low and highly variable. There is high uncertainty as to
22 whether other systemic tissues receive consistent exposure to Cr(VI) at these doses across
23 all the studies. Therefore, inconsistent pharmacokinetic and toxicological results among
24 studies for doses below 1 mg/kg-d are to be expected.
- 25 • At oral *ad libitum* doses greater than or equal to 1 mg/kg-d, Cr(VI) is absorbed by the GI
26 tract, exceeds the reducing capacity of the liver, and is widely distributed to systemic tissues
27 (e.g., kidney, lung, brain). Exposure to systemic tissues may still be highly variable, and
28 there may be some inconsistencies in dose-response between studies.
- 29 • For oral gavage doses at any level, Cr(VI) is widely distributed to systemic tissues, and
30 results in significantly higher internal doses than dietary and drinking water exposure. This
31 is because the gavage route greatly condenses the timescale of an exposure, surpassing
32 gastric reduction capacity (*ad libitum* exposures are distributed over a 24-hour period,
33 whereas gavage occurs over a very short period).
- 34 • Injection studies (intravenous or intraperitoneal) will expose systemic tissues to
35 significantly greater levels of Cr(VI) than oral gavage studies because there is not a first-
36 pass effect (reduction of Cr(VI) in the stomach and liver). Following injection, there will
37 also be (temporarily) more Cr(VI) available in the plasma prior to uptake to RBCs.




Figure ES-1. General assumptions regarding absorption and distribution of Cr(VI) ingested by rodents during *ad libitum* drinking water or dietary bioassays. At doses <1 mg/kg-d, it is assumed that Cr(VI) is absorbed by the small intestine, and most of the absorbed Cr(VI) is reduced by the liver. At doses ≥1 mg/kg-d, it is assumed that systemic absorption and distribution of Cr(VI) throughout the whole body will occur.

1 Despite uncertainties below 1 mg/kg-d, these assumptions were adequate for interpreting
2 the current Cr(VI) database because most studies were conducted using doses greater than 1
3 mg/kg-d. The 1 mg/kg-d dose level was not used as a cutoff for the inclusion of data or to make
4 inferences about low-dose extrapolation, but instead was used to generally evaluate the
5 uncertainties of results. For studies in which the daily oral *ad libitum* dose was much greater than 1
6 mg/kg-d, there is higher certainty that Cr(VI) reaches target tissues. For studies in which the daily
7 oral *ad libitum* doses were lower than 1 mg/kg-d, there is added uncertainty when analyzing data
8 outside of the GI or liver, because it cannot be assumed that Cr(VI) reaches other target systemic
9 tissues at high enough doses that can induce observable effects. In general, it can be assumed that
10 ingested Cr(VI), even at low doses, will expose at least the surface GI epithelial cells if not the liver.
11 For chronic exposure collection periods of the [NTP \(2008\)](#) distribution study (collection days 182
12 and 371, with 2-day washout period), liver chromium concentrations were significantly elevated at
13 all dose groups (including <1 mg/kg-d) in rats and mice.

1. INTRODUCTION

1.1. OVERVIEW

1 This Toxicological Review critically evaluates the publicly available studies on Cr(VI) in
2 order to identify its adverse human health effects and to characterize exposure-response
3 relationships. This assessment was prepared under the auspices of the U.S. Environmental
4 Protection Agency's (EPA's) Integrated Risk Information System (IRIS) Program. IRIS assessments
5 are not regulations but provide critical scientific support for human health risk assessments and
6 resulting decisions made by EPA, state and local health agencies, other federal agencies, and
7 international health organizations to protect human health.

8 This assessment updates a previous IRIS assessment of Cr(VI) (posted in 1998) that
9 included an oral reference dose (RfD) and inhalation reference concentration (RfC) for effects other
10 than cancer, a determination of carcinogenic potential, and inhalation unit risk (IUR) for
11 carcinogenic effects.

12 As part of the initial steps in assessment development, the IRIS Program undertook scoping
13 and initial problem-formulation activities. During scoping activities, the IRIS Program consulted
14 with EPA program and regional offices to identify the nature of the hazard characterization needed,
15 the most important exposure pathways, and the level of detail required to inform Agency decisions.
16 A broad, preliminary literature survey was conducted to assist in identifying the extent of the
17 evidence and health effects that have been studied for Cr(VI). The IRIS Program also undertook
18 problem-formulation activities to frame the scientific questions that are a focus of this assessment.
19 A summary of the IRIS Program's scoping and problem-formulation conclusions are contained in
20 the 2014 preliminary packages ([U.S. EPA, 2014b, c](#)). The preliminary packages were followed by
21 development of a Systematic Review Protocol (Appendix A), which presents detailed methods for
22 conducting the full systematic review and dose-response analysis. As discussed in the preliminary
23 materials and protocol, the IRIS assessment includes evaluations of the evidence relevant to all
24 cancer outcomes and noncancer effects for the following potential target systems: respiratory,
25 gastrointestinal (GI) tract, hepatic, hematologic, immunological, reproductive, and developmental.
26 For cancer and nasal irritation via the inhalation route, the systematic review focuses on data that
27 may improve the quantitative dose-response analysis, conducted in EPA's 1998 IRIS assessment.

28 Appendices for additional systematic review methods and results, pharmacokinetics, dose-
29 response modeling, and public comments are provided as Supplemental Information to this
30 assessment (see Appendices A to F).

1.1.1. Background

1 Elemental chromium is a Group 6 transition metal (atomic number 24 and atomic weight
2 52) on the periodic table, existing in nature in the form of various oxide minerals ([Anger et al.
3 2005](#)). It is present in the Earth's crust and has oxidation states ranging from -2 to +6, with the +3
4 (trivalent) and +6 (hexavalent) states being the most common ([Losi et al., 1994](#)). Chromium in the
5 environment can originate from both natural and anthropogenic sources (discussed in detail in
6 Section 1.1.3) ([Johnson et al., 2006](#); [USGS, 1995](#); [Calder, 1988](#); [Pacyna and Nriagu, 1988](#)). Cr(VI)
7 compounds are used for corrosion inhibition, pigment manufacturing (including textile dyeing,
8 printing inks, and colored glass and plastic), and metal finishing (chrome plating/electroplating)
9 ([NIOSH, 2013](#); [NTP, 2011](#)). Cr(VI) has been used in wood preservatives [as chromated copper
10 arsenate (CCA) in pressure treated wood; ([ATSDR, 2012](#); [Barnhart, 1997](#))]; however, this use began
11 to decline in 2003 due to a voluntary phaseout of all residential uses of CCA pressure treated wood
12 ([Bedinger, 2015](#); [NTP, 2011](#)). Other uses for Cr(VI) that have been discontinued in the United
13 States include leather tanning and corrosion inhibition within cooling systems ([NIOSH, 2013](#); [NTP,
14 2011](#)). Cr(VI) is also a byproduct of processes in the iron and steel industries ([Shaw
15 Environmental, 2006](#)).

1.1.2. Chemical Properties

16 A summary of the Cr(VI) compounds assessed in the human, animal, and mechanistic
17 studies considered pertinent to this assessment are contained in Table 1-1. This table is not an
18 exhaustive list of all Cr(VI) species that are relevant to human exposure but reflects those with data
19 to inform a human health assessment. Compounds of chromium complexed to other metals that
20 could potentially confound the results (such as lead chromate, barium chromate, zinc chromate,
21 copper dichromate, strontium chromate) were not included. A majority of the Cr(VI) compounds
22 evaluated by the human, animal, and mechanistic studies relevant to this assessment are known to
23 be highly water soluble. Calcium chromate, a form with low water solubility, was used in some
24 animal bioassays and pharmacokinetics studies and was therefore considered. Inhalation
25 pharmacokinetics differ between soluble and insoluble forms of Cr(VI) ([OSHA, 2006](#)) (see Section
26 3.1). This assessment will not make separate determinations of toxicity or carcinogenicity of
27 soluble vs. insoluble Cr(VI) compounds because the aim is to evaluate the toxicity and
28 carcinogenicity of Cr(VI) in all forms. Where applicable, issues related to solubility and particle size
29 that may impact study or data interpretations are discussed during study evaluation, hazard
30 identification, and dose-response.

31 Cr(VI) can exist as chromate (CrO_4^{2-}), hydrochromate (HCrO_4^{2-}) and dichromate ($\text{Cr}_2\text{O}_7^{2-}$)
32 anions, whose concentrations at equilibrium depend on the metal concentration in the solution and
33 pH ([Brito et al., 1997](#)). At physiological conditions (pH 7.4) and micromolar Cr(VI) concentrations,
34 the major form of Cr(VI) is chromate and the minor form is hydrochromate, with the latter
35 becoming a dominant form at $\text{pH} \leq 6$ ([Cieślak-Golonka, 1996](#)). These pH-relationships between

Toxicological Review of Hexavalent Chromium

1 Cr(VI) species were incorporated into the gastric reduction model used in this assessment
2 ([Schlosser and Sasso, 2014](#)). Because multiple Cr(VI) compounds are discussed in this assessment,
3 all exposure levels were converted to Cr(VI) equivalents (see Protocol Section 8.2, Appendix A)².
4 Even though the physical properties differ between compounds, they are all ionized to Cr(VI) in the
5 body and are considered to exert the same pharmacological and toxicological effects ([U.S. EPA,](#)
6 [2008](#)).

²In many studies, the administered compound is stated as “sodium dichromate” (Na₂Cr₂O₇) when the compound is administered in aqueous solution with mass units based on sodium dichromate dihydrate (Na₂Cr₂O₇ · 2H₂O). Unless otherwise noted, the conversion factor for sodium dichromate dihydrate (0.349) was used to convert parent compound concentrations and doses to Cr(VI) units for studies labeled as either sodium dichromate or sodium dichromate dihydrate. Due to variations in reporting, it may be unclear whether the mass per unit volume of the formulation was based on Na₂Cr₂O₇ · 2H₂O or Na₂Cr₂O₇ (which would yield a conversion factor of 0.397). In situations where the formulation was prepared based on units of Na₂Cr₂O₇ mass, doses and concentrations listed in this assessment would underestimate the dose by 12%.



Table 1-1. Chemical identity and physicochemical properties of Cr(VI)

Name	Calcium chromate	Sodium chromate	Sodium dichromate	Sodium dichromate, dihydrate
CASRN	13765-19-0	7775-11-3	10588-01-9	7789-12-0
Synonyms	Calcium chromate(VI); calcium chrome yellow; calcium monochromate; gelbin; yellow ultramarine; chromic acid, calcium salt	Sodium chromate(VI); chromium disodium oxide; disodium chromate; rchromate; chromic acid, disodium salt; chromate of soda	Sodium dichromate(VI); sodium bichromate; dichromic acid, disodium salt; bichromate of soda	Dichromic acid, disodium salt, dihydrate
Structure	$\text{Ca}^{+2} \left[\begin{array}{c} \text{O} \quad \text{O} \\ \diagdown \quad / \\ \text{Cr} \\ / \quad \diagdown \\ \text{O} \quad \text{O} \end{array} \right]^{2-}$	$2\text{Na}^{+} \left[\begin{array}{c} \text{O} \quad \text{O} \\ \diagdown \quad / \\ \text{Cr} \\ / \quad \diagdown \\ \text{O} \quad \text{O} \end{array} \right]^{2-}$	$2\text{Na}^{+} \left[\begin{array}{c} \text{O} \quad \text{O} \quad \text{O} \quad \text{O} \\ \diagdown \quad / \quad \diagdown \quad / \\ \text{Cr} \quad \text{O} \quad \text{Cr} \\ / \quad \diagdown \quad / \quad \diagdown \\ \text{O} \quad \text{O} \quad \text{O} \quad \text{O} \end{array} \right]^{2-}$	$2\text{Na}^{+} \left[\begin{array}{c} \text{O} \quad \text{O} \quad \text{O} \quad \text{O} \\ \diagdown \quad / \quad \diagdown \quad / \\ \text{Cr} \quad \text{O} \quad \text{Cr} \\ / \quad \diagdown \quad / \quad \diagdown \\ \text{O} \quad \text{O} \quad \text{O} \quad \text{O} \end{array} \right]^{2-} \cdot 2\text{H}_2\text{O}$
Molecular weight	156.07	161.972	261.965	297.995
Molecular formula	CaCrO_4	Na_2CrO_4	$\text{Na}_2\text{Cr}_2\text{O}_7$	$\text{Na}_2\text{Cr}_2\text{O}_7 \cdot 2\text{H}_2\text{O}$
Conversion factor ^a	0.333	0.321	0.397	0.349
Melting point	1020°C (Anger et al., 2005); decomposition	794°C (Lide, 2008)	357°C (Lide, 2008)	85°C (Lide, 2008); decomposition
Density	3.12 g/cm ³ (Anger et al., 2005)	2.72 g/cm ³ (Lide, 2008)	2.52 g/cm ³ (Anger et al., 2005)	2.35 g/cm ³ (Lide, 2008)
Water solubility	4.5 g/100 g H ₂ O (4.3 wt%) at 0°C (Anger et al., 2005)	87.6 g/100 g H ₂ O at 25°C (Lide, 2008)	187 g/100 g H ₂ O at 25°C (Lide, 2008)	272.9 g/100 g H ₂ O (73.18 wt%) at 20°C (Anger et al., 2005)
Stability/reactivity	Decomposes at 1,000°C (Lide, 2008); oxidizing agent (Lewis and Hawley, 2007)	Hygroscopic (Anger et al., 2005)	Strongly hygroscopic; decomposes above 400°C (Lide, 2008); strong oxidizing agent (Anger et al., 2005)	Very hygroscopic, deliquesces in air; strong oxidizing agent in acid solution (Lide, 2008; Anger et al., 2005)

Synonyms, structures, and molecular formulas and weights were obtained from ChemID Plus (<https://chem.nlm.nih.gov/chemidplus>), unless otherwise noted.

^aMass conversion factor from parent compound to Cr(VI) units.

Table 1-1. Chemical identity and physicochemical properties of Cr(VI) compounds (continued)

Name	Potassium chromate	Potassium dichromate	Chromium trioxide ^b	Chromic acid ^{b,c}
CASRN	7789-00-6	7778-50-9	1333-82-0	7738-94-5 (H ₂ CrO ₄); 13530-68-2 (H ₂ Cr ₂ O ₇)
Synonyms	Potassium chromate(VI); bipotassium chromate; dipotassium chromate; chromate of potash; tarapacaite; chromic acid, dipotassium salt	Potassium dichromate(VI); bichromate of potash; potassium bichromate; dipotassium bichromate; dipotassium dichromate; dipotassium dichromium heptaoxide; lopezite; dichromic acid dipotassium salt	Chromium(VI) oxide; hexavalent chromium oxide; chromic trioxide; chromic anhydride	Chromic(VI) acid; chromium hydroxide oxide; dichromic acid (H ₂ Cr ₂ O ₇)
Structure	$2K^+ \left[\begin{array}{c} O \\ \diagup \quad \diagdown \\ O-Cr-O \\ \diagdown \quad \diagup \\ O \end{array} \right]^{2-}$	$2K^+ \left[\begin{array}{c} O \quad O \\ \diagdown \quad \diagup \\ O-Cr-O-Cr-O \\ \diagup \quad \diagdown \\ O \quad O \end{array} \right]^{2-}$		
Molecular weight	194.188	294.181	99.993	118.008 (H ₂ CrO ₄) 218.001 (H ₂ Cr ₂ O ₇)
Molecular formula	K ₂ CrO ₄	K ₂ Cr ₂ O ₇	CrO ₃	H ₂ CrO ₄ ; H ₂ Cr ₂ O ₇
Conversion factor	0.268	0.353	0.520	0.441 (H ₂ CrO ₄) 0.477 (H ₂ Cr ₂ O ₇)
Melting point	974°C (Lide, 2008)	398°C (Lide, 2008)	197°C (Lide, 2008)	Not applicable
Density	2.73 g/cm ³ (Lide, 2008)	2.68 g/cm ³ (Lide, 2008)	2.7 g/cm ³ (Lide, 2008)	Not applicable
Water solubility	65.0 g/100 g H ₂ O at 25°C (Lide, 2008)	15.1 g/100 g H ₂ O at 25°C (Lide, 2008)	169 g/100 g H ₂ O at 25°C (Lide, 2008)	Not applicable
Stability/reactivity	Nonhygroscopic (Anger et al., 2005). Strong oxidizing agent, may explode in contact with organic materials (Lewis and Hawley, 2007)	Nonhygroscopic; decomposes at 500°C (Lide, 2008 ; Anger et al., 2005)	Deliquescent; decomposition begins above 198°C (Anger et al., 2005); strong oxidizing agent (O'Neil et al., 2006)	Strong oxidizing agent (Anger et al., 2005)

^bChromic acid is formed in aqueous solution when chromium(VI) oxide is dissolved in water; it cannot be isolated as a pure compound out of solution ([Anger et al., 2005](#); [Page and Loar, 2004](#)). The term chromic acid is sometimes used to reference chromium(VI) oxide; however, it should be noted that there is a structural difference between the anhydrous substance chromium(VI) oxide and the aqueous chromic acid that forms when the oxide is dissolved in water.

^cChromic acid exists in solution as both H₂CrO₄ and H₂Cr₂O₇ ([Anger et al., 2005](#); [Page and Loar, 2004](#); [Cotton et al., 1999](#)). H₂CrO₄ is the main species in basic solutions (pH > 6) while H₂Cr₂O₇ is the main species in strongly acidic solutions (pH < 1) ([Anger et al., 2005](#); [Page and Loar, 2004](#); [Cotton et al., 1999](#)). Both species are present in equilibrium in solutions that have a pH value between 2 and 6 ([Anger et al., 2005](#); [Page and Loar, 2004](#); [Cotton et al., 1999](#)).

1.1.3. Sources, Production, and Use

1 1.1.3.1. Soil

2 The EPA Toxics Release Inventory (TRI) estimates approximately 53 million pounds of
3 chromium and chromium compounds were released to the environment via land releases (such as
4 landfills, land treatment, and surface impoundments, excluding underground injections) ([U.S. EPA,
5 2018](#)). Sources of chromium releases into soil include the disposal of commercial products that
6 contain chromium, coal fly ash and bottom fly ash from electric utilities and other industries, solid
7 wastes from metal manufacturing and chrome-plating facilities, chromate production waste,
8 agricultural and food wastes, leather tannery waste, and cooling tower water containing rust
9 inhibitors ([Oregon DEQ, 2014](#); [ATSDR, 2012](#); [U.S. EPA, 2011b](#); [Pellerin and Booker, 2000](#); [Burke et
10 al., 1991](#); [Nriagu and Pacyna, 1988](#)). Air deposition to soil from combustion processes also occurs.

11 Cr(III) in soil may be present predominantly as chromium hydroxide (Cr(OH)₃) or
12 chromium oxide (Cr₂O₃) ([Apte et al., 2006](#); [Kim and Dixon, 2002](#)). These Cr(III) forms have low
13 solubility and reactivity. Cr(VI) may exist in soil as chromate (CrO₄⁻²), chromic acid (HCrO₄⁻),
14 dichromate (Cr₂O₇⁻²), and chromate salts (BaCrO₄, CaCrO₄, PbCrO₄, ZnCrO₄) ([ATSDR, 2012](#); [Apte et
15 al., 2006](#); [Kim and Dixon, 2002](#)). Conversion of Cr(VI) to Cr(III) may occur in the environment
16 under reducing conditions (by ferrous iron, sulfides, and organic matter), while conversion of
17 Cr(III) to Cr(VI) may occur under oxidizing conditions (by manganese oxide minerals) ([Hausladen
18 et al., 2018](#); [2017](#); [McClain et al., 2017](#); [Jardine et al., 2011](#); [Cummings et al., 2007](#); [Oze et al., 2007](#);
19 [2004](#); [Kim and Dixon, 2002](#); [Fendorf et al., 2000](#); [1995](#)). Fire-induced oxidation of Cr(III)-
20 substituted iron oxides in soils may also occur during wildfires ([Burton et al., 2019](#)).

21 Most Cr(III) compounds are insoluble in water and immobile in soils (which helps inhibit
22 oxidation), while most Cr(VI) compounds are readily soluble in water and highly mobile and
23 bioavailable ([Fendorf et al., 2000](#); [Fendorf, 1995](#)). In addition to being stabilized by low solubility
24 and mobility, Cr(III) compounds are more thermodynamically stable than Cr(VI) compounds under
25 most pH values encountered in the environment ([Fendorf, 1995](#)). And therefore, the predominant
26 direction of chromium transformation in the environment is Cr(VI) → Cr(III). See Figure 1-1.




Figure 1-1. Sources of Cr(VI) in soil and groundwater. Adapted from [Hausladen et al. \(2018\)](#).

1 **1.1.3.2. Water**

2 The EPA Toxics Release Inventory (TRI) estimates approximately 66,000 pounds of
 3 chromium and chromium compounds were released to the environment via surface water
 4 discharges, and 315,000 pounds were discharged for wastewater treatment in 2019 ([U.S. EPA,](#)
 5 [2018](#)). Data from USEPA’s Discharge Monitoring Report (DMR) estimates that approximately
 6 90,000 pounds of Cr(VI) was discharged in 2020 ([U.S. EPA, 2014a](#)). Most chromium released into
 7 water from anthropogenic sources is ultimately deposited in sediment. Chromium in the aqueous
 8 phase is mostly present as soluble Cr(VI) or as soluble Cr(III) complexes. Reduction of Cr(VI) to
 9 Cr(III) can occur in the presence of reducing agents (e.g., organic matter, hydrogen sulfide, sulfur,
 10 iron sulfide, ammonium, nitrate). The reduction half-life of Cr(VI) in water can be rapid (ranging
 11 from instantaneously to a few days) when reducing agents are present under anaerobic conditions
 12 but can extend from 4–140 days in water with soil and organic sediment ([Saleh et al., 1989](#)).
 13 Oxidation of Cr(III) to Cr(VI) can also occur within aquifers and water treatment systems ([Chebeir](#)
 14 [and Liu, 2016](#); [U.S. EPA, 1986a](#)). The ratio of Cr(VI) to Cr(III) has been measured to be higher in
 15 groundwater than in surface water ([Frey et al., 2004](#)). Oxidizing conditions within soil, as well as
 16 the natural Cr(VI) content of soil and rocks, also affect Cr(VI) content of water ([Vengosh et al.,](#)
 17 [2016](#)). Above-average groundwater levels of Cr(VI) have been reported in several areas in the
 18 Western US ([U.S. EPA, 2014d](#)).

19 **1.1.3.3. Air**

20 Approximately 222,840 pounds of chromium and chromium compounds were released
 21 from fugitive and point sources into air from reporting facilities in 2020 ([U.S. EPA, 2021c](#)). Based on
 22 data from the 2017 EPA National Emissions Inventory (NEI), approximately 64,208 pounds of
 23 Cr(VI), 1,392 pounds of chromic (VI) acid, 86 pounds of Chromium (VI) Trioxide, and 373,891
 24 pounds of chromium (III) were released into the air nationwide ([U.S. EPA, 2021b](#)). The NEI includes

1 additional emissions sources not reported under TRI (i.e., mobile sources). Atmospheric chromium
 2 particles resulting from industrial emissions have been reported to have a mass mean aerodynamic
 3 diameter (MMAD) of less than 10 µm, were found to remain airborne for 7–10 days, and were
 4 subject to long-range transport ([Kimbrough et al., 1999](#)). Atmospheric particulate matter is
 5 deposited on land and water via wet and dry deposition, and metals may deposit at a higher rate in
 6 urban areas relative to rural and remote locations ([Schroeder et al., 1987](#)). Transport of chromium
 7 from water to the atmosphere is possible via transport in windblown seasalt sprays ([Nriagu, 1989](#)).
 8 Major atmospheric chromium emissions from anthropogenic sources in the United States are
 9 outlined in Table 1-2.

Table 1-2. Major anthropogenic sources of atmospheric chromium in the United States [adapted from [ATSDR \(2012\)](#)]

Industrial processes and production	Cooling towers
Combustion of coal and oil	Utility industry cooling towers
Ferrochromium production	Chemical manufacturing cooling towers
Chromium chemical manufacturing	Petroleum refining cooling towers
Chrome plating	Glass manufacturing cooling towers
Chrome ore refining	Primary metal cooling towers
Refractory production	Comfort cooling towers
Cement production	Textile manufacturing cooling towers
Specialty/steel production	Tobacco cooling towers
Sewage sludge incineration	Tire and rubber cooling towers
Municipal refuse incineration	

Data of annual Cr(VI) emissions in the US can be obtained from the EPA National Emissions Inventory ([U.S. EPA, 2016a](#)).

10 Depending on the emission source, different forms of Cr(VI) may be emitted (i.e., Cr(VI) acid
 11 mists/dissolved aerosols, and Cr(VI) dusts). While information is limited regarding
 12 non-occupational inhalation exposures to chromic acid mists for the general U.S. population,
 13 residents of fence-line communities may be exposed to multiple forms of Cr(VI) ([OAQPS, 2012](#)).
 14 Chrome-plating facilities and private residencies may exist in close proximity in mixed land use
 15 communities ([CARB, 2004](#); [CalEPA, 2003](#)). Chromium trioxide (CrO₃) is the acidic anhydride of
 16 chromic acid (H₂CrO₄). Chromic acid in mists or vapors dehydrates to CrO₃ upon evaporation, and
 17 some CrO₃ may convert to H₂CrO₄ in moist environments (including the respiratory tract).

1.1.4. Environmental Occurrence

18 The mean soil concentration of total chromium in the United States is approximately 36
 19 mg/kg ([Smith et al., 2013](#)), and the ratio of Cr(VI) to Cr(III) depends on several factors (such as soil
 20 pH). Nationwide data for speciated chromium are unavailable, although some site-specific soil
 21 concentrations of Cr(VI) have been reported. For example, soil Cr(VI) concentrations in Montana
 22 were mostly below the limit of detection of 0.29 mg/kg ([Hydrometrics, 2013](#)). Cr(VI)
 23 concentrations near industrial facilities in Portland, Oregon were typically below 1 mg/kg but were

1 measured as high as 3 mg/kg ([Oregon DEQ, 2016a, c](#)). Bioaccumulation of Cr(VI) or Cr(III) from
2 soil to above ground plants, or biomagnification of chromium in terrestrial or aquatic food chains, is
3 not expected to occur ([ATSDR, 2012](#)).

4 Public water system data from EPA's Third Unregulated Contaminant Monitoring Rule
5 (UCMR3)³, includes both groundwater and surface water sources ([U.S. EPA, 2014d](#)). Mean Cr(VI)
6 concentrations in public water systems averaged approximately 0.48 µg/L for large systems ([U.S.
7 EPA, 2014d](#)). There was wide variability by region (Figure 1-2), and a maximum concentration of
8 97.4 µg/L.

9 Ambient air concentrations of Cr(VI) in the United States typically range from 0.01 to 0.05
10 ng/m³ ([U.S. EPA, 2016c](#))⁴, but have been measured at values above 1 ng/m³ for urban and
11 industrial areas ([Oregon DEQ, 2016b](#); [Huang et al., 2014](#)). Historically, Cr(VI) concentrations
12 measured in ambient air downwind of industrial facilities emitting Cr(VI) (such as chrome platers)
13 have been found to be highly correlated with concentrations measured at the facilities ([SCAQMD,
14 2016](#)). Between May 2001–May 2002, residential air near chrome-plating facilities in San Diego, CA
15 were measured up to 22.0 ng/m³ Cr(VI) ([CalEPA, 2004, 2003](#)).

³Cr(VI) was among 30 contaminants selected for monitoring at public water systems (PWS) for the Third Unregulated Contaminant Monitoring Rule (UCMR3) between 2013 and 2015. A PWS is a network of pipes and conveyances constructed to provide water for human consumption ([U.S. EPA, 2006a, b](#)). Small systems, serving 10,000 or fewer people, account for more than 97% of the total number of PWSs, while large systems, serving more than 10,000 people, account for the remaining 3% ([U.S. EPA, 2006a, b](#)). A majority of the U.S. population is served by large PWSs (nearly 90% ([U.S. EPA, 2006a, b](#))), and all of them (approximately 4,200) were tested under UCMR3. For small water systems, approximately 800 systems were randomly selected and used as a representative sample ([U.S. EPA, 2012c](#)). Small water systems were omitted from analyses presented in this section. Cr(VI) was selected for the UCMR3 cycle, and was not selected for monitoring for the UCMR4 or UCMR5 cycles.

⁴See also: <https://cfpub.epa.gov/roe/indicator.cfm?i=90#7>, containing 2008-2014 data from 14 sites across the United States.




Figure 1-2. Drinking water chromium (VI) concentrations in the United States by EPA region.⁵ Boxplots are based on the average values of samples of large public water systems within the region, from EPA’s Third Unregulated Contaminant Monitoring Rule (UCMR3) ([U.S. EPA, 2014d](#)). Boxes represent interquartile ranges. Whiskers are 1.5x the interquartile range away from the 25th/75th percentiles.

1.1.5. Potential for Human Exposure

1 1.1.5.1. General Population

2 General population exposures to Cr(VI) occur via inhalation of ambient air, ingestion of
 3 water or food, and non-dietary ingestion of soil or dust. Most human exposure to total chromium

⁵Region 1 - CT, ME, MA, NH, RI, and VT

Region 2 - NJ, NY, Puerto Rico, and the U.S. Virgin Islands

Region 3 - DE, DC, MD, PA, VA, WV and 7 federally recognized tribes

Region 4 - AL, FL, GA, KY, MS, NC, SC, and TN

Region 5 - IL, IN, MI, MN, OH, and WI

Region 6 - AR, LA, NM, OK, and TX

Region 7 - IA, KS, MO, and NE

Region 8 - CO, MT, ND, SD, UT, and WY

Region 9 - AZ, CA, HI, NV, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands, and Republic of Palau

Region 10 - AK, ID, OR, WA and 271 native tribes.

1 (sum of Cr(VI) and Cr(III)) is from dietary intake of Cr(III) that is naturally present in foods
2 ([Wisconsin DHS, 2010](#)). Cr(III) is generally understood to be essential to normal glucose, protein,
3 and fat metabolism and is thus an element with an Adequate Intake (AI)⁶ values ([IOM, 2011](#)),
4 although no Recommended Daily Allowance (RDA) has been established due to insufficient
5 evidence to establish a level of Cr(III) that is necessary for human health ([NIH, 2017](#); [Vincent, 2017](#);
6 [Vincent, 2013](#); [Stearns, 2000](#)). Dermal exposure may also occur during the use of consumer
7 products that contain chromium, such as some metals or leather treated with chromium-containing
8 compounds ([ATSDR, 2012](#); [NTP, 2011](#)).

9 Quantifying the non-dietary exposure to Cr(VI) via soil ingestion (hand-to-mouth contact
10 and pica behavior in children) is uncertain due to limited data on chromium speciation in soil. As
11 noted earlier, the Cr(VI)/Cr(III) concentration ratio in soil can vary due to factors such as soil pH
12 and mineral content, and no nationwide data on soil Cr(VI) currently exist. EPA's Office of Pesticide
13 Programs (OPP), in its reregistration eligibility decision (RED) for chromated copper arsenate
14 (CCA) pesticides ([U.S. EPA, 2008](#)), determined that dietary, residential, or other non-occupational
15 exposures to Cr(VI) was not expected to occur from wood preservative uses of chromated
16 arsenicals.

17 Dietary exposure to Cr(VI) via food ingestion is uncertain due to limited data on speciation
18 in food. Typical total chromium (sum of Cr(VI) and Cr(III)) levels in most foods have been reported
19 to range from <10 to 1,300 µg/kg, with the highest concentrations being found in meat, fish, fruits,
20 and vegetables ([WHO, 2003](#)). Dietary total chromium intake in the general U.S. population has been
21 estimated to range from 0.293–0.867 µg/kg-day ([ATSDR, 2012](#); [Moschandreas et al., 2002](#)). It is
22 possible that a fraction of this intake is in the form of Cr(VI) ([Hamilton et al., 2018](#)). [Mathebula et](#)
23 [al. \(2017\)](#) found that 33–73% of total chromium in bread may exist as Cr(VI) (at concentrations
24 between 19–64 µg/kg), and that oxidation of Cr(III) to Cr(VI) can occur from toasting. That study
25 also detected Cr(VI) in breakfast cereals at concentrations between 41–470 µg/kg. [Soares et al.](#)
26 [\(2010\)](#) estimated that 12% of total chromium in bread was hexavalent. However, nationwide data
27 for Cr(VI) content in food is limited. It is assumed that (total) chromium exposure to infants via
28 breastmilk is low ([EFSA CONTAM Panel, 2014](#)); however, no studies investigating levels of
29 speciated Cr(VI) in human milk were identified.

30 According to data collected between 2013 and 2015 under EPA's Third Unregulated
31 Contaminant Monitoring Rule (UCMR3), Cr(VI) has been reported above the minimum reporting
32 limit (0.03 µg/L) in approximately 90% of public water systems in the United States ([U.S. EPA,](#)
33 [2014d](#)). More detailed concentration data for Cr(VI) in large U.S. water systems are provided in
34 Section 1.1.4 (above) and in Appendix C.4. Based on this information, drinking water is expected to
35 be a significant source of exposure for the general population.

36 The general population may be exposed to Cr(VI) in air but will likely receive a lower
37 inhaled dose when compared to the oral ingestion pathway. A 70 kg individual drinking 2L/day

⁶Adequate intakes of chromium for adult males and females are 35 µg/day and 25 µg/day, respectively.

1 water containing 0.5 µg/L Cr(VI) will ingest a dose of 1.4×10^{-5} mg/kg-d Cr(VI). A 70 kg individual
2 with a respiratory rate of 20 m³/day inhaling air containing 4×10^{-5} µg/m³ Cr(VI) will inhale Cr(VI)
3 at a body weight-normalized rate of 1.1×10^{-8} mg/kg-d. Both air and water concentrations may
4 vary from the approximate mean values by a factor of 100 in extreme cases (see Appendix C.4).
5 Only in extreme cases is it possible for the inhaled dose to be comparable to the ingested dose for
6 people living in an area with low Cr(VI) in water and high Cr(VI) in air.

7 Inhalation of Cr(VI) in water droplets during showering can also occur. Since Cr(VI) cannot
8 volatilize, and because Cr(VI) compounds are typically water soluble, the metal will exist only in
9 water droplets and aerosols. An analysis of this exposure pathway was performed by California
10 EPA, and determined that a 70-kg adult breathing 20 m³ of air per day, taking a 10-minute shower
11 would inhale 27 mg of liquid water per shower (3.86×10^{-7} L/kg-d) ([CalEPA, 2011](#)). Assuming
12 water contains 0.5 µg/L Cr(VI) yields an inhaled dose of 1.9×10^{-10} mg/kg-d, which is five orders of
13 magnitude lower than the dose resulting from 2 L/day water ingestion at the same Cr(VI)
14 concentration (1.4×10^{-5} mg/kg-d).

15 Humans may be exposed via inhalation and incidental ingestion of house dust. A study of
16 house dust in areas with no known soil contamination by Cr(VI) in New Jersey measured a mean
17 Cr(VI) surface loading of 10 µg/m² (maximum of 169.3 µg/m²), and mean Cr(VI) concentration of
18 4.6 µg/g (maximum of 56.6 µg/g) ([Stern et al., 2010](#)). Nationwide data of Cr(VI) in house dust are
19 unavailable.

20 **1.1.5.2. Occupational Exposure**

21 Occupational exposures to Cr(VI) occur primarily via inhalation or dermal contact ([NIOSH,](#)
22 [2013](#)) and typically exceed non-occupational exposures ([NTP, 2011](#)). Workers can potentially
23 inhale Cr(VI) during its processing or manufacture and when working with mixtures containing the
24 chemical or chemical precursors. Dermal exposures may potentially result from the splashing or
25 spilling of chromium-containing materials that contact the skin or from contact with construction
26 materials containing Portland cement (due to a Cr(VI) impurity) ([NIOSH, 2013](#)). Portal-of-entry
27 sites may be exposed via hand-to-mouth contact and hand-to-nose contact ([OSHA, 2006](#)), and the
28 extent of these transfers depends on the industry, exposure matrix, and workplace hygiene
29 practices ([Cohen et al., 1974](#)). Industries that may have workers who are in contact with Cr(VI)-
30 containing materials include stainless-steel welding, painting, electroplating, steel mill, iron and
31 steel foundries, wood preserving, and occupations that produce paints, coatings, inks, plastic
32 colorants, chromium catalyst, and other chemicals (such as chromium dioxide and chromium
33 sulfate) ([NIOSH, 2013](#)). Other industries with limited potential exposures to Cr(VI) compounds
34 include textile dyeing, glass production, printing, leather tanning, brick production, woodworking,
35 solid waste incineration, oil and gas well drilling, construction and Portland cement production
36 ([NIOSH, 2013](#); [NTP, 2011](#)). EPA's OPP, in its RED for CCA pesticides ([U.S. EPA, 2008](#)), determined
37 that inhalation exposure to chromium may occur from these pesticide components in occupational
38 settings. Because exposure to Cr(VI) outside of the workplace is possible via contaminated

1 clothing, [OSHA \(2006\)](#) implemented workplace rules to ensure that clothing contaminated with
 2 Cr(VI) is not carried to employees’ cars and homes (which would expose both the workers and
 3 other individuals). Table 1-3 provides a list of industries that are potential sources of chromium
 4 exposure.

Table 1-3. Industries and occupations that may be sources of chromium exposure

Group 1: Industry sectors where majority of occupational exposures occur to hexavalent chromium	Group 2: Industry sectors with limited potential for occupational exposure to hexavalent chromium
Electroplating Welding Painting Producers of Chromates and Related Chemicals from Chromite Ore Chromate Pigment Production Chromated Copper Arsenate Producers Chromium Catalyst Production Paint and Coatings Production Printing Ink Producers Plastic Colorant Producers and Users Plating Mixture Production Wood Preserving Chromium Metal Production Steel Mills Iron and Steel Foundries	Chromium Dioxide Producers Chromium Dye Producers Chromium Sulfate Producers Chemical Distributors Textile Dyeing Producers of Colored Glass Printing Leather Tanning Chromium Catalyst Users Producers of Refractory Brick Woodworking Solid Waste Incineration Oil and Gas Well Drilling Portland Cement Producers Non-Ferrous Superalloy Producers and Uses Construction Producers of Pre-Case Concrete Products

Source: Analysis performed by OSHA ([Shaw Environmental, 2006](#)).

1.2. SUMMARY OF ASSESSMENT METHODS

5 The systematic review and dose-response methods used to conduct this assessment are
 6 summarized in the remainder of this section. A detailed description of these methods is provided in
 7 the preliminary materials released in 2014 ([U.S. EPA, 2014b, c](#)) and in the Systematic Review
 8 Protocol for Cr(VI), released in 2019 ([U.S. EPA, 2019](#)), which has been updated to reflect
 9 refinements made to the protocol during the assessment process. A link to the updated protocol
 10 can be found in the Supplementary Materials released with this Toxicological Review in Appendix
 11 A.

1.2.1. Literature Search and Screening

12 Literature search strategies were developed using key terms and words related to the PECO
 13 criteria and potentially relevant supplemental material. Relevant subject headings and text-words
 14 were crafted into a search strategy that was designed to maximize the sensitivity and specificity of
 15 the search results. The search strategy was run, and the results were assessed to ensure that all

1 previously identified relevant primary studies were retrieved in the search. Because each database
2 has its own search architecture, the resulting search strategy was tailored to account for the unique
3 search functionality of each database.

4 The following databases were searched:

- 5 • [PubMed](#) (National Library of Medicine)
- 6 • [Web of Science](#) (Thomson Reuters)
- 7 • [Toxline](#) (National Library of Medicine)⁷

8 Searches were not restricted by publication date, and no language restrictions were applied.
9 Web of Science results were limited using the research areas filter. All Web of Science research
10 areas identified in the search results were prioritized by a technical advisor as high priority
11 (e.g., toxicology), low priority (e.g., chemistry), and not relevant (e.g., forestry). Literature searches
12 were conducted in bibliographic databases as described in Appendix B and uploaded to EPA's
13 Health and Environmental Research Online (HERO) database.⁸

14 Additional relevant literature not found through database searching was sought by:

- 15 • Manually searching citations from review articles and studies considered to meet PECO
16 criteria after screening (“included” studies).
- 17 • Searches of gray literature, including primary studies that are not indexed in databases of
18 peer-reviewed literature (e.g., technical reports from government agencies or scientific
19 research groups; unpublished laboratory studies conducted by industry; working papers
20 from research groups or committees; and white papers), or other nontypical searches. Gray
21 literature is typically identified by searching the EPA Chemical Dashboard
22 (<https://comptox.epa.gov/dashboard>) during problem formulation, by engaging with
23 technical experts, and during solicitation of Agency, interagency, and public comment at
24 multiple steps in the IRIS process.
- 25 • “Backward” searches (to identify articles cited by included studies, reviews, or prior
26 assessments by other agencies).

27 The results returned (i.e., the number of “hits” from each electronic database or other
28 literature source), including the results of any literature search updates, are documented in the
29 literature flow diagrams, which also reflect the literature screening decisions (see Section 2.1).

30 The IRIS Program takes extra steps to ensure identification of pertinent studies by
31 (1) encouraging the scientific community and the public to identify additional studies and ongoing
32 research; (2) searching for publicly available data submitted under the Toxic Substances Control
33 Act and the Federal Insecticide, Fungicide, and Rodenticide Act; and (3) considering late-breaking

⁷TOXLINE was phased out in December 2019 and integrated into other NLM resources.

⁸Health and Environmental Research Online: <https://hero.epa.gov/hero/>.

1 studies that would impact the credibility of the conclusions, even during the review process.
2 Studies identified after peer review begins will only be considered for inclusion if they meet the
3 PECO criteria and may fundamentally alter the assessment's conclusions.

1.2.2. Evaluation of Individual Studies

4 The detailed approaches used for the evaluation of epidemiologic and animal toxicology
5 studies used in the Cr(VI) assessment are provided in the protocol (Appendix A). The general
6 approach for evaluating health effect studies meeting PECO criteria is the same for epidemiology
7 and animal toxicology studies although the specifics of applying the approach differ; thus, they are
8 described in detail in protocol Sections 6.2 and 6.3, respectively, in Appendix A.

- 9 • The key concerns for the review of epidemiology and animal toxicology studies are
10 potential bias (factors that affect the magnitude or direction of an effect in either direction)
11 and insensitivity (factors that limit the ability of a study to detect a true effect; low
12 sensitivity is a bias towards the null when an effect exists). In terms of the process for
13 evaluating individual studies, two or more reviewers independently arrive at judgments
14 regarding the reliability of the study results (reflected as study confidence determinations;
15 see below) with regard to each outcome or outcome grouping of interest; thus, different
16 judgments are possible for different outcomes within the same study. The results of these
17 reviews are tracked within EPA's version of the Health Assessment Workplace
18 Collaboration ([HAWC](#)).
- 19 • To develop these judgments, each reviewer assigns a category of *good*, *adequate*, *deficient*
20 (or *not reported*, which generally carries the same functional interpretation as *deficient*), or
21 *critically deficient* (listed from best to worst methodological conduct; see Section 6.1 of the
22 protocol in Appendix A for definitions) to each evaluation domain representing the different
23 characteristics of the study methods that were evaluated based on the criteria outlined in
24 HAWC. Reviewers assigning categories to each domain are guided by core and prompting
25 questions as well as additional considerations specific to Cr(VI) or the outcome of interest.
26 Exposure-specific considerations in epidemiology studies are described in Section 6.2.
27 Briefly, air concentration measurements were preferred to biomarker measurements.
28 Studies in which human exposure was quantified by measurements of total chromium in
29 urine, blood, plasma, or erythrocytes were considered for determination of hazard only if
30 conducted in workers with known occupational exposure to Cr(VI).

31 Once all evaluation domains were evaluated, the identified strengths and limitations are
32 considered as a whole by the reviewers in order to reach a final study confidence classification:

- 33 • *High* confidence: No notable deficiencies or concerns were identified; the potential for bias
34 is unlikely or minimal, and the study used sensitive methodology.
- 35 • *Medium* confidence: Possible deficiencies or concerns were noted, but the limitations are
36 unlikely to be of a notable degree or to have a notable impact on the results.
- 37 • *Low* confidence: Deficiencies or concerns were noted, and the potential for bias or
38 inadequate sensitivity could have a significant impact on the study results or their

1 interpretation. *Low* confidence results were given less weight compared to *high* or *medium*
2 confidence results during evidence synthesis and integration (see Sections 1.2.4 and 1.2.5).

- 3 • *Uninformative*: Serious flaw(s) were identified that make the study results unusable.
4 *Uninformative* studies were not considered further, except to highlight possible research
5 gaps.

6 Using the HAWC platform (and conflict resolution by an additional reviewer, as needed), the
7 reviewers reached a consensus judgment regarding each evaluation domain and overall
8 (confidence) determination. The specific limitations identified during study evaluation were
9 carried forward to help inform the synthesis (Section 1.2.4) within each body of evidence for a
10 given health effect along with other considerations. Additional details regarding study evaluation
11 are provided in Sections 6.1–6.5 of the protocol (Appendix A).

1.2.3. Data Extraction

12 The detailed data extraction approach is provided in Section 8 and Appendix B of the
13 protocol (Appendix A). Animal data extraction and content management were carried out using
14 HAWC, while data extracted from epidemiology studies were summarized in tabular format in the
15 assessment and appendices. Studies evaluated as being *uninformative* were not considered further
16 and study details are not summarized. In addition, study details and results for outcomes not
17 prioritized during PECO refinement (e.g., kidney and neurological) were not extracted or were only
18 partially extracted (Appendix A). The same was typically true for *low* confidence studies where a
19 number of *medium* and *high* confidence studies were available, unless the *low* confidence studies
20 included study designs lacking in the higher confidence studies (e.g., testing lower exposure levels,
21 or susceptible populations or life stages). The level of extraction for specific outcomes within a
22 study may differ (i.e., ranging from a narrative to full extraction of dose-response effect size
23 information). Data extraction was performed by one member of the evaluation team and checked
24 by at least one other member.

25 For animal data already extracted to evidence tables released in 2014 ([U.S. EPA, 2014b](#)),
26 data extraction procedures depended on data type (e.g., dichotomous, continuous, or qualitative).
27 For human data already extracted to evidence tables released in 2014 ([U.S. EPA, 2014c](#)), data
28 extraction procedures depended on the study evaluation judgment and the study design. Large-
29 scale epidemiological datasets, which are typically stored in databases and under the custody of
30 scientific researchers or institutions, were not extracted or uploaded into HAWC. A detailed
31 discussion of the methods used for data extraction are provided in Section 8 of the protocol
32 (Appendix A). Extracted data are available in [HAWC](#) and are also summarized in tabular or
33 graphical form in the hazard identification and dose-response sections.

1.2.4. Evidence Synthesis and Integration

1 For the purposes of this assessment, evidence synthesis and integration are considered
2 distinct but related processes (see Protocol Sections 9 and 10, Appendix A for full details). For each
3 assessed health effect, the evidence syntheses provide a summary discussion of each body of
4 evidence considered in the review that directly informs the integration across evidence to draw an
5 overall judgment for each health effect. The available human and animal evidence pertaining to the
6 potential health effects are synthesized separately, with each synthesis providing a summary
7 discussion of the available evidence that addresses considerations regarding causation that are
8 adapted from [Hill \(1965\)](#). Mechanistic evidence and other supplemental information is also
9 synthesized to address key science issues and/or to help inform key decisions regarding the human
10 and animal evidence.

11 The syntheses focus on describing aspects of the evidence that best inform causal
12 interpretations, including the exposure context examined in the sets of available studies. The
13 human and animal health effects evidence syntheses are based primarily on studies of *high* and
14 *medium* confidence. *Low* confidence studies may be used if few or no studies with higher
15 confidence are available to help evaluate consistency, or if the study designs of the *low* confidence
16 studies address notable uncertainties in the set of *high* or *medium* confidence studies on a given
17 health effect. If *low* confidence studies are used, then a careful examination of risk of bias and
18 sensitivity with potential impacts on the evidence synthesis conclusions is included in the narrative.
19 The synthesis of mechanistic evidence and other supplemental information informs the integration
20 of health effects evidence for both hazard identification (i.e., biological plausibility of the available
21 human or animal evidence; inferences regarding human relevance, or the identification of
22 susceptible populations and life stages across the human and animal evidence) and dose-response
23 evaluation.

24 For each assessed health effect, following the evidence syntheses, integrated judgments are
25 drawn across all lines of evidence. During evidence integration, a structured and documented
26 process was used, as follows:

- 27 • Building from the separate syntheses of the human and animal evidence, the strength of the
28 evidence from the available human and animal health effect studies was summarized in
29 parallel, but separately, using a structured evaluation of an adapted set of considerations
30 first introduced by Bradford Hill ([Hill, 1965](#)). These summaries incorporate the relevant
31 mechanistic evidence (or MOA understanding) that informs the biological plausibility and
32 coherence within the available human or animal health effect studies.
- 33 • The strength of the animal and human evidence was considered together in light of
34 inferences across evidence streams. Specifically, the inferences considered during this
35 integration include the human relevance of the animal and mechanistic evidence, coherence
36 across the separate bodies of evidence, and other important information (e.g., judgments
37 regarding susceptibility). Note that without evidence to the contrary, the human relevance
38 of animal findings is assumed.

- 1 • A summary judgment is drawn as to whether the available evidence base for each potential
 2 human health effect as a whole provides sufficient evidence to indicate that Cr(VI) exposure
 3 has the potential to cause the health effect in humans; insufficient evidence to assess
 4 whether Cr(VI) exposure has the potential to cause the health effect in humans; or, in rare
 5 instances, sufficient evidence that a hazard is unlikely.

6 The decision points within the structured evidence integration process are summarized in
 7 an evidence profile table for each assessed health effect.

8 The primary focus of this assessment is on the following potential target systems:
 9 respiratory, gastrointestinal (GI) tract, hepatic, hematologic, immunological, reproductive, and
 10 developmental. It is acknowledged that there is evidence for other health effects not assessed here,
 11 including renal and neurological toxicity, which can be induced by toxic metals in general
 12 ([Nordberg et al., 2015](#)). Kidney effects are known to occur following acute exposures to high doses
 13 or concentrations of Cr(VI) ([ATSDR, 2012](#)), but these effects are not observed following chronic,
 14 low-dose exposure. Neurotoxicity associated with Cr(VI) exposure has recently been reviewed by
 15 [Wise et al. \(2022\)](#); however, the evidence base is still relatively small and more research is needed
 16 in this area. Many studies of chromium and neurotoxicity would not meet PECO criteria due to lack
 17 of exposure information (e.g., studies of unspicated chromium in organs and tissues of humans
 18 would be excluded) or focus on non-PECO chromium compounds (e.g., lead chromate). In addition,
 19 some endpoints would be difficult to dissociate from one another (e.g., impaired olfactory function
 20 and nasal effects).

21 For cancer and nasal irritation via the inhalation route, the systematic review will focus on
 22 data that may improve the quantitative dose-response analysis, conducted in EPA’s 1998 IRIS
 23 assessment, for these outcomes. Outlines of the major endpoints assessed within each health effect
 24 domain are listed below in Table 1-4.

Table 1-4. Endpoint grouping categories

Relevant human health effect category ^a	Endpoints included ^b	Notes
General toxicity	<ul style="list-style-type: none"> • Body weight (not maternal or pup weights, or weights after developmental-only exposure) • Mortality, survival, or LD₅₀s • Growth curve • Clinical observations (non-behavioral) 	<ul style="list-style-type: none"> • Clinical chemistry endpoints are under hepatic or hematologic effects • Maternal or pup body-weight endpoints are under developmental effects • Pathology (including gross lesions) is organ specific

Toxicological Review of Hexavalent Chromium

Relevant human health effect category ^a	Endpoints included ^b	Notes
Hepatic effects	<ul style="list-style-type: none"> • Liver weight and histopathology (e.g., chronic inflammation, hyperplasia) • Serum or tissue liver enzymes (e.g., clinical chemistry measures such as ALT, ALP, and AST)* • Other liver tissue biochemical markers (e.g., albumin; glycogen; glucose)* • Liver-specific serum biochemistry (e.g., albumin; albumin/globulin)* • Liver tissue lipids: triglycerides, cholesterol • Serum lipids 	<ul style="list-style-type: none"> • Other liver tissue enzyme activity (e.g., catalase) or protein/DNA content are considered under mechanistic evidence for hepatic effects
Hematologic effects	<ul style="list-style-type: none"> • Red blood cells* • Blood hematocrit or hemoglobin* • Cell volume* • Blood platelets or reticulocytes* 	<ul style="list-style-type: none"> • White blood cell count and globulin are under immune effects • Serum liver markers are under hepatic effects
Immune effects	<ul style="list-style-type: none"> • Thymus weight and histopathology • Host resistance • General immune assays (e.g., white blood cell counts, immunological factors or cytokines in blood, lymphocyte phenotyping or proliferation)* • Any measure in lymphoid tissues (weight; histopathology; cell counts; etc.) • Immune cell counts or immune-specific cytokines in non-lymphoid tissues • Other immune functional assays (e.g., natural killer cell activity, mixed lymphocyte response, phagocytosis or bacterial killing by monocytes) • Immune responses in the respiratory system 	<ul style="list-style-type: none"> • Red blood cells are under hematologic effects • Immune responses in the respiratory tract (such as phagocytosis, cytokine signaling, inflammatory responses) are also under respiratory effects • Endpoints related to Cr(VI)-induced allergic hypersensitivity were considered under mechanistic evidence for immune effects
Male Reproductive effects	<ul style="list-style-type: none"> • Reproductive organ weight and histopathology • Markers of sexual differentiation or maturation (e.g., preputial separation) • Mating parameters (e.g., success, mount latency) • Reproductive hormones* 	<ul style="list-style-type: none"> • Birth parameters (e.g., litter size; resorptions, implantations, viability) are under developmental effects • If data indicate altered birth parameters are likely attributable to

Toxicological Review of Hexavalent Chromium

Relevant human health effect category ^a	Endpoints included ^b	Notes
	<ul style="list-style-type: none"> Sperm and semen parameters* 	female fertility, these data may be discussed under female reproductive effects
Female Reproductive effects	<ul style="list-style-type: none"> Reproductive organ weight and histopathology Markers of sexual differentiation or maturation (e.g., vaginal opening or estrous cycling) Birth parameters, if attributable to female fertility Reproductive hormones* 	<ul style="list-style-type: none"> Birth parameters (e.g., litter size; resorptions, implantations, viability) are under developmental effects
Developmental effects	<ul style="list-style-type: none"> Dam health (e.g., weight gain, food consumption) Pup viability/survival or other birth parameters (e.g., number of pups per litter) Pup weight or growth (includes measures into adulthood after developmental-only exposure) Developmental landmarks (eye opening, etc., but not including markers for other organ/system-specific toxicities) Pregnancy outcomes (e.g., spontaneous abortion, early pregnancy loss, pregnancy complications, infant health, congenital malformations/anomalies) [human only] 	<ul style="list-style-type: none"> Histopathology and markers of development specific to other systems are organ/system-specific (e.g., vaginal opening is under female reproductive effects; offspring liver weight is under hepatic effects)
Lower respiratory effects Note: Systematic review of evidence for nasal irritation via the inhalation route will focus on data for quantitative dose-response analysis.	<ul style="list-style-type: none"> Lung weight and histopathology Biochemical markers of cell injury (e.g., total protein, albumin, and lactate dehydrogenase activity in bronchioalveolar lavage fluid) Cellular responses (e.g., number of macrophages, neutrophils/granulocytes, and lymphocytes) Pulmonary function (e.g., FVC, FEV1.0, DLCO) [human only] 	<ul style="list-style-type: none"> Immune responses in the respiratory tract (such as phagocytosis, cytokine signaling, inflammatory responses) are also under immune effects
Gastrointestinal tract effects	<ul style="list-style-type: none"> Histopathology (e.g., chronic inflammation, hyperplasia, ulceration) 	<ul style="list-style-type: none"> Endpoints related to precancerous lesions are also considered under carcinogenicity

Relevant human health effect category ^a	Endpoints included ^b	Notes
Carcinogenicity Note: Systematic review of evidence for cancer via the inhalation route will focus on data for quantitative dose-response analysis.	<ul style="list-style-type: none"> • Tumors • Precancerous lesions (e.g., dysplasia) 	

ALT = alanine aminotransferase; AST = aspartate transaminase; DNA = deoxyribonucleic acid; LD₅₀ = median lethal dose; FVC: forced vital capacity; FEV1.0: forced expiratory volume in first second; DLCO: the ratio of FEV1.0/FVC, and diffusing capacity of lung for carbon monoxide.

^aHealth effect-relevant endpoints observed after developmental exposure will be discussed primarily in the health effect category indicated and then referenced in developmental effects.

^bEndpoints refer to animal data unless otherwise noted. An asterisk (*) indicates endpoints that are also measured in humans. Endpoints that are *only* measured in humans are noted by descriptive text. Some endpoints are relevant to multiple health effects. These endpoints may be categorized under only a single health effect for clarity. However, in the assessment, such outcome data may be discussed in each relevant health effect synthesis, with cross-referencing to the synthesis containing most of the evidence. The evidence (for or against an effect) will contribute to evidence integration decisions for all relevant health effects.

1.2.5. Dose-Response Analysis

1 Dose-response analysis to support derivation of toxicity values for Cr(VI) were performed
 2 consistent with EPA guidelines and support documents, especially EPA’s *Benchmark Dose Technical*
 3 *Guidance* ([U.S. EPA, 2012b](#)), EPA’s *Review of the Reference Dose and Reference Concentration*
 4 *Processes* ([U.S. EPA, 2002](#)), *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)), and
 5 *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA,](#)
 6 [2005b](#)). Section 11 of the Protocol (Appendix A) describes the general approach to dose-response
 7 analysis used in this assessment.

8 This assessment includes development of a reference dose (RfD), a reference concentration
 9 (RfC), an inhalation unit risk (IUR), and an oral slope factor (OSF). From among the body of
 10 evidence used for the hazard identification assessment, selection of the studies for dose-response
 11 assessment used information from the study confidence evaluations, with particular emphasis on
 12 conclusions regarding the characteristics of the study population, the accuracy of the exposure
 13 estimates for epidemiology studies or dosing methods for toxicology studies, the severity of the
 14 observed effects, and the exposure levels analyzed (see Table 11-1 in [U.S. EPA \(2020b\)](#)).

15 When suitable data are available, as described in [U.S. EPA \(2020b\)](#), toxicity values should
 16 always be developed for evidence integration conclusions of **evidence demonstrates** and
 17 **evidence indicates (likely)** as well as for carcinogenicity descriptors of **carcinogenic to humans**
 18 or **likely to be carcinogenic to humans**. In general, toxicity values would not be developed for
 19 **“evidence suggests”** for noncancer hazard or **“suggestive evidence of carcinogenic potential”**
 20 for cancer hazard conclusions, respectively.

21 Additional special considerations were made when selecting studies for dose-response for
 22 Cr(VI), and these are discussed in greater detail in Section 4:

Toxicological Review of Hexavalent Chromium

- 1 • Oral animal studies which did not include an exposed group below 20 mg/kg-d were not
2 considered for quantitative analysis⁹
- 3 • Inhalation animal studies which did not report measures of particle size and distribution
4 were not considered for quantitative analysis¹⁰.
- 5 • Human studies for nasal cavity effects which did not report clinical outcomes diagnosed by
6 a trained examiner (e.g., physician, otolaryngologist, or trained researcher) were not
7 considered for quantitative analysis. The preferred clinical outcome measures were
8 atrophy of the nasal mucosa; ulceration of the nasal mucosa or septum; perforation of the
9 septum; and bleeding nasal septum.

⁹A similar exposure consideration was not necessary for inhalation studies. Fewer animal inhalation studies were available, and concentrations were below levels that would cause severe toxicity.

¹⁰Availability of particle size distribution information for each study is provided in HAWC.

2. LITERATURE SEARCH AND STUDY EVALUATION RESULTS

2.1. LITERATURE SEARCH AND SCREENING RESULTS

1 Literature searches for studies relevant to the assessment of Cr(VI) have been conducted on
2 a yearly basis since 2013, with the most recent update current through August 2022.

3 The results of the screening process outlined in Section 4.3 of the protocol (Appendix A)
4 have been posted on the project page for this assessment in the HERO database
5 (https://hero.epa.gov/hero/index.cfm/project/page/project_id/2233), and studies have been
6 “tagged” with appropriate category descriptors (e.g., “included”, “potentially relevant supplemental
7 material,” “excluded”). Results have also been annotated and reported in a literature flow diagram
8 (see Figure 2-1). Note that because studies reporting multiple types of evidence may have more
9 than one tag, the sum of all tags in a category may be greater than the number of individual studies
10 in that category.

11 Of the 17,898 unique records undergoing title and abstract screening, 14,320 were excluded
12 because they either did not meet PECO criteria outlined in protocol Section 3.3 (Appendix A) or
13 were not determined to be potentially relevant supplemental material according to the criteria
14 outlined in protocol Section 4.3 (Appendix A). Using the sorting criteria outlined in protocol
15 Section 4.4 (Appendix A) for studies not meeting PECO criteria but still having information relevant
16 to the specific aims of the assessment, 3,933 records were identified. A total of 138 studies were
17 considered eligible for study evaluation (56 human health effects studies and 83 animal health
18 effects studies).




Figure 2-1. Literature search flow diagram for Cr(VI).

2.2. STUDY EVALUATION RESULTS

1 Human and animal studies have evaluated potential respiratory, gastrointestinal (GI) tract,
2 hepatic, hematological, immunological, reproductive, and developmental effects following exposure
3 to Cr(VI). The evidence informing these potential health effects is presented and assessed in
4 Section 3.2. Detailed rationales for each domain and overall confidence rating are available in
5 Health Assessment Workspace Collaborative ([HAWC](#)).

6 Overall confidence classifications are presented by effect in Section 3.2. Over 170 studies
7 met PECO criteria (with about an even number of human and animal studies). Many human and
8 animal studies contained information on multiple endpoints. With the exception of male
9 reproductive effects (which had some *medium* confidence human studies), all human studies
10 meeting PECO criteria that were included in the hazard identification analysis were rated *low*
11 confidence for all hazard domains. Hazard domains having strong animal databases (containing
12 *medium* and *high* confidence studies) were GI, hepatic, hematological, immune, and male and
13 female reproductive. Most animal respiratory studies were *medium* confidence, and most of the
14 animal developmental studies were rated *low* confidence.

15 For human health studies evaluated for dose-response data of nasal effects, three were
16 considered *medium* ([Gibb et al., 2000a](#); [Lindberg and Hedenstierna, 1983](#); [Cohen et al., 1974](#)), and
17 one was considered *low* confidence ([Hanslian et al., 1967](#)). For human health studies evaluated for
18 dose-response data of lung cancer, one was considered *high* confidence ([Gibb et al., 2020](#)), one was
19 considered *medium* confidence ([Proctor et al., 2016](#)), and two were considered *low* confidence ([Birk](#)
20 [et al., 2006](#); [Gerin et al., 1993](#)). No quantitative dose-response data for respiratory tract tumors
21 outside of the lung were suitable for IUR derivation. For example, studies that were identified of
22 tumors of the nasal cavity were classified as either case reports or review articles without suitable
23 dose-response data. Exclusion rationale for individual studies for lung cancer and noncancer
24 effects of the nasal cavity are provided in Appendix D.4.

25 Graphical representations focusing on outcome specific ratings are presented in the
26 organ/system-specific integration sections (Hazard Identification, Section 3.2).

3. HAZARD IDENTIFICATION

3.1. OVERVIEW OF PHARMACOKINETICS

1 A detailed review and literature inventory of the database regarding the absorption,
2 distribution, metabolism, and excretion (ADME) of Cr(VI) is available in Appendix C. This section
3 primarily focuses on Cr(VI) reduction to Cr(III) (i.e., metabolism) and localized absorption, which
4 have the greatest impact on assessment conclusions for cancer MOA, susceptibility, interspecies
5 differences and dose-response.

3.1.1. Pharmacokinetics

6 Inhaled or ingested Cr(VI) can be reduced to Cr(III) extracellularly by biological fluids
7 (e.g., blood, gastric juices and epithelial lining fluid) of humans and rodents. In the hexavalent
8 oxidation state, cellular uptake of chromium oxyanions occurs rapidly via ubiquitous nonspecific
9 sulfate and/or phosphate anion transporters due to the structural similarity of the chromate and
10 dichromate anions to these molecules (see Appendix C for more details). Once absorbed by cells,
11 intracellular reduction generates reactive intermediates Cr(V) and Cr(IV), and finally Cr(III)
12 ([Luczak et al., 2016](#)). In the trivalent oxidation state, chromium is poorly absorbed by cells via
13 passive diffusion and has been shown to induce significantly lower tissue chromium burden in
14 exposed rodents compared to Cr(VI) ([Collins et al., 2010](#)). Thus, *extracellular* reduction is believed
15 to be a pathway for detoxification because it decreases the systemic uptake and distribution of
16 Cr(VI) and reduces the exposure of epithelial cells, the first cells to interact with external factors, to
17 Cr(VI). In contrast, *intracellular* reduction of Cr(VI) is considered to be a pathway for its activation
18 following the cellular uptake of Cr(VI).

19 Due to site-specific Cr(VI) reduction differences by route of exposure, ingested Cr(VI) will
20 primarily distribute to gastrointestinal (GI) tract tissues and the liver, while inhaled Cr(VI) will
21 primarily distribute to the respiratory tract and more readily enter systemic circulation. This was
22 demonstrated by [O'Flaherty and Radike \(1991\)](#), which is described in further detail in Appendix
23 C.1.2. These pharmacokinetic factors have implications for Cr(VI)-induced toxicity and
24 carcinogenicity because target tissue doses will strongly depend on route of exposure. An overview
25 of ADME for inhaled and ingested Cr(VI) is provided in Figure 3-1.




Figure 3-1. Overview of the absorption, distribution, metabolism, and excretion of Cr(VI), with focus on extracellular transport and metabolism at portals of entry.

1 Table 3-1 outlines the general findings regarding Cr(VI) pharmacokinetics in different organ
 2 systems, and their implications for the toxicological assessment. It is ordered from external/portal-
 3 of-entry tissues to internal/systemic tissues and provides additional support for information
 4 provided in Figure 3-1.

Table 3-1. Overall findings by system and implications for the toxicological assessment

System	General findings	Implication for assessment, with rationale
Respiratory (extracellular)	Reduction of Cr(VI) possible by epithelial lining fluid (ELF) and pulmonary alveolar macrophages (PAM). Components of lung fluids reducing Cr(VI) include glutathione (GSH) and ascorbate (Asc). ¹¹	Extracellular reduction will not be quantified for inhalation dose-response modeling. Computational fluid dynamics studies of inhaled particulates indicate that respiratory tract deposition does not occur uniformly.
Respiratory (cellular/epithelial)	Rapid uptake of Cr(VI) into epithelial cells, and reduction to Cr(III). Reduction by lung tissue may involve peripheral lung parenchyma (PLP), Asc, GSH, cysteine, hydrogen peroxide, riboflavin, iron, and enzymatic pathways. Intracellular Cr in lung cells may cluster at the nucleus. ¹²	Thus, Cr(VI) will not evenly mix with all available reducing agent. Particulates may deposit locally in high amounts in regions of the respiratory tract with insufficient extracellular reducing capacity. Impaction in nasal/nasopharyngeal regions may also occur. Site-specific respiratory tract particle deposition and reduction may be highly variable between individuals.
Oral cavity (extracellular)	Reduction in saliva is possible ¹³ , although the extent or rate of localized reduction during the short timescale typical of human or rodent water swallowing is unknown.	Extracellular reduction in the oral cavity will not be quantified. Mixing of drinking water and saliva will not occur uniformly. High interindividual variability exists in oral health/saliva status and water consumption habits. Ingested water temporarily washes-away saliva from the oral cavity.
Oral cavity (cellular/epithelial)	Uptake to the sensitive oral sites is uncertain. Higher concentrations in oral tissues were detected in mice than in rats, but only rats were susceptible to oral squamous cell carcinoma in the NTP (2008) study. Morphology within different regions of the oral cavity is highly variable (hard palate, buccal mucosa, gingiva, ventral/dorsal tongue, lip), and may impact localized uptake and reduction. ¹⁴	A PBPK model will not be used to estimate oral cavity absorption for dose-response modeling. Modeling dynamics of this compartment are considered too uncertain (see above), although it will be assumed that direct contact between water and oral epithelium occurs.

¹¹[De Flora et al. \(1987\)](#), [Petrilli et al. \(1986\)](#).

¹²[Wong et al. \(2012\)](#), [Harris et al. \(2005\)](#).

¹³[Petrilli and De Flora \(1982\)](#).

¹⁴[Kirman et al. \(2012\)](#), [Jones and Klein \(2013\)](#).

Toxicological Review of Hexavalent Chromium

System	General findings	Implication for assessment, with rationale
Stomach and intestine (extracellular/lumen)	Gastric juices reduce Cr(VI) by 2nd-order reaction in a batch system. Total reducing capacity in all species generally between 10–30 mg/L. Components of gastric juice reducing Cr(VI) include ascorbate, glutathione, NADH, and sulfhydryls. Reduction rate decreases as pH increases. ¹⁵	A gastric PBPK model of the stomach will be used to estimate the Cr(VI) dose escaping stomach reduction. The adjusted daily dose may be used as the basis for an internal dose metric for dose-response modeling. Gastric juice and Cr(VI)-containing water are expected to have time to become well-mixed, and the system is single and continuous (similar to ex vivo batch systems used to study reduction kinetics). Higher uncertainty exists for the small intestine lumen. Multiple discontinuous pockets of water/gastric contents and intestinal secretions will not be well-mixed.
Stomach and intestine (cellular/epithelial)	Transport of Cr(VI) occurs rapidly by nonspecific phosphate and sulfate transporters. Transport of Cr(III) believed to be slower (diffusion). High variability in GI absorption for both Cr(VI) and Cr(III). Cr uptake may occur primarily in the villi. Reduction occurs in the tissue. ¹⁶	A PBPK model will not be used to estimate epithelial absorption of Cr(VI) in the stomach or intestine. There is high uncertainty in simultaneously quantifying Cr(VI) uptake/reduction, and Cr(III) uptake from lumen, plasma, or background exposure. However, stomach PBPK modeling of reduction/transit is sufficient for use in dose-response modeling without incorporating uptake kinetics. In this assessment, it will be assumed that the small intestinal epithelium is exposed to any unreduced Cr(VI) escaping the stomach.
Blood	Rapid uptake of Cr(VI) into RBCs. Uptake by anion transporters (i.e., band-3 protein). Rapid reduction of Cr(VI) in RBCs by GSH. Binding to hemoglobin and other components in RBC. Transport of Cr(III) into or out of RBCs occurs slowly (thus, bound or unbound Cr(III) may be “trapped” in RBC). Cr(VI) uptake into WBCs also rapid. Reduction of Cr(VI) in plasma occurs slowly. ¹⁷	A systemic PBPK model will not be used to estimate whole-body pharmacokinetics. Due to rapid clearance and reduction locally by liver, RBCs, and most other systemic tissues, BW ^{3/4} scaling of the available dose estimated to escape reduction in the stomach would be used for dose-response modeling for systemic endpoints outside the GI tract.
Liver	Uptake and reduction of Cr(VI) occurs rapidly. Reduction by GSH, ascorbate and other electron donors and enzymes. Uptake into cells by anion transporters. ¹⁸	

¹⁵[De Flora et al. \(1987\)](#), [De Flora et al. \(1997\)](#), [Proctor et al. \(2012\)](#) [Kirman et al. \(2013\)](#).

¹⁶[Alexander and Aaseth \(1995\)](#), [Shrivastava et al. \(2003\)](#), [Thompson et al. \(2015a\)](#).

¹⁷[Wiegand et al. \(1985\)](#), [Ottawaelder et al. \(1988\)](#), [Devoy et al. \(2016\)](#).

¹⁸[Alexander et al. \(1982\)](#), [Alexander et al. \(1986\)](#), [Wiegand et al. \(1986\)](#), [Alexander and Aaseth \(1995\)](#).

System	General findings	Implication for assessment, with rationale
All other systemic organs and tissues	In vivo studies at high doses (regardless of route) have measured widespread Cr in all or most tissues examined. Distribution may be dependent on route of exposure. ¹⁹ Localized reduction of Cr(VI) to Cr(III) occurs in all tissues. Systemic elimination of Cr(III) from the whole body occurs primarily via urinary excretion. Studies also detect chromium in tissues of control animals due to background dietary or drinking water chromium (believed to be in the trivalent form).	

1 **3.1.1.1. Oral Exposure**

2 Extracellular reduction and absorption

3 The extracellular reduction process is important for the oral route of exposure due to the
 4 acidity of gastric juice that influences the reduction of Cr(VI). Cr(VI) reduction occurs more rapidly
 5 at low pH (Figure 3-2). The pH of the stomach lumen for humans and rodents in the fasted state are
 6 approximately 1.3 and 4, respectively (Figure 3-3). Under such conditions, humans would reduce
 7 Cr(VI) more effectively than rodents. Because the pH of the small intestinal lumen is higher than
 8 that of the stomach, reduction is believed to be slower once Cr(VI) is emptied from the stomach. As
 9 a result, Cr(VI) that is not reduced in the stomach compartment may traverse the remaining
 10 sections of the GI tract.

¹⁹[O'Flaherty and Radike \(1991\)](#).




Figure 3-2. Reduction of Cr(VI) in samples of human gastric juice (fasted subjects) using data from [Proctor et al. \(2012\)](#). For these experiments, stomach contents were diluted 10:1 to highlight the effect of pH. Reduction of Cr(VI) in natural (undiluted) gastric juice occurs faster (see Appendix C.1.3).




Figure 3-3. GI tract pH values reported in [Mcconnell et al. \(2008\)](#) (rodents: female BALB/c mice and female Wistar rats) and [Parrott et al. \(2009\)](#) (humans).

- 1 Along the GI tract, the concentration of Cr(VI) will be highest at the portal of entry and in
- 2 the lumen close to the portals of entry (oral cavity, tongue, esophagus, stomach, duodenum).

1 Within the epithelium, a concentration gradient will exist across tissue depth, with the greatest
2 Cr(VI) concentration at the apical surface of the mucosa, and lower levels at deeper components of
3 the tissue. Differences in tissue morphologies and absorption across the various segments of the GI
4 tract result in variable Cr(VI) exposures for different tissue and cell types, which have implications
5 for site-specific uptake and pharmacodynamics (See Sections 3.2.2.3 and 3.2.3.3). Figures 3-4 and
6 3-5 illustrate how Cr(VI) will distribute and absorb within the GI tract tissues.

7 The oral epithelium is composed of multiple cell layers (Figure 3-4) ([Squier and Kremer,](#)
8 [2001](#)) and regenerates with stem cells located in the relatively deeper layers (e.g., the lamina
9 propria or basal layer) ([Jones and Klein, 2013](#); [Marynka-Kalmani et al., 2010](#)). The precise location
10 of the stem cells depends on the region of the oral mucosa (e.g., lip, hard palate, gingiva, tongue)
11 ([Jones and Klein, 2013](#); [Marynka-Kalmani et al., 2010](#)). The concentration of ingested Cr(VI) in the
12 oral cavity may not exhibit a proximal-to-distal gradient because very limited reduction and
13 dilution will occur in the lumen. However, the surface cell layers will receive higher exposure. The
14 small intestine is comprised of three anatomical sections, the duodenum, jejunum, and ileum
15 (Figure 3-5), each of which have different lengths and absorption surface areas ([Casteleyn et al.,](#)
16 [2010](#)). Within the small intestine, the concentration of ingested Cr(VI) that is not reduced in the
17 stomach will be the highest in the duodenum. The duodenal villi serve as the functional structures
18 for absorption. Villous epithelial cells are continuously lost and replaced by stem cells in the
19 bottom two-thirds of the crypt ([Potten et al., 2009](#); [Potten et al., 1997](#)). Stem cells differentiate as
20 they move upward from the crypt and are shed at the tip of the villi. Within the stomach, gastric
21 stem cells are located within glandular pits, and unlike the small intestine, they are nearer to the
22 lumen and more likely to be exposed to surface irritants ([Mills and Shivdasani, 2011](#)).

23 There are species differences in GI tract structure and drinking water consumption patterns
24 that may impact susceptibility to the effects of ingested Cr(VI). The rodent stomach is segmented
25 into a glandular stomach and non-glandular (keratinized) forestomach, whereas humans have a
26 single glandular stomach type ([Kararli, 1995](#))²⁰. Elevated pH has been measured in the
27 forestomach of rodents (relative to the glandular stomach) ([Kohl et al., 2013](#); [Browning et al., 1983](#);
28 [Kunstyr et al., 1976](#)), and pH variation might not follow the same fed/fasted pattern as the
29 glandular stomach ([Ward and Coates, 1987](#)). As a result, it is likely that kinetics within the
30 stomach, and Cr(VI) exposure to the absorptive regions of the stomach, differ between rodents and
31 humans. Within the oral cavity, the location and type of tissue keratinization (which decreases site-
32 specific absorption) differs by species, with a greater percentage of the rodent oral epithelium
33 being keratinized relative to humans ([Jones and Klein, 2013](#)). There are also interspecies
34 differences in the relative lengths and surface areas of small intestinal segments ([Casteleyn et al.,](#)
35 [2010](#)). With respect to the pattern of drinking water consumption, humans ingest beverages

²⁰A comparative 21-day pharmacokinetic study in guinea pigs (which do not have a forestomach), rats, and mice by [NTP \(2007\)](#) found no fundamental differences in pharmacokinetics that could be attributable to different stomach structure.

1 sporadically and within a short period of time, whereas rodents consume water at a more sustained
2 rate over the nocturnal period ([Yuan, 1993](#); [Spiteri, 1982](#)).

3 The characterization of interspecies differences in site-specific pharmacodynamics for
4 Cr(VI) is highly uncertain due to the nature of the observed tumors (see Section 3.2.3). [NTP \(2008\)](#)
5 observed tumors of the oral cavity in rats, and tumors of the small intestine of mice following
6 exposure to Cr(VI) in drinking water for two years. The lack of oral tumors in mice cannot be
7 explained by interspecies differences in pharmacokinetics because higher chromium
8 concentrations have been measured in the oral tissues of mice vs. rats following a 90-day Cr(VI)
9 drinking water study ([Kirman et al., 2012](#)). In addition, rats are generally more prone to oral
10 cancer development than mice, and mice are more prone to neoplasia in the small intestine
11 ([Ibrahim et al., 2021](#); [Chandra et al., 2010](#)) (Appendix D.2).

12 In GI tract tissues where tumors were not observed in rodents by [NTP \(2008\)](#) (such as the
13 stomach or colon), there are also interspecies differences that are difficult to model. For example,
14 chemically induced epithelial tumors of the forestomach in mice and rats are the most common
15 neoplasms of the GI tract observed by NTP and Carcinogenic Potency databases, but those of the
16 glandular stomach are rare ([Chandra et al., 2010](#)). However, glandular stomach cancer is one of the
17 major causes of cancer diagnosis and cancer death in humans worldwide ([Crew and Neugut, 2004](#)).
18 It is the 5th most commonly diagnosed cancer and the 7th most prevalent in the world ([Rawla and](#)
19 [Barsouk, 2019](#)). Morphologies of stomach tumors differ greatly between humans and rodents
20 ([Hayakawa et al., 2013](#); [Tsukamoto et al., 2007](#)), and therefore lack of Cr(VI)-induced stomach
21 tumors in rodent bioassays may not be directly applicable to humans. Because these interspecies
22 differences could not be quantified in a pharmacokinetic or pharmacodynamic model, site-specific
23 internal dose metrics were not derived for GI tract tissues.




Figure 3-4. Schematic of the rat oral cavity depicting the gradient of Cr(VI) concentration following ingestion of Cr(VI) in drinking water, both from anterior to posterior locations, as well as across the tissue depth. Drawn based in part on images by NRC (2011) and Jones and Klein (2013). Transmucosal uptake may lead to systemic absorption.




Figure 3-5. Schematic of the mouse upper GI tract (stomach and small intestine) depicting the gradient of Cr(VI) concentration following ingestion of Cr(VI) in drinking water. Gradient is both from anterior to posterior locations, as well as across the tissue depth. Drawn based on images by [Radtke and Clevers \(2005\)](#), [Fox and Wang \(2007\)](#), and [Kararli \(1995\)](#).

1 Data limitations of oral pharmacokinetic data

2 Even under controlled rodent pharmacokinetic studies, assessing the oral absorption and
 3 whole-body distribution of orally administered Cr(VI) at low doses contains some uncertainty.
 4 Only total chromium can be measured in tissues in vivo. Total chromium measured in tissues
 5 following oral Cr(VI) exposure results from:

6 Rapid cellular uptake of administered Cr(VI) that was absorbed into the body as Cr(VI).
 7 Because Cr(VI) transport is carrier-mediated via nonspecific sulfate and/or phosphate anion
 8 transporters, this uptake is rapid in the lumen and systemic tissues. The absorbed Cr(VI) may be
 9 transported throughout the body and reduced intracellularly to Cr(III) in tissues and red blood
 10 cells. Absorption of Cr(VI) by the intestine and reduction of Cr(VI) in the lumen are competitive
 11 processes.

- 1) Slow cellular uptake of Cr(III) that was absorbed into the body as Cr(III), formed from administered Cr(VI) that reduced to Cr(III) extracellularly and outside of systemic circulation (e.g., gastric juices). This process is slow and inefficient because Cr(III) transport occurs by passive diffusion, resulting in a low percent absorption of Cr(III) in the GI tract, and a low percent absorption of Cr(III) into systemic tissues from plasma. However, high concentrations of Cr(III) in the lumen may occur during controlled Cr(VI) studies (via extracellular reduction), leading to more uptake of Cr(III) than would typically occur from background dietary ingestion.
- 2) Slow cellular uptake of Cr(III) that was absorbed into the body as administered Cr(VI) and reduced by other components within systemic circulation (e.g., plasma, liver, red blood cells). While uptake of Cr(VI) into the intestinal lumen is rapid, systemic reduction to Cr(III) is also rapid. Once reduced, Cr(III) will diffuse slowly (into or out of) systemic tissues and circulate throughout the body in plasma. For example, plasma can reduce Cr(VI) extracellularly, and the resulting Cr(III) absorbed into tissues. RBCs can reduce Cr(VI) intracellularly, and the resulting Cr(III) can be released to systemic circulation (to be absorbed by other tissues) after RBCs are broken down.
- 3) Background uptake and distribution of dietary and drinking water chromium (Cr(III) and/or Cr(VI)) not administered or controlled in the bioassay. This is supported by the detection of chromium in the tissues of control animals.

Because chromium becomes trapped within RBCs following exposure to Cr(VI), elevated RBC chromium persists longer relative to plasma chromium levels following systemic Cr(VI) absorption. Based on analyses of the RBC:plasma ratios of exposed and unexposed rodents from the NTP ([2008](#), [2007](#)) studies (see Appendix C.1.2), it may be assumed that a significantly large percentage of oral *ad libitum* doses greater than 1 mg/kg-d likely escapes gastric and hepatic reduction in rodents and is widely distributed throughout the body. At lower doses, it may be difficult to interpret pharmacokinetic data due to background chromium exposure, and the fact that a lower percentage of the dose reaches systemic circulation.

3.1.1.2. Inhalation Exposure

Inhalation pharmacokinetics of Cr(VI) differ substantially from ingestion, and there is less detoxification via extracellular reduction. Deposition of particles along the respiratory tract is not uniformly distributed and is strongly dependent on particle size. Inhaled particles with a diameter greater than 5 μm will typically deposit proximal to the trachea (extrathoracic region). Particles with a diameter in the range of 2.5–5 μm generally deposit in the tracheobronchial region. Particles with a diameter less than 2.5 μm generally deposit in the pulmonary region. However, some proportion of larger particles (>2.5 μm) are still capable of reaching the pulmonary region ([OSHA, 2006](#)). Deposition of both larger particles and ultrafine particles (>0.1 μm) can occur in the head airways, including the nasal passages ([Hinds, 1999](#); [ICRP, 1994](#)). Particle size distributions in the air vary between industries or between different processes within the same industrial plant ([OSHA, 2006](#)). Particles of respirable size capable of depositing in the lower respiratory tract have been observed in some workplace settings ([Kuo et al., 1997a](#)). As a result, this assessment assumes

1 deposition in all regions of the respiratory tract is possible, and that some inconsistencies in
2 observed effects may be due to particle size. Deposition and transmucosal uptake in the oral cavity
3 are also considered to occur because humans may breathe through both the mouth and nose
4 (Figure 3-6), as compared to nose-only breathing in rodents.

5 Within the lower respiratory tract of the lung, particles may locally accumulate at high
6 quantities in susceptible areas such as airway bifurcation sites ([Balashazy et al., 2003](#); [Schlesinger
7 and Lippmann, 1978](#)). This is supported by studies showing high chromium deposition at these
8 sites in the lungs of chromate workers, and a correlation between lung chromium burden and lung
9 cancer ([Kondo et al., 2003](#); [Ishikawa et al., 1994a, b](#)).

10 The respiratory environment is less acidic than the gastric environment ([Krawic et al.,
11 2017](#)) and would be less likely to effectively reduce Cr(VI) in vivo. Unlike gastric juice, which exists
12 in the stomach as a single continuous pocket, respiratory tract epithelial lining fluid is a thin,
13 heterogeneous film ([Ng et al., 2004](#)). Inhaled Cr(VI) will not evenly mix with all the available
14 extracellular components of the lung that are capable of reducing Cr(VI) to Cr(III). Thus,
15 extracellular components capable of Cr(VI) reduction may be overwhelmed in local regions of the
16 respiratory tract where high deposition occurs ([Krawic et al., 2017](#)), regardless of the total reducing
17 capacity of components in the lung. As a result, PBPK modeling of extracellular Cr(VI) reduction in
18 the lung was not considered for this assessment.




Figure 3-6. Schematics of the human respiratory system (adapted from Kleinstreuer et al. (2008)²¹) depicting deposition of particles or mists containing Cr(VI). The term “generation” refers to the branching pattern of airways. Each division into a major daughter (larger in diameter) and minor daughter airway is termed a generation (U.S. EPA, 1994).

1 Inhalation pharmacokinetics and target internal doses to the lung and systemic organs will
 2 also vary depending on the solubility of the Cr(VI) compound being inhaled. Both high and low
 3 soluble forms of Cr(VI) are believed to be absorbed into lung tissue after deposition in the airways
 4 (OSHA, 2006). However, the accumulation rates in the lung and the extent of systemic absorption
 5 will differ. Highly soluble Cr(VI) may be rapidly absorbed by cells, leading to high localized Cr(VI)
 6 concentrations in the lung tissue. Because the highly soluble Cr(VI) would be rapidly absorbed and
 7 cleared, the high localized Cr(VI) lung concentrations may be temporary (O’Flaherty and Radtke,
 8 1991). Cr(VI) absorbed by the lungs is rapidly transported to the bloodstream and may expose

²¹Modified with permission from the Annual Review of Biomedical Engineering, Volume 10 © 2008 by Annual Reviews, <http://www.annualreviews.org>.

1 other systemic tissues ([OSHA, 2006](#)). Cr(VI) compounds with low solubility may persist in the lung
2 for longer periods of time and come into close contact with the bronchoalveolar epithelial cell
3 surface ([OSHA, 2006](#)). So while uptake would be slower, there may be a higher exposure over time.
4 Cr(VI) that is not readily absorbed into the lung may be transported to the stomach by mucociliary
5 clearance ([O'Flaherty and Radike, 1991](#)). As a result, inhaled Cr(VI) compounds with low solubility
6 may not reach other systemic tissues as readily as soluble Cr(VI), since most Cr(VI) swallowed by
7 mucociliary clearance would be reduced in the stomach.

8 Chromium-containing compounds such as the potassium/sodium/ammonium
9 chromates/dichromates and chromium trioxide are highly soluble in water, while some mixed salt
10 chromate pigments (such as lead and zinc chromate) are poorly soluble ([O'Flaherty and Radike,](#)
11 [1991](#)). While stainless-steel welding fume contains both high and low soluble components, the
12 Cr(VI) component of the fume is considered highly soluble and may be distributed throughout the
13 body ([Antonini et al., 2010a](#); [Antonini et al., 1999](#)).

14 **3.1.1.3. Intracellular Reduction (All Routes of Exposure)**

15 After Cr(VI) uptake by cells, Cr(III) is the ultimate product of the intracellular reduction of
16 Cr(VI). Depending on the Cr(VI) concentration and reducing agent involved (e.g., ascorbate, or
17 thiol-containing compounds such as glutathione and cysteine), various amounts of the unstable and
18 reactive intermediates Cr(V) and Cr(IV) can be generated prior to reduction to Cr(III). This has
19 implications for pharmacodynamics and mode-of-action (see Section 3.2.3.4). The reduction
20 pathway via ascorbate occurs with a two-electron reduction to primarily produce Cr(IV) ([Reynolds](#)
21 [and Zhitkovich, 2007](#)), although Cr(V) species have been detected following Cr(VI) reduction by
22 ascorbate ([Poljsak et al., 2005](#); [Stearns et al., 1995](#); [Stearns and Wetterhahn, 1994](#)). When Cr(VI) is
23 reduced via thiols such as glutathione, there are two distinct one-electron transfers producing both
24 intermediates Cr(V) and Cr(IV) ([Luczak et al., 2016](#); [O'Brien et al., 2003](#)). Both the one- and
25 two-electron reduction steps are immediately followed by one-electron reductions to produce
26 Cr(III) ([Levina and Lay, 2005](#)). Reduction by ascorbate is kinetically favorable, with an estimated
27 reduction rate 13x faster than cysteine and 61x faster than glutathione ([Quievryn et al., 2003](#)), and
28 the reduction pathway via ascorbate accounts for 90% of metabolism in vivo ([Standeven and](#)
29 [Wetterhahn, 1992, 1991](#); [Suzuki and Fukuda, 1990](#)). It has been shown that in vitro studies may
30 produce inaccurate results because standard cultured cells contain <1% of the normal in vivo
31 ascorbate levels ([Luczak et al., 2016](#)). Without adequate ascorbate, glutathione is the major
32 reducing agent, and the oxidative Cr(V) is the major intermediate; the additional Cr(V) also depletes
33 glutathione, thereby increasing the abundance of Cr(V) ([Luczak et al., 2016](#)). In addition, the
34 presence of ascorbate has been shown to stabilize the reactive intermediates generated by the
35 glutathione pathway, leading to even more potential interaction between Cr(V) and intracellular
36 components ([Martin et al., 2006](#)). These intracellular reduction pathways are summarized in
37 Figure 3-7; for further discussion of the biological consequences of the intracellular reduction of
38 Cr(VI), see Section 3.2.3.4.




Figure 3-7. Intracellular reduction pathways of Cr(VI). Adapted from [Zhitkovich \(2011\)](#). The reduction pathway via ascorbate occurs with a two-electron reduction to Cr(IV), immediately followed by a one-electron reduction to Cr(III). When Cr(VI) is reduced via thiols such as glutathione, there are two distinct one-electron transfers producing the intermediates Cr(V) and Cr(IV), and lastly another electron transfer producing Cr(III). There may be uncertainty whether the ascorbate pathway truly lacks a Cr(V) intermediate ([Poljsak et al., 2005](#); [Stearns et al., 1995](#); [Stearns and Wetterhahn, 1994](#)). In vivo and in vitro differences may arise from the media and ascorbate levels used for experiments in cultured cells. Ascorbate may have a stabilizing effect on the reactive intermediates produced via the glutathione pathway.

3.1.2. Description of Pharmacokinetic Models

1 A brief description of the available pharmacokinetic models for Cr(VI) are listed below in
 2 chronological order in Table 3-2. For this assessment, models adapted from [Sasso and Schlosser](#)
 3 [\(2015\)](#); [Schlosser and Sasso \(2014\)](#) were used for oral dose-response and rodent-to-human
 4 extrapolation (see Appendix C). Physiology parameters defined in [Sasso and Schlosser \(2015\)](#) were
 5 revised to account for the fed and fasted states in humans, and to use alternative gastric
 6 physiological parameters obtained from literature and other gastric modeling platforms. A minor
 7 structural change was also made to harmonize the volumes of stomach lumen and gastric juice (see
 8 Appendix C).

Table 3-2. Pharmacokinetic models for Cr(VI)

Reference	Species	Notes
O'Flaherty (1996) O'Flaherty (1993) O'Flaherty et al. (2001) O'Flaherty and Radike (1991)	Rat	Compartments include kidney, liver, bone, GI tract, two lung pools (for inhalation only), plasma, red blood cells, and lumped compartments for remaining tissues (rapidly and slowly perfused). A single lumped compartment represents the GI tract, and reduction kinetics do not include pH-reduction relationships. This model is not readily extendable to the mouse.
O'Flaherty et al. (2001)	Human	Calibrated to data from exposure via intravenous injection, gavage, inhalation (intratracheal), and drinking water (all data are from studies dated 1985 and earlier). Background Cr(III) exposure is simulated in the model and contributes to predicted total chromium concentrations.
Kirman et al. (2012)	Rat, mouse	Compartments include kidney, liver, bone, GI tract, plasma, red blood cells and a lumped compartment for remaining tissues. A multicompartment model represents the GI tract (oral cavity, stomach, duodenum, jejunum, ileum, large intestine), with reduction kinetics based on the model by Proctor et al. (2012) .
Kirman et al. (2013)	Human	Incorporates pharmacokinetic data from experiments designed by the study authors, and data from other studies. Only data for drinking water and dietary routes of exposure incorporated. Total concentrations in control groups subtracted from exposure groups to account for background Cr(III) exposure.
Schlosser and Sasso (2014) ; Sasso and Schlosser (2015)	Rat, mouse, human	Simulates Cr(VI) reduction kinetics and transit in the stomach. Incorporates pharmacokinetic model of the stomach lumen by Kirman et al. (2013 ; 2012), but with a revised model for Cr(VI) reduction based on reanalysis of ex vivo data to improve model/data fit.
Kirman et al. (2017 ; 2016)	Rat, mouse human	Same structure as Kirman et al. (2013 ; 2012), but incorporates a revised model for Cr(VI) reduction based on additional human gastric juice data. This model supersedes earlier models by the same investigators.
ICRP (Hiller and Leggett, 2020)	Human	Biokinetic model assuming linear 1st-order transfer rates among different systemic tissues. Compartments include respiratory tract, stomach, small intestine, red blood cells, plasma, liver, kidneys, other/soft tissue, trabecular bone, cortical bone, right colon, left colon, rectosigmoid colon, urinary bladder, urine, feces. Reduction of Cr(VI) to Cr(III) not explicitly modeled (assumed as a linear transfer between different special plasma compartments).

1 The O'Flaherty Cr(VI) model was adapted from a PBPK model for lead, and it does not
2 describe Cr(VI) kinetics in the target tissue or species of concern (the mouse GI tract). The models
3 by Kirman et al. ([2013](#); [2012](#)) simulate interspecies differences in gastric reduction kinetics in mice,
4 rats, and humans. These models have a structure similar to the human model by [O'Flaherty et al.](#)
5 ([2001](#)), but differ in their simulation of background Cr(III) exposure and kinetics of the GI tract and
6 bone. The model presented in [Sasso and Schlosser \(2015\)](#) and Appendix C.1.5 only incorporates

1 the GI lumen compartments necessary to simulate the non-systemic dose metrics. It incorporates
 2 in vivo gastric kinetics from the Kirman et al. (2013; 2012) models, but includes a revised ex vivo
 3 reduction model by Schlosser and Sasso (2014) to improve model fit to the ex vivo data of Proctor
 4 et al. (2012) and Kirman et al. (2013). Models of the GI tract incorporate ex vivo reduction models
 5 and may be run independently of the rest of the body if the internal dose is not impacted by blood
 6 or tissue concentrations (Figure 3-8). Some internal dose metrics for GI tract toxicity do not
 7 require estimates of tissue absorption, blood concentrations or systemic elimination. Validation of
 8 whole-body pharmacokinetics is complicated by background exposure and inability to speciate
 9 chromium oxidation states in vivo (see Section ES.7 and 3.1.1.1).

10 The ICRP model (Hiller and Leggett, 2020) was focused heavily on the distribution of Cr(III)
 11 in the body and had an over-simplified linear assumption for Cr(VI) reduction that would be
 12 inadequate for assessment of effects in the GI tract.




Figure 3-8. Relationship between ex vivo reduction models, in vivo gastric models, and whole-body PBPK models.

13 The Kirman et al. (2017) model made revisions to the previous Kirman et al. models by
 14 incorporating some ex vivo reduction concepts presented in Schlosser and Sasso (2014) (such as
 15 multiple-pathway reactions) and is calibrated to human gastric juice data for fed and fasted
 16 individuals (Kirman et al., 2016). Ex vivo data provided in Kirman et al. (2016) and De Flora et al.
 17 (2016) were used to assess model uncertainties and population variability and develop a fed-state
 18 gastric reduction capacity (see Appendix C.1). Minor updates to the Sasso and Schlosser (2015) in
 19 vivo model structure and physiology are documented in Appendix C.1.5.

1 **3.1.2.1. Rationale for Using a Gastric PBPK Model**

2 This toxicological review applies models describing the reduction kinetics and transit of
3 Cr(VI) in the stomach lumen (as opposed to whole-body PBPK models) for the oral dose-response
4 assessment and rodent-to-human extrapolation (Appendix C.1.5).

5 In the GI tract, the extent of reduction in the stomach compartment determines the
6 maximum Cr(VI) mass or concentration that enters the small intestine. As a result, the stomach
7 compartment is a major contributor to inter- and intraspecies pharmacokinetic variation. If
8 reduction does not occur effectively in the stomach, a greater amount of unreduced Cr(VI) will
9 persist in the small intestinal compartments (duodenum, jejunum, and ileum). Since values of pH in
10 the small intestinal compartments are higher than in the stomach for all species (Figure 3-3),
11 reduction may occur less effectively once chromium has emptied from the stomach. Furthermore,
12 the data underlying the ex vivo reduction model were generated under batch reaction conditions,
13 which is more similar to the stomach compartment than the dynamic intestine. Modeling the
14 stomach requires less extrapolation of the data.

15 The gastric PBPK models are consistent with both ex vivo and in vivo pharmacokinetics
16 studies. It is estimated that approximately 10% of an ingested dose of Cr(VI) is absorbed in the GI
17 tract of rodents ([Fébel et al., 2001](#); [Thomann et al., 1994](#)), and this is consistent with the percentage
18 of unreduced Cr(VI) emptying from the stomach predicted by the gastric PBPK model (Appendix C).
19 Under typical physiological conditions in the human (gastric pH of below 3, and gastric emptying
20 half-time of approximately 15–30 minutes), gastric PBPK models predict that approximately 1–
21 10% of ingested Cr(VI) may be emptied by the human stomach unreduced. This is in agreement
22 with pooled human gastric juice data by [De Flora et al. \(2016\)](#), which showed that approximately
23 93% of the chromium is reduced by undiluted gastric juice after 15 minutes. This is also consistent
24 with a Cr(VI) bioavailability study performed in an *in vitro* system, which found that human
25 bioaccessibility could be as high as 20% at low doses (0.005 mg/kg-d) at a gastric pH of 3.0 (but
26 drastically lower than 20% at low pH)([Wang et al., 2022](#)). Elevated chromium biomarkers (plasma,
27 red blood cells and urine) have been measured in human volunteers ingesting Cr(VI) ([Finley et al.,](#)
28 [1997](#); [Kerger et al., 1997](#); [Kerger et al., 1996](#); [Paustenbach et al., 1996](#)).

29 While reduction may still occur in small intestinal compartments, effects observed by [NTP](#)
30 [\(2008\)](#) in mice (see Sections 3.2.2 and 3.2.3.2) indicate that unreduced Cr(VI) may traverse the
31 small intestine. The jejunum and ileum exhibited lower incidences of effects in mice, which may
32 indicate that Cr(VI) was reduced and/or diluted by intestinal secretions and lumen contents. Data
33 by [Kirman et al. \(2012\)](#) also shows chromium concentrations decreasing in the distal direction in
34 the small intestine of mice exposed to Cr(VI) in drinking water for 90 days. While it is believed that
35 more Cr(VI) is absorbed in the proximal small intestine, this assessment will not quantify spatial
36 differences in absorption within the small intestine. It will be assumed that all Cr(VI) which
37 escapes the stomach and enters the small intestine is capable of exposing the intestinal epithelium
38 of any region.

3.2. SYNTHESIS AND INTEGRATION OF HEALTH HAZARD EVIDENCE BY ORGAN/SYSTEM

3.2.1. Respiratory Tract Effects Other Than Cancer

1 The respiratory tract is comprised of multiple tissues that are responsible for air intake and
 2 gas exchange. The upper respiratory tract is composed of the nose, nasal cavity, mouth, pharynx,
 3 and larynx. This region filters, warms and humidifies inhaled air prior to entering the lower
 4 respiratory tract, while also facilitating olfactory function. The lower respiratory tract
 5 (i.e., tracheobronchial, and pulmonary regions), which begins at the larynx below the vocal cords, is
 6 composed of the trachea, bronchi, bronchioles, and the alveoli. The pulmonary region facilitates gas
 7 exchange with the blood. The upper and lower airways and gas-exchange region can be affected by
 8 inhaled toxicants that are deposited along the different regions of the respiratory tract, resulting in
 9 a variety of adverse respiratory outcomes. For an overview of how the particle size and solubility
 10 of Cr(VI) compounds will impact the retention and absorption of Cr(VI) in different regions of the
 11 respiratory tract, see Section 3.1.

12 Effects in the nasal cavity (irritation/ulceration of the nasal mucosa or septum, perforation
 13 of the septum, and bleeding nasal septum) have been documented for decades in humans
 14 occupationally exposed to Cr(VI) in chromium-related industries ([Bloomfield and Blum, 1928](#)). As
 15 stated in the Cr(VI) IRIS Assessment Protocol (Appendix A), based on EPA's 1998 evaluation of the
 16 literature and the determination that the effects of Cr(VI) on the nasal cavity have been well
 17 established [e.g., [OSHA \(2006\)](#) and [U.S. EPA \(2014c\)](#)], EPA will not re-evaluate the qualitative
 18 evidence for an association between inhalation Cr(VI) exposure and nasal effects. Rather, the
 19 review of the evidence for nasal effects focuses on identifying studies that might improve the
 20 quantitative dose-response analysis for this outcome. The review of the evidence and dose-
 21 response for nasal effects can be found in Section 4.2.1.1.

22 For human studies, this assessment focuses on respiratory effects that may be sensitive and
 23 specific to the effects of inhaled Cr(VI) exposure. This includes decrements in lung function
 24 assessed using spirometry, with comparisons against lesser or unexposed individuals. Mortality or
 25 self-reported symptoms (such as cough) that are nonspecific and may be attributed to multiple
 26 other causes were not considered relevant for this assessment. For animal bioassays, this
 27 assessment considered relevant any reported respiratory effects. Animal studies of respiratory
 28 effects following Cr(VI) exposures typically focused on cellular responses (i.e., cell recruitment, cell
 29 function and cellular products), histopathology, and lung weight.

3.2.1.1. Human Evidence

Study evaluation summary

32 Table 3-3 summarizes the human studies considered in the evaluation of the effects of
 33 exposure to Cr(VI) on the lower respiratory tract. These comprise five occupational cohort studies

1 of workers in industrial settings in which exposure to Cr(VI) is known to occur (predominantly
2 through inhalation): a chrome electroplating department in Taiwan ([Kuo et al., 1997b](#)), a chromate
3 production plant in China ([Li et al., 2015b](#)), a chrome electroplating plant in Sweden ([Lindberg and
4 Hedenstierna, 1983](#)), several plants in France at which stainless-steel welding was performed
5 ([Sobaszek et al., 1998](#)), and one of the plants participating in the Occupational Chromate Exposure
6 Dynamic Cohort of China (although it is unclear whether this specific plant produced or applied
7 chromate, or both) ([Zhang et al., 2022](#)). Five additional studies were considered but were deemed
8 *uninformative* due to critical deficiencies ([Sitalakshmi et al., 2016](#); [Sharma et al., 2012](#); [Huvinen et
9 al., 2002b](#); [Nielsen et al., 1993](#); [Bovet et al., 1977](#)) and are not further discussed (see [HAWC](#) for
10 additional details).

11 Concentrations of Cr(VI) in air were measured in two of the five studies. Concentrations of
12 Cr(VI) from stationary monitors and personal samplers at a chrome-plating facility in Sweden
13 ranged from <0.2 to 46 µg/m³ ([Lindberg and Hedenstierna, 1983](#)). Concentrations of Cr(VI) from
14 personal samplers ranged from 0.2 to 230.0 µg/m³ in a study of chromium electroplaters in Taiwan
15 (mean [SD]: 63.2 [67.2] µg/m³ ([Kuo et al., 1997a, b](#))). In a third study, concentrations of total
16 chromium from stationary monitors indicated lower exposures compared to these two studies
17 (median²²[quartile]: 15.45 [19] µg/m³) in a study of chromate workers in China ([Li et al., 2015b](#)).

18 After study evaluation, all five studies were categorized as *low* confidence ([Zhang et al.,
19 2022](#); [Li et al., 2015b](#); [Sobaszek et al., 1998](#); [Kuo et al., 1997b](#); [Lindberg and Hedenstierna, 1983](#)). A
20 lack of air or biomarker measurements in the study of stainless-steel welders ([Sobaszek et al.,
21 1998](#)), inability to rule out substantial contribution of Cr(III) exposure to biomarker measurements
22 ([Zhang et al., 2022](#)), and potential for residual confounding in the other studies ([Li et al., 2015b](#);
23 [Kuo et al., 1997b](#); [Lindberg and Hedenstierna, 1983](#)), raised concerns about the ability of these
24 studies to appropriately characterize respiratory effects and resulted in *low* confidence ratings
25 despite other notable strengths in terms of study design and methods. In all the considered studies,
26 while the primary focus was on chromium exposure, coexposure to other occupational hazards may
27 also contribute to observed health effects. For example, other metallic elements in welding fume or
28 nickel in electroplating work could also impact respiratory health ([Antonini et al., 2010b](#); [ATSDR,
29 2005](#)). However, similar effects on respiratory outcomes from studies conducted across different
30 occupational settings, where the specific coexposures would be expected to differ, would alleviate
31 concern that any observed effects are due solely to coexposures rather than to Cr(VI).

32 The main results of the five studies considered are summarized in Table 3-4.

²²The article states this value as median and quartile; this appears consistent with an inter-quartile range.

Table 3-3. Summary of human studies for Cr(VI) lower respiratory effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a

[Click to see interactive data graphic for rating rationales.](#)

Author (year)	Industry	Location	Study Design	Pulmonary Function
Kuo et al. (1997b) (related: Kuo et al. (1997a))	Chrome electroplating	Taiwan	Cohort (occupational)	L
Li et al. (2015b)	Chromate production	China	Cohort (occupational)	L
Lindberg and Hedenstierna (1983)	Chrome electroplating	Sweden	Cohort (occupational)	L
Sobaszek et al. (1998)	Stainless-steel welding	France	Cohort (occupational)	L
Zhang et al. (2022) (related: Hu et al. (2022))	Chromate production	China	Cohort (occupational)	L

^aStudies excluded due to critical deficiency in one or more domains: [Nielsen et al. \(1993\)](#), [Bovet et al. \(1977\)](#), [Sharma et al. \(2012\)](#), [Sitalakshmi et al. \(2016\)](#), and [Huvinen et al. \(2002b\)](#) (related: [Huvinen et al. \(1996\)](#)). One of these studies ([Bovet et al., 1977](#)) met the PECO criteria but was found to be uninformative at the study evaluation stage due to publication prior to the availability of standardized spirometry guidelines from the American Thoracic Society.

1 Synthesis of human evidence

2 *Pulmonary function*

3 Four core endpoints were considered in the evaluation of the effects of exposure to Cr(VI)
 4 on pulmonary function: forced vital capacity (FVC), forced expiratory volume in first second
 5 (FEV1.0), the ratio of FEV1.0/FVC, and diffusing capacity of lung for carbon monoxide (DLCO). The
 6 first three of these are measured by spirometry. Other tests of pulmonary function (such as peak
 7 flow, airway responsiveness, and lung volume) were not utilized in any of the four studies
 8 considered. A key consideration for the evaluation of spirometry data is the adherence to
 9 guidelines published by the American Thoracic Society (ATS) ([ATS/ERS, 2019](#))²³ and use of
 10 appropriate reference population data for estimation of predicted values. The results from the four
 11 studies evaluating spirometry endpoints are shown in Tables 3-4 and 3-5.

²³These guidelines first developed in 1979 with subsequent updates; standardized guidelines were harmonized with the European Respiratory Society beginning in 2005 with subsequent updates and include detailed standardized protocols for the collection of spirometry data. Key features of the ATS guidelines include: recommendations regarding spirometer equipment specifications; protocols to be followed during the administration of spirometry tests; and the importance of considering age, sex, and height when interpreting results (ideally by expressing spirometry measurements as a percent of the measurement predicted, using reference values appropriately matched to the demographic characteristics of the study population).

Table 3-4. Summary of results from human studies of effects of Cr(VI) exposure on pulmonary function

Study	Exposure	Conf.	Result Format	N	FVC	FEV1.0	FEV1/FVC
Li et al. (2015b)	Chromate production Median total Cr ^a measured in air: 15.45 µg/m ³ (exposed) and 0.23 (referent) µg/m ³	L	Mean (SD) expressed as a percent of predicted values.	Exp: 91 Ref: 38	Exp: 72.34 (14.18) Ref: 81.01 (20.79) <i>p</i> = 0.196	Exp: 76.04 (16.20) Ref: 86.71 (24.53) <i>p</i> = 0.011	Exp: 116.18 (11.32) Ref: 114.08 (10.79) <i>p</i> = 0.044
Kuo et al. (1997b)	Chrome electroplating Mean Cr(VI) measured in air near electroplating tank: 8.0 µg/m ³ (Cr factors), 2.8 µg/m ³ (Cr-Ni factory) and <LOD (Zn factory) (published separately in Kuo et al. (1997a)); unclear whether for the same factories included in the study)	L	Adjusted regression coefficients (SE) and <i>p</i> -value	Exp: 26 Ref: 34	β: -556.4 (151.2) mL <i>p</i> < 0.01	β: -368.0 (163.9) mL <i>p</i> < 0.05	-
Lindberg and Hedenstierna (1983)	Chrome electroplating Cr(VI) exposure categories were low (<2 µg/m ³), high (≥2 µg/m ³) or mixed exposure to chromic acid and other acids and metallic salts	L	See table below	Multiple comparison groups. See table below	See table below	See table below	-
Sobaszek et al. (1998)	Stainless-steel welding No quantitative exposure measures	L	Mean (SD) expressed as percent of predicted values.	Exp: 130 Ref: 234	Exp: 103 (12) Ref: 101 (13) NS	Exp: 99 (15) Ref: 98 (14) NS	Exp: 95 (8) Ref: 96 (8) NS
Zhang et al. (2022)	Chromate production or application (unspecified whether one or both) Cr(VI) exposure based on measured blood chromium concentration (continuous variable or quartiles with Q1 as referent). Quartiles of blood Cr (µg/L) were Q1: (<1.06), Q2: (1.06-2.23), Q3: (2.24-4.90), Q4 :(>4.91)	L	Fully adjusted regression coefficients (95% CI) and <i>p</i> -value	Total: 515 (918 visits)	β: -1.03 (-2.42, 0.30) L, <i>p</i> = 0.115; Q2: 0.78 (-2.42, 4.24), Q3: -0.33 (-3.94, 3.03), Q4: -2.41 (-6.06, 1.21), <i>p trend</i> = 0.174	β: -1.80 (-3.15, -0.35) L, <i>p</i> = 0.009; Q2: 0.28 (-3.15, 3.85)-0.77, Q3: (-4.55, 2.80), Q4: -4.24 (-8.06, -0.35), <i>p trend</i> = 0.033	β: -0.77 (-1.43, -0.10) %, <i>p</i> = 0.024; - Q2: 0.93 (-2.69, 0.84), Q3: -0.42 (-2.25, 1.41), Q4: -1.81 (-3.75, 0.14), <i>p trend</i> = 0.124

^aTotal Cr includes Cr(III) and Cr(VI). No quantitative Cr(VI) exposure measurements reported.

Table 3-5. Summary of results from [Lindberg and Hedenstierna \(1983\)](#) study of effects of Cr(VI) exposure on pulmonary function

Study information	N	FVC	FEV
Exposure Chrome electroplating Study confidence Low Result format Mean (SD) expressed as actual volume (Liters of air) Note: Measurements were taken Monday morning before work, Thursday morning before work, and Thursday afternoon after work	Males only, Monday morning before work: Exp: 26 nonsmokers Exp: 48 smokers Ref: 52 nonsmokers Ref: 67 smokers	Nonsmokers, Exp: 5.61 (0.99) Nonsmokers, Ref: 5.20 (1.00) NS Smokers, Exp: 5.27 (0.90) Smokers, Ref: 5.66 (1.02) NS	Nonsmokers, Exp: 4.54 (0.92) Nonsmokers, Ref: 4.08 (0.85) NS Smokers, Exp: 4.31 (0.85) Smokers, Ref: 4.38 (0.92) NS
	Males and females, Non-smoker, High Exp (n = 6)	Mon. morning: 5.96 (1.64) Thurs. afternoon: 5.75 (1.58) $p < 0.01$	Mon. morning: 5.13 (1.37) Thurs. afternoon: 4.92 (1.29) $p < 0.05$
	Males and females, Non-smoker, Low Exp (n = 10)	Mon. morning: 5.41 (1.27) Thurs. afternoon: 5.35 (1.24) NS	Mon. morning: 4.45 (1.05) Thurs. afternoon: 4.43 (0.97) NS
	Males and females, Non-smoker, Mixed Exp (n = 15)	Mon. morning: 4.93 (1.17) Thurs. afternoon: 4.73 (1.22) $p < 0.01$	Mon. morning: 4.12 (0.92) Thurs. afternoon: 4.06 (0.95) NS
	Males and females, Smoker, All Exp (n = 48)	Mon. morning: 5.04 (1.04) Thurs. afternoon: 4.97 (0.97) $p < 0.05$	Mon. morning: 4.07 (0.95) Thurs. afternoon: 4.00 (0.91) NS

1 One low confidence study ([Li et al., 2015b](#)) reported lower FVC and FEV1.0 in chromate
 2 workers compared to referents (workers in the same plant in administrative offices) with little to
 3 no exposure to Cr(VI) in China ([Li et al., 2015b](#)) (Table 3-4). The percent predicted values for FVC
 4 and FEV1.0 in the exposed group were 72.34 (SD: 14.18) and 76.04 (SD: 16.20), respectively,
 5 compared with 81.01 (SD: 20.79) and 86.71 (SD: 24.53), respectively, in the referent group. The
 6 low percent predicted values in both the exposed and referent groups may in part reflect the high
 7 prevalence of smoking (39.56% of exposed and 28.95% of unexposed workers were current
 8 smokers), which was not accounted for in these analyses. Another possible reason for low percent
 9 predicted values across groups is that the referent group had undescribed exposure to Cr(VI) or
 10 other respiratory toxicants. Finally, it is possible that use of reference values from an ethnically
 11 different population (in this case, Japanese and European referent populations, per correspondence
 12 with study author ([Jia, 2021](#))) could have resulted in low percent predicted values ([Korotzer et al.,
 13 2000](#)). The use of an inappropriate referent to estimate predicted pulmonary function measures
 14 may not impede comparisons of FVC and FEV1.0 between groups within the same study; however,

1 the impact could differ for FVC compared with FEV1.0, thus there is greater uncertainty in
2 FEV1.0/FVC results (mean [SD]: 116.18 [11.32] in exposed, 114.08 [10.79]).

3 Another *low* confidence study comparing chrome electroplaters to zinc electroplaters in
4 Taiwan ([Kuo et al., 1997b](#)) reported average FVC and FEV values were 556.4 mL (SD: 151.2,
5 $p < 0.01$) and 368.0 mL (SD 163.9, $p < 0.05$) lower, respectively, in the group of chrome
6 electroplaters after adjusting for age and sex (Table 3-4). However, height (an important predictor
7 for these measures) was not accounted for in comparison of spirometry values.

8 A *low* confidence study of chromium electroplaters in Sweden ([Lindberg and Hedenstierna,
9 1983](#)) (Table 3-5) did not find significant differences between FVC or FEV1.0 comparing those with
10 low and high average exposure to chromic acid, nor when comparing exposed workers and a
11 referent group of auto mechanics. However, when evaluating spirometry measurements over the
12 course of the work week (pre-shift on Monday morning vs. post-shift on Thursday afternoon), there
13 were significant decrements in both measures for those in the high exposure group. This finding
14 demonstrates the potential for short-term effects of chromic acid exposure to impact lung function
15 within the same individual and is not affected by the potential for confounding by age and height
16 that is a primary concern for the comparison of exposed and referent group lung function
17 measures; however, it does not inform the difference between workers exposed to chromic acid
18 and referent workers.

19 The fourth *low* confidence study ([Sobaszek et al., 1998](#)) also did not report significant
20 differences in FVC, FEV1.0 (or the ratio of FEV1.0/FVC) between exposed and referent groups
21 (Table 3-4). There were no major concerns regarding selection bias, outcome measurement, or
22 statistical analyses in this study, which presented results as a percent of predicted values and
23 followed ATS protocols. Rather, the *low* confidence rating arose from concerns about the ability of
24 the study to detect an association in the presence of exposure misclassification arising from the lack
25 of quantitative exposure data ([Sobaszek et al., 1998](#)). However, an additional analysis conducted in
26 this study may provide supporting evidence of an association between chronic exposure to
27 stainless-steel welding fume and decreased pulmonary function. In this analysis, maximal
28 expiratory flow (MEF) first increased and then decreased with exposure quantified as years of
29 duration in welding. The initial increase in MEF may indicate that more susceptible workers
30 quickly left the workforce (i.e., healthy worker effect). Subsequently, the remaining workers
31 experienced a decrease in MEF after long-term exposure to stainless-steel welding fume (more than
32 25 years), a pattern that is consistent with the results of the *low* confidence study reporting
33 decreases in pulmonary function in workers exposed to Cr(VI) compared to lesser exposed workers
34 ([Li et al., 2015b](#)).

35 A fifth *low* confidence study ([Zhang et al., 2022](#)) reported a statistically significant decrease
36 in FEV1 (β : -1.80 (-3.15, -0.35) L, $p = 0.009$), as well as a statistically significant decrease in
37 FEV/FVC β : -0.77 (-1.43, -0.10) %, $p = 0.024$, per 1 $\mu\text{g/L}$ increase in blood chromium
38 concentration. No significant change in FVC was observed in relation to blood chromium. A

1 limitation of this study was the use of blood chromium concentrations to assess exposure to Cr (VI)
2 in the absence of job, process, or air data. Blood chromium does not distinguish exposure to
3 trivalent versus hexavalent chromium. In the exposure setting described, trivalent exposure was
4 likely, and it is not clear how much exposure to Cr (VI) contributed to chromium blood
5 concentration.

6 Overall, there is an indication in three *low* confidence human studies that higher Cr (VI)
7 exposure is associated with decrements in lung function assessed using spirometry, and the two
8 remaining *low* confidence studies may have had insufficient sensitivity to appropriately
9 characterize such associations.

10 **3.2.1.2. Animal Evidence**

11 Study evaluation summary

12 The eight animal toxicology studies that were considered in the evaluation of the effects of
13 Cr(VI) on the respiratory tract are summarized in Table 3-6. All these studies used the inhalation
14 route of exposure (nose only or whole body) using respirable aerosols²⁴ and examined respiratory
15 effects in male rats, mice, and rabbits. Female animals were not assessed. The exposure duration
16 for the mouse studies was 2 years, while the rabbit studies were limited to 4–6 weeks. The rat
17 studies ranged from 4 weeks to 18 months.

18 The outcomes reported can be generally grouped into three categories: cellular responses,
19 lung histology and lung weight. Cellular responses include cell recruitment (the transfer of vascular
20 cells; monocytes, granulocytes/neutrophils, and lymphocytes into the airways), cell function
21 (macrophage phagocytosis) and release of cellular products (proteins and enzymes). Cell
22 recruitment is evaluated using bronchoalveolar lavage (BAL) to obtain total cell counts, and relative
23 abundance of the various resident and recruited populations of cells recovered in the BAL fluid
24 (BALF) including monocytes, macrophages, granulocytes/neutrophils, and lymphocytes. Cell
25 function is evaluated by measuring the ability of macrophages to phagocytose foreign particles and
26 their ability to release protective oxidant enzymes. Cellular products released by protective cells
27 within the lumen of the lung that can be measured in the BALF include cytokines, intracellular
28 enzymes, and proteins, as well as other cell signaling chemicals.

29 Most of the study outcomes focusing on cellular responses and histopathology were rated as
30 *medium* confidence with minor concerns that did not negatively affect the overall outcome
31 confidence rating. Five study outcomes were rated as *low* confidence (four of these were for lung
32 weight, and one was for lung histopathology), and one was rated *uninformative* (Table 3-6).

²⁴For study evaluation, consideration was given to reporting (or lack of reporting) of particle size and distribution (such as mass median aerodynamic diameter [MMAD] and geometric standard deviation [GSD]). Lack of reporting on particle sizes negatively impacted the *exposure methods sensitivity* rating and *overall confidence* rating.

Table 3-6. Summary of included studies for Cr(VI) respiratory effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a

[Click to see interactive data graphic for rating rationales.](#)

Author (year)	Species (strain) ^b	Exposure design	Exposure route	Respiratory outcomes		
				Cellular responses	Histopathology	Lung weight
Cohen et al. (2003)	Rat (F344)	4, 8, 12, 24, 48 wk	Inhalation	M		
Glaser et al. (1985)	Rat (Wistar)	28 and 90 d	Inhalation	M	M	M
Glaser et al. (1986)	Rat (Wistar)	Chronic	Inhalation		U	L
Glaser et al. (1990)	Rat (Wistar)	30 d, 90 d, and 90 d with 30 d recovery	Inhalation	M	M	L
Johansson et al. (1986a)	Rabbit (not specified)	4–6 wk	Inhalation		M	L
Johansson et al. (1986b)	Rabbit (not specified)	4–6 wk	Inhalation	M	M	
Kim et al. (2004)	Rat (Sprague-Dawley)	90 d	Inhalation		M	L
Nettesheim et al. (1971)	Mouse (C57BL/6)	2 yr	Inhalation		L	

^aIn addition to these studies, four studies meeting PECO criteria were found to be *uninformative* at the study evaluation stage for all outcomes assessed: [Nettesheim et al. \(1970\)](#), due to incomplete reporting of histopathological findings in all the groups, and a group of non-English language studies (Adachi et al., [1987](#); [1986](#); [1981](#)), due to the English-language abstract and results indicating that the exposure vehicle purposefully contained additional contaminants in order to simulate a chromic acid bath. [Glaser et al. \(1986\)](#) was rated *uninformative* only for the outcome of histopathology due to incomplete reporting of histopathological findings in all the groups.

^bAll data are for male animals.

1 Synthesis of animal evidence

2 *Lung cellular responses in BALF*

3 When particulate matter is inhaled, the lungs typically respond by increasing phagocytic cell
4 populations to aid in clearance of the particles. Populations of macrophages in the lung increase by
5 replication of the resident lung macrophages ([Bitterman et al., 1984](#)), as well as by recruitment of
6 monocytes from the bloodstream that travel to the lung and mature to macrophages ([van Oud
7 Alblas and van Furth, 1979](#)). In addition, granulocytes (i.e., neutrophils) can be recruited to assist
8 in the phagocytosis of the foreign particles ([Kodavanti, 2014](#)). These changes in cell populations,
9 indicative of inflammation, may be accompanied by biochemical markers of cell injury, such as
10 changes in the amounts of total protein, albumin, and lactate dehydrogenase (LDH) activity in BALF
11 ([Henderson, 1984](#)). These cellular responses are protective immediately following exposure but

1 can become injurious to the organism if they are prolonged, leading to long-term changes such as
2 increased alveolar-capillary permeability (pulmonary edema).

3 Four of the included studies reported cellular response outcomes, all of which had *medium*
4 confidence ratings. Laboratory animals exposed to aerosols of Cr(VI) exhibited changes in the
5 protective cells that reside in or recruit to the lung. Findings included changes in the number of
6 macrophages, granulocytes/neutrophils, and lymphocytes, as well as changes in the total BAL cells.
7 Chromium concentration-related changes in the number of macrophages recovered in the BALF
8 were observed in all four studies ([Cohen et al., 2003](#); [Glaser et al., 1990](#); [Johansson et al., 1986b](#);
9 [Glaser et al., 1985](#)), although the direction of the effects were not consistent across studies or
10 durations of exposure (Figure 3-9).

11 Statistically significant increases in numbers of alveolar macrophages in BALF were
12 reported in male rabbits exposed to 0.9 mg/m³ Cr(VI) as sodium chromate aerosol for 4–6 weeks
13 ([Johansson et al., 1986b](#)) and in male Wistar rats exposed to Cr(VI) as sodium dichromate at
14 concentrations of 0.20 and 0.40 mg/m³ for 30 or 90 days ([Glaser et al., 1990](#)). In contrast, [Glaser et](#)
15 [al. \(1985\)](#) reported no significant changes in the number of BALF macrophages in male Wistar rats
16 after 28 days of Cr(VI) exposure, and a significant concentration-dependent decrease in the number
17 of BALF macrophages from rats exposed to Cr(VI) concentrations of 0.050 and 0.20 mg/m³ for
18 90 days. The numbers of BALF macrophages in F344 rats exposed to Cr(VI) in the form of calcium
19 chromate aerosol (0.36 mg/m³) for durations of 4, 8, 12, 24, and 48 weeks were decreased relative
20 to controls at most intervals ([Cohen et al., 2003](#)).

21 While data for the number of BALF macrophages were variable in the available studies,
22 macrophages were shown by one research group to undergo replication as a consequence of Cr(VI)
23 exposure via inhalation. Significant increases in specific macrophage populations including
24 polynuclear macrophages ([Glaser et al. \(1985\)](#), 90 day, LOAEL 0.05 mg/m³), macrophages in
25 telophase ([Glaser et al. \(1985\)](#), 90 day, LOAEL 0.025 mg/m³) and dividing macrophages ([Glaser et](#)
26 [al. \(1990\)](#), 90 day, LOAEL 0.05 mg/m³) were observed in Wistar rats. In addition, an increase in the
27 average macrophage diameter was noted following a 90-day exposure ([Glaser et al., 1990](#); [Glaser et](#)
28 [al., 1985](#)). In contrast, macrophage diameter in male rabbits exposed to 0.9 mg/m³ Cr(VI) for 4–6
29 weeks was not different from that in controls, although the number of macrophages was
30 significantly increased ([Johansson et al., 1986b](#)). The inconsistency in effects on BALF macrophages
31 could be related to the differences in study design (i.e., form of chromium administered, animal
32 species and strain, exposure design, endpoint methodology). The ability to synthesize results
33 across studies is limited due to the small number of studies reporting a particular outcome.

34 Only two studies examined changes in BALF cell populations other than macrophages after
35 inhalation exposure to Cr (VI). Significant increases in the percentage of BALF lymphocytes were
36 observed in Wistar rats after 28 and 90 days of exposure to 0.025 mg/m³ and 0.05 mg/m³ Cr (VI).
37 However, after 90 days of exposure at a higher dose (0.2 mg/m³) the percentage of BALF
38 lymphocytes was not significantly different from control. Similarly, the percentage of BALF

1 granulocytes / neutrophils was significantly increased over control only after exposure to
2 0.05 mg/m³ Cr(VI), and decreased compared to control at the higher dose of 0.2 mg/m³ ([Glaser et
3 al., 1985](#)). However, the percentage of BALF granulocytes / neutrophils was demonstrated to
4 significantly increase over time following exposure to 0.36 mg/m³ Cr(VI) in a different study using
5 F-344 rats ([Cohen et al., 2003](#)). The differences in rat strains and exposure levels limit ability to
6 draw conclusions for these other cell populations, but the two studies do demonstrate changes at
7 both lower and higher levels of exposure.

8 Limited investigation of BAL cells provides equivocal evidence of changes in functional
9 activity of the macrophages. Specifically, no functional changes were observed in macrophages
10 from rabbits exposed to 0.9 mg/m³ Cr(VI) for 4–6 weeks ([Johansson et al., 1986b](#)) based on
11 measures of oxidative metabolic activity (via ability to reduce nitro blue tetrazolium) and
12 phagocytic activity (using fluorescently-labeled yeast cells). However, male Wistar rats exposed to
13 0.05 mg/m³ Cr (VI) for 28 days, and to 0.025 mg/m³ and 0.05 mg/m³ for 90 days displayed
14 significant increases in phagocytosis of latex particles. Interestingly, at higher concentrations
15 (0.2 mg/m³) phagocytosis was significantly reduced ([Glaser et al., 1985](#)). In addition, exposure to
16 0.2 mg/m³ Cr(VI) for 42 days prior and 49 days post challenge with iron oxide particles
17 demonstrated significant reductions in early and late phase clearance ([Glaser et al., 1985](#)).

18 One *medium* confidence study evaluated several biochemical markers of cell injury ([Glaser
19 et al., 1990](#)). They reported significant increases in total protein, albumin, and LDH activity in the
20 BALF at all Cr(VI) concentrations in male Wistar rats exposed for both 30 and 90 days (90-day time
21 point, LOAEL 0.05 mg/m³); increases were concentration-related and were statistically significant
22 at most concentrations investigated. [Glaser et al. \(1990\)](#) also included a group of rats exposed for
23 90 days with a 30-day recovery period. The author found that many of the BALF endpoints,
24 including total number of macrophages, number of dividing macrophages, and LDH levels, had
25 returned to approximately control values at the end of the recovery period. However, BALF total
26 protein remained statistically significantly elevated at all exposure concentrations, and BALF
27 albumin remained statistically significantly elevated in the two highest concentration groups (0.20
28 and 0.40 mg/m³) even after recovery (Figure 3-9). Although only evaluated in one *medium*
29 confidence study, there is additional support for these findings. [Zhao et al. \(2014\)](#) (considered a
30 supplemental study due to use of intratracheal instillation exposure) reported statistically
31 significant increases in albumin and total protein levels in BALF isolated from male Sprague-
32 Dawley rats exposed to 0.022 or 0.22 mg/kg Cr (VI) once per week for four weeks via intratracheal
33 instillation.

34 Although increases in BALF total protein are characteristic of acute lung injury, this marker
35 alone is considered insufficient to indicate lung injury due to its nonspecific nature and unknown
36 source. BALF protein can increase due to leakage of vascular fluid, and/or lung cells releasing more
37 protein in the alveolar lining fluid. A more specific indicator is the observation of increased BALF
38 albumin, which comprises a major portion of BALF protein. Albumin in BALF can only come from

1 vascular leakage, since lung cells will not make and release albumin to the lumen ([Kodavanti](#),
 2 [2014](#)); consequently, increased albumin indicates an alteration in the epithelial and vascular
 3 permeability of the lung. While the database that evaluated BALF albumin, protein and LDH only
 4 includes one to two studies, the positive evidence suggests lung epithelial and vascular injury
 5 following Cr (VI) exposure.




Figure 3-9. Lung cellular responses in BALF in male animals. The 120-day observation time in [Glaser et al. \(1990\)](#) incorporates 90 days of exposure followed by a 30-day period of no exposure (recovery time). [Click to see interactive graphic](#). A graphic containing 30-day data by [Glaser et al. \(1990\)](#) can be found in [HAWC](#). An expression of dose-response for selected cellular responses can be found in Section 4.2.1 and in [HAWC](#).

6 *Lung histopathology*

7 Histopathology is a classic approach used in evaluating effects on the lung and can detect a
 8 large range of effects from minor changes in cell populations to significant structural alterations.
 9 Seven of the included studies reported histopathological outcomes, comprising five *medium*

1 confidence, one *low* confidence, and one *uninformative* study. [Nettesheim et al. \(1971\)](#) was rated
2 *low* confidence for the outcome of histopathology. Results for this study were only provided
3 qualitatively and without identifying lesions in any specific treatment group or comparison to
4 control (see [HAWC](#) for details).

5 One of the *medium* confidence studies dealt specifically with in vitro ultrastructural electron
6 microscopy of macrophages with no additional tissue characterization ([Johansson et al., 1986b](#)). In
7 general, three of the four remaining *medium* confidence, short-term and subchronic studies of
8 Cr(VI) in rats and rabbits provide consistent evidence of histiocytosis (macrophage accumulation)
9 in the lung ([Kim et al., 2004](#); [Glaser et al., 1990](#); [Johansson et al., 1986a](#)) while one subchronic rat
10 study ([Glaser et al., 1985](#)) reported normal histopathology findings following Cr(VI) exposure
11 (Figure 3-10).

12 In one *medium* confidence study, the incidence of accumulation of macrophages in the
13 alveolar and peribronchial region of the lung was increased in male Wistar rats exposed to
14 0.050–0.40 mg/m³ Cr(VI) as sodium dichromate for exposure durations of 30 days (incidence:
15 30%–80%; the concentration-response curve was nonmonotonic, with maximal incidence at
16 0.10 mg/m³), 90 days (incidence: 90%–100%), and 90 days with a 30-day recovery period
17 (incidence: 50%–100%) ([Glaser et al., 1990](#)). A second *medium* confidence study of similar design
18 by the same authors did not appear to have investigated these effects ([Glaser et al., 1985](#)).

19 Additionally, macrophage aggregation and the accumulation of foamy cells were observed
20 in male Sprague-Dawley rats exposed to Cr(VI) as chromium trioxide aerosol for 90 days [Kim et al.](#)
21 [\(2004\)](#). All rodents in the high concentration group (1.25 mg/m³) exhibited accumulation of
22 macrophage aggregations and foamy cells in the alveolar region. This effect was observed to a
23 lesser extent at 0.5 mg/m³ but was not observed at 0.2 mg/m³. This indicates a dose-response
24 relationship; quantitative data for these effects were not presented in this study but the pattern can
25 be inferred based on statements regarding number of animals (i.e., ‘all’, ‘less than all’, ‘none’).

26 Finally, increased intra-alveolar or intrabronchiolar accumulation of macrophages was
27 reported in 4 of 8 male rabbits exposed to 0.9 mg/m³ Cr(VI) in the form of sodium chromate for
28 4–6 weeks ([Johansson et al., 1986a](#)). Some macrophages were enlarged, multinucleated or
29 significantly vacuolated and accumulated in a nodular formation. In this study and a companion
30 study that examined macrophages lavaged from the right lung of these rabbits ([Johansson et al.](#)
31 [1986b](#)), ultrastructural examination of macrophages revealed large lysosomes with dark or
32 electron-dense patchy inclusions and short membranous fragments or lamellae. The percentage of
33 cells that contained inclusions and the percentage of macrophages with a smooth surface were
34 stated to be significantly increased in the Cr(VI)-exposed group ($p < 0.02$; however, quantitative
35 data were not presented ([Johansson et al., 1986b](#)).

36 Evidence for Cr(VI)-related histopathologic changes in the lungs other than macrophage
37 accumulation is limited, and there is some suggestion of a transient effect. A high incidence of
38 bronchioalveolar hyperplasia (70–100%) was reported in male Wistar rats after 30 days of

1 exposure to 0.050–0.40 mg/m³ Cr(VI) relative to the control (10%) (Glaser et al., 1990). The same
 2 study reported lower incidence of this effect after 90 days of exposure, and after 90 days of
 3 exposure with a 30-day recovery period. There was an increased incidence of fibrosis (10–40%) in
 4 the groups exposed for 30 days to concentrations at or above 0.1 mg/m³ Cr(VI), but no increase for
 5 the 90-day exposure groups. Glaser et al. (1990) also stated that the upper airways of male Wistar
 6 rats exposed 0.1–0.40 mg/m³ Cr(VI) showed focal inflammation; however, incidence data were not
 7 reported, and the exposure period was not stated. Other investigators did not discuss examination
 8 of the upper respiratory tract in experimental animals. Glaser et al. (1985) noted qualitatively that
 9 all Wistar male rats exposed for 90 days to 0.025–0.20 mg/m³ Cr(VI) exhibited normal histologic
 10 findings in the lung. Nettesheim et al. (1971) exposed mice to calcium chromate dust from
 11 6 months to approximately 120 weeks at a single concentration of 13 mg/m³. This concentration
 12 was significantly higher than those used in the Glaser et al. studies. The study observed marked
 13 changes in the small airways (ranging from epithelial necrosis and atrophy to marked hyperplasia).
 14 In addition, the study observed bronchiolarization of the alveoli, and alveolar proteinosis with
 15 distention of the terminal bronchioli and alveoli.

16 In general, histiocytosis and other effects observed in macrophages were observed in the
 17 lung following Cr(VI) exposure. Less data was available for bronchiolar hyperplasia, and there is
 18 some indication those effects did not persist. The study design by Glaser et al. (1990) allowed for
 19 histopathological effects to be observed as a function of concentration and time (including after a
 20 recovery period). Bronchiolar hyperplasia peaked at the earliest time point examined (30 days)
 21 and diminished over time. Histiocytosis peaked at 90 days and only slightly diminished during the
 22 30-day recovery period. Based on the 30- and 90-day experiments, and the recovery period data,
 23 the structural changes in the lung appear to be transient while the influx of cells persists.




Figure 3-10. Histopathological results and effects in macrophages in male rat lungs. Results from Kim et al. (2004) were qualitative, and dose ranges and the noted statistically significant dose groups are presented here for comparative purposes. The 120-day observation time from Glaser et al. (1990) incorporates 90

days of exposure followed by a 30-day period of no exposure (recovery time). [Click to see interactive graphic](#). [A figure containing incidence data of selected histopathological outcomes](#) can be found in Section 4.2.1 or in [HAWC](#).

1 *Lung weight*

2 Increases in lung weight, a nonspecific indicator of lung injury, can occur from a variety of
3 pulmonary conditions, including edema, inflammation (including macrophage accumulation),
4 fibrosis, accumulation of foreign matter, or abnormal tissue growth (e.g., tumors). Changes in lung
5 weight were examined in five of the included studies, one of which was *medium* confidence while
6 the remaining four were considered *low* confidence for this endpoint.

7 The relative lung weight outcome in [Glaser et al. \(1990\)](#) was rated as *low* confidence
8 because the study lacked sufficient methodological details for measuring lung weight and reduced
9 body weight gain in exposed rats. The relative lung weight outcome in [Glaser et al. \(1986\)](#) was
10 rated as *low* confidence because the study lacked sufficient methodological details for measuring
11 lung weight, only included data for the high dose group, and did not report absolute lung weight
12 (despite reporting end-of-study body weight loss). The lung weight outcome in [Johansson et al.](#)
13 [\(1986a\)](#) was rated *low* confidence for several reasons: inconsistent exposure times on study,
14 variable weight/age of animals in the control and exposure groups, lack of documentation of end-
15 of-study weight, and reporting of absolute lung weight only. The [Kim et al. \(2004\)](#) study was also
16 rated *low* confidence for lung weight due to reporting of only relative weights, when both relative
17 and absolute weights of the lung and other organs are preferred for assessing effects from body
18 weight changes and differing types of lung toxicity.

19 Increased lung weight, which was attributed to accumulation of macrophages, was
20 observed in one *medium* confidence and one *low* confidence study following subchronic inhalation
21 exposure to Cr(VI). [Glaser et al. \(1985\)](#), reported increased mean relative lung weights (9–35%) in
22 Wistar rats exposed for 90 days to Cr(VI) at concentrations of 0.05–0.20 mg/m³. Study authors also
23 noted that relative lung weights were also increased after 28 days of exposure to Cr(VI)
24 concentrations ≥0.05 mg/m³; however, quantitative lung weight data were not presented for these
25 higher doses. In a similarly designed study by the same investigators, [Glaser et al. \(1990\)](#) reported
26 a concentration-dependent increase in relative lung weight in Wistar rats following both 30 and 90
27 days of exposure (9–48%), and following a 90-day exposure with a 30-day recovery period (5–
28 23%); the increase was statistically significant at concentrations of 0.10–0.40 mg/m³ at all time
29 points, and at the lowest concentration (0.05 mg/m³) after 30 days of exposure. In contrast,
30 statistically significant changes in lung lower left lobe weight were not observed in male rabbits
31 exposed to 0.9 mg/m³ for 4–6 weeks ([Johansson et al., 1986a](#)), and changes in relative lung weight
32 were not observed in male Sprague-Dawley rats exposed at concentrations ranging from 0.2–
33 1.25 mg/m³ for 90 days ([Kim et al., 2004](#)).

34 In the only available chronic study ([Glaser et al., 1986](#)), mean relative lung weight in Wistar
35 rats exposed to 0.10 mg/m³ (highest concentration tested) for 18 months and kept on study for

1 another 12 months (total time on study: 30 months) was 15% greater compared with controls,
 2 although this change cannot be interpreted as clearly due to macrophage accumulation given the
 3 observation of lung tumors at this concentration. Lung weights were not reported for the low- and
 4 mid-concentration exposure groups where tumors did not develop, but no changes were noted by
 5 the study authors.

6 To summarize, although there were some inconsistencies in the evidence, increases in lung
 7 weights in Wistar rats were observed in the only *medium* confidence study available and a second
 8 *low* confidence study by the same authors (Figure 3-11). These changes in lung weight may
 9 represent an indicator of nonspecific lung injury or inflammation associated with Cr(VI) inhalation.
 10 The studies reveal that changes in lung weight may vary by species, strains, and exposure duration
 11 and may attenuate over time.




Figure 3-11. Lung weight in male animals. The 120-day observation time incorporates 90 days of exposure followed by a 30-day period of no exposure (recovery time). [Click to see interactive graphic.](#)

12 *Other findings*

13 Various clinical findings that could be related to either upper or lower respiratory tract
 14 effects were observed in two studies. Obstructive respiratory dyspnea was reported in male Wistar
 15 rats exposed for 30 days to 0.2 or 0.4 mg/m³ Cr(VI) in a 30 and 90-day study, although data were
 16 not provided regarding incidence, severity, persistence or recovery ([Glaser et al., 1990](#)). This may
 17 indicate hypersecretion of mucus and accumulation in the upper respiratory tract ([Kodavanti,](#)
 18 [2014](#)). In a 13-week inhalation study ([Kim et al., 2004](#)), “peculiar sound during respiration” was
 19 observed from weeks 1–7 in male Sprague-Dawley rats exposed to 0.2–1.25 mg/m³ Cr(VI) in the
 20 form of chromium trioxide aerosol mists.

21 Summary of lower respiratory effects in animals

22 Based on the evidence presented above, BALF parameters were the most sensitive
 23 indicators of potential lung injury by chromium exposure, which were observed in multiple *medium*
 24 confidence studies in rats and rabbits. These studies typically exposed laboratory animals to
 25 aqueous aerosols of Cr(VI) (with the exception of [Nettesheim et al. \(1971\)](#) which used dust and was
 26 a *low* confidence study). Thus, the effects observed in *medium* confidence studies were unrelated to

1 particle response²⁵. Increases in BALF total protein, albumin, and lactate dehydrogenase (LDH)
2 activity are characteristic of acute lung injury. While total protein is a nonspecific indicator, the
3 concentration of albumin in the BALF is normally very low, and an increase indicates an alteration
4 in the epithelial and vascular permeability of the lung. Damage to cells releases the cytosolic
5 enzyme LDH; increased enzymatic activity of LDH in the BALF is a common finding with acute lung
6 injury ([Henderson et al., 1985](#)). The increase in BALF albumin and LDH activity provide evidence of
7 lung injury following Cr(VI) exposure via inhalation; however, it should be noted that this evidence
8 came from a single study, and no other studies examined these effects. These findings were
9 accompanied by some evidence of histiocytosis (macrophage accumulation) and increased
10 leukocytes in plasma (see Section 3.2.6), which are supportive of inflammatory lung responses
11 ([Nikula et al., 2014](#)), although these findings generally lessened with longer chromium exposure
12 durations and may reflect adaptation or resolution of the cellular responses during these later time
13 points of exposure.

14 The evidence base of histopathological effects in the lung were mostly limited to
15 macrophage accumulation, which were observed by multiple studies of *medium* quality. Findings
16 for other histopathological changes, such as bronchioalveolar hyperplasia, were only reported in
17 one study.

18 Increased lung weight was observed in the single *medium* confidence study in Wistar rats,
19 but not in lower confidence studies in other species and strains. However, lung weight is a
20 nonspecific indicator of lung injury and may be a consequence of multiple other more sensitive
21 outcomes (such as increased macrophages).

22 **3.2.1.3. Mechanistic Evidence**

23 Mechanistic evidence indicating the biological pathways involved in respiratory toxicity
24 following the inhalation of Cr(VI) is summarized below. Studies of human occupational inhalation
25 exposures, in vivo studies in mammals that were exposed via inhalation or intratracheal instillation,
26 and in vitro studies in human primary or immortalized lung cells were prioritized for informing
27 interpretations of respiratory health effects following inhalation exposure to Cr(VI) in humans,
28 although systemic markers of toxicity following inhalation exposures were also considered. These
29 studies focused primarily on oxidative stress and cellular toxicity of the lung and are summarized in
30 Appendix Table C-31 unless otherwise noted.

31 Oxidative stress

32 Cr(VI) compounds are strong oxidizers and can readily enter cells, where they interact with
33 intracellular reductants to form Cr(VI) intermediate species [Cr(V) and Cr(IV)] and the stable

²⁵For control groups, studies typically exposed rodents to filtered air or inert aerosols (with diluent likely being sterile water, although none of the articles provided details). Neither of these are expected to have adverse effects on the airways.

1 Cr(III). These intermediate species form reactive oxygen species (ROS) that at high levels can
2 damage intracellular components, including DNA. Increased oxidative stress induced by Cr(VI) has
3 been consistently reported in many species and cell types (reviewed in Cancer, Section 3.2.3)

4 Twenty-three observational studies measuring various indicators of oxidative stress in
5 humans exposed to Cr(VI) were identified that detected systemic biomarkers of oxidative damage
6 in urine and/or blood (Appendix Table C-56). While a few occupational exposure studies did not
7 detect statistically significant indicators of oxidative stress in exposed workers ([Wultsch et al.](#)
8 [2014](#); [Pournourmohammadi et al., 2008](#); [Kim et al., 1999](#); [Faux et al., 1994](#); [Gao et al., 1994](#)), most
9 studies reported statistically significant increased incidences of oxidative stress through increased
10 levels of relevant markers (e.g., 8-OHdG adducts, lipid peroxidation, decreased levels of antioxidant
11 enzymes) that correlated with exposure to Cr(VI) in urine and blood ([El Safty et al., 2018](#); [Hu et al.,](#)
12 [2018](#); [Yazar and Yildirim, 2018](#); [Pan et al., 2017](#); [Mozafari et al., 2016](#); [Elhosary et al., 2014](#);
13 [Zendehtdel et al., 2014](#); [Wang et al., 2012b](#); [Zhang et al., 2011](#); [Kalahasthi et al., 2006](#); [Goulart et al.,](#)
14 [2005](#); [De Mattia et al., 2004](#); [Maeng et al., 2004](#); [Kuo et al., 2003](#); [Huang et al., 1999](#); [Gromadzińska](#)
15 [et al., 1996](#)). One group investigated welders exposed to Cr(VI), finding significant upregulation of
16 a glycoprotein, Apolipoprotein J/Clusterin, that correlated with chromium levels in blood and urine;
17 ApoJ/CLU has been shown to be involved in cellular senescence and is implicated in diseases
18 related to oxidative stress, inflammation, and aging ([Alexopoulos et al., 2008](#)).

19 Less evidence is available for oxidative stress measured in the lung. One study in exposed
20 workers, [Kim et al. \(1999\)](#), analyzed respiratory epithelial cells from exposed lead chromate
21 pigment factory workers and did not detect a difference in 8-OHdG levels compared to office
22 workers in the same factory. However, the chromium levels measured in the blood were similar
23 between the exposed and referent groups, indicating that perhaps exposure misclassification could
24 have contributed to the null findings. In animals, [Maeng et al. \(2003\)](#) exposed rats via inhalation to
25 0.18 or 0.9 mg/m³ sodium chromate for 1, 2, or 3 weeks and reported increased formation of 8-
26 OHdG adducts after 1 week exposure that resolved at weeks 2–3, despite consistently diminished
27 activity of the enzymes that repair these lesions at weeks 1–3. These results are supported by two
28 studies exposing rats to Cr(VI) via intratracheal instillation that detected significantly increased
29 oxidative DNA lesions (8-OHdG) in the lung following four weekly intratracheal instillations of
30 0.063 or 0.630 mg Cr/kg ([Zhao et al., 2014](#)) or once daily administrations of 0.09 mg Cr(VI)/kg for
31 three consecutive days ([Izzotti et al., 1998](#)).

32 Inhalation exposures provide a direct route for Cr(VI) compounds to be absorbed by the
33 bronchial epithelium, and increased oxidative stress induced by Cr(VI) has been confirmed in
34 studies of human lung cells. Cells deficient in the ability to repair oxidative DNA lesions were
35 reported to have a significant increase in cytotoxicity and cell cycle delay following Cr(VI) exposure
36 ([Reynolds et al., 2012](#); [Reynolds and Zhitkovich, 2007](#)). Cr(VI) exposure has also been observed to
37 cause oxidative stress with minimal or no cytotoxicity, indicating that oxidative stress may in some
38 instances be induced at levels that do not affect cell viability. [Caglieri et al. \(2008\)](#) noted increased

1 lipid peroxidation in BEAS-2B human bronchial epithelial cells with cytotoxicity but also in A549
2 human lung adenocarcinoma cells at subtoxic levels. Asatiani et al. (2011; 2010) observed
3 increased ROS and the antioxidant enzymes glutathione peroxidase, glutathione reductase, and
4 catalase at transiently toxic Cr(VI) concentrations. Martin et al. (2006) found that adding
5 glutathione to Cr(VI)-treated cells decreased levels of ROS; conversely, addition of ascorbate
6 (Vitamin C), a primary intracellular reducer of Cr(VI), increased levels of ROS. The authors theorize
7 that the ascorbate reduction pathway could interact with reactive Cr(V) intermediates that are
8 generated via the glutathione pathway, stabilizing Cr(V) and leading to more potential interaction
9 between Cr(V) and intracellular components. In addition, ascorbate reduction of Cr(VI) occurs at a
10 much faster rate than glutathione and has been shown to result in higher levels of genotoxicity than
11 glutathione (Zhitkovich, 2011). Another group reported that cellular thioredoxins and
12 peroxiredoxins are especially sensitive to oxidation by Cr(VI), disrupting redox signaling and
13 affecting cell survival (Myers et al., 2011; Myers et al., 2010; Myers and Myers, 2009; Myers et al.,
14 2008).

15 Cytotoxicity

16 Apoptosis, or programmed cell death, typically plays a protective role in eliminating
17 damaged cells from the body but can also be triggered by excessive levels of ROS, contributing to
18 tissue damage and inflammation. The evidence from studies of exposed workers for specific
19 measures of apoptosis is sparse due to inadequate information to characterize Cr(VI) exposures.
20 Gambelunghe et al. (2003) did not detect an increase in apoptosis in lymphocytes among chrome-
21 plating workers, although this study was estimating cell death using the comet assay, which is an
22 insensitive method of measuring apoptosis (Appendix Table C-59). Wultsch et al. (2017) reported
23 increased cytotoxicity in the exfoliated buccal and nasal cells of electroplaters indicated by
24 histopathological evidence of nuclear anomalies consistent with apoptosis; however, this study was
25 evaluated for another nuclear effect, micronuclei (Section 3.2.3.2), and was found to be
26 *uninformative* due to critical deficiencies in the exposure domain. Halasova et al. (2010)
27 determined that expression of the apoptosis inhibitor survivin protein was decreased and pro-
28 apoptotic p53 was increased in former chromium workers with lung cancer compared to
29 unexposed lung cancer patients, but the authors did not describe methods for exposure assessment
30 and characteristics of the exposed and unexposed groups that may also affect the apoptosis
31 measures were not compared. In animal models, one intratracheal instillation exposure study in
32 rats observed increased apoptosis in bronchial epithelium and lung parenchyma (D'Agostini et al.,
33 2002).

34 Cytotoxicity occurring at micromolar Cr(VI) levels that increases with dose and duration of
35 exposure has been consistently observed in numerous in vitro studies in human lung cells (Yang et
36 al., 2017; Reynolds et al., 2012; Asatiani et al., 2011; Asatiani et al., 2010; Caglieri et al., 2008;
37 Reynolds and Zhitkovich, 2007; Martin et al., 2006; Pascal and Tessier, 2004; Carlisle et al., 2000;
38 Popper et al., 1993), with some studies specifically detecting increases in apoptotic cell death

1 ([Reynolds et al., 2012](#); [Azad et al., 2008](#); [Reynolds and Zhitkovich, 2007](#); [Gambelunghe et al., 2006](#);
2 [Carlisle et al., 2000](#)). Evidence for the involvement of a p53-mediated pathway for the induction of
3 apoptosis was conflicting; [Carlisle et al. \(2000\)](#) observed a 4–6 fold increase in p53 in LL-24 human
4 lung fibroblasts, and [Gambelunghe et al. \(2006\)](#) observed increased expression of p53 in MOLT-4
5 lymphoblastic leukemia cells, but a similar increase in p53 was not observed in BEAS-2B human
6 bronchial epithelial cells, and [Reynolds and Zhitkovich \(2007\)](#) determined that p53 status had no
7 effect on apoptosis (or cytotoxicity) in primary human lung IMR90 fibroblasts or H460 human lung
8 epithelial cells. Similarly, information on the identification of caspases involved in Cr(VI)-induced
9 apoptosis was conflicting, with one group reporting that inhibiting caspase-3, -8 and -9 did not
10 reduce apoptosis in MOLT-4 lymphoblastic leukemia cells ([Gambelunghe et al., 2006](#)), while
11 another group reported a significant decline in apoptosis after specific suppression of caspase-9 in
12 H460 human lung epithelial cells ([Azad et al., 2008](#)). Autophagy, another cellular defense
13 mechanism that can alternately induce or suppress cell death, was reported following Cr(VI)
14 exposure in A549 human lung adenocarcinoma cells ([Yang et al., 2017](#)). The autophagy was
15 correlated with a transcription factor, HMGA2, that is highly expressed in lung cancer patients, and
16 was suppressed by silencing HMGA2.

17 Cytotoxicity appeared to be dependent on cell type, possibly reflecting underlying
18 differences in sensitivity, with A549 lung adenocarcinoma cells slightly more resistant to
19 cytotoxicity than BEAS-2B bronchial epithelial cells derived from non-tumorigenic cells. [Asatiani et](#)
20 [al. \(2011\)](#) observed that at doses $\leq 5 \mu\text{M}$, the cytotoxicity in HLF fetal human lung fibroblasts and L-
21 41 human epithelial-like cells resolved after 24 h, but these concentrations were sufficient to
22 induce oxidative stress and an upregulation of antioxidant enzymes. Increasing levels of ascorbate
23 to better simulate physiological levels, were found to potentially increase oxidative damage ([Martin](#)
24 [et al., 2006](#)) or promote cytotoxicity and apoptosis by forming Cr-DNA adducts ([Reynolds et al.,](#)
25 [2012](#); [Reynolds and Zhitkovich, 2007](#); [Carlisle et al., 2000](#)). This evidence implies that the
26 pathways for Cr(VI)-induced apoptosis and toxicity in human lung cells are complex and likely to
27 differ substantially among species and cell type.

28 Lung cellular inflammation

29 Specific support for the lung cellular responses in animals discussed in the above evidence
30 synthesis is also provided by two supplemental studies in animals that did not meet PECO criteria
31 due to the route of exposure used (intratracheal instillation). [Zhao et al. \(2014\)](#) reported
32 statistically significant increases in relative lung weight and in albumin and total protein levels in
33 BALF isolated from male Sprague-Dawley rats exposed to 0.063 or 0.630 mg Cr(VI)/kg once per
34 week for four weeks via intratracheal instillation. These effects were concurrent with increases in
35 oxidative damage (8-OHdG lesions) and NF- κ B, consistent with oxidative stress and inflammation.
36 In another study in rats exposed to 0.0035, 0.017, or 0.087 mg Cr(VI)/kg, 5x/week, or 0.017, 0.087,
37 or 0.44 mg/kg, 1x/week via intratracheal instillation for 30 weeks, lungs of animals dosed with

1 ≤0.087 mg/kg Cr(VI) contained macrophage foci, while in the high dose group, in addition to benign
2 and malignant tumors, severe damage and fibrosis to the bronchioloalveolar region of the lung was
3 observed, alongside inflammatory foci that included alveolar macrophages, epithelial cell
4 proliferation, and inflammatory thickening of the alveolar septa ([Steinhoff et al., 1986](#)).

5 Studies investigating immune toxicity (Section 3.2.6) have observed changes in various
6 cytokine signaling in the blood, serum, and plasma of chromate workers exposed to Cr(VI) ([Qian et
7 al., 2013](#); [Mignini et al., 2009](#); [Kuo and Wu, 2002](#)) (Appendix Table C-38), although one study
8 specific to the lung in rats exposed via inhalation to 0.119 mg Cr(VI)/m³ for 5 h/d for 5 consecutive
9 days reported no detectable changes in several cytokines in BALF ([Cohen et al., 2010](#)). In human
10 lung cells in vitro, cytotoxicity was shown to correlate with a net loss of urokinase-type
11 plasminogen activator activity that has been shown to promote pulmonary fibrosis ([Shumilla and
12 Barchowsky, 1999](#)), as well as an inflammatory response via protein phosphorylation and cytokine
13 signaling ([Pascal and Tessier, 2004](#)). Although the direction of these changes was not consistent
14 across studies, fluctuations in systemic cytokine levels and redox imbalance are characteristic of an
15 inflammatory response and may be indicative of a disruption in the regulatory balance that dictates
16 normal immune system function.

17 **3.2.1.4. Integration of Evidence**

18 Overall, the available **evidence indicates** that Cr(VI) likely causes lower respiratory tract
19 effects in humans. Cr(VI) is a known lung carcinogen, but the evidence for noncancer effects in the
20 respiratory tract (with the exception of nasal effects) is more sparse. This evidence integration
21 conclusion is based on observations of decreased lung function among chromium-exposed workers
22 in three of the five *low* confidence human studies and of biochemical effects indicative of lung injury
23 (albumin, LDH, and total protein in BALF) in *medium* confidence animal studies, supported by
24 supplemental and mechanistic observations consistent with an inflammatory tissue response
25 following Cr(VI) exposure. The exposure conditions relevant to these effects are further defined in
26 Section 4.2.

27 The development of the ATS guidelines in 1987 greatly increased the reliability of
28 spirometry measurements. These improvements to outcome measurement technology and
29 methods coincide with or came after changes to industrial processes aimed at reducing Cr(VI)
30 exposures in workers. Thus, while researchers were in a better position to reduce outcome
31 measurement error after the ATS guidelines become available, at the same time, the contrast in
32 exposures was reduced compared to previous decades, impacting study sensitivity. All five of the
33 included human studies thus had potential for decreased sensitivity due to lower exposure levels
34 attributed to industrial hygiene and process changes in more recent years. All five included human
35 studies were found to be *low* confidence, and three of these reported decreases in lung function in
36 chromate workers compared to referents ([Zhang et al., 2022](#); [Li et al., 2015b](#); [Kuo et al., 1997b](#)).
37 Given the consistency of the findings from these three *low* confidence studies and biological
38 plausibility provided by supporting evidence for changes in inflammatory, oxidative stress, and

1 cytotoxicity biomarkers in workers exposed to Cr(VI) (described under “Mechanistic Evidence”),
2 the human studies are interpreted to provide *slight* evidence for lower respiratory tract effects.

3 The pathogenesis of chronic pulmonary disease induced by chemicals toxic to the lung
4 involves the accumulation of inflammatory macrophages ([Laskin et al., 2019](#)). In the available
5 animal studies, which together provide moderate evidence of lung inflammation, histopathological
6 changes in the lung following Cr(VI) exposure included histiocytosis (macrophage accumulation)
7 observed in four out of the five *medium* confidence animal studies. Infiltration of histiocytes was
8 also observed in multiple other organs following oral exposure in rodents (see a broader discussion
9 in Section 3.2.6, Immune Effects), which increases confidence that this inflammatory effect is a
10 result of Cr(VI) exposure. For inhalation exposure, histiocytosis was biologically significant
11 because it accompanied markers in bronchoalveolar lavage fluid (BALF), and increased leukocytes
12 in plasma (see Section 3.2.6), which are observations supportive of inflammatory lung responses
13 ([Nikula et al., 2014](#)). Cellular responses consistent with injury in the lung following Cr(VI) exposure
14 were also observed in animal studies, including increased albumin, total protein, and LDH activity
15 in BALF, biomarkers known to be evidence of injury and vascular leakage in the lower airway and
16 deep lung ([Kodavanti, 2014](#)). Additionally, findings of increased lung weights in a single study of
17 Wistar rats (but not other strains or species examined in lower confidence studies) and clinical
18 findings in two rodent studies of obstructive respiratory dyspnea ([Glaser et al., 1990](#)) and “peculiar
19 sound during respiration” and periodic nose bleeds ([Kim et al., 2004](#)), are coherent with the
20 inflammatory changes consistently indicated in the available animal studies.

21 As described in Section 3.1, inhaled chromium can accumulate in high concentrations at
22 portal-of-entry tissues (such as the respiratory epithelium), resulting in absorption into the
23 epithelial cells in the lung and lung airways, and particles may accumulate in susceptible areas such
24 as airway bifurcation sites. Studies investigating the underlying mechanisms involved in Cr(VI)-
25 induced lung toxicity report significant cytotoxicity at micromolar concentrations in vitro,
26 concurrent with indications of an inflammatory response (oxidative stress, cytokine and nuclear
27 transcription factor activation) as well as increased programmed cell death (apoptosis, autophagy)
28 in response to Cr(VI) exposure. These data support the biological plausibility of the inflammatory
29 tissue responses observed in Cr(VI)-exposed animals. Although the available mechanistic studies in
30 humans were measuring systemic markers of oxidative stress and inflammation in the blood and
31 urine rather than specifically in the lung, consistent evidence of increased reactive oxygen species
32 generation and cytokine modulation in exposed workers is consistent with an inflammatory
33 response that contributes to health effects.

34 For lower respiratory tract effects, there were inconsistencies in the data that may be
35 explained by differences in study design and particle size. Large inhaled particles (with diameter
36 >5 µm) will deposit in the extrathoracic region, particles greater than 2.5 µm are generally
37 deposited in the tracheobronchial regions, and particles less than 2.5 µm are generally deposited in
38 the pulmonary region ([OSHA, 2006](#)). The rodent study of sodium dichromate aerosols by Glaser et

1 al. ([1990](#); [1985](#)) likely induced effects in the lower respiratory tract due to the small particle sizes
2 achieved by the experiment (MMAD < 0.4 µm). For the human occupational studies, particle sizes
3 may have been larger and more variable ([Kuo et al., 1997a](#)), causing a lower proportion of Cr(VI) to
4 deposit in the pulmonary region. However, human studies of occupationally exposed workers still
5 provide some evidence for pulmonary function deficits with increased Cr(VI) exposure. Animal and
6 human studies also differed with respect to the types of data collected, which precluded the ability
7 to directly compare effects. Human data were based on functional measures (pulmonary function
8 evaluated using spirometry), whereas animal data were based on histopathological measures and
9 cellular responses. The endpoints reported by studies in humans and animals were
10 complementary; overall the currently available **evidence indicates** that Cr(VI) is likely to cause
11 lower respiratory toxicity in humans.

Table 3-7. Evidence profile table for respiratory effects other than cancer

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from studies of exposed humans					⊕⊕⊖
<p>PULMONARY FUNCTION Five low confidence studies in occupationally exposed adult workers: Kuo et al. (1997b) Li et al. (2015b) Lindberg and Hedenstierna (1983) Sobaszek et al. (1998) Zhang et al. (2022)</p>	<p>Exposure to Cr(VI) was associated with decreased FVC and FEV1.0 in three <i>low</i> confidence studies (association not statistically significant for FVC in two of the three studies). Exposure to Cr(VI) was associated with decreased FEV1/FVC in one of two <i>low</i> confidence studies that included that endpoint.</p> <p>No association between Cr(VI) and FVC, FEV1.0, or FEV1/FVC was found in the two remaining <i>low</i> confidence studies.</p>	<ul style="list-style-type: none"> • Coherence of observed effects on multiple measures of pulmonary function (apical studies) • Exposure-response gradient 	<ul style="list-style-type: none"> • Imprecision of effect estimates • Low confidence studies • Lack of consistency, though partially explained by differences in study sensitivity and exposure levels 	<p>⊕⊖⊖ <i>Slight</i> Based on decreased pulmonary function with higher exposure to Cr(VI) in three <i>low</i> confidence studies.</p>	<p>The evidence indicates that Cr(VI) inhalation is likely to cause lower respiratory toxicity in humans given sufficient exposure conditions, based on <i>moderate</i> evidence in rats showing increases in biochemical indicators of lung injury and evidence of lung inflammation. This is supported by <i>slight</i> human evidence of decreased pulmonary function from <i>low</i> confidence studies of exposed workers and supportive mechanistic evidence for increases in oxidative stress and cytotoxicity biomarkers.</p> <p>The findings in animals are consistent with known biomarkers of human pulmonary dysfunction and thus considered relevant to humans.</p>
Evidence from animal studies					
<p>LUNG CELLULAR and BIOCHEMICAL RESPONSES, including HISTOPATHOLOGY Six medium confidence studies in rats and rabbits: Kim et al. (2004)</p>	<p><u>Inflammatory changes in BALF</u> Increases in neutrophils/granulocytes in two <i>medium</i> confidence studies, and increased lymphocytes up to 90 days in one <i>medium</i> confidence study.</p>	<ul style="list-style-type: none"> • Consistent evidence of some inflammatory changes in two <i>medium</i> 	<ul style="list-style-type: none"> • Indirect biomarker evidence of lung injury is less specific 	<p>⊕⊕⊖ <i>Moderate</i> Coherent and largely consistent increases in</p>	<p>The evidence is inadequate to determine whether oral Cr(VI) exposure might be capable of causing noncancer respiratory effects. No respiratory effects were observed following ingestion. As described in Section 3.1, Cr(VI) can expose portal-of-</p>

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>Cohen et al. (2003) Glaser et al. (1985) Glaser et al. (1990) Johansson et al. (1986a) Johansson et al. (1986b) One low confidence study in mice: Nettesheim et al. (1971)</p>	<p>Increased macrophages in two <i>medium</i> confidence studies, but no changes or slight decreases in two others.</p> <p><u>Macrophage Functional changes</u> Increased phagocytosis in one <i>medium</i> confidence study (at concentrations ≤ 0.05 mg/m³), but no change in another.</p> <p><u>BALF Biochemistry</u> Increased protein, albumin and LDH in one <i>medium</i> confidence study.</p> <p><u>Histiocytosis</u> Four of five <i>medium</i> confidence studies reported the accumulation of macrophages in the lung by histopathology.</p> <p><u>Other Histological Changes</u> Mixed evidence for bronchiolar hyperplasia (one <i>medium</i> confidence study); epithelial hyperplasia, atrophy, and necrosis (one <i>low</i> confidence study); and normal histopathology (one <i>medium</i> confidence study).</p>	<p>confidence studies in two rat strains</p> <ul style="list-style-type: none"> • Coherence of observed effects across different biomarkers of lung injury • <i>Medium</i> confidence studies • Concentration-response gradient for most effects • Large effect magnitude for histopathologic effects • Biological plausibility (mechanistic evidence of lung oxidative stress and apoptosis in animal models, primarily from 	<p>than pathology</p> <ul style="list-style-type: none"> • Lack of duration-dependence (some effects weakened with longer exposures) • Some unexplained inconsistency in findings for macrophages in BALF and their functional changes • Unclear adversity of some inflammatory changes and lack of expected coherence with more overt histopatholog 	<p>biomarkers of pulmonary injury and inflammatory cells in BALF and lung tissue, as well as mechanistic findings supportive of inflammatory changes in lung.</p>	<p>entry tissues, and reduction of Cr(VI) in these tissues and red blood cells decreases uptake by other organ systems.</p>

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
		instillation and in vitro studies)	ical markers of injury		
<p>LUNG WEIGHT One <i>medium</i> confidence study in rats: Glaser et al. (1985) Four <i>low</i> confidence studies in rats and rabbits: Glaser et al. (1986) Kim et al. (2004) Glaser et al. (1990) Johansson et al. (1986a)</p>	<p><u>Lung Weight</u> Increased lung weights were reported in the only <i>medium</i> confidence study and one <i>low</i> confidence study, both in Wistar rats, with exposures for up to 90 days and for 18 months; however, effects were not observed in other <i>low</i> confidence studies of male rabbits exposed for 4–6 weeks or male Sprague-Dawley rats exposed for 90 days.</p>	<ul style="list-style-type: none"> • Concentration-response gradient in two studies • Effect magnitude (up to 48% increased relative lung weight) • Coherence with some evidence of increased macrophages (leading to increased lung weight) 	<ul style="list-style-type: none"> • Some inconsistency across studies, although inconsistent studies were <i>low</i> confidence 	<p>⊕⊖⊖ <i>Slight</i> Changes in lung weight were reported in one rat strain but not in <i>low</i> confidence studies of a different strain or in rabbits.</p>	
Mechanistic evidence					
Biological events or pathways	Summary of key findings and interpretations			Judgments and rationale	
Oxidative stress	<p><i>Interpretation:</i> Inhalation exposure to Cr(VI) induces a disruption of the cellular redox balance in the lung that is a key component of Cr(VI)-induced lung toxicity.</p> <p><i>Key findings:</i></p>			Biologically plausible, consistent, and coherent	

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<ul style="list-style-type: none"> Consistent evidence of significant increases in oxidative stress in 17 studies of workers exposed to Cr(VI) that correlated with levels of Cr(VI) in urine and blood Increased formation of 8-OHdG DNA adducts in one study of rats exposed to Cr(VI) via inhalation In vitro evidence of oxidative stress with exposure to Cr(VI), including increased ROS production, oxidation of lipids and proteins, and increased antioxidant enzyme activity, in human primary and immortalized lung cells Deficiency in DNA repair of 8-OHdG lesions led to increased cytotoxicity and cell cycle delay following Cr(VI) exposure in vitro 			<p>observations of oxidative stress, leading to cytotoxicity and possibly involving inflammation, which are interrelated processes involved in cellular stress signaling that can underlie the respiratory effects reported in humans and in animals exposed to Cr(VI). Fluctuations in cytokine levels and redox imbalance are characteristic of an inflammatory response and may be indicative of a disruption in the regulatory balance that dictates normal immune system function.</p>	
Cytotoxicity	<p><i>Interpretation:</i> Inhaled Cr(VI) is presumed to be cytotoxic to portal-of-entry tissues; this toxicity, primarily shown by one study in animals and multiple studies of human cells in vitro, may involve programmed cell death in the lung.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Increased apoptosis in the lung of rats exposed to Cr(VI) via intratracheal instillation in one study Consistent in vitro evidence of dose- and time-dependent increases in apoptosis following Cr(VI) exposure in human lung cells Some evidence of increased p53 (which can be pro-apoptotic) with Cr(VI) exposure in humans or human lung cells in vitro 				
Inflammation	<p><i>Interpretation:</i> Inflammation induced by inhalation exposure to Cr(VI) may involve pro-inflammatory cytokine signaling and enhanced ROS generation.</p> <p><i>Key findings:</i></p>				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<ul style="list-style-type: none"> Supplemental evidence of inflammatory cellular changes, histopathology, and increased lung weight in Cr(VI) animal intratracheal instillation studies support animal evidence judgments; these effects were concurrent with increases in oxidative stress and inflammatory cell signaling Cytokine signaling changes in chromate workers (Appendix C.2.5.2) 				

1

3.2.2. Gastrointestinal Tract Effects Other Than Cancer

1 Studies of the GI tract following ingestion of Cr(VI) in humans and animals have generally
2 reported an increased incidence in nonneoplastic lesions in the stomach and portions of the small
3 intestine. The GI tract is responsible for the digestion, absorption, and excretion of ingested
4 substances. The main function of the stomach is storage and digestion; it is lined with epithelial
5 cells with tight junctions that lack the absorptive villi found in the intestines. In the small intestine,
6 the villi in the semipermeable mucosa consist of epithelial cells characterized by a brush border of
7 microvilli that further increase absorptive capacity. Between the villi are deep cavities called
8 crypts. Both crypts and villi contain epithelial enterocytes and goblet cells that secrete mucus. A
9 schematic of the epithelial morphologies of the stomach and small intestine is provided in
10 Section 3.1.1 Pharmacokinetics, Figure 3-5. While the small intestine has a large absorptive
11 capacity it also serves as a barrier (e.g., by mucus secretion) that prevents potentially toxic
12 substances in the lumen, including bacteria, from entering systemic circulation. The crypts in the
13 small intestine supply rapidly dividing stem cells for the renewal of the intestinal epithelium, which
14 turns over within days ([Potten et al., 2009](#); [Potten et al., 1997](#)). Within the stomach, gastric stem
15 cells are located within glandular pits, and unlike the small intestine, they are nearer to the lumen
16 and more likely to be exposed to surface irritants ([Mills and Shivdasani, 2011](#)). In animal studies,
17 the areas of the small intestine that are closer to the stomach (the duodenum and jejunum) appear
18 to be more susceptible to injury than the ileum.

3.2.2.1. Human Evidence

19 The literature search for this assessment did not identify epidemiological studies that met
20 PECO criteria for this health effect. The ATSDR Toxicological Profile ([ATSDR, 2012](#)) describes
21 multiple case reports of deaths among adults and children resulting from ingesting Cr(VI)
22 compounds and subsequent damage to the GI tract and other organs. GI effects reported in acute
23 oral poisoning studies identified in the literature search for this assessment include stomach and
24 esophageal pain, diarrhea, lesions of the stomach and duodenum, hemorrhage of the GI tract, and
25 gut mucosal necrosis ([Goullé et al., 2012](#); [Baresic et al., 2009](#); [Hantson et al., 2005](#); [Kolacinski et al.,
26 2004](#); [Sharma et al., 2003](#); [Stift et al., 2000](#); [Kołaciński et al., 1999](#); [Loubières et al., 1999](#); [Stift et al.,
27 1998](#); [Kurosaki et al., 1995](#); [van Heerden et al., 1994](#)). The ATSDR Toxicological Profile ([ATSDR,
28 2012](#)) also describes reports of stomach pain, GI ulcer, and gastritis among workers employed in
29 electroplating and chromate production from studies published from 1950–1978. The exposures
30 could have occurred via both inhalation and ingestion of Cr(VI) dusts in the workplace. ATSDR
31 concluded that these studies included no or inappropriate comparison groups and therefore a
32 direct association between Cr(VI) exposure and these signs and symptoms could not be drawn.
33

1 **3.2.2.2. Animal Evidence**

2 Study evaluation summary

3 Table 3-8 summarizes the four animal bioassays that were considered in the evaluation of
 4 noncancer effects in the GI tract from ingested Cr(VI). The studies, conducted by two organizations,
 5 the US National Toxicology Program (NTP) ([NTP, 2008, 2007](#)) and ToxStrategies, Inc. ([Thompson et al., 2012b](#); [Thompson et al., 2011](#)), exposed mice and rats of both sexes to Cr(VI) in drinking water,
 6 and were of subchronic duration except for the [NTP \(2008\)](#) 2-year bioassay. Results in all studies
 7 were limited to histopathological observations and mechanistic evidence; the latter is also
 8 described with the evidence for GI tract cancer in Section 3.2.3.2.
 9

Table 3-8. Summary of included studies for Cr(VI) GI histopathological outcomes and overall confidence classification. [Click to see interactive data graphic for rating rationales.](#)

Author (year)	Species (strain)	Exposure design	Exposure route	Histopathology
NTP (2007)	Rat (F344/N), male and female; Mouse (B6C3F1, BALB/c, C57BL/6), male and female	Subchronic	Drinking water	H
NTP (2008)	Rat (F344/N), male and female; Mouse (B6C3F1), male and female	Chronic	Drinking water	H
Thompson et al. (2011)	Mouse (B6C3F1), female	Subchronic	Drinking water	H
Thompson et al. (2012b)	Rat (F344), female	Subchronic	Drinking water	H

High (H), medium (M), low (L), or uninformative (U).

10 Synthesis of evidence in animals

11 All four *high* confidence studies in rats and mice reported various histological effects in the
 12 GI tract associated with oral exposure to Cr(VI). In the small intestine these included diffuse
 13 epithelial/crypt cell hyperplasia, histiocytic cellular infiltration, and degenerative changes in the
 14 villi (vacuolization, atrophy, and apoptosis); in the glandular stomach these included squamous
 15 metaplasia and gastric ulceration ([Thompson et al., 2012b](#); [Thompson et al., 2011](#); [NTP, 2008,](#)
 16 [2007](#)). Across studies, the most commonly observed nonneoplastic GI lesion was epithelial cell
 17 hyperplasia in the mouse small intestine ([Thompson et al., 2012b](#); [Thompson et al., 2011](#); [NTP,](#)
 18 [2008, 2007](#)). Results from studies in mice and rats are summarized in Figures 3-12 and 3-13, and
 19 study design differences are outlined in Table 3-9 (detailed results are summarized in Appendix
 20 Table C-32). Dose-dependent histiocytic infiltration, described by [NTP \(2008\)](#) as being of unknown

- 1 biological significance, was also observed in the small intestine of exposed animals across studies,
- 2 sexes, and species.

Table 3-9. Design features of studies that examined GI tract effects via the oral route of exposure

Study reference	Species/strain and sex	Exposure duration	Number of animals/group	Dose groups (mg Cr(VI)/kg-d)
NTP (2008) ^a	B6C3F1 mouse, male and female	2 years	50	0, 0.450, 0.914, 2.40, 5.70 (M) 0, 0.302, 1.18, 3.24, 8.89 (F)
NTP (2008)	F344 Rat, male and female	2 years	50	0, 0.200, 0.796, 2.10, 6.07 (M) 0, 0.248, 0.961, 2.60, 7.13 (F)
NTP (2007)	F344 Rat, male and female	90 days	10	0, 1.74, 3.14, 5.93, 11.2, 20.9 (M) 0, 1.74, 3.49, 6.28, 11.5, 21.3 (F) ^a
NTP (2007)	B6C3F1 mouse, male and female	90 days	10	0, 3.1, 5.3, 9.1, 15.7, 27.9 (M+F)
NTP (2007)	B6C3F1 mouse, male	90 days	5	0, 2.8, 5.2, 8.7
NTP (2007)	BALB/c mouse, male	90 days	5	0, 2.8, 5.2, 8.7
NTP (2007)	am-C57BL/6 mouse, male	90 days	5	0, 2.8, 5.2, 8.7
Thompson et al. (2012b)	F344 Rat, female	7 days	5	0, 0.015, 0.21, 2.9, 7.2, 20.5
		90 days	10	
Thompson et al. (2011)	B6C3F1 mouse, female	7 days	5	0, 0.024, 0.32, 1.1, 4.6, 11.6, 31.1
		90 days	10	

^aNote: In the synthesis, male and female doses were rounded to the same values for simplicity.




Figure 3-12. Diffuse epithelial hyperplasia in Cr(VI) treated mice in high confidence studies. Note: NTP (2008, 2007) did not present quantitative no-effect

data. However, the dose levels and ranges for the exposure groups without effects are displayed here for comparative purposes. [Click to see interactive data graphic.](#)




Figure 3-13. Diffuse epithelial hyperplasia in Cr(VI) treated rats in high confidence studies. Note: NTP (2008, 2007) did not present quantitative no-effect data. However, the dose levels and ranges for the exposure groups without effects are displayed here for comparative purposes. [Click to see interactive data graphic.](#)

1 In subchronically exposed B6C3F1 mice, statistically significant elevated incidences of
 2 minimal to mild²⁶ diffuse duodenal epithelial cell hyperplasia were observed in both [males](#) and
 3 [females](#) at all doses (≥ 3 mg Cr(VI)/kg-d, incidence increasing with dose) (NTP, 2007). In a
 4 companion subchronic strain comparison study, statistically significant increases in the incidence
 5 of diffuse epithelial hyperplasia in the duodenum were also observed across all three strains of
 6 male mice tested (i.e., B6C3F1, BALB/c, and am3C57BL/6) (NTP, 2007). A separate subchronic
 7 study also showed a significant increase in duodenal hyperplasia in B6C3F1 mice at doses ≥ 11.6 mg
 8 Cr(VI)/kg-d (Thompson et al., 2011). This study did not show increasing incidence with dose, but
 9 the lowest dose level at which the epithelial hyperplasia was observed in Thompson et al. (2011)
 10 (~ 12 mg Cr(VI)/kg-d) was about 4x higher than for NTP (2007) (~ 3 mg Cr(VI)/kg-d), and resulted
 11 in dose-dependent apoptosis (which was statistically significant at the highest dose of 31.1 mg
 12 Cr(VI)/kg-d), which likely degenerated the duodenal tissue. The subchronic results of hyperplasia
 13 in the duodenum were consistent with a 2-year study that showed statistically significant elevated
 14 incidences of minimal to mild diffuse epithelial cell hyperplasia in the duodenum of the same
 15 severity but at lower doses (≥ 0.3 mg Cr(VI)/kg-d, incidence increasing with dose with the exception
 16 of the high dose males that had a slightly lower incidence than the second highest dose group)
 17 (NTP, 2008). In the jejunum, there were no significantly elevated increases in epithelial cell
 18 hyperplasia in either sex of B6C3F1 mice in a subchronic study at doses up to 28 mg Cr(VI)/kg-d
 19 (NTP, 2007), but in a second subchronic study, female mice of the same strain showed statistically
 20 significant elevated epithelial cell hyperplasia in the jejunum at doses ≥ 11.6 mg Cr(VI)/kg-d
 21 (Thompson et al., 2011). In the 2-year mouse study, this effect was observed in the jejunum of

²⁶According to NTP severity grading: 1=minimal, 2=mild, 3=moderate, 4=marked.

1 female mice at the highest dose (8.89 mg Cr(VI)/kg-d) ([NTP, 2008](#)). Together, these results show a
2 consistent pattern of minimal to mild diffuse epithelial hyperplasia in mice, which was present in
3 subchronic studies at higher doses compared to the chronic study.

4 In subchronic and chronic NTP studies in F344 rats, increased diffuse epithelial hyperplasia
5 was not observed in the small intestine ([NTP, 2008, 2007](#)). In contrast, a statistically significant
6 increase in these lesions was observed following ≥ 7.2 mg Cr(VI)/kg-d exposures for 7 and 90 days
7 in female F344 rats in a study by a separate group ([Thompson et al., 2012b](#)). The differences in the
8 presence or absence of these lesions in F344 rats across studies is unknown, but this may have
9 been affected by differences in water intake between the two study groups, leading to higher
10 exposures to the rats in the the [Thompson et al. \(2012b\)](#) study. At the administered Cr(VI)
11 concentrations, which were nearly equivalent between the studies, the mg/kg-d doses in the NTP
12 subchronic bioassay ([NTP, 2007](#)) and the time weighted average doses from weeks 1–13 in the NTP
13 chronic bioassay ([NTP, 2008](#)) were approximately twofold lower than the mg/kg-d doses in
14 [Thompson et al. \(2012b\)](#)). In addition, [Thompson et al. \(2012b\)](#) noted that the animal vendor
15 sources for the F344 rats were different between groups (NTP used animals from Taconic Farms,
16 Inc. ([NTP, 2008, 2007](#)) and [Thompson et al. \(2012b\)](#) used animals from Charles River Laboratories
17 International, Inc.), although the mice used by each group were also procured from these two
18 different sources, respectively.

19 In the rat glandular stomach, there were also observations of epithelial hyperplasia along
20 with several other lesion types in a subchronic but not chronic studies. These lesions were not
21 observed in a subchronic study of three different strains of mice, nor in a chronic mouse study.
22 Statistically significant increased incidences of epithelial hyperplasia, squamous metaplasia, and
23 ulcers in the glandular stomach were reported in male and female F344 rats exposed to 21 mg
24 Cr(VI)/kg-d (the highest dose) in the 13-week NTP study ([NTP, 2007](#)). No statistically significant
25 increased incidences of glandular stomach or forestomach lesions were reported in the 2-year
26 studies of F344 rats and B6C3F1 mice ([NTP, 2008](#)), or in the [NTP \(2007\)](#) 13-week studies of
27 B6C3F1, BALB/c, or *am3-C57BL/6* mice. Neither of the Thompson et al. ([2012b; 2011](#)) 13-week
28 studies conducted histologic examinations of the forestomach or glandular stomach of mice or rats.
29 The inconsistency between subchronic and chronic study results in rats is likely attributable to
30 dose selection; in the 13-week study, stomach lesions occurred at an exposure that was threefold
31 higher than the highest dose administered in the 2-year chronic assay.

32 Degenerative changes to the cells lining the GI tract can manifest as necrosis, apoptosis, and
33 subsequent villous stunting, resulting in crypt abscess and ulceration ([Betton, 2013](#)). The NTP
34 subchronic bioassay reported that the duodenal villi of B6C3F1 mice were short, thick, and blunted,
35 with cytoplasmic vacuolization in the epithelial cells lining the villi tips at doses up to 27.9 mg
36 Cr(VI)/kg-d (results were not presented quantitatively) ([NTP, 2007](#)). Consistent with these results,
37 the NTP 2-year bioassay qualitatively reported degenerative effects in mouse duodenal villi
38 (described as short, broad, and blunt) at doses up 8.89 mg Cr(VI)/kg-d. These effects were not

1 reported in F344 rats at doses up to 21 or 7.13 mg Cr(VI)/kg-d after subchronic exposure or
2 chronic exposure respectively ([NTP, 2008, 2007](#)). GI tissue atrophy and apoptosis were not
3 reported in the NTP bioassays in either species ([NTP, 2008, 2007](#)). Although cytoplasmic
4 vacuolization, when irreversible, can be considered a marker of cell death due to cytoprotective
5 autophagy in response to stress ([Shubin et al., 2016](#)), the vacuolization observed in epithelial cells
6 at the tips of villi in mice in the subchronic study was not interpreted by NTP to be indicative of
7 atrophy or apoptosis and was not observed in the 2-year bioassay ([NTP, 2008, 2007](#)). There was an
8 increased incidence of minimal to mild salivary gland atrophy in female rats after two years at the
9 two highest doses (the effect at the highest dose lacked statistical significance), although this effect
10 is of unknown biological significance.

11 [Thompson et al. \(2011\)](#) reported degenerative changes in the intestines of female B6C3F1
12 mice after subchronic exposure including statistically significant atrophy in villi of the duodena and
13 jejunum (31.1 mg Cr(VI)/kg-d, highest dose), apoptosis in the duodenal villi (31.1 mg Cr(VI)/kg-d),
14 and cytoplasmic vacuolization in the duodena and jejunum (≥ 4.6 mg Cr(VI)/kg-d) (Figure 3-14).
15 These results are generally consistent with the descriptive observations reported by NTP in mice
16 after subchronic and chronic exposure. While the subchronic NTP study did not report identical
17 histopathological findings, it stated that “the epithelial cells lining the tips of the villi of many of the
18 exposed mice were swollen and had vacuolated cytoplasm. Collectively, these duodenal lesions
19 suggest regenerative hyperplasia secondary to previous epithelial cell damage or degeneration”
20 ([NTP, 2007](#)). The subchronic study in female F344 rats by [Thompson et al. \(2012b\)](#) also reported
21 apoptosis of the duodenal villi at the two highest doses (7.2 and 20.5 mg Cr(VI)/kg-d), but no
22 atrophy or vacuolization (Figure 3-14).

23 Two follow-up publications using the same experimental subchronic dataset in female
24 B6C3F1 mice ([Thompson et al., 2011](#)) reported increases in some markers of duodenal villus
25 cytotoxicity described as karyorrhectic nuclei, desquamation, villous blunting, and disruption of
26 cellular architecture in the duodenal villi at doses ≥ 4.6 mg Cr(VI)/kg-day ([Thompson et al., 2015a](#);
27 [O'Brien et al., 2013](#)). It should be noted that [O'Brien et al. \(2013\)](#) only evaluated one animal in the
28 next-lowest dose group (1.1 mg Cr(VI)/kg-day) for desquamation and disruption of cellular
29 arrangement. In the crypt compartment, although increases in crypt length, area, and number of
30 crypt enterocytes were reported, there were no statistically significant or dose-responsive changes
31 in mitotic or apoptotic indices ([Thompson et al., 2015a](#); [O'Brien et al., 2013](#)). Observations after 7-
32 day exposures reported by this group (considered supporting evidence due to the short duration)
33 include duodenal hyperplasia, villous atrophy, and cytoplasmic vacuolization, but again with no
34 changes in crypt apoptosis indices, mitotic activity, or increases in karyorrhectic nuclei in the crypt
35 compartment ([Thompson et al., 2015b](#); [Thompson et al., 2011](#)). The authors attribute this
36 discrepancy to either the 24-hour period without Cr(VI) exposure prior to sacrifice and/or to the
37 sudden increase in the number of crypt enterocytes that then migrated toward the villus and

1 became post-mitotic in that 24-hour period, apparently as mitotic figures were being measured
 2 ([Thompson et al., 2015a](#); [O'Brien et al., 2013](#)).

3 While [NTP \(2008\)](#) noted short, broad, and blunt duodenal villi in mice, they did not report
 4 observing duodenal villus atrophy. In a second review of the NTP 2-year bioassay mouse
 5 histopathology slides by [Cullen et al. \(2015\)](#), these authors reported villus atrophy and blunting in
 6 all mice in the highest dose group. [Cullen et al. \(2015\)](#) also only observed cytoplasmic vacuolization
 7 in males; NTP made a general statement that vacuolization was observed in the tips of the villi
 8 without presenting incidence or details. While there were some descriptive reporting differences
 9 across studies for nonneoplastic histopathological lesions, an independent expert pathology review
 10 ([Francke and Mog, 2021](#)) of the diagnostic criteria used by these reports ([Cullen et al., 2015](#);
 11 [Thompson et al., 2015a](#); [NTP, 2008, 2007](#)) confirmed there was no meaningful difference or
 12 improvement when comparing the five histological diagnoses applied by this second review ([ACC,](#)
 13 [2015](#); [Cullen et al., 2015](#)) to those used by NTP. In fact, NTP addressed four of the five diagnostic
 14 terms used by [Cullen et al. \(2015\)](#) (i.e., histiocytic cellular infiltrates, atrophy/blunting, enterocyte
 15 vacuolation, and epithelial hyperplasia), with the exception of single-cell necrosis (i.e., apoptosis).
 16 Thus, the “short, broad, blunt” duodenal villi of exposed mice reported by [NTP \(2008\)](#) are
 17 analogous to the [Cullen et al. \(2015\)](#) report of “atrophy/blunting” of the villus.




Figure 3-14. Cr(VI)-induced degenerative changes in the small intestines of mice and rats in high confidence studies. [Click here to see interactive graphic.](#)

18 Increased infiltration of histiocytes (macrophage immune cells) in the duodenum and
 19 jejunum was consistently observed in both sexes of rats and mice orally exposed both chronically
 20 and subchronically to Cr(VI) ([Thompson et al., 2012b](#); [Thompson et al., 2011](#); [NTP, 2008, 2007](#)).
 21 [NTP \(2008\)](#) indicated that the biological significance of the histiocytic infiltration is not known, but
 22 surmised that the infiltration of macrophages may reflect phagocytosis of an insoluble chromium
 23 precipitate. It should be noted that while macrophage accumulation may be associated with
 24 inflammation, NTP did not report chronic inflammation in the GI tract, or the influx of other
 25 inflammatory cells associated with the histiocytic infiltration in the small intestine ([NTP, 2008,](#)
 26 [2007](#)).

1 In summary, diffuse epithelial hyperplasia of the small intestine was consistently observed
2 in the three *high* confidence studies in mice, occurring at higher doses in the subchronic studies
3 compared to the chronic study, with similar severity across studies. Diffuse epithelial hyperplasia
4 was also observed in the rat small intestine, but these findings were inconsistent between the two
5 reporting groups. Similar degenerative changes in the duodenal villi were consistently observed
6 across studies, and although the description of these effects varied, the results were essentially the
7 same. Histiocytic infiltration was also consistently observed, though this effect was interpreted by
8 the report authors to be of unknown biological significance ([NTP, 2008](#)) and is likely not adverse on
9 its own.

10 **3.2.2.3. Mechanistic Evidence**

11 The screening and identification of mechanistic studies for evidence relevant to Cr(VI)-
12 induced oxidative stress, cell proliferation and cell death in the GI tract prioritized both oral
13 exposure studies in animals and studies via all routes in animals if results were presented for GI
14 tissues, as well as in vitro studies in human cells derived from GI tissues (primary and
15 immortalized); this prioritization strategy and a summary of the studies can be found in Appendix
16 C.2.2.2. No human oral exposure studies or human studies of cytotoxicity or cell proliferation
17 specific to the GI tract were identified. Because mechanistic evidence from studies of non-
18 malignant toxic effects specific to the GI tract (in vivo or in vitro) following the ingestion of Cr(VI) is
19 also relevant to cancer of the GI tract, a summary of this evidence is presented in Section 3.2.3.3.
20 The evidence supports a consistent, coherent, and biologically plausible role for oxidative stress,
21 cytotoxicity, and cell proliferation induced by Cr(VI) exposure in both the nonneoplastic toxicity
22 and carcinogenic effects of Cr(VI) in the GI tract.

23 Three in vivo studies were identified that reported biomarkers of oxidative stress in GI
24 tissues after oral exposure ([Thompson et al., 2012b](#); [Thompson et al., 2011](#); [De Flora et al., 2008](#)).
25 In addition, a gavage study ([Sengupta et al., 1990](#)) reported various oxidative stress parameters in
26 GI tissue after administration of potassium dichromate at doses of 1500 mg/kg for three days and
27 300 mg/kg for 30 days. However, the inclusion of doses that are higher than the LD50 (130 mg/kg)
28 for rats ([Thermo Fisher, 2009](#)) is considered a limitation for interpreting the results of this study.

29 In female B6C3F1 mouse GI tract tissues, the reduced-to-oxidized glutathione ratio
30 (GSH/GSSG), which is considered a biomarker of redox status, showed statistically significant, dose-
31 dependent decreases in the oral and duodenal epithelium in mice exposed to Cr(VI) in drinking
32 water (≥ 11.6 mg Cr(VI)/kg-d and ≥ 4.6 mg Cr(VI)/kg-d, respectively) after 7 days of exposure,
33 indicating an increase in oxidative stress, with no correlated change in the GSH/GSSG ratio in
34 plasma ([Thompson et al., 2011](#)). After 90 days, there was still a significant decrease in the
35 GSH/GSSG ratio in the small intestinal epithelia of the duodenum (up to a 38.5% decrease at the top
36 dose) and jejunum (up to a 52% decrease at the top dose), but not in the ileum, at concentrations
37 ≥ 1.1 mg Cr(VI)/kg-d and decreases in plasma at higher concentrations (≥ 11.6 mg Cr(VI)/kg-d), but
38 no decreases were detected in the oral mucosa despite a measurable chromium concentration in

1 these tissues. While GSH/GSSG ratio measurement is a generally accepted indicator of oxidative
2 stress, ascorbate is the preferred in vivo reductant accounting for 90% of Cr(VI) oxidative
3 metabolism (described in detail in Section 3.1.1.). Although the expected primary oxidative
4 pathway is not captured in these experiments, the decreased GSH/GSSG ratio with increasing dose
5 implies some level of Cr(VI)-induced oxidative stress was occurring in the duodenum. However,
6 protein carbonyls, an indicator of protein oxidation, were only slightly elevated in the duodenum
7 after 90 days ([Thompson et al., 2011](#)), possibly indicating that the ROS mediated damage is being
8 preferentially directed at nucleic acids rather than proteins, although the reason for this preference
9 is not known.

10 This study also did not observe increases in 8-OHdG DNA adducts in the oral cavity or
11 duodenal tissue of mice ([Thompson et al., 2011](#)). The absence of oxidatively induced 8-OHdG
12 adducts in mouse GI tissues is consistent with a study by [De Flora et al. \(2008\)](#), which found no
13 increase in these lesions in the forestomach, glandular stomach, or duodenum after female SKH-1
14 mice were exposed for 9 months via drinking water at concentrations of 1.20 and 4.82 mg
15 Cr(VI)/kg-d. The reason for the lack of oxidative DNA lesions associated with the oxidative stress in
16 these studies is not known.

17 In female F344/N rats, [Thompson et al. \(2012b\)](#) reported no statistically significant changes
18 in GSH/GSSG ratios in either the oral cavity or the small intestine of female rats after 7 days of
19 Cr(VI) exposure to concentrations 0.1–180 mg/L Cr(VI), with the exception of decreases in the
20 jejunum at the high concentration of 180 mg/L Cr(VI) and a decrease at 0.1 mg/L Cr(VI) in the oral
21 mucosa. After 90 days, statistically significant and dose-dependent reductions in the GSH/GSSG
22 ratio in the oral mucosa and jejunum were observed at concentrations ≥ 20 mg/L Cr(VI) ([Thompson
23 et al., 2012b](#)). These results are in partial contrast to experiments in mice from the same research
24 group (described above), which showed decreases in GSH/GSSG ratio in the duodenum but not the
25 oral mucosa at 90 days despite mice having measurable total chromium concentrations in the oral
26 cavity ([Thompson et al., 2011](#)). The plasma GSH/GSSG ratio was also decreased at concentrations
27 ≥ 60 mg/L Cr(VI). No changes in the GSH/GSSG ratio were observed in the duodenum at 90 days,
28 and there were no changes in 8-isoprostane, a marker of lipid peroxidation, in the oral mucosa or
29 duodenum.

30 Although in vitro exposures may lead to exaggerated cell stress and oxidative responses,
31 limiting their ability to predict physiological conditions in vivo, these studies can provide
32 supplemental evidence indicating the potential contribution of oxidative stress and the signaling
33 pathways involved. Evidence from cells exposed in vitro consistently demonstrates increased
34 oxidative damage induced by Cr(VI), where ROS levels, lipid and protein oxidation, and decreased
35 levels of antioxidant enzymes correlate with DNA damage that is increased in test systems with
36 disabled DNA excision repair processes or abrogated with antioxidant pretreatment (Appendix
37 Table C-57). This includes studies performed with human colon and gastric cancer cell lines to
38 study oxidatively induced DNA damage and cytotoxicity. In vitro, it appears that Cr(VI) exposure

1 can result in oxidative stress with minimal or no cytotoxicity, as shown in human colorectal
2 adenocarcinoma Caco-2 cells ([Thompson et al., 2012a](#)). [Thompson et al. \(2012a\)](#) measured both
3 8-OHdG adducts and levels of phosphorylated histone H2AX (γ H2AX), a marker of DNA double-
4 strand breaks that could arise from various sources including ROS and/or direct chemical
5 interactions. After 24 hours, cytotoxic concentrations of Cr(VI) increased 8-OHdG and γ H2AX
6 levels, while non-cytotoxic concentrations only elevated 8-OHdG, suggesting that oxidative stress
7 could be a mechanism for DNA damage other than double-strand breaks at lower concentrations in
8 in vitro test systems. Notably, these results conflict with the in vivo study results following
9 subchronic Cr(VI) exposure in drinking water presented above, which consistently showed no
10 changes in 8-OHdG.

11 In the same study, [Thompson et al. \(2012a\)](#) reported that differentiated Caco-2 cells were
12 more resistant to cytotoxicity than undifferentiated cells. There were no reported changes in
13 immunofluorescence staining of differentiated Caco-2 cells for p53 or annexin-V (apoptosis
14 markers) or LCB3 (an autophagy indicator). There was, however, a dose-dependent translocation
15 of ATF6 to the nucleus in differentiated cells, which is an indicator of endoplasmic reticulum stress
16 and supports in vivo toxicogenomic data indicating this response in duodenal tissue ([Kopeck et al.,](#)
17 [2012b](#); [Thompson et al., 2012a](#)). A study by a separate group with the human gastric cancer cell
18 line SGC-7901 showed that Cr(VI) treatment in cells modified by knockdown of URI (a transcription
19 factor and oncogene) enhanced ROS production and cell death compared to control cells treated
20 with Cr(VI) ([Luo et al., 2016](#)). This suggests URI may have a role in suppressing Cr(VI)-induced
21 oxidative stress and apoptosis.

22 Tissue injury induced by cytotoxicity and oxidative stress in the GI tract may lead to
23 necrosis and/or regenerative proliferation, evidenced by the histological degenerative changes in
24 the small intestinal villi of mice exposed to Cr(VI) up to 2 years, as well as in the small intestine and
25 glandular stomach of rats exposed for 3 months. While ultimately only mice developed intestinal
26 tumors, the observations of hyperplasia, metaplasia, and ulcer in the stomach and villous wounding
27 in the intestine of rats are similarly demonstrative that Cr(VI) may cause GI toxicity through tissue
28 injury. As described in the synthesis of animal evidence, observations indicative of degenerative
29 changes in the mouse small intestine were reported across studies and suggest a regenerative
30 response to epithelial cell injury ([Thompson et al., 2011](#); [NTP, 2008, 2007](#)). These Cr(VI)-specific
31 effects in the small intestine are supported by X-ray fluorescence data showing ingested Cr
32 concentrates in the duodenal villi of mice ([Thompson et al., 2015b](#); [Thompson et al., 2015a](#); [O'Brien](#)
33 [et al., 2013](#); [Thompson et al., 2011](#)). In the duodenum, diffuse hyperplasia was observed at all
34 doses after both subchronic (≥ 3 mg Cr(VI)/kg-d) and chronic (≥ 0.3 mg Cr(VI)/kg-d) exposure, and
35 focal hyperplasia was observed after chronic exposure at doses ≥ 2.4 mg Cr(VI)/kg-day.

36 Tissue injury in the mouse duodenal villi may lead to a compensatory proliferative response
37 in the crypt compartment and hyperplasia observed in the intestinal mucosa as observed by dose-
38 dependent crypt enterocyte proliferation ([Thompson et al., 2015b](#); [O'Brien et al., 2013](#)), although

1 the relationship between this measure of increased cell proliferation after a 7-day exposure and the
2 observations of villous hyperplasia after 3 months or 2 years of exposure are unclear. These
3 investigators observed increased numbers of crypt enterocytes but did not detect a treatment-
4 related increase in mitotic indices in these crypts, which would appear to be inconsistent with
5 regenerative crypt hyperplasia ([Thompson et al., 2015b](#); [O'Brien et al., 2013](#)).

6 Perturbations in cell signaling pathways that enhance cellular proliferation may contribute
7 to the hyperplastic effects observed in the small intestine of B6C3F1 mice. Gene expression
8 profiling studies of the tissues collected in the subchronic drinking water exposure study by
9 [Thompson et al. \(2011\)](#) found that Ki-67 expression, a protein associated with cell proliferation
10 used to label proliferative intestinal crypt compartment cells ([Li et al., 2015a](#); [Basak et al., 2014](#)),
11 was increased within the duodenal mucosa in mice at the two highest doses (11.6 and 31 mg/kg-d
12 Cr(VI)) by day 91 (with dose-dependent increases at ≥ 4.6 mg/kg-day Cr(VI) at day 8) ([Rager et al.,](#)
13 [2017](#); [Kopec et al., 2012a](#)). A separate group reported that after 60 days of exposure to Cr(VI) in
14 drinking water, the c-Myc oncogene showed a dose-dependent increase in the stomach (gene
15 expression and protein levels ≥ 3.5 mg/kg-day Cr(VI)) and colon (gene expression ≥ 1.7 mg/kg-day
16 and protein levels ≥ 5.2 mg/kg-day Cr(VI)) of male Wistar rats ([Tsao et al., 2011](#)), consistent with
17 the promotion of cell cycle progression and cell proliferation. The same study also reported a
18 decrease in the expression of RKIP (Raf kinase inhibitor protein; ≥ 5.2 mg/kg-day Cr(VI)), which is
19 thought to negatively regulate MAPK (mitogen activated protein kinase) signaling involved in
20 cellular proliferation ([Vandamme et al., 2014](#)). The gene expression and protein levels of tumor
21 suppressor and cell cycle regulator p53 were also downregulated in the stomach (gene expression
22 ≥ 3.5 mg/kg-day and protein levels ≥ 1.7 mg/kg-day Cr(VI)) and colon (gene expression and protein
23 levels ≥ 5.2 mg/kg-day Cr(VI)) ([Tsao et al., 2011](#)). Consistent with these studies, toxicogenomic
24 analyses of GI tissues in Cr(VI)-treated animals have identified differentially expressed genes
25 (DEGs) associated with activation of c-Myc, MAPK, and a variety of additional pathways associated
26 with cell cycle, proliferation, and apoptosis. A summary of gene expression changes and
27 toxicogenomic results most pertinent to both noncancer and cancer GI effects can be found in
28 Appendix C.3.3 and C.3.4, respectively, and is discussed in the context of cancer MOA in Section
29 3.2.3.

30 Although the molecular pathways leading to the cytotoxic effects of Cr(VI) in the GI tract
31 following oral exposures are not clear, it is likely to involve chronic oxidative stress known to occur
32 across multiple tissues following Cr(VI) exposures (see Section 3.2.3.3), though there are also
33 indications of oxidative stress occurring in the absence of cytotoxicity. The data from studies of
34 Cr(VI) provide consistent support for oxidative stress as a mechanism of Cr(VI) toxicity in the lung
35 (Section 3.2.1), liver (Section 3.2.4), male and female reproductive organs (Sections 3.2.7 and 3.2.8,
36 respectively), and fetal development (Section 3.2.9), though in vivo results specific to the GI tract
37 are mixed ([Thompson et al., 2013](#)). Proliferative cell signaling pathways show upregulation in the
38 GI tract that is generally consistent with the pathological evidence of tissue regeneration in the

1 mouse small intestine, though it cannot be conclusively determined whether these dose-dependent
2 gene expression and protein level changes are associated with compensatory cell proliferation
3 following cytotoxicity or are induced by Cr(VI) exposure via another pathway.

4 **3.2.2.4. Integration of Evidence**

5 Overall, the currently available **evidence indicates** that oral exposure to Cr(VI) likely
6 causes GI tract toxicity in humans. This evidence is summarized in Table 3-10; the exposure
7 conditions sufficient to elicit these effects are further defined in Section 4.1. This conclusion is
8 based on *robust* studies in rodents that found Cr(VI) causes nonneoplastic effects in the GI tract.
9 These effects include dose-responsive diffuse epithelial hyperplasia in mice after both subchronic
10 and chronic exposure at all doses, and degenerative changes in the rat and mouse intestine. Human
11 evidence for nonneoplastic effects in the GI tract was *indeterminate* due to a lack of studies of
12 chronic, nonneoplastic GI effects in humans. The ATSDR Toxicological Profile ([ATSDR, 2012](#))
13 described multiple case reports of Cr(VI) induced GI toxicity or deaths among adults and children
14 but none included an appropriate comparison group.

15 The animal toxicological database provides *robust* evidence that Cr(VI) is toxic to the GI
16 tract. The primary nonneoplastic effects associated with both chronic and subchronic oral
17 exposure to Cr(VI) in the GI tract are consistent and biologically coherent, and include epithelial cell
18 hyperplasia, degenerative changes, and histiocytic cellular infiltration in the small intestine. Diffuse
19 epithelial hyperplasia of the small intestine was predominant in mice across all studies, with
20 incidence increasing with dose. NTP observed diffuse epithelial hyperplasia, which involved the
21 entire small intestinal mucosa, in all exposed groups (≥ 0.3 mg/kg-d Cr(VI)) of males and females in
22 both subchronic and chronic studies ([NTP, 2008, 2007](#)). The incidence rate was high ($>26\%$) at the
23 lowest dose. Other subchronic experiments, including a strain comparison study by NTP, also
24 observed these lesions in mice ([Thompson et al., 2011; NTP, 2007](#)). The dose-response relationship
25 for epithelial hyperplasia was stronger in the proximal small intestine (duodenum) than it was in
26 the jejunum (see Figure 3-12), indicating the effects of Cr(VI) are diminished by a decrease in
27 concentration as the chemical traverses the small intestine²⁷. In addition to diffuse hyperplasia,
28 there was a low, nonsignificant incidence of focal epithelial hyperplasia in the duodenum observed
29 by NTP after 2 years in both male and female mice at the mid and high doses. These lesions are
30 discussed further in Section 3.2.3.2 as they may be more indicative of a direct treatment-related
31 preneoplastic response.

32 In rats, epithelial hyperplasia and villus atrophy/blunting were only reported in one
33 subchronic study limited to females (≥ 7.2 mg and 31.1 mg/kg-d Cr(VI) respectively) ([Thompson et](#)
34 [al., 2012b](#)). Histopathological discrepancies in the rat small intestine between these findings and

²⁷As Cr(VI) traverses the small intestine, the concentration of Cr(VI) in the lumen decreases due to 1) reduction of Cr(VI) to Cr(III), 2) uptake to the small intestine epithelium, 3) dilution by GI contents (including by ongoing intestinal secretions). See Section 3.1 for more detail.

1 the NTP ([2008, 2007](#)) studies are a source of uncertainty, but could involve differences in study
2 variables such as those described by [Thompson et al. \(2012b\)](#) (e.g., different vendor sources,
3 differences in water intake), or differences in analyses (i.e., comprehensive pathology reporting by
4 NTP vs. hypothesis-driven MOA studies by Thompson et al. ([Francke and Mog, 2021](#))). In the
5 glandular stomach, a significantly increased incidence of nonneoplastic lesions was seen in male
6 and female F344 rats exposed to the highest dose (21 mg/kg-d Cr(VI)) in the subchronic NTP study;
7 this effect was not observed at any dose after two years ([NTP, 2008, 2007](#)). This is likely explained
8 by differences in dosing, as the rat stomach lesions observed after 13 weeks occurred at an
9 exposure threefold higher than the highest dose in the 2-year chronic assay.

10 Observations of histiocytic infiltration in the small intestine were consistent across studies,
11 sexes, and species; however, this effect is of unknown biological significance. Histiocytic infiltration
12 (to varying degrees) was also observed in the liver and the pancreatic and mesenteric lymph nodes
13 ([NTP, 2008, 2007](#)). A plausible explanation for this effect is increased phagocytosis due to an
14 insoluble precipitate of the test material. Cr(III), the reduced form of Cr(VI), is not a substrate for
15 active transport through the cell membrane and would therefore enter cells through passive
16 diffusion or phagocytosis ([Eastmond et al., 2008](#)). Therefore, the observed histiocytosis is most
17 compatible with phagocytically active macrophages containing Cr(III). An alternative explanation
18 could be that histiocytosis occurred as a result of chronic inflammation; however, neither pathology
19 consistent with inflammation nor the presence of other inflammatory cells types were observed in
20 rats or mice following drinking water exposures ([NTP, 2008, 2007](#)).

21 Together, these effects provide consistent, biologically coherent evidence of GI toxicity
22 involving tissue wounding by the test substance leading to degenerative changes, regenerative
23 proliferation, and hyperplasia. The hyperplasia in the GI tract following oral exposures is
24 considered to be representative of the constellation of histopathological observations that together
25 result in a change in tissue function that is considered an adverse noncancer effect, independently
26 from the significance of this lesion as a preneoplastic effect in the potential progression to cancer.
27 Mechanistic evidence from in vitro and in vivo models provides additional support for GI tissue
28 cytotoxicity and apoptosis occurring as a result of Cr(VI) exposure, as well as a proliferative
29 response that may be directly associated with a Cr(VI)-induced stimulation of proliferative cell
30 signaling pathways, an indirect consequence of compensatory cell proliferation following tissue
31 injury, or a combination of both.

Table 3-10. Evidence profile table for effects in the GI tract other than cancer

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from studies of exposed humans (occupational multi-route)					⊕⊕⊖
No human studies met PECO criteria for nonneoplastic GI effects	For human evidence of cancer of the GI tract, see Section 3.2.3.2 and Table 3-24 (Evidence profile table for cancer of the GI tract).			⊖⊖⊖ <i>Indeterminate</i>	The evidence indicates that Cr(VI) is likely to cause GI toxicity in humans given sufficient exposure conditions.
Evidence from animal studies (oral)					
HISTOPATHOLOGICAL CHANGES High confidence: NTP (2008) NTP (2007) Thompson et al. (2012b) Thompson et al. (2011)	Degenerative changes in intestinal villi and hyperplasia of the small intestine observed in male and female mice by NTP (2008, 2007), and in female mice and rats by Thompson et al. (2012b; 2011). Histiocytic cellular infiltration observed in the small intestine of male and female rats and mice in all studies and bioassays. Because these effects can also represent preneoplastic lesions that are part of the morphologic and biologic continuum leading to cancer (Boorman et al., 2003), additional discussions are provided in Section 3.2.3.2 (Gastrointestinal Tract Cancer) and Table 3-24.	<ul style="list-style-type: none"> Consistent findings in mice in four <i>high</i> confidence studies reporting multiple bioassays (both sexes and multiple strains of mice) Coherent, biologically related findings across studies Large magnitude of effects Strong dose-response gradient 	<ul style="list-style-type: none"> Inconsistent observations of hyperplasia between mice and rats, though this is explained in part by pharmacokinetic differences 	⊕⊕⊕ <i>Robust</i> Histopathological changes reported in <i>high</i> confidence studies (proliferative changes) observed across the animal evidence base database are coherent following chronic and/or subchronic oral exposures in rats and mice and suggest adverse effects of Cr(VI) on the GI tract (specifically, the small intestine), findings that are supported by mechanistic evidence of oxidative stress and cell proliferation.	<i>Robust</i> evidence in rats and mice shows consistent findings of histopathological changes indicative of epithelial damage and changes in GI epithelial architecture following oral exposure. Although these effects are presumed to be relevant to humans, the lack of human evidence demonstrating that the changes observed in rodents would occur and progress in humans precludes a higher conclusion level (i.e., <i>evidence demonstrates</i>). Mechanistic findings in animals provide some evidence supportive of oxidative stress in the GI tract as a potential mechanism for

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
		<ul style="list-style-type: none"> Mechanistic evidence (oxidative stress, cell proliferation) provides plausibility 			degenerative GI effects in multiple animal species. This mechanism is presumed relevant to humans. The evidence is inadequate to determine whether Cr(VI) inhalation exposure might be capable of causing noncancer GI effects. No noncancer GI effects were observed following inhalation. As described in Section 3.1, Cr(VI) can expose portal-of-entry tissues, and reduction of Cr(VI) in these tissues and red blood cells decreases uptake by other organ systems.
Mechanistic evidence					
Biological events or pathways	Summary of key findings and interpretations			Judgments and rationale	
Oxidative stress	<p><i>Interpretation:</i> Cr(VI) is a potent oxidizer that can produce reactive oxygen species and oxidative stress via intracellular intermediate species, leading to cytotoxicity in the GI tract following oral exposures. This supports evidence of degenerative lesions in the GI tract (see animal evidence, above).</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Decreased GSH/GSSG ratio in small intestinal epithelium at 8 and 90 days in mice and 90 days in rats, and in oral mucosa in mice at 8 days and rats at 90 days, although no 8-OHdG adducts or protein oxidation in any tissues (Thompson et al., 2011; De Flora et al., 2008) In vitro evidence of increased oxidative stress in human colorectal adenocarcinoma Caco-2 cells, though this also occurred at concentrations that induced minimal or no cytotoxicity (Thompson et al., 2012a) 			Biologically plausible mechanistic evidence supports involvement of oxidative stress in the histopathological findings of degenerative effects, although there are some inconsistencies in the animal findings in the GI tract following oral exposures. Evidence of increased cell proliferation in affected tissues is consistent with hyperplasia but cannot be conclusively associated with tissue regeneration following injury.	
Cell proliferation	<p><i>Interpretation:</i> Evidence of increased cell proliferation is consistent with the histopathological observations of hyperplasia in the mouse small intestine following oral exposure to Cr(VI) (see animal evidence, above), although these measures do not indicate the molecular stimuli for the proliferation and it is unknown whether they are indicative of regenerative proliferation. Increased cell proliferation has not been detected in the rat oral cavity.</p>				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<p><i>Key findings:</i></p> <ul style="list-style-type: none"> • The cellular replication marker Ki-67 was increased in isolated duodenal mucosal cells from the small intestine of mice exposed to Cr(VI) via drinking water for 7 and 90 days (Rager et al., 2017; Kopec et al., 2012a) • Dose-dependent increases in the protein and gene expression of c-Myc, an oncogenic cell proliferation promoter, and downregulation of cell cycle regulator p53, in rat stomach and colon exposed to doses as low as 5 mg/kg-d Cr(VI) in drinking water for 60 days of exposure to Cr(VI) in drinking water (Tsao et al., 2011) • Toxicogenomic analyses of GI tissues in Cr(VI)-treated animals have identified differentially expressed genes (DEGs) associated with activation of c-Myc, MAPK, and a variety of additional pathways associated with cell cycle and proliferation (see Appendix C.3.4) 				

3.2.3. Cancer

3.2.3.1. *Respiratory Tract Cancer*

In 1998, the EPA IRIS Toxicological Review of Hexavalent Chromium classified Cr(VI) as a “known human carcinogen” by the inhalation route of exposure ([U.S. EPA, 1998c](#)). This determination was based on the revised carcinogenicity guidelines, which were proposed at that time ([U.S. EPA, 1996c](#)) and finalized in 2005 ([U.S. EPA, 2005a](#)). The “known human carcinogen” classification replaced the classification as a “Group A - known human carcinogen” by the inhalation route of exposure under the previous carcinogenicity guidelines ([U.S. EPA, 1986b](#)). This classification was based on consistent evidence that inhaled Cr(VI) causes lung cancer in humans and supporting evidence of carcinogenicity in animals. The same conclusion has since been reached by other authoritative federal and state health agencies and international organizations and the carcinogenicity of Cr(VI) is considered to be well established for inhalation exposures ([TCEQ, 2014](#); [IPCS, 2013](#); [NIOSH, 2013](#); [IARC, 2012](#); [CalEPA, 2011](#); [NTP, 2011](#); [OSHA, 2006](#)). Thus, the current review of cancer by the inhalation route adopts the same EPA cancer descriptor for this route, “carcinogenic to humans,” and the analyses focus on data that may improve the quantitative exposure-response analysis conducted in EPA’s 1998 IRIS assessment, as stated in the 2014 preliminary packages ([U.S. EPA, 2014b, c](#)) and the Systematic Review Protocol (Appendix A). An overview of the literature screening and study evaluation for exposure-response data is presented in Section 4.4.

3.2.3.2. *Gastrointestinal Tract Cancer*

Human evidence via the oral route of exposure

Study evaluation summary

Three studies analyzed stomach cancer risk in populations exposed to Cr(VI) in drinking water. Three additional studies were identified but excluded due to critically deficient ratings in at least one domain, and are not discussed further ([Fryzek et al., 2001](#); [Bick et al., 1996](#); [Bednar and Kies, 1991](#)). The three included, *low* confidence studies are ecological analyses of cancer mortality in residential populations with potential exposure to Cr(VI)-contaminated drinking water in China and Greece (Table 3-11).

Two of the studies were ecological analyses of cancer mortality in relation to groundwater contamination in the same exposed population in Liaoning Province, China ([Kerger et al., 2009](#); [Beaumont et al., 2008](#)). The [Beaumont et al. \(2008\)](#) and [Kerger et al. \(2009\)](#) studies are reanalyses of [Zhang and Li \(1987b\)](#), the original scientific report published in the Chinese Journal of Preventive Medicine. Another publication, [Zhang and Li \(1997\)](#), has been challenged for conflict-of-

1 interest due to undisclosed funding²⁸. Investigators compared cancer mortality rates (total
2 between 1970–1978) between five contaminated regions identified along a groundwater plume of
3 Cr(VI) and four presumed uncontaminated regions surrounding a ferrochromium production plant.
4 The contaminated areas included five communities downgradient of the alloy plant along a dry
5 riverbed where plant wastewater effluent from chromium smelting had been disposed since 1960.
6 The communities without contamination included the town adjacent to the alloy plant (TangHeZi)
7 and three agricultural areas to the north, west and south. Another study with an ecological design,
8 Linos et al. (2011), analyzed cancer mortality and Cr(VI) exposure via drinking water in Oinofita
9 municipality, Greece, with data on residents from 1999–2009. Processed liquid industrial waste
10 containing Cr(VI) was dumped into Asopos River starting around 1969, which was the source for
11 drinking water in wells within the municipality from 1970–2009 (Linos et al., 2011).

12 The definition of Cr(VI) exposure in these studies was based on living in towns or areas
13 proximate to contaminated rivers, which were the source of drinking water, and assumed
14 consumption. Individual-level data on the source or amount of drinking water consumed was not
15 collected. Sampling to measure Cr(VI) concentrations in drinking water was limited in terms of
16 timespan as well as geographical coverage. In addition, only drinking water in the areas with
17 suspected contamination was sampled; Cr(VI) concentrations were not measured in drinking water
18 in areas considered to be unexposed, which could lead to unrecognized exposure and subsequent
19 misclassification (Linos et al., 2011; Kerger et al., 2009; Beaumont et al., 2008). Based on data for
20 Liaoning Province reported by the Jinzhou Health and Anti-epidemic Station in 1986,
21 concentrations of Cr(VI) in drinking water (analytical methods were not available) in 1965, when
22 the contamination was identified, ranged between 0.002–20.0 mg/L in villages along the plume
23 that extended from the disposal site located near the chromium alloy plant (Kerger et al., 2009;
24 Beaumont et al., 2008). Well water samples collected in Oinofita municipality between 2007–2010
25 ranged between 0.010–0.156 mg/L (Linos et al., 2011).

26 The studies of both populations were classified as *low* confidence, primarily due to
27 limitations in the exposure assessment. In each study, exposure was defined at the population
28 level; no individual-level exposure assignments were possible. Beaumont et al. (2008) and Kerger
29 et al. (2009) assigned exposure status based on residence information in the death certificate.
30 Residence at the time of death may not represent residence location – and thus inferred Cr(VI)
31 exposure – at the critical time window for initiation and progression of cancer, although such
32 misclassification of the exposure proxy is expected to be nondifferential. In addition, the duration
33 of follow-up in both studies was not adequate to allow for the long latency of cancer development.
34 These limitations are expected to result in bias in a direction toward a null association. Finally, age-
35 adjusted site-specific cancer mortality by region for the study years in China was not available to
36 the investigators and had to be estimated using other available data.

²⁸Zhang and Li (1997) was retracted by the journal because “financial and intellectual input to the paper by outside parties was not disclosed” (Smith, 2008; Brandt-Rauf, 2006).

Table 3-11. Summary of human studies for Cr(VI) cancer of the GI tract and overall confidence classification. [Click to see interactive data graphic for rating rationales.](#)

Author (Year)	Location	Exposure Assessment	Study Design	Selection	Exposure	Outcome	Confounding	Analysis	Sensitivity	Self-reporting	Overall confidence
Beaumont et al. (2008)^a	Liaoning Province, China	Communities downstream of a ferrochromium plant versus unexposed communities (assumed)	Semi-ecologic cancer mortality	D	D	D	D	A	D	A	Low
Kerger et al. (2009)^a	Liaoning Province, China	Communities downstream of a ferrochromium plant versus unexposed communities (assumed)	Semi-ecologic cancer mortality	D	D	D	D	A	D	A	Low
Linos et al. (2011)	Oinofita, Greece	Residents of Oinofita, a contaminated region versus surrounding residents	Semi-ecologic cancer mortality	A	D	A	A	A	D	A	Low

G = good; A = adequate; D = deficient.

^aStudies are reanalyses of Zhang and Li ([1997](#); [1987a](#)).

1 Each of the three studies selected the referent, or unexposed population, as residents of the
2 larger area surrounding the exposed area ([Linos et al., 2011](#); [Kerger et al., 2009](#); [Beaumont et al.](#)
3 [2008](#)), and were not able to account for differing lifestyles, occupational histories, or background
4 rates of cancer in the referent population that may influence cancer risk. [Beaumont et al. \(2008\)](#)
5 compared cancer mortality in the contaminated villages to mortality in either the surrounding
6 unexposed villages, or the entire Liaoning Province, with both comparison groups including the
7 industrial city of TangHeZi. Larger populations, such as a province or state, have the advantage of
8 providing relatively stable estimates, particularly for low-incident events such as site-specific
9 cancers, but may obscure differences by demographic and other characteristics important for the
10 study population. [Kerger et al. \(2009\)](#) compared cancer mortality in the chromium-exposed
11 agricultural areas to the unexposed agricultural areas and to the unexposed city of TangHeZi
12 separately to address potential residual confounding by demographic and socioeconomic factors.
13 Mortality rates for stomach cancer in TangHeZi were lower than those in the unexposed
14 agricultural areas. Although an analysis of gastric cancer rates in China in 1990–1992 showed
15 lower mortality rates in urban areas (15.3 per 100,000) compared with rural areas (24.4 per
16 100,000), possibly in response to economic development and urbanization (e.g., sanitation,
17 refrigeration) ([Yang, 2006](#)), this same study reported little difference between urban and rural

1 rates in 1973–1975 (20.1 and 19.4 per 100,000 in urban and rural areas, respectively), the relevant
 2 time period with respect to the Liaoning Province studies given the anticipated latency of cancer
 3 development and diagnosis following the onset of exposure. Therefore, while it is possible that
 4 demographic differences influenced the difference in mortality rates, another factor may have been
 5 statistical instability due to small population sizes.

6 *Synthesis of human evidence*

7 Results of the studies on Cr(VI) oral exposure and cancer are presented in Table 3-12. The
 8 analyses of stomach cancer in two exposed populations in Liaoning Province, China, and Oinofita,
 9 Greece, showed an association with Cr(VI), although effect estimates were imprecise. While the
 10 results of two reanalyses of Zhang and Li (1987a) indicated an increased risk when comparing the
 11 exposed villages to the unexposed referent group, inclusion of the industrial city of TangHeZi in the
 12 referent group increased the magnitude of the relative risk, which became statistically significant
 13 (including TangHeZi, RR 1.82, 95% CI: 1.11, 2.91; excluding TangHeZi, RR 1.22, 95% CI: 0.74, 2.01)
 14 (Kerger et al., 2009; Beaumont et al., 2008). The mortality rate from stomach cancer was much
 15 lower in TangHeZi, the reason why inclusion of the city was influential. However, Beaumont et al.
 16 (2008) also used the mortality experience of the larger province as a referent and observed an
 17 elevated, statistically significant risk (SMR: 1.69, 95% CI: 1.12–2.44). The number of deaths from
 18 stomach cancer was not reported for one of the villages with higher contamination levels, which
 19 makes it difficult to compare results between the two studies.

Table 3-12. Associations between drinking water exposures to Cr(VI) and cancer in low confidence epidemiology studies

Reference	Exposure	Cancer Deaths (N)	Relative Risk	Ratio Measure (95% CI) N
Linos et al. (2011) Oinofita, Greece	Cr(VI) in drinking water Mortality in exposed areas compared to surrounding area (assumed to be unexposed)	All cancers (118) Stomach (6) ^a	SMR (95% CI)	All cancers: 113.6 (94.1, 136.1) Stomach: 120.9 (44.4, 263.2)
Beaumont et al. (2008) Liaoning Province, China	Cr(VI) in drinking water Mortality in exposed communities compared to nearby regions (assumed to be unexposed) and to province as a whole	All cancer (262) ^b Stomach cancer (75) ^{b, c}	Rate ratio (95% CI)	<i>Compared to unexposed regions:</i> All cancers: 1.13 (0.86, 1.46) Stomach: 1.82 (1.11, 2.91) <i>Compared to larger province:</i> All cancers: 1.23 (0.97, 1.53) Stomach: 1.69 (1.12, 2.44)
Kerger et al. (2009) Liaoning Province, China	Cr(VI) in drinking water Mortality in exposed communities (C) compared to (A) industrial town, or (B) three unexposed agricultural villages	All cancer (263) ^b Stomach cancer (89) ^{b, c}	Rate ratio (95% CI)	<i>C vs. B</i> All cancers: 1.10 (0.80, 1.51) Stomach: 1.22 (0.74, 2.01) <i>B vs. A</i> All cancers: 1.03 (0.77, 1.39)

Toxicological Review of Hexavalent Chromium

Reference	Exposure	Cancer Deaths (N)	Relative Risk	Ratio Measure (95% CI) N
				Stomach: 1.70 (1.00, 2.89) <i>C vs. A</i> All cancers: 1.14 (0.85, 1.52) Stomach: 2.07 (1.25, 3.44)

^aSite-specific cancer risk presented for number of cases >5.

^bNumber deaths in the study villages were estimated as described by authors.

^cMortality rates were missing for stomach cancer in one contaminated village, Nuer River Village.

1 The studies of both of the populations exposed to Cr(VI) in drinking water reported
 2 increased SMRs when their mortality experience was compared to unexposed communities in the
 3 surrounding areas. These estimates were imprecise and changed in magnitude depending on the
 4 definition of the unexposed communities. The lack of individual estimates of exposure, the
 5 uncertain nature of the mortality data, and the potential impact of confounding by differences in
 6 SES between comparison groups make it difficult to draw any conclusions.

7 Human evidence via the inhalation route of exposure

8 EPA conducted a review and meta-analysis of GI cancer risk from studies of workers with
 9 occupational inhalation exposure to Cr(VI). Exposure via inhalation may pose an increased risk of
 10 cancer in the GI tract in occupationally exposed populations either as a result of systemic
 11 absorption and distribution, or via deposition in airways, mucociliary clearance, and swallowing of
 12 particles ([Sedman et al., 2006](#)). Numerous studies have evaluated the association between Cr(VI)
 13 exposure and cancers of the GI tract, including at least three recent meta-analyses ([Deng et al.,](#)
 14 [2019](#); [Suh et al., 2019](#); [Welling et al., 2015](#)) and two older meta-analyses ([Gatto et al., 2010](#); [Cole](#)
 15 [and Rodu, 2005](#)) (Table 3-13). These meta-analyses varied in their scope and the specific research
 16 question under study. Among the more recent meta-analyses, the Welling et al. study ([Welling et](#)
 17 [al., 2015](#)) concluded that Cr(VI) exposure was associated with increased risks of stomach cancer,
 18 while Suh et al. ([2019](#)) had the opposite conclusion; the work by Deng et al. ([2019](#)), which
 19 considered additional cancer sites, concluded that there was no evidence for increased risk of death
 20 due to digestive system cancers overall, but that the findings for rectal cancer specifically were
 21 suggestive of increased risk, and the risk of oral cancer incidence (not mortality) was significantly
 22 increased. EPA performed an updated literature search to identify studies for inclusion in a new
 23 meta-analysis of Cr(VI) exposure in relation to GI tract cancers. The goal of the meta-analysis was
 24 to calculate summary effect estimates for persons with likely occupational exposure to Cr(VI) from
 25 an updated set of studies with similar design. Methods for the systematic review and meta-analysis
 26 are in Appendix C.3.1.

Table 3-13. Meta-analyses of GI tract cancers and Cr(VI) occupational exposure

Study	Outcome	Included	Excluded	Summary effect estimate and 95% confidence interval for specified cancer sites (number of included studies)
Cole and Rodu (2005)	Relative risk (RR) estimates for stomach cancer	Began with set of known relevant studies, then performed a literature search; included those published after 1950	'no usable data'; 'occupational settings with little or no chrome exposure'	Stomach (n = 32): 1.13 (1.03, 1.24)
Gatto et al. (2010)	Measures of effect or data available to calculate relative risk (RR) for GI tract cancers	Published after 1950; occupational exposure (inhalation or ingestion); exposure potential stated explicitly or from industry with recognized exposure potential: chromate production, stainless-steel welding, chrome pigment production, chrome plating, ferrochrome production		Esophagus (n = 15): 1.17 (0.90, 1.51) Stomach (n = 29): 1.09 (0.93, 1.28) Colon (n = 13): 0.89 (0.70, 1.12) Rectum (n = 20): 1.17 (0.98, 1.39)
Welling et al. (2015)	Relative risk (RR) estimates for stomach cancer	Chromate or chromium production and plating; leather work and tanning; Portland cement work; and stainless-steel production, welding, polishing and grinding	Occupations such as painting, general foundry work, construction and shoe (non-leather) manufacturing; Welding or metal plating studies that did not evaluate stainless-steel or chromium work; Studies involving work with asbestos cement	Stomach (n = 56): 1.27 (1.18, 1.38)
Deng et al. (2019)	Standardized mortality or incidence ratio (SMR or SIR) estimates for cancer of the digestive system	"the exposure factor was clear and exposure was to Cr(VI)" Chromate production, cement production, cement industry workers, aircraft manufacturing workers, chromium platers, tanners, welders, masons	Occupational exposure to materials other than Cr(VI), such as asbestos or nickel; professions such as shoemaking (non-leather) or general building work. Based on study quality evaluation using Newcastle-Ottawa scale, excluded studies with ratings <6	Esophagus (n = 14): 0.88 (0.73, 1.05) Stomach (n = 33): 0.93 (0.78, 1.09) Colon (n = 12): 1.06 (0.93, 1.21) Rectum (n = 23): 1.14 (0.98, 1.33)
Suh et al. (2019)	Stomach cancer morbidity and/or mortality	Chromate production, stainless-steel welding, chrome pigment production, chrome plating/ electroplating,	PMR studies, Registry studies where "Specifications of Cr(VI) exposures are not indicated by the authors"—includes studies such as Andersen et al. (1999)	Stomach (n = 44): 1.08 (0.96, 1.21)

Toxicological Review of Hexavalent Chromium

Study	Outcome	Included	Excluded	Summary effect estimate and 95% confidence interval for specified cancer sites (number of included studies)
		ferrochrome production industries, Leather tanners (if indicate exposure to Cr(VI) or process such as “two bath” process), Cement workers (if involved cement production); Other occupations if Cr(VI) exposure indicated by authors	and Pukkala et al. (2009) . Based on study quality evaluations using NTP OHAT Risk of Bias Rating Tool for Human and Animal Studies, tiered studies and excluded tier 3.	

1 Occupational studies that analyzed cancer risks related to Cr(VI) exposure were identified
2 as part of the overall assessment search strategy process described in the Cr(VI) Protocol ([U.S. EPA,](#)
3 [2019](#)). This search strategy, which was conditioned on terms for Cr(VI), identified 35 potentially
4 relevant citations. Since these searches only identified references that mentioned chromium or
5 related terms in the title or abstract, an additional search strategy was developed to identify studies
6 of occupational groups with likely exposure to Cr(VI). The search terms and literature
7 identification results are found in Appendix C.3.1. In total, 35 references from the previous
8 literature searches for the assessment, 93 references from the subsequent occupationally-focused
9 search for the meta-analysis, and 20 references identified by looking through the reference lists in
10 the three most recent meta-analyses were included in this review. Of these, 21 studies were not
11 included because they were earlier follow-ups with more recent reports available, the cohorts were
12 not exposed to Cr(VI), or they did not contain results for site-specific GI tract cancers.

13 A comparison of the studies included in the three most recent meta-analyses and this
14 analysis with a rationale for decisions to exclude is in the appendix (Appendix Table C-44, Section
15 C.3.1). The studies included in each meta-analysis comprised a partially overlapping set of studies
16 reflecting the various time periods used for the literature searches, the inclusion criteria, and the
17 results of the evaluations of study “quality” used in the studies. The meta-analyses focused on the
18 studies considered to be *medium* or *high* overall confidence, for which EPA had greater certainty in
19 the exposure assessment for Cr(VI) and minimal concern for other sources of bias. In this analysis,
20 the primary reason for considering a study to be of *low* confidence was that exposure to Cr(VI) in
21 the population was too uncertain.

22 The studies included in EPA’s meta-analysis reported a variety of effect estimates, including
23 standardized incidence or mortality ratios, standardized risk ratios, odds ratios, and proportionate
24 mortality ratios. Studies that calculated proportionate mortality ratios were not included. In some
25 instances, multiple risk estimates were reported—for example, for men or women separately, for

1 exposure or occupational subgroups, or by latency period. A priori, risk estimates were preferred if
2 they (1) were adjusted for potential confounders including age, sex, time period, and geographic
3 region; (2) were estimated for the longest latency period; (3) were from the most recent follow-up
4 of a specific study cohort; (4) were estimated for the most highly exposed subgroup of the study
5 population. When reviewing the studies captured by the literature search and evaluation of the
6 studies, there were some cancer sites or groupings that were difficult to reconcile across studies
7 due to differences in ICD codes included, for example, or changes in coding practices and diagnostic
8 naming conventions over time and across geographical sites. Consequently, it was hard to
9 determine whether the same cancer sites were contained within some of the groupings. Further, in
10 some cases the number of studies for a given cancer site was small enough (and heterogeneous
11 enough) that a meta-analysis seemed unlikely to yield useful information. Consequently, a
12 quantitative meta-analysis was performed to derive summary risk estimates for a subset of GI tract
13 cancers by site: esophagus, stomach, colon, and rectum. For each of these four sites, there was a
14 larger number of studies to include in a summary effect estimate, and these studies used relatively
15 consistent definitions for these specific cancer sites.

16 Separate meta-analyses were performed to obtain summary estimates from studies
17 reporting odds ratios (stomach cancer, esophageal cancer), and from studies reporting SMR, SIR, or
18 SRR estimates (all four sites). All analyses were performed using the 'metafor' package in R
19 ([Viechtbauer, 2010](#)), with a random effects model. This package was also used to generate forest
20 plots (see Figures 3-15 to 3-21). The potential for publication bias was evaluated using the Egger's
21 test ([Egger et al., 1997](#)) for funnel plot asymmetry. The I^2 statistic value for each study is used to
22 represent the percentage of variation across studies that is due to heterogeneity rather than
23 chance.

24 As shown in Table 3-14, the summary effect estimates showed small increases in risk for
25 each cancer site associated with Cr(VI) exposure, although only the estimate for rectal cancer was
26 statistically significant. There were few studies reporting odds ratios, but in each case (esophagus
27 and stomach), summary effect estimates based on these studies were somewhat higher compared
28 with summary estimates based on other relative risk measures (although neither odds ratio-based
29 estimate was statistically significant). There was no evidence of funnel plot asymmetry based on
30 Egger's regression test, indicating that publication bias was not likely to be present.

31 Summary effect estimates were also derived for each cancer site, stratified by occupational
32 grouping (see Appendix Table C-45). This separation by occupational grouping did show some
33 expected patterns for colon cancer risk estimates in that the occupations with a higher certainty of
34 exposure to Cr(VI) (i.e., ferrochromium, chromate production, stainless-steel workers, chromium
35 pigment exposed workers) showed higher summary effect estimates. However, there remained
36 inconsistencies among the studies overall, and the results for cancer of the rectum did not show a
37 similar pattern of risk. The results of these more detailed analyses are discussed in Appendix
38 C.3.1.3.

Table 3-14. Summary effect estimates from random effects meta-analysis, by cancer site and type of effect estimate

Cancer Site	Effect Estimate Type	Number of individual effect estimates	Summary effect estimate (95% confidence interval)	p-value for funnel plot asymmetry
Esophagus	Odds Ratio	2	1.43 (0.19, 11.09)	Not computed
	Relative Risk (SMR, SIR, or SRR)	21	1.08 (0.92, 1.37) ^a	0.33
Stomach	Odds Ratio	4	1.38 (0.77, 2.49)	0.79
	Relative Risk (SMR, SIR, or SRR)	48	1.01 (0.89, 1.15)	0.08
Colon	Relative Risk (SMR, SIR, or SRR)	19	1.10 (0.97, 1.25)	0.53
Rectum	Relative Risk (SMR, SIR, or SRR)	32	1.18 (1.01, 1.37)	0.94

^aWarning displayed during estimation of the summary estimate indicates that results may not be stable due to the large range of sampling variance between included estimates.

1 Due to misclassification and heterogeneity of Cr(VI) exposure among and within the
2 included studies, there may have been a decreased ability to detect an association if it existed.
3 Although this analysis included studies that analyzed associations among occupational groups or
4 subgroups with greater certainty of exposure to Cr(VI), variation in the prevalence, frequency and
5 magnitude of exposure is likely within the exposure groups. Other factors that could contribute to
6 the observed heterogeneity of risk estimates include presence of coexposures and bias due to the
7 use of occupational cohorts. Cancer risk in these industries is likely affected by prevalent exposures
8 to other carcinogens in addition to Cr(VI), which would vary both within and across occupational
9 groupings. As noted in Appendix Table C-43, two industry groupings with higher certainty of Cr(VI)
10 prevalence, ferrochromium, chromate production, and stainless-steel workers, and chromium
11 pigment exposed workers, had occupational settings characterized by different coexposures, which
12 argues against a strong common confounder. In some cases, authors did attempt to adjust for
13 coexposures or restrict the study population to minimize their effect. The majority of the studies
14 estimated relative risk using SMRs, which also are subject to a bias toward the null due to the
15 healthy worker effect. The summary effect estimates for esophageal and stomach cancers
16 calculated using odds ratios from the few case-control studies was not subject to this bias and
17 indicated a higher risk. However, these odds ratio estimates are based on very few studies and are
18 highly uncertain.

19 Previous meta-analyses reported summary effect estimates for stomach cancer which
20 ranged between 0.93 ([Deng et al., 2019](#)) to 1.27 ([Welling et al., 2015](#)). A statistically significant
21 increase in risk of stomach cancer was reported from two of the previous five estimates ([Welling et](#)
22 [al., 2015](#); [Cole and Rodu, 2005](#)). This assessment’s finding of no increased risk (summary relative

1 risk of 1.01) is within the range of these previous estimates. Two of the five previous meta-analyses
2 included estimates for cancers of the esophagus, colon and rectum ([Deng et al., 2019](#); [Gatto et al.](#)
3 [2010](#)). This assessment's summary estimate of 1.08 for esophageal cancer was not significantly
4 elevated, and was slightly less than that from [Gatto et al. \(2010\)](#). The effect estimate for colon
5 cancer of 1.10 (95% CI: 0.97, 1.25), was close to the estimate reported by [Deng et al. \(2019\)](#).
6 Finally, this assessment's estimate of rectal cancer risk was significantly elevated, and very similar
7 to those previously reported (1.18, 95% CI: 1.01, 1.37), compared with 1.17 ([Gatto et al., 2010](#)) and
8 1.14 ([Deng et al., 2019](#))).

9 Animal evidence via the oral route of exposure

10 *Synthesis of neoplastic animal evidence*

11 Neoplastic lesions following oral administration of Cr(VI) via drinking water were observed
12 in the 2-year study conducted by [NTP \(2008\)](#) in both sexes of B6C3F1 mice and F344/N rats. This
13 was the only animal study examining the potential for tumor development via the oral route of
14 exposure and was rated as *high* confidence. An overview of the confidence classification for the GI
15 histopathology reported in this study can be found in Section 3.2.2, Table 3-8 and in [HAWC](#).

16 In this study, both sexes of F344/N rats exhibited an increased incidence and trends of
17 squamous cell carcinomas or papillomas in the oral cavity (mucosa or tongue), uncommon tumor
18 types. Tumor incidence was statistically significant at the highest doses tested, 6.07 and 7.13 mg
19 Cr(VI)/kg-d in male and female rats, respectively. The overall tumor incidence at the high dose was
20 14% in male rats and 22% in female rats ([NTP, 2008](#)), as compared to no tumors in control males
21 and 2% incidence in females. There was also a nonsignificant, low incidence (4%) of oral cavity
22 tumors in female rats receiving 2.6 mg Cr(VI)/kg-d. In both male and female rats, the increasing
23 trend of oral tumors was statistically significant. Microscopic examination of the tumors present in
24 the oral cavity of rats indicated they were highly invasive, originating in the oral mucosa of the
25 palate adjacent to the upper molar teeth with spread to the tongue, Harderian gland, the soft tissues
26 surrounding the nose, and the brain ([NTP, 2008](#)).

27 In the same study, male and female B6C3F1 mice exhibited increased incidences and trends
28 of adenomas and carcinomas in the small intestine, with most tumors occurring in the duodenal
29 section (proximal small intestine, nearest to the stomach). In male mice, there was a significant
30 trend for increased incidence of adenoma and carcinomas in the small intestine. Statistically
31 significant increases in adenomas or carcinomas were observed at doses ≥ 2.4 mg Cr(VI)/kg-d with
32 an overall incidence of 40% at the high dose ([NTP, 2008](#)). Female mice also showed a significant
33 trend for increased incidence of adenomas and carcinomas in the small intestine. At doses ≥ 3.24
34 mg Cr(VI)/kg-d, incidence of adenomas was statistically significantly increased and reached up to
35 44%. While most tumors in both sexes were located in the duodenum (first section of the small
36 intestine), female mice also showed a significant increase (10%) in overall incidence in the jejunum
37 (middle section of the small intestine) at the highest dose. Three adenomas were observed in the

Toxicological Review of Hexavalent Chromium

1 male mouse jejunum at the highest dose (and while not significant when compared to controls, this
2 constitutes a statistically significant increasing trend and exceeded the historical control range for
3 drinking water studies and for all routes of administration ([NTP, 2008](#))). Histopathological
4 evaluation of the adenomas in mice were described as discrete, broad based and focally extensive;
5 composed of irregular, elongated crypts; epithelial cells with oval to elongated nuclei; and
6 increased mitotic activity ([NTP, 2008](#)). Carcinomas were characterized as extensive with invasion
7 of the submucosa and/or muscularis mucosa; epithelial cells with round, oval, or elongated nuclei;
8 and with atypical mitosis that was of greater extent than observed in adenomas.

9 The data for both species and sexes are summarized in Table 3-15 and Figure 3-15.

Table 3-15. Data on neoplastic lesions in a *high* confidence study of rats and mice (NTP, 2008)

Tumor type and species/sex		Administered mg/L, mg/kg-d Cr(VI) ^a and incidence/total				
		0 mg/L	5	10	30	90
Male B6C3F1 mice		0 mg/L	5	10	30	90
		0 mg/kg-d	0.450	0.914	2.40	5.70
Adenomas (duodenum)		1/50	0/50	1/50	5/50	15/50*
Carcinomas (duodenum)		0/50	0/50	0/50	2/50	3/50
Adenomas or carcinomas (duodenum, jejunum, or ileum)	Incidence / Total	1/50	3/50	2/50	7/50*	20/50*
	Incidence / Total (adj) ^b	1/50	3/49	2/49	7/50*	20/50*
Animals dead prior to day 365		0	1	1	0	0
Female B6C3F1 mice		0 mg/L	5	20	60	180
		0 mg/kg-d	0.302	1.18	3.24	8.89
Adenomas (duodenum)		0/50	0/50	2/50	13/50*	12/50*
Carcinomas (duodenum)		0/50	0/50	0/50	1/50	6/50*
Adenomas or carcinomas (duodenum, jejunum, or ileum)	Incidence / Total	1/50	1/50	4/50	17/50*	22/50*
	Incidence / Total (adj) ^b	1/49	1/50	4/49	17/50*	22/49*
Animals dead prior to day 365		1	0	1	0	1
Male F344 rats		0 mg/L	5	20	60	180
		0 mg/kg-d	0.200	0.796	2.10	6.07
Squamous cell carcinoma (oral mucosa)		0/50	0/50	0/49	0/50	6/49*
Squamous cell papilloma (oral mucosa)		0/50	0/50	0/49	0/50	1/49
Squamous cell carcinoma (tongue)		0/49	1/50	0/47	0/49	0/48
Squamous cell papilloma (tongue)		0/49	0/50	0/47	0/49	1/48
Squamous cell carcinoma or papilloma (oral mucosa or tongue)	Incidence / Total	0/50	1/50	0/49	0/50	7/49*
	Incidence / Total (adj) ^b	0/50	1/47	0/47	0/50	7/49*
Animals dead prior to day 365		0	3	2	0	0
Female F344 rats		0 mg/L	5	20	60	180
		0 mg/kg-d	0.248	0.961	2.60	7.13
Squamous cell carcinoma (oral mucosa)		0/50	0/50	0/50	2/50	11/50*
Squamous cell carcinoma (tongue)		0/45	0/49	0/48	1/48	0/48
Squamous cell papilloma (tongue)		1/45	1/49	0/48	0/48	0/48

Tumor type and species/sex		Administered mg/L, mg/kg-d Cr(VI) ^a and incidence/total				
Squamous cell carcinoma (oral mucosa or tongue)	Incidence / Total	1/50	1/50	0/50	2/50	11/50*
	Incidence / Total (adj) ^b	1/50	1/50	0/50	2/50	11/50*
Animals dead prior to day 365		0	0	0	0	0

^aTime-weighted average daily doses calculated from NTP water consumption data.

^bTumor incidences adjusted based on the number of animals surviving beyond 365 days. First tumor onset: 451 days for intestinal tumors in mice, and 506 days for oral tumors in rats (both occurring at the highest doses).

*Denotes significant difference from the control group reported by [NTP \(2008\)](#) using the Poly-3 test ($p < 0.05$).




Figure 3-15. Fractional incidence of mice with adenomas or carcinomas in the small intestine (SI tumors), and fractional incidence of rats with squamous cell carcinomas or papillomas in the oral mucosa or tongue (oral tumors).

Data presented on a basis of (A) administered mg/L Cr(VI), where incidence data for male and females were combined, and (B) administered mg/kg-d Cr(VI), where incidence data for males and females are separated due to differences in water intake and dose. For mice, both males and females were exposed to 5 mg/L, while all other nonzero doses differed between males and females. For rats, both males and females were exposed to the same mg/L Cr(VI) concentration levels. Incidence data adjusted for rodents surviving at least one year.

- 1 Notably, at the lower doses, incidences of specific neoplasms in the GI tract observed during
- 2 the 2-year study exceeded NTP historical controls in both B6C3F1 mice and F344 rats. Therefore,
- 3 some tumors which were not statistically significant versus concurrent controls at low doses may
- 4 be biologically significant due to the increasing trend and low historical control incidence
- 5 (Appendix D.2). Tumors of the oral cavity are rare ([Ibrahim et al., 2021](#); [Leininger and Schutten,](#)
- 6 [2018](#); [Chandra et al., 2010](#)). In the 2-year [NTP \(2008\)](#) bioassay, one squamous cell carcinoma was
- 7 identified in the tongue of a male rat in the lowest dose group (0.2 mg Cr(VI)/kg-d), and in the
- 8 tongue of a female rat at 2.6 mg Cr(VI)/kg-d. The historical controls for squamous cell carcinoma of

1 the tongue are 1/1499 for male rats and 0/1449 for female rats (see Appendix D.2). The historical
2 rates of squamous cell carcinomas and papillomas in the whole oral cavity in rats are less than 1%
3 in both males and females. In the 2-year bioassay, there was an increasing trend in these tumor
4 types in both male and female rats (Figure 3-15), with a 22% incidence in female rats at the highest
5 dose. Tumors of the small intestine of mice are also rare (historical rates of 2.6% and 0.6% in males
6 and females, respectively). These tumors were observed in all exposed groups of mice (including
7 3/49 at the lowest dose in males), with an incidence of $\geq 40\%$ in the highest dose groups in both
8 sexes. One tumor each was observed in the control groups of male and female mice (leading to a
9 2% incidence for controls). In general, historically, rats are more prone to oral cancer development
10 than mice, and mice are more prone to neoplasia in the small intestine ([Ibrahim et al., 2021](#);
11 [Chandra et al., 2010](#)) (Appendix D.2). The reason is unknown, but likely multifactorial in nature,
12 possibly involving differences in the microbiome ([Ibrahim et al., 2021](#)).

13 **3.2.3.3. Genotoxicity Evidence (All Routes)**

14 Cr(VI) is a human lung carcinogen when inhaled. When ingested, Cr(VI) has been shown to
15 cause tumors in the GI tract in animals exposed in drinking water ([NTP, 2008](#)). Evidence relevant
16 to the potential key events and pathways involved in Cr(VI)-induced cancer via oral or inhalation
17 exposures was systematically identified (Section 1.2) and is summarized in the next section, 3.2.3.4,
18 and in Appendix C.3.2 organized by the key characteristics of carcinogens ([Smith et al., 2016](#)). The
19 majority of studies informing these key events were not evaluated for risk of bias and sensitivity
20 concerns. However, a set of genotoxicity studies with designs best suited to examining whether and
21 to what extent Cr(VI)-induced tumorigenesis involves a mutagenic MOA were prioritized and
22 subject to an additional level of review (discussed in more detail below). This includes studies
23 measuring gene or chromosomal mutation endpoints in occupationally exposed humans and
24 studies in experimental animals in inhalation or oral exposure scenarios. An increased focus of
25 analysis on these studies is warranted because the results of the analyses of whether Cr(VI) acts via
26 a mutagenic MOA for cancer influences dose-response decisions, including the application of age-
27 dependent adjustment factors (ADAFs) and low-dose linear extrapolation ([U.S. EPA, 2005b](#)). It is
28 also for this reason that this MOA analysis includes consideration of both GI and lung tumors;
29 although the hazard for lung cancer is not being revisited (see Section 3.2.3.1), a determination of
30 whether a mutagenic MOA is applicable to lung tumors is important to consider for dose-response.
31 The summary and evaluation of the mechanistic evidence most informative to evaluating the role of
32 mutagenicity is synthesized in the following sections. These studies were initially tagged as
33 mechanistic supplemental literature and prioritized for analysis as described in the Cr(VI) Protocol
34 ([U.S. EPA, 2019](#)). The inferences drawn from these syntheses form the basis of mutagenic MOA
35 analysis for carcinogenesis; this analysis, and whether a mutagenic MOA could be secondary to
36 tissue injury and compensatory proliferation induced by Cr(VI), are presented in Section 3.2.3.4,
37 “Cancer mode-of-action summary.”

1 A mutation is a permanent, transmissible change in the genetic material of an organism.
2 Mutations can be caused by alterations in the DNA sequence of a gene, as well as structural
3 (clastogenic) and numerical (aneugenic) chromosome alterations ([Eastmond et al., 2009](#)).
4 Genotoxicity is a more comprehensive term, referring to the ability of an exogenous agent to alter
5 genetic material. Some genotoxicity assays directly measure mutations, while others measure DNA
6 damage; proficient DNA repair of these genetic alterations depends on many factors including the
7 type of genetic damage and the repair capacity of the individual. Although both terms will be used
8 in the following sections, the more inclusive term “genotoxicity” will be used when discussing
9 evidence for a mutagenic MOA in a broader context. Consideration of both types of genotoxicity
10 evidence and a broad survey of multiple genotoxicity endpoints, when available, is important for a
11 comprehensive characterization of an agent’s genotoxicity and the underlying genotoxic processes.

12 A large body of evidence is available to inform the genotoxicity of Cr(VI). Many genotoxicity
13 studies of Cr(VI) were conducted in test systems primarily used to screen substances for genotoxic
14 potential, which are useful but also include endpoints measuring genetic damage that may not
15 represent damage that is transmissible to daughter cells, or that use exposure methods that are
16 expected to result in higher concentrations of Cr(VI) at the cell membrane, including i.p.
17 administration and in vitro studies, leading to a greater quantity of Cr(VI) being taken up by the cell
18 and reduced to Cr(III). These studies have largely shown that intracellular Cr(III) can form DNA
19 adducts (reviewed in [Zhitkovich \(2011\)](#)) and is mutagenic (reviewed in [Chen et al. \(2019\)](#), [Wise et
20 al. \(2018\)](#) and [Nickens et al. \(2010\)](#)). This section is focused on the phenotypic evidence for Cr(VI)-
21 induced genotoxicity; the evidence for the mechanisms underpinning this genotoxicity, including
22 cellular uptake and reduction of Cr(VI) and the formation of Cr-DNA adducts and oxidative DNA
23 lesions, is summarized in the key events for the cancer MOA in Section 3.2.3.4. All studies informing
24 genotoxic mechanisms are considered, but a more specific and critical analysis below focuses on
25 evidence that most directly informs the ability of Cr(VI) to cause mutations in exposed humans.
26 Namely, using the study prioritization and evaluation criteria described in Appendix C.3.2.2, this
27 analysis focuses on studies that use assays to detect transmissible genetic damage (i.e., gene
28 mutation, micronuclei, and chromosomal aberrations) observed in exposed humans or in
29 mammalian test systems in vivo utilizing routes of exposure more applicable to humans (i.e., oral
30 and inhalation).

31 Human study evaluation summary

32 Studies of occupationally or environmentally exposed humans were considered to be most
33 relevant to a mutagenic MOA analysis for cancer if they included measures of gene mutation (prior
34 to tumorigenesis), micronuclei induction, or chromosomal aberrations. Human studies were only
35 considered if they included a comparison or referent population exposed to Cr(VI) at lower levels
36 (or no exposure/exposure below detection limits) or for shorter periods of time. Twenty-nine
37 studies of chromosomal aberrations and/or micronuclei in humans were identified according to
38 these prioritization considerations (see Appendix C.3.2.2 and Table C-47) and evaluated for risk of

1 bias and sensitivity. Six studies were considered but deemed *uninformative* due to critical
2 deficiencies in either the exposure or outcome domain ([Wultsch et al., 2017](#); [Coelho et al., 2013](#);
3 [Sellappa et al., 2010](#); [Hilali et al., 2008](#); [Cid et al., 1991](#); [Sarto et al., 1990](#)) and are not discussed
4 further. The confidence judgments of the 23 informative studies, all conducted in workers
5 occupationally exposed to Cr(VI) that are expected to primarily be inhalation exposures, are
6 summarized in Table 3-16. All of the included studies were cross-sectional in design, comparing
7 individuals employed in occupations with known potential for chromium exposure to referent
8 groups, with the specific occupations, geographic locations, and exposure measurement methods
9 are summarized in Table 3-16. No oral exposure studies in humans were identified.

10 All studies were categorized as *low* or *medium* confidence. Among *low* confidence studies,
11 common reasons for decreased confidence ratings included small sample size/low power ([Linqing
12 et al., 2016](#); [Wultsch et al., 2014](#); [Medeiros et al., 2003](#); [Benova et al., 2002](#); [Vaglenov et al., 1999](#);
13 [Deng et al., 1988](#); [Husgafvel-Pursiainen et al., 1982](#); [Sarto et al., 1982](#)), presence of coexposures to
14 other occupational hazards that may also contribute to the observed genotoxicity (e.g., nickel) not
15 accounted for in the design or analysis ([Wultsch et al., 2014](#); [Qayyum et al., 2012](#); [Iarmarcovai et al.,
16 2005](#)), residual confounding due to minimal or no control for covariates ([Balachandar et al., 2010](#);
17 [Vaglenov et al., 1999](#); [Koshi et al., 1984](#)), limitations in outcome assessment techniques or
18 inadequate reporting ([Qayyum et al., 2012](#); [Balachandar et al., 2010](#); [Danadevi et al., 2004](#); [Koshi et
19 al., 1984](#); [Littorin et al., 1983](#); [Sarto et al., 1982](#)), and insufficient description to allow for evaluation
20 of potential for bias (including selection bias) ([Linqing et al., 2016](#); [Qayyum et al., 2012](#);
21 [Balachandar et al., 2010](#); [Halasova et al., 2008](#); [Iarmarcovai et al., 2005](#); [Danadevi et al., 2004](#);
22 [Maeng et al., 2004](#); [Medeiros et al., 2003](#); [Benova et al., 2002](#); [Koshi et al., 1984](#); [Sarto et al., 1982](#)).
23 Among *medium* confidence studies, the most common reason for decreased confidence rating was
24 insufficient description to allow for evaluation of potential for bias (including selection bias) ([Long
25 et al., 2019](#); [El Safty et al., 2018](#); [Hu et al., 2018](#); [Halasova et al., 2012](#)).

26 For all studies, exposure to chromium was inferred based on occupational group. Given the
27 likelihood of chromium exposure in the industries evaluated an exposure assessment that did not
28 include a precise estimate of exposure levels was not identified as a primary limitation in most of
29 these studies for consideration with respect to mechanistic interpretations. However, lack of
30 certainty about differentiation of exposure between comparison groups (including the potential for
31 exposure among “controls”) was a concern in several studies ([Halasova et al., 2012](#); [Vaglenov et al.,
32 1999](#); [Migliore et al., 1991](#); [Deng et al., 1988](#)). In all but two studies ([Sudha et al., 2011](#); [Migliore et
33 al., 1991](#)), chromium biomarker and/or air concentrations were also measured; these data served
34 to confirm that exposure occurred and provided context for results, but these measurements were
35 not a requirement in the evaluation criteria.

Table 3-16. Summary of included human cross-sectional occupational studies for Cr(VI) mutagenic effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. [Click to see interactive data graphic for rating rationales.](#)

Author (year)	Industry	Location	Exposure Measurement/Cr Validation Measures	Gene mutation	Chromosomal aberrations	Micronuclei
Balachandar et al. (2010)	Tannery	India	Job category/urine and air samples	-	L	L
Benova et al. (2002)	Chrome electroplating	Bulgaria	Job category/urine and air samples	-	L	L
Danadevi et al. (2004)	Welding	India	Job category/ blood samples	-	-	L
Deng et al. (1988)	Chrome electroplating	China	Job category/ air, hair, and stool samples	-	L	-
El Safty et al. (2018)	Chrome electroplating	Egypt	Job category/ serum samples	-	-	M
Halasova et al. (2008)	Welding	Slovak Republic	Job category/ blood samples	-	L	-
Halasova et al. (2012)	Welding	Slovak Republic	Job category/blood samples	-	M	-
Hu et al. (2018)^a	Unspecified factory work with exposure to chromate	China	Job category/ blood and air samples	-	-	M
Husgafvel-Pursiainen et al. (1982)	Welding	Finland	Job category/ urine samples	-	L	-
Iarmarcovai et al. (2005)	Welding	France	Job category/blood and urine samples	-	-	L
Koshi et al. (1984)	Stainless-steel welding	Japan	Job category/ urine samples	-	L	-

Toxicological Review of Hexavalent Chromium

Author (year)	Industry	Location	Exposure Measurement/Cr Validation Measures	Gene mutation	Chromosomal aberrations	Micronuclei
Linqing et al. (2016)	Chrome electroplating	China	Job category/blood samples	-	-	L
Littorin et al. (1983)	Stainless-steel welding	Sweden	Job category/ urine and air samples	-	L	U
Long et al. (2019)	Chromate production	China	Job category/blood samples	-	-	M
Maeng et al. (2004)	Chrome electroplating and buffing	South Korea	Job category/urine, blood, and air samples	-	L	-
Medeiros et al. (2003)	Stainless-steel welders; Tannery	Portugal	Job category/plasma and urine samples	-	-	L
Migliore et al. (1991)	Tannery	Italy	Job category	-	-	L
Qayyum et al. (2012)	Chrome electroplating	India	Job category/plasma samples	-	-	L
Sarto et al. (1982)	Chrome electroplating	Italy	Job category/urine samples	-	L	-
Sudha et al. (2011)	Welding	India	Job category	-	-	M
Vaglenov et al. (1999)	Hydraulic machinery; Chrome electroplating	Bulgaria	Job category/air, red blood cells, urine samples	-	-	L
Wultsch et al. (2014)	Chrome electroplating	Austria	Job category/whole blood samples	-	-	L
Xiaohua et al. (2012)	Chromate production	China	Job category/urine, blood, air samples			L

^aTwo other studies by the same group ([Li et al., 2014a](#); [Li et al., 2014b](#)) reported the same micronucleus frequency data and were tagged as “related to included study” supplemental material.

1 Synthesis of human genotoxicity evidence

2 Among the 23 informative studies prioritized for evaluating mutagenicity, 16 evaluated
3 micronucleus incidence and 10 evaluated chromosomal aberrations (three studies evaluated more
4 than one of these endpoints). The study details are summarized in Table 3-17 and Appendix Table
5 C-47.

Table 3-17. Associations between Cr(VI) exposure and prioritized genotoxicity outcomes in epidemiology studies^a

Reference	Population	Duration of work in exposed group (mean (SD) yrs)	Cr measurements (mean (SD) unless otherwise indicated)	Endpoints ^b
El Safty et al. (2018) <i>Medium confidence</i>	Cross-sectional study in Egypt Exposed: 41 electroplating workers Referents: 41 administrative workers	26.68 (11.21)	<u>Air</u> (mg/m ³) <i>Total Cr</i> Exposed: median: 15.5 (IQR: 19.0) Referents: median: 0.2 (IQR: 0.4) <u>Blood</u> (µg/L) Exposed: 8.5 (1.3) Referents: 4.1 (1.4)	In exfoliated buccal cells: ↑ MN in exposed compared to controls ($p < 0.001$) ↑ serum Cr correlates with ↑ MN ↑ serum 8-OHdG in exposed compared to controls ($p < 0.001$)
Halasova et al. (2012) <i>Medium confidence</i>	Cross-sectional study in Slovak Republic Exposed: 73 welders Referents: 73 individuals without known exposures	10.2 (1.7)	<u>Blood</u> (µmol/L) <i>Total Cr</i> Exposed: 0.07 (0.04) Referents: 0.03 (0.007)	In cultured lymphocytes: No significant differences in CAs between exposed and control groups ↑ CAs in individuals with Gln/Gln genotype compared to Arg/Gln or Arg/Arg genotypes in XRCC1 Arg399Gln; more pronounced in Cr-exposed workers ($p = 0.01$) (no correlation with XRCC3 polymorphisms)
Hu et al. (2018) <i>Medium confidence</i>	Cross-sectional study in China Exposed: 87 workers at factory with chromate exposure Referents: 30 administrative workers	Median: 5.0 IQR: 7.0	<u>Air</u> (µg/m ³) Exposed: median: 15.5 (IQR:19.0) Referents: median: 0.2 (IQR: 0.4) <u>Blood</u> (µg/L) Exposed: GM: 8.5 (1.3) Referents: GM:4.1(1.4)	↑ MN in peripheral lymphocytes in exposed workers compared with referent
Long et al. (2019) <i>Medium confidence</i>	Cross-sectional study in China Exposed: 120 chromate production facility workers Referents: 97 unexposed workers at the same factory	14.57 (5.85)	<u>Blood</u> (µg/L) Exposed: median: 2.81 (IQR: 3.86) Referents: median: 0.99 (IQR: 1.21)	↑ MN frequency ratio in lymphocytes of exposed Interactions between Cr exposure and MN frequency in lymphocytes for some SNPs

Toxicological Review of Hexavalent Chromium

Reference	Population	Duration of work in exposed group (mean (SD) yrs)	Cr measurements (mean (SD) unless otherwise indicated)	Endpoints ^b
Sudha et al. (2011) <i>Medium confidence</i>	Cross-sectional study in India Exposed: 66 welders Referents: 60 general population controls	Range: 5–20	NR	In exfoliated buccal cells: ↑ MN frequency and comet tail length in welders compared to controls; increased with duration of work ($p < 0.05$)
Balachandar et al. (2010) <i>Low confidence</i>	Cross-sectional study in India Exposed 1: 36 directly exposed (DE) through tannery work Exposed 2: 36 indirectly exposed (IE) through residential proximity to tanneries Referents: 36 unexposed individuals	DE (tannery) workers (% by duration) 0–5: 17% 5–10: 33% 10–15: 36% 15–20: 11% 20–25: 3%	<u>Air</u> (mg/m ³) <i>Cr(VI)</i> DE 0.021 (0.003) IE: 0.013 (0.005) Referents: 0.006 (0.001) <u>Urine</u> DE: 2.11 (1.01) IE: 1.81 (0.88) Referents: 0.54 (0.39) (Units not provided)	In cultured lymphocytes: ↑ CAs in DE group compared to IE group and controls ↑ MN among directly exposed subjects compared to indirectly exposed & controls; further elevated in those with longer duration of exposure ↑ mean tail length for comet assay in DE group compared to IE group and controls
Benova et al. (2002) <i>Low confidence</i>	Cross-sectional study in Bulgaria Exposed: 15 chrome-plating workers Referents: 23 individuals (15 workers and 8 rural residents)	N by duration: 2–5: 3 6–10: 1 11–15: 4 16–20: 4 >20: 3	<u>Air</u> (mg/m ³) <i>Cr(VI)</i> High exposed workers: 0.0249 (SE: 0.004) Low exposed workers: 0.0075 (SE: 0.001) Referents: 0.0004 (SE: 0) <u>Urine</u> (µg/L) High exposed workers: 104.22 (SE: 27.51) Low exposed workers: 18.63 (SE: 3.16) Referents: 1.18 (SE: 0.23)	In cultured lymphocytes and exfoliated buccal cells: No significant difference in frequencies of CAs or SCEs in exposed workers compared to controls ↑ MN in workers compared to controls (lymphocytes: $p < 0.01$; buccal: $p < 0.001$)

Toxicological Review of Hexavalent Chromium

Reference	Population	Duration of work in exposed group (mean (SD) yrs)	Cr measurements (mean (SD) unless otherwise indicated)	Endpoints ^b
Danadevi et al. (2004) Low confidence	Cross-sectional study in India Exposed: 102 welders Referents: 102 general population controls	Range: 1–24	<u>Blood</u> (µg/L) Exposed: 151.65 (SD not provided) Referents: 17.86 (SD not provided)	↑ MN in exfoliated buccal cells compared to controls ($p < 0.001$), correlated with duration of work, age, and Cr level in blood ↑ mean comet tail length in whole blood cells compared to controls ($p < 0.001$)
Deng et al. (1988) Low confidence	Cross-sectional study in China Exposed 1: 7 electroplating workers exposed to chromium Exposed 2: 7 electroplating workers exposed to nickel Referents: 10 officer workers	12.8 (range: 4–18)	<u>Air</u> (mg/m ³) <i>Total Cr</i> Workers: 8×10^6 (SE: 3.7×10^6) <u>Stool</u> (µg/g) Workers: 8.5 (SE: 3.2) <u>Hair</u> (µg/g) Workers: 35.7 (11.5)	In cultured lymphocytes: ↑ CAs in chromium workers compared to nickel workers & controls ↑ SCE in chromium & nickel workers compared to controls
Halasova et al. (2008) Low confidence	Cross-sectional study in Slovak Republic Exposed: 39 welders Referents: 31 individuals without known exposures	10.2 (1.7)	<u>Blood</u> (µmol/L) <i>Total Cr</i> Exposed: 0.07 (0.04) Referents: 0.03 (0.007)	In cultured lymphocytes: Nonsignificant ↑ CAs in exposed compared to control groups ↑ CAs ($p < 0.05$) in lymphocytes in individuals with Gln/Gln genotype compared to Arg/Gln or Arg/Arg genotypes in XRCC1 Arg399Gln (no correlation with XRCC3 polymorphisms)
Husgafvel-Pursiainen et al. (1982) Low confidence	Cross-sectional study in Finland Exposed: 23 welders Referents: 22 employees at printing company	21 (10)	<u>Urine</u> (µmol/L) <i>Total Cr</i> Exposed: range: 0.20–1.55	In cultured lymphocytes: No significant differences in frequency of CAs or SCEs between welders and controls

Reference	Population	Duration of work in exposed group (mean (SD) yrs)	Cr measurements (mean (SD) unless otherwise indicated)	Endpoints ^b
Iarmarcovai et al. (2005) Low confidence	Cross-sectional study in France Exposed: 60 welders n = 27 working in areas "without any collective protection device" n = 33 working in places with "smoke extraction systems" Referents: 30 office workers	Range: 0.5–45	<u>Blood</u> (µg/L) Exposed: 123.8–145.8 (58.8–87.7) ^c Referents: 92.0 (15.0) <u>Urine</u> (µg/g creatinine) Exposed: 18.6–33.0 (11.0–21.4) ^c Referents: 12.8 (6.6)	In cultured lymphocytes: ↑ MN in non-protected welders compared to controls ($p = 0.03$) ↑ mean comet tail length in welders at the end of the work week ($p < 0.001$); not significant at the start of the week ↑ mean comet tail length in individuals with Gln/Gln genotype compared to Arg/Gln or Arg/Arg genotypes in XRCC1 Arg399Gln (no correlation with XRCC3 polymorphisms)
Koshi et al. (1984) Low confidence	Cross-sectional study in Japan Exposed: 51 stainless-steel welders Referents: 33 office/research workers	12 (range: 5–20)	<u>Urine</u> (µg/L) Exposed: 9.8 (9.2) Referents: 4.2 (1.2) µg/L	In cultured lymphocytes: ↑ CAs and SCEs in welders compared to controls
Linqing et al. (2016) Low confidence	Cross-sectional study in China Exposed: 29 chrome-plating workers Referents: 29 workers without chromate exposure history	NR	<u>Blood</u> (µg/L) Exposed: 15.2 (range: 2.1–42) Referents: 4.6 (range: 0.2–28)	In cultured lymphocytes: ↑ MN frequencies in workers compared to controls ($p = 0.0048$) No correlation between blood Cr concentration and MN ↓ methylation of MT-TF and MT-RNR1 genes in mitochondrial DNA correlated with blood Cr

Toxicological Review of Hexavalent Chromium

Reference	Population	Duration of work in exposed group (mean (SD) yrs)	Cr measurements (mean (SD) unless otherwise indicated)	Endpoints ^b
Littorin et al. (1983) Low confidence	Cross-sectional study in Sweden Exposed: 24 stainless-steel welders Referents: 24 matched individuals without occupational mutagenic exposures	19 (range: 7–41)	<u>Air</u> (mg/m ³) <i>Cr VI</i> Exposed: 0.055 (range: 0.005–0.321) <u>Urine</u> (µmol/L) Exposed: 47 (range: 5–155) Referents: 1.5 (range: <0.4–7.0)	In cultured lymphocytes: No significant differences in CAs or SCEs between exposed and control groups No significant differences in MN between exposed and control groups
Maeng et al. (2004) Low confidence	Cross-sectional study in South Korea Exposed: 51 male chrome-plating/buffing workers Referents: 31 office workers	9.1 (range: 0–40)	<u>Air</u> (mg/m ³) <i>Cr VI</i> Exposed: GM: 0.0032 (range: 0.0003–0.09) Referents: GM: 3×10^{-5} (range: 1.4×10^{-5} – 6.1×10^{-5}) <u>Blood</u> (µg/dL) Exposed: GM: 0.86 (range: 0.11–8.99) Referents: GM: 0.17 (range: 0.00–0.67) <u>Urine</u> (µg/g creatinine) Exposed: GM: 12.82 (range: 0.66–8.74) Referents: GM: 3.39 (range: 0.40–9.04)	In cultured lymphocytes: Nonsignificant ↑ CAs detected by solid Giemsa staining in exposed compared with unexposed that were statistically correlated with higher blood Cr ↑ CAs with ↑ frequency of chromosome translocations in exposed compared with unexposed ($p < 0.01$) detected by FISH ↑ MDA in blood plasma in exposed compared to controls ($p < 0.01$)

Toxicological Review of Hexavalent Chromium

Reference	Population	Duration of work in exposed group (mean (SD) yrs)	Cr measurements (mean (SD) unless otherwise indicated)	Endpoints ^b
Medeiros et al. (2003) Low confidence	Cross-sectional study in Portugal Exposed 1: 5 welders Exposed 2: 33 tannery workers Referents: 20–30 unexposed individuals	NR	<u>Plasma</u> (µg/L) Tannery workers: 2.43 (2.11) Welders: 1.55 (0.67) Referents: 0.41 (0.11) <u>Urine</u> : (µg/g creatinine) Tannery workers: 2.63 (1.62) Welders: 1.90 (0.37) Referents: 0.70 (0.38)	In cultured lymphocytes: ↑ MN in tannery workers compared to controls ($p < 0.01$) Nonsignificant ↑ MN in welders ($n = 5$) ↑ DNA-protein crosslinks in tanners ($p < 0.001$) and welders ($p < 0.05$) compared to controls
Migliore et al. (1991) Low confidence	Cross-sectional study in Italy Exposed: 17 tannery workers and 2 reference groups from different industries	NR	NR	No effects on MN frequency in cultured lymphocytes
Qayyum et al. (2012) Low confidence	Cross-sectional study in India Exposed: 100 electroplating workers (grouped by length of work) Referents: 50 individuals with no known exposure to nickel or chromium	Group 1: range: 1–9 Group 2: range: 10–25	<u>Plasma</u> (µg/L) Group 1: 2.9 (0.8) Group 2: 1.7 (0.6) Referents: 0.6 (0.8)	In buccal cells of Group II compared to Group I, and in Group III compared to Group II: ↑ MN frequency ($p < 0.05$) MN also correlated with Cr levels in plasma ($p < 0.01$)
Sarto et al. (1982) Low confidence	Cross-sectional study in Italy Exposed: 38 plating factory workers (bright plating and hard plating) Referent 1: 35 sanitary workers Referent 2: 14 healthy blood donors	Hard plating: 7 (3) Bright plating: 9 (11)	<u>Urine</u> (µg/g creatinine) Exposed—Hard plating: 10.0 (7.5) Exposed—Bright plating: 6.1 (2.8) Referents: 1.9 (1.4)	In cultured lymphocytes: ↑ CAs (mostly CSAs) among all exposed bright platers ($p < 0.001$) and hard platers ($p < 0.01$) compared to controls ↑ SCEs in hard platers compared to blood donors

Toxicological Review of Hexavalent Chromium

Reference	Population	Duration of work in exposed group (mean (SD) yrs)	Cr measurements (mean (SD) unless otherwise indicated)	Endpoints ^b
Vaglenov et al. (1999) Low confidence	Cross-sectional study in Bulgaria Exposed: 30 hydraulic machinery workers (grouped by high and low exposure) & 10 hospitalized electroplating workers Referents: 18 administrative workers	Overall range: 4–25 High exposed mean: 11.63 Low exposed mean: 10.44	<p style="text-align: center;"><u>Air</u> (mg/m³)</p> High exposed: 0.083 (SE: 0.010) Low exposed: 0.043 (SE: 0.01) Referents: 0.0003 (SE: 0.0001) <p style="text-align: center;"><u>Erythrocytes</u> (µg/L)</p> High exposed: 8.40 (SE: 1.93) Low exposed: 4.31 (SE: 1.03) Referents: 0.57 (SE: 0.05) <p style="text-align: center;"><u>Urine</u> (µg/L)</p> High exposed: 5.0 (SE: 1.52) Low exposed: 3.97 (SE: 1.98) Referents: 0.49 (SE: 0.06)	↑ MN and binucleated cells carrying MN in lymphocytes of exposed compared to control Correlations of Cr measured in air, erythrocytes and urine, with higher MN in lymphocytes
Wultsch et al. (2014) Low confidence	Cross-sectional study in Austria Exposed: 22 chrome-plating workers Referents: 22 jail warden controls	NR	<p style="text-align: center;"><u>Blood</u> (µg/L)</p> Exposed: 2.3 (1.5) Referents: 0.2 (0.2)	In exfoliated cells of exposed chrome platers compared to referent: ↑ MN frequency in nasal cells ($p = 0.005$) No significant effect on MN frequency in buccal cells (23% increase; $p = 0.516$) ↑ nuclear anomalies in buccal and nasal cells

Reference	Population	Duration of work in exposed group (mean (SD) yrs)	Cr measurements (mean (SD) unless otherwise indicated)	Endpoints ^b
Xiaohua et al. (2012) <i>Low confidence</i>	Cross-sectional study in China Exposed: 79 chromate production workers Referents: 112 peasant volunteers without occupational chromate exposure	Mean: 14.89 SE: 8.65	<u>Air</u> (µg/m ³) Exposed: 13.01 (range:1.03–56.60) Referents: 0.073 (range: 0.023–0.235) <u>Blood</u> (µg/L) Exposed: 9.19 (range: 1.17–51.88) Referents: 3.44 (range: 0.25–22.51) <u>Urine</u> (µg/g creatinine) Exposed: 17.03 (range: 2.78–97.23) Referents: 2.49 (range: 0.39–26.82)	↑ MN in binucleated blood cells in exposed group compared to controls Moderate correlations (0.353–0.517) between BNMN and Cr concentrations in blood, urine, air

GM = geometric mean; IQR = interquartile range; SE = standard error; CA = chromosomal aberration; MN = micronuclei; NR = not reported.

^aStudies presented by study confidence (high to low) first, then alphabetically by author.

^bSome endpoints reported by the same study but not included in the PECO are also included here for context. p-values are added to provide additional context but should not be the sole focus for interpretation.

^cThis study reported subgroup means and SD; therefore, this table reports the range of means and the range of SDs for these groups.

1 *Micronuclei*

2 Micronuclei are formed when dividing cells contain whole chromosomes or acentric
3 chromosome fragments that have lagged behind during anaphase, indicating aneuploidy or the
4 presence of chromosomal aberrations. Additional procedures to detect the presence of a
5 centromere in the micronucleus can distinguish between loss of a whole chromosome or
6 chromosome fragments. All prioritized studies in humans focused on the detection of micronuclei
7 or chromosomal aberrations in peripheral blood lymphocytes or exfoliated nasal or buccal cells
8 (epithelial cells inside the mouth/cheek). In humans, it has been shown that an increased
9 frequency of micronuclei in circulating blood is positively associated with an increased risk of
10 cancer (Bonassi et al. (2011b; 2007)). In addition, micronuclei detected in exfoliated epithelial cells
11 from the oral buccal or nasal mucosa is an effective measure of genetic damage in directly exposed
12 tissues (Bonassi et al., 2011a).

13 Among the 16 studies evaluating micronuclei, four were rated as *medium* confidence and 12
14 were rated as *low* confidence. All four of the *medium* confidence studies reported increased
15 micronuclei, with two studies reporting these increases in lymphocytes (Long et al., 2019; Hu et al.,
16 2018), and two reporting increases in buccal cells (El Safty et al., 2018; Sudha et al., 2011). These
17 studies included populations from several industries with chromium exposure including
18 electroplating, chromate production, and welding. While these studies compared groups defined by
19 job category, three of the four studies augmented the exposure assessment by including data from
20 supplemental biomarker and/or air measures that showed total Cr levels were higher in exposed
21 workers and in exposure settings, confirming that exposures occurred and providing context for
22 the positive results (Long et al., 2019; El Safty et al., 2018; Hu et al., 2018) (see Table 3-17).

23 Among the 11 *low* confidence studies, there were ten that reported increased micronuclei
24 for at least one cell type. Three evaluated buccal cells (Qayyum et al., 2012; Danadevi et al., 2004;
25 Benova et al., 2002), six evaluated lymphocytes and/or leukocytes in peripheral blood (Linqing et
26 al., 2016; Balachandar et al., 2010; Iarmarcovai et al., 2005; Medeiros et al., 2003; Benova et al.,
27 2002; Vaglenov et al., 1999), and one evaluated nasal cells (Wultsch et al., 2014) (this study also
28 reported a slight nonsignificant increase in micronuclei in buccal cells). These studies were
29 comprised of populations exposed to chromium via welding, electroplating, hydraulic machinery,
30 and tanneries. These studies also confirmed exposure in biomarker and/or air measures of total Cr
31 or Cr(VI), though Linqing et al. (2016) did not detect a significant correlation between the increased
32 blood Cr levels and statistically significantly increased micronucleus frequency in exposed workers
33 (Table 3-17 and Appendix Table C-47). The potential direction of bias in these *low* confidence
34 studies could not be determined.

35 One *low* confidence study reported no significant effects on micronucleus endpoints. In this
36 study, Migliore et al. (1991), there is uncertainty regarding the potential for chromium exposure
37 among the tannery workers evaluated and no accompanying biomarker measurements to provide
38 confirmation; misclassification of individuals with regards to exposure group may produce bias

1 towards the null. In the absence of quantitative measures of exposure, it cannot be determined
2 whether a negative result reflects low exposures, a lack of mutagenicity, or both.

3 Dose-response concordance for the observed increases in micronuclei was observed in
4 several studies, most reliably based on correlations between Cr levels measured in blood and
5 micronuclei in buccal cells in the *medium* confidence study by [El Safty et al. \(2018\)](#) and also in the
6 *low* confidence studies by [Qayyum et al. \(2012\)](#) and [Danadevi et al. \(2004\)](#). [Danadevi et al. \(2004\)](#)
7 also noted a correlation between Cr levels and duration of work and age. A correlation between
8 work duration and increased micronucleus frequency was also noted in buccal cells in the *medium*
9 confidence study by [Sudha et al. \(2011\)](#) and in lymphocytes in the *low* confidence study by
10 [\(Balachandar et al., 2010\)](#).

11 Several of these studies also reported other significantly increased systemic genotoxicity
12 markers in exposed workers that may be coherent with the observed micronuclei increases,
13 including serum 8-OHdG ([El Safty et al., 2018](#)) and comet tail length in blood cells ([Sudha et al.,](#)
14 [2011](#); [Danadevi et al., 2004](#)).

15 Overall, all four *medium* confidence studies across different study populations and
16 industrial settings (Table 3-16) and covering both lymphocytes and exfoliated epithelial cells
17 provide evidence for an association between chromium exposure and increased micronuclei. These
18 results are supported by the large majority of the available *low* confidence studies. Despite their
19 limitations, *low* confidence studies provide supporting evidence for this endpoint in conjunction
20 with the conclusions from *medium* confidence studies. In addition, when looking broadly across
21 studies and evaluating the evidence base as a whole, concerns about any particular study deficiency
22 is attenuated given that ten of the 11 *low* confidence studies demonstrated increases in micronuclei
23 despite differences in population and exposure scenarios.

24 *Chromosomal aberrations*

25 Structural or numerical chromosomal aberrations, observable during metaphase in cells
26 undergoing mitosis, are typically detected using simple, solid-staining techniques that allow visual
27 identification of chromosome and chromatid breaks, but do not detect translocations or other more
28 complex forms of chromosomal damage. Use of G-banding techniques or molecular fluorescent
29 probes (e.g., FISH) increase the type and complexity of detectable cytogenetic damage. In humans,
30 it has been shown that an increased frequency of chromosomal aberrations in circulating blood is
31 positively associated with an increased risk of cancer ([Bonassi et al., 2008](#); [Norppa et al., 2006](#)).

32 All included studies evaluating chromosomal aberrations were rated as *low* confidence
33 except for one *medium* confidence study, [Halasova et al. \(2012\)](#), that identified chromosomal
34 aberrations only within genetically susceptible populations but did not identify differences
35 between the broader exposed and control groups. It should be noted, however, that a concern for
36 bias towards the null due to potential insensitivity was identified for this study. The mean levels of
37 blood chromium among the exposed group in this study were low (0.07 $\mu\text{mol/L}$ = 3.64 $\mu\text{g/L}$) and
38 within the range reported for the referent groups in other studies of chromosomal aberrations

1 (e.g., [Maeng et al. \(2004\)](#): 2.0 µg/L) and micronuclei (e.g., [Linqing et al. \(2016\)](#): 4.6 µg/L). Lack of
2 control for potential confounders is also a concern in this study ([Halasova et al., 2012](#)).

3 Among the nine *low* confidence studies, six reported increased chromosomal aberrations
4 among exposed compared to unexposed individuals ([Balachandar et al., 2010](#); [Halasova et al., 2008](#);
5 [Maeng et al., 2004](#); [Deng et al., 1988](#); [Koshi et al., 1984](#); [Sarto et al., 1982](#)). These studies examined
6 individuals exposed to chromium in a range of settings, such as tanneries, mining, electroplating,
7 and welding. While several studies had deficiencies that pose substantial concern for bias, such as
8 limited evaluation of confounders or potential for selection bias ([Koshi et al., 1984](#); [Sarto et al.,](#)
9 [1982](#)), others had deficiencies that primarily relate to sensitivity, such as small sample size and
10 unclear differentiation between exposure groups ([Balachandar et al., 2010](#); [Halasova et al., 2008](#);
11 [Deng et al., 1988](#)). Identification of effects on chromosomal aberrations despite sensitivity
12 concerns in these studies that may bias results towards the null can provide stronger evidence of
13 effect despite the individual overall study evaluation ratings of *low*.

14 Three *low* confidence studies evaluating populations of welders or chrome-plating workers
15 reported no changes in chromosomal aberrations in exposed individuals compared to controls
16 ([Halasova et al., 2008](#); [Benova et al., 2002](#); [Littorin et al., 1983](#)). It should be noted that two of these
17 studies may have limited power to detect the outcome of interest due to small sample size ([Benova](#)
18 [et al., 2002](#); [Husgafvel-Pursiainen et al., 1982](#)).

19 Overall, while the evidence base is mostly consistent regarding the association between
20 chromium exposure and chromosomal aberrations across a variety of exposure scenarios,
21 biomarkers, and geographic regions, these observations are only available from studies rated as *low*
22 confidence and a single *medium* confidence study with mixed results. Although considering the
23 entire evidence base mitigates concerns about any particular deficiency in a single *low* confidence
24 study and some of these studies detected effects despite limitations in power and sensitivity
25 ([Coelho et al., 2013](#); [Balachandar et al., 2010](#); [Halasova et al., 2008](#); [Deng et al., 1988](#)), it is difficult
26 to draw definitive judgments from the predominantly *low* confidence evidence base on
27 chromosomal aberrations.

1 Animal study evaluation summary

2 As described above in the introduction to the mutagenic MOA evaluation approach and in
3 Appendix C.3.2.2, the available animal evidence prioritized as the most relevant for informing a
4 mutagenic MOA analysis for cancer includes measures of gene mutation (prior to tumorigenesis),
5 micronuclei induction, and chromosomal aberrations. These studies were prioritized for evaluation
6 and synthesis in this section based on study design, namely if they were conducted in animals
7 exposed via inhalation or intratracheal instillation, or via the oral route, including drinking water,
8 diet, or gavage. Gavage and intratracheal instillation exposures were considered with the
9 acknowledgment that these dosing regimens condense the exposure time while potentially
10 inhibiting reduction kinetics leading to increased point-of-contact Cr(VI) exposure. Studies
11 measuring DNA damage or indicators of DNA damage or using more direct methods of chemical
12 administration (i.e., i.p. injection) were not prioritized but are still considered as supplemental
13 evidence to mutation and are summarized in Appendix C.3.2.2.

14 Table 3-18 summarizes the overall classification judgments for 15 animal studies of Cr(VI)-
15 induced mutagenicity via inhalation or oral exposures (reporting 16 total endpoints) that were
16 prioritized for evaluation. These consist of six studies measuring mutation frequency following
17 short-term and subchronic exposures to drinking water ([Aoki et al., 2019](#); [Thompson et al., 2017](#);
18 [Thompson et al., 2015c](#); [O'Brien et al., 2013](#); [Kirpnick-Sobol et al., 2006](#)) or via intratracheal
19 instillation (Cheng et al. ([2000](#); [1998](#)); the preliminary and primary study results were reported in
20 two separate publications), three studies detecting chromosomal aberrations following a single
21 gavage dose ([Mukherjee et al., 1997](#); [Sarkar et al., 1996, 1993](#)), six studies measuring micronucleus
22 incidence following acute, short-term, or chronic drinking water and/or gavage exposures
23 ([Thompson et al., 2015b](#); [O'Brien et al., 2013](#); [NTP, 2007](#); [De Flora et al., 2006](#); [Mirsalis et al., 1996](#);
24 [Shindo et al., 1989](#)), and one dominant lethal test in rats exposed via intragastric instillation ([Marat](#)
25 [et al., 2018](#)). Three additional studies reporting the micronucleus test in rats ([Elshazly et al., 2016](#))
26 and chromosomal aberrations in mice ([Mukherjee et al., 1999](#); [Go'ldina et al., 1989](#)) were found to
27 be *uninformative* for these endpoints and were not considered further.

28 The endpoints specific to mutation, identified using the prioritization criteria for
29 mutagenicity evidence relevant to cancer (Appendix C.3.2.2), were evaluated separately from any
30 apical endpoints that may have also been reported in these animal bioassays (see Table 3-8). The
31 majority of the prioritized studies are in vivo assays considered to be complementary, as the
32 transgenic rodent assay primarily detects point mutations and small deletions ([Dobrovolsky and](#)
33 [Heflich, 2018](#)), and the micronucleus assay can detect chromosomal aberrations and aneuploidy
34 ([Hayashi, 2016](#)). Following study evaluation, all 15 studies of mutagenic endpoints were
35 categorized as *low confidence*.

36 For many of the considered studies ([Aoki et al., 2019](#); [Thompson et al., 2017](#); [Thompson et](#)
37 [al., 2015c](#); [Thompson et al., 2015b](#); [O'Brien et al., 2013](#); [NTP, 2007](#); [De Flora et al., 2006](#); [Mirsalis et](#)
38 [al., 1996](#)), the concern was not with the “quality” of the study, but rather with study designs that

1 were not optimized for genotoxic endpoints and thus lacked sensitivity for detecting an effect if one
2 were to be present, leading to deficiencies in the exposure sensitivity domain. According to the test
3 guidelines (TG) adopted by the Organisation for Economic Cooperation and Development (OECD)
4 for the transgenic rodent assay (TG 488, [\(OECD, 2020\)](#)) and the mammalian erythrocyte
5 micronucleus test (TG 474, [\(OECD, 2016a\)](#)), the two endpoints reported in most of the prioritized
6 studies, these studies should include a range of doses with the top dose representing the maximum
7 tolerated dose (MTD) that produces non-lethal toxicity in the animals (or, if not achievable, a daily
8 dose of 1000 mg/kg for a 28 day administration)²⁹. This is to ensure the study is capable of
9 characterizing the mutagenic potential of the chemical on the target tissue(s) by confirming the
10 substance has reached the target tissue at levels high enough to induce toxicity, which is often the
11 bone marrow for standard micronucleus tests in polychromatic erythrocytes. Testing for
12 mutagenicity up to toxic levels is particularly important for increasing confidence in null findings in
13 vivo for a substance known to be mutagenic in vitro, such as Cr(VI). The motivation for selecting a
14 dose range to specifically study the induction of mutagenic effects at the same dose levels (albeit
15 with shorter exposure durations) that caused preneoplastic lesions and tumors in these animals
16 (e.g., up to 31.1 mg/kg-d Cr(VI) in female mice) is understandable. However, a bioassay properly
17 designed to detect potential mutagenic effects from ingested Cr(VI)³⁰, a known carcinogen and a
18 mutagen via other routes of exposure, was not identified.

19 Other concerns about the ability of these studies to appropriately characterize mutagenicity
20 also contributed to their *low* confidence ratings. Deficiencies in the outcome sensitivity domain
21 included studies that counted too few plaque-forming units in the transgenic rodent assay (Cheng
22 et al. [\(2000; 1998\)](#)) or polychromatic erythrocytes in the micronucleus assay ([O'Brien et al., 2013;](#)
23 [Shindo et al., 1989](#)), a mutation frequency background too high to reliably detect an effect ([O'Brien](#)
24 [et al., 2013](#)), or failed positive controls ([Thompson et al., 2015b](#)). A few studies were deficient in
25 results display sensitivity, including a failure to account for litter effects in a mutation study of

²⁹TG 474 ([OECD, 2016a](#)): “The study should aim to identify the maximum tolerated dose (MTD), defined as the highest dose that will be tolerated without evidence of study-limiting toxicity, relative to the duration of the study period (for example, by inducing body weight depression or hematopoietic system cytotoxicity, but not death or evidence of pain, suffering or distress necessitating humane euthanasia. The highest dose may also be defined as a dose that produces toxicity in the bone marrow (e.g., a reduction in the proportion of immature erythrocytes among total erythrocytes in the bone marrow or peripheral blood of more than 50%, but to not less than 20% of the control value)...If the test chemical does not produce toxicity in a range-finding study or based on existing data, the highest dose for an administration period of 14 days or more should be 1000 mg/kg body weight/day, or for administration periods of less than 14 days, 2000 mg/kg/body weight/day.” TG 488 ([OECD, 2020](#)): “The top dose should be the Maximum Tolerated Dose (MTD). The MTD is defined as the dose producing signs of toxicity such that higher dose levels, based on the same dosing regimen, would be expected to produce lethality.”

³⁰There were issues with Cr(VI) palatability at high drinking water concentrations (above ~90 mg/L Cr(VI) in the [NTP \(2007\)](#) strain comparison study and at higher doses in the toxicity study), but in these cases it would also be acceptable to use gavage administration to confirm delivery of a sufficient dose of Cr(VI). Only one study included a gavage-administered dose that reached sufficient bone marrow toxicity, but this study was judged *low* confidence due to deficiencies in the reporting, confounding, and endpoint sensitivity domains ([Shindo et al., 1989](#)).

1 exposures in mice in utero ([Kirpnick-Sobol et al., 2006](#)), not reporting the total number of cells
 2 scored for micronuclei ([O'Brien et al., 2013](#)), or pooling total micronuclei from multiple animals
 3 ([Thompson et al., 2015b](#)). One dominant lethal test identified did not report the strain of animals,
 4 test compound, or vehicle used ([Marat et al., 2018](#)). And three *low* confidence studies were
 5 identified that used a single gavage dose of Cr(VI) in mice to induce chromosomal aberrations in
 6 order to test the effectiveness of anticlastogenic botanicals and were thus not optimized for an
 7 objective assessment of genetic damage ([Mukherjee et al., 1997](#); [Sarkar et al., 1996, 1993](#)). The
 8 prioritized studies are summarized in Table 3-19.

Table 3-18. Summary of prioritized animal studies for investigating Cr(VI)-induced mutagenicity and overall confidence classification [high (H), medium (M), low (L)] by endpoint^a. [Click to see interactive data graphic for rating rationales.](#)

Author (year)	Species (strain)	Exposure duration	Exposure route	Mutagenic endpoints			
				Gene mutation	Chromosomal aberrations	Micronuclei	Dominant Lethal test
Aoki et al. (2019)	Mouse (transgenic gpt delta), male	28 and 90 days	Drinking water	L	-	-	-
Cheng et al. (2000 ; 1998)	Mouse (C57BL/6 Big Blue [®] and nontransgenic C57BL/6), female	1, 2, or 4 wks post-instillation	Intratracheal instillation	L	-	-	-
De Flora et al. (2006)	Mouse (BDF ₁), male and female; Mouse (Swiss albino) pregnant dams and fetuses	20 or 210 days or pregnancy duration	Drinking water, gavage, i.p.	-	-	L	-
Kirpnick-Sobol et al. (2006)	Mouse (C57BL/6Jp ^{un} /p ^{un}), pregnant dams and offspring	GD 10.5–20.5	Drinking water	L	-	-	-
Marat et al. (2018)	Rat (“mature white outbred”), male	60 days	Intragastric administration	-	-	-	L
Mirsalis et al. (1996)	Mouse (Swiss-Webster), male and female	2 days	Drinking water, gavage	-	-	L	-
Mukherjee et al. (1997)	Mouse (Swiss albino), male	Bolus dose (acute)	Gavage	-	L	-	-
NTP (2007)	Mouse (B6C3F ₁), male and female;	90 days	Drinking water	-	-	L	-

Author (year)	Species (strain)	Exposure duration	Exposure route	Mutagenic endpoints			
				Gene mutation	Chromosomal aberrations	Micronuclei	Dominant Lethal test
	Mouse (B6C3F ₁ , BALB/c, am3-C57BL/6), male						
O'Brien et al. (2013) [related study: (Thompson et al., 2011)]	Mouse (B6C3F ₁), female	90 days	Drinking water	L	-	L	-
Sarkar et al. (1993)	Mouse (Swiss albino), male	Bolus dose (acute)	Gavage	-	L	-	-
Sarkar et al. (1996)	Mouse (Swiss albino), male	Bolus dose (acute)	Gavage	-	L	-	-
Shindo et al. (1989)	Mouse (MS/Ae and CD-1), male	Bolus dose (acute)	Gavage, i.p.	-	-	L	-
Thompson et al. (2015b)	Mouse (B6C3F ₁), female	7 days	Drinking water	-	-	L	-
Thompson et al. (2015c)	Rat (transgenic Big Blue® TgF344), male	28 days	Drinking water	L	-	-	-
Thompson et al. (2017)	Rat (transgenic Big Blue® TgF344), male	28 days	Drinking water	L	-	-	-

^aStudies excluded due to critical deficiency in one or more domains: [Elshazly et al. \(2016\)](#), [Mukherjee et al. \(1999\)](#), and [Go'ldina et al. \(1989\)](#).

1 Synthesis of animal genotoxicity evidence

- 2 The studies prioritized for being most informative for a mutagenic MOA analysis are
 3 summarized in Table 3-19.

Table 3-19. Prioritized genotoxicity studies in animals exposed to Cr(VI)

Reference	System/ Exposure	Endpoint/Results ^a	Comments
Tests in lung tissue			

Toxicological Review of Hexavalent Chromium

Reference	System/ Exposure	Endpoint/Results ^a	Comments
Cheng et al. (2000; 1998) <i>Low confidence</i>	Mouse, transgenic C57BL/6 Big Blue®, female Intratracheal instillation (single administration): 0, 1.7, 3.4, or 6.8 mg/kg Cr(VI) Measured mutation frequency in lung at 1, 2, or 4 weeks post-exposure	Significantly increased mutation frequency at all doses; increased with dose and duration post-treatment Mutation spectrum: increased frequency of G:C to T:A transversions, associated with oxidative damage	Preliminary experiment identified doses >6.75 mg/kg were lethal Potentially underpowered with 4 mice per dose group Positive control not concurrently tested with Cr(VI)-treated group Inconsistent/low numbers of PFUs scored per animal Spontaneous mutations primarily G:C to A:T transitions
Tests in GI tissue			
Aoki et al. (2019) <i>Low confidence</i>	Mouse, transgenic gpt delta, male Drinking water, 28 d: 0, 30, or 90 mg/L Cr(VI) (0, 13, or 30 mg/kg-d Cr(VI)) Drinking water, 90 d: 0, 3, 10, or 30 mg/L Cr(VI) (0, 1.6, 6, or 17 mg/kg-d Cr(VI)) Measured mutation frequency in duodenum at 28 and 90 days	In mouse duodenum: No increased mutation frequency (gpt delta locus) relative to control at 28 or 90 d Mutation spectrum: slightly increased A:T to T:A transversions at 28 d but not at 90 d (significance unknown)	Study selected doses based on NTP 2-yr bioassay and did not include a top MTD, potentially biasing toward the null Positive control not concurrently tested with Cr(VI)-treated groups 90-d study potentially underpowered with 4 mice per dose group Spontaneous mutations primarily G:C to A:T transitions Positive control potassium bromate (but not Cr(VI)) had increased G:C to T:A transversions, associated with oxidative damage
Thompson et al. (2015c) <i>Low confidence</i>	Rat, transgenic Big Blue((R)) TgF344, male Drinking water: 180 mg/L Cr(VI), 28 d	In oral mucosa (upper inner gingiva and adjacent palate tissue and the upper outer gingiva and adjacent buccal tissue): No increase in mutation frequency (cII gene) relative to control	Study used single dose group based on NTP 2-yr bioassay top dose and did not include a top MTD, potentially biasing toward the null Cr levels in the gingival/ buccal and gingival/palate regions were 0.66 and 1.0 µg/g, respectively, compared to untreated Tg344 rats, which were 0.17 and 0.33 µg/g respectively in the gingival/buccal and gingival/palate regions Authors reported in vitro results showing enriched responses for p53, cell proliferation and apoptosis

Toxicological Review of Hexavalent Chromium

Reference	System/ Exposure	Endpoint/Results ^a	Comments
Thompson et al. (2017) Low confidence		In duodenum: No increase in mutation frequency (cII gene) relative to control	Study used single dose group based on NTP 2-yr bioassay top dose and did not include a top MTD, potentially biasing toward the null Positive control not concurrently tested with Cr(VI)-treated group Rat small intestine is not a tumor target tissue
O'Brien et al. (2013) Low confidence	Mouse, B6C3F1, female Drinking water: 0, 0.1, 1.4, 4.9, 20.9, 59.3, and 181 mg/L Cr(VI) (0, 0.024, 0.32, 1.1, 4.6, 11.6, or 31.1 mg/kg-d Cr(VI)) 7 or 90 d (Continued analysis of tissues from Thompson et al. (2011))	Micronucleus assay, in crypt and villous cells from scraped duodenal epithelium: No increase in micronucleus frequency in crypt cells Statistically significantly increased micronuclei in villous cells from animals exposed to 11.6 mg/kg-d Cr(VI) for 90 days or 31.1 mg/kg-d Cr(VI) for 7 or 90 days ACB-PCR, in scraped duodenal epithelium: No induction of GGT to GAT mutations in KRAS codon 12 detected by ACB-PCR relative to control	Micronucleus assay: No baseline incidence of micronuclei established in these tissues Crypt cell data pooled from all animals per dose group and large variation in total cells counted per dose Total number of villous cells analyzed not presented ACB-PCR: High background mutant frequency Both endpoints: Study selected doses based on NTP 2-yr bioassay and did not include a top MTD, potentially biasing toward the null Positive control not concurrently tested with Cr(VI)-treated group
Thompson et al. (2015b) Low confidence	Mouse, B6C3F1, female Drinking water: 0, 1.4, 20.9, and 180 mg/L Cr(VI) (0, 0.32, 4.6, and 31.1 mg/kg-d Cr(VI)) 7 d	In duodenal crypts (villi not reported): No increase in micronucleus frequency relative to control No effect on levels of γ H2AX	Study selected doses based on NTP 2-yr bioassay and did not include a top MTD, potentially biasing toward the null No baseline MN incidence established for these tissues, positive control DMH was null, number of cells analyzed inadequate to measure an effect 21 and 180 mg/L Cr(VI) significantly increased the number of crypt enterocytes, although no increase in crypt mitotic activity was detected No aberrant crypt or villous foci; no apoptosis in crypt cells

Toxicological Review of Hexavalent Chromium

Reference	System/ Exposure	Endpoint/Results ^a	Comments
Tests in other tissues			
Kirpnick-Sobol et al. (2006) Low confidence	Mouse, C57BL/6Jp ^{un} /p ^{un} , female Drinking water: 0, 22, or 44 mg/L Cr(VI) at 10.5 to 20.5 days postcoitum (average dose of 4.4 or 8.8 mg/kg-day)	In 20-day-old offspring harvested to visualize eyespots corresponding to DNA deletions in their retinal pigment epithelium (RPE): Increased deletions with dose ($p < 0.01$)	Failed to account for litter effects, potentially biasing away from the null No information on blinding, concerning for this type of assay that requires manual counting of eyespots Positive control not concurrently tested with Cr(VI)-treated group No signs of toxicity observed
Marat et al. (2018) Low confidence	Rat, white outbred males Intra-gastric administration, 1 mg Cr/kg body mass, single dose, 60 days prior to mating with virgin female rats	Survival of F1 fetuses from F0 males exposed to Cr(VI): Ratio of live fetuses in the Cr(VI) treatment group compared to the control group = 0.665 indicating increased dominant lethal mutation frequency in exposed male rats	Deficiencies in reporting and information on lab proficiency/reproducibility Study also reported increased micronucleus frequency in bone marrow in rats exposed to a single i.p. dose of K ₂ Cr ₂ O ₇
NTP (2007) Low confidence	Study 1: Mouse, B6C3F ₁ (5/sex/group) Drinking water: 0, 21.8, 43.6, 87.2, 174.5, or 350 mg/L Cr(VI), 90 d NTP estimated daily doses at 0, 3.1, 5.2, 9.1, 15.7, or 27.9 mg Cr(VI)/kg	In peripheral blood: B6C3F ₁ : No effect on %MN NCEs (males: $p = 0.857$; females: $p = 0.158$)	The reduction of PCE/NCE ratio in treatment groups was slight, indicating mild bone marrow toxicity, though this did not increase with dose
	Study 2: Mouse, B6C3F ₁ (5/group), BALB/c (5/group), and <i>am3</i> -C57BL/6 (10/group), males Drinking water: 0, 21.8, 43.6, or 87.2 mg/L Cr(VI), 90 d NTP estimated average daily doses at 0, 2.8, 5.2, or 8.7 mg Cr(VI)/kg	In peripheral blood: B6C3F ₁ : NTP determined this result to be equivocal due to a trend test p-value very nearly significant ($p = 0.031$; α level = 0.025) and a significant response ($p = 0.0193$) in the highest dose group of 87.2 mg/L. BALB/c: No effect on %MN NCEs ($p = 0.680$) <i>am3</i> -C57BL/6: ↑ %MN NCEs ($p < 0.001$)	No effect on PCE/NCE ratio and no clinical signs of toxicity observed; failure to include an MTD potentially biases toward the null <i>am3</i> -C57BL/6 transgenic mice intended to measure mutation frequency, but technical difficulties prevented completion of this study

Toxicological Review of Hexavalent Chromium

Reference	System/ Exposure	Endpoint/Results ^a	Comments
Mirsalis et al. (1996) Low confidence	Mouse, Swiss-Webster, M&F (5/sex/group) Drinking water: 0, 1, 5, or 20 mg/L Cr(VI), 48 h Gavage: 20 mL/kg of 0, 1, 5, or 20 mg/L Cr(VI), 2 doses, 24 and 48 h	In bone marrow: No effect on %MN PCEs	Study did not include enough information to accurately calculate a dose for either experiment Study did not include a top MTD (no effect on PCE/NCE ratio) potentially biasing toward the null
De Flora et al. (2006) Low confidence	Experiment 1: Mouse, BDF ₁ males Drinking water: 0, 10, or 20 mg/L Cr(VI), 20 d Daily intake estimated at 3 and 6 mg/kg for 10 and 20 mg/L, respectively Gavage or i.p.: 0 or 17.7 mg/kg Cr(VI), single dose, 24 h	Drinking water, in peripheral blood, day 0, 5, 12, and 20: no effect on %MN NCEs Drinking water, in bone marrow, day 20: no effect on %MN PCEs Gavage, in bone marrow, 24 h: no effect on %MN PCEs i.p. injection, in bone marrow, 24 h: significant increase in %MN PCEs ($p < 0.001$)	Results of %MN NCEs at day 5–20 are uninterpretable; evaluation of MN in mature erythrocytes requires 4 weeks of continuous treatment (Macgregor et al., 1990) Per os exposure groups did not include a top MTD (no effect on PCE/NCE ratio) potentially biasing toward the null
	Experiment 2: Mouse, BDF ₁ M&F Drinking water: 0, 5, 50, and 500 mg/L Cr(VI), 210 d Daily intake estimates per dose group, respectively: Males: 1.65, 16.5, and 165 mg Cr(VI)/kg Females: 1.4, 14, and 140 mg Cr(VI)/kg	In peripheral blood, day 0, 14, 28, 56, and 147: no effect on %MN NCEs In bone marrow, day 210: no effect on %MN PCEs	Results of %MN NCEs at day 14 are uninterpretable; evaluation of MN in mature erythrocytes requires 4 weeks of continuous treatment Study did not include a top MTD (no effect on PCE/NCE ratio) potentially biasing toward the null Cr(VI) groups had similar drinking water consumption at all doses Slight decrease in body weight in Cr(VI)-treated animals, especially females
	Experiment 3: Mouse, pregnant Swiss albino Drinking water: 0, 5, or 10 mg/L Cr(VI) (as both sodium dichromate dihydrate (SDD) and potassium dichromate (PDC)) throughout pregnancy duration, 18 d i.p.: 0 or 17.7 mg/kg Cr(VI) (as both SDD and PDC), PD 17, 24 h	In the bone marrow of dams or in the liver or peripheral blood of fetuses: Drinking water: no effect on %MN PCEs i.p. exposures: micronuclei significantly increased in all tissues ($p < 0.001$)	Per os exposure groups did not include a top MTD (no effect on PCE/NCE ratio) potentially biasing toward the null No effect on fetus body weights

Reference	System/ Exposure	Endpoint/Results ^a	Comments
Shindo et al. (1989) Low confidence	Mouse, MS/Ae and CD-1, male Gavage and i.p. injection: 2.68, 5.36, 10.7, 21.4, 42.8, and 85.7 mg Cr(VI)/kg, bolus dose, 24 h	Gavage, in bone marrow: No effect on %MN PCEs up to acutely toxic oral gavage doses that reduced PCE/NCE ratio >50% i.p. injection, in bone marrow: Dose-dependent increase in %MN PCEs and decrease in PCE/NCE ratio	Calculated LD50s: MS/Ae mice LD50: 80.3 mg Cr(VI)/kg p.o., 13.4 mg Cr(VI)/kg i.p. CD-1 mice LD50: 48.2 mg Cr(VI)/kg p.o., 8.57 mg Cr(VI)/kg i.p. Study reported mean/SD per dose group but did not report the number of animals tested per group Baseline MN incidence extremely low
Tests using Cr(VI) to induce genotoxicity			
Mukherjee et al. (1997) Low confidence	Mouse, Swiss albino, male Gavage: 7.1 mg Cr(VI)/kg	In bone marrow: significant increase in chromosomal aberrations (excluding gaps) per cell ($p < 0.01$)	Study designed to test the effectiveness of black tea in preventing Cr(VI)-induced clastogenicity
Sarkar et al. (1993) Low confidence	Mouse, Swiss albino, male Gavage: 10.4 mg Cr(VI)/kg	In bone marrow: significant increase in chromosomal aberrations (excluding gaps) per cell ($p < 0.001$)	Study designed to test the effectiveness of chlorophyllin in preventing Cr(VI)-induced clastogenicity
Sarkar et al. (1996) Low confidence	Mouse, Swiss albino, male Gavage: 7.1 mg Cr(VI)/kg	In bone marrow: significant increase in chromosomal aberrations (excluding gaps) per cell ($p < 0.05$)	Study designed to test the effectiveness of a spinach-beet leaf extract in preventing Cr(VI)-induced clastogenicity

^aResults reported in the same study of genotoxicity endpoints or exposure routes that did not meet PECO have also been included here for study context.

1 *Gene mutations*

2 Three studies in mice and rats were identified that used transgenic models to measure
3 mutation frequency in tumor target tissues after short-term or subchronic exposures to Cr(VI) in
4 drinking water ([Aoki et al., 2019](#); [Thompson et al., 2015c](#)) or in the lung following intratracheal
5 instillation (Cheng et al. ([2000](#); [1998](#))). The rodents contain transgenes (i.e., reporter genes
6 integrated into their genome) that can detect point mutations in any tissue studied. Cheng et al.
7 ([2000](#); [1998](#)) exposed female transgenic C57BL/6 Big Blue® mice to Cr(VI) via intratracheal
8 instillation, then measured the mutation frequency in the *lacI* transgene in lung tissues after 1, 2, or
9 4 weeks post-instillation. This study was found to be *low* confidence, primarily due to concerns
10 regarding the number of animals per dose group (four; five is the current minimum
11 recommendation ([OECD, 2020](#))) and the low and inconsistent number of plaque-forming units
12 evaluated, which were pooled per dose group and not reported per mouse. A preliminary study
13 determined that doses ≤6.75 mg/kg were not lethal; the second experiment included dose groups

1 exposed to 0, 6.8, 3.4, and 1.7 mg/kg Cr(VI). The study reported increasing mutation frequency
2 with dose and time post-instillation; at the top dose after 4 weeks, the mutation frequency was 4.7-
3 fold of background levels, although there is some concern that the mutation frequency in the
4 vehicle control providing comparison was only assessed at 1 week post-treatment. The observed
5 increase of mutation frequency with time up to 4 weeks post-treatment corresponds to the average
6 cell turnover time of 28 days in lung tissue.

7 In a study conducted by members of the same group that created the transgenic *gpt* delta
8 mouse used in the study (Nohmi et al., 1996), Aoki et al. (2019) used male mice to examine
9 mutation frequency in the duodenum after 28 or 90 days of exposure via drinking water, at
10 concentrations of 0, 30, and 90 mg/L Cr(VI) (28 days) or 0, 3, 10, and 30 mg/L Cr(VI) (90 days).
11 This group selected doses for both exposure periods based on the doses used in the NTP 2-year
12 bioassay with the exception of the lowest dose selected [3 mg/L Cr(VI)], which was less than the
13 lowest dose used by NTP [5 mg/L Cr(VI)]. No significant increase in mutation frequency was
14 detected after either time period. Although this study was otherwise well-conducted, deficiencies
15 in study design led to sensitivity concerns indicating potential for bias toward the null, leading to
16 overall *low* confidence. Use of concurrently run positive controls and inclusion of a dose that
17 induced clear clinical signs of toxicity would have increased confidence in the negative findings for
18 this assay.

19 A transgenic 28-day Big Blue® TgF344 rat study conducted by Thompson et al. (2017;
20 2015c) reported exposure to 180 mg/L Cr(VI) in drinking water also did not significantly increase
21 the mutant frequency in the gingival/buccal or gingival/palate regions in the oral cavity of rats or in
22 the rat duodenum. Similar to Aoki et al. (2019), the selection of a single Cr(VI) exposure group that
23 was not high enough to induce systemic toxicity in a short-term bioassay led to reduced confidence
24 in the sensitivity of this study design to detect a positive result and an overall *low* confidence
25 judgment. In addition, the inclusion of rat duodenal tissues in this mutation assay provides little
26 value to mechanistic interpretation given the small intestine is not a tumor target tissue in rats.

27 In another *low* confidence mutation study by the same group, O'Brien et al. (2013)
28 conducted an analysis of KRAS codon 12 GGT to GAT mutations in mice, which are associated with
29 human colorectal cancer and metastasis (Jones et al., 2017; Margonis et al., 2015). The study used
30 tissues obtained from a previous subchronic bioassay in female mice (Thompson et al., 2011). The
31 detection method, allele-specific competitive blocker polymerase chain reaction (ACB-PCR), was
32 developed and validated by one of the study authors (Mckinzie and Parsons, 2002) and is a
33 sensitive method for detecting specific mutations. There were no statistically significant Cr(VI)
34 treatment-related increases measured for KRAS codon 12 GAT mutations; however, results were
35 difficult to interpret due to the lack of a concurrent positive control and the high background
36 mutation incidence (10^{-2} to 10^{-3}) compared to previous findings of spontaneous mutation
37 frequency in mouse lung [3.88×10^{-4} ; (Meng et al., 2010)], rat distal colon [12.9×10^{-5} ; (Mckinzie
38 and Parsons, 2011)], or human colonic mucosa [1.44×10^{-4} ; (Parsons et al., 2010)]. Although this

1 was a 90-day study, the dose levels tested in drinking water were selected to replicate those used in
2 the 2-year NTP bioassay [up to 180 mg/L Cr(VI)] and did not include a higher dose to determine
3 whether mutations would have been induced at toxic levels, reducing the sensitivity of this study to
4 detect an effect.

5 In a mouse model for measuring mutant frequency, the C57BL/6J p^{un}/p^{un} mouse strain takes
6 advantage of a naturally occurring mutation, a tandem duplication at the pink-eyed dilution (p)
7 locus, which causes the mice to have pink eyes ([Brilliant et al., 1991](#)). Exposure to mutagens that
8 induce deletions via homologous recombination during fetal development can lead to reversion of
9 this unstable mutation back to black-pigmented cells, or eyespots, which are visible and
10 quantifiable. Although this assay developed by [Schiestl et al. \(1997\)](#) has not become part of the
11 standard testing battery for the detection of mutagens, it represents a highly sensitive assay for
12 detecting deletion mutations in single cells that are caused by transplacental exposures during
13 embryonic development. The Schiestl lab ([Kirpnick-Sobol et al., 2006](#)) exposed female C57BL/6J
14 p^{un}/p^{un} mice to 22 or 44 mg/L Cr(VI) in drinking water from 10.5 to 20.5 days post-coitum. Despite
15 a somewhat elevated background frequency ($\sim 10^{-4}$), dose-dependent, statistically significant
16 increases in mutations were observed in offspring ($p < 0.01$). However, the results of this study
17 were presented as the mean of individual pups without taking litter effects into account, potentially
18 overestimating the statistical significance of experimental findings ([Haseaman et al., 2001](#)) and
19 leading to bias away from the null. Therefore, this study was judged to be *low* confidence for this
20 outcome.

21 One rodent dominant lethal test was identified ([Marat et al., 2018](#)). This assay detects gene
22 and/or chromosomal mutations produced in male germ cells during a pre-mating exposure period,
23 causing fetal death ([OECD, 2016b](#)). [Marat et al. \(2018\)](#) reported a dominant lethal mutation
24 frequency of 0.665 by comparing the number of live F1 fetuses to control after exposure of F0 male
25 rats to 0.353 mg/kg-day Cr(VI) by oral gavage, with increases in pre- and post-implantation loss.
26 The dominant lethal test appears to have been conducted appropriately and detected a 10-fold
27 increase in post-implantation loss, but this study was found to be *low* confidence due primarily to
28 reporting deficiencies.

29 *Micronuclei*

30 Mutation studies can also measure increased incidences of heritable genetic alterations due
31 to numerical or structural changes in the chromosomes of animals exposed to Cr(VI) in vivo. Four
32 studies measuring changes in micronucleus frequency in the peripheral blood or bone marrow of
33 mice exposed to Cr(VI) via drinking water or oral gavage were identified. In a bioassay conducted
34 by [NTP \(2007\)](#), two micronucleus assays were conducted in mice exposed to Cr(VI) in drinking
35 water for 90 days; a minimum of 30 days is recommended for micronuclei in mature erythrocytes
36 to reach a steady state when a repeat-dose study design is used ([Macgregor et al., 1990](#)). Study 1
37 exposed B6C3F₁ male and female mice up to 350 mg/L Cr(VI), and Study 2 exposed male B6C3F₁,
38 BALB/c, and *am3*-C57BL/6 mice up to 87.2 mg/L Cr(VI). B6C3F₁ mice did not have increased

1 frequencies of micronuclei in Study 1, but in Study 2, the result was considered equivocal due to a
2 nearly statistically significant increased trend ($p = 0.031$; the one-tailed trend test required a
3 $p < 0.025$ for significance). For the two other strains tested in Study 2, BALB/c mice also showed no
4 increase in micronucleus frequency, but the top two dose groups of *am3*-C57BL/6 mice had
5 statistically significant increases in micronuclei ($p = 0.0025$ and 0.0001 at 43.6 and 87.2 mg/L,
6 respectively), as well as a statistically significant trend ($p < 0.001$), with no evidence of bone
7 marrow toxicity. Although 5 animals per dose group is the minimum required for this test, it is of
8 note that the micronucleus test with the only clear, statistically significant positive result reported
9 by [NTP \(2007\)](#), in *am3*-C57BL/6 mice, tested twice as many animals (10/dose group), increasing
10 the power of this study to detect an effect. This transgenic strain of mice was specifically included
11 to perform an analysis of mutation frequency that was unsuccessful due to technical difficulties;
12 however, there is no known reason to suspect that the endogenous genome of transgenic mice
13 would be unusually sensitive to clastogenic or aneugenic damage, and no data exist to suggest
14 strain-specific susceptibility.

15 The interpretation of negative results for the hazard identification of micronucleus
16 incidence in erythrocytes requires confirmation that the test agent reached the bone marrow at a
17 sufficient dose to induce erythropoietic toxicity; although it is possible for an agent to reach the
18 bone marrow without inducing toxicity, the OECD Test Guidelines ([OECD, 2016a](#)) recommend that
19 the highest dose should reduce the percentage of polychromatic erythrocytes (PCEs, also known as
20 reticulocytes) among total erythrocytes (normochromatic erythrocytes, or NCEs) by at least 50% to
21 ensure that any null findings can be interpreted as indicating a lack of genotoxic effect and not a
22 lack of exposure. In Study 1, a slight decrease in %PCEs among total NCEs was noted, indicative of
23 toxicity in the bone marrow, but this reduction was relatively small (19% and 25% reduction
24 compared to controls in male and female mice, respectively, at 350 mg/L) and did not increase with
25 dose. The mice in Study 2, exposed to lower concentrations of Cr(VI), had no decreases in %PCEs.
26 These results are consistent with those reported in [NTP \(2008\)](#) in female B6C3F₁ mice, where no
27 changes in reticulocyte or nucleated erythrocyte counts were observed at 22 days, 90 days, 3
28 months, or 12 months following doses up to 180 mg/L in drinking water. It was noted in [NTP](#)
29 [\(2007\)](#) that the top doses from Studies 1 and 2 caused reductions in body weight gain (which the
30 study authors attributed to decreased palatability causing reduced food intake and not to Cr(VI)-
31 induced toxicity) indicating that higher doses could not have been administered in drinking water.
32 The NTP study, a well-conducted bioassay, was *high* confidence for the histopathological measures,
33 but for the reasons described above was found to be *low* confidence for this endpoint. Although
34 some toxicity was measured in the bone marrow in one (of two) arm of the study, a study design
35 including more animals and higher doses, perhaps administered via gavage to avoid palatability
36 issues, would have increased the sensitivity of this study to detect a positive result and/or
37 increased confidence in the negative/equivocal findings.

1 Two otherwise well-conducted in vivo micronucleus studies were found to be *low*
2 confidence for sensitivity concerns. [Mirsalis et al. \(1996\)](#) dosed mice via drinking water and gavage
3 up to 20 mg/L Cr(VI) for 48 hours and did not detect an increase in micronucleus frequency or any
4 effect on PCE/NCE ratio in the bone marrow. In another large study using far higher doses for a
5 longer duration, [De Flora et al. \(2006\)](#) exposed mice to up to 500 mg/L in drinking water for
6 210 days in addition to exposures to pregnant dams of 10 mg/L in drinking water for the duration
7 of pregnancy. However, no increased incidence of micronuclei or effect on PCE/NCE ratio was
8 observed in the peripheral blood or bone marrow of exposed adults or in the liver or blood of
9 fetuses exposed in utero. In another branch of this study, [De Flora et al. \(2006\)](#) also dosed mice
10 with single i.p. injections of 17.7 mg/kg Cr(VI), which produced positive results for micronucleus
11 induction; these subtoxic exposures were considered positive controls for the route comparison
12 study, emphasizing the importance of pharmacokinetic considerations for Cr(VI) exposures. This
13 study also screened NCEs from peripheral blood for micronuclei after 10 or 20 mg/L drinking
14 water exposures for 20 days but these data are not considered (i.e., *uninformative*) as this exposure
15 duration is insufficient for detecting micronuclei in mature erythrocytes ([Macgregor et al., 1990](#)).

16 One study, [Shindo et al. \(1989\)](#), did include a top dose (85.7 mg Cr(VI)/kg) that reached
17 sufficient bone marrow toxicity. This well-conducted study was part of a larger effort by the
18 Collaborative Study Group for the Micronucleus Test to establish best practices for this assay. The
19 group conducted a pilot test to determine LD50s for each strain and route (oral and i.p.). A
20 micronucleus test was then conducted, finding no increases in micronucleus frequency from acute
21 oral exposures that reached a maximum tolerated dose in each strain. This study, however, was
22 determined to be *low* confidence due to lack of reporting the number of animals tested and not
23 establishing a sufficient background level of micronucleated PCEs to ensure adequate detection
24 sensitivity in the study; for the CD-1 mice, the background micronucleus frequency was zero.

25 While the micronucleus assay has been traditionally performed in PCEs from peripheral
26 blood or bone marrow, it has been developed for use in other tissues provided the test is optimized
27 for sensitivity (e.g., ensuring the test captures cells during the first cell division post-exposure).
28 Notably, some GI tract mutagens [e.g., N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl-N-
29 nitrosourethane (NMUT)], do not show increased micronucleus frequency in the peripheral blood
30 or bone marrow due to pharmacokinetic considerations, and adapting the MN assay for use in the
31 GI tract, where the cellular turnover rate is 3–5 days, has yielded positive results for GI carcinogens
32 known to be mutagenic (e.g., [Okada et al. \(2019\)](#)). Only two studies, conducted by the same group,
33 were identified that specifically measured micronuclei in duodenal epithelial cells of mice exposed
34 to Cr(VI) in drinking water ([Thompson et al., 2015b](#); [O'Brien et al., 2013](#)).

35 [O'Brien et al. \(2013\)](#) identified micronuclei as well as mitotic and apoptotic cells in fully
36 intact crypts from formalin-fixed and paraffin-embedded duodenal tissues obtained from a
37 previous subchronic bioassay in female mice ([Thompson et al., 2011](#)). Because the bioassay had
38 been conducted previously, appropriate positive controls were not run concurrently, which would

1 be useful for establishing proficiency in this less standardized tissue for this assay (compared to the
2 bone marrow or peripheral blood) for which no historical control data is available. In crypt cells,
3 zero micronuclei were reported for every dose group; this, and the lack of cytotoxicity detected in
4 these tissues even at the top dose (as measured by mitotic indices), indicate that the study was also
5 likely not sensitive enough to detect an effect in these tissues, leading to a judgment of *low*
6 confidence. At a minimum, scoring enough cells to detect a background rate for micronuclei
7 incidence would have helped increase confidence in these findings. In the villous cells, however,
8 statistically significantly increased numbers of cells with micronuclei were observed at the top dose
9 at day 7 and the two highest dose groups (60 and 180 mg/L Cr(VI)) at day 90. The micronuclei
10 counts were pooled per dose group, and the total number of cells scored was not reported, so
11 frequency cannot be determined, contributing to the *low* confidence judgment for this endpoint.

12 In the second micronucleus study in the GI tract by this group, [Thompson et al. \(2015b\)](#) also
13 reported no increased micronuclei in duodenal crypt cells, but this study did not investigate
14 whether there were again increased micronuclei in villous cells. Concerns regarding the sensitivity
15 of the study design primarily involve the lack of establishing proficiency in this nonstandard assay.
16 Specifically, again, a baseline number of micronucleated cells in crypts and/or duodenal
17 enterocytes was not established; two exposure groups [180 mg/L Cr(VI), and the positive control,
18 65 mg/kg DMH] reported zero micronuclei in 5161 and 3153 cells, respectively. These groups had
19 lower numbers of cells analyzed than the vehicle control, which screened 6694 cells to identify four
20 micronucleated enterocytes (0.06%). Therefore, sufficient numbers of cells should have been
21 counted for all dose groups to increase confidence in the sensitivity of this assay to detect reliable
22 negative result. In addition, the top dose did not induce a change in mitotic indices in the crypts
23 which was interpreted as a lack of cytotoxicity, indicating a lack of sensitivity for this endpoint (see
24 above discussion on sensitivity concerns for this assay).

25 Of primary concern regarding the sensitivity of [Thompson et al. \(2015b\)](#) is the lack of
26 micronuclei detection or other nuclear damage in animals dosed with 65 mg/kg DMH via gavage, or
27 the low, nonsignificant levels of micronuclei reported for i.p. injection of DMH. DMH
28 (1,2-dimethylhydrazine) is a colon carcinogen and alkylating agent widely used to induce colon
29 tumors in animal models ([Vanhouwaert et al., 2001](#)) and has been used as a positive control to
30 validate the micronucleus assay in the GI tract by other groups ([Coffing et al., 2011](#); [Ohyama et al.,](#)
31 [2002](#); [Goldberg et al., 1983](#)). When administered via gavage or i.p., it induces increased
32 micronucleus frequency in the mouse colon ([Ohyama et al., 2002](#); [Vanhouwaert et al., 2001](#);
33 [Goldberg et al., 1983](#)). Another study validating the micronucleus assay in GI tissues dosed mice
34 with DMH via gavage at 16.5, 33, 50, and 66 mg/kg and reported statistically significant, dose-
35 dependent increases in micronuclei in the duodenum and colon at all doses tested ([Coffing et al.,](#)
36 [2011](#)), with micronuclei detected at a higher frequency in the duodenum than in the colon.
37 Therefore, this study was judged to be *low* confidence for this endpoint.

1 *Chromosomal aberrations*

2 Three studies from the same laboratory group ([Mukherjee et al., 1997](#); [Sarkar et al., 1996](#),
3 [1993](#)) used Cr(VI) exposure to induce genetic damage (as a positive control) in order to test
4 botanical extracts for their ability to mitigate chromosomal damage. Justification for the use of
5 Cr(VI) administered via gavage as a clastogenic agent in the bone marrow was provided by citing
6 results from the unpublished Ph.D. thesis by the first author in a review article ([Singh et al., 1990](#)).
7 These are the only published studies of chromosomal aberrations following oral exposures to
8 Cr(VI) in animals that were not found to be *uninformative*, with all three studies reporting a
9 statistically significant increased incidence in the bone marrow compared to vehicle controls.
10 However, *low* confidence in these studies limits the ability to consider these results as informative
11 to the evaluation of mutagenicity from oral Cr(VI) exposure.

12 Integration of genotoxicity evidence

13 Cr(VI) has been shown to be genotoxic and induce mutations in animals exposed via i.p.
14 injection and in vitro (Appendix Tables C-52 and C-53), providing mechanistic support for the
15 mutagenicity of Cr(VI) in these specific exposure scenarios. The evidence is less clear from in vivo
16 exposures, where pharmacokinetics can influence the ability and extent of Cr(VI) reaching the
17 tissues at concentrations capable of inducing detectable mutations. Therefore, genotoxicity studies
18 were prioritized to identify gene and chromosomal mutation studies in vivo using inhalation and
19 oral routes of exposure more relevant to humans.

20 Occupational exposure studies provide the most human relevant information for mutagenic
21 risk from Cr(VI) exposures. Consistent evidence of the mutagenic and genotoxic effects associated
22 with Cr(VI) exposure is provided by human studies across a diversity of study populations and
23 industrial settings (summarized in Table 3-17 and Appendix Table C-47). In studies detecting
24 transmissible genetic damage (i.e., micronuclei and chromosomal aberrations), increased
25 micronucleus frequency and, to a lesser extent, chromosomal aberrations were consistently
26 detected in the peripheral blood lymphocytes and exfoliated nasal and buccal epithelial cells of
27 exposed workers. These biomarkers have been shown to be positively associated with an increased
28 risk of cancer in humans (Bonassi et al. ([2011b](#); [2008](#); [2007](#)), ([Norppa et al., 2006](#))). The data for
29 micronuclei and chromosomal aberrations are supported by additional evidence of genotoxic
30 responses to Cr(VI) exposure in humans, including DNA strand breaks, adducts, and crosslinks
31 (summarized in Appendix Table C-49).

32 No studies investigating genotoxicity in nonneoplastic lung tissues were identified in the
33 occupational exposure studies, but there was consistent evidence of increased micronucleus
34 frequency in buccal cells from workers occupationally exposed to Cr(VI) via chrome plating and
35 welding from two *medium* confidence studies ([El Safty et al., 2018](#); [Sudha et al., 2011](#)) supported by
36 findings reported in three *low* confidence studies ([Qayyum et al., 2012](#); [Danadevi et al., 2004](#);
37 [Benova et al., 2002](#)). Although occupational exposure occurs primarily via inhalation, changes in

1 buccal cells can serve as a surrogate of direct Cr(VI) exposures to the GI tract in humans if ingested
2 Cr(VI) is able to reach those tissues in comparable amounts. Micronucleus frequency in these
3 workers was found to correlate with blood chromium levels ([El Safty et al., 2018](#); [Qayyum et al.,](#)
4 [2012](#); [Danadevi et al., 2004](#)), with work duration ([Danadevi et al., 2004](#)), and with systemic
5 measures of DNA damage (e.g., 8-OHdG adducts, DNA strand breaks) ([El Safty et al., 2018](#); [Sudha et](#)
6 [al., 2011](#); [Danadevi et al., 2004](#)).

7 The experimental evidence base of gene and chromosomal mutation studies in animals is
8 smaller and composed entirely of *low* confidence studies (see Appendix Figures C-22 to C-25 for a
9 visual comparison of the reported findings from the oral exposure studies). One study was
10 identified that exposed animal lung tissues directly to Cr(VI) (via intratracheal instillation) and
11 reported dose-dependent increases in mutation frequency that increased with time from 1 to 4
12 weeks post-exposure ([Cheng et al. \(2000; 1998\)](#)). Although this is only one *low* confidence study, it
13 is coherent with the findings in exposed humans and demonstrates the mutagenicity of Cr(VI) when
14 it comes into direct contact with tissues.

15 A slightly higher number of studies investigating mutagenicity via the oral route are
16 available. Four drinking water and/or gavage studies in mice measured micronucleus frequency in
17 the peripheral blood or bone marrow, the tissues most commonly studied in the micronucleus
18 assay due to the requirement of exposing actively dividing cells. Acute and subchronic studies by
19 NTP found mixed results among three strains of mice ([NTP, 2007](#)), while three additional studies
20 reported negative results in the bone marrow and/or peripheral blood ([De Flora et al., 2006](#);
21 [Mirsalis et al., 1996](#); [Shindo et al., 1989](#)). When interpreting genotoxicity results, particularly
22 negative results for a substance known to be mutagenic in other exposure scenarios, it is important
23 to confirm that the test substance reached the tissues tested. In vivo micronucleus assays are
24 designed to inform decisions regarding the mutagenic potential of a chemical ([Eastmond et al.,](#)
25 [2009](#)), but if the doses selected for testing are lower than levels inducing some toxicity in the target
26 tissues, it is not possible to conclude the chemical would not be a mutagen at higher, subtoxic or
27 even toxic doses. For some of these studies, there is reason to suspect the exposures were not high
28 enough to achieve adequate tissue concentrations in the bone marrow. For example, although
29 pharmacokinetic findings by [NTP \(2007\)](#) indicate that Cr(VI) can reach the bone (or femur) at
30 concentrations above 10 mg/L Cr(VI) (approximately 1–2 mg/kg-d), two of these studies exposing
31 animals to concentrations up to 20 mg/L Cr(VI) in drinking water ([De Flora et al., 2006](#); [Mirsalis et](#)
32 [al., 1996](#)) did not detect increases in micronuclei, and also did not detect decreases in the PCE/NCE
33 ratio, which would indicate toxicity in the bone marrow as specified by standard guidance for this
34 assay ([OECD, 2016a](#)). A third study, exposing animals via gavage to much higher doses (bolus dose,
35 up to 86 mg/kg Cr(VI)³¹), also reported negative findings that were observed in animals with
36 significant bone marrow toxicity, but this study was *low* confidence due to the lack of establishing a

³¹As a comparison, drinking water exposure of the top concentration of 350 mg/L Cr(VI) in Study 1 by [NTP \(2007\)](#) yields a daily dose of approximately 20 mg/kg-d, which is distributed over a longer period of time.

1 background spontaneous rate of micronucleus incidence and not reporting the number of animals
2 tested ([Shindo et al., 1989](#)). Three other studies that used lower doses in a single gavage
3 administration to study chromosomal aberrations in the bone marrow of mice (7.1 or 10.4 mg
4 Cr(VI)/kg) did report positive findings ([Mukherjee et al., 1997](#); [Sarkar et al., 1996, 1993](#)), but *low*
5 confidence in these studies limits the ability to conclude that Cr(VI) can reach the bone marrow and
6 induce genotoxicity following a gavage exposure to Cr(VI).

7 The subchronic bioassay by NTP exposed male and female B6C3F₁ mice to concentrations in
8 drinking water up to 350 mg/L Cr(VI) and did not detect increases in micronucleus frequency;
9 these animals had a slight induction of bone marrow toxicity, though decreased palatability in these
10 animals prevented these investigators from achieving a higher tissue concentration and led to the
11 selection of lower doses for their second study ([NTP, 2007](#)). There were some positive findings in
12 the second study, a mouse strain comparison of toxicity responses that dosed up to 87.2 mg/L
13 Cr(VI), with *am3-C57BL/6* positive, *BALB/c* negative, and *B6C3F₁* nearly statistically significant
14 (see Table 3-19). This was despite a complete lack of toxicity in the bone marrow in these animals.
15 It is possible that, due to pharmacokinetic variability, Cr(VI) concentrations in drinking water do
16 not always reach sufficient concentrations in the bone marrow to induce significant mutagenicity in
17 that tissue, making this test in bone marrow tissues or cells a less sensitive measure for detecting
18 mutagenic potential in GI tissues following drinking water exposures. To enter bone marrow, orally
19 ingested Cr(VI) must escape 1) extracellular reduction in the GI tract lumen, 2) extracellular
20 reduction or cellular uptake in the liver and portal blood, and 3) extracellular reduction or cellular
21 uptake in systemic blood. Unlike gastrointestinal tract tissues which may be more directly exposed
22 to higher sustained levels of Cr(VI), the bone marrow may receive lower levels of exposure.

23 Evidence in tumor target tissues, as with the mutation study in the lung, is considered more
24 informative due to the point of contact uptake of Cr(VI) and intracellular reduction that initiates
25 potential carcinogenic pathways associated with Cr(VI) exposure (see Section 3.2.3.4). Three
26 studies directly investigated mutation frequency in tissues in the mouse duodenum or the rat oral
27 cavity following drinking water exposures. Two are gene mutation studies that examined target
28 tissues in the mouse duodenum ([Aoki et al., 2019](#)) or the rat oral cavity ([Thompson et al., 2015c](#)) of
29 transgenic rodents following subchronic drinking water exposures. Neither of these *low* confidence
30 studies observed significant increases in mutation frequencies. These studies designed the dosing
31 regimen based on the NTP 2-year bioassay and did not cover a range of doses that included a toxic
32 dose, which would have increased confidence in this study's ability to detect an effect.

33 A third study, [O'Brien et al. \(2013\)](#), did not detect an increase in KRAS codon 12 GGT to GAT
34 mutations in the mouse duodenal tissues. While KRAS mutations, primarily occurring in codons 12
35 and 13, have been identified in 35–45% of human colorectal cancers ([Nguyen and Duong, 2018](#)),
36 and many types of codon 12 mutations have been identified in tumors of the GI tract in humans
37 ([Peng and Zhao, 2014](#)), there are no data to establish the presence of codon 12 GGT to GAT
38 mutations in tumors from Cr(VI)-exposed workers, or in oral rat or duodenal mouse tumors

1 induced by Cr(VI). Furthermore, a comparison study with spontaneous mutations in untreated
2 animals has not been conducted. Considering these factors, and the high background incidence of
3 mutation frequency in this study decreasing the sensitivity for detecting an effect, no inferences can
4 be made regarding the significance of these results.

5 Although micronucleus detection in bone marrow or peripheral blood is standard practice,
6 this assay can be used for any tissue with actively dividing cells. Two studies by the same group
7 tested intact duodenal tissues from mice exposed to Cr(VI) in drinking water for 7 or 90 days,
8 separately counting micronuclei in crypt and villous cells. Both studies, testing dose ranges based
9 on the NTP 2-year bioassay that did not include a group with a maximum tolerated dose, reported
10 no increased incidence of micronuclei in crypt cells from Cr(VI)-exposed animals. The first, [O'Brien
11 et al. \(2013\)](#), did not observe a single micronucleus in crypt cells at any dose. It is possible that cells
12 with DNA damage were eliminated by apoptosis, explaining the lack of micronuclei. Indeed, in the
13 original report for these animals ([Thompson et al., 2011](#)), duodenal crypt histopathology consistent
14 with apoptosis was observed in 3/10 animals at 11.6 mg/kg and in 4/10 animals (statistically
15 significant) at 31.1 mg/kg. However, [O'Brien et al. \(2013\)](#) reported no treatment-related changes
16 in karyorrhectic nuclei, indices indicative of apoptosis or necrosis, at any dose. The failure of
17 establishing a background incidence, paired with no concurrent positive controls, make these
18 results difficult to interpret. In their second study of crypt cells, although an extremely low
19 background incidence was observed, two exposure groups again were observed to have zero
20 micronuclei: the top concentration (180 mg/L Cr(VI)), and one positive control, DMH
21 (1,2-dimethylhydrazine) ([Thompson et al., 2015b](#)). This is of some concern considering this
22 chemical has been used as a positive control to validate the micronucleus assay in the GI tract by
23 other groups ([Coffing et al., 2011](#); [Ohyama et al., 2002](#); [Vanhouwaert et al., 2001](#); [Goldberg et al.,
24 1983](#)).

25 Of these two studies, only [O'Brien et al. \(2013\)](#) also scored villous enterocytes for
26 micronuclei and reported a statistically significant increase at the top dose at day 7 and the two
27 highest exposure groups (60 and 180 mg/L Cr(VI)) at day 90. Although the incidences were pooled
28 for all animals and the total number of cells scored was not reported, this is an intriguing finding.
29 Micronuclei cannot be formed in cells that are not actively dividing. Although intestinal villous cells
30 have a rapid turnover rate of 3–5 days, it is the crypt cells that are the rapidly dividing progenitor
31 cells; these cells proliferate and differentiate, migrating up the villi to form the cells lining the
32 intestinal villi ([Gelberg, 2018](#)). The nonproliferative, fully differentiated villous enterocytes are
33 continually sloughed into the lumen as they are replaced by new cells ([Potten et al., 2009](#)).
34 Therefore, to discover micronuclei in the villous cells, and not in crypt cells (assuming that the
35 study design was sufficient to detect mutational changes in this region), either demonstrates that
36 genetic damage occurring in the crypt cells suddenly ceased or was repaired in the 24 hours
37 between the end of the exposure and sacrifice, pushing the last micronucleated cells into the villus,
38 or, that in response to Cr(VI), the villous enterocytes absorbing Cr(VI) began dedifferentiating and

1 migrating back toward the crypt cells, leaving them vulnerable to the genotoxic effects of Cr(VI)
2 (consistent with the “top-down” theory for colorectal cancer, ([Hanahan, 2022](#); [Schwitalla et al.,](#)
3 [2013](#); [Shih et al., 2001](#))). Either instance indicates a potential for Cr(VI) to induce genetic damage
4 in intestinal villi; however, better designed experiments would be needed to draw any
5 interpretations with confidence.

6 In vitro studies of GI tissues comparing genotoxicity across species have shown that cellular
7 responses are similar in gastric mucosal cells between humans and rodents ([Pool-Zobel et al.,](#)
8 [1994](#)). However, other genotoxicity endpoints from in vivo oral exposure studies specific to GI
9 tissues were negative, including γ H2AX, a marker of DNA double-strand breaks ([Thompson et al.,](#)
10 [2015b](#); [Thompson et al., 2015a](#)), and DNA-protein crosslinks were not increased in the
11 forestomach, glandular stomach, and duodenum ([De Flora et al., 2008](#)). In addition, several in vivo
12 studies found no increase in 8-OHdG adducts in target tissues across species ([Thompson et al.,](#)
13 [2012b](#); [Thompson et al., 2011](#); [De Flora et al., 2008](#)), suggesting that oxidative DNA damage may
14 not be a primary source of permanent DNA alteration.

15 Two positive but *low* confidence in vivo mutation studies were not conducted in portal-of-
16 entry or tumor target tissues but were designed to detect mutations induced in germ cells and the
17 developing fetus. Although the focus of this analysis is to inform an MOA for cancer, an agent that
18 causes mutation in germ cells is of added concern due to the potential for generating heritable
19 mutations that can be passed to offspring if the agent is anticipated to reach the germinal tissues
20 ([U.S. EPA, 1986c](#)). [Marat et al. \(2018\)](#) reported increased dominant lethal mutation frequency,
21 indicative of increased chromosomal aberrations and/or gene mutations arising in the exposed F0
22 male. The second study found a significant dose-dependent increase in mutations in mice after
23 gestational drinking water exposures despite elevated background frequency ([Kirpnick-Sobol et al.,](#)
24 [2006](#)), although there are indications this study may have been biased away from the null.
25 Although it cannot be determined from these two *low* confidence studies that ingested Cr(VI)
26 reaches these tissues in sufficient concentrations to conclude there is a potential mutagenic hazard
27 to germ cells and the developing fetus, further research is needed.

28 Although the current evidence base has not consistently identified signature mutations
29 associated with Cr(VI) exposure, there may be some indications from in vitro studies that Cr(VI)
30 induces mutations in vivo primarily through larger deletions or structural changes, versus smaller
31 point mutations or frameshifts that would be detected by the transgenic rodent assay. Additional
32 investigation of preserved tissues from animal bioassays could allow the analysis of higher
33 numbers of cells to increase the sensitivity of micronucleus detection. Future testing for mutation
34 induction in the GI tract could increase sensitivity by harvesting dissociated mucosal epithelial cells
35 to increase the number of cells for analysis ([Okada et al., 2019](#); [Coffing et al., 2011](#)), and flow
36 cytometric scoring of micronucleated cells can dramatically increase the sensitivity of this assay
37 ([Dertinger et al., 2011](#)). Updated technologies in DNA sequencing and the identification of

1 mutational signatures are also capable of resolving these evidence gaps (e.g., [Riva et al. \(2020\)](#);
2 [Valentine et al. \(2020\)](#)).

3 In conclusion, there is consistent and coherent evidence that a mutagenic MOA for Cr(VI)-
4 induced carcinogenesis is biologically plausible and relevant to humans. The implications of this
5 evidence in the context of human pharmacokinetics and the full complement of carcinogenic
6 pathways, including interpretations regarding tissue type-specific induction in the lung and GI tract
7 that can be initiated by Cr(VI) exposure, is discussed in the next section.

8 **3.2.3.4. Mode-of-Action Integration of Evidence for Carcinogenesis**

9 Cr(VI) is a human lung carcinogen when inhaled. When ingested, Cr(VI) has been shown to
10 cause tumors in the GI tract in animals exposed in drinking water ([NTP, 2008](#)). Evidence relevant
11 to the potential key events and pathways involved in Cr(VI)-induced cancer via oral or inhalation
12 exposures was systematically identified (Section 1.2) and is presented in Appendix C.3.2 organized
13 by the key characteristics of carcinogens ([Smith et al., 2016](#)). The key characteristics of Cr(VI) with
14 the largest evidence bases and most relevant study designs are DNA reactivity
15 (electrophilicity/formation of DNA adducts), genotoxicity, altered DNA repair processes and
16 genomic instability, epigenetic effects, oxidative stress, and altered cell division and death. This
17 evidence, along with the evidence of tumors and preneoplastic lesions from animal bioassays and
18 from gene expression (Appendix C.3.3) and toxicogenomic studies (Appendix C.3.4), informed the
19 identification of the steps and key events involved in Cr(VI)-induced cancer as described in EPA's
20 cancer guidelines ([U.S. EPA, 2005a](#)).

21 There are multiple mechanistic processes induced by Cr(VI) exposure that appear to
22 contribute to carcinogenesis. The large majority of the mechanistic evidence relevant to
23 interpretations of upstream mechanistic processes induced by Cr(VI) that may lead to
24 tumorigenesis is summarized here. The key events identified to be involved in the carcinogenic
25 process induced by Cr(VI) are the distribution, cellular uptake, and intracellular reduction of Cr(VI);
26 the DNA reactivity of chromium and the formation of Cr-DNA adducts; oxidative stress and free
27 radical-induced cytotoxicity and DNA damage; epigenetic modifications; altered DNA repair; the
28 silencing of tumor suppressor genes and the activation of oncogenes; genomic instability; gene and
29 chromosomal mutation; the suppression of apoptosis; cytotoxicity and degenerative cellular
30 changes; cell proliferation and regenerative hyperplasia; and chronic inflammation. The studies
31 informing these key events were not evaluated for risk of bias and sensitivity concerns using
32 predefined metrics. A prioritized set of studies with designs best suited to examining whether and
33 to what extent Cr(VI)-induced tumorigenesis involves a mutagenic MOA were subject to an
34 additional level of review (Section 3.2.3.3).

35 Figure 3-16 summarizes the key events (organized by levels of biological complexity) and
36 mechanistic pathways that have been identified to be involved in the carcinogenic process induced
37 by Cr(VI). Evidence supporting each key event (boxes) and key event relationship (arrows) is
38 presented in more detail in Table 3-20. The corresponding key characteristic of carcinogens

Toxicological Review of Hexavalent Chromium

1 (Appendix C.3.2, ([Smith et al., 2016](#))) is identified with each key event where applicable, as well as
2 whether the key event is recognized to be a hallmark or enabling characteristic of cancer ([Hanahan,](#)
3 [2022](#); [Hanahan and Weinberg, 2011](#)). The visualization of key events in this figure resembles the
4 layout commonly used in adverse outcome pathway (AOP) networks, but this diagram is chemical-
5 specific. Although some events clearly precede others, due to the complexity of the key event
6 pathways the key events themselves have not been numbered to avoid the suggestion of an
7 overarching temporal order.

1




Figure 3-16. Key events and mechanistic pathways induced by Cr(VI) exposure that can lead to cancer.

Table 3-20. Evidence for key events and key event relationships involved in Cr(VI)-induced carcinogenesis

Key event	Key event relationship and evidence	References for Cr(VI)-specific evidence ^a
Pharmacokinetic-dependent molecular initiating event		
Distribution, cellular uptake and intracellular reduction of Cr(VI)	Once Cr(VI) reaches the target tissue(s) in sufficient amounts, the Cr(VI) oxyanion is taken up by cells via nonspecific anion transporters where it is reduced via intracellular reductants to Cr(V), Cr(IV), and the kinetically stable Cr(III). The predominant intracellular reduction pathways and intermediates depend on available ascorbate, glutathione, and cysteine.	Reviewed in Section 3.1.1, Zhitkovich (2011) , Nickens et al. (2010) (see below summary of key events)
Macromolecular		
DNA reactivity, adduct and crosslink formation, and DNA double-strand breaks	Cr(VI) is not DNA reactive, but Cr(III), the final reduction product, can form bulky Cr-DNA and Cr-protein adducts and crosslinks, leading to replication fork stalling and DNA double-strand breaks.	Reviewed in Zhitkovich (2005) (see below summary of key events)
Oxidation of biological macromolecules and ROS generation	Redox reactions during the intracellular reduction of Cr(VI) generates reactive intermediates Cr(V) and Cr(IV) that produce reactive oxygen species, directly damaging intracellular molecules including DNA, proteins and lipids, and inducing cell signaling pathways and transcription factors associated with inflammation, cytotoxicity, apoptosis and necrosis, including TNF- α , NF- κ B, and NRF2. Cr(VI) is a strong oxidizing agent and can abstract electrons from a number of intracellular ligands, forming oxyradical species and leading to oxidative stress and cytotoxicity.	Reviewed in Levina and Lay (2005) , Zhitkovich (2011) (see below summary of key events)
Oxidative DNA damage	Reactive oxygen species generated by intracellular reduction of Cr(VI) can cause DNA strand breaks, both directly through free radical damage and base modifications (e.g., 8-OHdG adducts), and indirectly via ROS generation, lipid and protein peroxidation, and depletion of intracellular antioxidants and DNA repair capacity. DNA damage correlates with ROS levels and treatment with antioxidants reduces DNA damage.	Reviewed in Shi et al. (2004)

Key event	Key event relationship and evidence	References for Cr(VI)-specific evidence ^a
Epigenetic modifications	Cr(VI) exposure induces extensive promoter-specific methylation, global hypomethylation, post-translational histone modifications, and microRNA dysregulation, affecting the expression of an extensive number of genes shown to be altered by Cr(VI) exposure, including those involved in cytotoxicity/cell proliferation and DNA repair. This pattern of hypermethylation of CpG islands, downregulating tumor-suppressor genes, and concomitant hypomethylation of global (non-CpG) regions, upregulating tumor promoter genes, contributes to genomic instability, and has been observed in many idiopathic cancers including adenocarcinomas of the GI tract.	Reviewed in Chen et al. (2019) ; also Rager et al. (2019)
Altered DNA repair	Cr(VI) exposure alters DNA repair processes by the suppression of DNA repair genes via epigenetic silencing of mismatch repair (MMR) genes. Epigenetic silencing of DNA repair genes leads to suppression of proficient DNA repair pathways, including mismatch repair (MMR), leading to microsatellite instability, and homologous recombination repair (HR), leading to an increased frequency of replication fork stalling and DNA double-strand breaks. Increased global hypomethylation and increased promoter-specific hypermethylation of CpG islands in DNA repair genes have been observed in the lung tumors of chromate-exposed workers, contributing to mutagenesis and genomic instability, a hallmark of cancer.	Reviewed in Chen et al. (2019) ; see also Guo et al. (2019) ; Wang and Yang (2019) ; Hu et al. (2018) ; Li et al. (2016) ; Wang et al. (2012b)
Inadequate DNA repair (connector event)	If the DNA damage produced by Cr(VI) reduction and the formation of DNA adducts and ROS damage cannot be adequately repaired (or removed by programmed cell death), this can lead to gene mutations, aneuploidy, and genomic instability. In humans, decreased DNA repair synthesis has been observed in lymphocytes among individuals exposed to chromium occupationally. The suppression of DNA damage response and repair genes increases the probability that Cr(VI)-induced genetic damage will lead to mutations.	Rudnykh and Zasukhina (1985)
Silencing of tumor suppressor genes and activation of oncogenic pathways	A number of tumor suppressor genes have been shown to be downregulated by Cr(VI) exposure, with some known to be due to epigenetic silencing, including APC, P16 ^{ink4a} , CFTR, and possibly p53, though there is conflicting evidence for p53 involvement. Activation of the c-Myc and Wnt/β-catenin oncogenic pathways has also been implicated.	Ali et al. (2011) , Hu et al. (2016) , Kondo et al. (2006) , Tsao et al. (2011) , Li et al. (2017) , Lu et al. (2018) , Park et al. (2017) , Mezencev and Auerbach (2021)
Cellular and Tissue Level		

Toxicological Review of Hexavalent Chromium

Key event	Key event relationship and evidence	References for Cr(VI)-specific evidence ^a
Genomic instability	Genomic and chromosomal instability induced by Cr(VI) contributes to tumorigenesis and manifests primarily as microsatellite instability, caused by the epigenetic suppression of mismatch repair genes, and aneuploidy.	Reviewed in Wise and Wise (2010) ; also Ali et al. (2011) , Hirose et al. (2002) , Peterson-Roth et al. (2005) , Takahashi et al. (2005)
Gene and chromosomal mutation	Bulky Cr-DNA lesions lead to replication fork stalling and DNA double-strand breaks, which can become fixed mutations if not efficiently repaired or targeted for cell death by apoptosis. Some of these mutation may confer a growth advantage, leading to a clonal outgrowth of the mutated cells and tumorigenesis, a process that is more likely to occur in rapidly proliferating cells.	See mutagenic MOA evidence synthesis, Section 3.2.3.3
Suppression of apoptosis	Unlike the cytotoxicity-related apoptosis induced by the direct cellular injury caused by initial Cr(VI) exposures, the downstream suppression of programmed cell death via apoptosis contributes to the fixation of mutations and unchecked cell proliferation, leading to tumorigenesis. Cr(VI) was shown to initiate signaling pathways that promote cell proliferation and inhibit apoptosis in GI target tissues in rats exposed via drinking water for 60 days.	Tsao et al. (2011)
Cytotoxicity	The oxidative damage induced by Cr(VI) can lead to frank cytotoxicity, which has been observed as increased levels of apoptosis in the lung and small intestine in animals following inhalation and drinking water exposures, respectively. This cytotoxicity contributes to degenerative changes and regenerative hyperplasia. Cytotoxicity has not been detected in the rat oral cavity.	Reviewed in Levina and Lay (2005) , Shi et al. (2004)
Cell proliferation	Cr(VI) exposure to the lung and GI tract has been shown to induce cell proliferation, both by inducing proliferative signaling pathways and by evading apoptotic signals that regulate uncontrolled cell growth in normal cells, contributing to hyperplasia and tumorigenesis. Increased cell proliferation can lead to increased genomic instability and the potential for the clonal selection of mutations that confer tumorigenic hallmarks. Cell proliferation has not been detected in the rat oral cavity.	Kopeck et al. (2012a) , Rager et al. (2017) , Tsao et al. (2011) , Katabami et al. (2000)

Key event	Key event relationship and evidence	References for Cr(VI)-specific evidence ^a
Degenerative cellular changes	Biochemical and histopathological evidence of cellular injury has been observed in the rat lung following inhalation exposures and in the mouse and rat small intestine following drinking water exposures, indicative of degenerative changes that can initiate compensatory cell proliferation. No observations of degenerative cellular changes have been observed in the rat oral cavity.	Glaser et al. (1990) , NTP (2007) , NTP (2008) , Thompson et al. (2011) , Thompson et al. (2012b)
Regenerative hyperplasia	Hyperplasia consistent with regeneration following cell injury has been reported following oral exposures in the small intestine of mice and rats and following inhalation exposures in the lung in rats. Hyperplasia has not been observed in the rat oral cavity following Cr(VI) exposures.	NTP (2008) , NTP (2007) , Glaser et al. (1990) , Thompson et al. (2011) , Thompson et al. (2015b) , Thompson et al. (2012b)
Inflammation	Chronic inflammation is an enabling characteristic of cancer. Evidence consistent with inflammatory lung responses has been observed following Cr(VI) inhalation. However, no histopathological evidence of chronic inflammation has been reported in the GI tract following oral exposures in animals or humans. Some suggestive evidence from oxidative stress, cytokine fluctuations, and proinflammatory signaling pathways (e.g., NF-κB) may be indirectly indicative but this evidence is inconclusive.	Johansson et al. (1986b) , Glaser et al. (1990) , Glaser et al. (1985) , Cohen et al. (2003) , Kim et al. (2004)
Organ		
Tumor formation	<ul style="list-style-type: none"> • Lung (inhalation): Cr(VI) is a human lung carcinogen. • Oral cavity (ingestion): Increased incidence of squamous cell carcinomas or papillomas (mucosa or tongue) in both sexes of F344/N rats (NTP 2-year bioassay). Statistically significant at highest dose (≥6 mg/kg-d in males, ≥7.13 mg/kg-d in females) with dose-response trend in lower dose groups, in drinking water. See Figure 3-16 and Table 3-15. Tumors are rare (see Appendix D.2). • Small intestine (ingestion): Increased incidences of adenomas and carcinomas in both sexes of B6C3F1 mice (NTP 2-year bioassay). Statistically significant at two highest exposures (≥2.4 mg/kg-d in males, ≥3.2 mg/kg-d in females) with dose-response trend in lower dose groups, in drinking water. See Figure 3-16 and Table 3-15. Tumors are rare (see Appendix D.2). 	U.S. EPA (1998c) , NTP (2008)

^aComplete references for the evidence provided in the table can be found in the below summaries of each key event.

1 Key events for Cr(VI)-induced cancer

2 *Pharmacokinetic-dependent molecular initiating event: The distribution, cellular uptake and*
3 *reduction of Cr(VI)*

4 The effects induced by Cr(VI) can only occur if Cr(VI) reaches the target tissue prior to
5 extracellular reduction, which essentially inactivates its toxic and carcinogenic potential.
6 Therefore, consideration of the pharmacokinetics and the competing processes of reduction and
7 uptake of inhaled or ingested Cr(VI) are central to assessing the carcinogenic potency of Cr(VI).
8 Chromium (VI) compounds have been traditionally considered nonreactive towards purified DNA
9 under physiological conditions. Their ability to induce oxidative stress and DNA damage in exposed
10 cells and tissues in vitro and in vivo (discussed in the following sections) is explained by the
11 uptake-reduction model of Cr(VI)-mediated genotoxicity ([Standeven and Wetterhahn, 1989](#)).
12 Based on this model and irrespective of target cell type, Cr(VI) is taken up by cellular anion
13 transporters, where it then undergoes intracellular reduction predominantly driven by ascorbate,
14 glutathione and cysteine to form the DNA-reactive and/or oxidative damage-inducing
15 intermediates Cr(V) and Cr(IV), and eventually the thermodynamically stable Cr(III), which
16 accumulates in cells via its binding to DNA and other molecules ([Zhitkovich, 2011, 2005](#)). These
17 nonspecific anion transporters, present in all cell types, rapidly take up soluble Cr(VI) due to the
18 structural similarity of the tetrahedral configuration of the chromate (CrO_4^{2-}) anion to that of
19 phosphate (HPO_4^{2-}) and sulfate (SO_4^{2-}) anions ([Alexander and Aaseth, 1995](#); [Standeven and](#)
20 [Wetterhahn, 1989](#)).

21 Reduction of Cr(VI) is a kinetically controlled process, and the role of specific reductants
22 reflects their reaction rates with Cr(VI) compounds and intracellular concentrations. The highest
23 rate of Cr(VI) reduction was found for ascorbate, followed by cysteine and glutathione with
24 respective rate ratios of 61:13:1 ([Quievryn et al., 2003](#)). Since typical intracellular concentrations
25 of ascorbate (1-2 mM) and glutathione (1-10 mM) are comparable and considerably higher than
26 that of cysteine (0.03-0.2 mM) ([Tian et al., 2014](#)), the principal intracellular reducer of Cr(VI) is
27 ascorbate, accounting for 80-90% of its metabolism ([Zhitkovich, 2011, 2005](#)). Ascorbate and
28 glutathione also display a synergistic effect on the reduction of Cr(VI), as the rate of this reduction
29 by a mixture of ascorbate and glutathione under physiologically relevant conditions was found to
30 be higher than the sum of the reduction rates of each of these reductants ([Suzuki, 1990](#)).

31 It should be noted that studies performed in cell-free or cell-based systems that do not fully
32 reflect physiological conditions and concentrations of intracellular reducers may not fully represent
33 cellular and molecular processes that occur in human tissues under environmental exposures to
34 Cr(VI). This limitation affects mechanistic cell-free studies that use certain non-physiological
35 buffers and cell-based studies that employed ascorbate-depleted cells grown in standard growth
36 media ([Quievryn et al., 2002](#)). Since ascorbate represents a major intracellular reductant of Cr(VI)

1 ([Suzuki and Fukuda, 1990](#)), restoration of ascorbate in cell-based systems is necessary for a correct
2 assessment of the fate of Cr(VI) and DNA damage following its intracellular uptake.

3 Reduction of Cr(VI) by ascorbate generates variable amounts of Cr(V), Cr(IV), and carbon-
4 based radicals ([Stearns and Wetterhahn, 1994](#)). At physiologically relevant molar ratios of
5 ascorbate to Cr(VI) exceeding 2:1, the only detectable intermediate reduction product is reportedly
6 Cr(IV). The presence of Cr(V) is detectable only at non-physiological ratios of equimolar or lower
7 ratio of ascorbate to Cr(VI), or in ascorbate-depleted cells ([Zhitkovich, 2011](#); [Stearns and](#)
8 [Wetterhahn, 1994](#)). Reduction of Cr(VI) by ascorbate under physiologically relevant conditions is a
9 low oxidant-generating process that differs remarkably from reduction of Cr(VI) by glutathione,
10 which generates substantially more reactive oxygen species ([Wong et al., 2012](#)). However, in spite
11 of reduced DNA oxidative damage in cells with restored ascorbate, these cells can still experience a
12 large increase in genotoxicity, as displayed by an increased frequency of DNA double-strand breaks
13 ([Wong et al., 2012](#)) and DNA-protein crosslinks ([Sugiyama et al., 1991](#)) (see next section, “DNA
14 reactivity”).

15 The reduced form of glutathione (GSH) is a major intracellular reducer of Cr(VI) in cells
16 cultured without restoration of ascorbate (Figure 3-7 in Section 3.1.1). This reduction can be a one-
17 or two-electron process ([Zhitkovich, 2011](#)), but more typically it proceeds as a one-electron process
18 sequentially producing Cr(V), Cr(IV) and Cr(III) ([Marin et al., 2018](#)). Reduction by cysteine in the
19 presence of variable amounts of glutathione is also a one- or two-electron process, with the one-
20 electron process dominating in the physiological range of concentrations ([Quievryn et al., 2001](#)).

21 As described in Section 3.1.1.2, inhaled Cr(VI) that deposits in the upper and lower
22 respiratory tract will come in direct contact with epithelial cells. Reduction of Cr(VI) by epithelial
23 lining fluid is less effective than gastric fluid, and both high and low-soluble compounds can pose a
24 hazard to respiratory tract epithelial cells. Although highly soluble Cr(VI) compounds may clear the
25 lungs faster than low-soluble forms, they have the potential to be more readily taken up by cells.
26 Low-soluble forms are absorbed more slowly and may be cleared in the mucus but may expose the
27 epithelial cells for a longer period of time. In addition, high localized accumulation of Cr(VI)-
28 containing particulates may occur in susceptible lung regions such as airway bifurcation sites
29 ([Balashazy et al., 2003](#); [Schlesinger and Lippmann, 1978](#)). This is supported by studies showing
30 high chromium deposition at these sites in the lungs of chromate workers, and a correlation
31 between lung chromium burden and lung cancer ([Kondo et al., 2003](#); [Ishikawa et al., 1994a, b](#)).
32 There is an extensive mechanistic database demonstrating the toxicity and mutagenicity of Cr(VI)
33 in humans via the inhalation route of exposure (see Section 3.2.3.3 and Appendix C.3.2.2).
34 Therefore, it will be assumed that inhaled Cr(VI) at any concentration is capable of exposing the
35 epithelial cells in the respiratory tract, and that compared to GI epithelial cells after Cr(VI) ingestion
36 (discussed below), the respiratory epithelial cells have an increased potential for Cr(VI) uptake and
37 Cr(VI)-mediated cytotoxicity and the induction of mutations in these cells.

1 Following ingestion, evidence shows that approximately 10% of the Cr(VI) dose is absorbed
2 in the GI tract of rodents ([Fébel et al., 2001](#); [Thomann et al., 1994](#)). In humans, it is estimated that
3 <10% is absorbed in the GI tract (depending on the dose and stomach pH), and this number may be
4 10% or higher in susceptible populations (see Section 3.3.1 and Appendix C.1.5). Therefore, it is
5 likely that a portion of ingested Cr(VI) interacts with the epithelial cells of the GI tract in all species.
6 Effects observed by [NTP \(2008\)](#) in mice indicate that unreduced Cr(VI) may traverse the entire
7 small intestine. The highest incidences of tumors and potentially preneoplastic lesions were
8 observed in the duodenum, the region immediately distal to the stomach. This region has a higher
9 surface area per unit length of intestine ([Casteleyn et al., 2010](#)), increasing the absorptive capacity
10 in this tissue. The combination of high Cr(VI) concentration at the epithelial surface and high
11 absorptive surface capacity are the likely main contributors to the lesions observed in mice by [NTP](#)
12 [\(2008\)](#).

13 In contrast to the duodenum, the absorption surface area of the stomach is low ([Casteleyn](#)
14 [et al., 2010](#)), which may account for the lack of stomach tumors in the [NTP \(2008\)](#) bioassay. The
15 jejunum and ileum have lower absorption surface areas than the duodenum (but still higher than
16 the stomach), and these segments exhibited lower incidences of tumors in mice than the
17 duodenum. Lower tumor incidence also may have been a result of Cr(VI) reduction and dilution by
18 intestinal secretions and lumen contents. Data by [Kirman et al. \(2012\)](#) shows chromium
19 concentrations decreasing in the distal direction in the small intestine of mice exposed to Cr(VI) in
20 drinking water for 90 days. While the absorption surface area of the oral cavity is also low, as the
21 first tissue of contact, it is being exposed to the highest concentration of Cr(VI). This may make oral
22 tissues more prone to neoplastic effects in rats. However, pharmacokinetics cannot explain why
23 rats and mice differ with respect to oral and small intestinal tumors, since these differences may be
24 due to a variety of other factors ([Ibrahim et al., 2021](#); [Chandra et al., 2010](#)). Figure 3-17 illustrates
25 the ordering of tissues within the GI tract and is annotated with the types of tumors observed by
26 [NTP \(2008\)](#) in both mice and rats.




Figure 3-17. Reported tumors of the digestive tract tissues for all rodents exposed to Cr(VI). Points indicate primary adenomas and carcinomas for the mouse small intestine, and primary squamous cell carcinomas and squamous cell papillomas for the rat oral cavity (oral mucosa and tongue). Multiple tumors per animal per tissue are included, but tumors which were known to have metastasized from other sites were not included.

1 In the small intestine, the localization of total chromium in different intestinal
2 compartments provides some mechanistic information on the ability of Cr(VI) to reach the crypts
3 (where stem cells reside), which could give rise to cytotoxicity as well as fixed mutations in these
4 highly proliferative cells. Thompson et al. (2015b; 2015a) used X-ray fluorescence
5 microspectroscopy to examine the concentrations of total chromium in the cells residing within
6 mouse villi and crypts after 1 and 13 weeks of exposure. All analysis was performed in the middle
7 section of the duodenum, which may be a significant source of bias because (1) ingested Cr(VI)
8 tissue concentrations are expected to be highest in the section of the duodenum (proximal small
9 intestine closest to the stomach) because reduction/dilution will occur as Cr(VI) traverses the
10 intestine, and (2) the human duodenum is much shorter than that of the rodent duodenum
11 (Casteleyn et al., 2010), and therefore the middle section of the rodent duodenum may not be as
12 relevant to humans. After 13 weeks of exposure, Thompson et al. (2015a) detected a weak Cr signal
13 (0.4 µg/g) in the 24 small intestine crypts that were examined, with a 35-fold higher (14 µg/g)
14 mean concentration in the villi. A separate 7-day study reported the absence of Cr in the crypt
15 compartment without quantitative results; however, these observations may be biased toward the
16 null due to the rapid movement of cells from the crypt compartment and the 24-hour recovery time
17 before imaging was performed (Thompson et al., 2015b). In a subsequent gene expression study

1 that analyzed microdissected crypts and villi in preserved mouse small intestinal tissues from
2 [Thompson et al. \(2011\)](#), a robust response in gene expression changes was detected in crypts at
3 ≥ 4.6 mg Cr(VI)/kg-d and in villi at all doses (≥ 0.024 mg Cr(VI)/kg-d) after 7 and 90 day exposures,
4 demonstrating that Cr(VI) does reach the crypts at these concentrations in drinking water
5 ([Chappell et al., 2022](#)).

6 In light of the pharmacokinetic evidence, this assessment assumes that ingested Cr(VI)
7 escaping stomach reduction is capable of coming into contact with cells of the epithelium of the
8 lower GI tract (small and large intestine), although the Cr(VI) concentration exposing the cells will
9 be lower than the ingested concentration. Furthermore, this assessment assumes that ingested
10 Cr(VI) at any concentration is capable of coming into direct contact with the epithelial cells of the
11 upper GI tract (oral cavity, esophagus, and stomach) prior to stomach reduction. The Cr(VI)
12 concentration exposing the cells of the oral cavity is likely very close to the ingested concentration.
13 Ingested Cr(VI) may expose cells of the GI tract, prior to systemic uptake and reduction to Cr(III) by
14 the liver and red blood cells.

15 *DNA reactivity (KC#1)*

16 Cr(VI) itself is not known to be DNA reactive. In contrast, the intermediate Cr(IV) and Cr(V)
17 and terminal Cr(III) species that are generated during intracellular reduction of Cr(VI) can induce
18 DNA damage directly through interactions with DNA and indirectly via oxidative damage ([Arakawa
19 et al., 2012](#)). The reduction of Cr(VI) in cell-free, cell-based and in vivo systems generates variable
20 amounts of intermediate chromium species depending on the nature and concentration of the
21 reductants and concentrations of Cr species ([Borges et al., 1991](#)). The relative abundance of
22 specific intermediate species is likely to be a major factor in determining the DNA damaging activity
23 of Cr(VI) ([Sugden and Stearns, 2000](#)). Although the specific role of Cr-species and Cr-induced DNA
24 lesions in the toxicity and carcinogenicity of Cr(VI) has not yet been conclusively established,
25 depending on experimental conditions, the reduction of Cr(VI) has been found to produce binary
26 Cr-DNA and ternary ligand-Cr-DNA adducts, interstrand crosslinks, DNA-protein crosslinks,
27 oxidative damage to bases and deoxyribose, DNA strand breaks, and DNA abasic sites, which have
28 been associated, to various extents, with cell cycle arrest, DNA repair, cell death and mutagenesis
29 ([Sugden et al., 2001](#); [Arakawa et al., 2000](#); [Casadevall et al., 1999](#); [Stearns and Wetterhahn, 1997](#);
30 [Zhitkovich et al., 1996](#); [Bridgewater et al., 1994](#)). The kinetics of intracellular reduction are
31 reviewed in Section 3.1.1.3, and the specific experimental support for the in vivo generation of the
32 intermediate and terminal Cr species, as well as their direct and indirect genotoxicity potential, is
33 described in Appendix C.3.2.

34 *Oxidative stress and oxidative DNA damage (KC#5)*

35 Oxidative stress induced by Cr(VI) exposure appears to lead to several toxicity pathways
36 causing cytotoxicity, inflammation (in the lung), cell proliferation, and DNA damage. Redox
37 reactions during the intracellular reduction of Cr(VI) generate reactive intermediates Cr(V) and

1 Cr(IV) that produce reactive oxygen species, which can cause cytotoxicity and directly damage
2 intracellular molecules including DNA, proteins and lipids, and in the process, induce cell signaling
3 pathways associated with inflammation and cell proliferation (reviewed in [Levina and Lay \(2005\)](#)).
4 Radical species formed when Cr(VI) oxidizes intracellular macromolecules can also induce
5 oxidative damage (reviewed in [Zhitkovich \(2011\)](#)). Reactive oxygen species generated by
6 intracellular reduction of Cr(VI) can cause free radical damage to DNA via base modifications
7 (e.g., 8-OHdG adducts), lipid and protein peroxidation, and depletion of intracellular antioxidants
8 (reviewed in [Shi et al. \(2004\)](#)). Because these effects have been well-documented in review articles,
9 this section will focus on evidence of oxidative stress in occupationally exposed humans and in
10 animals exposed to Cr(VI) via oral or inhalation, or in vitro studies using human cells derived from
11 lung or GI tissues. Oxidative stress induced by Cr(VI) exposure has been characterized in other
12 health effects sections of this assessment, including oxidative damage contributing to Cr(VI)-
13 induced toxicity of the lung (Section 3.2.1), GI tract (Section 3.2.2), liver (Section 3.2.4), male and
14 female reproductive organs (Sections 3.2.7 and 3.2.8, respectively), and fetal development (Section
15 3.2.9). Therefore, the evidence from the lung and GI tract in animals will be briefly summarized
16 again here, along with systemic evidence of oxidative stress following inhalation or oral exposures.

17 As summarized in Section 3.2.1, many observational studies reported statistically
18 significantly increased incidences of systemic disruption in cellular redox status that correlated
19 with exposure to Cr(VI) in urine and blood of industrial workers and rodents exposed to Cr(VI);
20 these are also summarized in Appendix C.3.2.5. In tumor target tissues, one study relevant to lung
21 tissues did not detect increased 8-OHdG adducts in the sputum of lead chromate pigment factory
22 workers ([Kim et al., 1999](#)). No studies examining oxidative stress in GI tissues were identified in
23 exposed humans.

24 A small number of animal studies were identified that evaluated oxidative stress in tumor
25 target tissues. Oxidative DNA damage in the rat lung, evidenced by increased formation of 8-OHdG
26 adducts, was reported following inhalation or intratracheal instillation exposures in rats ([Zhao et
27 al., 2014](#); [Maeng et al., 2003](#); [Izzotti et al., 1998](#)). Three in vivo studies were identified that reported
28 biomarkers of oxidative stress in GI tissues after oral exposure ([Thompson et al., 2012b](#); [Thompson
29 et al., 2011](#); [De Flora et al., 2008](#)). None of these studies observed an increase in 8-OHdG adducts in
30 the mouse or rat small intestine or oral cavity following Cr(VI) drinking water exposures. However,
31 an increased proportion of oxidized glutathione (GSSG) relative to reduced glutathione (GSH),
32 indicative of oxidative stress, was observed in the mouse small intestine after 7 and 90 days of
33 exposure, with a correlated change in the GSH/GSSG ratio in plasma after 90 days at doses ≥ 59
34 mg/L Cr(VI) ([Thompson et al., 2011](#)). A decreased GSH/GSSG ratio was also observed in the mouse
35 oral mucosa after 7 days, but this resolved after 90 days despite a significantly higher total
36 chromium concentration in these tissues compared with the control ([Thompson et al., 2011](#)).
37 Changes in GSH/GSSG ratios were generally not observed in the oral cavity of rats after 7 days of
38 Cr(VI) exposure (the ratio was decreased at 0.1 mg/L Cr(VI) in the oral mucosa) but were

1 significant and dose-dependent in the oral mucosa and jejunum (and not the duodenum) at ≥ 20 mg
2 Cr(VI)/L for 90 days ([Thompson et al., 2012b](#)), with a significantly decreased ratio in plasma at
3 ≥ 170 mg/L. While GSH/GSSG ratio measurement is a generally accepted indicator of oxidative
4 stress, ascorbate is the preferred in vivo reductant, accounting for 90% of Cr(VI) oxidative
5 metabolism. Therefore, though the primary oxidative pathway is not captured in these
6 experiments, the level of involvement of GSH implies extensive oxidative stress was occurring in
7 these tissues. Other indicators of protein or lipid oxidation were not elevated in the duodenum of
8 mice after 90 days ([Thompson et al., 2011](#)) or in the rat in the oral mucosa or duodenum
9 ([Thompson et al., 2012b](#)). The reason for the lack of oxidative DNA lesions associated with the
10 oxidative stress in these studies is not known. The significance of the oxidative stress detected in
11 tissues that do not develop tumors, or the potential physiological reasons for the inconsistencies
12 between species, is also not clear.

13 A large body of evidence from cells exposed in vitro exists to support and investigate the
14 oxidative damage induced by Cr(VI) (Appendix Table C-57). These studies include tests in model
15 systems where ROS levels, lipid and protein oxidation, and decreased levels of antioxidant enzymes
16 all correlate with DNA damage. Although in vitro exposures may lead to exaggerated cell stress and
17 oxidative responses, limiting their ability to predict physiological conditions in vivo, these studies
18 can provide supporting evidence indicating the potential contribution of oxidative stress and the
19 signaling pathways involved. This DNA damage is increased in test systems deficient in processes
20 involved in repairing free radical damage and is decreased in many test systems with antioxidant
21 pre-treatment. The evidence base includes studies performed with human lung or colon and gastric
22 cancer cell lines to study oxidatively induced DNA damage and cytotoxicity. These in vitro studies
23 have been summarized in “Mechanistic Evidence” in Sections 3.2.1 (Respiratory Tract Effects Other
24 Than Cancer) and 3.2.2 (Gastrointestinal Tract Effects Other Than Cancer).

25 In addition to oxidative stress initiating cytotoxicity and DNA damage following Cr(VI)
26 exposure, there is evidence that oxidative stress can result in pro-inflammatory signaling pathways
27 that contribute to cancer. The nuclear transcription factor NF- κ B is activated in response to redox
28 cell signaling and cytokines and is involved in cell survival, proliferation and inflammation
29 ([Taniguchi and Karin, 2018](#)). NF- κ B has been found to be upregulated in response to Cr(VI)
30 exposure in numerous studies and test systems, including in the Cr(VI)-exposed rat lung ([Zhao et
31 al., 2014](#)), in human lung cells in vitro ([Wang et al., 2019](#); [He et al., 2013](#); [Zuo et al., 2012](#); [Kim et al.,
32 2003](#)), and in other human cells in vitro ([Tully et al., 2000](#); [Kaltreider et al., 1999](#)). The increases in
33 NF- κ B levels correlated with increasing ROS levels and were abrogated by antioxidant treatments
34 ([Kim et al., 2003](#)). TNF- α , which activates NF- κ B, is a pro-inflammatory cytokine produced by
35 immune cells that are involved in redox signaling ([Blaser et al., 2016](#)). It has been shown to be
36 induced systemically by Cr(VI) in rats ([Mitrov et al., 2014](#)), in LPS-stimulated mice ([Jin et al., 2016](#)),
37 and in HaCaT immortalized human keratinocyte cells in vitro ([Lee et al., 2014](#); [Wang et al., 2010b](#)).
38 However, these findings were not predictive of the results in three studies of occupationally

1 exposed humans, which did not detect increased systemic TNF- α levels in blood or serum ([Qian et](#)
2 [al., 2013](#); [Mignini et al., 2009](#); [Kuo and Wu, 2002](#)).

3 The transcription factor NRF2 binds to and activates genes regulated by Antioxidant
4 Response Element (ARE) in response to oxidative stress, transactivating genes for antioxidant
5 enzymes and promoting cell survival ([He et al., 2020](#)). NRF2 has been observed to be upregulated
6 in human liver cells ([Zhong et al., 2017a](#)) and constitutively activated in Cr(VI)-transformed human
7 lung cells in vitro ([Clementino et al., 2019](#)). In vivo, the gene that codes for NRF2, NFE2L2, was
8 found to be upregulated in the duodenum of mice exposed for 91 days to Cr(VI) in drinking water
9 ([Kopec et al., 2012a](#)).

10 Gene expression changes in genes involved in ROS homeostasis have also been observed in
11 human lung, hepatic, and epithelial cells treated with Cr(VI) in vitro (e.g., NOX, SOD1, SOD2, CAT,
12 GSR) ([Zhong et al., 2017b](#); [Zhong et al., 2017a](#); [Zeng et al., 2013](#); [Russo et al., 2005](#); [Asatiani et al.,](#)
13 [2004](#)). In addition, Cr(VI) was found to oxidize and inhibit mitochondrial and cellular thioredoxins
14 and peroxiredoxins involved in cell survival and redox signaling in immortalized human bronchial
15 epithelial cells, leading to increased sensitivity to ROS damage (Myers et al. ([2011](#); [2010](#); [2009](#);
16 [2008](#))).

17 Overall, there is a consistent, coherent, and biologically plausible evidence base available to
18 describe the intracellular reduction and redox imbalance, oxidative stress, and cellular oxidative
19 damage due to free radical generation caused by Cr(VI) exposure, potentially contributing to
20 cytotoxicity, genetic damage, and cell proliferative signaling pathways.

21 *Epigenetic modifications (KC#4)*

22 Epigenetic modifications are heritable changes in gene expression that occur without
23 altering the genetic material ([Sharma et al., 2010](#)). This “nonmutational epigenetic
24 reprogramming,” which can be mediated through modifications to histones, DNA methylation, and
25 noncoding RNAs (e.g., microRNA), is considered an enabling characteristic of cancer ([Hanahan,](#)
26 [2022](#)). Five studies evaluated epigenetic changes in humans in relation to chromium exposure.
27 [Kondo et al. \(2006\)](#) reported increased methylation of P16^{ink4a}, a tumor-suppressor gene, in
28 chromate factory workers with lung cancer who had occupational chromate exposure compared to
29 those without chromate exposure. Similarly, they observed increased methylation of P16^{ink4a} with
30 increased duration of chromium exposure (≥ 15 years) among lung cancer cases ([Kondo et al.,](#)
31 [2006](#)). Increased methylation was also observed in DNA MMR genes hMLH1 and hMSH2 when
32 comparing lung cancer cases with and without chromate exposure ([Ali et al., 2011](#); [Takahashi et al.,](#)
33 [2005](#)) and in the CpG islands (promoter regions) of MMR and HR genes (i.e., MGMT, HOGG1, XRCC1,
34 ERCC3, and RAD51) in exposed factory workers compared to controls ([Hu et al., 2018](#)). Another
35 study identified inverse associations between blood chromium and the microRNA miR-3940-5p,
36 which functions as an epigenetic tumor-suppressor by targeting cyclin D1 and ubiquitin specific
37 peptidase-28 ([Ren et al., 2017](#)), as well as between miR-3940-5p and the DNA repair genes BRCC3
38 and XRCC2, involved in DNA damage response and homologous DNA repair ([Li et al., 2014b](#)). [Ali et](#)

1 [al. \(2011\)](#) also observed increased methylation at MGMT, which encodes an enzyme that repairs
2 DNA adducts at the O6 position of guanine, in chromate lung tumors compared to lung tumors in
3 referents, as well as in APC, a tumor-suppressor gene that is suppressed via promoter
4 hypermethylation or mutation in over 85% of colorectal cancers ([Zhu et al., 2021](#); [Juanes, 2020](#)).
5 Two additional studies reported decreased methylation across global DNA ([Wang et al., 2012b](#)) as
6 well as mitochondrial genes (MT-TF and MT-RNR1) specifically ([Linqing et al., 2016](#)) in chromium-
7 exposed workers (chromate production workers and chrome-plating workers, respectively)
8 compared to controls.

9 The findings in humans are supported by studies in vitro showing that Cr(VI) exposure
10 induces extensive promoter-specific hypermethylation, global hypomethylation, post-translational
11 histone modifications, and microRNA dysregulation, demonstrating that Cr(VI)-mediated
12 epigenetic alterations may play a role in affecting the expression of an extensive number of genes
13 shown to be altered by Cr(VI) exposure (reviewed in [Chen et al. \(2019\)](#)). The results from
14 toxicogenomic studies (reviewed in Appendix C.3.4) showing multiple pathways affected by Cr(VI)
15 with relevance to carcinogenesis are consistent with the scope of genes shown to be affected by
16 Cr(VI)-induced epigenetic alterations. These findings are coherent with a recent analysis of existing
17 toxicogenomic data that identified transcriptional alterations corresponding to epigenetic
18 modifications following Cr(VI) exposure that were found to influence gene expression in pathways
19 corresponding to cytotoxicity/cell proliferation and suppression of DNA repair ([Rager et al., 2019](#)).
20 A pattern of hypermethylation of CpG islands and concomitant hypomethylation of global (non-
21 CpG) regions has been observed in many idiopathic cancers including adenocarcinomas of the GI
22 tract ([Locke et al., 2019](#); [CGARN, 2018a](#)).

23 *Altered DNA repair (KC#3)*

24 Although there are numerous processes contributing to the repair of genetic damage when
25 it occurs, these processes are not failsafe, and any alterations to these activities can result in an
26 increased risk of heritable mutation ([Chatterjee and Walker, 2017](#)). As reviewed in the next
27 section, epigenetic modifications induced by Cr(VI) exposure have been shown to silence genes
28 involved in DNA repair, an effect that is found in a significant number of lung tumors from chromate
29 workers compared to lung tumors in people not exposed to Cr(VI) and has been found to increase
30 with dose ([Hu et al., 2018](#); [Li et al., 2014b](#); [Ali et al., 2011](#); [Takahashi et al., 2005](#)). [Hirose et al.](#)
31 [\(2002\)](#) reported finding microsatellite instability (MSI) at two or more loci in 78.9% of lung cancers
32 with chromate exposure compared to lung cancers without chromate exposure. MSI is the result of
33 a state of genetic hypermutability that is caused by defective mismatch repair and is found in
34 approximately 15% of colorectal cancers ([Boland and Goel, 2010](#)). Subsequent studies identified
35 hypermethylation of the CpG island promoter regions of MMR genes hMLH1 and hMSH2 in lung
36 tumors of workers exposed to chromate compared to lung tumors from unexposed subjects ([Ali et](#)
37 [al., 2011](#); [Takahashi et al., 2005](#)). In vitro, Cr(VI) exposure of human colon cells lacking MLH1
38 protein led to increased resistance to apoptosis, providing a selective growth advantage ([Peterson-](#)

1 [Roth et al., 2005](#)). This epigenetic silencing of genes involved in DNA repair observed in workers
2 exposed to Cr(VI) may contribute to mutagenesis and genomic instability, a hallmark of cancer.

3 Another study of workers in the chromium industry investigated the effect of prolonged
4 exposure to Cr(VI) on the ability of the cell to correct errors during DNA replication. Evidence of
5 decreased DNA repair synthesis was observed in isolated lymphocytes exposed to UV light to
6 compare DNA repair synthesis between Cr(VI)-exposed workers and unexposed subjects ([Rudnykh
7 and Zasukhina, 1985](#)). A nonmonotonic relationship with duration of exposure was also identified,
8 though sample size was limited within each category of duration.

9 This slowing of DNA replication could be explained by the formation of bulky Cr-DNA
10 adducts, which can stall replication forks, leading to increased formation of DNA double-strand
11 breaks. There are two main DNA double-strand break repair pathways: homologous recombination
12 (HR) and non-homologous end joining (NHEJ). NHEJ is the predominant repair process in the G1
13 phase of the cell cycle, prior to synthesis, when only one chromatid is present; it is more error-
14 prone than HR, which occurs primarily in S/G2, using the sister chromatid as a template for repair.
15 Cr(VI) has been shown to induce DNA double-strand breaks and Rad51 foci formation, inducing HR
16 in vitro ([Bryant et al., 2006](#)). However, several studies have also reported a specific inhibition of
17 genes involved in HR, including Rad51 ([Speer et al., 2021](#); [Hu et al., 2018](#); [Browning et al., 2016](#); [Li
18 et al., 2016](#); [Qin et al., 2014](#)). Cr(VI)-induced targeting of Rad51 following prolonged in vitro
19 exposures to Cr(VI) has also been shown to involve alterations in Rad51-mediated nucleofilament
20 assembly, which the authors speculated was due to a Cr(VI)-mediated inhibition of Rad51 nuclear
21 import ([Browning and Wise, 2017](#); [Browning et al., 2016](#)) and Rad51 foci formation at DNA double-
22 strand breaks ([Speer et al., 2021](#); [Qin et al., 2014](#)). This evidence suggests that a Cr(VI)-mediated
23 influence on Rad51 may result in modifications to HR, increasing reliance on NHEJ and potentially
24 leading to unrepaired DNA double-strand breaks and increased aneuploidy and genomic instability.

25 *Silencing of tumor suppressor genes and activation of oncogenic pathways*

26 The ability to evade growth inhibition by suppressing genes that limit cell proliferation is a
27 hallmark of cancer ([Hanahan and Weinberg, 2011](#)). The decreased expression of a number of
28 tumor suppressor genes has been observed following Cr(VI) exposure. For some of these genes, the
29 mechanism of decreased expression involves epigenetic silencing, and it has been observed that GI
30 tumors have significantly higher frequencies of DNA hypermethylation at CpG islands than non-GI
31 tumors ([CGARN, 2018a](#)). Cr(VI) was found to induce methylation at CpG sites in the promoter
32 region of the P16^{ink4a} tumor-suppressor gene; inactivation of this gene is commonly found in lung
33 cancers and was observed in lung tumors of workers exposed to chromate, which increased with
34 duration of exposure ([Hu et al., 2016](#); [Ali et al., 2011](#); [Kondo et al., 2006](#)). Methylation of the APC
35 (adenomatous polyposis carcinoma) gene, a tumor-suppressor gene that maintains genome
36 integrity by preventing instability, has also been shown to occur more frequently in the lung tumors
37 of chromate-exposed workers compared to lung tumors in referents ([Ali et al., 2011](#)). APC

1 suppression by mutation or CpG island hypermethylation is present in over 85% of colorectal
2 cancers ([Zhu et al., 2021](#)).

3 P53 is a tumor-suppressor that normally regulates cell cycle arrest and apoptosis to protect
4 against tumor formation; the induction of p53 target genes can indicate the presence of DNA
5 damage, and inactivation of p53 is associated with carcinogenesis ([Williams and Schumacher,
6 2016](#)). P53 gene expression and protein levels were suppressed in the stomach (gene expression
7 ≥ 3.5 mg/kg-day and protein levels ≥ 1.7 mg/kg-day Cr(VI)) and colon (gene expression and protein
8 levels ≥ 5.2 mg/kg-day Cr(VI)) of male Wistar rats after 60 days of exposure to Cr(VI) in drinking
9 water ([Tsao et al., 2011](#)). No studies of p53 expression in human GI tissues or nonneoplastic lung
10 tissues are available, but studies in lung tumor tissues from chromate exposed vs. referent workers
11 detected either no difference ([Katabami et al., 2000](#)) or increases ([Halasova et al., 2010](#)) in p53
12 protein expression, or reduced levels of p53 mutations ([Kondo et al., 1997](#)), and two studies of the
13 peripheral blood of exposed workers detected increased p53 protein expression ([Elhosary et al.,
14 2014](#); [Hanaoka et al., 1997](#)). However, although these studies in humans were not evaluated for
15 risk of bias and sensitivity, little information was given regarding potential coexposures, making it
16 difficult to draw conclusions from these findings. In vitro, some studies show p53 activation in
17 human lung cells increased with higher Cr(VI) concentrations ([Hu et al., 2016](#)) or occurring in vitro
18 and not in vivo ([Rager et al., 2017](#)), so the nature of how p53 expression may be affected by Cr(VI)
19 is not understood.

20 The oncogene c-Myc has also been shown to be differentially methylated in response to
21 Cr(VI). Myc was found to show a dose-dependent increase (protein and mRNA) in the stomach and
22 colon of male Wistar rats after 60 days of exposure in drinking water to Cr(VI) in the stomach (≥ 3.5
23 mg/kg-d) and colon (≥ 1.7 mg/kg-d) ([Tsao et al., 2011](#)). In context, these findings are consistent
24 with the other observed effects of Cr(VI) exposure given the activity of this broad ranging
25 oncogene, whose transcriptional control overlaps pathways of DNA damage response, cell
26 proliferation and metabolism. Myc can be activated by another oncogenic pathway, the Wnt/ β -
27 catenin signaling pathway. Although no studies were identified that specifically investigated this
28 pathway following Cr(VI) exposure, its involvement has been indirectly implicated by studies of
29 Cr(VI)-induced methylation and subsequent downregulation of APC, a Wnt antagonist, as well as by
30 the downregulation of serine/threonine kinase 11 and depletion of the Gene 33 protein ([Lu et al.,
31 2018](#); [Li et al., 2017](#); [Park et al., 2017](#)).

32 An analysis of the toxicogenomic data reported in Kopec et al. ([2012b](#); [2012a](#)) from mice
33 exposed to Cr(VI) in drinking water has identified a potential role for CFTR (cystic fibrosis
34 transmembrane conductance regulator) in the carcinogenic effects of Cr(VI) ([Mezencev and
35 Auerbach, 2021](#)). A tumor suppressor function has been demonstrated for CFTR in the GI tract of
36 *Cftr* knockout mice ([Than et al., 2016](#)). *Cftr* gene expression was decreased in mice exposed to
37 Cr(VI) levels as low as 0.1 mg/L Cr(VI) (0.024 mg/kg-d) in drinking water for 8 days. Loss of CFTR
38 expression in humans was found to correlate with the severity of colorectal cancer, and in animals

1 with a mutated *Apc* gene, to potentiate tumor progression [Than et al. \(2016\)](#). Although this effect
2 has not been characterized beyond this single analysis, the implications of a specific Cr(VI)-induced
3 CFTR suppression contributing to cancer risk in humans warrants further investigation.

4 *Genomic instability (KC#3)*

5 Genomic instability, an increased rate in the acquisition of genomic alterations, is an
6 enabling characteristic of cancer and is present in nearly all human cancers ([Hanahan and](#)
7 [Weinberg, 2011](#); [Negrini et al., 2010](#)). As mentioned above, Cr(VI) exposure induces the
8 suppression of DNA repair genes involved in mismatch repair. Defective mismatch repair leads to a
9 form of genomic instability, microsatellite instability, which is a state of genetic hypermutability
10 that is closely associated with colorectal cancer in humans ([Boland and Goel, 2010](#)). Microsatellite
11 instability has been detected in the lung tumors of chromate workers compared to referent
12 workers ([Hirose et al., 2002](#)), suggesting that Cr(VI) exposure may facilitate increased genomic
13 instability, and ultimately cancer initiation and progression.

14 In addition to microsatellite instability, Cr(VI) exposure is also associated with increased
15 aneuploidy, a numerical chromosomal aberration that involves chromosome malsegregation and
16 breakage ([Eastmond et al., 2009](#)) that is endemic of chromosomal instability and is a hallmark of
17 cancer ([Ben-David and Amon, 2020](#)). Delayed, persistent, transmissible genomic instability has
18 been observed in immortalized human cells in vitro, manifest as increased structural chromosomal
19 aberrations, micronuclei, and aneuploidy, and decreased clonogenic cell survival ([Glaviano et al.](#)
20 [2006](#)). The delayed, persistent effects were confirmed in other in vitro studies that observed
21 aneuploidy increasing with exposure duration ([Wise et al., 2016](#); [Holmes et al., 2006](#)). Several
22 additional studies have shown the ability of Cr(VI) to induce aneuploidy in human cells in vitro,
23 summarized in Appendix Table C-54 and by [Wise and Wise \(2010\)](#). While most of these studies
24 used solid-stained chromosomal analysis to detect aneuploidy, the findings have been confirmed by
25 detection in kinetochore-positive micronuclei ([Güerci et al. \(2000\)](#), Seoane et al. ([2002](#); [2001](#),
26 [1999](#))) or by chromosome painting with fluorescent probes ([Figgitt et al., 2010](#)), methods with
27 greater specificity. Exogenous agents inducing aneuploidy may act by interfering with the mitotic
28 spindle apparatus via disruption of the microtubule cytoskeleton, a mechanism that is consistent
29 with several mechanistic investigations of Cr(VI)-induced aneuploidy ([Martino et al. \(2015\)](#), [Nijs](#)
30 [and Kirsch-Volders \(1986\)](#), Seoane et al. ([2002](#); [2001](#), [1999](#))). It is also plausible that altered DNA
31 damage and repair pathways (e.g., loss of functional p53 and activation of driver oncogenes like
32 Myc, reviewed above) can increase aneuploidy by promoting cell cycle progression before repair
33 pathways can be initiated, resulting in chromosome malsegregation. APC, a tumor-suppressor gene
34 associated with colorectal cancer when suppressed via promoter hypermethylation or mutation,
35 has also been shown to have a key role in mitotic spindle orientation ([Juanes, 2020](#)). Although the
36 mechanism for induction of aneuploidy by Cr(VI) is not known, the APC gene was found to be
37 silenced by hypermethylation in the lung tumors of chromate-exposed workers ([Ali et al., 2011](#)),

1 providing a hypothesis for how aneuploidy may be induced by Cr(VI), disrupting cell division and
2 contributing to carcinogenesis; further research is warranted.

3 *Gene and chromosomal mutation (KC#2)*

4 The evidence for the genotoxic effects of Cr(VI) is presented and synthesized in Section
5 3.2.3.3. There is consistent and coherent evidence that a mutagenic MOA for Cr(VI)-induced
6 carcinogenesis is biologically plausible and relevant to humans. Primary evidence is provided by
7 *medium* and *low* confidence studies of occupationally exposed humans; some evidence is available
8 in animals exposed directly in the lung or GI tract, but this evidence base is small and consists of *low*
9 confidence studies, many of which were not optimized for reliably detecting genotoxicity.
10 Genotoxicity studies employing more direct exposures to Cr(VI) (e.g., in vitro and in animals
11 exposed via i.p. injection) are largely positive (summarized in Appendix C.3.2.2), consistent with
12 what is known regarding the intracellular pharmacokinetics and DNA reactivity of Cr(VI), as
13 discussed above.

14 *Suppression of apoptosis (KC#10)*

15 The ability to resist cell death is a hallmark of cancer, contributing to the fixation of
16 mutations and unchecked cell proliferation ([Hanahan and Weinberg, 2011](#)). Although initial
17 exposures to Cr(VI) induce cytotoxicity (see below), there is evidence from one study of longer
18 duration exposures that Cr(VI) can lead to the downstream suppression of programmed cell death
19 via apoptosis in tumor target tissues. [Tsao et al. \(2011\)](#) measured protein and mRNA levels in the
20 stomach and colon of male rats following 60-day exposures to Cr(VI) in drinking water and
21 reported decreased expression of p53 (gene and protein), the mediator of a primary cellular fate
22 determination pathway, which would lead to suppression of apoptosis ([Tsao et al., 2011](#)). This
23 suggests a possible mechanism for a Cr(VI)-specific suppression of apoptosis via disruption of p53-
24 mediated pathways that respond to cellular stress, although this is an area that requires further
25 investigation.

26 *Cytotoxicity and degenerative cellular changes (KC#10)*

27 Cr(VI), a strong oxidizer, is known to be cytotoxic in vitro and may trigger apoptosis
28 through increased oxidative stress, leading to DNA and protein damage, mitochondrial dysfunction,
29 and modulation of pro-apoptotic signaling pathways. The reduction of Cr(VI) generates reactive
30 intermediates Cr(V) and Cr(IV) that produce reactive oxygen species that can lead to apoptosis and
31 necrosis, as well as induce cell signaling pathways associated with cell death (reviewed in [Levina
32 and Lay \(2005\)](#) and [Shi et al. \(2004\)](#)). Because this evidence is relevant to both cancer and
33 noncancer mechanisms of toxicity, these effects are reviewed in Sections 3.2.3.1 and 3.2.3.2 for the
34 lung and GI tract, respectively. To summarize, this evidence supports a toxicity pathway of tissue
35 injury induced by cytotoxicity in the lung and GI tract that may lead to necrosis and/or regenerative
36 proliferation. In the lung, studies investigating the underlying mechanisms involved in Cr(VI)-

1 induced lung toxicity report significant cytotoxicity at micromolar concentrations in vitro,
2 concurrent with indications of increased programmed cell death (apoptosis, autophagy) in
3 response to Cr(VI) exposure. In the GI tract, evidence of GI tract toxicity that involves Cr(VI)-
4 induced cytotoxicity and apoptosis leading to degenerative changes and regenerative hyperplasia,
5 as well as cell proliferation directly induced by Cr(VI). Other evidence of gene expression changes
6 indicate cell signaling pathways induced by Cr(VI) exposure that are involved in the evasion of
7 apoptosis contributing to tumorigenesis, indicating a downstream role independent of the cytotoxic
8 effects of Cr(VI) that separately contributes to carcinogenesis by suppressing apoptosis. These
9 cellular and molecular processes underlie the histopathological changes, including hyperplasia of
10 the small intestine (described in Animal Evidence), that are considered potentially preneoplastic
11 events.

12 *Cell proliferation (KC#10)*

13 Cancer is the result of sustained and uninhibited cell proliferation ([Hanahan and Weinberg,](#)
14 [2011](#)). Several studies have identified proliferative markers and signaling pathways that are
15 upregulated by Cr(VI) exposure. Increases in transcript expression of Ki-67, a nuclear protein
16 associated with cellular proliferation, and in some cases malignant metastasis and tumor growth ([Li](#)
17 [et al., 2015a](#)), was detected in the duodenum of mice after exposure to 11.6 and 31 mg/kg Cr(VI)-
18 day in drinking water; levels were increased approximately 4-fold after 7 days of exposure but
19 diminished to approximately 2-fold after 90 days (data from [Kopec et al. \(2012a\)](#) was presented
20 graphically in [Thompson et al. \(2013\)](#)). In another drinking water exposure study, a dose-
21 dependent upregulation of the *c-Myc* oncogene was found in the stomach (≥ 3.5 mg/kg-d) and colon
22 (≥ 1.7 mg/kg-d) of male Wistar rats after 60 days of exposure to Cr(VI) in drinking water ([Tsao et](#)
23 [al., 2011](#)). MYC functions as a transcription factor that upregulates genes involved in cell
24 proliferation and other processes contributing to neoplastic transformation ([Gabay et al., 2014](#)).

25 Another transcription factor, AP-1, was found to be significantly activated by Cr(VI)
26 exposure in studies of gene expression changes in human lung cells ([Zuo et al., 2012](#); [O'Hara et al.,](#)
27 [2004](#)) and in human breast cancer and rat hepatoma cells ([Kaltreider et al., 1999](#)). The AP-1
28 complex, which is composed of oncogenic proteins (Jun, Fos, ATF, MAF) ([Eferl and Wagner, 2003](#)),
29 is induced by JNK and ERK/MAPK signaling cascades in response to stress and inflammatory
30 cytokines ([Gazon et al., 2017](#)), leading to increased cell proliferation or inhibition of apoptosis, in
31 part through the activation of cyclin D1 ([Guo et al., 2020](#)). Cyclin D1, a regulator and promoter of
32 cell cycle progression, has been detected at significantly increased levels in the lung tumor tissues
33 of chromate-exposed patients compared to unexposed lung cancer patients ([Katabami et al., 2000](#)).
34 Increased expression of cyclin D1 has been associated with cell proliferation and tumorigenesis
35 ([Guo et al., 2020](#)). These findings are consistent with an induction of biological processes by Cr(VI)
36 that can lead to sustained cell proliferation and contribute to cancer. It is currently unknown to
37 what extent these proliferation-promoting pathways are initiated by Cr(VI)-induced epigenetic
38 repression of transcriptional regulators or are the result of a compensatory response to cytotoxicity

1 and DNA damage sensing and repair machinery (discussed below), or if other direct or indirect
2 factors induced by Cr(VI) are involved.

3 *Regenerative hyperplasia*

4 Hyperplasia is the enlargement of a tissue or organ resulting from increased cell
5 proliferation and can be induced as an adaptive or compensatory response to cellular and tissue
6 damage. In the evaluation of noncancer effects in the GI tract from ingested Cr(VI), hyperplasia is
7 considered to be an adverse effect (Section 3.2.3), but it can also represent preneoplastic lesions
8 that are part of the morphologic and biologic continuum leading to cancer ([Hanahan and Weinberg,
9 2011](#); [Boorman et al., 2003](#)). Because hyperplasia can also be a reversible effect, it is important to
10 consider several relevant factors when determining the contribution of hyperplasia to
11 tumorigenesis, including whether there is a common cellular origin for hyperplasia and tumors, the
12 presence or absence of a morphological continuum within the study between hyperplasia and
13 neoplasia, histologic similarities, whether there is treatment-related toxicity, and other information
14 about the test compound, including mutagenicity and ADME considerations ([Boorman et al., 2003](#)).

15 The diffuse intestinal epithelial hyperplasia observed in mice across studies is described in
16 detail in Section 3.2.2.2. In the [NTP \(2008\)](#) 2-year bioassay, minimal to mild diffuse hyperplasia
17 was significantly increased in the duodenum of all exposed male and female mice. These animals
18 also exhibited tumors of epithelial origin (adenomas and carcinomas) that were statistically
19 significant at the two highest exposures (≥ 2.4 mg/kg-d in males, ≥ 3.2 mg/kg-d in females) with a
20 dose-response trend in lower dose groups. There were multiple shared pathological features
21 between the diffuse hyperplasia and the neoplastic lesions, including elongated crypts with
22 increased numbers of epithelial cells and mitotic figures ([NTP, 2008](#)). These observations are
23 generally consistent with the intestinal hyperplasia observed in mice in subchronic studies by [NTP
24 \(2007\)](#) and Thompson et al. ([2015a](#); [2011](#)), lending further evidence of a consistent response in
25 animals exposed to Cr(VI) via drinking water.

26 However, even with the presence of these morphologic similarities, in the absence of
27 experiments with recovery groups to distinguish these lesions from reversible hyperplasia induced
28 by Cr(VI), it cannot be concluded with certainty that the hyperplasia observed in the subchronic
29 studies would have progressed to neoplasia. As discussed in Section 3.2.2.3, some discrepancies
30 have been noted, including the lack of increased mitotic activity in hyperplastic duodenal crypt cells
31 in mice ([Thompson et al., 2015b](#); [O'Brien et al., 2013](#)), although follow-up analysis of the mice
32 exposed via drinking water for 7 and 90 days ([Thompson et al., 2011](#)) reported a significant
33 response in gene expression changes related to cell cycle progression phenotypically anchored to
34 the histopathological results in duodenal crypts at doses ≥ 4.6 mg Cr(VI)/kg-d ([Chappell et al.,
35 2022](#)). In addition, as discussed above, although [Thompson et al. \(2013\)](#) reported levels of the
36 cellular replication marker Ki-67 were increased compared to untreated controls in mice exposed
37 for 7 or 90 days in drinking water, these levels declined in the mice exposed for 90 days, and Ki-67

1 cannot distinguish between chemically induced cell proliferation and proliferation secondary to
2 cellular toxicity without concurrent detection of cellular markers for apoptosis and necrosis.

3 The presence of tissue injury is also important in interpreting the relevance of these lesions
4 to neoplasia. Tissue-specific hyperplasia and neoplasia with an inciting factor such as cellular
5 degeneration and compensatory regeneration may suggest a carcinogenic response that is
6 secondary to chronic tissue injury ([Boorman et al., 2003](#)). As reviewed in Section 3.2.2.2, the
7 authors of both sets of studies ([Thompson et al., 2012b](#); [Thompson et al., 2011](#); [NTP, 2008, 2007](#))
8 considered the hyperplastic lesions to be consistent with regenerative hyperplasia resulting from
9 Cr(VI)-induced epithelial damage and degenerative changes seen in the mouse villi. This suggests a
10 mechanism in the carcinogenic process that may be secondary to chronic tissue injury.

11 In addition to the diffuse hyperplasia, a non-statistically significant incidence of focal
12 epithelial hyperplasia was observed in male mice at ≥ 2.4 mg/kg Cr(VI)-day that increased slightly
13 in severity grading (3.0–3.5) with dose. Female mice also showed a low incidence of focal
14 hyperplasia with increasing severity grading (2.0–3.0) at 1.2 and 3.2 mg/kg Cr(VI)-day with no
15 reported incidences at the high dose ([NTP, 2008](#)). NTP considered the focal hyperplasia to be
16 biologically significant preneoplastic lesions due to the pathological similarities to neoplastic
17 growths, including crypts and villi that were lined by increased numbers of cuboidal to tall
18 columnar epithelial cells that were morphologically similar to those of the adenomas ([NTP, 2008](#));
19 see [Francke and Mog \(2021\)](#) for further description). In addition, these lesions, located in the
20 superficial mucosa rather than the crypt mucosa, arose from the same tissue type (duodenal
21 epithelium) as the neoplastic growths³². The focal hyperplastic lesions were distinguished from
22 adenomas by their smaller size and less discrete margins that tended to blend with the normal
23 surrounding mucosal epithelium.

24 While diffuse hyperplasia may have an origin in a regenerative response that is secondary
25 to chemically induced tissue degeneration, focal hyperplasia that is morphologically similar to
26 neoplasia without evidence of concurrent tissue injury may be indicative of a direct neoplastic
27 response ([Boorman et al., 2003](#)). Although the focal hyperplasia could be a part of the proliferative
28 continuum of lesions, progressing from diffuse hyperplasia to focal hyperplasia (preneoplastic), to
29 adenoma (autonomous growth), to carcinoma (malignant neoplasia) originating from a common
30 precursor cell type, this cannot be confirmed due to the absence of histopathological observations
31 from interim sacrifices.

32 [Thompson et al. \(2012b\)](#) also reported duodenal hyperplasia and villous apoptosis in rats
33 treated with ≥ 7.2 mg Cr(VI)/kg-d in drinking water for 7 and 90 days, as well as villous atrophy at
34 7.2 mg Cr(VI)/kg-d. Rats were not observed to develop intestinal lesions or tumors in the bioassays
35 by NTP ([2008, 2007](#)). Rats developed tumors in the oral cavity, but there were no observations of
36 lesions or hyperplasia in the rat oral cavity by any of these studies.

³²Most (76%) tumor-bearing animals were observed to have exhibited nonneoplastic lesions in the small intestine (see Appendix D.5).

1 Hyperplasia has also been observed in the rat lung following inhalation exposures to Cr(VI)
2 for 30 and 90 days ([Glaser et al. \(1990\)](#), see Section 3.2.1.2). A high incidence of bronchioalveolar
3 hyperplasia (70–100%) was reported in male Wistar rats after 30 days of exposure to 0.050–0.40
4 mg/m³ Cr(VI) relative to the control (10%) ([Glaser et al., 1990](#)). The same study reported lower
5 incidence of this effect after 90 days of exposure, and after 90 days of exposure with a 30-day
6 recovery period, suggesting this may have been a transient effect.

7 Overall, there is evidence for regenerative hyperplasia as a key event for tumors of the small
8 intestine in mice. Theoretically, any increase in the rate of cell proliferation over the background
9 basal rate of cell division, even if transient, can increase the probability of the formation and
10 fixation of mutations that may confer a selective advantage to the cell and promote the subsequent
11 clonal outgrowth of the mutated cells, leading to tumorigenesis. There are some inconsistencies
12 that create uncertainty in drawing a conclusion that Cr(VI)-induced regenerative hyperplasia is a
13 primary event driving carcinogenesis, including hyperplastic responses that did not increase in
14 severity with dose, and the presence of degenerative lesions and hyperplasia in the rat small
15 intestine with no induction of tumors at this site in this species. Regenerative hyperplasia may be a
16 contributing factor to carcinogenicity in the lung, as toxicity and hyperplasia have been observed in
17 the lung following inhalation exposures, though there is not enough evidence to assume a key role
18 in this tissue. There is no evidence to conclude regenerative hyperplasia is involved in the
19 tumorigenic process in the rat oral cavity.

20 *Chronic inflammation (KC#6)*

21 Cr(VI) has been shown to induce effects consistent with an inflammatory response by
22 generating oxidative stress that can stimulate pro-inflammatory cytokines and activate nuclear
23 transcription factors associated with inflammation (e.g., NF-κB). The evaluation of evidence for
24 effects of Cr(VI) on the immune system, presented in Section 3.2.6, suggests that Cr(VI) may have a
25 stimulatory effect on the immune system, largely based on primary immune response assays
26 indicating increased antibody responses, WBC function and numbers, and total immunoglobulin
27 levels following Cr(VI) exposure in animals (see Section 3.2.6). Although exposure-related
28 stimulation of the immune system can lead to exaggerated inflammatory responses associated with
29 chronic systemic inflammation, the role of inflammation in the carcinogenesis of the GI tract
30 induced by Cr(VI) exposure (Section 3.2.2) is not clear.

31 The GI tract contains the majority of immunoglobulin-producing cells that are present in the
32 human body, and toxicity to the GI tract commonly results in immune system-mediated
33 inflammation ([Gelberg, 2018](#)). Chronic inflammation could have driven the diffuse hyperplasia
34 observed prior to carcinogenesis in the mouse small intestine in the NTP subchronic and chronic
35 bioassays, as this is a well-characterized step in inflammatory neoplastic progression, and is an
36 enabling characteristic of cancer ([Hanahan and Weinberg, 2011](#); [Westbrook et al., 2010](#)). The
37 development of idiopathic GI cancers has been shown to involve chronic inflammation that can
38 induce neoplastic genetic and epigenetic changes mediated by proinflammatory cytokines and ROS

1 ([Chiba et al., 2012](#)). In addition, immunogenomic profiling of data from over 10,000 tumors
2 collected by the Cancer Genome Atlas used cluster analysis to identify six immune subtypes
3 commonly associated across multiple tumor types; one identified immune subtype, "wound
4 healing," was associated with colorectal cancer, lung squamous cell carcinomas, head and neck
5 squamous cell carcinomas, and the chromosomal instability (CIN) pathway of colorectal cancer
6 pathogenesis ([CGARN, 2018b](#)), tumor tissues also associated with Cr(VI)-induced cancer. However,
7 NTP reported that the rat oral cavity had neither hyperplasia nor inflammation preceding tumor
8 formation, and no signs of inflammation were observed in the mouse small intestine after two years
9 of drinking water exposure to Cr(VI). NTP did report an increased infiltration of histiocytes
10 (macrophage immune cells) in the duodenum and jejunum that was consistently observed in both
11 sexes of rats and mice orally exposed both chronically and subchronically to Cr(VI) ([Thompson et](#)
12 [al., 2012b](#); [Thompson et al., 2011](#); [NTP, 2008, 2007](#)), but this was not accompanied by an influx of
13 other inflammatory cells or other histological features consistent with inflammation in the small
14 intestine and was interpreted by the authors to be of unknown biological significance.

15 Evidence following inhalation exposures to Cr(VI) is more robust, with consistent evidence
16 of histiocytosis in the lung from several studies in animals accompanied by inflammatory markers
17 in BALF and increased leukocytes in plasma, observations supportive of inflammatory lung
18 responses (Section 3.2.1). The histiocytic/macrophage infiltration leads to cytokine release and cell
19 to cell signaling conducive to an inflammatory environment ([Kodavanti, 2014](#)). Studies
20 investigating immune toxicity (Section 3.2.6) in chromate workers have also observed changes in
21 cytokine signaling (Appendix C.2.5.2). Although the direction of these changes was not consistent
22 across studies or exposure durations, fluctuations in systemic cytokine levels and increased
23 oxidative stress are characteristic of an inflammatory response and may indicate a disruption in the
24 regulatory balance that dictates normal immune system function. However, while there is evidence
25 of oxidative stress and activation of pro-inflammatory cytokines and nuclear transcription factors
26 including NF- κ B, the characterization of chronic inflammation that may occur prior to the
27 development of neoplasms induced by Cr(VI) exposure remains an evidence gap.

28 *Tumor formation*

29 Neoplastic effects were not observed in subchronic 13-week studies in mice and rats
30 ([Thompson et al., 2012b](#); [Thompson et al., 2011](#); [NTP, 2007](#)), though notably some of the
31 observations in the subchronic studies, including elongated intestinal crypts and increased mitotic
32 activity, were also reported in the histopathological analysis of adenomas and carcinomas in the 2-
33 year bioassay. The lack of tumor formation in the subchronic experiments is likely due to
34 insufficient latency time. The earliest appearance of tumors of the mouse small intestine reported
35 by NTP in the two-year bioassay ([NTP, 2008](#)) was at 451 days in males and at 625 days in females
36 exposed to the highest tested Cr(VI) doses (5.7 mg/kg-d and 8.9 mg/kg-d in males and females,
37 respectively). In all other dose groups, tumors in the mouse small intestine were reported at
38 terminal sacrifice (729 days). The earliest recorded incidences of tumors of the rat oral cavity

1 reported by [NTP \(2008\)](#) were at 506 days in females and at 543 days in males exposed to the
2 highest tested Cr(VI) doses (7.1 mg/kg-d and 6.1 mg/kg-d in females and males, respectively).
3 Several models have been proposed for the histopathogenesis of GI cancers that are potentially
4 relevant to Cr(VI). One example is the classical model of transformation and clonal expansion of
5 rapidly dividing, self-renewing stem cells at the bottom of the intestinal crypts, or the 'bottom up'
6 model ([Schwitalla et al., 2013](#); [Shih et al., 2001](#); [Bach et al., 2000](#)). Alternatively, a 'top down' model
7 of adenoma morphogenesis in a transgenic c-Myc mouse model system suggests that dysplastic
8 cells at the luminal surface of the crypts have the ability to dedifferentiate and spread laterally and
9 downward, forming new crypt-like foci ([Schwitalla et al., 2013](#)). This type of cellular phenotypic
10 plasticity driven by oncogenic signaling, observed in colon cancers, is considered a hallmark
11 capability of cancer ([Hanahan, 2022](#)). Expression of c-Myc also increases in the stomach and colon
12 of rats after subchronic oral Cr(VI) exposure ([Tsao et al., 2011](#)), and toxicogenomic data
13 demonstrate comprehensive activation of the c-Myc pathway and concurrent changes in known
14 downstream target genes ([Rager et al., 2017](#); [Kopec et al., 2012b](#); [Kopec et al., 2012a](#); [Thompson et
15 al., 2011](#)). The dysplastic cells at the luminal surface are stem-like, preneoplastic, and represent
16 mutant clones containing genetic alterations not found in the morphologically normal cells at the
17 bottom of the crypt ([Shih et al., 2001](#)). This model is based in part on the frequent observation that
18 early adenomatous polyps are found at the top of colonic crypts without stem cell compartment
19 contact ([Shih et al., 2001](#)). Mechanistically, [Schwitalla et al. \(2013\)](#) proposed that NF- κ B can
20 enhance Wnt signaling leading to dedifferentiation of epithelial non-stem villus cells into tumor-
21 initiating cells. In addition, the cell proliferation marker Ki-67, which was increased in the duodena
22 of mice after exposure to Cr(VI) in drinking water ([Rager et al., 2017](#); [Kopec et al., 2012a](#)), has been
23 shown to be increased in the dysplastic crypt orifices of idiopathic human intestinal adenomas
24 ([Shih et al., 2001](#)).

25 Evidence favoring the 'bottom up' model is provided by a follow-up analysis of the mice
26 exposed via drinking water for 7 and 90 days ([Thompson et al., 2011](#)), which determined that a
27 robust response in gene expression changes was present in the crypts at doses ≥ 4.6 mg Cr(VI)/kg-
28 d, and that the enrichment of gene sets related to cell cycle progression and DNA damage were
29 more robust in the crypts compared to the villi ([Chappell et al., 2022](#)). Alternatively, there is
30 evidence for the 'top-down' model, as X-ray fluorescence microspectroscopy in a separate study by
31 this group detected a 35-fold higher mean Cr(VI) concentration in the villi compared to the
32 intestinal crypts ([Thompson et al., 2015a](#)). The precise mechanism for how Cr(VI) would initiate a
33 'top-down' process is unknown but could plausibly involve mutagenic processes; although
34 inconclusive due to incomplete reporting and analysis, [O'Brien et al. \(2013\)](#) reported increased
35 micronucleus frequency in the duodenal villi of Cr(VI)-exposed mice. Neither model can be reliably
36 ruled out without further investigation.

37 There is considerable uncertainty regarding the origin of the tumors observed in the rat
38 oral cavity by [NTP \(2008\)](#). A recent review of chemicals that have been shown to cause oral

1 squamous cell neoplasms by the NTP suggests multiple mechanisms can promote rat oral tumors
2 ([Ibrahim et al., 2021](#)). Some studies have indicated that a Cr(VI)-induced effect in the bone marrow
3 or blood cells may have exacerbated an effect occurring at the epithelium. Two studies exposed the
4 skin of hairless mice to UV light while simultaneously exposing some groups to Cr(VI) in drinking
5 water ([Uddin et al., 2007](#); [Davidson et al., 2004](#)). Ingested Cr(VI) significantly increased
6 susceptibility to UV-induced skin tumors in a dose-dependent manner. One commonality between
7 the [NTP \(2008\)](#) studies and the [Davidson et al. \(2004\)](#) and [Uddin et al. \(2007\)](#) studies is that the
8 skin and alimentary tract are sites where bone marrow-derived stem cells can engraft ([Krause et
9 al., 2001](#)) and possibly transform to malignant epithelial tumors ([Bessède et al., 2015](#); [Quante et al.,
10 2013](#); [Quante et al., 2011](#); [Gonda et al., 2009](#); [Quante and Wang, 2009, 2008](#); [Fox and Wang, 2007](#);
11 [Li et al., 2006](#); [Houghton et al., 2004](#)). An unknown mechanism involving these cells could have
12 contributed to the initiation and/or growth of the skin and oral tumors. Another group reporting
13 an i.p. injection experiment in female Wistar rats showed effects on the submandibular gland that
14 may support the findings of oral cancer in rats. Submandibular acinar saliva-secreting cells showed
15 an increase in cystatin staining, which may play a role in tumorigenesis, metastasis, and
16 immunomodulation ([Ochieng and Chaudhuri, 2010](#); [Cohen et al., 1993](#)). Inducible type 2 cystatin
17 was not detected in the parotid or sublingual glands, trachea, lung, stomach, small intestine, large
18 intestine, spleen, liver or pancreas, suggesting that Cr(VI)-induced effects on cystatins are likely to
19 be localized. These inferences, however, are highly speculative. Overall, the underlying
20 mechanisms induced by Cr(VI) that lead to oral tumors in rats are unknown.

21 Cancer mode-of-action summary

22 The mechanistic events identified above and depicted in Figure 3-18 have some level of
23 Cr(VI)-specific evidence to indicate their involvement in the carcinogenic effects of Cr(VI). These
24 events are biologically plausible in that they are known to be associated with carcinogenesis and
25 can occur in humans, with interrelated pathways that emerge involving mutagenicity, cytotoxicity
26 and regenerative cellular proliferation. The molecular events involved in these effects are assumed
27 to be relevant to all routes of exposure. The evidence-based assumption is that some amount of
28 unreduced Cr(VI) can reach target tissues when ingested or inhaled and can be quickly taken up by
29 the cells in these tissues, where it will be reduced intracellularly to reactive intermediates that
30 induce toxic and carcinogenic effects. At the tissue level, differences in the evidence for each tumor
31 type also emerge, therefore it is unclear whether some mechanistic events are key for every tumor,
32 as the mechanistic effects may be dependent on the specific pattern or duration of activation of
33 certain events. These may occur based on cell type-specific properties such as their baseline
34 proliferative rate or ability to mitigate the effects of oxidative stress. Cr(VI) is a known human lung
35 carcinogen, therefore specifics of lung tumors will not be discussed here in the context of
36 mechanistic evidence, but the mechanistic evidence from studies of the exposed lung is considered
37 relevant and discussed along with mechanistic evidence for the tumors of the mouse small
38 intestine. There is a lack of empirical mechanistic evidence from the rat oral cavity.




Figure 3-18. Cellular processes involved in the mutagenic MOA of Cr(VI).

1 There is extensive evidence of the mutagenicity of Cr(VI) when reduced intracellularly to
 2 Cr(III) in studies conducted among in vitro test systems. A mutagenic MOA is also supported in test
 3 animals when considering the evidence in the context of pharmacokinetic considerations. Although
 4 the evidence of mutation from oral exposures is less consistent, the genotoxicity observed in animal
 5 i.p. studies in vivo has been consistently observed. Therefore, evidence of transmissible and
 6 permanent genetic alterations have been prioritized for the analysis of a mutagenic MOA if
 7 observed following oral or inhalation exposures in GI or lung tissues.

8 Cr(VI) is a known lung carcinogen, and a mutagenic MOA is supported for lung tumors
 9 following inhalation exposures primarily by evidence of increased micronuclei detected in the
 10 blood and exfoliated nasal and oral epithelial cells from occupationally exposed humans. Mutagenic
 11 activity also correlates with blood chromium levels in *medium* confidence studies, and several *low*
 12 confidence human studies that demonstrate increased chromosomal aberrations despite many
 13 having limitations that would potentially lead to bias toward the null. Supporting evidence is also
 14 provided by studies showing increased levels of DNA damage in exposed workers, as well as one
 15 *low* confidence study of mutations in the mouse lung that increased with dose and time following
 16 intratracheal instillation, providing biological plausibility that mutation is involved in the
 17 development of Cr(VI)-induced lung cancers. Therefore, a mutagenic MOA for lung tumors is
 18 considered to be relevant to humans and sufficiently supported in laboratory animals after
 19 inhalation exposure, based on the following: 1) the evidence-based interpretation that some
 20 amount of inhaled Cr(VI) (at physiologically relevant doses) escapes detoxification and is taken up

1 by target cells; 2) this uptake is expected to occur more readily in regions of the lung showing a
2 high chromate deposition that correlate with sites of lung tumors in exposed workers; 3)
3 demonstrations of increased chromosomal mutations in the exfoliated nasal and buccal cells and in
4 the peripheral blood of occupationally exposed workers; 4) gene mutations in the mouse lung that
5 increased with dose and time post-intratracheal instillation; 5) other genotoxic effects in the
6 peripheral blood of exposed workers and in lung-derived cell cultures in vitro; and 6) mutagenicity
7 of Cr(VI) when it reaches cells of various tissue types in vivo and in vitro. The implications of a
8 mutagenic MOA for the dose-response analysis and inhalation unit risk calculation for lung cancer
9 are presented in Section 4.4.3.

10 The evidence for a mutagenic MOA following oral exposures is less clear. There are no
11 human oral exposure studies of mutation in the GI tract, although consistent evidence of increased
12 micronucleus frequency in the oral epithelial cells of exposed workers may support the evidence
13 that Cr(VI) can induce mutagenic effects when it comes into contact with cells in the GI tract, and
14 contributes to an evaluation of whether mutation may be a primary neoplastic event. The database
15 of in vivo oral animal genotoxicity studies that are specific to GI tissues is limited to a small number
16 of *low* confidence studies, most of which have deficiencies in sensitivity for detecting an effect or
17 other concerns that introduce a large amount of uncertainty.

18 The mutagenicity assays used by these studies were originally designed and optimized for
19 purposes of identifying hazard, namely, whether a chemical is capable of inducing increased
20 mutagenic damage, regardless of dose. Although several doses are typically employed, these assays
21 are not optimized for dose response, and typically use a minimal number of animals (1-5).
22 Therefore, it is important that these assays use a range of doses that include a maximum tolerated
23 dose (MTD) or otherwise indicate that the chemical reached the target tissue to ensure sensitivity
24 ([Hayashi, 2016](#)) and strengthen a conclusion that, when reported, null findings represent a true
25 lack of effect (versus a deficiency in study design). As with all genotoxicity assays, these tests are
26 often considered in an MOA analysis for cancer, with the hypothesis that evidence of mutation in
27 the tumor target tissue occurs earlier than the induction of tumors, in the same species, and at the
28 same doses causing tumors supports a mutagenic MOA. Evaluations of this hypothesis often
29 presume the converse also applies, in that a negative result will indicate a lack of mutagenicity and
30 therefore support an alternate MOA that does not involve mutagenicity. This assumption often
31 relies on testing results within an acute to subchronic exposure period in a small number of
32 animals. It is difficult to make a definitive conclusion that Cr(VI) is not mutagenic in the GI tract
33 following oral exposures from an evidence base in animals composed of mostly null results from a
34 small number of *low* confidence studies, given that Cr(VI) has been shown to be mutagenic
35 following more direct exposures (i.e., i.p., in vitro), and we can reasonably expect that ingested
36 Cr(VI) will reach the GI tract.

37 High levels of cytotoxicity can lead to the detection of increased DNA damage in some test
38 systems. For this reason, the interpretation of genotoxicity evidence from chemicals inducing

1 excessive toxicity includes efforts to determine whether increases in genotoxicity are potentially
2 secondary to cytotoxicity. For the Cr(VI) in vivo oral exposure database, there is not enough
3 evidence to determine whether and to what extent Cr(VI)-induced genotoxicity might be the result
4 of (secondary) cytotoxic DNA damage in the GI tract. Most notably, while many of the animal
5 studies examining the most relevant genotoxicity endpoints did not detect substantial evidence of
6 genotoxicity at doses that also caused histological effects in the GI tract, including diffuse
7 epithelial/crypt cell hyperplasia and degenerative changes in the villi (vacuolization, atrophy, and
8 apoptosis), one study did observe statistically significantly increased micronuclei in villous cells
9 from animals exposed to doses that similarly induced villous atrophy and apoptosis. Because no
10 studies were available that specifically examine the presence or absence of genotoxicity in the GI
11 tract as the MTD was approached and exceeded, this uncertainty cannot currently be addressed.

12 Although it is presumed that ingested Cr(VI) can reach the target tissues in at least a
13 fraction of humans and animals, there are pharmacokinetic differences between oral and inhalation
14 exposure routes that indicate lower concentrations of Cr(VI) will reach target tissues when
15 ingested than when inhaled. In this context, however, it is still not possible to conclude that there is
16 no potential risk of increased mutations occurring in humans ingesting Cr(VI) in drinking water,
17 particularly when taking into consideration human subpopulations with a diminished ability to
18 reduce Cr(VI) in the stomach due to low gastric pH (see ‘Susceptible populations’ in the following
19 section). Therefore, given the uncertainty in the evidence base of ingestion studies in animals due
20 to a lack of study designs adequately testing for mutagenicity in target tissues, a mutagenic MOA is
21 supported for GI tumors after oral exposure, based on the following: 1) the evidence-based
22 interpretation that some amount of ingested Cr(VI) (at physiologically relevant doses) escapes GI
23 detoxification and reaches target cells; 2) the demonstrated chromosomal mutations in buccal cells
24 of occupationally exposed workers; and 3) the demonstrated mutagenicity of Cr(VI) when it comes
25 into direct contact with any cell type in various tissues in vivo and in vitro.

26 The mutagenic effects of Cr(VI) in the lung and GI tract are expected to be amplified by
27 promutagenic effects that are also anticipated to be key events for cancer induced by Cr(VI).
28 Oxidative stress induced by reactive Cr(VI) intermediates can damage DNA and intracellular
29 proteins and lead to an imbalance between free radicals and antioxidants. Direct and indirect
30 suppression of DNA repair processes via epigenetic silencing may lead to increased DNA damage,
31 DNA double-strand breaks, and genomic instability including microsatellite instability and
32 aneuploidy. The epigenetic modifications induced by Cr(VI) include extensive promoter-specific
33 hypermethylation, global hypomethylation, post-translational histone modifications, and microRNA
34 dysregulation. These perturbations can affect the expression of an extensive number of genes
35 including tumor suppressors and oncogenes associated with lung and colorectal cancers that
36 involve the promotion of unchecked cellular proliferation along with the suppression of apoptosis.
37 Although epigenetic changes are not permanent changes to the gene sequence, their overall effect
38 can be analogous to mutation in that they are heritable changes affecting gene expression. The

1 oxidative stress, oxidative DNA damage, direct or epigenetic suppression of DNA repair processes,
2 and genomic instability induced by Cr(VI) are all likely to be key events for carcinogenesis
3 applicable to oral and inhalation exposures for all tumor types. These effects combine to produce a
4 promutagenic microenvironment that promotes the formation and fixation of mutations from DNA
5 damage, regardless of whether the genetic damage was produced endogenously, by Cr(VI), or from
6 another source.

7 Consistent evidence of an inflammatory response in the lung following inhalation Cr(VI)
8 exposures in animals indicates this effect is likely to be a key event for lung cancer. Although
9 idiopathic cancer development in the GI tract has also been shown to involve chronic inflammation
10 ([Chiba et al., 2012](#)), no histopathological evidence of GI inflammation induced by Cr(VI) oral
11 exposure was observed in animals exposed via drinking water. However, the inflammatory
12 response associated with GI tract cancers has been shown to be mediated by proinflammatory
13 cytokines and ROS, effects that are known to result from Cr(VI) oral exposures and can lead to
14 genetic and epigenetic changes that promote neoplastic transformation. Combined, these data
15 suggest that inflammation could still be involved in the neoplastic effects of the small intestine in
16 mice.

17 An alternative MOA for carcinogenicity induced by ingested Cr(VI) is regenerative
18 proliferation caused by tissue injury, leading to a higher probability of spontaneous mutations that
19 may result in tumorigenesis. Cr(VI), a strong oxidizer, is known to be cytotoxic in vitro and may
20 trigger apoptosis through increased oxidative stress, mitochondrial dysfunction, and modulation of
21 pro-apoptotic signaling pathways. Following oral exposures, regenerative hyperplasia interpreted
22 to be the result of regressive changes such as villous blunting, villous atrophy, and apoptosis of
23 enterocytes was consistently observed in the mouse small intestine ([Thompson et al., 2012b](#);
24 [Thompson et al., 2011](#); [NTP, 2008, 2007](#)). Inconsistencies in the hyperplastic responses to these
25 degenerative changes have been noted, however, including hyperplasia that did not increase in
26 severity with dose, and no statistically significant or dose-responsive changes in mitotic or
27 apoptotic indices in tissue regions where increased crypt length, area, and number of crypt
28 enterocytes were reported. The diffuse hyperplasia of the small intestine is likely to be a key event
29 for tumors in this tissue, although these hyperplastic lesions, which were also observed in the rat
30 small intestine by [Thompson et al. \(2012b\)](#), do not always progress to cancer and can represent a
31 functionally adverse change on their own.

32 The GI tract has a high capacity for tissue regeneration following cellular injury, which
33 makes it more sensitive to exposures that may interfere with the process of cell division ([Nolte et
34 al., 2016](#)). At least some of the molecular events affecting cell cycle regulation that are altered by
35 Cr(VI) exposure also appear to underlie the regenerative histopathological changes in animals
36 exposed to Cr(VI). A toxicogenomic analysis comparing gene expression changes in the duodenal
37 crypts and villi of the mice exposed via drinking water for 7 and 90 days ([Thompson et al., 2011](#))
38 found a robust response in the crypts at doses ≥ 4.6 mg Cr(VI)/kg-d, and that the enrichment of

1 gene sets related to cell cycle progression and DNA damage were more robust in the crypts
2 compared to the villi ([Chappell et al., 2022](#)). Other toxicogenomic evidence consistent with
3 increased cellular proliferation in the mouse small intestine, including increased expression of
4 oncogenic c-Myc and the proliferative marker Ki-67, provides additional support for increased cell
5 proliferation occurring in the preneoplastic small intestine, although these markers are not specific
6 to regenerative hyperplasia. It is also not clear whether the degenerative and regenerative effects
7 are key events for other tumor types. No lesions or hyperplasia have been reported in the rat oral
8 cavity, and while cellular injury and hyperplasia were observed in the rat lung following inhalation
9 exposures, the hyperplasia diminished with longer exposures and following a recovery period.

10 The focal hyperplasia observed only in the mouse small intestine, although not statistically
11 significant or dose-dependent, represents a biologically important preneoplastic event that could
12 result from the interaction between Cr(VI)-induced regenerative processes and mutagenic effects
13 ([NTP, 2008](#)). These lesions were observed closer to the hyperplastic villous region of the
14 superficial intestinal mucosa, where Cr(VI) has been shown to concentrate ([Thompson et al.,
15 2015a](#)). Some evidence of micronuclei and oncogenic transformation has also been observed in this
16 tissue ([O'Brien et al., 2013](#); [Tsao et al., 2011](#)). This indicates the potential for a combined MOA for
17 Cr(VI)-induced tumorigenesis in the small intestine after oral exposure, where mutagenic effects
18 occur concurrently with hyperplasia, providing an environment that can support the clonal
19 expansion of mutated cells.

20 Although no histopathological changes were observed in the rat oral cavity preceding tumor
21 formation in subchronic or chronic bioassays of Cr(VI) in drinking water, and no increases in
22 mutation frequency were observed in these tissues in a single study investigating this endpoint,
23 mutagenicity is a biologically plausible mechanism and is coherent with the evidence of increased
24 micronuclei in the buccal cells of exposed humans. Although site concordance is not a requirement
25 when considering the evidence for a mutagenic MOA, there is currently not an understanding of
26 why humans do not show evidence of oral tumors, or why rats do not have tumors of the small
27 intestine. It is plausible that extensive epigenetic alterations, which have been shown to account for
28 phenotypic differences among individuals as well as among different tissue and cell types ([Zhang et
29 al., 2013](#)), may influence the differences in carcinogenic response and the carcinogenic potency of
30 Cr(VI) at the tissue level or even among individuals and across species.

31 In conclusion, the available mechanistic evidence supports key events at the molecular and
32 cellular level that are expected to be applicable to all exposure types and tumors. These key events
33 are summarized in Table 3-21 and Figures 3-16 and 3-18. Cr(VI) that is not reduced extracellularly
34 may be taken up by cells near the point of contact, which is generally expected to be the lung for
35 inhalation exposures and the GI tract for oral exposures. The GI tract, including the oral cavity, is
36 expected to be exposed by both of these routes in humans (impaction of dusts in the mouth and
37 tongue resulting from oral breathing and mucociliary clearance may result in GI exposure via the
38 inhalation route). Oxidative stress occurs within the cell, generated by the reactive chromium

Toxicological Review of Hexavalent Chromium

1 intermediate species, inducing DNA damage and cytotoxicity. Chromium-DNA adducts can be
2 formed by the ultimate Cr(III) species and, in combination with suppressed DNA repair processes
3 via epigenetic modifications, these adducts and other oxidative DNA damage may be fixed as
4 mutations in these cells. Cr(VI) may also promote aneuploidy and microsatellite instability by
5 suppressing DNA mismatch repair. These promutagenic effects, combined with epigenetic
6 modifications influencing the suppression of apoptosis and increased cell proliferation, combine to
7 create a tumor microenvironment supporting the clonal outgrowth of mutated cells. In addition,
8 there is evidence from the small intestine of mice exposed via drinking water that Cr(VI) exposure
9 can induce degenerative effects at the tissue level, with a proliferative response that should
10 promote the selection of cells with a growth advantage, leading to tumorigenesis, though it is
11 unclear whether this occurs in all tumor types. These processes also likely involve chronic
12 inflammation, though there is inconsistent evidence of this in all tumor tissues.

Table 3-21. Evidence profile table for the carcinogenic mechanisms of inhaled or ingested Cr(VI)

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
<p>Distribution of Cr(VI) (Sections 3.1.1 and 3.2.3.4; Appendix C.1.2)</p>	<p>Lung:</p> <ul style="list-style-type: none"> • Inhaled Cr(VI) comes into direct contact with lung epithelial cells and is expected to be directly absorbed with minimal extracellular reduction (i.e., detoxification) due to a less favorable reduction environment in lung tissues • Cr(VI) accumulates at lung bifurcation sites in the lungs of chromate workers • Cr(VI) burden in the lung correlates with lung cancer incidence <p><i>Oral cavity:</i> Following inhalation or oral exposures, cellular uptake may occur in the epithelium of the oral mucosa, tongue, and esophagus (prior to Cr(VI) reduction in the stomach), although the surface area for mass transfer is low</p> <p><i>Stomach:</i> While reduction (i.e., inactivation) of ingested Cr(VI) occurs in the stomach, it will compete with gastric emptying of Cr(VI) to the small intestine. Uptake in the stomach epithelium is also possible, although the surface area for mass transfer is low</p> <p>Small intestine:</p> <ul style="list-style-type: none"> • Cr(VI) bioavailability and kinetic considerations suggest that 10–20% of ingested Cr(VI) escapes human gastric inactivation and could expose the GI tract epithelium • Cr(VI) exposure to the proximal small intestine will be greater than exposure to the distal small intestine, as the Cr(VI) concentration decreases • The surface area for mass transfer in the small intestine is high 	<p>Following exposure to Cr(VI), it has been demonstrated that inhaled Cr(VI) can reach cells in the lung and oral cavity, and after ingestion, Cr(VI) can reach cells in the oral cavity (either by movement through the GI tract after inhalation and deposition into the oral cavity, or by direct ingestion), stomach, and small intestine, both potentially in appreciable amounts to elicit an effect. Distribution is strongly dependent on route of exposure (inhalation → respiratory tract, oral ingestion → gastrointestinal tract and liver).</p>
<p>Cellular uptake of Cr(VI) (Sections 3.1.1 and 3.2.3.4; Appendix C.1.1)</p>	<p><i>All cell types:</i> Cr(VI) is rapidly taken up by nonspecific sulfate and phosphate transporters due to the structural similarity of Cr(VI).</p> <p><i>Lung:</i> Particulates may deposit and absorb locally; the amount taken up is dependent on location, particle size, and solubility.</p>	<p>Ingested or inhaled Cr(VI) can be taken up by cells in tumor target tissues.</p>

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
	<p><i>Oral cavity:</i> Morphology within different regions of the oral cavity is highly variable (hard palate, buccal mucosa, gingiva, ventral/dorsal tongue, lip), and may impact localized cellular uptake.</p> <p><i>Stomach:</i> Lower absorptive surface area and different morphology than the small intestine. Some uptake may occur prior to gastric emptying.</p> <p><i>Small intestine:</i> Highly absorptive surface area increases uptake of Cr(VI) (primarily by the villi).</p>	
<p>Intracellular reduction of Cr(VI) (Sections 3.1.1.3 and 3.2.3.4; Appendix C.3.2.1)</p>	<p><i>All cell types:</i> Following cellular uptake, Cr(VI) is reduced primarily by ascorbate, but other biological reductants (e.g., cysteine, GSH) are also capable of reducing Cr(VI). This leads to the intracellular formation of the reactive intermediate species Cr(V) and Cr(IV) and the stable Cr(III).</p>	<p>Intracellular reduction is considered an activation pathway, generating reactive intermediates capable of damaging DNA directly or indirectly via oxidative damage.</p>
<p>DNA reactivity (Section 3.2.3.4; Appendix C.3.2.1)</p>	<p><i>All cell types:</i> Intracellular Cr(III) has been demonstrated to be DNA reactive and can form stable complexes with DNA, RNA, amino acids and proteins, including Cr(III)-DNA adducts, DNA-DNA crosslinks, and DNA-protein crosslinks.</p>	<p>Intracellular Cr(III) can bind to DNA, which can form bulky adducts that cause replication fork stalling, DNA double-strand breaks and mutations if not adequately repaired or eliminated by apoptosis.</p>
<p>Oxidative stress and oxidative DNA damage (Section 3.2.3.4; Appendix C.3.2.5)</p>	<p><i>Inhalation exposure:</i></p> <ul style="list-style-type: none"> • Consistent evidence of significant increases in oxidative stress in workers exposed to Cr(VI) that correlated with levels of Cr(VI) in urine and blood (see Appendix C.2.1 and C.3.9) • Increased formation of 8-OHdG DNA adducts in rats exposed to Cr(VI) via inhalation (Maeng et al., 2003) or intratracheal instillation (Zhao et al., 2014; Izzotti et al., 1998) <p><i>Oral exposure:</i></p> <ul style="list-style-type: none"> • Decreased GSH/GSSG ratio in small intestinal epithelium after 7 and 90 days of oral dosing in mice and after 90 days in rats, and in oral mucosa in mice after 7 days and rats 	<p>A consistent and coherent evidence base shows redox reactions during intracellular reduction of Cr(VI) produce reactive oxygen species that cause DNA damage in occupationally exposed humans, experimental animal studies, and in vitro studies, although the evidence in animals exposed orally is less consistent.</p>

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
	<p>at 90 days, although no 8-OHdG adducts or protein oxidation in any tissues (Thompson et al., 2011; De Flora et al., 2008)</p> <ul style="list-style-type: none"> • Activation of genes involved in oxidative stress in the duodenum of mice exposed to Cr(VI) for 90 days but not after 7 days <p><i>In vitro:</i></p> <ul style="list-style-type: none"> • Detection of reactive intermediates in acellular systems • Oxidative stress in human primary and immortalized lung or GI cells after exposure to Cr(VI), including increased ROS production, oxidation of lipids and proteins, and increased antioxidant enzyme activity • Increased intracellular reduction via ascorbate correlates with free radical production, oxidative DNA damage (e.g., 8-OHdG adducts, DNA strand breaks, DNA-protein crosslinks, alkali labile sites) and lipid peroxidation • Addition of antioxidants reduces/eliminates oxidative DNA damage; suppression of antioxidants or use of DNA repair deficient cell line increases oxidative DNA damage • Dose-dependent activation of NF-κB and AP-1, pro-inflammatory transcription factors and redox-sensitive signaling molecules 	
<p>Epigenetic modifications (Section 3.2.3.4; Appendix C.3.2.4)</p>	<p><i>Inhalation exposure:</i></p> <ul style="list-style-type: none"> • Hypermethylation of tumor-suppressor genes P16^{ink4a} (Kondo et al., 2006) and APC (Ali et al., 2011) in chromate factory workers with lung cancer who had occupational chromate exposure compared to those without chromate exposure, and dysregulation of tumor suppressor microRNAs that correlate with Cr blood levels (Li et al., 2014b). • Hypermethylation of DNA mismatch repair and homologous recombination repair genes in lung cancer cases with chromate exposure (Hu et al., 2018; Ali et al., 2011; Takahashi et al., 2005), leading to microsatellite instability • Global hypomethylation in chromium-exposed workers (Lingling et al., 2016; Wang et al., 2012b) 	<p>Consistent, coherent evidence of epigenetic alterations (heritable changes in gene expression that are not caused by changes in DNA sequence) that correlate with Cr(VI) exposure in humans and are known to contribute to microsatellite instability, mutagenicity, and carcinogenesis.</p>

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
	<p><i>In vitro</i>: Extensive evidence of the epigenetic mechanisms of Cr(VI) (including methylation, histone modifications, and miRNA) (reviewed in Chen et al. (2019)) and increased resistance to apoptosis in human colon cells lacking a key mismatch repair gene when exposed to Cr(VI). Transcriptomic changes consistent with epigenetic modifications in genes involved in cytotoxicity/cell proliferation and DNA repair (Rager et al., 2019).</p>	
<p>Inhibition of DNA repair (Section 3.2.3.4; Appendix C.3.2.3)</p>	<p><i>Inhalation exposure</i>: epigenetic suppression of genes involved in DNA repair in Cr(VI)-exposed workers (summarized above)</p> <p><i>In vitro</i>: Inhibition of genes involved in mismatch repair (see above) and homologous recombination repair, including RAD51 (Browning et al., 2016; Hu et al., 2016; Li et al., 2016; Bryant et al., 2006)</p>	<p>Consistent, coherent evidence of the epigenetic suppression of DNA mismatch repair (see above) and homologous recombination repair, leading to increased DNA double-strand breaks that are more likely to cause mutations.</p>
<p>Genomic instability (Section 3.2.3.4; Appendix C.3.2.3)</p>	<p><i>In vitro</i>: Consistent evidence of aneuploidy induced by Cr(VI) (Figgitt et al., 2010), (Güerci et al., 2000), Seoane et al. (2002; 2001, 1999))</p>	<p>Besides the microsatellite instability induced by epigenetic suppression of DNA mismatch repair (see above), Cr(VI) may also cause aneuploidy, a hallmark of cancer. This evidence is primarily from <i>in vitro</i> studies.</p>
<p>Genotoxicity and mutagenicity (Section 3.2.3.3; Appendix C.3.2.2)</p>	<p><i>Inhalation exposure</i>:</p> <ul style="list-style-type: none"> • Consistent evidence of increased micronucleus frequency from <i>medium</i> confidence studies of the blood, nasal and oral cavity of exposed workers that correlated with blood chromium levels (Long et al., 2019; El Safty et al., 2018; Hu et al., 2018; Sudha et al., 2011) • Ten of 11 <i>low</i> confidence studies found increased micronuclei in workers despite differences in population and exposure scenarios (Linging et al., 2016; Wultsch et al., 2014; Qayyum et al., 2012; Balachandar et al., 2010; Iarmarcovai et al., 2005; Danadevi et al., 2004; Medeiros et al., 2003; Benova et al., 2002; Vaglenov et al., 1999) • Consistent evidence of increased chromosomal aberrations in <i>low</i> confidence studies of workers despite sensitivity concerns that biased toward the null (Balachandar et al., 	<p>Consistent observations of heritable structural and numerical genetic damage in exposed humans, supported by a small number of <i>low</i> confidence studies in animals exposed via inhalation or ingestion, with other supporting evidence of genotoxicity provided by supplemental studies humans, animals, and <i>in vitro</i>.</p>

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
	<p>2010; Halasova et al., 2008; Maeng et al., 2004; Deng et al., 1988; Koshi et al., 1984; Sarto et al., 1982)</p> <ul style="list-style-type: none"> Increased mutation frequency in the lungs of transgenic rodents exposed via intratracheal instillation, increasing with dose and post-exposure time, provides biological plausibility for mutations in exposed target tissues (Cheng et al. (2000; 1998)) Consistent supporting evidence of genotoxicity in studies of exposed humans and animals dosed via i.p. injection, including DNA strand breaks, adducts, crosslinks, or other DNA damage and repair-related endpoints (e.g., sister chromatid exchange) (Appendix Table C-52) Correlation of systemic Cr levels and other genotoxic endpoints (El Safty et al., 2018; Qayyum et al., 2012; Sudha et al., 2011; Danadevi et al., 2004) Correlation of MN with work duration (Danadevi et al., 2004) <p><i>Oral exposure:</i></p> <ul style="list-style-type: none"> Some mixed evidence of micronucleus frequency in one <i>low</i> confidence study in the bone marrow of Cr(VI)-exposed mice (NTP, 2007) and positive findings of mutation in two <i>low</i> confidence studies in the developing mouse fetus (Schiestl et al., 1997) and in male rat germ cells (Marat et al., 2018) Largely null findings of gene mutation or micronuclei in <i>low</i> confidence studies in the bone marrow (De Flora et al., 2006; Mirsalis et al., 1996; Shindo et al., 1989) or GI tract (Aoki et al., 2019; Thompson et al., 2015c; Thompson et al., 2015b; O'Brien et al., 2013) of mice or rats, though all but one of these studies lacked sensitivity for detection due to nontoxic dose ranges tested <p><i>In vitro:</i></p> <ul style="list-style-type: none"> DNA reactivity and genotoxicity has been confirmed in a large evidence base of in vitro studies (Appendix Table C-53) 	
<p>Cytotoxicity and degenerative cellular changes</p>	<p><i>Biochemical markers of cell injury in the lung:</i></p>	<p>Consistent evidence of cytotoxicity and degenerative cellular changes observed in the lung and small</p>

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
<p>(Sections 3.2.1, 3.2.2, 3.2.3.4)</p>	<ul style="list-style-type: none"> • Concentration-related increases in total protein, albumin, and LDH activity have been observed in rats exposed via inhalation for 30 and 90 days to ≥ 0.05 mg/m³ Cr(VI) (Glaser et al., 1990) <p><i>Atrophy and blunting of small intestinal villi:</i></p> <ul style="list-style-type: none"> • Observed to increase with dose in mice following drinking water exposures to ≥ 11.6 Cr(VI)/kg-d after 7 and 90 days (Thompson et al., 2011) • Observed in a significant proportion of mice at all doses after 90 day (≥ 3 mg Cr(VI)/kg-d) or 2 year (≥ 0.3 mg/kg-d) drinking water exposures in mice (not observed in rats) (NTP, 2008, 2007) • Also observed in rats at 7.2 mg Cr(VI)/kg-d in drinking water (Thompson et al., 2012b) <p><i>Cytoplasmic vacuolization of small intestinal villi:</i></p> <ul style="list-style-type: none"> • Observed in mice following ≥ 11.6 mg Cr(VI)/kg-d in drinking water for 7 days and ≥ 4.6 mg Cr(VI)/kg-d in drinking water for 90 days (not observed in rats) (Thompson et al., 2011) • Observed at all doses (≥ 3 mg Cr(VI)/kg-d) in drinking water after 90 days exposure in drinking water (qualitative data) (not observed in rats) (NTP, 2007) <p><i>Apoptosis in the lung and small intestine:</i></p> <ul style="list-style-type: none"> • Lung: One intratracheal instillation exposure study in rats observed increased apoptosis in bronchial epithelium and lung parenchyma; in vitro studies support dose and time-dependent increases in apoptosis following Cr(VI) exposure in human lung cells (Reynolds et al., 2012; Azad et al., 2008; Reynolds and Zhitkovich, 2007; Gambelunghe et al., 2006; D'Agostini et al., 2002; Carlisle et al., 2000) • Small intestine, mouse: Apoptotic villi increasing with dose ≥ 11.6 Cr(VI)/kg-d in drinking water for 90 days; not observed after 7 days (Thompson et al., 2015b; Thompson et al., 2015a; O'Brien et al., 2013; Thompson et al., 2011) • Small intestine, rat: Apoptotic villi at ≥ 7.2 mg Cr(VI)/kg-d in drinking water (Thompson et al., 2012b) 	<p>intestine of animals following inhalation and drinking water exposures, respectively.</p>

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
<p>Suppression of apoptosis (Section 3.2.3.4; Appendix C.3.2.10 and C.3.3)</p>	<p><i>Oral exposures:</i></p> <ul style="list-style-type: none"> • Inhibition of the MAPK inhibitor RKIP was observed in the stomach and colon of male Wistar rats after 60 days of exposure to Cr(VI) in drinking water, leading to the activation of the ERK/MAPK signaling pathway (Tsao et al., 2011) • Activation of the ERK/MAPK signaling pathway promotes cell proliferation (via c-Myc expression activation) and has been observed in rat stomach and colon after oral exposure (Tsao et al., 2011) 	<p>Biologically plausible evidence of the suppression of apoptosis, a hallmark of cancer, in the stomach and colon of animals exposed via drinking water.</p>
<p>Cell proliferation (Section 3.2.3.4; Appendix C.3.2.10 and C.3.3)</p>	<p><i>Inhalation exposures:</i></p> <ul style="list-style-type: none"> • Cyclin D1, a regulator and promoter of cell cycle progression, has been detected at significantly increased levels in the lung tumor tissues of chromate-exposed patients compared to unexposed lung cancer patients. Increased expression of cyclin D1 has been associated with cell proliferation and tumorigenesis (Katabami et al., 2000) <p><i>Oral exposures:</i></p> <ul style="list-style-type: none"> • The cellular replication marker Ki-67, which is upregulated in human intestinal adenomas, has been found to be increased in isolated duodenal mucosal cells from the small intestine of mice exposed to Cr(VI) via drinking water for 7 and 90 days (Rager et al., 2017; Kopec et al., 2012a) • The c-Myc oncogene codes for a pro-proliferation transcription factor and can be activated by Wnt or the MAPK/ERK pathway, though it can also be blocked by NF-κB signaling. A dose-dependent increase in the c-Myc oncogene was found in the stomach and colon of male Wistar rats after 60 days of exposure to Cr(VI) in drinking water (Tsao et al., 2011) • Galectin-1, associated with gastric cancer cell motility and overexpressed in gastric tumor cells and digestive cancers, was increased in the stomach and colon of male Wistar rats after 60 days of exposure to Cr(VI) in drinking water (Tsao et al., 2011) 	<p>Biologically plausible evidence of increased cell proliferation, a hallmark of cancer, as interpreted by the aberrant expression of genes related to cell cycle regulation in lung tumor tissues of humans exposed to Cr(VI) and in the stomach, duodenum and colon of animals exposed via drinking water.</p>
<p>Regenerative hyperplasia</p>	<p><i>Focal epithelial hyperplasia of the small intestine:</i></p>	<p>Consistent evidence of hyperplasia interpreted to be the result of</p>

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
<p>(Sections 3.2.1, 3.2.2, 3.2.3.4)</p>	<ul style="list-style-type: none"> • Observed in mice exposed to ≥ 1.18 mg (females) and ≥ 2.4 mg (males) Cr(VI)/kg-d in drinking water for 2 years. The responses were not statistically significant, but this is considered a biologically significant pre-neoplastic lesion due to morphologic similarity to adenoma (NTP, 2008) <p><i>Diffuse epithelial hyperplasia of the lung and small intestine:</i></p> <ul style="list-style-type: none"> • Lung: Bronchioalveolar hyperplasia (70–100%) observed in rats following 0.050–0.40 mg/m³ Cr(VI) inhalation exposure for 30 days, but incidence was decreased at 90 days (Glaser et al., 1990) • Small intestinal crypt cells, mice: Hyperplasia reported in mice exposed for 7 days at 31.1 mg Cr(VI)/kg-d (NS) in drinking water with no changes in mitotic activity in crypt cells and following 90 days at ≥ 11.6 mg Cr(VI)/kg-d (non-dose-dependent) (Thompson et al., 2015b; Thompson et al., 2011) • Small intestine, mice: Hyperplasia observed at all doses (≥ 3 mg Cr(VI)/kg-d) in drinking water for 90 days, minimal to mild severity, 100% incidence at mid/high dose levels, with increased numbers of mitotic figures in the hyperplastic epithelium (in females and four male datasets in multiple strains). Also observed at all doses (≥ 0.3 mg Cr(VI)/kg-d) in drinking water for 2 years, increasing with dose, minimal to mild severity, with increased numbers of mitotic figures in the hyperplastic epithelium (NTP, 2008, 2007) • Small intestinal villous cells, rats: Hyperplasia observed at ≥ 7.2 mg Cr(VI)/kg-d in drinking water for 7 and 90 days (Thompson et al., 2012b) 	<p>regeneration following cell injury following oral exposures in the small intestine of mice and rats and following inhalation exposures in the lung in rats.</p>
<p>Inflammation (Section 3.2.3.4; Appendix Table C-38)</p>	<p><i>In the lung:</i></p> <ul style="list-style-type: none"> • Increases in macrophages in BALF at 0.9 mg/m³ Cr(VI) inhalation exposure for 4-6 weeks in rabbit and at 0.20 and 0.40 mg/m³ Cr(VI) for 30 and 90 days in rats (Glaser et al., 1990; Johansson et al., 1986b) • In rats exposed for 28 and 90 days, increased lymphocytes in BALF at 0.025 mg/m³ and 0.05 mg/m³ Cr(VI); increased granulocytes/neutrophils at 0.05 mg/m³ Cr(VI); no change or decreased number of macrophages at 0.050 and 0.20 mg/m³ Cr(VI) inhalation exposure. In rats exposed for 4-48 weeks, increased granulocytes/neutrophils; no 	<p>Consistent evidence of chronic inflammation, an enabling characteristic of cancer, has been observed in the lung of animals following Cr(VI) inhalation. There is no histopathological evidence in the GI tract consistent with chronic inflammation reported following oral exposures in animals, although some indirect evidence consistent with inflammation has been reported.</p>

Biological events (and relevant sections)	Summary of key findings	Interpretations, judgments, and rationale
	<p>change or decreased number of macrophages at 0.36 mg/m³ Cr(VI) inhalation exposure (Cohen et al., 2003; Glaser et al., 1985)</p> <ul style="list-style-type: none"> Histiocytosis (macrophage accumulation) associated with inflammation observed in rats and rabbits exposed via inhalation for 30-90 days (Kim et al., 2004; Glaser et al., 1990; Johansson et al., 1986a) <p><i>In the GI tract:</i></p> <ul style="list-style-type: none"> Cytokine fluctuations observed in the duodenum (and not the oral mucosa) of mice (↓ IL-1β and TNF-α) and rats (↑ IL-1α, IL-6; ↓ IL-4) following Cr(VI) exposure in drinking water Induction of proinflammatory signaling pathways (e.g., NF-κB) in animals following oral exposures 	

1

1 Susceptible populations and life stages

2 A number of different factors were identified that could predispose some populations of
3 humans to be more susceptible to Cr(VI) carcinogenicity when ingested. These factors are listed
4 below and in Section 3.3.1.

5 *Low stomach acid*

6 Because extracellular reduction of Cr(VI) to Cr(III) serves as a detoxifying mechanism,
7 conditions that would lower an individual's ability to effectively reduce Cr(VI) could lead to a
8 higher rate of Cr(VI) absorption into the cells lining the GI tract. Following oral ingestion, gastric
9 emptying to the small intestine competes with the rapid extracellular reduction to Cr(III) by gastric
10 juices ([Proctor et al., 2012](#); [De Flora et al., 1997](#)). However, there is significant interindividual
11 variability of stomach pH in the human population. Individuals taking medication to treat
12 gastroesophageal reflux disease (GERD), including calcium carbonate-based acid reducers and
13 proton pump inhibitors, have an elevated stomach pH during treatment. Individuals with a
14 preexisting low stomach acid condition (hypochlorhydria, also known as achlorhydria) consistently
15 have a high gastric pH of approximately 8 ([Kalantzi et al., 2006](#); [Feldman and Barnett, 1991](#);
16 [Christiansen, 1968](#)). This condition may be caused or exacerbated by multiple other preexisting
17 gastric conditions, including *H. pylori* infection. The prevalence of hypochlorhydria (see above) is
18 believed to be high in elderly populations (age 65 and up) ([Doki et al., 2017](#)). The general healthy
19 population also exhibits high variability in stomach pH. Among adults without hypochlorhydria
20 and who do not regularly take antacids, 5% of men may exhibit basal pH exceeding 5, and 5% of
21 women may exhibit basal pH exceeding 6.8 ([Feldman and Barnett, 1991](#)). Neonates have neutral
22 stomach pH at birth ([Neal-Kluever et al., 2019](#)) (see Section 3.3.1.3).

23 *Genetic polymorphisms*

24 Individuals with genetic polymorphisms conveying haploinsufficiencies in DNA repair or
25 tumor suppressor genes may have increased susceptibility to Cr(VI)-induced cancer. Several
26 studies in humans have identified polymorphisms in genes related to DNA repair and tumor
27 suppression that were correlated with increased genetic damage and lung cancer (summarized
28 above and in Appendix C.3.14; see also ([Urbano et al., 2012](#))). DNA adducts formed directly by
29 chromium or indirectly via oxidative damage are substrates for nucleotide excision repair (for
30 bulky lesions) and mismatch repair (for misincorporated bases during DNA replication and
31 homologous recombination); heritable deficiencies in the effectiveness of these repair processes
32 can cause a higher rate of unprocessed genetic damage leading to the formation of heritable
33 mutations.

1 *Carriers of the cystic fibrosis mutant allele*

2 The analyses by US EPA (see Appendix C.3.4.2 and [Mezencev and Auerbach \(2021\)](#)) of the
3 toxicogenomic data reported in Kopec et al. ([2012b](#); [2012a](#)) from mice exposed to Cr(VI) (reviewed
4 earlier in this section) have identified a potential role for CFTR in the carcinogenic effects of Cr(VI).
5 Tumorigenicity of impaired CFTR activity in animal models supports the relevance of the Cr(VI)-
6 mediated inactivation of CFTR for the development of small intestinal tumors in mice exposed to
7 Cr(VI) in drinking water ([Than et al., 2016](#)), and CFTR has been shown to act as a tumor suppressor
8 in the human colon ([Than et al., 2016](#)). These findings may indicate that carriers of the mutated
9 CFTR allele could be more sensitive to the Cr(VI)-mediated carcinogenicity. In the US alone, more
10 than 10 million people are carriers of a mutated CFTR allele that confers an approximate 50%
11 reduction in CFTR expression levels. Although these individuals do not develop cystic fibrosis, the
12 deficit in CFTR function has been shown to lead to an increased risk for several conditions
13 associated with the disease, including colorectal cancer (OR = 1.44, 95% CI: 1.01–2.05) ([Miller et al.,](#)
14 [2020](#)). CFTR suppression induced by low Cr(VI) exposures in drinking water can be expected to
15 occur in all exposed populations, but a more significant effect would be expected in humans already
16 producing low levels of this protein.

17 **3.2.3.5. *Integration of Evidence for Cancer of the GI Tract***

18 The integrated evidence for Cr(VI)-induced cancer of the GI tract is summarized in Table 3-
19 22. Overall, Cr(VI) is **likely to be carcinogenic** to the human GI tract. This conclusion is based on
20 *robust* evidence of cancer from a *high* confidence 2-year cancer bioassay conducted by NTP, which
21 showed a statistically significant increase in oral cavity tumors in male and female F344/N rats and
22 small intestine neoplasms in B6C3F1 male and female mice ([NTP, 2008](#)). Notably, at the lower
23 doses where tumor occurrence was nonsignificant compared to concurrent controls, incidences
24 exceeded NTP historical controls in both species. Therefore, some tumors that were not
25 statistically significant may be biologically significant due to the increasing trend and low historical
26 control incidence (Appendix D.2).

27 The evidence of carcinogenicity of the GI tract from human studies is *slight* based on studies
28 of the oral route of exposure. Results for two populations exposed to Cr(VI) through drinking water
29 in China and Greece were available in the epidemiological evidence base that analyzed stomach
30 cancer risk ([Linos et al., 2011](#); [Kerger et al., 2009](#); [Beaumont et al., 2008](#)). The studies reported
31 increased SMRs when their mortality experience was compared to other communities in the
32 surrounding areas or to the mortality experience in the province where the exposed communities
33 were located. While uncertainties in the study methods and analyses resulted in *low* confidence
34 ratings, the studies in both populations reported increased risk estimates, supporting a judgment of
35 *slight*.

36 The evidence from the meta-analysis of GI tract cancer risk from the occupational studies of
37 workers with inhalation exposure to Cr(VI) is *indeterminate*. The summary effect estimates showed

1 small increases in risk for each cancer site, and this increase was statistically significant for rectal
2 cancer. There were few studies reporting odds ratios, but in each case (esophagus and stomach),
3 summary effect estimates based on these studies were somewhat higher compared with summary
4 estimates based on other relative risk measures (although neither odds ratio-based estimate was
5 statistically significant). However, there were not clear patterns of risk by either occupational
6 group or specific cancer site. Due to potential misclassification and heterogeneity of Cr(VI)
7 exposure among and within the included studies, there may have been a decreased ability to detect
8 an association if it existed.

9 Although interspecies correlation is lacking for the exact tumor site within the intestinal
10 tract, the available evidence in animals and humans with overall species concordance spanning the
11 entire alimentary tract, including the oral cavity, is robust (with the acknowledgment that there is
12 not a requirement to establish site concordance to draw a conclusion for cancer hazard). While it is
13 difficult to draw conclusions regarding an association between human exposure to Cr(VI) through
14 drinking water or inhalation and GI tract cancer from the available epidemiological evidence, there
15 is consistency among species (human, rat, and mouse) regarding the potential for Cr(VI) to cause
16 cancer at various sites along the GI tract.

17 Potential MOAs for carcinogenicity induced by ingested Cr(VI) in the mouse small intestine
18 include mutagenicity and regenerative proliferation caused by tissue injury leading to a higher
19 probability of the clonal outgrowth of spontaneous mutations. These mechanistic processes are not
20 mutually exclusive, and there is evidence that Cr(VI)-induced carcinogenesis in the GI tract after
21 oral exposure involves both MOAs.

22 Bioavailability results and kinetic considerations (see Section 3.1 and Appendix C.1) lead to
23 the conclusion that approximately 10–20% of ingested low dose Cr(VI) escapes human gastric
24 inactivation and could therefore reach the target cells in appreciable amounts and would thus be
25 reasonably anticipated to act as a mutagen in the GI tract epithelium. Given the cellular capacity for
26 uptake of Cr(VI) in highly absorptive intestinal tissues, it is biologically plausible that Cr(VI) can
27 induce genetic damage in the human GI tract. By assuming significant (80–90%) but incomplete
28 gastric detoxification, the capacity for autonomous growth may remain latent for weeks, months, or
29 years, during which time an initiated cell may be phenotypically indistinguishable from other
30 parenchymal cells in that tissue. The average tumor diagnosis was over 700 days (100 weeks) for
31 both sexes of mice (first onset at 451 days and most observed at terminal sacrifice). Most human
32 and animal neoplasms studied to date are of monoclonal origin. There are several salient
33 characteristics of initiation. It can occur following a single exposure to a known carcinogen.
34 Changes produced by the initiator may be latent for weeks or months and are considered
35 irreversible. The hyperplasia observed at the 2-year evaluation endpoint may, therefore, be a
36 manifestation of intestinal responses to late clonal expansion following an early initiation. Also,
37 with age, spontaneous DNA replication becomes more error prone resulting in small intestinal

1 tumors. Therefore, the hyperplastic changes described could support either MOA (cytotoxicity with
2 regenerative cell proliferation and mutagenicity).

3 The hypothesis that continuous wounding results in regenerative proliferation that may
4 give rise to spontaneous mutations progressing to neoplasia is largely supported by
5 histopathological findings that indicate degenerative changes including villous blunting/atrophy
6 accompanied by cytoplasmic vacuolization and crypt hyperplasia. Importantly, it is unlikely that
7 this MOA is solely operational in the intestinal tumors observed by NTP after 2 years. While a
8 ‘wounding and regenerative cell proliferation’ MOA is supported by short-term (7 and 28 day) and
9 subchronic (90 day) bioassays, these studies were (a) too short in duration to show that
10 regenerative hyperplasia progressed to tumor formation (which could support a threshold dose)
11 and (b) did not demonstrate that a mutagenic MOA could reliably be excluded. Therefore, whether
12 the clonal selection and outgrowth of spontaneous mutations is responsible for Cr(VI)
13 tumorigenesis remains a data gap; DNA sequencing data may assist with assessing the validity of
14 this hypothesis.

15 No direct mechanistic evidence in the rat oral mucosa is available to support an MOA for
16 tumorigenesis of the rat oral cavity induced by ingested Cr(VI). It is important to note that the
17 apical membrane of the human tongue, oral mucosa, and esophagus will come into direct contact
18 with Cr(VI) in ingested drinking water before gastric detoxification. This is supported by consistent
19 observations of increased micronuclei in oral epithelial cells from humans occupationally exposed
20 to Cr(VI). Importantly, the proposed wounding and regenerative proliferation MOA for the
21 intestinal tumors in mice does not address the Cr(VI) oral cavity tumors of rats, in which neither
22 degenerative changes nor hyperplasia were observed. Only one *low* confidence study investigated
23 the mutation frequency in the rat oral cavity and did not find an increase after a 7-day exposure to
24 Cr(VI) in drinking water. Additional studies designed to be sensitive for detecting mutations as
25 well as other potential mechanisms involved in carcinogenicity of the oral mucosa are needed.

26 Overall, the determination of a mutagenic MOA, the incompleteness of gastric detoxification,
27 and the development of oral cavity tumors without any apparent tissue injury or regenerative
28 proliferation argue against a threshold for low dose extrapolation of cancer risk for both oral and GI
29 tract tumors from ingested Cr(VI). Because a mutagenic mode of action for Cr(VI) carcinogenicity is
30 “sufficiently supported in (laboratory) animals” and “relevant to humans,” EPA uses a linear low
31 dose extrapolation from the POD in accordance with Guidelines for Carcinogen Risk Assessment
32 ([U.S. EPA, 2005a](#)). The oral slope factor derivation for cancer is described in Section 4.3.

Table 3-22. Evidence profile table for cancer of the GI tract^a

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from studies of exposed humans					⊕⊕⊖
GASTRIC CANCER (ORAL) Low confidence: Beaumont et al. (2008) Kerger et al. (2009) Linos et al. (2011)	Results for two populations (three publications) in China and Greece exposed to Cr(VI) in drinking water showed increased SMRs. Ecological study designs (lack of individual estimates of exposure), the uncertain nature of the mortality data for that period in China, and the potential impact of confounding by differences in SES between comparison groups are sources of uncertainty.	<ul style="list-style-type: none"> Consistency across geographical locations and multiple referent groups 	<ul style="list-style-type: none"> Low confidence studies 	⊕⊖⊖ <i>Slight</i> Despite findings of increased SMRs in two separate studies, these <i>low</i> confidence ecological study designs reported imprecise estimates that changed in magnitude depending on the definition of the unexposed communities.	Cr(VI) is likely to be carcinogenic to humans via the oral route of exposure. Robust evidence shows tumors of the GI tract in mice (small intestine) and rats (oral cavity) in both sexes; the oral cavity tumors were rare indicating increased biological significance. Evidence from humans is slight but is consistent in

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>GI TRACT CANCER (INHALATION/ORAL) Medium confidence: 43 occupational studies of cancer mortality or incidence</p>	<p>A meta-analysis of GI tract cancer risk from occupational studies of workers with inhalation and oral (swallowing dust) exposure to Cr(VI) showed small increases in risk for each cancer site.</p> <p>Occupations with a higher certainty of exposure to Cr(VI) showed higher summary effect estimates.</p> <p>The summary estimates for SMR/SIR analyses of rectal cancer were statistically significant. The summary estimates for the few studies reporting odds ratios (esophagus and stomach) were somewhat higher (although neither odds ratio-based estimate was statistically significant).</p>	<ul style="list-style-type: none"> Precision across studies in meta-analysis increased by combining information across multiple studies for certain analyses Effects observed despite reduced sensitivity resulting from expected exposure misclassification Exposure-response gradient (in studies with better exposure assessment methods) 	<ul style="list-style-type: none"> Lack of coherence by cancer site and occupational groupings 	<p>○○○ <i>Indeterminate</i></p> <p>Although the risk estimate for rectal cancer was statistically significant, and coherent results for colon cancer risk were found when stratified by occupational groupings expected to have higher exposures to Cr(VI), inconsistencies in patterns of risk across occupational groups raise uncertainties.</p>	<p>reporting some risk of cancers of the GI tract in humans exposed via drinking water.</p> <p>Biological plausibility for the small intestinal tumors is provided by histopathological evidence of tissue degeneration and hyperplasia in the small intestine of mice and molecular evidence of cell proliferation and oxidative stress in these animals prior to tumor formation.</p> <p>A primary role for mutagenicity, evident in oral cavity tissues of exposed humans and known to occur when Cr(VI) comes into direct contact with cells, in GI tract tumorigenesis (and in particular, in tumors of the rat oral cavity) is not clear</p>
Evidence from animal studies					

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>GI TRACT TUMORS (ORAL) High confidence: NTP (2008)</p>	<p>Statistically significant increases in tumors of the GI tract were reported in a <i>high</i> confidence 2-year animal bioassay: adenomas and carcinomas of the small intestine (male and female mice), and squamous cell carcinomas and papillomas of the oral mucosa and tongue (male and female rats). Tumors of the oral cavity and small intestine have a very low historical incidence.</p>	<ul style="list-style-type: none"> • Consistent findings in one <i>high</i> confidence 2-year study that contained bioassays in rats and mice of both sexes • Coherent, biologically related findings within the GI tract • Large magnitude of effects • Strong dose-response gradient • Mechanistic evidence provides biological plausibility 	<ul style="list-style-type: none"> • No factors noted 	<p>⊕⊕⊕ <i>Robust</i></p> <p>Consistent findings in one large <i>high</i> confidence study finding tumors in the GI tract in two species and both sexes.</p> <p>Animal mechanistic evidence informing biological plausibility (hyperplasia in mouse small intestine may be a precursor event for tumors).</p>	<p>but also cannot be ruled out. A mutagenic mode of action for Cr(VI) carcinogenicity is considered sufficiently supported in (laboratory) animals and relevant to humans.</p> <p>Susceptibility is assumed for humans with impaired ability to reduce Cr(VI) in the stomach.</p>
<p>HISTOPATHOLOGICAL CHANGES (ORAL) High confidence: NTP (2008) NTP (2007) Thompson et al. (2012b) Thompson et al. (2011)</p>	<p>Degenerative changes in intestinal villi and hyperplasia of the small intestine observed in male and female mice by NTP (2008, 2007), and in female mice and rats by Thompson et al. (2012b; 2011).</p>	<ul style="list-style-type: none"> • Consistent findings in chronic and subchronic studies that contained multiple bioassays in rats and mice of both sexes, and 	<ul style="list-style-type: none"> • Inconsistent observations of hyperplasia between mice and rats, though this is explained in part by 	<p>⊕⊕⊕ <i>Robust</i></p> <p>Histopathological changes reported in <i>high</i> confidence studies (tissue injury and proliferative changes) observed across the animal evidence base database are coherent</p>	

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	Histiocytic cellular infiltration observed in the small intestine of male and female rats and mice in all studies and bioassays.	multiple strains of mice <ul style="list-style-type: none"> • Large magnitude of effects • Strong dose-response gradient • <i>High</i> confidence studies observing an effect • Mechanistic evidence provides plausibility • Coherence as potential preneoplastic lesions in the mouse small intestine only 	pharmacokinetic differences	following chronic and/or subchronic oral exposures in rats and mice and suggest adverse effects of Cr(VI) on the GI tract, findings that are supported by mechanistic evidence.	

^aSee Table 3-21 for the summary of key mechanistic events involved in Cr(VI)-induced cancer.

3.2.4. Hepatic effects

1 The liver is a common site of toxicity as it functions to metabolize exogenous as well as
2 endogenous chemicals. The liver is considered an accessory digestive organ because it synthesizes
3 proteins and compounds necessary for digestion as well as filtering and metabolizing nutrients and
4 toxicants absorbed by the small intestine (first-pass effect). The liver also metabolizes chemicals
5 absorbed into the bloodstream from other routes (such as intravenous injection or inhalation).
6 Because of the first-pass effect, the liver may be affected more severely by toxic chemical exposure
7 via the oral route as compared to the inhalation route.

8 3.2.4.1. Human Evidence

9 Study evaluation summary

10 There are four studies that reported on the association between Cr(VI) exposure and
11 hepatic-related clinical chemistry measures, including alanine aminotransferase (ALT), aspartate
12 aminotransferase (AST), and alkaline phosphatase (ALP). Increases in serum ALT and AST are
13 considered indicative of hepatocellular damage, with ALT considered to be the more sensitive and
14 specific indicator (EMEA, 2008; Boone et al., 2005). Increases in ALP can be associated with liver
15 cholestasis, however, ALP is not as specific to liver injury as extrahepatic sources of ALP exist
16 (Boone et al., 2005). Other serum measures evaluated which can help inform liver toxicity,
17 included: bilirubin, albumin, total protein, creatinine, and albumin/globulin ratio. In general,
18 increased serum bilirubin and decreased serum albumin/total protein can indicate impaired liver
19 function (EMEA, 2008; Boone et al., 2005). A fifth study, Tong and Zhang (2003), reported
20 hepatomegaly among chromium workers but was found to be *uninformative* due to multiple critical
21 deficiencies and is not further discussed.

22 With respect to [confidence in the human studies](#), one study (Khan et al., 2013) was
23 classified as *uninformative* because exposure was based on tannery work, and there was insufficient
24 information provided on the specific tanning processes used at the facility³³. This study was not
25 considered further. The three remaining studies were included and classified as *low confidence*
26 (see Table 3-23), with two (Saraswathy and Usharani, 2007; Lin et al., 1994) conducted in
27 occupational populations with exposure primarily via inhalation and one (Sazakli et al., 2014) in the
28 general population with exposure primarily via the oral route. Lin et al. (1994) had adequate
29 exposure measurement due to use of air sampling with appropriate methods and categorization
30 into three levels of exposure, but was *deficient* due to incomplete reporting of results and
31 confounding. In the remaining two studies, the primary limitation was *deficient* exposure

³³Leather tanning processes that can potentially lead to Cr(VI) exposure include: (1) use of a two-bath process, (2) on-site production of tanning liquors, and (3) leather finishing steps that involve Cr(VI) (e.g., use of Cr(VI)-containing pigments) (Shaw Environmental, 2006). If these processes are not specified by the study, it cannot be determined whether exposure was to Cr(VI) or Cr(III).

1 measurement, primarily due to concerns about potential for nondifferential exposure
 2 misclassification that would be likely to bias the results towards the null ([Sazakli et al., 2014](#);
 3 [Saraswathy and Usharani, 2007](#)). In [Sazakli et al. \(2014\)](#), exposure was estimated based on water
 4 intake and blood and hair Cr concentrations, but there were poor correlations across measures. In
 5 [Saraswathy and Usharani \(2007\)](#), no air data was available and there was no quantitative
 6 measurement of exposure. These considerations on exposure measurement are the primary basis
 7 for the clinical chemistry outcome judgments presented in Table 3-23.

Table 3-23. Summary of human studies for Cr(VI) hepatic effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. [Click to see interactive data graphic for rating rationales.](#)

Author (year)	Industry	Location	Exposure Measurement	Study Design	Clinical Chemistry
Lin et al. (1994)	Chrome plating	Taiwan	Urine, Air, Work category	Cross-sectional	L
Sazakli et al. (2014)	General population	Greece	Urine, Hair, Modeled lifetime Cr(VI) exposure dose	Cross-sectional	L
Saraswathy and Usharani (2007)	Chrome plating	India	Work category	Cross-sectional	L

^aStudies excluded due to critical deficiency in one or more domains: [Khan et al. \(2013\)](#) and [Tong and Zhang \(2003\)](#).

8 Synthesis of evidence in humans

9 Two studies ([Sazakli et al., 2014](#); [Saraswathy and Usharani, 2007](#)) reported statistically
 10 significant changes consistent with liver dysfunction in at least one of the tests (i.e., higher levels of
 11 ALT, AST, ALP, or bilirubin and/or lower levels of total protein or albumin with higher exposure) as
 12 shown in Table 3-24. These associations were observed despite the potential for exposure
 13 misclassification that may have reduced sensitivity. [Saraswathy and Usharani \(2007\)](#) observed an
 14 exposure-response gradient across the three exposure categories for ALT, AST, ALP, and total
 15 protein. However, there is some inconsistency in the direction of results for total protein and
 16 albumin between the two studies. The third study ([Lin et al., 1994](#)) evaluated serum ALT, AST,
 17 creatinine, and albumin/globulin ratio. The study authors did not report quantitative results but
 18 reported that there were no significant differences among workers in the four exposure groups.

Table 3-24. Associations between Cr(VI) and liver clinical chemistries in epidemiology studies

Reference, confidence	Population	Exposure comparison and effect estimate	ALT	AST	ALP	Total protein	Other
Sazakli et al. (2014) , low confidence	Cross-sectional in Greece, general population; two drinking water exposure groups (n = 237) and controls (n = 67)	Regression coefficients for calculated lifetime exposure dose and hair biomarkers	Lifetime: -0.03 (for ln-ALT) Hair: 0.05 (for ln-ALT)	Lifetime: 0.04 Hair: 0.04	Lifetime: 0.12* Hair: 0.22*	Lifetime: 0.14* Hair: 0.24*	Lifetime: Albumin 0.21* Bilirubin -0.11 Hair: Albumin 0.23* Bilirubin -0.07
Saraswathy and Usharani (2007) , low confidence	Cross-sectional in India, two chrome plater groups (n = 130) and male area residents (n = 130)	Means ± SD for control/ exposed 8–15 yrs (A)/ exposed 16–25 yrs (B)	Control: 22.0 ± 1.7 Exposed A: 34.3 ± 2.5* Exposed B: 43.3 ± 1.7*	Control: 19.2 ± 2.1 Exposed A: 32.9 ± 3.7* Exposed B: 38.6 ± 4.0*	Control: 60.8 ± 5.7 Exposed A: 70.2 ± 6.2* Exposed B: 83.7 ± 7.6*	Control: 7.8 ± 0.4 Exposed A: 7.5 ± 0.1* Exposed B: 6.1 ± 0.1*	NR
Lin et al. (1994) , low confidence	Cross-sectional in Taiwan, three chrome plater groups (n = 79) and aluminum plater referent group (n = 40)	Analysis and quantitative results not reported.	ALT, AST, serum creatinine and albumin/globulin ratio evaluated, however, authors report no significant difference among workers across exposure groups (results not shown).				

*p < 0.05.

NR: not reported.

1 In addition, four studies (presented in five publications) reported on mortality attributable
2 to cirrhosis of the liver, all based on occupational cohorts ([Birk et al., 2006](#); [Moulin et al., 2000](#);
3 [Moulin et al., 1993b](#); [Moulin et al., 1993a](#); [Moulin et al., 1990](#)). These studies indicated no increase
4 in cirrhosis mortality with higher exposure levels, but this evidence is considered inadequate to
5 assess the association with Cr(VI) due to [several limitations](#), including lack of control of potential
6 confounding (such as by alcohol consumption), concerns about sensitivity and specificity of the
7 exposure measures, and the sensitivity of mortality as the outcome measure.

8 Overall, there is an indication in the available human studies that higher Cr(VI) exposure
9 may be associated with increased liver dysfunction, but there is some inconsistency in the available
10 results, and limitations especially with respect to exposure measurement.

1 **3.2.4.2. Animal Evidence**

2 Study evaluation summary

3 Information relevant to the evaluation of an association between Cr(VI) exposure and liver
 4 effects comes from oral and inhalation studies in mice and rats involving subchronic, chronic, and
 5 gestational exposures. Liver effects evaluated in this synthesis include changes in liver histology,
 6 clinical chemistry, and relative liver weight. As displayed in Table 3-25, studies reporting liver
 7 effects in the Cr(VI) evidence base were of varying study quality (based on factors including
 8 strength of study design and transparency of reporting), with the most informative evidence from
 9 the NTP chronic and subchronic drinking water bioassays in rats and mice ([NTP, 2008, 2007](#)).

Table 3-25. Summary of included animal studies for Cr(VI) liver effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a
[Click to see interactive data graphic for rating rationales.](#)

Author (year)	Species (strain)	Exposure design	Exposure route	Liver outcomes		
				Organ weight	Clinical chemistry	Histopathology
Acharya et al. (2001)	Rat (Wistar), male	Chronic	Drinking water		L	L
Chopra et al. (1996)	Rat (Wistar), female	Subchronic	Drinking water	M	L	L
Elshazly et al. (2016)	Rat (Sprague-Dawley)	Subchronic	Drinking water	-	M	M
Glaser et al. (1985)	Rat (Wistar)	Subchronic	Inhalation	L	L	M
Glaser et al. (1986)	Rat (Wistar)	Chronic	Inhalation	L	L	U
Kim et al. (2004)	Rat (Sprague-Dawley)	Subchronic	Inhalation	M	M	-
Krim et al. (2013)	Rat (Albino)	Subchronic	Gavage	-	M	-
Meenakshi et al. (1989)	Rat (Wistar)	Subchronic	Gavage	-	L	U
Mo et al. (2018)	Rabbit (New Zealand), male and female	Subchronic	Gavage	-	-	L
Navya et al. (2017a)	Rat (Wistar), male	Subchronic	Gavage	-	M	L
NTP (1997)	Mouse (BALB/c)	Reproductive study-continuous breeding (F0 to F2)	Diet	H		H
NTP (1996a)	Mouse (BALB/c)	Subchronic	Diet			H
NTP (1996b)	Rat (Sprague-Dawley)	Subchronic	Diet			H
NTP (2007)	Rat (F344/N); Mouse (B6C3F1, BALB/c, C57BL/6)	Subchronic	Drinking water	H	H	H

Author (year)	Species (strain)	Exposure design	Exposure route	Liver outcomes		
				Organ weight	Clinical chemistry	Histopathology
NTP (2008)	Rats (F344/N); Mouse (B6C3F1)	Chronic	Drinking water		H	H
Rafael et al. (2007)	Rat (Wistar)	Subchronic	Drinking water	-	M	L
Wang et al. (2015)	Rat (Sprague-Dawley), male	Subchronic	Drinking water	M	M	M
(Younan et al., 2019)	Rat (Wistar), male	Subchronic	Diet	L	M	U

³⁴Seven studies reporting liver endpoints met PECO criteria but were considered to be *uninformative* at the study evaluation stage: [Kumar and Barthwal \(1991\)](#), [Geetha et al. \(2003\)](#); [Asmatullah and Noreen \(1999\)](#), [Nettesheim et al. \(1971\)](#), [Soudani et al. \(2013\)](#), [Sánchez-Martín et al. \(2015\)](#), and [MacKenzie et al. \(1958\)](#).³⁴

1 Synthesis of evidence in animals

2 *Histopathology*

3 Several subchronic and chronic studies in rats and mice reported histological lesions in the
4 liver associated with oral exposure to Cr(VI). These lesions include increased inflammation and
5 infiltration of immune cells ([Elshazly et al., 2016](#); [NTP, 2008, 2007](#)), cytoplasmic vacuolation (fatty
6 changes) ([Elshazly et al., 2016](#); [NTP, 2008](#); [Acharya et al., 2001](#); [NTP, 1997](#); [Chopra et al., 1996](#);
7 [NTP, 1996a](#)), indications of apoptosis and necrosis ([Elshazly et al., 2016](#); [Acharya et al., 2001](#);
8 [Chopra et al., 1996](#)), and increased hepatocellular foci ([Elshazly et al., 2016](#); [NTP, 2008](#)). These
9 findings are presented in more detail below (see also Figure 3-19). While some NTP studies
10 observed histological lesions, several other NTP studies failed to find altered histological findings in
11 the liver. These studies include an oral study that exposed male and female SD rats to doses of up
12 to approximately 10 mg Cr(VI)/kg-day for 9 weeks ([NTP, 1996b](#)), as well as a 3-month study in
13 three different strains of mice ([NTP, 2007](#)). A 3-month study in B6C3F1 mice reported a lack of
14 histological changes in the liver ([NTP, 2007](#)) as well as a 9-week oral study in BALB/c mice
15 (although some non-statistically significant increases in vacuolation were observed) ([NTP, 1996a](#)).
16 In addition, no treatment-related lesions in the liver were found in male and female BALB/c F0 or
17 F1 mice exposed orally in a continuous breeding study at doses of 30–50 mg Cr(VI)/kg-day for
18 approximately 20 weeks ([NTP, 1997](#)). Across the evidence base, there is some indication that mice
19 may be more resistant than rats to Cr(VI)-induced changes in the liver, and that histological
20 changes that were not observed following subchronic exposure durations may be apparent after
21 chronic exposure. For instance, a study of male and female B6C3F1 mice exposed at doses up to
22 ~28 mg Cr(VI)/kg-day for 12 weeks ([NTP, 2007](#)) did not find evidence of liver histological changes;

³⁴This study was the basis of the previous RfD posted to IRIS in 1998 ([U.S. EPA, 1998c](#)).

1 however, after 2 years of exposure, histiocytic infiltration was noted in female mice (but not males)
2 ([NTP, 2008](#)).

3 The available inhalation studies (*medium* and *low* confidence) investigated, but did not
4 observe, histological alterations in the liver in rats exposed for 12 weeks at concentrations of up to
5 1.25 mg Cr(VI)/m³ ([Kim et al., 2004](#)) or 0.2 mg Cr(VI)/m³ ([Glaser et al., 1985](#)), or for longer
6 durations (18 months followed by a 12 month unexposed period) at concentrations of up to 0.1 mg
7 Cr(VI)/m³ ([Glaser et al., 1986](#)). However, liver chromium concentration following inhalation
8 exposure to Cr(VI) is expected to be approximately 1–2 orders of magnitude lower than
9 concentrations following oral exposure due to the first-pass effect ([O'Flaherty and Radike, 1991](#)).
10 As a result, the extent of hepatotoxicity would be expected to differ by route of exposure.

11 *Inflammation-related hepatotoxicity*

12 Inflammation-related histological changes in the liver (increased inflammation and
13 infiltration of immune cells) were reported in several *high* confidence studies of Cr(VI) exposure in
14 F344 rats ([NTP, 2008, 2007](#)) and B6C3F1 mice ([NTP, 2008](#)). In female F344 rats, statistically
15 significantly increased incidences of chronic focal inflammation were reported for females in the
16 highest dose group following 3 months of exposure at 20.9 mg Cr(VI)/kg-day ([NTP, 2007](#)) and at
17 lower doses (0.2–7 mg Cr(VI)/kg-day) after two years of exposure, with incidences increasing
18 monotonically with dose ([NTP, 2008](#)). In male F344 rats exposed for 3 months, no statistically
19 significant increase in liver lesions was found ([NTP, 2007](#)); however, after 2 years of exposure,
20 chronic inflammation was increased in males in the second highest dose group (56%) relative to
21 controls, although control incidence was high (38%) and no clear dose-response was apparent for
22 this endpoint ([NTP, 2008](#)). In a 2-year study, a statistically significantly increased incidence of
23 chronic inflammation was observed in female B6C3F1 mice in the second highest exposure group
24 (3.2 mg Cr(VI)/kg-day) but not in other exposed groups (high dose: 8.9 mg Cr(VI)/kg-day) or in
25 male mice at doses up to 5.7 mg Cr(VI)/kg-day ([NTP, 2008](#)). Increased Kupffer cell (stellate
26 macrophage) activation was observed in a high dose, *medium* confidence study in male SD rats
27 exposed to approximately³⁵ 25 mg Cr(VI)/kg-day for six months ([Elshazly et al., 2016](#)). In a
28 continuous breeding study in BALB/c mice, no increased inflammatory changes in the liver were
29 observed in F0 or F1 male or female mice exposed for approximately 20 weeks at doses up to 30–
30 50 mg/kg-day ([NTP, 1997](#)).

31 In damaged tissues, infiltrating histiocytes (macrophages) display functions such as
32 modulation of inflammatory cells, removal of damaged tissues/cellular debris, and antigen
33 presentation, as well as fibrogenic stimulation ([Yamate et al., 2016](#)). The incidence of infiltration of
34 histiocytes in the liver was statistically significantly elevated in female F344 rats exposed for
35 3 months at doses ≥ 3.5 mg Cr(VI)/kg-day ([NTP, 2007](#)) and in female F344 rats exposed at lower

³⁵[Elshazly et al. \(2016\)](#) did not contain enough information to accurately calculate a dose in mg/kg-d. Using drinking water factors for SD rats from [U.S. EPA \(1988\)](#), the dose may be as high as 25 mg/kg-d (although this does not take into account decreased palatability of the drinking water at 180 mg/L).

1 doses (≥ 0.96 mg Cr(VI)/kg-day) for two years ([NTP, 2008](#)). Histiocytic infiltration was not
2 observed in male F344 rats exposed for 3 months at doses up to 20.9 mg Cr(VI)/kg-day but was
3 statistically significantly elevated in high dose male rats (5.9 mg Cr(VI)/kg-day) following 2 years of
4 exposure. Increased incidences of minimal to mild histiocytic infiltration were also observed in all
5 exposed groups of female mice (0.3 to 8.9 mg Cr(VI)/kg-day), showing an increasing response with
6 dose, in a 2-year study, but not in male mice ([NTP, 2008](#)). Hepatic infiltration of inflammatory cells
7 was also noted in a *medium* confidence study which exposed male rats to approximately 25 mg
8 Cr(VI)/kg-day for six months ([Elshazly et al., 2016](#)). [NTP \(2008\)](#) stated that the significance of
9 histiocytic infiltration is unknown but hypothesized that infiltration of macrophages may reflect
10 phagocytosis of an insoluble precipitate. However, specific data investigating chromium removal
11 from the liver has not been identified. It is important to acknowledge that activated macrophages
12 can also damage tissue by secreting cytotoxic factors indicative of an innate inflammatory response
13 and creating an inflammatory environment (([Koyama and Brenner, 2017](#); [Yamate et al., 2016](#)); see
14 [Francke and Mog \(2021\)](#) for further description) and chronic hepatic inflammation can lead to
15 fibrosis ([Koyama and Brenner, 2017](#)). Histiocytic cellular infiltration with exposure to Cr(VI) was
16 also observed in several other tissues (including the duodenum and mesenteric and pancreatic
17 lymph nodes) in both rats and mice ([NTP, 2008](#)). See the immune effects section (Section 3.2.6) for
18 further discussion of this effect.

19 *Necrosis and apoptosis*

20 Few chronic or subchronic studies across the evidence base reported liver necrosis or
21 indications of apoptosis. The incidence of necrosis was not increased in Cr(VI)-exposed animals in
22 the large (50/sex/group), *high* confidence, 2-year NTP bioassay in F344 rats or B6C3F1 mice at
23 doses of up to 6–9 mg Cr(VI)/kg-day ([NTP, 2008](#)) or in an NTP continuous breeding study in F0 and
24 F1 BALB/c mice ([NTP, 1997](#)). However, a high dose, *medium* confidence study observed necrosis in
25 all SD rats exposed to 25 mg Cr(VI)/kg-day for six months ([Elshazly et al., 2016](#)). Another *medium*
26 confidence study observed bile duct necrosis in rabbits exposed by gavage to doses as low as 0.35
27 mg Cr(VI)/kg-day for three months ([Mo et al., 2018](#)). Several *low* confidence studies (discussed
28 below) of shorter duration in Wistar rats reported evidence of necrosis or apoptosis associated
29 with Cr(VI) exposure. [Rafael et al. \(2007\)](#) described histological changes indicative of apoptosis as
30 well as necrosis in Wistar rats exposed to approximately 3 mg Cr(VI)/kg-day for 10 weeks. This
31 study also reported immunohistochemical evidence for increased expression of caspase-3, a marker
32 for apoptosis, in male rats ([Rafael et al., 2007](#)). Mechanistic markers of apoptosis also have been
33 observed with Cr(VI). A 28-day study in male rats gavaged with 10.6 mg Cr(VI)/kg-d reported
34 increased expression of genes involved in apoptosis concurrent with increases in liver enzymes
35 (ALT, AST, and ALP) ([Navya et al., 2017a](#)). Regarding evidence of necrosis, two related publications
36 qualitatively described periportal necrosis in Wistar rats exposed to 1.4 mg Cr(VI)/kg-day for 22
37 weeks ([Acharya et al., 2001](#); [Chopra et al., 1996](#)). While low levels of hepatocellular apoptosis may
38 be difficult to detect in chronic and subchronic toxicity studies, numerous short-term mechanistic

1 studies indicate the upregulation of apoptotic genes as well as the detection of specific markers of
2 apoptosis (e.g., caspase-3) following Cr(VI) exposure (see *Mechanistic Evidence* below and Table 3-
3 26).

4 *Fatty changes and vacuolation*

5 Fatty changes, or steatosis, the accumulation and retention of fat in hepatocytes, is an early
6 pathological change associated with liver disease. Histologically, fatty change is sometimes noted
7 as vacuolation, with lipid accumulating in hepatocytes as vacuoles. Fatty changes often coincide
8 with hepatic inflammation ([Kaiser et al., 2012](#); [Day and James, 1998](#)). If the insult responsible for
9 steatosis persists, more severe pathologies can develop including fibrosis and cirrhosis ([Kaiser et](#)
10 [al., 2012](#); [Day and James, 1998](#)). Liver vacuolation associated with oral exposure to Cr(VI) was
11 reported in several publications ([Elshazly et al., 2016](#); [NTP, 2008](#); [Acharya et al., 2001](#); [Chopra et al.,](#)
12 [1996](#); [NTP, 1996a](#)) but not others ([NTP, 2007, 1997, 1996b](#)). An increased incidence of scattered
13 hepatocytes with cytoplasmic vacuoles containing lipid, characterized as “fatty changes,” was noted
14 in female (but not male) F344 rats at doses ≥ 0.96 mg Cr(VI)/kg-day in the *high* confidence 2-year
15 [NTP \(2008\)](#) study. Furthermore, two similarly designed *low* confidence studies qualitatively
16 reported liver vacuolation in Wistar rats exposed to 1.4 mg Cr(VI)/kg-day for 22 weeks ([Acharya et](#)
17 [al., 2001](#); [Chopra et al., 1996](#)). A high dose, *medium* confidence study observed vacuolation in all
18 male SD rats exposed to approximately 25 mg Cr(VI)/kg-day for six months ([Elshazly et al., 2016](#)).
19 Hepatic vacuolation was also observed in a *high* confidence study of male and female BALB/c mice
20 exposed via diet at doses ≥ 5.6 mg Cr(VI)/kg-day for 9 weeks ([NTP, 1996a](#)). Study authors reported
21 that the vacuoles were suggestive of lipid accumulation ([NTP, 1996a](#)). However, these findings
22 were not supported by other *high* confidence studies of this strain of mice treated for 3 months
23 ([NTP, 2007, 1997](#)) or a similarly designed 9-week study in rats ([NTP, 1996b](#)). No increase in the
24 3-month study ([NTP, 2007](#)) or in F0 male and female BALB/c mice in a continuous breeding study
25 at doses up to ~ 30 – 50 mg Cr(VI)/kg-day for approximately 20 weeks ([NTP, 1997](#)).

26 *Other histological effects*

27 Hepatocellular degeneration, altered hepatocellular foci of mixed type, bile duct
28 hyperplasia, oval cell hyperplasia, and periductal fibroplasia were observed in a *medium* confidence
29 study in male SD rats exposed to approximately 25 mg Cr(VI)/kg-day for six months ([Elshazly et al.,](#)
30 [2016](#)). Necrosis and bile duct toxicity (bile duct hyperplasia and cholangiofibrosis) were also
31 observed in rabbits exposed by gavage to doses as low as 0.35 mg Cr(VI)/kg-day for three months
32 ([Mo et al., 2018](#)). Other isolated histological changes were reported in the evidence base, including
33 the observation of basophilic hepatocellular foci, a preneoplastic lesion. In F344 rats, authors
34 reported an exposure-related increased incidence of basophilic hepatocellular foci in the 2-year
35 study in male rats, but not in females ([NTP, 2008](#)).

1 *Summary of histological effects*

2 Overall, there is consistent evidence of Cr(VI)-induced hepatic histological effects, across
3 species and sexes, in animals exposed via the oral route (see Figure 3-19). Increases in chronic
4 inflammation and histiocyte infiltration as well as increased fatty change and associated
5 vacuolation were reported in several *high* confidence studies following chronic and/or subchronic
6 oral exposures in rats and mice. Evidence of cell death (necrosis and apoptosis) was reported in
7 several *low* confidence studies and is supported by short-term mechanistic studies; however, these
8 endpoints were unchanged in higher confidence studies testing similar doses, for longer durations.
9 Histopathological effects were not observed in *low* and *medium* confidence studies following
10 inhalation exposures, potentially due to differences in target tissue dose across routes of exposure.

11 In general, female rodents appear to be more sensitive to Cr(VI) induced histological
12 changes (e.g., hepatic inflammation and fatty changes; [NTP \(2008\)](#)). However, few studies are
13 available in the database that evaluated both males and females; most study designs used either
14 male or female animals. In the 2 year rat study ([NTP, 2008](#)), chronic inflammation and histiocytic
15 inflammation and were significantly increased in females at lower doses than males (approximately
16 6–10 fold lower than in male animals).³⁶ Increased fatty changes were also seen in [female rats](#) at
17 doses as low as 0.94 mg/kg-day and were not significantly elevated in [males](#) at doses as high as
18 5.9 mg/kg-d. However, basophilic foci (often considered a preneoplastic effect), was noted in [male](#)
19 [rats](#) at doses as low as 0.77 mg/kg-d and was not observed in female rats, although male rats were
20 observed to have a much higher background rates of this lesion. For mice, which generally
21 appeared to be less sensitive than rats to hepatic effects with Cr(VI) exposure, statistically
22 significant increases in chronic inflammation and histiocytic infiltration were seen in female, but
23 not male mice ([NTP, 2008](#)).³⁷

³⁶Inflammation: click to see rat data in [females](#) and [males](#) in HAWC.

Infiltration: click to see rat data in [females](#) and [males](#) in HAWC.

³⁷Inflammation: click to see mouse data in [females](#) and [males](#) in HAWC. Infiltration: click to see mouse data in [females](#) and [males](#) in HAWC.




Figure 3-19. Hepatic effects of oral Cr(VI) exposure in animals (histopathology). [Click to see an interactive graphic.](#)

1 *Clinical chemistry*

2 Many studies in the animal evidence base have examined serum indicators that are
 3 potentially informative for predicting hepatotoxicity including ALT, AST, ALP, and sorbitol
 4 dehydrogenase (SDH) (see Figure 3-20). Several studies by the oral route reported statistically
 5 significant increases in serum enzymes; however, no statistically or biologically significant
 6 increases in serum enzyme activities were observed in the available inhalation studies ([Kim et al.,](#)
 7 [2004](#); [Glaser et al., 1986](#); [Glaser et al., 1985](#)).

8 Statistically significant increases in ALT were reported in most of the studies in rats that
 9 measured this enzyme; increases ≥100% of the control mean were reported in approximately half
 10 of these studies ([Younan et al., 2019](#); [Elshazly et al., 2016](#); [NTP, 2008, 2007](#); [Rafael et al., 2007](#);
 11 [Acharya et al., 2001](#); [Chopra et al., 1996](#)). ALT is found abundantly in the cytosol of the hepatocyte;
 12 in the case of hepatocellular injury, necrosis, or reparative activity, ALT is released into the

1 bloodstream ([Kim et al., 2008](#); [Boone et al., 2005](#)). An increase in ALT of >100% (of the control
2 mean) generally raises concern for hepatic injury ([EMEA, 2008](#); [Boone et al., 2005](#)) and is
3 considered biologically relevant. Biologically significant increases in ALT (>100%) were observed
4 across studies in F344 and Wistar rats that were exposed to Cr(VI) for durations ranging from three
5 months to two years at doses as low as 1–2 mg/kg-day ([NTP, 2008, 2007](#); [Acharya et al., 2001](#);
6 [Chopra et al., 1996](#)). ALT was also statistically significantly elevated in some strains of mice
7 following three months of exposure; however, these increases were smaller in magnitude (<100%
8 of control) ([NTP, 2007](#)). Click [here](#) to see the magnitude of ALT changes in HAWC for NTP ([2008](#),
9 [2007](#)).

10 Statistically significant increases in AST were also observed across rat studies (of various
11 subchronic durations), with the magnitude of increase ranging from 60–113% above control mean
12 ([Younan et al., 2019](#); [Navya et al., 2017a](#); [Krim et al., 2013](#); [Soudani et al., 2013](#); [Acharya et al., 2001](#);
13 [Chopra et al., 1996](#); [Meenakshi et al., 1989](#)). However, many studies in the evidence base did not
14 measure AST, including the *high* confidence NTP bioassays. AST is considered a less specific and
15 sensitive indicator of hepatocellular injury than ALT ([EMEA, 2008](#); [Boone et al., 2005](#)).

16 Increases in ALP, an indication of hepatobiliary damage ([Boone et al., 2005](#)), were less
17 consistent across the evidence base, with some studies noting significant increases and other
18 studies noting decreases in ALP. Several *high* confidence studies reported small (10–31%) but
19 statistically significant decreases in ALP in F344 rats ([NTP, 2008, 2007](#)) and in one strain of male
20 mice ([NTP, 2007](#)). However, decreases in ALP are not seen as a reflection of hepatobiliary toxicity,
21 but are thought to be related to decreased food consumption ([Travlos et al., 1996](#)) or conditions
22 including malnutrition, mineral deficiencies, and anemia ([Lum, 1995](#)), a finding noted in the NTP
23 studies ([2008, 2007](#)). Four *medium* or *low* confidence studies in rats found statistically significant
24 increases in ALP of 59–165% ([Younan et al., 2019](#); [Navya et al., 2017a](#); [Elshazly et al., 2016](#); [Krim et al., 2013](#);
25 [Chopra et al., 1996](#)). An increase in ALP was noted in male Wistar rats exposed to 5.3–
26 10.6 mg Cr(VI)/kg-day for 28–30 days ([Navya et al., 2017a](#); [Krim et al., 2013](#)) and in female Wistar
27 rats treated with 1.4 mg Cr(VI)/kg-day for 5.5 months ([Chopra et al., 1996](#)). No change relative to
28 control was seen in male Wistar rats exposed to 1.4 mg Cr(VI)/kg-day for 5.5 months ([Acharya et al., 2001](#)).
29

30 Sorbitol dehydrogenase (SDH), considered to be a supplemental indicator of hepatotoxicity
31 ([Boone et al., 2005](#)), was evaluated in two NTP studies ([NTP, 2008, 2007](#)). NTP reported
32 statistically significant increases in SDH of 77–458% compared to controls in F344 male and female
33 rats exposed to ≥1.7 mg Cr(VI)/kg-day for 3 months ([NTP, 2007](#)). Changes in SDH, in male rats
34 only, were also observed in a 2-year NTP study conducted in the same rat strain that examined
35 clinical chemistry endpoints at 3, 6, and 12 months ([NTP, 2008](#)). This study found more muted
36 responses than the 3-month study ([NTP, 2007](#)), with statistically increased levels of SDH (24–69%)
37 in the top two dose groups at the 6-month time point, but not at the 3- or 12-month time points

1 ([NTP, 2008](#)). In mice, small but statistically significant decreases in SDH were observed in two
2 strains of mice; however, decreases in SDH are not indicative of liver damage ([NTP, 2007](#)).

3 Hepatic glycogen levels may be affected by exposure to hepatotoxic chemicals. In animals
4 exposed to Cr(VI), glycogen depletion was noted in two strains of male mice ([NTP, 2007](#)) and in two
5 related studies in male and female Wistar rats ([Acharya et al., 2001](#); [Chopra et al., 1996](#)). In [NTP](#)
6 ([2007](#)), two strains of mice examined histologically showed glycogen depletion at doses ≥ 5.2 mg
7 Cr(VI)/kg-day (B6C3F1) and ≥ 2.8 mg Cr(VI)/kg-day (*am3-C57BL/6*) but no glycogen depletion was
8 found in exposed BALB/c mice ([NTP, 2007](#)). [Acharya et al. \(2001\)](#) and [Chopra et al. \(1996\)](#) also
9 noted statistically significant decreased liver glycogen in rats exposed at 1.4 mg Cr(VI)/kg-day (the
10 only dose tested) for 5.5 months. Hepatic glycogen levels are also dependent on caloric intake. [NTP](#)
11 ([2007](#)) noted that the glycogen depletion was likely a result of depressed food consumption, often
12 observed when water consumption is decreased, as it was at the high dose in this study; however,
13 food consumption data was not reported.

14 Overall, significant increases in serum markers of liver damage were reported in several
15 *high* and *medium* confidence oral exposure studies. Generally consistent elevations of ALT and AST
16 were seen across multiple well-conducted studies in both rats and mice, with the magnitude of
17 change in ALT considered to be biologically significant and a specific indication of liver damage.
18 Changes to ALP and SDH were inconsistent across the evidence base and the biological significance
19 of decreased glycogen observed in several studies is difficult to interpret. No effects on serum
20 markers of liver damage were reported following inhalation exposures.

Toxicological Review of Hexavalent Chromium




Figure 3-20. Hepatic effects of oral Cr(VI) exposure in animals (clinical chemistry). [Click to see interactive graphic.](#) To view the magnitude of changes in ALT from NTP (2008, 2007) data, [click here.](#) To view data by [Elishazly et al. \(2016\)](#) (where dose could not be estimated), [click here.](#)

1 *Liver weight*

2 Several studies reported statistically significant changes (both increases and decreases) in
3 absolute and relative liver weight (see Figure 3-21) following short-term or subchronic oral
4 exposures; liver weight was not measured in the 2-year [NTP \(2008\)](#) bioassay. Liver weight relative
5 to body weight has been shown to be more informative in the evaluation of liver toxicity, as
6 compared to absolute liver weight, especially when changes in body weight are observed ([Bailey et
7 al., 2004](#)). Therefore, this discussion focuses on changes in relative liver weight where available.

8 In the only *high* confidence study in rats, relative liver weights were decreased by about
9 10% in F344 males exposed to Cr(VI) in drinking water for three months in the two highest dose
10 groups (11.2 and 20.9 mg Cr(VI)/kg-day) compared with control values; no significant liver weight
11 changes were found in any female exposed group ([NTP, 2007](#)). Relative liver weight was
12 substantially increased (>twofold) in female Wistar rats exposed to 1.4 mg Cr(VI)/kg-day in
13 drinking water for 22 weeks in a *medium* confidence study ([Chopra et al., 1996](#)). A *low* confidence
14 study found relative liver weight was increased 20-30% in male Wistar rats exposed in the diet to
15 3–9 mg Cr(VI)/kg-day for 90 days ([Younan et al., 2019](#)). A shorter duration *medium* confidence
16 study (4 weeks) in male Sprague-Dawley rats at doses up to 21 mg Cr(VI)/kg-day reported no
17 change in liver weight ([Wang et al., 2015](#)).

18 In mice, several *high* confidence experiments conducted by NTP across three different
19 strains observed a consistent pattern of absolute liver weight changes in high dose animals (9–30
20 mg Cr(VI)/kg-day) exposed to Cr(VI) through drinking water for about 3 months. Statistically
21 significant decreases in absolute liver weights, but not relative liver weight, were observed in
22 B6C3F1, BALB/c and *am3*-C57BL/6 mice ([NTP, 2008, 2007](#)). However, study authors reported that
23 decreases in absolute liver weight in these studies were correlated with decreased body weights
24 seen at higher doses ([NTP, 2008, 2007](#)). Several older NTP studies in BALB/c mice did not measure
25 liver weight ([NTP, 1997, 1996a](#)).

26 Regarding inhalation exposure, no changes in relative liver weight were observed in two
27 90-day rat studies at concentrations of 0.2 mg Cr(VI)/m³ ([Glaser et al., 1985](#)) or 1.25 mg Cr(VI)/m³
28 ([Kim et al., 2004](#)); however, an 18-month study at concentrations of up to 0.1 mg Cr(VI)/m³
29 observed a statistically significant increase (13.5%) in relative liver weight ([Glaser et al., 1986](#)).

30 Overall, inconsistent findings were observed for relative liver weight changes in *high* and
31 *medium* confidence oral exposure and *low* confidence inhalation studies, with decreases in relative
32 liver weight observed in *high* confidence studies, and evidence for increased liver weight primarily
33 limited to the *low* confidence studies.

Toxicological Review of Hexavalent Chromium




Figure 3-21. Hepatic effects of oral Cr(VI) exposure in animals (relative liver weight). [Click to see an interactive graphic.](#)

1 **3.2.4.3. Mechanistic Evidence**

2 The mechanistic data for liver toxicity indicates that several key events contribute to the
3 hepatic effects observed in humans and animals. Exposure to Cr(VI) may cause oxidative and
4 endoplasmic reticulum stress and mitochondrial dysfunction. These events can lead to
5 inflammation and apoptosis, which can account for histopathological and serum indicators of liver
6 injury seen in animals. In vivo experiments in rodents report that ingested and (to a lesser extent)
7 inhaled Cr(VI) can accumulate in the liver ([Jin et al., 2014](#); [NTP, 2008](#); [Cheng et al., 2000](#)),
8 demonstrating the metal can reach the target tissue and further supporting the biological
9 plausibility for Cr(VI)-induced liver toxicity. For chronic oral exposure in the [NTP \(2008\)](#) tissue
10 distribution study (collection days 182 and 371, with a 2-day washout period), liver chromium
11 concentrations were significantly elevated at all dose groups compared to controls, indicating
12 accumulation of chromium in this organ. A pharmacokinetic study by [O'Flaherty and Radike \(1991\)](#)
13 demonstrated that following inhalation or oral exposure to nearly equivalent target absorbed doses
14 of Cr(VI), oral exposure resulted in liver concentrations that were 1–2 orders of magnitude higher
15 than those from inhalation exposure (See Appendix C.1.2). As a result, the extent of hepatotoxicity
16 would be expected to differ by route of exposure.

17 A large body of mechanistic information (125 studies) exists to inform the potential
18 hepatotoxicity of Cr(VI) (see Appendix C.2.3). Therefore, studies which are more informative for
19 chronic human exposure were prioritized for further analysis and interpretation. These included
20 mammalian studies that focused on exposure routes more relevant to humans (e.g., oral and
21 inhalation studies), as well as repeat dose studies of longer durations (≥ 28 days). Shorter duration
22 studies utilizing oral and inhalation routes of administration and in vitro studies in human cell lines
23 also provided insight into biological plausibility and human relevance of the observed mechanisms.

24 Oral repeat dose studies provide support for oxidative stress, mitochondrial damage,
25 inflammation, and apoptosis as mechanisms of Cr(VI)-induced liver effects. A 36-day dietary study
26 in male mice receiving 1 and 4 mg/kg/ $K_2Cr_2O_7$ -day (0.35 and 1.41 mg/kg-d Cr[VI]) reported
27 significant increases in hepatic lipid peroxidation and other markers of ROS-related stress ([Jin et al.,](#)
28 [2014](#)), similar to a 10-week gavage study in rabbits receiving 5 mg/kg-day ([El-Demerdash et al.,](#)
29 [2006](#)). [Rafael et al. \(2007\)](#) described immunohistochemical evidence for increased expression of
30 Caspase-3, a marker for apoptosis in Wistar rats exposed to approximately 3 mg Cr(VI)/kg-day for
31 10 weeks. A 28-day study in male rats receiving 30 mg/kg/ $K_2Cr_2O_7$ -day (10.6 mg/kg-d Cr[VI]) by
32 gavage ([Navya et al., 2017a](#); [Navya et al., 2017b](#)) also reported increases in lipid peroxidation and
33 decreased SOD, CAT, and GST activity, concurrent with increases in serum indicators of liver
34 toxicity (ALT, AST, and ALP) and histological changes in the liver (described as feathery
35 degeneration). These effects were concurrent with the upregulation of some genes involved in
36 oxidative stress, inflammation, and apoptosis, such as TNF- α , MAPK, Atf-1, GADD-45, Bax, and
37 Caspase-1, while anti-apoptotic genes, including Bcl-2 and OGG-1, were downregulated ([Navya et](#)
38 [al., 2017a](#); [Navya et al., 2017b](#)). Ninety- and 120-day studies in rats exposed to $Na_2Cr_2O_7$ (3.97 mg

1 Cr(VI)/kg-day and 0.99 mg Cr(VI)/kg-day, respectively) reported lipid peroxidation in hepatic
2 mitochondria and microsomes accompanied by increased urinary excretion of metabolites
3 indicative of lipid peroxidation such as MDA ([Bagchi et al., 1997](#); [Bagchi et al., 1995a](#)).

4 Oral studies in rats and mice of shorter, acute durations provide further support for an MOA
5 for Cr(VI)-induced liver effects involving oxidative stress and apoptosis. Similar to longer term
6 repeat dose studies, shorter term and single-dose studies report increased chromium content in the
7 liver, increased lipid peroxidation and ALT and AST, free radical production, indicators of
8 inflammation, upregulation of pro-apoptotic genes and proteins, and down-regulation of anti-
9 apoptotic genes and proteins in liver tissue ([Zhong et al., 2017c](#); [Wang et al., 2010c](#); [Bagchi et al.,](#)
10 [2002](#); [Bagchi et al., 2001](#); [Bagchi et al., 2000](#); [Bagchi et al., 1995b](#); [Kumar and Rana, 1982](#)).

11 In vitro studies in human cell lines provide additional support for the biological plausibility
12 of these liver toxicity mechanisms in humans. Human liver carcinoma cell lines show increases in
13 ROS production and MDA at various concentrations as well as effects on antioxidant enzymes and
14 mitochondrial function ([Zhong et al., 2017a](#); [Zeng et al., 2013](#); [Patlolla et al., 2009](#)). Similar results
15 were observed in human fetal hepatocytes including increased mitochondrial stress, ER stress-
16 related mechanisms, and the activation of apoptotic and senescence signaling cascades ([Liang et al.,](#)
17 [2019](#); [Xiao et al., 2019](#); [Zhang et al., 2019](#); [Liang et al., 2018a](#); [Liang et al., 2018b](#); [Yi et al., 2017](#);
18 [Zhang et al., 2017](#); [Zhong et al., 2017b](#); [Zhong et al., 2017c](#); [Zhang et al., 2016](#); [Xiao et al., 2014](#); [Xie](#)
19 [et al., 2014](#); [Xiao et al., 2012a](#); [Xiao et al., 2012b](#); [Yuan et al., 2012b](#); [Yuan et al., 2012a](#)). In vitro
20 study results also support the upregulation of pro-inflammatory cytokines and signaling molecules
21 such as NF- κ B, TNF- α , LBT4, and IL1 β ([Zhong et al., 2017c](#); [Yi et al., 2016](#)).

22 Collectively, the data indicate oxidative stress, mitochondrial dysfunction, inflammation,
23 and apoptosis as possible interconnected mechanisms for liver toxicity. The toxicological evidence
24 in animals taken together with mechanistic evidence, particularly data from oral, in vivo studies
25 suggest a possible MOA of Cr(VI)-induced liver toxicity involving the production of free radicals and
26 reactive intermediates through intracellular Cr(VI) reduction. In this possible MOA, the production
27 of these reactive species alters antioxidant enzyme activity and stresses the endoplasmic reticulum
28 and mitochondria, triggering an apoptotic signaling cascade. Oxidative stress may lead to liver
29 inflammation and the upregulation of genes involved in an inflammatory response.

30 **3.2.4.4. Integration of Evidence**

31 Overall, the available **evidence indicates** that Cr(VI) likely causes hepatic effects in
32 humans. This conclusion is based on studies in animals that observed hepatic effects following
33 exposure to Cr(VI) in drinking water. The human evidence for Cr(VI)-induced liver effects is
34 limited in terms of number and confidence of studies. However, two of the available three studies
35 (one occupational and one general population study) provide an indication of exposure-related
36 alterations of liver clinical chemistry ([Sazakli et al., 2014](#); [Saraswathy and Usharani, 2007](#)). Given
37 the plausible support for these findings from in vitro studies of human hepatic cells, the human
38 evidence is interpreted to provide *slight* evidence of hepatic toxicity associated with Cr(VI).

1 Integrated evidence of the hepatic effects of Cr(VI) exposure from human, animal, and mechanistic
2 studies is summarized in an evidence profile table, Table 3-26. The exposure conditions relevant to
3 hepatic effects are further defined in Section 4.1.

4 The available animal studies provide *moderate* evidence for liver effects in rats and mice
5 orally exposed to Cr(VI) compounds, based primarily on elevated serum enzymes suggestive of
6 liver toxicity, as well as histological evidence of inflammatory effects and fatty changes in the liver
7 that are supported by a large and coherent database of in vivo mechanistic studies. This conclusion
8 is specific to oral exposure to Cr(VI) as few, lower confidence inhalation studies evaluated liver
9 toxicity and were generally null, possibly owing to the known differences in pharmacokinetics
10 across routes.

11 Elevations of ALT and AST were seen across the oral evidence base, with biologically
12 significant elevations in ALT (>100%) seen in multiple studies. ALT in particular is considered a
13 sensitive and specific indicator of liver injury ([Kim et al., 2008](#); [Boone et al., 2005](#)). Increased ALT
14 is roughly correlated with the degree of hepatic inflammation, with patients with high ALT levels
15 tending to have more severe inflammation in the liver than those with normal ALT values ([Kim et](#)
16 [al., 2008](#)).

17 Chronic inflammation in the liver is a concern as it can lead to liver fibrosis ([Koyama and](#)
18 [Brenner, 2017](#)). Dose-dependent increases in chronic inflammation were most evident in female
19 F344 rats exposed for three months to two years ([NTP, 2008](#)). Lesser increases in chronic
20 inflammation were also seen in male F344 rats and female (but not male) B6C3F1 mice exposed for
21 two years, although background incidence of this lesion was high ([NTP, 2008, 2007](#)).

22 Fatty change (steatosis) is a common pathological change associated with liver disease,
23 often leading to, or coinciding with, inflammation. If the insult responsible for steatosis persists,
24 more severe pathologies can develop, including fibrosis and cirrhosis ([Kaiser et al., 2012](#); [Day and](#)
25 [James, 1998](#)). Histological findings of vacuolation and fatty changes were also observed in several
26 studies ([NTP, 2008](#); [Acharya et al., 2001](#); [Chopra et al., 1996](#); [NTP, 1996a](#)). Fatty changes are
27 thought to be mediated by impaired mitochondrial function, which was observed in several studies
28 of Cr(VI) exposure to human hepatic cells in vitro ([Yi et al., 2017](#); [Zhong et al., 2017c](#); [Zhong et al.,](#)
29 [2017a](#); [Zhang et al., 2016](#); [Xiao et al., 2014](#); [Xie et al., 2014](#); [Zeng et al., 2013](#); [Xiao et al., 2012a](#); [Yuan](#)
30 [et al., 2012a](#); [Patlolla et al., 2009](#)).

31 Severe histological changes such as necrosis and fibrosis were not observed in the
32 high-confidence NTP three-month or two-year studies in F344 rats and B6C3F1 mice ([NTP, 2008,](#)
33 [2007](#)). However, several lower confidence subchronic studies in rats noted increased evidence of
34 apoptosis or necrosis ([Elshazly et al., 2016](#); [Rafael et al., 2007](#); [Acharya et al., 2001](#); [Chopra et al.,](#)
35 [1996](#)). These effects are supported by mechanistic evidence that suggests a possible MOA of
36 Cr(VI)-induced liver toxicity involving the production of free radicals and reactive intermediates
37 through intracellular Cr(VI) reduction resulting in oxidative stress, mitochondrial dysfunction,
38 inflammation, and apoptosis. Taken together, the serum enzyme and histopathology data from

Toxicological Review of Hexavalent Chromium

- 1 human, animal, and in vitro studies support biologically significant changes in the livers of rodents
- 2 orally exposed to Cr(VI).

Table 3-26. Evidence profile table for hepatic effects

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from studies of exposed humans					⊕⊕⊖
CLINICAL CHEMISTRY Low confidence: Sazakli et al. (2014) Saraswathy and Usharani (2007) Lin et al. (1994)	Statistically significant changes in at least one marker of liver dysfunction (ALT, AST, ALP, bilirubin or total protein) were reported in 2 out of 3 <i>low</i> confidence studies, though the direction of the associations was not coherent for all endpoints across studies (i.e., increases in ALT, AST, ALP, and bilirubin would be expected to accompany decreases in total protein, but this was not consistently the case).	<ul style="list-style-type: none"> Exposure-response gradient between exposure groups in one study for ALT, AST, ALP, and TP 	<ul style="list-style-type: none"> Lack of expected coherence <i>Low</i> confidence studies 	⊕⊖⊖ <i>Slight</i> Based on changes in clinical chemistry markers of liver dysfunction in two <i>low</i> confidence studies.	The evidence indicates that Cr(VI) is likely to cause liver toxicity in humans given sufficient exposure conditions. Effects on clinical chemistry were observed in both human and animal studies. <i>Moderate</i> evidence in rats and mice shows consistent findings of elevated liver enzymes indicative of hepatocellular damage and changes in liver architecture following oral exposure.
Evidence from animal studies					
HISTOPATHOLOGY (Oral) High confidence: NTP (1996a) NTP (1997) NTP (2007) NTP (2008) Medium confidence: Wang et al. (2015) Elshazly et al. (2016) Low confidence: Acharya et al. (2001) Chopra et al. (1996)	Increased chronic inflammation, histiocyte infiltration, fatty change and vacuolation with subchronic and chronic exposures in male and female rats and mice. No increase in necrosis in <i>high</i> confidence studies; however, lower confidence studies and numerous mechanistic studies have indicated an increase in necrosis and markers of apoptosis.	<ul style="list-style-type: none"> Mostly <i>high</i> and <i>medium</i> confidence studies Generally consistent findings regarding inflammatory changes and fatty changes/vacuola 	<ul style="list-style-type: none"> No increase in necrosis in <i>high</i> confidence studies 	⊕⊕⊖ <i>Moderate</i> Findings of histopathological changes (particularly inflammation-related effects and fatty changes/vacuolation) coupled with significant increases in ALT and AST are considered to be	Mechanistic findings in animals provide evidence supportive of histopathological endpoints in the liver. Oxidative stress was identified as a potential mechanism for liver effects in multiple animal species. This mechanism

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Rafael et al. (2007)		<p>tion across most species and sexes</p> <ul style="list-style-type: none"> • Coherence with increases in ALT and AST • Mechanistic evidence provides biological plausibility 		<p>adverse and a specific indication of liver injury.</p> <p>Hepatic effects were generally not observed following inhalation exposures.</p>	<p>is presumed relevant to humans.</p> <p>Hepatic effects were inconsistent following inhalation. Because of the first-pass effect, the liver may be affected more severely by Cr(VI) exposure via the oral route as compared to the inhalation route.</p>
<p>HISTOPATHOLOGY (Inhalation) Medium confidence: Kim et al. (2004) Low confidence: Glaser et al. (1985)</p>	<p>No histological changes in rats treated for 12 weeks or 18 months.</p>				
<p>CLINICAL CHEMISTRY (Oral) High confidence: Krim et al. (2013) NTP (2007) NTP (2008) Medium confidence: Navya et al. (2017a) Rafael et al. (2007) Wang et al. (2015) Elshazly et al. (2016) Low confidence:</p>	<p>Statistically significant elevations of ALT and AST seen across studies.</p> <p>Biologically significant increases in ALT (>100%) were observed across studies and at doses as low as 1–2 mg/kg-day.</p> <p>Changes to ALP were less consistent across the evidence base.</p>	<ul style="list-style-type: none"> • Consistent increases in ALT and AST • <i>High and medium</i> confidence studies • Magnitude of effect: large effect size for ALT and AST 	<ul style="list-style-type: none"> • No factors noted 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Acharya et al. (2001) Chopra et al. (1996) Meenakshi et al. (1989)		<ul style="list-style-type: none"> • Dose-response gradient within studies • Coherence with histopathology (inflammation and fatty changes) • Mechanistic evidence of oxidative stress provides biological plausibility 			
CLINICAL CHEMISTRY (Inhalation) Medium confidence: Kim et al. (2004) Low confidence: Glaser et al. (1985) Glaser et al. (1986)	No significant changes in enzymatic markers of liver damage (ALT, AST, ALP, SDH) following inhalation.				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>ORGAN WEIGHT (Oral) High confidence: NTP (2007) NTP (1997) Medium confidence: Chopra et al. (1996) Wang et al. (2015) Low confidence: (Younan et al., 2019)</p>	<p>Inconsistent findings for relative liver weight changes in <i>high</i> and <i>medium</i> confidence oral studies, with no change or decreased relative liver weight observed in <i>high</i> and <i>medium</i> confidence studies and evidence for increased relative liver weight primarily limited to <i>low</i> confidence studies.</p> <p>Decreases in absolute liver weight in mice likely correlated with body weight decreases seen at high doses.</p>	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Unexplained inconsistency across studies 		
<p>ORGAN WEIGHT (Inhalation) Medium confidence: Kim et al. (2004) Low confidence: Glaser et al. (1985) Glaser et al. (1986)</p>	<p>Changes in liver weight were inconsistent following inhalation exposures. One 18 month study observed a statistically and biologically significant (>10%) increase in relative liver weight (Glaser et al., 1986).</p>				
Mechanistic evidence					
Biological events or pathways	Summary of key findings and interpretations			Judgments and rationale	
Oxidative and endoplasmic reticulum stress	<p><i>Interpretation:</i> Consistent in vivo and in vitro evidence of Cr(VI)-induced oxidative and ER stress evidenced by increased lipid peroxidation, ROS, and decreased antioxidant enzyme activity concurrent with biomarkers of liver injury.</p> <p><i>Key findings:</i></p>			Biologically plausible, consistent, coherent observations of oxidative stress and endoplasmic reticulum	

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<ul style="list-style-type: none"> Consistent evidence of significant increases in lipid peroxidation in liver tissue in chronic, subchronic and acute dose animal studies (Navya et al., 2017a; Zhong et al., 2017c; Jin et al., 2014; Wang et al., 2010c; Bagchi et al., 2002; Bagchi et al., 2001; Bagchi et al., 2000; Bagchi et al., 1997; Bagchi et al., 1995b; Bagchi et al., 1995a; Kumar and Rana, 1982) Increased oxidative stress (decreased antioxidant enzyme activity) concurrent with serum biomarkers of liver injury (increased ALT, AST, and ALP) in a 28-day study in rats (Navya et al., 2017a) Increased oxidative stress (lipid peroxidation, free radical production) concurrent with serum biomarkers of liver injury (increased ALT and AST) in liver tissue in short-term and acute oral exposure studies in rats and mice (Zhong et al., 2017c; Wang et al., 2010c; Bagchi et al., 2002; Bagchi et al., 2001; Bagchi et al., 2000; Bagchi et al., 1995b; Kumar and Rana, 1982) In vitro evidence of increased ROS production and MDA and effects on antioxidant enzymes in human liver carcinoma cell lines (Zhong et al., 2017a; Zeng et al., 2013; Patlolla et al., 2009) In vitro evidence of ER stress-related mechanisms in human cells (Zhang et al., 2017) 			stress, mitochondrial dysfunction, inflammation, and apoptosis concurrent with apical observations of liver toxicity following (oral) exposures to Cr(VI) in animals, supported by in vitro evidence in human cells.	
Mitochondrial dysfunction	<p><i>Interpretation:</i> In vitro evidence in human liver cell lines of Cr(VI)-induced mitochondrial dysfunction.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> In vitro evidence of effects on mitochondrial function in human liver carcinoma cell lines (Zhong et al., 2017a; Zeng et al., 2013; Patlolla et al., 2009) In vitro evidence of increased mitochondrial stress in human fetal hepatocytes (Yi et al., 2017; Zhong et al., 2017c; Zhang et al., 2016; Xiao et al., 2014; Xie et al., 2014; Xiao et al., 2012a; Yuan et al., 2012a) 				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Inflammation	<p><i>Interpretation:</i> Consistent in vivo and in vitro evidence of Cr(VI)-induced liver inflammation.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Increased indicators of inflammation concurrent with serum biomarkers of liver injury (increased ALT and AST) in liver tissue in short-term and acute oral exposure studies in rats and mice (Zhong et al., 2017c; Wang et al., 2010c; Bagchi et al., 2002; Bagchi et al., 2001; Bagchi et al., 2000; Bagchi et al., 1995b; Kumar and Rana, 1982) In vitro evidence of the upregulation of pro-inflammatory cytokines and signaling molecules such as NF-κB, TNF-α, LBT4, and IL1β in human cells (Zhong et al., 2017c; Yi et al., 2016) 				
Apoptosis	<p><i>Interpretation:</i> Cr(VI) alters protein and gene expression of biomarkers associated with apoptosis in vivo concurrent with liver injury.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Increased expression of caspase-3 and histological changes indicative of apoptosis in a 10-week rat study (Rafael et al., 2007) Upregulated transcription of pro-apoptotic genes and downregulated transcription of anti-apoptotic genes concurrent with serum biomarkers of liver injury (increased ALT, AST, and ALP) in a 28-d rat study (Navva et al., 2017a) Upregulation of pro-apoptotic genes and proteins and downregulation of anti-apoptotic genes and proteins concurrent with serum biomarkers of liver injury (increased ALT and AST) in liver tissue in short-term and acute oral exposure studies in rats and mice (Zhong et al., 2017c; Wang et al., 2010c; Bagchi et al., 2002; Bagchi et al., 2001; Bagchi et al., 2000; Bagchi et al., 1995b; Kumar and Rana, 1982) In vitro evidence of the activation of apoptotic signaling cascades in human fetal hepatocytes (Yi et al., 2017; Zhong et al., 2017c; Zhang et 				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	al., 2016 ; Xiao et al., 2014 ; Xie et al., 2014 ; Xiao et al., 2012a ; Yuan et al., 2012a)				

3.2.5. Hematologic effects

1 Hematology is a subgroup of clinical pathology concerned with morphology, physiology,
 2 and pathology of blood and blood-forming tissues. Hematology parameters, as part of a routinely
 3 measured complete blood count (CBC), are described in Table 3-27. A CBC is a common blood test
 4 providing quantitative and qualitative information regarding the general health of a patient or
 5 research subject. Examples of quantitative information include total counts of red blood cells
 6 (RBCs), white blood cells (WBCs) and platelets; qualitative information, such as the RBC indices,
 7 give a morphological estimation of the RBC size and color. RBCs carry oxygen throughout the body,
 8 while WBCs are involved in immune function (discussed in Section 3.2.6) and platelets are involved
 9 in blood clotting. RBCs also carry most of the body’s iron, which can be indirectly measured in
 10 blood by measuring transferrin, a membrane-bound transporter of ferric (Fe⁺³) iron, and total iron
 11 binding in blood. Hematology along with clinical pathology measures (e.g., blood proteins,
 12 enzymes, chemicals and waste products) and other general health status indicators are useful for
 13 assessing overall health status, monitoring disease, and determining if follow-up testing is needed.

14 RBCs act as a sink for chromium in the blood. Cr(VI) is rapidly taken up by RBCs, where it is
 15 reduced to Cr(III) and remains trapped for the lifetime of the cell (see Section 3.1 and Appendix C
 16 for more details). After RBCs are broken down, the Cr(III) is released to systemic circulation and
 17 may be absorbed by other tissues or excreted in urine. Because Cr(III) cannot readily cross cell
 18 membranes, the RBC chromium level is commonly used as a biomarker for Cr(VI) exposure in
 19 industrial settings ([Miksche and Lewalter, 1997](#)). The focus of this section is primarily on RBCs and
 20 related components. Cr(VI) effects on white blood cell parameters are discussed in the context of
 21 the immune system in Section 3.2.6.

Table 3-27. Hematologic endpoints commonly evaluated in routine blood testing

Endpoint	Description
Hemoglobin (Hgb, g/dL)	Iron-containing oxygen-transport metalloprotein in RBCs
Hematocrit (Hct)	Percentage (by volume) of the blood that consists of RBCs Hematocrit (%) = MCV × RBC / 10
Red blood cell (RBC; erythrocyte) count	The most common blood cell responsible for systemic oxygen delivery. Expressed as number of RBCs per μL of blood
Reticulocytes	Immature non-nucleated RBCs containing residual RNA; indicates rate of new RBC production. The normal range depends on your level of hemoglobin. Hemoglobin is a protein in red blood cells that carries oxygen. The range is higher if hemoglobin is low, from bleeding or if red cells are destroyed.
Mean cell volume (MCV)	Average volume of the RBC MCV = hematocrit × 10 / RBC Low MCV: microcytic (smaller RBCs, possibly caused by iron deficiency and anemia); high MCV: macrocytic (larger RBCs, possibly caused by excess iron).
Mean cell hemoglobin (MCH)	Average weight of hemoglobin (Hgb) in the RBC

Endpoint	Description
	$MCH = Hgb \times 10 / RBC, (g/dL)$ Hemoglobin concentration normalized as amount of hemoglobin per cell. High MCH: may indicate macrocytic anemia (large red blood cell volume leading to low Hgb concentration), while low MCH may indicate other types of anemia (e.g., from iron deficiency).
Mean cell hemoglobin concentration (MCHC)	Average concentration of Hgb in the RBC volume $MCHC = Hgb \times 100 / \text{hematocrit} (g/dL)$ Hemoglobin concentration normalized to red blood cell volume. Low MCHC: hypochromic (RBCs paler than normal); high MCHC: hyperchromic (RBCs more pigmented than normal)

1 **3.2.5.1. Human Evidence**

2 Study evaluation summary

3 There are five studies that reported on the association between Cr(VI) exposure and
 4 hematologic parameters pertaining to the erythron (circulating RBC mass); specifically, complete
 5 blood counts (CBC), including RBC, hemoglobin (Hgb), and hematocrit (Hct). Four studies were
 6 classified as *low* confidence (Table 3-28). [Sazakli et al. \(2014\)](#) was limited due to exposure
 7 measurement; exposure was estimated using water intake and historic water concentration
 8 records as well as hair and blood concentrations. Correlations between these measures were low.
 9 It is likely that any exposure misclassification would be nondifferential and therefore lower the
 10 precision of the effect estimates but is less likely to bias the results away from the null. [Sharma et](#)
 11 [al. \(2012\)](#) was limited in most domains, and exposure classification was based on residence in a
 12 geographic area with contaminated groundwater, which does not distinguish the heterogeneity of
 13 exposure across exposed participants. [Lacerda et al. \(2019\)](#) was limited due to potential for
 14 selection bias and confounding and [Song et al. \(2012\)](#) was limited due to potential for confounding.
 15 The remaining study ([Khan et al., 2013](#)) was classified as *uninformative* because exposure
 16 classification was based on tannery work and there was insufficient information provided on the
 17 specific tanning processes used at the facility to infer Cr(VI) exposure³⁸.

³⁸Leather tanning processes that can potentially lead to Cr(VI) exposure include: 1) use of a two-bath process, 2) on-site production of tanning liquors, and 3) leather finishing steps that involve Cr(VI) (e.g., use of Cr(VI)-containing pigments) ([Shaw Environmental, 2006](#)). If these processes are not specified by the study, it cannot be determined whether exposure was to Cr(VI) or Cr(III).

Table 3-28. Summary of human studies for Cr(VI) hematologic effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.

[Click to see interactive data graphic for rating rationales.](#)

Author (year)	Industry	Location	Exposure Measurement	Study Design	Clinical Pathology
Lacerda et al. (2019)	Chrome-plating workers	Brazil	Exposure group validated by urine, blood sampling	Cross-sectional	L
Sazakli et al. (2014)	General population	Greece	Urine, Hair, Modeled lifetime chromium exposure dose	Cross-sectional	L
Sharma et al. (2012)	General population	India	Residence in geographic area with contaminated groundwater vs. control	Cross-sectional	L
Song et al. (2012)	Chromate production workers	China	Work category validated by air, blood sampling	Cross-sectional	L
Khan et al. (2013)	Tannery	Pakistan	Blood, Urine, Work category	Cross-sectional	U

1 Synthesis of evidence in humans

2 One of the included *low* confidence studies ([Sazakli et al., 2014](#)) reported statistically
3 significant decreases in Hgb and Hct (Table 3-29), inconsistent with another *low* confidence study
4 that reported statistically significant increases in the same endpoints ([Lacerda et al., 2019](#)). [Song et](#)
5 [al. \(2012\)](#) reported no association with hemoglobin but did not report on hematocrit. Another *low*
6 confidence study reported higher RBC counts and lower mean cell volume (MCV) in exposed
7 participants, stratified by sex (all statistically significant except MCV in women) ([Sharma et al.,](#)
8 [2012](#)). None of the other studies reported an association between Cr(VI) exposure and RBC count,
9 and none examined associations with diagnosed anemia, other hematological disease, or
10 hematologic parameters dichotomized based on clinical adversity. Platelet findings were also
11 inconsistent. [Sharma et al. \(2012\)](#) reported lower platelets in exposed participants, while [Sazakli et](#)
12 [al. \(2014\)](#) reported higher platelets with higher exposure, both statistically significant.

Table 3-29. Associations between Cr(VI) and hematologic parameters in epidemiology studies

Reference, confidence	Population	Exposure comparison and effect estimate	RBC (10 ¹² /L)	Hgb (g/dL)	Hct (%)
Lacerda et al. (2019) , low	Cross-sectional in Brazil, chrome-plating workers (n = 50) and controls (n = 50)	Means ± SD for chromium unexposed/exposed	Unexposed: 5.34 ± 0.79 Exposed: 5.95 ± 0.90	Unexposed: 14.16 ± 0.40 Exposed: 15.70 ± 0.14*	Unexposed: 39.18 ± 0.49 Exposed: 43.30 ± 0.36*
Sazakli et al. (2014) , low	Cross-sectional in Greece, general population; Two exposure groups (n = 237) and controls (n = 67)	Regression coefficients for calculated lifetime exposure dose and Cr in hair	Lifetime: 0.007 Hair: -0.09	Lifetime: -0.09* Hair: -0.06	Lifetime: -0.09* Hair: -0.1*
Sharma et al. (2012) , low	Cross-sectional in India, general population with residence in contaminated area (n = 186) or not (n = 230)	Means ± SD for chromium unexposed/exposed	Males Unexposed: 4.28 ± 0.69 Exposed: 5.55 ± 1.39* Females Unexposed: 3.89 ± 0.71 Exposed: 5.67 ± 1.26*	NR	NR
Song et al. (2012) , low	Cross-sectional in China, chromate production workers (n = 100) and controls (n = 80)	Means ± SD for chromium unexposed/exposed	Unexposed: 4.7 ± 0.4 Exposed: 4.8 ± 0.8	Unexposed: 144.8 ± 12.6 Exposed: 148.8 ± 27.2	NR

*p < 0.05. Shading indicates results supportive of an association between Cr(VI) and hematologic parameters in the direction of anemia (i.e., decrease in red blood cells, hemoglobin, and hematocrit).

NR: not reported.

1 Due to inconsistent results across *low* confidence studies, there is no clear evidence of an
 2 association between Cr(VI) exposure and hematologic effects in humans. Conflicting results may
 3 stem from differences in exposure scenarios, exposure assessment methods, and study sensitivity.
 4 Because this is a very limited evidence base in terms of number and confidence of studies, further
 5 exploration of patterns by exposure levels or type of analysis is not possible.

6 **3.2.5.2. Animal Evidence**

7 Study evaluation summary

8 Table 3-30 provides a summary of the animal toxicology studies considered in the
 9 evaluation of the hematologic effects of Cr(VI). The available evidence included 14 studies
 10 conducted in rats (three strains) and mice (three strains). Exposure durations and routes included

1 one chronic oral study ([NTP, 2008](#)), one subchronic oral study ([NTP, 2007](#)), seven oral 3–9 week
 2 studies ([Wang et al., 2015](#); [Krim et al., 2013](#); [NTP, 2006a, b, 2005, 1996a, b](#)), one study conducted
 3 using NTP’s Reproductive Assessment by Continuous Breeding (RACB) protocol ([NTP, 1997](#)), and
 4 four inhalation studies ranging from short-term to chronic exposure durations ([Kim et al., 2004](#);
 5 [Glaser et al., 1990](#); [Glaser et al., 1986](#); [Glaser et al., 1985](#)).

6 Of the 15 included studies, 10 were considered *medium* or *high* confidence studies, and
 7 included eight National Toxicology Program (NTP) studies with exposure durations ranging from 4
 8 days to 12 months (Table 3-30). Three of the four inhalation studies and one of the 11 oral studies
 9 that examined hematologic endpoints were considered *low* confidence mostly because of limited
 10 reporting of study methods and/or results. Six additional studies with hematologic data were
 11 judged *uninformative* based on critical deficiencies identified when the studies were evaluated
 12 (i.e., [Anwar et al. \(1961\)](#) mixed animals of different breeds; [Kumar and Barthwal \(1991\)](#) did not use
 13 concurrent controls; [Shrivastava et al. \(2005a\)](#) lacked information on sex, number of mice, and
 14 control group; and [Zabulyte et al. \(2009\)](#) and [Zabulyte et al. \(2006\)](#) had multiple deficiencies
 15 including randomization procedures, lack of vehicle control, and others). [MacKenzie et al. \(1958\)](#)³⁹
 16 was rated uninformative due to insufficient reporting of the outcomes, mortality due to a
 17 respiratory infection, and sample sizes of evaluated animals. Full study evaluation details are
 18 available in [HAWC](#).

Table 3-30. Summary of included studies for Cr(VI) hematologic effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a
[Click to see interactive data graphic for rating rationales.](#)

Author (year)	Species (strain)	Exposure design	Exposure route	Hematologic outcomes ^b
Glaser et al. (1985)	Rat (Wistar), male	28 and 90 d	Inhalation	L
Glaser et al. (1986)	Rat (Wistar), male	18 months	Inhalation	L
Glaser et al. (1990)	Rat (Wistar), male	30 and 90 d	Inhalation	L
Kim et al. (2004)	Rat (Sprague-Dawley), male	90 d	Inhalation	M
Krim et al. (2013)	Rat (Wistar), male	30 d	Oral (Gavage)	M
NTP (1996a)	Mouse (BALB/c)	3, 6, and 9 wk	Oral (Diet)	H
NTP (1996b)	Rat (Sprague-Dawley)	3, 6, and 9 wk	Oral (Diet)	H
NTP (1997)	Mouse (BALB/c)	Continuous breeding design	Oral (Diet)	H

³⁹Normally in situations concerning poor reporting, authors may be contacted for clarifications that may result in upgraded confidence ratings, but this was not possible due to the age of the publication. This study was the basis of the previous RfD posted to IRIS in 1998 ([U.S. EPA, 1998c](#)).

Toxicological Review of Hexavalent Chromium

Author (year)	Species (strain)	Exposure design	Exposure route	Hematologic outcomes ^b
NTP (2005)	Mouse (B6C3F1), female	28 d	Oral (Drinking water)	H
NTP (2007)	Rat (F344/N) Mouse (B6C3F1) Mouse (B6C3F1, BALB/c, <i>am3</i> -C57BL/6), male—comparative toxicity study	90 d	Oral (Drinking water)	H
NTP (2008)	Rat (F344/N), male Mouse (B6C3F1), female	2 yr	Oral (Drinking water)	H
NTP (2006b)	Rat (Sprague-Dawley), female	28 d	Oral (Drinking water)	M
NTP (2006a)	Rat (F344), female	28 d	Oral (Drinking water)	M
Samuel et al. (2012a)	Rat (Wistar), female	Pregnant dams, GD 9–21	Oral (Drinking water)	L
Wang et al. (2015)	Rat (Sprague-Dawley), male	28 d	Oral (Drinking water)	M

^aStudies in this table were ordered first by route of exposure, and then by confidence rating. Within a confidence rating, studies were ordered chronologically.

^bWithin each study, multiple hematologic outcomes (such as those in Table 3-27) were typically measured using analytical methods for complete blood counts. For this reason, multiple outcome sensitivity ratings are not presented.

1 Synthesis of evidence in animals

2 Evidence informing Cr(VI) effects on hematologic endpoints was available from several
3 (mostly short-term) *medium* and *high* confidence oral exposure studies (Table 3-30). There were
4 two *high* confidence studies, one subchronic ([NTP, 2007](#)) and one chronic ([NTP, 2008](#)) bioassay,
5 reporting hematologic outcomes in F344 rats and B6C3F1 mice that were useful for evaluating the
6 potential subchronic and lifetime hematologic effects of Cr(VI) exposure in humans. Both studies
7 are discussed below in detail and are summarized in [HAWC](#) and in Figure 3-22 below (note that
8 only observation times at 90 days and greater are presented).⁴⁰ Methodological considerations for
9 evaluating hematology findings in general included alterations in water intake, fasted/fed status,
10 life stage, and sex.

⁴⁰Older data from other *medium* and *high* confidence studies performed by the National Toxicology Program ([NTP, 2006a, b, 2005, 1997, 1996a, b](#)) are consistent with results by NTP ([2008, 2007](#)). Only the most recent NTP results are synthesized, because they provide data at a wide dose range for multiple species and strains, and also provide data from multiple timepoints within its 2-year study.




Figure 3-22. Hematology findings from NTP (2007) and NTP (2008) in rats and mice exposed by gavage to Cr(VI) for 90 days or 12 months (full details available in HAWC).

1 Direct measures of hematopoietic health include RBCs, Hgb, and Hct levels (see Table 3-27).
2 RBCs were increased across study designs, sexes, and species in both a *high* confidence subchronic
3 study ([NTP, 2007](#)) and a *high* confidence chronic bioassay ([NTP, 2008](#)) (Figure 3-22). Statistically
4 significant treatment effects corresponded with an approximately 2–4% change in the 20 mg/L
5 dose group, 4–8% change at 60 mg/L, and 5–18% change from controls in the 180 mg/L dose group
6 ([NTP, 2008](#)) (click to view [RBC findings](#))⁴¹. Note that RBC counts were greater at 90 days than 12
7 months within each dose group and sex. [Hgb](#) was decreased in both male and female rats and
8 female mice at 9 and 12 month observation times at doses ≥ 174.5 mg/L. The magnitude of change
9 was <5% from control mean for all findings except in the ≥ 174.5 mg/L dose groups. [Hct](#) increased
10 in female mice at 90 days and decreased in male and female rats at doses ≥ 174.5 mg/L. No changes
11 in Hct were observed in either species at 12 months Cr(VI) exposure.

12 The RBC, Hgb, and Hct findings at 90 days were considered to be potentially adverse based
13 on data from *high* confidence studies showing a large magnitude of change, increasing responses
14 with dose, and consistency across species and sexes, supported by coherent changes in other RBC
15 indicators (MCV, MCH, and MCHC). The adversity of effects at 12 months, however, were less
16 certain and potentially adaptive. Decreased mean cell volume ([MCV](#)) values (i.e., smaller RBCs)
17 were consistently observed across study designs, sexes, and species (although male rats were the
18 most sensitive) in both *high* confidence NTP bioassays ([NTP, 2008, 2007](#)), but while MCV decreases
19 were dose-responsive across rat 90 day observation times, with a maximal response of a ~30%
20 change from control in male rats receiving 349 mg/L for 90 days, when comparing the MCV
21 response to Cr(VI) exposure from 90 days to 12 months, the 12 month response was less robust
22 (23% decrease compared with 7% at 12 months). Cr(VI) effects on [MCH](#) were consistent and
23 coherent with MCV; decreases were dose-responsive across 90 day and 12 month observation
24 times, with a maximal response of ~30% at 349 mg/L (90 days), but similar to MCV, the response
25 was less intense at 12 months (~8% decrease from control) compared with same dose at 90 day
26 observation time (~27% change) in rats. The [MCHC](#) response to Cr(VI) exposure in rats and mice
27 was muted compared with MCV and MCH, with a maximum response of 5–10% change from control
28 in male and female rats exposed for 90 days to ≥ 174.5 mg/L. The dose-response was less clear at
29 12 months exposure. The pattern of response, however, was similar to MCH and MCV when
30 comparing the MCHC response between exposure durations and species, with a greater response at
31 90 days compared to 12 months, and in rats compared with mice.

⁴¹Exposures for [NTP \(2008\)](#) and [NTP \(2007\)](#) are expressed in the text as concentration in drinking water (mg Cr(VI)/L) rather than daily dose (in mg Cr(VI)/kg-day). Differences in rodent drinking water consumption rates relative to body weight during the growth period lead to different mg/kg-d doses at the different collection times within the same exposure group of the 2-year study. Discussion in units of drinking water concentrations simplifies the group-level comparisons. Estimates of time weighted average daily doses at different observation time are available [here](#) (for [NTP \(2008\)](#)) and [here](#) (for [NTP \(2007\)](#)). At 20 mg/L Cr(VI) in rats for the 2-year study, the time weighted average dose was 2 mg/kg-d at 22 days, 1.5 mg/kg-d at 90 days, and 0.88 mg/kg-d at 1 year.

1 Reticulocytes (RET) and nucleated reticulocytes are immature RBCs and their levels may
2 indicate alterations in RBC production ([Whalan, 2015, 2000](#)). Reticulocytes and nucleated
3 erythrocytes were [increased](#), but the finding was inconsistent across species and sexes, with no
4 changes observed in mice, and with increases observed in male rats only at the maximum dose
5 ([NTP, 2008, 2007](#)) and in all female rat dose groups at 90 days ([NTP, 2007](#)). Microscopic evaluation
6 of blood smears at exposure durations up to 90 days identified erythrocyte fragments and
7 keratocytes (evidence of stress or damage to the bone marrow and evidence of increased RBC
8 injury or turnover) ([NTP, 2008, 2007](#)). Similar microscopic findings from blood smears were not
9 observed after 12 months Cr(VI) exposure.

10 Although the focus of the assessment is on the development of chronic reference values, it is
11 noted that hematologic effects were observed in studies with exposure durations <90 days. In
12 general, the direction of change was similar to the later time points, but the magnitude of response
13 was greater at observation times <90 days. For example, [Hgb](#) decreased by up to 35% at 22 days,
14 but 15% at 90 days, and a similar amelioration was observed for [MCV](#) and other hematological
15 markers ([NTP, 2008](#)). Other *medium* and *high* confidence studies were also available at exposure
16 durations ≤9 weeks. In general, these studies reported limited or no statistically significant changes
17 in hematologic parameters at the same dose levels where effects were observed in the subchronic
18 and chronic studies. Decreased MCV and MCH levels (≤6%) were observed in Sprague-Dawley rats
19 exposed to ≥10 mg Cr(VI)/kg-day (via diet) for up to 9 weeks ([NTP, 1996b](#)). In two other 28-day
20 studies by NTP, hematologic effects at doses ≥9 mg Cr(VI)/kg-day exposure (via drinking water)
21 were not observed for RBCs, hemoglobin, hematocrit, and MCHC in female Sprague-Dawley and
22 F344 rats ([NTP, 2006a, b](#)). MCV and MCH findings were not dose responsive nor considered
23 biologically meaningful.

24 The hematologic effects of inhalation exposure were reported in one *medium* confidence
25 study ([Kim et al., 2004](#)) where findings included increased RBC count (8%), decreased hematocrit
26 (≤11%), and decreased hemoglobin (≤8%) in Sprague-Dawley rats exposed for 90 days to Cr(VI)
27 concentrations ranging from 0.2–1.25 mg/m³. No effects on MCV or MCHC were observed. No
28 effects on RBCs were reported in male Wistar rats in three *low* confidence studies with exposure
29 durations that ranged from 28 days to 18 months ([Glaser et al., 1990](#); [Glaser et al., 1986](#); [Glaser et](#)
30 [al., 1985](#)), whereas the 30- and 90-day experiments did not specify which hematologic parameters
31 were examined. The highest concentrations tested ranged from 0.1–0.4 mg/m³; the highest
32 concentration tested in the 18-month study by [Glaser et al. \(1986\)](#) (0.1 mg/m³) was lower than the
33 lowest concentration tested by [Kim et al. \(2004\)](#) (0.2 mg/m³).

34 **3.2.5.3. Mechanistic Evidence**

35 The subchronic and chronic studies provide evidence for microcytic hypochromic anemia
36 (characterized by low Hgb concentrations in abnormally small RBCs) after 90 days. After 12
37 months exposure, most findings returned to near control levels (Hgb, Hct, MCHC). The clinical
38 pathology and microscopic evaluation indicated small RBCs (microcytic) that were hypochromic

1 (pale in color, consistent with decreased Hgb). The mechanistic studies described below provide
2 evidence for connecting these findings to upstream events, including altered iron metabolism
3 leading to iron deficiency, and oxidative stress potentially leading to RBC damage, smaller size, and
4 increased turnover.

5 Effects on iron homeostasis

6 Iron is a critical requirement for metabolic processes including oxygen transport,
7 deoxyribonucleic acid (DNA) synthesis, and electron transport ([Abbaspour et al., 2014](#)). Iron
8 imbalance, deficiency, and overload have known health effects in humans including iron-deficient
9 anemia and iron toxicity. Iron is absorbed from the diet by villous enterocytes in the small
10 intestine. Cellular iron import involves both receptor-mediated endocytosis (by transferrin) of
11 ferric iron (Fe^{+3}) as well as uptake of reduced iron ferrous iron (Fe^{+2}) by membrane-bound
12 transporters. A majority of the iron is contained by RBCs where iron is stored in complexes with
13 ferritin (in the ferric state), complexed by heme in the ferrous state (Fe^{+2}), or to a smaller extent
14 labile in the cytosolic pool in the ferrous state (Fe^{+2}). Several studies provided evidence that Cr(VI)
15 intereferes with iron homeostasis, thereby decreasing iron bioavailability. Although blood iron
16 measures were not available from the NTP studies, a subchronic study by [Suh et al. \(2014\)](#) reported
17 a dose-responsive reduction in iron levels in serum, duodenum, liver, and bone marrow in F344
18 rats and B6C3F1 mice administered Cr(VI) (as sodium dichromate dihydrate) in drinking water for
19 90 days (0.1–180 mg Cr(VI)/L) compared to controls. Decreased iron was accompanied by altered
20 expression of genes involved in iron transport and absorption. Based on these findings and the
21 knowledge that Cr(VI), Cr(V), and Cr(IV) can oxidize ferrous iron (Fe^{+2}) to ferric iron (Fe^{+3}) ([Buerge](#)
22 [and Hug, 1997](#); [Fendorf and Li, 1996](#)), [Suh et al. \(2014\)](#) hypothesized that Cr(VI) may oxidize
23 ferrous (Fe^{+2}) iron to ferric (Fe^{+3}), thereby interfering not only with (Fe^{+2}) absorption in the
24 intestinal lumen, but also competing with (Fe^{+2}) for heme binding and ferric iron (Fe^{+3}) storage by
25 ferritin in RBCs. Cr(VI), but not Cr(III) ([NTP, 2010](#); [Stout et al., 2009](#)), hinders iron aborption in the
26 small intestine, leading to iron deficiency in rats and to a lesser extent in mice. Consistent with this
27 hypothesis, Cr(VI) reduced to Cr(III) has been shown to bind transferrin under physiological
28 conditions ([Levina et al., 2016](#); [Deng et al., 2015](#)). Consistent with [Suh et al. \(2014\)](#), [Wang et al.](#)
29 [\(2015\)](#) also observed dose-related decreases in iron levels in the liver, kidney, duodenum, and lung
30 in rats exposed to concentrations up to 106.1 mg/L Cr(VI) in drinking water for four weeks; no
31 changes were detected in blood iron levels, but significant decreases in Hgb, MCH, and MCHC levels
32 and increased RBC counts were observed. This evidence that Cr(VI) can inhibit iron absorption
33 suggests that humans with preexisting blood conditions (e.g., anemia, iron deficiency, intestinal
34 bleeding disorders) would be expected to be more sensitive to any potential hematologic effects of
35 Cr(VI) exposure. This includes pregnant women, who are susceptible to developing iron-deficient
36 anemia ([American Pregnancy Association, 2021](#); [O'Brien and Ru, 2017](#); [Rahman et al., 2016](#)).

37 Oxidative stress, RBC membrane damage and eryptosis

1 Both iron deficiency and Cr(VI) exposure have been shown to independently increase
2 oxidative damage. Potassium dichromate, like iron, is a charged heavy metal, and it has been
3 proposed that interaction between iron bound by RBCs alters erythrocyte function and/or
4 formation particularly by targeting the erythron ([NTP, 2007, 1997, 1996a, b](#)). Cr(VI) redox results
5 in oxidative damage both to hemoglobin and to the RBC membrane ([ATSDR, 2012; NTP, 2007](#)). The
6 increased oxidative damage can initiate pathways leading to erythrocyte injury and eryptosis
7 (i.e., erythrocyte apoptosis) as well as smaller RBCs ([Kempe et al., 2006](#)), consistent with
8 observations of decreased MCV in rats and mice ([NTP, 2008, 2007](#)).

9 As discussed in Section 3.2.1, “Respiratory effects other than cancer,” evidence of oxidative
10 stress (i.e., increased oxidative 8-OHdG DNA adducts and lipid peroxidation levels, decreased
11 antioxidant levels) has been detected at significant levels in the blood (RBCs, plasma, serum) of
12 workers exposed to Cr(VI) ([El Safty et al., 2018; Hu et al., 2018; Xu et al., 2018; Mozafari et al., 2016;](#)
13 [Elhosary et al., 2014; Zendejdel et al., 2014; Kalahasthi et al., 2006; De Mattia et al., 2004; Maeng et](#)
14 [al., 2004; Wu et al., 2001; Huang et al., 1999; Gromadzińska et al., 1996](#)) (see Appendix Table C-56).
15 In animals, one 4-week drinking water study in male F344 rats exposed to 10.6–106 mg Cr(VI)/L
16 and found increased plasma malondialdehyde (MDA), a reactive marker of lipid peroxidation, and
17 decreased glutathione peroxidase (GSH-Px), an antioxidant enzyme ([Wang et al., 2015](#)). Other
18 findings consistent across in vitro studies with primary human RBCs included observation of
19 oxidative stress indicators and eryptosis, including increased MDA levels, changes in antioxidant
20 activity, increased cytosolic Ca²⁺, increased phosphatidylserine on the outer membrane surface, and
21 decreased ATP ([Sawicka and Długosz, 2017; Zhang et al., 2014; Lupescu et al., 2012; Ahmad et al.,](#)
22 [2011; Fernandes et al., 1999; Koutras et al., 1964](#)). These effects indicate a loss of membrane
23 integrity, coherent with the microscopic evaluations of blood smears from exposed rats and mice,
24 where evidence of erythrocyte injury, including poikilocytes, erythrocyte fragments/schizocytes,
25 and keratocytes, were observed after 90 days of Cr(VI) exposure in drinking water ([NTP, 2008,](#)
26 [2007](#)). Collectively, the findings of RBC oxidative stress leading to cell membrane damage and
27 eryptosis are a possible pathway leading to the observed changes in RBC size, and are correlative
28 with an erythrogenic response supported by increased RBC counts. However, study durations were
29 limited to ≤90 days and it is not clear if these mechanistic effects would be persistent long-term.

30 **3.2.5.4. Integration of Evidence**

31 Overall, the currently available **evidence suggests** that Cr(VI) exposure may cause
32 hematologic effects in humans. The conclusion of *evidence suggests* is based primarily on *moderate*
33 animal evidence from *high* and *medium* confidence subchronic and chronic studies in rats and mice
34 reporting consistent (across similar exposure durations and doses, sexes, and species), dose-
35 related, and coherent findings (i.e., in RBC, Hgb, MCHC, MCH, and MCV) at 90 days exposure. The
36 *indeterminate* human evidence consists of four *low* confidence studies that show inconsistent
37 effects on hematocrit and hemoglobin (positive, negative, and null associations). One *low*

1 confidence study identified increased RBC and decreased MCV in exposed humans, whereas the
2 other *low* confidence studies identified no association with RBCs. No epidemiological study was
3 identified that evaluated associations with exposure to Cr(VI) and anemia or other hematological
4 diseases or parameters.

5 Confidence in the findings in animal studies, however, is diminished due to the decrease in
6 magnitude of the collective effect by 12 months, with many findings returning to normal or near
7 normal levels (generally, with a magnitude of change <10% compared to controls). Given the
8 absence of correlative findings of apparent RBC injury from blood smears (other than smaller RBCs
9 that were hypochromic) and the absence of supportive mechanistic findings (such as iron
10 deficiency and oxidative stress) at 12 months, there exists uncertainty regarding the adverse versus
11 adaptive nature of the observed effects at exposure durations greater than 90 days. In particular,
12 the biological significance of the response at 12 months is uncertain, since most markers were
13 within 10% of controls.

14 Although the adversity or clinical relevance of the observed changes in any one of the
15 individual hematologic parameters in isolation is unclear and there is uncertainty in the adversity
16 of the effect at 12 months, the interpretation of the collective animal evidence still signals a
17 potential concern. Supporting evidence of Cr(VI)-induced iron deficiency and oxidative stress
18 indicates potential pathways leading to the observed findings of hypochromic microcytic anemia,
19 consistent with the microscopic evaluation of blood smears (with findings of damage to the
20 erythron), strengthens the evidence for an effect at 90 days. Information including iron levels and
21 ferritin tests that are useful for evaluating the amount of stored iron were not available at exposure
22 durations >90 days, making it difficult to confirm whether the diminished effects at 12 months
23 should be considered adverse. Therefore, although there remains a (weaker) signal for an effect at
24 12 months, there exists a large amount of uncertainty as to the adversity of the effect. Integrated
25 evidence for the hematologic effects of Cr(VI) exposure from human, animal, and mechanistic
26 studies is summarized in an evidence profile table (Table 3-31). However, the mechanistic
27 evidence suggests that humans with preexisting blood conditions (e.g., anemia, iron deficiency,
28 intestinal bleeding disorders) would be expected to be more sensitive to any potential hematologic
29 effects of Cr(VI) exposure. This includes pregnant women, who are susceptible to developing iron-
30 deficient anemia ([American Pregnancy Association, 2021](#); [O'Brien and Ru, 2017](#); [Rahman et al.,
31 2016](#)).

Table 3-31. Evidence profile table for hematologic effects

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from studies of exposed humans					⊕⊕⊖
HEMATOLOGIC PARAMETERS Four <i>low</i> confidence studies, two in occupationally exposed adult workers and two in general population adults	Exposure to Cr(VI) was associated with lower hemoglobin and/or hematocrit in one study ($p < 0.05$), while two studies reported in the opposite direction (higher hemoglobin and hematocrit in one study, higher red blood cells in one), and one study reported no association.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> <i>Low</i> confidence studies 	⊖⊖⊖ <i>Indeterminate</i> The available evidence is inconsistent across <i>low</i> confidence studies.	The evidence suggests that Cr(VI) may cause hematologic effects in humans given sufficient exposure conditions. Consistent findings in <i>high</i> and <i>medium</i> confidence animal studies across species and dose duration with coherent effects on RBC indices and decreased Hgb suggesting microcytic anemia, with supportive mechanistic findings of Cr(VI)-induced iron deficiency and RBC damage. However, the confidence in these findings is reduced by the uncertainty regarding the adverse versus adaptive nature of the observed effects, particularly given the near amelioration of effects after one year, precluding a higher confidence judgment (i.e., <i>evidence indicates</i>). Human evidence was primarily inconsistent and <i>low</i> confidence. Without evidence to the contrary, effects in rats and mice are considered relevant to humans.
Evidence from animal studies					
Hematology Six <i>high</i> confidence studies in adult rats and mice <ul style="list-style-type: none"> 28-day oral 9-week oral (2 studies) Continuous breeding oral 90-day oral 2-year oral Five <i>medium</i> studies in adult male and female rats	Hematologic effects included consistent decreases in Hgb, MCV, MCH, and MCHC, and increased RBC counts at 90 days; marginal (near low-normal) decreases in MCV, MCH and increase in RBC at 12 months. Most findings returned to near normal by 12 month exposures. 90 day findings were coherent with microscopic findings of RBC damage including smaller size and hypochromic appearance that were consistent with Cr(VI)-induced iron deficiency.	<ul style="list-style-type: none"> Consistent findings of decreased Hgb, MCH, MCHC, MCV, and increased RBC across species and sexes in subchronic and chronic studies Coherence of decreased Hgb, MCH, MCHC, and MCV with increased RBC 	<ul style="list-style-type: none"> Lack of duration-dependence (effects of Cr(VI) decreased with longer-term exposures) Uncertainty of the biological significance of effects at 12 months 	⊕⊕⊖ <i>Moderate</i> Based primarily on <i>high</i> and <i>medium</i> confidence subchronic and chronic studies with consistent findings across species and sexes and coherent effects across multiple related endpoints. Strong dose response relationship primarily at 90 days, though some uncertainty in biological relevance of	

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<ul style="list-style-type: none"> • 28-day oral (3 studies) • 30-day oral • 90-day inhalation <p>Four <i>low</i> confidence studies in male rats and mice</p> <ul style="list-style-type: none"> • 28- and 90-day inhalation (2 experiments, 1 study) • 30- and 90-day inhalation (2 experiments, 1 study) • 18-month inhalation • Short-term oral study during pregnancy 	<p>Hct and reticulocyte changes were inconsistent across species and sexes.</p>	<ul style="list-style-type: none"> • <i>High and medium</i> confidence studies • Large magnitude of effect ≤90 days • Dose-response gradient for RBC, MCH, MCV, MCHC, Hgb (rat, 90-day) • Mechanistic evidence provides biological plausibility 		<p>the effect as the magnitude of the change compared to controls decreased by 12 mo.</p> <p>Strong mechanistic support for anemia provided by mechanistic studies demonstrating Cr(VI) induced iron deficiency and oxidative damage in the blood of exposed humans and animals, and regenerative responses consistent with smaller RBC size.</p>	<p>Mechanistic findings of iron deficiency and altered pathways involved in iron metabolism in rats exposed for ≤90 days provide evidence supportive of hematologic effects. These mechanisms are presumed to be relevant to humans and are consistent with findings of oxidative stress in the blood of occupationally exposed humans.</p> <p>People with preexisting blood conditions (e.g., anemia, iron deficiency, chronic intestinal bleeding disorders, pregnancy) are expected to be susceptible to hematological effects from Cr(VI).</p>

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Mechanistic Evidence					
Biological events or pathways	Summary of key findings and interpretation			Judgments and rationale	
Oxidative Stress	<p><i>Interpretation:</i> Oxidative stress caused by Cr(VI) reactive intermediates may lead to erythrocyte lipid peroxidation, membrane damage, and eryptosis.</p> <p><i>Key Findings:</i></p> <ul style="list-style-type: none"> • Consistent evidence of oxidative stress in the blood of workers exposed to Cr(VI) (see Section 3.2.1, “Respiratory effects other than cancer”) • Increased oxidative stress levels in plasma in one in vivo study of rats exposed in drinking water for 4 weeks • Cr(VI) increased markers of oxidative stress, cellular injury and death in primary human RBCs in vitro, including MDA, decreased antioxidant enzymes, increased cytosolic Ca²⁺, membrane destabilization, and decreased ATP 			<p>Biologically plausible pathways leading to the observed clinical pathology and microscopic evaluation of blood smears that included Cr(VI) oxidation of ferrous to ferric iron, potentially altering bioavailability, oxidative damage to the RBC leading to increased turnover and smaller size, and Cr(VI) interference with iron metabolism leading to iron deficiency. Support for oxidative stress occurring in the blood of humans is provided by consistent findings of increased markers of oxidative stress in exposed workers.</p>	
Iron Deficiency	<p><i>Interpretation:</i> Interference with iron homeostasis due to interactions with Hgb, iron and its transporter proteins may also contribute to hematologic toxicity.</p> <p><i>Key Findings:</i></p> <ul style="list-style-type: none"> • Cr(VI) interaction with iron may alter RBC binding and erythrocyte function or formation • Cr(VI) reduced to Cr(III) may bind transferrin, an iron transporter, under physiological conditions • Additional in vivo evidence suggests Cr(VI)-induced alterations in iron homeostasis including dose-dependent decreases in total iron in various tissues, altered gene regulation, and increased ratios of RBC Cr(VI):plasma Cr(VI) 				

3.2.6. Immune effects

1 The purpose of the immune system is to provide protection from infections and, in some
2 cases, the development of neoplasms. A properly functioning immune system involves a delicate
3 interplay among many cell types working in concert to properly regulate the immune response.
4 The immune system is integrated into tissues, organs and peripheral sites throughout the body. For
5 this reason, xenobiotic exposure by virtually any route can adversely impact components of the
6 immune system. Modulation of the immune system in either direction can result in dysfunction.
7 Xenobiotic exposure can alter primary immune sites important for immune cell maturation,
8 including the bone marrow, liver, thymus, and Peyer's patches. Secondary lymphoid sites
9 (i.e., spleen, lymph nodes, tonsils) can also be impacted by exposure to immunotoxicants.
10 Immunotoxicity may be expressed as immunosuppression, unintended stimulation of immune
11 responses, hypersensitivity, or autoimmunity ([IPCS, 2012](#)). Data from functional assays provide the
12 most sensitive and specific evidence of immune hazard.

13 This synthesis is organized and summarized based on the World Health Organization's
14 *Guidance for Immunotoxicity Risk Assessment for Chemicals* ([IPCS, 2012](#)) that describes best
15 approaches for weighing immunotoxicological data. Within this framework, data from endpoints
16 observed in the absence of an immune stimulus (e.g., levels of serum immunoglobulins, white blood
17 cell (WBC) counts, WBC differentials, T cell subpopulations, immune organ weights) are not
18 sufficient on their own to draw a conclusion regarding immune hazard but may provide useful
19 supporting evidence, especially when evaluated in the broader context of functional data ([IPCS,](#)
20 [2012](#)). Consequently, the sections that follow are organized into two categories: the more
21 informative measures of immune system function and supporting immune system data.

3.2.6.1. Human Evidence

Study evaluation summary

24 Table 3-32 summarizes the human epidemiology studies considered in the evaluation of the
25 potential effects of Cr(VI) on the immune system. There were nine included human studies, all of
26 which were classified as *low* confidence. Four additional studies were identified and classified as
27 *uninformative* due to critical deficiencies in exposure methods sensitivity and/or confounding and
28 were not considered further ([Islam et al., 2019](#); [Khan et al., 2013](#); [Katiyar et al., 2008](#); [Snyder et al.,](#)
29 [1996](#)). All nine included studies were cross-sectional, and all but one were occupational studies
30 conducted among workers in industries with known risk of exposure to Cr(VI), in a range of
31 geographical locations. They include two studies of chrome-plating workers ([Kuo and Wu, 2002](#);
32 [Verschoor et al., 1988](#)), two studies of tannery workers ([Mignini et al., 2009](#); [Mignini et al., 2004](#)),
33 two studies of chemical plant workers ([Qian et al., 2013](#); [Tanigawa et al., 1998](#)), one study of
34 chromate production workers ([Wang et al., 2012a](#)) and one study of plastic workers ([Boscolo et al.,](#)
35 [1997](#)). In addition, one cross-sectional study assessed the effects of Cr(VI) exposure on the general

1 population in Greece ([Sazakli et al., 2014](#)). Information on study evaluation is provided in the text
 2 below and in Table 3-32. Available evidence in human studies was limited to *ex vivo* WBC function,
 3 white blood cells (number, type, and T cell subpopulations), immunoglobulin levels, complement
 4 levels, and cytokine levels.

5 While cytokines are critical for maintaining immune homeostasis, cytokine data, especially
 6 measures of blood cytokines, can be challenging to interpret as primary evidence of immune hazard
 7 ([Tarrant, 2010](#)). Changes in cytokine levels can be associated with many different types of tissues
 8 and toxicities, as part of cell differentiation to different immune cell types, or including site-specific
 9 inflammation, which reflects an immune response to tissue injury but not necessarily an impact on
 10 or impairment of immune function. For this reason, cytokine secretion data (in the absence of a
 11 stimulus) were not considered apical outcomes for the purpose of identifying immune hazard, but
 12 rather as supporting evidence for understanding mechanisms of immune disruption and are
 13 summarized in the Mechanistic and Supporting Evidence section below without systematic review.

14 Allergic sensitization can occur in some individuals exposed to Cr(VI) ([OSHA, 2006](#)).
 15 Because the primary exposure route (i.e., dermal) is outside the scope defined by the PECO criteria,
 16 evidence for allergic hypersensitivity responses following Cr(VI) exposure has not been
 17 comprehensively reviewed, but is briefly summarized in the Mechanistic and Supporting Evidence
 18 section below if the exposures or outcomes were relevant to non-dermal Cr(VI) exposures

Table 3-32. Summary of human studies for Cr(VI) immune effects and overall confidence classification [high (H), medium (M), low (L)] by outcome. [Click to see interactive data graphic for rating rationales.](#)

Author (year)	Industry	Location	Exposure Measurement	Study Design	<i>Ex vivo</i> white blood cell function ^a	White blood cells (hematology)	White blood cells (subpopulations)	Immunoglobulin levels
Boscolo et al. (1997)	Plastic workers exposed to lead chromate	Italy	Air	Cross-sectional	-	L	L	L
Kuo and Wu (2002)	Chrome-plating workers	Taiwan	Urine, air	Cross-sectional	-	-	L	-
Mignini et al. (2004)	Tannery workers	Italy	Dust, blood, urine	Cross-sectional	L	-	L	-
Mignini et al. (2009)	Tannery workers	Italy	Air, blood, urine	Cross-sectional	L	-	L	-

Author (year)	Industry	Location	Exposure Measurement	Study Design	Ex vivo white blood cell function ^a	White blood cells (hematology)	White blood cells (subpopulations)	Immunoglobulin levels
Qian et al. (2013)	Chemical plant workers	China	Work categories, validated by air, urine, blood samples	Cross-sectional	-	-	-	L
Sazakli et al. (2014)	General population	Greece	Urine, Hair, Modeled lifetime chromium exposure dose	Cross-sectional	-	L	-	-
Tanigawa et al. (1998)	Chemical plant workers	Japan	Work category	Cross-sectional	-	-	L	-
Verschoor et al. (1988)	Chrome platers, stainless-steel welders	Netherlands	Work categories, validated by urine samples	Cross-sectional	-	-	-	L
Wang et al. (2012a)	Chromate production workers	China	Urine	Cross-sectional	-	L	-	-

^aEx vivo white blood cell function is more informative of immune system function, while the other measures provide supporting immune system data.

1 Synthesis of human evidence

2 *More informative measures of immune system function*

3 Ex vivo WBC functional assays (e.g., NK cell activity, phagocytosis, proliferative responses)
4 are performed outside the body using isolated cells collected from exposed individuals. These
5 assays are considered clear evidence of adverse immunosuppression ([IPCS, 2012](#)). Two studies
6 examined the association between occupational Cr(VI) exposure and ex vivo WBC function (Table
7 3-32). Both studies of tannery workers were *low* confidence, with deficient ratings in participant
8 selection, exposure measurement, and sensitivity domains ([Mignini et al., 2009](#); [Mignini et al.,](#)
9 [2004](#)). Among Cr(VI) exposed workers, there was no effect on phagocytosis by PMNs or NK cell
10 activity [Mignini et al. \(2009\)](#); however, there was an increase in mitogen-induced proliferative
11 response that was not seen in workers without Cr(VI) exposure ([Mignini et al., 2009](#); [Mignini et al.,](#)
12 [2004](#)) (Table 3-33). Compared to controls, lymphocytes harvested from the exposed workers were
13 stimulated to proliferate to a greater extent in the presence of the T cell mitogens
14 phytohemagglutinin (PHA) ([Mignini et al., 2009](#)) and concanavalin A (ConA) ([Mignini et al., 2009](#);

1 [Mignini et al., 2004](#)), and there was evidence that the effect of Cr(VI) exposure on ConA stimulation
 2 may be affected by HLA haplotype ([Mignini et al., 2004](#)). Cr(VI) exposure had no effect on
 3 lymphocyte proliferation in the presence of the B cell mitogen lipopolysaccharide (LPS) ([Mignini et](#)
 4 [al., 2009](#)).

Table 3-33. Associations between Cr(VI) exposure and *ex vivo* WBC function in epidemiology studies

Reference, confidence	Population	Exposure measure	Exposure levels	Comparison and effect estimate	Endpoint
Mignini et al. (2004) , <i>low</i>	Cross-sectional study in Italy of 20 exposed and 24 unexposed workers	Cr levels in blood and urine	NR	ANOVA and the Student's t test	Significant increase in mitogen-stimulated lymphocyte proliferation (ConA) in exposed groups (pooled data from both exposure groups)
					Significant increase in mitogen-stimulated lymphocyte proliferation in exposed HLA-B8-DR3-negative group to ConA, but not in the HLA-B8-DR3-positive group (pooled data from both exposure groups)
Mignini et al. (2009) , <i>low</i>	Cross-sectional study in Italy of 40 exposed tannery workers and 44 unexposed workers	Cr levels in urine, 3 categories	~0.6, 0.4, 0.2 ug/L	Means by exposure category (not reported)	Significant increase in mitogen-stimulated lymphocyte proliferation in high exposure group to PHA and ConA, but not to LPS
					No effect on percent phagocytosis, phagocytosis index, or killing percent by PMNs
					No effect on NK cell activity, data not shown

5 *Supporting immune system data*

6 *Immunoglobulin levels*

7 Three studies examined the association between Cr(VI) exposure and nonspecific
 8 immunoglobulin levels (Table 3-32). All three studies were *low* confidence, with deficiencies in
 9 participant selection, outcome ascertainment, and confounding ([Qian et al., 2013](#); [Boscolo et al.,](#)
 10 [1997](#); [Verschoor et al., 1988](#)). Immunoglobulin levels are difficult to interpret alone without a
 11 controlled immune challenge preceding the measurement. Among these studies (Table 3-34),
 12 which did not include controlled immune challenges, Cr(VI)-exposed workers had lower levels of
 13 IgA and IgG [Qian et al. \(2013\)](#), but levels were unaffected in [Boscolo et al. \(1997\)](#). Levels of IgG
 14 were also unaffected in [Verschoor et al. \(1988\)](#). Serum levels of IgM were unaffected by Cr(VI)

- 1 exposure in the only two studies that investigated this isotope ([Qian et al., 2013](#)). IgE levels were
 2 unaffected in the only study that investigated this isotope ([Boscolo et al., 1997](#)).

Table 3-34. Associations between Cr(VI) exposure and immunoglobulin (Ig) levels in epidemiology studies

Reference, confidence	Population	Exposure measure	Exposure levels	Comparison and effect estimate	IgG	IgM	IgA	IgE
Boscolo et al. (1997) , <i>low</i>	Cross-sectional study in Italy of 15 plastic workers exposed to lead chromate and 15 unexposed workers from the same area	Exposed/unexposed. Chromium levels measured in blood and urine. Levels in exposed were significantly higher in urine, but similar to unexposed in blood	Chromate ranged in air from 0.1 to 5.7 µg/m ³	Median in mg/dl (25th–75th) for exposed and unexposed	Exposed: 1240 (991–1296) Unexposed: 1151 (942–1276)	Exposed: 118 (75–140) Unexposed: 79 (58–111)	Exposed: 193 (182–282) Unexposed: 277 (186–292)	NA
Verschoor et al. (1988) , <i>low</i>	Cross-sectional study in the Netherlands of 21 chrome platers, 38 SS welders, 16 boilermakers, and 63 unexposed workers	Work categories, validated by urine samples	9, 3, 1, 0.4 µg/g creatinine in urine	Mean ± SD	Chrome platers: 11.6 ± 3.2 SS welders: 11.1 ± 2.6 Boilermakers: 11.1 ± 2.8 Controls: 11.6 ± 2.4	NA	NA	NA
Qian et al. (2013) , <i>low</i>	Cross-sectional study in China of 56 workers exposed to potassium dichromate and 50 unexposed individuals living 20 km from factory	Exposed/unexposed validated by air sampling	14.4 ± 18.1 µg/m ³	Except for IgE, mean in g/L ± SD for exposed and unexposed	Exposed: 10.9 ± 2.5 Unexposed: 12.4 ± 2.1 <i>p</i> = 0.03*	Exposed: 1.2 ± 0.5 Unexposed: 1.0 ± 0.4	Exposed: 2.4 ± 0.9 Unexposed: 2.8 ± 1.2 <i>p</i> = 0.04*	Exposed (Median g/L (quartile)] 55.2 (157.4) Unexposed 81.9 (237.1)

NA = not applicable.

- 3 *WBC counts (hematology)*
 4 Three studies reported WBC counts, or related measures, including counts of total WBCs,
 5 lymphocytes and granulocytes (Table 3-35). All studies were *low* confidence. [Sazakli et al. \(2014\)](#)
 6 was deficient only in exposure measurement, while the remaining studies were deficient in
 7 multiple domains, including participant selection ([Wang et al., 2012a](#); [Boscolo et al., 1997](#)),
 8 confounding ([Wang et al., 2012a](#); [Boscolo et al., 1997](#)), and outcome ascertainment ([Boscolo et al.](#)

Toxicological Review of Hexavalent Chromium

1 [1997](#)). Among these studies, one reported a statistically significant increase in total WBCs with
2 higher exposure to Cr(VI) ([Wang et al., 2012a](#)). Non- significant increases were also observed for
3 lymphocytes and neutrophils ([Wang et al., 2012a](#)). Two other studies indicated no increase
4 ([Sazakli et al., 2014](#); [Boscolo et al., 1997](#)), with one indicating non-statistically significant decreases
5 for lymphocytes and WBCs ([Boscolo et al., 1997](#)) (Table 3-35).

Table 3-35. Associations between Cr(VI) exposure and WBC counts in epidemiology studies

Reference, confidence	Population	Exposure measure	Exposure levels	Comparison and effect estimate	Total WBC (count 10 ⁹ /L)	Lymphocytes (count 10 ⁹ /L)	Granulocytes (count 10 ⁹ /L)	Neutrophils (count 10 ⁹ /L)
Sazkli et al. (2014) <i>low</i>	Cross-sectional in Greece, general population; Two exposure groups (n = 237) and controls (n = 67)	Chromium levels measured in blood and hair. Estimated lifetime chromium exposure dose calculated using concentration in drinking water, intake rate, and body weight	NR	Regression coefficients for calculated lifetime exposure dose and Cr in hair	Lifetime dose: -0.03 Hair: 0.07 p = 0.59	Lifetime dose: 0.02 Hair: 0.1 p = 0.71	Lifetime dose: -0.01 Hair: 0.03 p = 0.81	NA
Boscolo et al. (1997) <i>low</i>	Cross-sectional study in Italy of 15 plastic workers exposed to lead chromate and 15 unexposed workers from the same area	Exposed/ unexposed. Chromium levels measured in blood and urine. Levels in exposed were significantly higher in urine, but similar to unexposed in blood	Chromate ranged in air from 0.1 to 5.7 µg/m ³	Median (25th–75th) for exposed and unexposed	Exposed: 6764 (5940–7180) Unexposed: 6776 (5680–8190) p > 0.05	Exposed: 2340 (1490–2915) Unexposed: 2730 (2300–3090) p > 0.05	NA	NA
Wang et al. (2012a) <i>low</i>	Cross-sectional study in China of 86 chromate production workers and 45 unexposed workers	Exposed/ unexposed. Chromium levels measured in urine were significantly higher in exposed workers	<50 µg/m ³	Mean (SD) for exposed and unexposed	Exposed: 7.0 (1.7) Unexposed: 6.2 (1.3) p = 0.03 Mixed WBC ^a Exposed: 0.6 (0.3) Unexposed: 0.4 (0.1)	Exposed: 2.2 (0.7) Unexposed: 2.1 (0.5) p = 0.19	NA	Neutrophils Exposed: 4.1 (1.4) Unexposed: 3.7 (1.0) p = 0.06

NA = not applicable.

^aCell mixture containing neutrophils, eosinophils, basophils and mast cells.

1 *Lymphocyte subpopulations*

2 Five studies examined the association between Cr(VI) exposure and lymphocyte
3 subpopulations (Table 3-32). All five studies were *low* confidence cross-sectional studies of Cr(VI)
4 exposure and white blood cell counts ([Qian et al., 2013](#); [Mignini et al., 2009](#); [Mignini et al., 2004](#);
5 [Tanigawa et al., 1998](#); [Boscolo et al., 1997](#)). All studies were deficient in multiple domains,
6 including selection or performance ([Qian et al., 2013](#); [Mignini et al., 2009](#); [Mignini et al., 2004](#);
7 [Tanigawa et al., 1998](#); [Boscolo et al., 1997](#)), exposure methods sensitivity ([Mignini et al., 2009](#);
8 [Mignini et al., 2004](#); [Tanigawa et al., 1998](#)), outcomes measures and results display sensitivity ([Qian](#)
9 [et al., 2013](#); [Boscolo et al., 1997](#)), confounding ([Qian et al., 2013](#); [Tanigawa et al., 1998](#); [Boscolo et](#)
10 [al., 1997](#)), analysis ([Qian et al., 2013](#); [Tanigawa et al., 1998](#); [Boscolo et al., 1997](#)), selective reporting
11 ([Qian et al., 2013](#)), and sensitivity ([Mignini et al., 2009](#); [Mignini et al., 2004](#); [Tanigawa et al., 1998](#);
12 [Boscolo et al., 1997](#)). Three studies reported decreased CD4+, CD8+, and CD3+ cells with higher
13 exposure to Cr(VI) ([Kuo and Wu, 2002](#); [Tanigawa et al., 1998](#); [Boscolo et al., 1997](#)). Two studies did
14 not report data for changes in levels of CD3+, CD4+, CD8+, DC19 ([Mignini et al., 2009](#); [Mignini et al.,](#)
15 [2004](#)), CD56 ([Mignini et al., 2004](#)), CD16+/CD56+ and CD4/CD8 ([Mignini et al., 2009](#)), but stated
16 there were no significant associations with measures of Cr(VI) exposure (Table 3-36).

Table 3-36. Associations between Cr(VI) exposure and lymphocyte subpopulations in epidemiology studies

Reference, confidence	Population	Exposure measure	Exposure levels	Comparison and effect estimate	CD4+	CD8+	CD3+	CD19	CD56
Boscolo et al. (1997) , low	Cross-sectional study in Italy of 15 plastic workers exposed to lead chromate and 15 unexposed workers from the same area	Exposed/unexposed. Chromium levels measured in blood and urine. Levels in exposed were significantly higher in urine, but similar to unexposed in blood	Chromate ranged in air from 0.1 to 5.7 µg/m ³	Median (25th–75th) for exposed and unexposed	Exposed: 870 (585–1135) Unexposed: 1140 (970–1240) <i>p</i> < 0.05*	Exposed: 710 (435–795) Unexposed: 810 (570–870)	Exposed: 1630 (1035–1995) Unexposed: 1890 (1680–2170)	Exposed: 180 (150–280) Unexposed: 330 (260–460)	NA
Tanigawa et al. (1998) , low	Cross-sectional study in Japan of 19 retired chromate workers and 13 unexposed workers	Exposed/unexposed. No validation of exposure levels.	NR	Mean ± SD for exposed and unexposed, by smoking status	Exposed smokers: 790 ± 260 Exposed nonsmokers: 870 ± 510 Unexposed smokers: 1660 ± 570 Unexposed non-smokers: 1250 ± 450 <i>p</i> < 0.05*	Exposed smokers: 470 ± 250 Exposed nonsmokers: 330 ± 200 Unexposed smokers: 540 ± 280 Unexposed nonsmokers: 670 ± 480 <i>p</i> < 0.05*	Exposed smokers: 1140 ± 380 Exposed nonsmokers: 1150 ± 640 Unexposed smokers: 2110 ± 530 Unexposed nonsmokers: 1840 ± 650 <i>p</i> < 0.05*	NA	NA
Kuo and Wu (2002) , low	Cross-sectional study in Taiwan of 27 workers from 5 Cr	Chromium levels in air samples and urine.	NR	Beta (SE) for moderate and high urine Cr vs. low group	Moderate: –0.03 (2.5) High: –0.2 (4.0)	Moderate: –1.8 (2.3) High: –6.5 (3.6)	NA	NA	NA

Toxicological Review of Hexavalent Chromium

Reference, confidence	Population	Exposure measure	Exposure levels	Comparison and effect estimate	CD4+	CD8+	CD3+	CD19	CD56
	electroplating plants and 19 unexposed workers			Correlation coefficient with airborne Cr	-0.06	-0.08	NA	NA	NA
Mignini et al. (2004) , low	Occupational exposure study in Italy of 20 exposed and 24 unexposed workers	Cr levels in blood and urine	NR	ANOVA and the Student's t test	No changes reported, data not shown				
Mignini et al. (2009) , low	Cross-sectional study in Italy of 40 exposed tannery workers and 44 unexposed workers	Cr levels in urine, 3 categories	~0.6, 0.4, 0.2 ug/L	Mean ± SD for exposed and unexposed, Duncan Multiple Range, 'Newman-Keuls, Mann-Whitney test	No changes reported, data not shown				

NA = not applicable.

1 **3.2.6.2. Animal Evidence**

2 This section focuses on outcomes considered informative for the identification of
3 chemical-induced adverse effects on the immune system ([IPCS, 2012](#); [U.S. EPA, 1998b](#)), particularly
4 changes in response to an immune challenge, including effects on antibody responses, host
5 resistance, and *ex vivo* white blood cell (WBC) function. Supporting data collected from animals in
6 the absence of an immune challenge were also considered, including effects on immune organ
7 pathology, nonspecific immunoglobulin levels, immune organ weights, WBC counts (spleen,
8 thymus, bone marrow and hematology), and lymphocyte subpopulations. In addition to the
9 evidence syntheses below, the study findings have been summarized in Appendix C.2.5.1.

10 Study evaluation summary

11 Table 3-37 summarizes the animal toxicology studies considered in the evaluation of the
12 effects of Cr(VI) on the immune system. These studies consist of one oral diet ([NTP, 1996a](#)), one
13 oral gavage ([Krim et al., 2013](#)), 11 drinking water ([Karaulov et al., 2019](#); [Jin et al., 2016](#); [Wang et al.,](#)
14 [2015](#); [NTP, 2008, 2007, 2006a, b, 2005](#); [Shrivastava et al., 2005a](#); [Shrivastava et al., 2005b](#); [Snyder](#)
15 [and Valle, 1991](#)), and eight inhalation studies ([Cohen et al., 2010](#); [Cohen et al., 2006](#); [Kim et al.,](#)
16 [2004](#); [Cohen et al., 1998](#); [Glaser et al., 1990](#); [Glaser et al., 1986](#); [Johansson et al., 1986b](#); [Glaser et al.,](#)
17 [1985](#)). These studies used a variety of mouse and rat strains, including BALB/c, B6C3F1,
18 *am3*-C57BL/6, and Swiss mice ([NTP, 2008, 2007, 2005](#); [Shrivastava et al., 2005a](#); [Shrivastava et al.,](#)
19 [2005b](#); [NTP, 1996a](#)) and Sprague-Dawley, F344, F344/N, Wistar, and albino Wistar rats ([Karaulov](#)
20 [et al., 2019](#); [Wang et al., 2015](#); [Krim et al., 2013](#); [Cohen et al., 2010](#); [NTP, 2008, 2007](#); [Cohen et al.,](#)
21 [2006](#); [NTP, 2006a, b](#); [Kim et al., 2004](#); [Cohen et al., 1998](#); [Snyder and Valle, 1991](#); [Glaser et al., 1990](#);
22 [Glaser et al., 1986](#); [Glaser et al., 1985](#)).

Table 3-37. Summary of included studies for Cr(VI) immunological effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a

[Click to see interactive data graphic for rating rationales.](#)

Author (year)	Species (strain)	Exposure design	Exposure route	More informative measures ^b			Supporting evidence				
				Host resistance	Antibody responses	Ex vivo WBC function	Immune organ pathology	Immunoglobulin levels	Immune organ weights	WBC counts and differentials (spleen, thymus, bone marrow)	WBC counts (hematology)
Cohen et al. (1998)	Rat (F-344)	Short-term	Inhalation	-	-	M	-	-	-	-	-
Cohen et al. (2006)	Rat (F-344)	Short-term	Inhalation	M	-	-	-	-	-	-	-
Cohen et al. (2010)	Rat (F-344)	Short-term	Inhalation	M	-	-	-	-	-	-	-
Glaser et al. (1985)	Rat (Wistar)	Short-term & subchronic	Inhalation	-	L	L	-	M	M	-	L
Glaser et al. (1986)	Rat (Wistar)	Chronic	Inhalation	-	-	-	M	L	L	-	M
Glaser et al. (1990)	Rat (Wistar)	Short-term & subchronic	Inhalation	-	-	-	-	L	-	-	M
Jin et al. (2016)	Mouse (ICR)	Short-term	Drinking water	-	-	-	-	-	M	-	-
Johansson et al. (1986b)	Rabbit (strain not specified)	Chronic	Inhalation	-	-	M	-	-	-	-	-
Karaulov et al. (2019)	Rat (Wistar)	Chronic	Drinking water	-	-	M	M	-	M	M	-
Kim et al. (2004)	Rat (Sprague-Dawley)	Subchronic	Inhalation	-	-	-	-	-	M	-	M
Krim et al. (2013)	Rat (albino Wistar)	Short-term	Gavage	-	-	-	-	-	-	-	M
NTP (1996a)	Mouse (BALBC)	Subchronic	Diet	-	-	-	H	-	-	-	H
NTP (2005)	Mouse (B6C3F1)	Short-term	Drinking water	-	H	H	H	H	H	H	M
NTP (2006b)	Rat (Sprague-Dawley)	Short-term	Drinking water	-	H	H	M	H	H	H	M

Toxicological Review of Hexavalent Chromium

Author (year)	Species (strain)	Exposure design	Exposure route	More informative measures ^b			Supporting evidence				
				Host resistance	Antibody responses	Ex vivo WBC function	Immune organ pathology	Immunoglobulin levels	Immune organ weights	WBC counts and differentials (spleen, thymus, bone marrow)	WBC counts (hematology)
NTP (2006a)	Rat (F344)	Short-term	Drinking water	-	H	H	M	H	H	H	M
NTP (2007)	Rat (F344/N); Mice (B6C3F1, BALB/c, am3- C57BL/6)	Subchronic	Drinking water	-	-	-	H	-	H	-	H
NTP (2008)	Rat (F344/N); Mice (B6C3F1)	Chronic	Drinking water	-	-	-	H	-	-	-	H
Shrivastava et al. (2005a)	Mouse (Swiss)	Short-term & subchronic	Drinking water	-	-	-	-	-	-	-	L
Shrivastava et al. (2005b)	Mouse (Swiss)	Short-term & subchronic	Drinking water	-	-	L	-	-	L	-	-
Snyder and Valle (1991)	Rat (F344)	Short-term	Drinking water	-	-	L	-	-	-	-	-
Wang et al. (2015)	Rat (Sprague-Dawley)	Short-term	Drinking water	-	-	-	-	-	-	-	M

^aIn addition to these included studies, there were three animal toxicology studies reporting immunotoxicity outcomes that met PECO criteria but were found to be *uninformative* at the study evaluation stage for reporting or attrition [Geetha et al. \(2003\)](#), outcomes measures [Nettesheim et al. \(1971\)](#), and outcomes measures, exposure methods, reporting or attrition, confounding variable control, and selection or performance [Kumar and Barthwal \(1991\)](#).

^bHost resistance, antibody responses, and *ex vivo* WBC function are more informative as measures of immune system function. The remaining measures provide supporting immune system data.

1 Synthesis of Animal Evidence

2 *More informative measures of immune system function*

3 *Host resistance*

4 Host resistance assays are considered the gold standard of immunotoxicity testing because
5 clearance of a self-replicating infectious agent or neoplastic disease requires the integration of
6 immune system responses to protect the host, and disruption of this integrated response at any

1 point can be detected as a reduction in host resistance. The effect of exposure to Cr(VI)
2 (0.119 mg/m³ for 5 h/d for 5 consecutive days) on in situ clearance of pneumonia-inducing *Listeria*
3 *monocytogenes* (24, 48 and 72 h timepoints) was investigated in two *medium* confidence studies of
4 male F344 rats ([Cohen et al., 2010](#); [Cohen et al., 2006](#)). Compared to the air-exposed control,
5 pathogen clearance was reduced in rats exposed to high soluble (Na₂CrO₄) and low soluble
6 (CaCrO₄) Cr(VI), but only when measured at the 72 h timepoint ([Cohen et al., 2010](#); [Cohen et al.,](#)
7 [2006](#)). The authors noted that the reduction in pathogen clearance did not correlate with lung
8 chromium burden ([Cohen et al., 2010](#); [Cohen et al., 2006](#)). Overall, available data suggest that
9 short-term exposure to chromium may reduce *in situ* bacterial clearance in the lung (i.e., phagocyte
10 recruitment and bacterial lysis). Since the model used in these studies is a targeted host resistance
11 model designed to evaluate local pathogen clearance by macrophages, future studies using a
12 comprehensive host resistance model (e.g., influenza virus) would be useful for developing a better
13 understanding of the potential for Cr(VI) exposure to impair host resistance.

14 *Antibody responses*

15 Cr(VI) exposure increased IgM antibody-forming cell responses to sheep red blood cells in
16 three *high* confidence 28-day NTP studies ([NTP, 2006a, b, 2005](#)), but the effect was only significant
17 in two of the studies ([NTP, 2006a, 2005](#)) and the same effect was not observed in a repeat assay
18 performed by [NTP \(2005\)](#). One 90-day inhalation study, found to be *low* confidence due to
19 deficiencies in the presentation of results, also reported increased IgM antibody-forming cell
20 responses to sheep red blood cells ([Glaser et al., 1985](#)). These investigations were performed in
21 female B6C3F1 mice and two different strains of female rat exposed to a broad and overlapping
22 range of Cr(VI) in drinking water (5–180 mg/L) and according to experimental protocols sufficient
23 for the detection of alterations in antibody cell forming responses.

24 Antibody response studies only provide information on the number of antibody producing
25 plasma cells at the time of assay completion, but these studies do not provide any information on
26 the levels of antigen-specific antibodies in the serum of Cr(VI)-exposed animals. Three *high*
27 confidence NTP studies in mice and rats exposed to Cr(VI) in drinking water for 28 days showed no
28 effect on serum titers of total IgM antibodies specific for two different T cell-dependent antigens
29 ([NTP, 2006a, b, 2005](#)). Recognizing that serum antibody titers are a relatively insensitive measure
30 of the antibody response, these findings are not inconsistent with the antibody-forming cell
31 responses discussed above.

32 Overall, Cr(VI) exposure increased antibody responses to sheep red blood cells but did not
33 alter the serum antibody titer following exposure to Cr(VI).

34 *Ex vivo WBC function*

35 In a *low* confidence study by [Glaser et al. \(1985\)](#), phagocytic activity was significantly
36 increased compared to the control group in alveolar lung macrophages isolated from male Wistar
37 rats exposed to Cr(VI) (up to 0.050 mg/m³) as sodium dichromate by inhalation for 28 and 90 days
38 but was decreased significantly following a 90-day exposure to 0.20 mg/m³. Findings by the

1 companion study ([Glaser et al., 1990](#)) also showed changes characteristic of acute lung injury and
2 inflammatory lung responses (see Section 3.2.1.2). In a second, *medium* confidence inhalation
3 exposure study, phagocytosis by rabbit alveolar macrophages was unaffected following exposure to
4 0.9 ± 0.4 mg/m³ Cr(VI) as sodium chromate for 4–6 weeks ([Johansson et al., 1986b](#)). The absence
5 of an effect in [Johansson et al. \(1986b\)](#) may have been due to a 3-day gap between cessation of
6 exposure to Cr(VI) and evaluation of phagocytic activity. In [Glaser et al. \(1985\)](#), the clearance of
7 inhaled iron oxide was lower in the lungs of rats exposed to 0.20 mg/m³ Cr(VI) for 42 days, though
8 the number of lung macrophages was also reduced relative to the control group. Consequently, the
9 observed decrease in lung clearance cannot be attributed definitively to a defect in phagocytosis. In
10 a third *low* confidence study, however, phagocytic activity of mouse splenic macrophages was
11 reduced from 92% in control male Swiss mice to 36% in mice exposed to 14.8 mg/kg-day Cr(VI) in
12 drinking water for 9 weeks ([Shrivastava et al., 2005b](#)).

13 Cr(VI) exposure had no effect on natural killer (NK) cell activity, mixed lymphocyte
14 response (MLR), and anti-CD3 stimulation of lymphocytes in three *high* confidence drinking water
15 studies ([NTP, 2006a, b, 2005](#)) and one *low* confidence drinking water study ([Snyder and Valle,
16 1991](#)). The studies were performed in female B6C3F1 mice and two different strains of female rats
17 (Sprague-Dawley and F344) exposed to a broad and overlapping range of Cr(VI) in drinking water
18 (5–180 mg/L) and according to experimental protocols sufficient for the detection of alterations in
19 cell-mediated responses.

20 Mitogen-induced proliferative response was consistent in three *low* confidence studies
21 ([Shrivastava et al., 2005b](#); [Snyder and Valle, 1991](#); [Glaser et al., 1985](#)). Spleen cells isolated from
22 male Swiss mice exposed to Cr(VI) in drinking water (14.8 mg/kg-day) for 9 weeks were stimulated
23 to proliferate with ConA, but the investigators did not conduct statistical analyses of the findings
24 ([Shrivastava et al., 2005b](#)). Increased proliferation was observed in splenocytes isolated from F344
25 rats exposed to Cr(VI) in drinking water (100 or 200 mg/L) for 3 weeks when stimulated with the T
26 lymphocyte mitogen ConA or B lymphocyte mitogen lipopolysaccharide (LPS) ([Snyder and Valle,
27 1991](#)). Spleen cells isolated from rats exposed to Cr(VI) by inhalation (0.20 mg/m³) for 90 days
28 were stimulated to proliferate to a greater extent than controls by ConA ([Glaser et al., 1985](#)).

29 Mitogen-induced cytokine secretion was evaluated in two *medium* confidence studies
30 ([Karaulov et al., 2019](#); [Cohen et al., 1998](#)). Spleen cells isolated from rats exposed to Cr(VI) in
31 drinking water for 45, 90, and 135 days and stimulated with ConA secreted less IL-6 (day 135) and
32 more IL-4 (day 45, 90, and 135) than controls, while secretion of IL-10 and IFN γ were unaffected by
33 treatment ([Karaulov et al., 2019](#)). Compared to control, secretion of IL-1 and TNF α were decreased
34 in pulmonary alveolar macrophages harvested from rats exposed to Cr(VI) by inhalation for 4
35 weeks and stimulated with LPS whereas a nonsignificant increase in IL-6 secretion was observed
36 ([Cohen et al., 1998](#)).

37 Compared to the control group, exposure to Cr(VI) (0.36 mg/m³) by inhalation for 28 days
38 had no effect on spontaneous O₂⁻ and H₂O₂ production in the presence or absence of IFN- γ at

1 4 weeks, but increased opsonized zymosan-stimulated O₂⁻, and decreased H₂O₂ production
2 stimulated by opsonized zymosan in the presence of IFN-γ (Cohen et al., 1998). Cr(VI) had no effect
3 on LPS-stimulated nitric oxide (NO) production at 4 weeks but reduced NO production stimulated
4 by IFN-γ at 4 weeks; the authors did not make statistical comparisons between the LPS-stimulated
5 and IFN-γ-stimulated groups (Cohen et al., 1998).

6 Overall, Cr(VI) exposure had no effect on NK cell activity, MLR, and anti-CD3 stimulation of
7 lymphocytes in three *high* confidence drinking water studies (NTP, 2006a, b, 2005). Other studies
8 provide some evidence for effects on mitogen-stimulated splenocyte proliferation, reactive oxygen
9 species production, and phagocytic activity. However, data supporting effects on mitogen-
10 stimulated splenocyte proliferation come from three *low* confidence studies (Shrivastava et al.,
11 2005b; Snyder and Valle, 1991; Glaser et al., 1985). Data supporting effects on phagocytosis are
12 limited to two *low* (Shrivastava et al., 2005b; Glaser et al., 1985) and one *medium* confidence studies
13 (Johansson et al., 1986b) whereas data on reactive oxygen species are limited to only one *low*
14 confidence study (Cohen et al., 1998). Consequently, additional studies are necessary to better
15 understand the potential effect of Cr(VI) on these endpoints, particularly studies that more
16 thoroughly document exposure conditions, exposure dose, group size, data processing, and
17 attrition.

18 *Supporting immune system data*

19 *Immune organ pathology*

20 No gross pathological changes were reported in six *medium* or *high* confidence NTP oral
21 studies where rats or mice were exposed to Cr(VI) for 28 days to 2 years (NTP, 2008, 2007, 2006a,
22 b, 2005, 1996a) and one *medium* confidence chronic inhalation study that included a 12-month
23 recovery period (Glaser et al., 1986). In one *medium* confidence drinking water study in male
24 Wistar rats of unknown age exposed to Cr(VI) (20 mg/kg-day) for up to 135 days, evaluation of the
25 thymus (day 90) revealed structural changes including decreased epithelial reticular cells and
26 physiologically important associations between these cells and T cells, potentially leading to
27 functional impairment of the central immune system (Karaulov et al., 2019). In the same study,
28 structural effects including an increased B-zone and a decreased T-zone were observed in the
29 spleen across all timepoints (45, 90, and 135 days). Although the specific type of lymph node was
30 not reported, lymph node size was increased and was attributed to changes in cellular elements
31 including reticulocytes and lymphocytes.

32 Although unlikely to be an indicator of impaired immune function, infiltration of histiocytes
33 (macrophages) was observed in liver, small intestine, and mesenteric and pancreatic lymph nodes
34 in rats and mice in two *high* confidence NTP studies at oral exposure durations up to 2 years (NTP,
35 2008, 2007). In damaged tissues, infiltrated macrophages display functions such as modulation of
36 inflammatory cells, removal of damaged tissues/cellular debris, and antigen presentation, as well as
37 fibrogenic stimulation (Yamate et al., 2016). Histiocytic infiltrates were characterized by study
38 authors as small, individual clusters and sometimes as syncytia of histiocytes that were large

1 (approximately 20–80 microns in diameter) and had pale, lightly eosinophilic, faintly stippled
2 cytoplasm and single, small, peripheral, dark basophilic nuclei. This finding was distinct from the
3 histopathological finding of chronic inflammation in the liver that NTP characterized as small,
4 randomly scattered aggregates of macrophages, lymphocytes, and neutrophils. Dose-related
5 findings of histiocytic infiltration were also observed in the lung following inhalation exposure ([Kim](#)
6 [et al., 2004](#); [Glaser et al., 1990](#); [Glaser et al., 1986](#); [Johansson et al., 1986b](#); [Johansson et al., 1986a](#))
7 (see Section 3.2.1.2). The NTP authors ([NTP, 2008, 2007](#)) noted that the biological significance of
8 the histiocytic cellular infiltrates is unknown but suggested this finding may indicate phagocytosis
9 of an insoluble chemical precipitate. However, it is important to acknowledge that activated
10 macrophages can also damage tissue by secreting cytotoxic factors indicative of an innate
11 inflammatory response and create an inflammatory environment ([Yamate et al., 2016](#)).

12 Overall, one *medium* confidence oral study ([Karaulov et al., 2019](#)) reported structural
13 changes in the thymus and spleen and cellular content of lymph nodes after 90 days. Cr(VI)
14 exposure had no effect on spleen or thymus pathology in six *medium* or *high* confidence oral studies
15 and one *medium* confidence inhalation study (28-day or 90 days with a recovery period).

16 *Immunoglobulin levels*

17 Short-term, subchronic and chronic inhalation exposures to Cr(VI) (0.025, 0.05, and 0.1
18 mg/m³) did not alter total serum immunoglobulin levels in one *low* confidence study performed in
19 male Wistar rats ([Glaser et al., 1990](#)). However, in a *medium* confidence study by the same authors,
20 [Glaser et al. \(1985\)](#) observed a dose-dependent increase in serum immunoglobulins in male rats
21 following inhalation exposure for 90 days (0.025–0.10 mg/m³); serum immunoglobulin levels
22 returned to baseline when rats were exposed to a higher Cr(VI) concentration (i.e., 0.20 mg/m³).
23 Although quantitative data were not reported, serum immunoglobulins were also reported to
24 decrease following inhalation exposure to Cr(VI) (as chromium oxide) for 6 months (0.1 mg/m³) in
25 a *low* confidence study ([Glaser et al., 1986](#)). Changes in total serum immunoglobulin levels alone
26 are not considered sensitive enough to detect mild to moderate immunotoxicity or predictive
27 enough to identify immunotoxicants ([IPCS, 2012](#); [Luster et al., 1993](#); [Luster et al., 1992](#)). However,
28 in combination with data on measures of immune function, these results may provide supporting
29 evidence of immunomodulation.

30 *Immune organ weight*

31 Absolute thymus weight was unchanged in two *high* confidence NTP studies performed in
32 female Sprague-Dawley and F344 rats exposed to a range of Cr(VI) concentrations (5–180 mg/L) in
33 drinking water for 28 days ([NTP, 2006a, b](#)). However, absolute thymus weight was decreased in
34 one *high* confidence NTP study performed in male B6C3F1 and am3-C57BL/6 mice exposed to
35 Cr(VI) (90 mg/L, high dose group only) in drinking water for 3 months ([NTP, 2007](#)). When
36 evaluated using a higher concentration, the absolute thymus weight was unchanged in one *high*
37 confidence NTP study performed in male and female mice and rats (B6C3F1, BALB/c, and F344/N)
38 exposed to a range of Cr(VI) concentrations (20–350 mg/L) in drinking water for 3 months ([NTP,](#)

1 [2007](#)). In one *medium* confidence study, absolute thymus weight decreased in rats exposed to
2 Cr(VI) (20 mg/kg-d) in drinking water for up to 135 days ([Karaulov et al., 2019](#)).
3 [NTP \(2005\)](#) reported a decrease in relative spleen weight in female mice exposed to
4 11 mg/L Cr(VI) in drinking water for 28 days; these findings were not replicated when the study
5 authors repeated the experiment. Relative spleen weight was not affected by exposure to Cr(VI) in
6 drinking water for 28 days in other NTP studies ([NTP, 2006a, b](#)). However, relative spleen weight
7 was also decreased in F344/N rats and *am3*-C57B mice subchronically exposed to Cr(VI) at
8 concentrations ≥ 90 mg/L in drinking water ([NTP, 2007](#)). Similarly, in a *low* confidence study,
9 relative spleen weight decreased gradually over time in mice exposed to Cr(VI) (14.8 mg/kg) in
10 drinking water for nine weeks ([Shrivastava et al., 2005b](#)). In one *medium* confidence study,
11 absolute spleen weight and body weight decreased in rats exposed to Cr(VI) (20 mg/kg-d) in
12 drinking water for up to 135 days ([Karaulov et al., 2019](#)). Relative spleen weight was significantly
13 increased in a *medium* confidence drinking water study following exposure to 50 mg/L Cr(VI) for 7
14 days, but not following 21 days exposure to 200 mg/L ([Jin et al., 2016](#)). These results suggest the
15 effect may recover with time or there may be a nonmonotonic dose-response. In a *medium*
16 confidence inhalation study, relative spleen weight increased following Cr(VI) exposure for 28 or
17 90 days at concentrations ≥ 0.050 mg/m³ ([Glaser et al., 1985](#)). However, this effect was not
18 observed in a *low* confidence chronic inhalation study using the same model system when the study
19 design incorporated a 12-month recovery period following an 18-month exposure ([Glaser et al.,](#)
20 [1986](#)). Spleen weight was also reported to be unaffected in rats exposed by inhalation to higher
21 Cr(VI) concentrations (i.e., 0.20–1.25 mg/m³) for 13 weeks ([Kim et al., 2004](#)).

22 Overall, Cr(VI) exposure only reduced absolute thymus weight in a single drinking water
23 study and the effect was not observed in a second study exposing the same strain of mice to a
24 broader and higher range of doses. However, absolute thymus weight was decreased in a longer
25 duration drinking water study. Depending on the concentration of Cr(VI) tested, the exposure
26 duration, and the route of administration, Cr(VI) exposure was shown to either have no effect, to
27 increase, or to decrease relative spleen weight. Recognizing that immune organ weights are often
28 confounded by stress responses, results of immune organ weight is of limited utility for immune
29 organ pathology.

30 *WBC counts and differentials (spleen, thymus, bone marrow)*

31 No effects on the absolute number of splenic WBCs (total), or lymphocyte subtypes were
32 observed in two *high* confidence NTP studies performed in female Sprague-Dawley rats and
33 B6C3F1 mice exposed to Cr(VI) in drinking water for 28 days (5–180 mg/L) ([NTP, 2006b, 2005](#)). In
34 another *high* confidence 28-day drinking water study in female F344 rats, the total number of
35 splenic WBCs was also unaffected, but the numbers of NK cells and macrophages were increased at
36 doses of 4 mg/kg-d and 0.5 mg/kg-d Cr(VI), respectively ([NTP, 2006a](#)). In both instances, the
37 observed increase in cell number was only detected at 1 out of 4 dose levels tested in the study and
38 always at levels that fell within the range of concentrations tested in the other two drinking water

1 studies ([NTP, 2006b, 2005](#)). In one *medium* confidence drinking water study in male Wistar rats
2 exposed to Cr(VI) (20 mg/kg-day) for up to 135 days, the absolute number of splenic T cells and T
3 helper cells was decreased on days 90 and 135, but the relative values were unaffected for these
4 timepoints ([Karaulov et al., 2019](#)). The absolute and relative number of CD8+ T cells were
5 decreased in the spleens of rats on day 90, but not at any other timepoint. The absolute number of
6 splenic karyocytes, and myeloid cells decreased, and effects on the absolute number of plasma cells
7 either increased or decreased depending on the timepoint ([Karaulov et al., 2019](#)). In the same
8 study, the absolute number of thymocytes decreased. The absolute number of bone marrow
9 myeloid cells, neutrophils, lymphocytes, and karyocytes were increased at the 135-day timepoint
10 ([Karaulov et al., 2019](#)).

11 Overall, recognizing that splenic WBC counts and differentials have only been evaluated in a
12 small number of drinking water studies, the effects of Cr(VI) exposure on splenic WBC and splenic
13 WBC differentials varied across studies. These differences in outcome may relate to experimental
14 design parameters including rodent species, test article concentration and study duration. Based
15 on a single *medium* quality study, Cr(VI) exposure has the potential to alter the number of
16 thymocytes and bone marrow cells. Additional studies are needed to better understand the effects
17 of Cr(VI) on WBC counts and differentials.

18 *WBC counts (hematology)*

19 Dose-related increases in total WBCs and some WBC types were reported in F344/N rats
20 exposed to Cr(VI) for up to 14 weeks ([NTP, 2008, 2007](#)); however, WBC counts were similar to the
21 control at 6 months and decreased at 12 months of exposure ([NTP, 2008](#)). Increased total WBC
22 number was also reported in one *medium* confidence inhalation study performed in rats for 30 and
23 90 days but the effect reversed in animals exposed for 90 days followed by a 30-day observation
24 period ([Glaser et al., 1990](#)). In a *low* confidence drinking water study in Swiss mice, total WBC
25 number and some WBC types decreased after 3 weeks of Cr(VI) exposure ([Shrivastava et al.,](#)
26 [2005a](#)).

27 No effects on WBCs (total or differentials) were observed in mice in three *high* confidence
28 NTP studies ([NTP, 2007, 2005, 1996a](#)), in mice or rats in seven *medium* confidence studies ([Krim et](#)
29 [al., 2013; NTP, 2006a, b; Kim et al., 2004; Glaser et al., 1986](#)), and in rats in two *low* confidence
30 studies ([Shrivastava et al., 2005a; Glaser et al., 1985](#)). These short-term, subchronic, and chronic
31 exposure studies included oral exposures via the diet (approximately 1–50 mg/kg-d Cr(VI)) ([NTP,](#)
32 [1996a](#)), oral gavage (5.3 mg/kg Cr(VI)) ([Krim et al., 2013](#)), and drinking water (approximately
33 0.5–10 mg/kg-d Cr(VI)) ([NTP, 2007, 2006a, b, 2005](#)) as well as inhalation exposures
34 (0.025–1.25 mg/m³) ([Kim et al., 2004; Glaser et al., 1986; Glaser et al., 1985](#)) in rats and mice.
35 Overall, evidence for Cr(VI)-related changes in WBC count is inconsistent.

1 **3.2.6.3. Mechanistic and Supporting Evidence**

2 Available evidence from studies of apical immune endpoints in human and animals suggests
3 that Cr(VI) exposure may have the capacity to modulate the immune system by stimulating some
4 elements of immune responses (antibody response, mitogen-stimulated lymphocyte proliferation,
5 total WBC counts (hematology), complement levels) and suppressing others (pathogen clearance).
6 The sections that follow describe mechanistic data from studies of mechanistic endpoints that
7 might inform immune effects derived from human ex vivo and in vivo animal investigations.
8 Summary tables of mechanistic studies are presented in Appendix C.2.5.2.

9 Immune modulation

10 Several lines of mechanistic information support the conclusion that Cr(VI) exposure may
11 have the potential to modulate the immune system. For organizational purposes, available
12 mechanistic and supporting evidence was organized into effect categories of key characteristics
13 common to immunotoxicants; these studies are summarized in Appendix Table C-37.

14 *Effects on immune cell differentiation or activation*

15 Alterations in dendritic cell maturation and T cell activation could impact antigen
16 presentation, a process central to the development of adaptive immune responses. In human
17 monocyte-derived dendritic cells in vitro, exposure to Cr(VI) increased expression of dendritic cell
18 maturation marker CD86 but had no effect on expression of CD83 ([Toebak et al., 2006](#)). Cr(VI)
19 exposure decreased anti-CD3/anti-CD28-stimulated expression of T cell activation markers CD69
20 and CD25 in primary mouse T cells ([Dai et al., 2017](#)).

21 *Effects on immune effector cell function*

22 Effector functions of innate (i.e., myeloid cell-mediated phagocytosis, cytokine production,
23 and respiratory burst; natural killer cell function) and acquired (i.e., plasma cells and antibody
24 production, helper T cells and cytokine production, cytotoxic T cell function) immunity cells can be
25 altered by xenobiotic exposure. The 28-day NTP drinking water studies in rats and mice (reviewed
26 above, under “Antibody responses”) showed no effect on serum titers of total IgM antibodies
27 specific for two different T cell-dependent antigens ([NTP, 2006a, b, 2005](#)). However, in an
28 additional study where Cr(VI) was administered by a route of administration that did not meet
29 PECO criteria, serum titers specific for T-1 bacteriophage, a T cell-dependent antigen, were reduced
30 ([Figoni and Treagan, 1975](#)). In this study, female Sprague Dawley rats immunized with *E. coli*
31 bacteriophage T-1 were administered Cr(VI) by subcutaneous injection (4.3 mg/kg Cr(VI)) for up to
32 44 days. The degree of antibody suppression observed in this study correlated with exposure
33 duration, which extended longer than the NTP drinking water exposure studies. Differences in
34 pharmacokinetics due to the different exposure scenarios complicate our ability to compare the
35 results of the two studies. Nonetheless, this study provides additional evidence that exposure to
36 Cr(VI) has the potential modulate immune responses.

1 Phagocytosis is important in both innate and adaptive immune responses by removing
2 pathogens and debris and as a key event in antigen presentation. The available animal studies
3 (reviewed above, under “Ex vivo WBC function”) reported inconsistent effects of Cr(VI) exposure
4 on phagocytic activity (i.e., increased, decreased, or no effect) in alveolar macrophages ([Johansson
5 et al., 1986b](#); [Glaser et al., 1985](#)) and decreased activity in splenic macrophages ([Shrivastava et al.,
6 2005b](#)). In vitro studies were more consistent in demonstrating that exposure to Cr(VI) decreased
7 phagocytic activity of human PMNs isolated from workers exposed to Cr(VI) ([Mignini et al., 2009](#)),
8 bovine alveolar macrophages ([Hooftman et al., 1988](#)), mouse peritoneal macrophages ([Christensen
9 et al., 1992](#)), and mouse RAW264.7 macrophages ([Badding et al., 2014](#)). However, only two of these
10 studies measured cell viability to take into account a potential role for cytotoxicity as a causative
11 factor ([Badding et al., 2014](#); [Hooftman et al., 1988](#)). Additional in vivo and in vitro studies would
12 help to better understand the effects of Cr(VI) exposure on phagocytic activity.

13 Other in vitro studies reported diminished activity in important effector cell functions
14 including IgG production ([Borella and Bargellini, 1993](#)), cell mobility ([Christensen et al., 1992](#)), and
15 NK cell degranulation ([Dai et al., 2017](#)). Pokeweed mitogen-stimulated IgG production by human
16 primary lymphocytes was reduced by Cr(VI) exposure ([Borella and Bargellini, 1993](#)). Random cell
17 migration was decreased in stimulated mouse primary peritoneal macrophages ([Christensen et al.,
18 1992](#)). Activation of T cells stimulated by anti-CD3 and expression of CDa107a, a marker for NK cell
19 degranulation, was reduced in mouse splenocytes following Cr(VI) exposure ([Dai et al., 2017](#)).

20 In general, although conflicting evidence was reported in the three in vivo animal studies
21 identified, Cr(VI) exposure consistently decreased immune effector cell function in vitro. However,
22 caution should be taken when interpreting these data, since only the studies by [Badding et al.
23 \(2014\)](#), [Dai et al. \(2017\)](#), and [Hooftman et al. \(1988\)](#) evaluated cell viability as a potential causative
24 factor for observed effects following exposure to Cr(VI).

25 *Effects on immune cell proliferation*

26 As discussed in the section “Ex vivo WBC function” above, the effect of Cr(VI) exposure on
27 spleen cell proliferation ex vivo has been investigated using three approaches: mitogen stimulation,
28 anti-CD3 ± anti-CD28 stimulation, and the MLR. Exposure to Cr(VI) in vivo increased spleen cell
29 proliferation in rats and mice in the presence of ConA, a T cell mitogen ([Shrivastava et al., 2005b](#);
30 [Snyder and Valle, 1991](#); [Glaser et al., 1985](#)). Consistent with this finding, ConA-induced spleen cell
31 proliferation was increased when lymphocytes collected from Cr(VI) exposed workers were
32 cultured in the presence of Cr(VI) in vitro ([Mignini et al., 2009](#)). Furthermore, in vitro exposure to
33 Cr(VI) increased activation by ConA in human lymphocytes, but decreased activation when
34 exposure was to a higher dose ([Mignini et al., 2009](#)). [Snyder and Valle \(1991\)](#) reported inhibition of
35 in vitro ConA-stimulated proliferation, whereas [Mignini et al. \(2004\)](#) reported no effect. Spleen cell
36 proliferation was also investigated using PHA. Addition of Cr(VI) to lymphocytes cultured from
37 exposed workers lead to an increase in proliferation stimulated by PHA ([Mignini et al., 2009](#)).
38 When exposed to Cr(VI) in vitro, the proliferation response was biphasic in PHA-stimulated human

1 primary lymphocytes ([Mignini et al., 2009](#); [Borella and Bargellini, 1993](#)). The effect of in vivo
2 exposure to Cr(VI) on spleen cell proliferation stimulated by LPS has only been investigated in a
3 single report ([Snyder and Valle, 1991](#)) (see Ex vivo WBC function). In that study, the low dose of
4 LPS (100 mg/L), but not the high dose (200 mg/L), decreased rat splenic lymphocyte proliferation.
5 LPS-induced spleen cell proliferation was also decreased in lymphocytes cultured in vitro in the
6 presence of Cr(VI) ([Mignini et al., 2009](#)).

7 Cr(VI) exposure had no effect on anti-CD3 spleen cell proliferation in three rodent studies
8 ([NTP, 2006a, b, 2005](#)). In contrast, exposure to Cr(VI) in vitro decreased anti-CD3 and
9 anti-CD3/anti-CD28 stimulated primary human lymphocyte proliferation ([Dai et al., 2017](#); [Akbar et
10 al., 2011](#)).

11 In vivo studies showed no effect of Cr(VI) exposure on MLR ([NTP, 2005](#); [Snyder and Valle,
12 1991](#)). However, MLR was increased when splenocytes collected from Cr(VI)-exposed rats were
13 exposed to additional Cr(VI) in vitro ([Snyder and Valle, 1991](#)). When the only source of Cr(VI)
14 exposure was in vitro, either no effect or a stimulatory effect on MLR was observed ([Snyder and
15 Valle, 1991](#)). Recognizing that these the in vitro studies performed by were part of an investigation
16 ([Snyder and Valle, 1991](#)) using the same study design parameters (i.e., rat strain, exposure
17 duration, Cr(VI) concentration, stimulator), the discrepancy may be attributable to low study
18 replication.

19 *Effects on communication between immune cells*

20 *Complement levels*

21 One low confidence cross-sectional study investigated the effects of Cr(VI) exposure on
22 complement levels (Table 3-32). In that study, exposure to Cr(VI) increased levels of complement
23 C3 (mean: 0.91 ± 0.13 g/L unexposed, 1.20 ± 0.24 g/L exposed) and C4 (mean: 0.23 ± 0.05 g/L
24 unexposed, 0.32 ± 0.07 g/L exposed) in serum ([Qian et al., 2013](#)). Serum complement levels
25 increased two- to threefold above baseline are associated clinically with infection or acute
26 inflammation ([Ritchie et al., 2004](#)). But even subtle increases in baseline complement C3 and C4
27 are associated with other inflammatory markers and have been identified as a risk factor for
28 disorders associated with systemic inflammation, including cardiometabolic disease ([Hertle et al.,
29 2012](#); [Engström et al., 2007b](#); [Engström et al., 2007a](#); [Engström et al., 2005](#)).

30 *Mitogen-stimulated cytokine secretion*

31 Effects of in vivo Cr(VI) exposure on mitogen-induced cytokine secretion by isolated cells in
32 vitro was evaluated in two medium confidence studies with ConA ([Karaulov et al., 2019](#)) or LPS
33 ([Cohen et al., 1998](#)). A single in vivo study observed increased secretion of TNF- α and IL-6 in the
34 serum of LPS challenged mice ([Jin et al., 2016](#)). There are no in vitro studies available assessing the
35 effects of Cr(VI) exposure on ConA-stimulated cytokine secretion.

1 *Cytokine measurements in biological media*

2 Twenty-one studies investigated the effects of Cr(VI) on immune cell communication (see
3 Appendix Tables C-37 and C-38). A primary mechanism of communication for cells of the immune
4 system is through production and release of cytokines, which are low molecular weight
5 glycoproteins involved in immune responses and are commonly classified as pro-inflammatory
6 (i.e., immune stimulating) or anti-inflammatory (i.e., immunosuppressive). In practice, however,
7 the distinction between the classes of cytokines is not clear cut. Interpretation of cytokine data
8 collected from biological medium is challenging because, depending on context, the same cytokine
9 can have either activating or suppressing effects on a particular cell type ([Nature, 2019](#)).
10 Furthermore, reduction in the level of a pro-inflammatory cytokine can have an anti-inflammatory
11 effect and vice versa. The effects of Cr(VI) exposure on levels of 30 cytokines (i.e., IL-1a, IL-1b, IL-2,
12 IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-17, IL-17A, TNF- α , IFN- γ , IFN- α , MIP-2,
13 CXCL10, CXCL11, CCL5, CCL17, CCL18, CCL20, CCL22, eotaxin, G-CSF, GM-CSF, MCP-1, and MIP1 α)
14 have been investigated. These studies include cytokine measurements conducted following in vivo
15 and in vitro exposures to Cr(VI) in human and animal models. Generally, the specific cytokines
16 measured included in each study varied, making interpretation of consistency for a given cytokine
17 difficult. Interpretation is further hampered by the mix of responses reported for the same
18 cytokine. Irrespective, the available data suggest that Cr(VI) exposure has the potential to alter
19 levels of some cytokines, potentially disrupting the regulatory balance that dictates normal immune
20 system function. While the predictive value of cytokine levels for hazard assessment is unclear, the
21 observed alterations in cytokine levels do add to the weight of the evidence evaluation of Cr(VI) and
22 its potential to modulate the immune system.

23 Vascular cell adhesion molecule 1 (VCAM-1), endothelial-leukocyte adhesion molecule 1
24 (ELAM-1), and intracellular adhesion molecule 1 (ICAM-1) play an important role in endothelial
25 transmigration, the process whereby immune cells enter tissues. Expression of these important
26 proteins is up-regulated by certain cytokines (e.g., IL-1, TNF- α). [Mignini et al. \(2009\)](#) reported no
27 effect of Cr(VI) exposure had no effect on levels of these proteins.

28 Cr(VI) exposure had no effect on E-rosetting by human lymphocytes collected from exposed
29 workers and treated with additional Cr(VI) in vitro. E-rosetting occurs when human T cells
30 spontaneously bind to sheep red blood cells, a process that involves CD2 (i.e., the E-rosette
31 receptor), which plays an important role in T cell activation.

32 *Allergic hypersensitivity*

33 Hypersensitivity responses are the result of an over-reaction of the immune system.
34 Allergic hypersensitivity to Cr(VI) is generally observed following occupational exposure ([Hedberg,](#)
35 [2018](#)). Hypersensitivity reactions are organized into four different classes, Type I, II, III, and IV
36 ([Murphy and Weaver, 2016](#)). There are only a few anecdotal case reports and a small number of
37 animal studies associating Cr(VI) with Type I hypersensitivity (antibody mediated) responses that
38 cause allergic asthma ([ATSDR, 2012](#); [Ban et al., 2010](#); [Fernández-Nieto et al., 2006](#); [OSHA, 2006](#);

1 [Bright et al., 1997](#); [Olaguibel and Basomba, 1989](#)); however, there is strong and compelling
2 evidence that Cr(VI) causes Type IV hypersensitivity responses. Type IV hypersensitivity responses
3 are mediated by T cells and are responsible for allergic contact dermatitis (ACD) resulting from
4 dermal exposure. As described in the protocol (Appendix A), a review of the evidence for
5 Cr(VI)-induced ACD is not included in this toxicological review because the scope of the Cr(VI) IRIS
6 assessment is comprised of potential health effects by the inhalation and oral routes of exposure.
7 Consequently, Cr(VI)-induced ACD was not comprehensively reviewed but was considered as
8 supporting evidence for the effects of Cr(VI) exposure on the immune system. The strongest
9 evidence for Cr(VI) Type IV hypersensitivity reactions comes from dermal patch testing in humans
10 ([ATSDR, 2012](#); [OSHA, 2006](#)). Human clinical evidence of Type IV hypersensitivity is supported by
11 data from in vivo and ex vivo investigations performed in Guinea pigs ([Wang et al., 2010a](#); [Ikarashi](#)
12 [et al., 1996](#); [Helmbold et al., 1993](#); [Saloga et al., 1988](#); [Christensen et al., 1984](#); [Parker et al., 1984](#);
13 [Jirova et al., 1983](#); [Siegenthaler et al., 1983](#); [Lindberg et al., 1982](#); [Turk and Parker, 1977](#); [Miyamoto](#)
14 [et al., 1975](#); [Schneeberger and Forck, 1974](#)) and mice ([Lindemann et al., 2008](#); [Mandervelt et al.,](#)
15 [1997](#); [Basketter et al., 1994](#); [Ikarashi et al., 1992](#); [Vreeburg et al., 1991](#); [Kimber et al., 1990](#); [Mor et](#)
16 [al., 1988](#); [Lischka, 1971](#)).

17 **3.2.6.4. Integration of Evidence**

18 Overall, the **evidence suggests** that Cr(VI) may cause immune effects in humans. Cr(VI)
19 may modulate the immune system through both stimulatory and suppressive actions. This
20 conclusion is primarily based on coherent evidence of effects on ex vivo WBC function across
21 human and animal studies, antibody responses to T cell-dependent antigen measured in animals,
22 and reduction in host resistance to bacterial infection reported in animal studies. However,
23 confidence in the evidence was reduced because some of the studies are *low* confidence and
24 reported findings often differed across studies. Integrated evidence of immune system effects of
25 Cr(VI) exposure from human, animal, and mechanistic studies is summarized in an evidence profile
26 table (Table 3-38).

27 The evidence of an association between Cr(VI) exposure and immunotoxicological effects in
28 humans is *slight*. The available studies are *low* confidence. Data obtained from supporting immune
29 system studies lack consistency across studies and across endpoints within studies. However, there
30 is some evidence from the most informative studies (i.e., ex vivo WBC function) that Cr(VI) has the
31 potential to stimulate at least some aspects of immune function. In addition, the large evidence
32 base demonstrating that exposure to Cr(VI) can induce allergic hypersensitivity responses in
33 humans further supports this conclusion ([Hedberg, 2018](#); [ATSDR, 2012](#)).

34 Evidence from animal toxicology studies and supportive mechanistic data from in vivo and
35 in vitro studies provide *slight* evidence that Cr(VI) has both stimulatory and suppressive effects on
36 the immune system. Cr(VI) exposure increased antibody responses to T cell-dependent antigen
37 (i.e., sheep red blood cells), and effects on this critical function of the immune system were
38 observed in mice exposed orally and in rats exposed orally or by inhalation ([NTP, 2006a, 2005](#);

1 [Glaser et al., 1985](#)). The body of evidence in support of this effect is small, but the findings are
2 supported by evidence from some studies of increases in ex vivo WBC function ([Shrivastava et al.,](#)
3 [2005b](#); [Cohen et al., 1998](#); [Snyder and Valle, 1991](#); [Glaser et al., 1985](#)), WBC numbers ([NTP, 2008,](#)
4 [2007](#); [Glaser et al., 1990](#)), and total immunoglobulin levels following in vivo Cr(VI) exposure ([Glaser](#)
5 [et al., 1985](#)). Some mechanistic evidence has demonstrated an increased response to antigenic
6 stimuli in one-way mixed lymphocyte cultures when splenocytes collected from Cr(VI)-exposed
7 rats were exposed to additional Cr(VI) in vitro ([Snyder and Valle, 1991](#)) and increased
8 mitogen-stimulated spleen cell proliferation with in vitro Cr(VI) exposure ([Mignini et al., 2009](#);
9 [Borella and Bargellini, 1993](#)). Data demonstrating that exposure to Cr(VI) can result in allergic
10 hypersensitivity responses bolster these findings ([ATSDR, 2012](#)).

11 There is also evidence of an effect on host resistance, with short-term inhalation exposure
12 decreasing in situ clearance of bacteria from the lungs of Cr(VI)-exposed rats ([Cohen et al., 2010](#);
13 [Cohen et al., 2006](#)). The host resistance model used for these studies is designed to evaluate local
14 pathogen clearance by alveolar macrophages. While the effect cannot be directly attributed to a
15 defect in phagocytosis, lung clearance of inhaled iron oxide was reduced in rats exposed to Cr(VI)
16 by the inhalation route ([Glaser et al., 1985](#)). Furthermore, phagocytic activity of PMNs collected
17 from exposed workers ([Mignini et al., 2009](#)) and splenic macrophages collected from mice exposed
18 to Cr(VI) in drinking water was reduced ([Shrivastava et al., 2005b](#)), and several in vitro mechanistic
19 studies showed decreased phagocytic activity by human primary PMNs ([Mignini et al., 2009](#)),
20 bovine alveolar macrophages ([Hooftman et al., 1988](#)), mouse peritoneal macrophages ([Christensen](#)
21 [et al., 1992](#)), and mouse RAW264.7 macrophages ([Badding et al., 2014](#)). Cr(VI) exposure also
22 impaired the mobility of mouse alveolar macrophages ([Christensen et al., 1992](#)). Together, these
23 findings suggest that Cr(VI) can alter key functions of cells of the innate immune system, but
24 additional studies would be useful for identifying the most relevant exposure contexts and the
25 overall impact of these effects on immunity.

26 It is not without precedent for a single chemical to exert both stimulatory and suppressive
27 effects on various immune parameters ([IPCS, 2012](#)). Exposure-related stimulation of the immune
28 system might increase susceptibility to allergic disease or autoimmunity and can include
29 exaggerated or inappropriately prolonged inflammatory responses associated with systemic
30 chronic inflammation, which can increase risk of developing other serious health conditions such as
31 cardiometabolic disease or cancer ([Furman et al., 2019](#); [IPCS, 2012](#)). In addition, because
32 continuous, uncontrolled immune stimulation represents a disruption of the homeostatic processes
33 required to maintain a balanced immune response, stimulation of the immune system may be
34 accompanied by immunosuppression, potentially altering host resistance as was observed here in a
35 limited number of studies. Additional studies are necessary to better understand the effects of
36 Cr(VI) exposure on the immune system, particularly with respect to studies of host resistance.

Table 3-38. Evidence profile table for immune effects

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from studies of exposed humans					⊕○○○
EX VIVO WBC FUNCTION Low confidence: Mignini et al. (2004) Mignini et al. (2009)	<p>Increased lymphocyte proliferation induced by two different T cell mitogens but not by a B cell mitogen in two <i>low</i> confidence studies.</p> <p>No effect on phagocytosis by PMNs or NK cell activity in one <i>low</i> confidence study.</p>	<ul style="list-style-type: none"> • Coherent response with two different T cell mitogens • Consistent ex vivo proliferative responses to T cell mitogens in rats and mice (see <i>Mechanistic evidence and supplemental information</i> below) 	<ul style="list-style-type: none"> • <i>Low</i> confidence studies 	<p>⊕○○○</p> <p><i>Slight</i></p> <p>Although coherent changes in T cell mitogen-induced lymphocyte proliferation, WBC counts, and some WBC populations and immunoglobulin levels were reported, available data were inconsistent and derived from <i>low</i> confidence studies.</p>	<p>The evidence suggests that Cr(VI) may cause immune modulation in humans given sufficient exposure conditions based on:</p> <p><i>Slight</i> evidence from <i>low</i> confidence cross-sectional studies of workers with known risk of Cr(VI) exposure showing increased ex vivo WBC function (i.e., stimulated proliferative responses to T cell mitogens).</p> <p><i>Slight</i> evidence from <i>high, medium, and low</i> confidence studies in animals demonstrating stimulatory effects on antibody response, ex vivo WBC function, WBC number, and Ig levels and suppressive effects on host resistance.</p>
WBC COUNTS Low confidence: Boscolo et al. (1997) Sazakli et al. (2014) Wang et al. (2012a) Kuo and Wu (2002) Mignini et al. (2004) Mignini et al. (2009)	<p>A positive association with white blood cell counts was observed in 1/3 studies, while an inverse association was also observed in 1/3 studies.</p>	<ul style="list-style-type: none"> • No factors noted 	<ul style="list-style-type: none"> • Unexplained inconsistency in WBC counts across studies, although some degree of variability in these 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
			<ul style="list-style-type: none"> measures is expected • <i>Low</i> confidence studies 		Supportive mechanistic evidence from animal in vivo, ex vivo, and in vitro models demonstrating the potential for multiple mechanisms of immune system toxicity.
WBC SUBPOPULATIONS <i>Low confidence:</i> Boscolo et al. (1997) Kuo and Wu (2002) Mignini et al. (2004) Mignini et al. (2009) Tanigawa et al. (1998)	Decreased CD4+ cell number in workers (2 of 2 studies) and in exposed and unexposed smokers and nonsmokers (1 of 1 studies). Decreased CD8+ cell number in workers (1 of 2 studies) and in exposed smokers (1 of 1 study).	<ul style="list-style-type: none"> • Consistent findings regarding CD4+ subpopulations in three studies 	<ul style="list-style-type: none"> • <i>Low</i> confidence studies 		
IMMUNOGLOBULIN LEVELS <i>Low confidence:</i> Boscolo et al. (1997) Qian et al. (2013) Verschoor et al. (1988)	A consistent stimulatory effect on serum levels of IgA and IgM was reported in two studies whereas effects on IgG were inconsistent in three studies.	<ul style="list-style-type: none"> • Coherent findings regarding serum IgA and IgM levels in two studies 	<ul style="list-style-type: none"> • Unexplained inconsistency in IgG levels • <i>Low</i> confidence studies 		
Evidence from animal studies					
ANTIBODY RESPONSES <i>High confidence:</i> NTP (2005) NTP (2006b) NTP (2006a) <i>Low confidence:</i> Glaser et al. (1985)	Increased IgM antibody-forming cell responses was associated with exposures in three <i>high</i> confidence drinking water studies (one lacked statistical significance) and one <i>low</i> confidence inhalation study; the effect was not internally reproducible in one <i>high</i> confidence study.	<ul style="list-style-type: none"> • Consistency across studies performed in rats and mice following 	<ul style="list-style-type: none"> • Antibody response was inconsistent in <i>high</i> confidence studies 	⊕ ⊖ ⊖ <i>Slight</i> Cr(VI) induced changes in the most meaningful immunological endpoints	

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
		exposure via two different routes <ul style="list-style-type: none"> • Mostly <i>high</i> confidence studies 		(i.e., antibody response, host resistance and ex vivo WBC function) and endpoints that provide supporting evidence (i.e., immune organ weight, immunoglobulin levels, and WBC counts).	
HOST RESISTANCE <i>Medium confidence:</i> Cohen et al. (2006) Cohen et al. (2010)	Exposure to Cr(VI) compounds with high and low solubility was associated with decreased in situ bacterial clearance in the lung.	<ul style="list-style-type: none"> • Consistent findings regarding in situ bacterial clearance • Mechanistic evidence for immune effector function provides biological plausibility • <i>Medium</i> confidence studies 	<ul style="list-style-type: none"> • No factors noted 		
EX VIVO WBC FUNCTION <i>High confidence:</i> NTP (2005) NTP (2006b) NTP (2006a) <i>Medium confidence:</i>	Effects on phagocytosis by macrophages were observed in two <i>low</i> confidence studies. Increased mitogen-induced proliferative response (ConA) observed in three <i>low</i> confidence studies.	<ul style="list-style-type: none"> • Coherent findings of effects on phagocytosis and mitogen-induced proliferative responses across 	<ul style="list-style-type: none"> • <i>Low</i> confidence studies 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>Cohen et al. (1998) Johansson et al. (1986b) Low confidence: Glaser et al. (1985) Snyder and Valle (1991) Shrivastava et al. (2005b)</p>	<p>Effects on superoxide and hydrogen peroxide production (with zymosan) and nitric oxide (with IFN-γ) in one <i>low</i> confidence study.</p> <p>No effects on NK cell activity, the MLR, or anti-CD3-stimulated spleen cell proliferation were observed in three <i>high</i> confidence short-term drinking water studies performed in rats and mice.</p>	<p>animal in vivo studies</p> <ul style="list-style-type: none"> Consistency with effects observed in animal cells in vitro 			
<p>IMMUNE ORGAN PATHOLOGY High confidence: NTP (1996a) NTP (2005) NTP (2007) NTP (2008) Medium confidence: Karaulov et al. (2019) NTP (2006b) NTP (2006a) Glaser et al. (1986)</p>	<p>Microscopic structural effects of the rat thymus and spleen were reported in one <i>medium</i> confidence oral exposure study.</p> <p>No effects on immune organ gross pathology were reported in six <i>medium</i> or <i>high</i> confidence NTP oral exposure studies and one <i>medium</i> confidence inhalation study.</p>	<ul style="list-style-type: none"> <i>Medium</i> confidence study 	<ul style="list-style-type: none"> No factors noted 		
<p>IMMUNOGLOBULIN LEVELS – TOTAL Medium confidence: Glaser et al. (1985) Low confidence: Glaser et al. (1986) Glaser et al. (1990)</p>	<p>A dose-dependent increase in serum immunoglobulins following inhalation exposure for 90 days (0.025–0.10 mg/m³ Cr(VI)) in a <i>medium</i> confidence study; effects not observed at higher Cr(VI) concentrations (i.e., 0.20 mg/m³). Two other <i>low</i> confidence inhalation studies of short-term, subchronic, and chronic exposure</p>	<ul style="list-style-type: none"> Dose-response gradient <i>Medium</i> confidence study Coherent with effects on 	<ul style="list-style-type: none"> No factors noted 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	duration reported no alterations or decreases in total serum immunoglobulin levels.	antibody responses			
IMMUNE ORGAN WEIGHT High confidence: NTP (2005) NTP (2006b) NTP (2006a) NTP (2007) Medium confidence: Glaser et al. (1985) Jin et al. (2016) Karaulov et al. (2019) Kim et al. (2004) Low confidence: Glaser et al. (1986) Shrivastava et al. (2005b)	<p>Following drinking water exposures, treatment-related decreases in absolute thymus weight was observed in one <i>high</i> confidence subchronic exposure study in mice and one <i>medium</i> confidence long-term study in rats but not in three other <i>high</i> confidence subchronic studies in mice and rats.</p> <p>Effects of Cr(VI) exposure on absolute and relative spleen weight were observed in some studies, but not others. Results do not consistently correlate with dose, route of administration, exposure duration or species.</p>	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Unexplained inconsistency across study types 		
WBC COUNTS High confidence: NTP (2005) NTP (2006b) NTP (2006a) Medium confidence: Karaulov et al. (2019)	<p>The absolute number of macrophages and percentage NK cells were increased in one <i>high</i> confidence study, and the absolute and/or relative number of several lymphocyte subtype populations varied by timepoint in one <i>medium</i> confidence study. No effects on lymphocyte subtypes in two <i>high</i> confidence studies. No effects on the absolute number of splenic WBCs in three <i>high</i> confidence and one</p>	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Unexplained inconsistency across study types, although some degree of variability in these measures is expected 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<i>medium</i> confidence drinking water studies.				
WBC COUNTS (HEMATOLOGY) High confidence: NTP (1996a) NTP (2007) NTP (2008) Medium confidence: NTP (2005) NTP (2006b) NTP (2006a) Glaser et al. (1986) Glaser et al. (1990) Kim et al. (2004) Krim et al. (2013) Wang et al. (2015) Low confidence: Glaser et al. (1985) Shrivastava et al. (2005a)	Effects on WBC counts were reported in one of five studies performed in mice (4 drinking water, 1 diet) and four of nine studies performed in rats (2 drinking water, 2 inhalation). These effects were observed more often in studies of exposure durations <90 days, but this was not a consistent finding.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Unexplained inconsistency across study types 		
ANTIGEN-SPECIFIC ANTIBODY TITER High confidence: NTP (2005) NTP (2006b) NTP (2006a)	No effect on serum titer of total IgM antibodies specific for two different T cell-dependent antigens in three <i>high</i> confidence NTP studies of 28-day exposures in drinking water.	<ul style="list-style-type: none"> No factors 	<ul style="list-style-type: none"> No factors 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Mechanistic evidence and supplemental information					
Biological events or pathways	Summary of key findings and interpretation			Judgment(s) and rationale	
Effects on immune effector function of specific cell types	<p><i>Interpretation:</i> Consistent in vitro evidence that Cr(VI) decreases phagocytosis by macrophages. Phagocytosis is important in both innate and adaptive immune responses by removing pathogens and debris and also as a key event in antigen presentation.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> • Reduced phagocytosis in PMNs collected from exposed workers and treated with additional Cr(VI) in vitro (Mignini et al., 2009) • Consistent in vitro evidence of decreased phagocytic activity by macrophages (splenic, alveolar) harvested from murine and bovine sources and by the RAW2643.7 macrophage cell line (Badding et al., 2014; Christensen et al., 1992; Hooftman et al., 1988) • Exposure to Cr(VI) in vitro had no effect on random migration in mouse primary peritoneal macrophages exposed to non-cytotoxic concentrations of Cr(VI) (Christensen et al., 1992) • In vitro evidence of decreased IgG production in human primary lymphocytes (Borella and Bargellini, 1993) • In vitro evidence of decreased cell surface expression of CD107a, a marker for NK cell degranulation {Dai, 2017, 4453480 			<p>Biologically plausible observations of effects on phagocytosis in vitro that are consistent with the in vivo findings in animals, and coherent with other immune effects (e.g., mitogen-induced proliferative responses).</p> <p>T cell proliferative responses are consistent among ex vivo evidence from exposed humans and animals, but less consistent among in vitro exposures and lack coherence with direction of effects on T cell activation, likely</p>	

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Effects on immune cell differentiation or activation	<p><i>Interpretation:</i> In vitro exposure studies indicate Cr(VI) has the potential to affect activation of dendritic cells, which serve an important role in innate and adaptive immune responses. Cr(VI) exposure decreased T cell activation in vitro.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> • Dose-dependently increased expression of cell surface marker CD86 (dendritic cell maturation marker) but no effect on CD83 (activation marker for antigen presenting cells) expression in human monocyte-derived dendritic cells in vitro (Toebak et al., 2006) • Decreased activation of T cells stimulated with anti-CD3 and anti-CD28 in vitro (Dai et al., 2017) 			<p>due to differing experimental conditions.</p> <p>There is not enough information for the remaining mechanistic evidence base (e.g., for effects on immune cell communication) to make a determination.</p>	
Effects on immune cell proliferation	<p><i>Interpretation:</i> Consistent with findings in human occupational exposure studies, Cr(VI) exposure in vitro has the potential to alter T cell proliferative responses.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> • Ex vivo spleen cell proliferation increased in rats and mice in response to T cell mitogen ConA (Shrivastava et al., 2005b; Snyder and Valle, 1991; Glaser et al., 1985) • Some in vitro evidence of potential alterations in proliferative responses to T cell mitogens PHA and ConA in cells from humans and rats exposed to Cr(VI), where lower concentrations appear more likely to induce an effect (Mignini et al., 2009; Mignini et al., 2004; Borella and Bargellini, 1993; Snyder and Valle, 1991) • In vitro evidence that Cr(VI) exposure decreases proliferation of lymphocytes stimulated by anti-CD3/anti-CD28 (Dai et al., 2017; Akbar et al., 2011) <p><i>Limitations:</i></p> <ul style="list-style-type: none"> • Inconsistent evidence for effects on the MLR between ex vivo and in vitro exposures (Snyder and Valle, 1991) 				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<ul style="list-style-type: none"> • Difficulty in comparing results due to differing test conditions • Some inconsistencies in proliferative responses between ex vivo and in vitro exposures 				
Effects on immune cell communication	<p><i>Interpretation:</i> Cr(VI) increases complement factors, which may indicate recent infection or development of inflammatory disease.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> • Cr(VI) exposure increased complement factors C3 and C4 in one <i>low</i> confidence study of serum collected from workers occupationally exposed to Cr(VI) (Qian et al., 2013) 				

3.2.7. Male Reproductive Effects

1 The male reproductive system consists of internal and external organs that are regulated by
2 a balanced interplay of hormones from the hypothalamus-pituitary-gonadal (HPG) axis. The
3 development and function of the male reproductive system can be affected by toxicants that
4 directly reach reproductive tissues or by the disruption of hormone activity at any point along the
5 HPG axis ([Creasy and Chapin, 2018](#)). Common endpoints evaluated to gauge male reproductive
6 toxicity include semen parameters and male reproductive hormone levels in human studies, as well
7 as changes in fertility and fecundity, sperm parameters, reproductive system organ weights and
8 histopathology, structural abnormalities, and changes in sexual behavior in animal studies ([U.S.
9 EPA, 1996b](#)). This section considers reproductive effects in males exposed to Cr(VI) at any life
10 stage, including exposures occurring preconception and for all stages of development. This is in
11 accordance with EPA's *Framework for Assessing Health Risk of Environmental Exposures to Children*
12 ([U.S. EPA, 2006d](#)), which recommends that evidence for organ system toxicity be considered for all
13 life stages in order to identify populations or life stages that may be more susceptible to chemical-
14 induced toxicity. Reproductive effects resulting from developmental exposures are also considered
15 in the "Developmental effects" section.

16 3.2.7.1. Human Evidence

17 Study evaluation summary

18 Table 3-39 summarizes the human epidemiology studies considered in the evaluation of the
19 effects of Cr(VI) on the male reproductive system. These consist of six cross-sectional occupational
20 studies conducted among workers in two industries with known risk of exposure to Cr(VI) in
21 Denmark and India. They include five studies of stainless-steel welders ([Danadevi et al., 2003](#);
22 [Hjollund et al., 1998](#); [Bonde and Ernst, 1992](#); [Bonde, 1990](#); [Jelnes and Knudsen, 1988](#)). Two of
23 these studies were performed on the same cohort of workers using different analyses ([Bonde and
24 Ernst, 1992](#); [Bonde, 1990](#)) and therefore were evaluated as a single study (Table 3-39), although
25 there are differences in the analyses and results between the two studies as discussed below. In
26 addition, one study conducted in chromium (III) sulfate production workers was considered
27 relevant due to evidence of exposure to Cr(VI) among the workers that could be explained by the
28 location of the chromium sulfate operations within a chromate production plant ([Kumar et al.,
29 2005](#)). The study evaluations resulted in one *medium* confidence study ([Bonde and Ernst, 1992](#);
30 [Bonde, 1990](#)) and four *low* confidence studies ([Kumar et al., 2005](#); [Danadevi et al., 2003](#); [Hjollund et
31 al., 1998](#); [Jelnes and Knudsen, 1988](#)). Results of the male reproductive effects in these studies—
32 specifically, semen parameters and serum reproductive hormones—are summarized in Table 3-40.

33 In all studies, the primary exposure route was inhalation of Cr(VI) in air. Air concentrations
34 of Cr(VI) (mean [SD] = 3.6 [2.8] ug/m³) were reported in one cohort of stainless-steel welders
35 ([Bonde, 1990](#)) (Protocol, Section 6, Appendix A for more on consideration of welding studies in this

1 assessment). No other studies of Cr(VI) exposure and male reproductive effects in humans
 2 reported air concentrations of Cr(VI) or total chromium.

3 Lack of air concentration measurements in all studies except one ([Bonde, 1990](#)) contributed
 4 to concerns about potential bias from exposure misclassification. These concerns were mitigated
 5 when job-based dichotomous exposure categories were consistent with reported concentrations of
 6 chromium in urine ([Bonde and Ernst, 1992](#)) or blood ([Danadevi et al., 2003](#)). In one study of
 7 workers on a site where both trivalent and hexavalent chromate products were produced ([Kumar
 8 et al., 2005](#)), it is unclear whether blood concentrations of chromium reflected Cr(VI) specifically;
 9 however the high rate of nasal perforation among the workers in this study indicate a history of
 10 Cr(VI) exposure. Other study evaluation concerns included potential residual confounding ([Kumar
 11 et al., 2005](#); [Jelnes and Knudsen, 1988](#)) and concerns about outcome measurement ([Kumar et al.,
 12 2005](#); [Hjollund et al., 1998](#)).

Table 3-39. Summary of human studies for Cr(VI) male reproductive effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a [Click to see interactive data graphic for rating rationales.](#)

Author (year)	Industry	Location	Study Design	Sperm Parameters	Hormones
Bonde and Ernst (1992) , Bonde (1990)	SS Welding	Denmark	Cohort (occupational)	M	M
Danadevi et al. (2003)	SS Welding	India	Cohort (occupational)	L	-
Hjollund et al. (1998)	SS Welding	Denmark	Cohort (occupational)	L	U ^b
Jelnes and Knudsen (1988)	SS Welding	Denmark	Cohort (occupational)	L ^c	-
Kumar et al. (2005)	Chromium sulfate ^d	India	Cohort (occupational)	L	-

SS = stainless steel.

^aIn addition to these included studies, two additional studies reported male reproductive outcomes that met PECO criteria but were found to be *uninformative* at the study evaluation stage: [Tielemans et al. \(1999\)](#); [Li et al. \(2001\)](#).

^bAnalysis of hormone concentrations in [Hjollund et al. \(1998\)](#) compared all welders to referents (no analysis comparing SS welders to referents) and therefore was found to be *uninformative* for this outcome.

^c*Uninformative* for motility only. *Low* confidence for other sperm parameters.

^dThough chromium sulfate is trivalent, there is evidence of simultaneous or recent exposure to Cr(VI) in the exposed group.

13 Synthesis of evidence in humans

14 *Semen parameters*

15 Four core endpoints were considered in the evaluation of the effects of exposure to Cr(VI)
 16 on semen parameters: volume, concentration, morphology and motility. A key consideration when

1 assessing the quality of outcome measurements for these endpoints was the window of time
2 following collection of samples ([Radke et al., 2019](#)). Other quality control procedures related to
3 collection and processing of samples were considered, including but not limited to collection of
4 more than one sample from the same individual and abstinence period duration before sample
5 collection.

6 One *medium* confidence study reported mild decreases in semen volume and sperm motility
7 in stainless-steel welders (mean [SD] = 2.4 [1.1] mL; 51.0 [15.7] percent motile) compared to
8 nonwelders (mean [SD] = 3.1 [1.3] mL; 57.7 [14.8] percent motile), but no differences in sperm
9 concentration or morphology between these two groups ([Bonde, 1990](#)). In the same cohort,
10 comparisons of sperm concentration, morphology and motility among three exposure groups
11 characterized by urine chromium measurements were indicative of an effect but did not reach
12 statistical significance ([Bonde and Ernst, 1992](#)) (Table 3-40). Both air concentrations and urine
13 chromium concentration were higher among stainless-steel welders compared to mild steel
14 welders or nonwelders, and these exposure data lent confidence to the exposure characterization of
15 participants in both analyses. These data also reveal some exposure misclassification in both
16 analyses that may have decreased study sensitivity. The detection of a statistically significant
17 decrease in volume and motility despite limits to study sensitivity increased confidence in the
18 findings of this study.

Table 3-40. Summary of results from human studies of Cr(VI) male reproductive effects

Study	Exposure	Conf.	Result Format	N	Semen Parameters				Hormones		
					Vol (mL)	Concentration (million/mL)	% Normal forms	% Motile	T (nmol/L)	LH (IU/L)	FSH (IU/L)
Danish Welders ^a Bonde (1990)	SS welding v. ref	M	Mean (SD) and p-value	Exp: 35 Ref: 54	Exp: 2.4 (1.1) Ref: 3.1 (1.3) <i>p</i> < 0.05	Exp: 58.4 (16.7) Ref: 58.6 (23.9) NS	Exp: 65.8 (15.7) Ref: 66.7 (17.1) NS	Exp: 51.0 (15.7) Ref: 57.7 (14.8) <i>p</i> < 0.05	Exp: 17.3 (5.8) Ref: 21.2 (8.0) <i>p</i> < 0.05	Exp: 6.1 (2.4) Ref: 7.2 (2.7) NS	Exp: 4.4 (5.1) Ref: 4.9 (2.8) NS
Danish Welders ^a Bonde and Ernst (1992)	3-level ^a	M	Unadjusted regression beta; Mean (SD) and p-value	Low: 60 Med: 24 High: 23	β : 0.2 Low: 2.9 (1.3) Med: 3.0 (1.6) High: 3.2 (1.4) NS	β : -1.5 Low: 54.5 (26.9) Med: 62.8 (21.7) High: 50.7 (20.9) NS	β : -1.6 Low: 65.8 (17.8) Med: 61.0 (17.1) High: 56.8 (20.5) NS	β : -0.5 Low: 55.2 (14.6) Med: 54.8 (11.9) High: 51.6 (16.4) NS	β : -1.2 Low: 21.0 (7.8) Med: 18.7 (7.3) High: 16.4 (5.6) NS	β : -0.1 Low: 6.8 (3.0) Med: 6.8 (2.4) High: 6.7 (2.8) NS	β : -0.1 Low: 4.7 (2.9) Med: 5.0 (2.6) High: 4.5 (2.2) NS
Danadevi et al. (2003)	Welders ^b v. Controls	L	Mean (SD) and p-value	Exp: 57 Ref: 57	Exp: 2.4 (0.5) Ref: 2.5 (0.5) NS	Exp: 14.5 (24.0) Ref: 62.8 (43.7) <i>p</i> < 0.001	Exp: 37.0 (14.3) Ref: 69.0 (8.0) <i>p</i> < 0.001	% IMMOTILE: Exp: 31.0 (16.6) Ref: 12.4 (7.0) <i>p</i> < 0.001	-	-	-
Hjollund et al. (1998)^c	SS welding v. ref	L	Median (crude and adj)	Exp: NR Ref: NR (29, 205 respectively at enrollment)	-	Exp: 56.0 (crude) Exp: 65.5 (adj) Ref: 50.0 (crude) Ref: 46.4 (adj)	-	-	Uninformative for this endpoint	Uninformative for this endpoint	Uninformative for this endpoint
Jelnes and Knudsen (1988)	SS welding v. ref	L	Median and p-value	Exp: 75–77 Ref: 67–68	Exp: 3.0 Ref: 3.0 <i>p</i> = 0.50–0.70	Exp: 58.6 Ref: 58.2 <i>p</i> = 0.95	Exp: 36.0 Ref: 36.5 <i>p</i> = 0.70–0.90	Uninformative for this endpoint	-	-	-
Kumar et al. (2005)	Chromate workers v. ref	L	Mean (SD) and p-value	Exp: 54–61 Ref: 10–15	Exp: 2.67 (0.964) Ref: 2.54 (0.641) <i>p</i> = NR	Exp: 49.57 (36.3) Ref: 43.75 (29.9) <i>p</i> = NS	Exp: 27.87 (2.5) Ref: 45.10 (13.4) <i>p</i> < 0.005	Exp: 73.77 (11.79) Ref: 76.89 (5.76) <i>p</i> = NS	-	-	-

NS = not significant, as reported the study; exact p-values are included in the table when available. NR = not reported.

^aTwo analyses in the same cohort ([Bonde and Ernst, 1992](#); [Bonde, 1990](#)). Exposure variable characterization by job category (supported by air concentration data) in 1990 analysis, exposure characterization by urine chromium (supported by job history) in 1992 analysis.

^bWelding type not specified, blood chromium higher in welders compared to referents, coexposure to Ni.

^cStainless steel and non-stainless-steel welders were pooled in the analysis of the male hormone concentrations; therefore, the hormone analysis from this study was considered *uninformative*.

1 Of the four other studies considered, all four measured sperm concentration and were
2 judged to be *low* confidence for that outcome ([Kumar et al., 2005](#); [Danadevi et al., 2003](#); [Hjollund et](#)
3 [al., 1998](#); [Jelnes and Knudsen, 1988](#)) (Table 3-39). Three of the studies also measured semen
4 volume and sperm morphology and motility and were judged to be *low* confidence for all outcomes
5 ([Kumar et al., 2005](#); [Danadevi et al., 2003](#); [Jelnes and Knudsen, 1988](#)), with the exception of one
6 study that was *uninformative* for motility ([Jelnes and Knudsen, 1988](#)). One *low* confidence study
7 reported a statistically significant decrease in sperm concentration in occupationally exposed
8 groups compared to referents ([Danadevi et al., 2003](#)). One *low* confidence study reported an
9 increase in sperm concentration in stainless-steel workers that may have been explained by a
10 shorter period of abstinence before sample collection in that group compared to the referent
11 ([Hjollund et al., 1998](#)); in addition, sperm samples in this study were frozen before analysis raising
12 concerns about the quality of the outcome measurements ([WHO, 2010](#)). In all other studies,
13 samples were not frozen and were analyzed within a short time of collection. Also consistent with
14 the findings of the *medium* confidence study discussed previously, two *low* confidence studies that
15 investigated sperm motility reported decreases in the exposed group compared to referents. These
16 findings were statistically significant in one of the studies ([Danadevi et al., 2003](#)), but did not reach
17 significance in the other study ([Kumar et al., 2005](#)). Both studies also reported changes in
18 morphology (i.e., decreased percent normal forms) in the occupationally exposed group compared
19 to referents ([Kumar et al., 2005](#); [Danadevi et al., 2003](#)). One *low* confidence study reported no
20 effect of Cr(VI) exposure on volume, concentration, or morphology, but limited description of the
21 methodology impeded the study evaluation ([Jelnes and Knudsen, 1988](#)).

22 Consistency in the findings across several of the five studies, including one *medium*
23 confidence study, suggests that Cr(VI) exposure by the inhalation route at levels observed in
24 occupational settings may impact semen quality. Sperm concentration, morphology, and motility
25 were decreased in exposed groups compared to referents in three of the five studies ([Kumar et al.,](#)
26 [2005](#); [Danadevi et al., 2003](#); [Bonde, 1990](#)), and these results were statistically significant for
27 concentration ([Danadevi et al., 2003](#)), morphology ([Danadevi et al., 2003](#)), and motility ([Kumar et](#)
28 [al., 2005](#); [Danadevi et al., 2003](#); [Bonde, 1990](#)) despite the likely impact of exposure misclassification
29 on study sensitivity. Evidence of a dose-response pattern to effects of Cr(VI) exposure on
30 concentration, morphology, and motility provides further supporting evidence of a relationship
31 between such exposures and semen quality ([Bonde and Ernst, 1992](#)). Two studies reported
32 findings that were inconsistent with the other studies, but these may be explained by study
33 limitations such as the use of frozen sperm samples or study quality issues ([Hjollund et al., 1998](#);
34 [Jelnes and Knudsen, 1988](#)). Results for semen volume were inconsistent across studies and within
35 analyses in the same cohort, suggesting that Cr(VI) exposure is not associated with this specific
36 endpoint.

1 *Male hormones*

2 The male reproductive hormones testosterone, luteinizing hormone (LH), and follicle
3 stimulating hormone (FSH) were considered when assessing the effects of exposure to Cr(VI) on
4 male hormones in humans ([Radke et al., 2019](#)). The effects of Cr(VI) on other male reproductive
5 hormones that potentially serve as endpoints for the evaluation of reproductive effects, especially
6 for onset of puberty, such as sex hormone binding globulin and dehydroepiandrosterone (DHEA),
7 were not investigated in the studies included in this analysis. A key consideration in the evaluation
8 of studies of male hormones is the timing of sample collection; morning collection is recommended
9 to account for diurnal variation in serum testosterone concentrations.

10 One *medium* confidence study described in two publications was considered in the
11 evaluation of the effect of Cr(VI) exposure on male hormones ([Bonde and Ernst, 1992](#); [Bonde,](#)
12 [1990](#)). A study by [Hjollund et al. \(1998\)](#) reported male hormones in welders and nonwelders, but
13 the results were considered *uninformative* and are not discussed further because stainless-steel and
14 non-stainless-steel welders were pooled in this analysis. The *medium* confidence study reported
15 significantly decreased serum testosterone concentration in stainless-steel welders (mean
16 [SD] = 17.3 [5.8] nmol/L) compared with nonwelders (mean [SD] = 21.2 [8.0] nmol/L) (Table 3-40)
17 ([Bonde, 1990](#)). A dose-response dependent decrease in serum testosterone was also reported in
18 the same cohort, though results of that analysis did not reach statistical significance ([Bonde and](#)
19 [Ernst, 1992](#)). In the same study, decreased serum LH and FSH concentrations were also reported in
20 stainless-steel welders compared to nonwelders, but these results did not reach statistical
21 significance. In an alternative analysis, serum LH and FSH decreased with increased exposure to
22 Cr(VI) characterized by urine concentration, but evidence of a dose-response trend was not as
23 strong for these endpoints as it was for testosterone. As discussed previously in the section on
24 semen parameters, data on air concentrations, urine chromium concentration and job history
25 support the categorization of exposure in the *medium* confidence study; however, these data also
26 point to exposure misclassification in both analyses that may have decreased study sensitivity. The
27 detection of a statistically significant exposure-dependent decrease in testosterone as well as
28 nonsignificant decreases in all three hormones measured (testosterone, LH, and FSH) despite
29 limitations in study sensitivity increased confidence in the findings of this study.

30 Due to the small number of studies that assessed the relationship between Cr(VI) exposure
31 and male reproductive hormones, consistency could not be assessed. However, evidence from two
32 separate analyses in a *medium* confidence study indicates that exposure may impact serum
33 concentrations of testosterone and these results are coherent with evidence for semen parameters
34 described separately. Evidence of a relationship between Cr(VI) and serum concentration of LH
35 and FSH was not as strong for these hormones as it was for testosterone. The *medium* confidence
36 study found a small inverse association between Cr(VI) exposure and serum LH and FSH that was
37 not statistically significant and was not supported by the findings of the *low* confidence study.

1 **3.2.7.2. Animal Evidence**

2 Study evaluation summary

3 Table 3-41 summarizes the animal toxicology studies considered in the evaluation of the
 4 effects of Cr(VI) on the male reproductive system. These consist of a two-generation reproductive
 5 study with dietary exposure using NTP’s Reproductive Assessment by Continuous Breeding (RACB)
 6 protocol ([NTP, 1997](#)); subchronic oral exposure studies using diet ([NTP, 1996a, b](#)), drinking water
 7 ([NTP, 2007](#); [Bataineh et al., 1997](#); [Elbetieha and Al-Hamood, 1997](#)), or gavage/unspecified oral
 8 administration ([Bashandy et al., 2021](#); [Marat et al., 2018](#); [Rasool et al., 2014](#); [Yousef et al., 2006](#));
 9 short-term exposure studies using drinking water ([Wang et al., 2015](#)) or unspecified oral
 10 administration ([Kim et al., 2012](#)); a chronic inhalation exposure study ([Glaser et al., 1986](#));
 11 subchronic inhalation exposure studies ([Kim et al., 2004](#); [Glaser et al., 1985](#)); and studies that
 12 evaluated F1 males that had been exposed during gestation ([Navin et al., 2021](#); [Shobana et al., 2020](#);
 13 [Zheng et al., 2018](#); [Al-Hamood et al., 1998](#)) or during gestation and lactation ([Kumar et al., 2017](#)).
 14 The three available inhalation studies only reported information on male gonad weights ([Kim et al.,](#)
 15 [2004](#); [Glaser et al., 1986](#)) or histopathology ([Kim et al., 2004](#); [Glaser et al., 1985](#)), whereas the
 16 available oral exposure studies provided more specific measurements of male reproductive
 17 function including fertility, sperm parameters, hormone levels, and sexual behavior. The report by
 18 [NTP \(2007\)](#) included two separate studies: a 3-month study in rats (F344/N) and mice (B6C3F1),
 19 and a second 3-month comparative study using three strains of mice (B6C3F1, BALB/c, C57BL-6).

20 NTP’s RACB study ([NTP, 1997](#)) and subchronic exposure studies ([NTP, 2007, 1996a, b](#)) and
 21 the gestational exposure study by [Zheng et al. \(2018\)](#) were well-reported and well-designed to
 22 evaluate reproductive outcomes and were therefore rated as *high* confidence for almost all
 23 reported outcomes (Table 3-41). The subchronic study by [Bashandy et al. \(2021\)](#) was rated as
 24 *medium* confidence for the evaluation of sperm parameters and hormone levels, but *low* confidence
 25 for organ weights and histopathology due to reporting limitations for those endpoints. The
 26 remaining studies had reporting limitations and other substantial concerns raised during study
 27 evaluation and were rated as *low* confidence across all outcomes. Endpoint-specific concerns
 28 identified during study evaluation are discussed in the respective sections below. Three of the *low*
 29 confidence studies ([Al-Hamood et al., 1998](#); [Bataineh et al., 1997](#); [Elbetieha and Al-Hamood, 1997](#))
 30 exposed animals to high concentrations (350–1770 mg/L) of Cr(VI) in drinking water, which was
 31 considered a potential confounding variable as it is not possible to determine whether reproductive
 32 effects may have been exacerbated by reduced water consumption and/or systemic toxicity; for
 33 instance, drinking water concentrations of 350 mg/L Cr(VI) have been associated in rats with
 34 decreased water consumption and site of contact toxicity (80 and 100% incidence of ulcers in the
 35 glandular stomach of males and females, respectively) ([NTP, 2007](#)).

Table 3-41. Summary of included animal studies for Cr(VI) male reproductive effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a [Click to see interactive data graphic for rating rationales.](#)

Author (year)	Exposure route	Species (strain)	Exposure life stage and duration	Fertility, Fecundity	Sperm evaluation	Histopathology	Hormones	Organ weights	Sexual behavior	Anogenital distance
Al-Hamood et al. (1998)	Drinking water	Mouse (BALBC)	F1 offspring; GD 12–PND 20	L	-	-	-	L	-	-
Bashandy et al. (2021)	Gavage	Rat (Wistar)	Adult males; 8 weeks	-	M	L	M	L	-	-
Bataineh et al. (1997)	Drinking water	Rat (Sprague-Dawley)	Adult males; 12 weeks	L	-	-	-	L	L	-
Elbetieha and Al-Hamood (1997)	Drinking water	Mouse (Swiss)	Adult males; 12 weeks	L	-	-	-	L	-	-
Glaser et al. (1986)	Inhalation	Rat (Wistar)	Adult males; 18 months	-	-	-	-	L	-	-
Glaser et al. (1985)	Inhalation	Rat (Wistar)	Adult males; 28 or 90 days	-	-	L	-	-	-	-
Kim et al. (2004)	Inhalation	Rat (Sprague-Dawley)	Adult males; 90 days	-	-	L	-	L	-	-
Kim et al. (2012)	Oral (unspecified)	Rat (Sprague-Dawley)	Adult males; 6 days	-	L	-	-	L	-	-
Kumar et al. (2017)	Drinking water	Rat (Wistar)	F1 offspring; GD 9–14	-	L	L	L	L	-	L
Marat et al. (2018)	Gavage	Rat (white outbred)	Adult males; 60 days	L	-	-	-	-	-	-
Navin et al. (2021)	Drinking water	Rat (Wistar)	F1 offspring; GD 9-14	-	-	L	L	L	-	-
NTP (1996a)	Diet	Mouse (BALBC)	Adult males; 3, 6, or 9 weeks	-	H	-	-	H	-	-
NTP (1996b)	Diet	Rat (Sprague-Dawley)	Adult males; 3, 6, or 9 weeks	-	H	-	-	H	-	-
NTP (1997)	Diet	Mouse (BALBC)	Reproductive Assessment by Continuous Breeding (F0 to F2)	H	H	-	-	H	-	-
NTP (2007)	Drinking water	<i>Study 1:</i> Rat (F344/N), Mouse (B6C3F1) <i>Study 2:</i> Mouse (B6C3F1, BALB/c, C57BL-6)	<i>Study 1:</i> Adult males; 3 months <i>Study 2:</i> Adult males, 3 months	-	H	M	-	H	-	-
Rasool et al. (2014)	Oral (unspecified)	Mouse (strain not reported)	Adult males; 30 or 60 days	-	-	L	-	-	-	-

Author (year)	Exposure route	Species (strain)	Exposure life stage and duration	Fertility, Fecundity	Sperm evaluation	Histopathology	Hormones	Organ weights	Sexual behavior	Anogenital distance
(Shobana et al., 2020)	Drinking water	Rat (Wistar)	F1 offspring; GD 9-14 or GD 15-21	-	-	-	L	-	-	-
Wang et al. (2015)	Drinking water	Rat (Sprague-Dawley)	Adult males; 4 weeks	-	-	L	-	L	-	-
Yousef et al. (2006)	Gavage	Rabbit (NZ white)	Adult males; 10 weeks	-	L	-	L	L	L	-
Zheng et al. (2018)	Gavage	Rat (Sprague-Dawley)	F1 offspring; GD 12–21	-	-	H	H	-	-	-

GD = gestation day; PND = postnatal day.

^aIn addition to these included studies, there were seven animal toxicology studies reporting male reproductive outcomes that met PECO criteria but were found to be *uninformative* at the study evaluation stage: Aruldas et al. (2006; 2005; 2004); Chowdhury and Mitra (1995); Li et al. (2001); Subramanian et al. (2006); Zabulyte et al. (2009); and Zahid et al. (1990).

1 Synthesis of evidence in animals^{42,43}

2 *Fertility and fecundity*

3 No effects on the ability to impregnate females (i.e., fertility parameters) were observed
4 across the five studies in rats or mice that evaluated this outcome. These consisted of the *high*
5 confidence RACB study in mice by [NTP \(1997\)](#) that evaluated F0 and F1 parental animals at oral
6 doses in diet ranging from 6.8–30.3 mg/kg/day Cr(VI) (F0) or 7.9–37.1 mg/kg/day Cr(VI) (F1); two
7 *low* confidence studies that evaluated adult male rats or mice that had been exposed to 350 mg/L or
8 up to 1770 mg/L Cr(VI), respectively, in drinking water for 12 weeks prior to mating ([Bataneh et](#)
9 [al., 1997](#); [Elbetieha and Al-Hamood, 1997](#)); one *low* confidence study that evaluated adult male rats
10 that had been exposed to 0.353 mg/kg-day Cr(VI) via gavage for 60 days prior to mating ([Marat et](#)
11 [al., 2018](#)); and one *low* confidence study that evaluated adult F1 male mice that had been exposed
12 to maternal doses of 350 mg/L Cr(VI) in drinking water during gestation and lactation ([Al-Hamood](#)
13 [et al., 1998](#)). However, [Elbetieha and Al-Hamood \(1997\)](#) observed a statistically significant

⁴²Data are available in HAWC for: [NTP \(1997\)](#) ([here](#))
[NTP \(1996a\)](#) ([here](#))
[NTP \(1996b\)](#) ([here](#))
[NTP \(2007\)](#) ([male B6C3F1 mice](#), [male BALBC mice](#), [male am3-C57BL/6 mice](#)).

⁴³For many of the oral studies presented here, it was not possible to estimate an average daily mg/kg dose due to lack of reporting. To estimate an average daily dose, paired records of body weight and daily intake of test article are required. This is particularly important for Cr(VI) reproductive and developmental studies, because rapid changes in maternal body weight are expected during pregnancy, and Cr(VI) affects palatability (which affects both Cr(VI) intake rate and body weight). Doses of Cr(VI) are presented where possible, however many cross-study comparisons are done on the basis of mg/L Cr(VI) in drinking water.

1 decrease in the number of implantations and viable fetuses when Cr(VI)-exposed male Swiss mice
2 were mated with untreated females; this effect was observed in 710 or 1410 mg/L Cr(VI) dose
3 groups, but not the highest dose group (1770 mg/L). Similarly, increased pre- and post-
4 implantation loss in rats dosed with 0.353 mg/kg-day Cr(VI) by oral gavage prior to mating was
5 observed by [Marat et al. \(2018\)](#), who reported a dominant lethal mutation frequency of 0.665 by
6 comparing the number of live fetuses in the Cr(VI) treatment group to the control group. No effects
7 on offspring viability were observed in rats or mice in other studies following paternal exposure
8 ([Al-Hamood et al., 1998](#); [Bataineh et al., 1997](#); [NTP, 1997](#)). Overall, decreased fetal viability
9 following paternal-only exposure (indicative of dominant lethal mutations in sperm) was observed
10 across two studies, but interpretation is limited because these studies were considered *low*
11 confidence and the only available *high* confidence study failed to observe similar effects.

12 *Sperm evaluation*

13 No effects on sperm were observed in the *high* confidence subchronic exposure studies in
14 rats and a variety of mouse strains by NTP at oral doses ranging from 0.35–32.5 mg/kg-day Cr(VI)
15 in drinking water or diet ([NTP, 2007, 1996a, b](#)), or in the *high* confidence RACB study in mice that
16 evaluated F0 and F1 males at doses ranging from 6.8–30.3 mg/kg/day Cr(VI) (F0) or 7.9–
17 37.1 mg/kg-day Cr(VI) (F1) in diet ([NTP, 1997](#)). These studies reported multiple measurements
18 aimed at evaluating effects on spermatogenesis. The NTP RACB and 3-month drinking water
19 studies included measurements of testicular sperm head count ([NTP, 2007, 1997](#)), epididymal
20 sperm density ([NTP, 2007, 1997](#)), epididymal sperm morphology ([NTP, 1997](#)), and evaluation of
21 epididymal sperm motility using computer-assisted sperm motion analysis ([NTP, 1997](#)) or visual
22 motility analysis by two observers ([NTP, 2007](#)). Sperm from both F0 and F1 males were evaluated
23 in the RACB study ([NTP, 1997](#)). In the 3-month dietary exposure studies by NTP ([1996a, b](#)),
24 animals underwent whole-body perfusion with fixative after 3, 6, or 9 weeks of exposure and
25 effects on spermatogenesis were evaluated by counting the ratio of preleptotene spermatocytes
26 and Sertoli cell nuclei in Stage X or XI tubules, with investigators blinded to the dose group.
27 Perfusion fixation is considered the gold standard for histopathological evaluation of the testis
28 ([Haschek et al., 2009](#); [Foley, 2001](#)), and blinding is considered appropriate for reducing observation
29 bias for this relatively subjective measurement. There were no notable concerns about these
30 evaluations.

31 In contrast, one *medium* confidence study ([Bashandy et al., 2021](#)) and three *low* confidence
32 studies ([Kumar et al., 2017](#); [Kim et al., 2012](#); [Yousef et al., 2006](#)) observed exposure-related
33 decreases in sperm quality or quantity. These studies did not indicate whether investigators were
34 blinded during outcome evaluation and had additional reporting and study design concerns
35 identified during study evaluation. [Bashandy et al. \(2021\)](#) reported decreased sperm motility and
36 epididymal sperm counts and increased sperm abnormalities in adult rats following eight weeks of
37 exposure to 3.5 mg/kg-day Cr(VI) via oral gavage. [Yousef et al. \(2006\)](#) reported a statistically
38 significant decrease in packed sperm volume, sperm concentration, total sperm output, and sperm

1 motility, and a statistically significant increase in the percentage of dead sperm in ejaculates
2 measured weekly from adult rabbits exposed via oral gavage to 3.6 mg/kg-day Cr(VI) for 10 weeks.
3 Concerns were raised about the interpretation of results because the numerical data presented by
4 the authors (means \pm SE) appeared to be an average of weekly measurements across 10 weeks of
5 exposure, which is difficult to interpret. Graphical data were shown for weekly measurements, but
6 only as means without a measure of variance. [Kumar et al. \(2017\)](#) reported a statistically
7 significant decrease in epididymal sperm forward motility (measured visually under a microscope),
8 sperm viability, and sperm count in adult F1 rats that had been exposed during gestation at
9 maternal doses of 17.7–70.7 mg/L Cr(VI) in drinking water. These measurements were presented
10 as the mean of individual animals without accounting for potential litter effects, which has the
11 potential to overestimate statistical significance ([Haseman et al., 2001](#)). [Kim et al. \(2012\)](#) reported
12 a statistically significant decrease in sperm head count and motility but no effect on the percentage
13 of abnormal sperm in adult rats exposed to 10 mg/kg-day Cr(VI) for 6 days. This short exposure
14 duration does not cover the duration of spermatogenesis, and therefore lacks sensitivity for
15 detecting potential effects on spermatogonia. Overall, although these studies report that Cr(VI)
16 exposure can affect sperm quality and quantity, interpretation of the *low* confidence studies is
17 limited due to the study design and reporting concerns. It is possible that differences in route of
18 exposure could explain why effects on sperm were observed in the study by [Bashandy et al. \(2021\)](#)
19 (gavage), whereas the NTP studies (drinking water or diet) did not observe effects at equal or
20 higher dose levels.

21 *Histopathology*

22 Almost all studies that evaluated histopathological outcomes in male reproductive tissues
23 used conventional fixation in formalin or formaldehyde, which is not recommended for the testis
24 because it gives poor penetration and may cause artifacts ([Haschek et al., 2009](#); [Foley, 2001](#)). This
25 was considered a sensitivity concern and reduced the confidence in this dataset. [Zheng et al.](#)
26 [\(2018\)](#) is the only study that used Bouin’s solution, which is considered a preferable fixative for the
27 testis ([Creasy and Chapin, 2018](#); [Foley, 2001](#)). The study by [NTP \(2007\)](#) reported that slides used
28 for histopathological evaluation were peer reviewed and the final diagnoses represents a consensus
29 of contractor pathologists and the NTP Pathology Working Groups, which is considered a best
30 practice for histopathological evaluations ([Crissman et al., 2004](#)). None of the other studies
31 indicated that any steps were taken to reduce observational bias.

32 No dose-related lesions were observed in the testis, epididymis, prostate, or preputial gland
33 in the 3-month drinking water exposure studies by [NTP \(2007\)](#) in rats and in a variety of mouse
34 strains at oral doses up to 20.9 mg/kg-day Cr(VI) (Study 1 rats), 27.9 mg/kg-day Cr(VI) (Study 1
35 mice), or 8.7 mg/kg-day Cr(VI) (Study 2 mice). These studies by [NTP \(2007\)](#) were considered
36 *medium* confidence for the testicular evaluation due to the use of formalin fixative and *high*
37 confidence for other male reproductive organs. There were also no reported histopathological
38 changes in the gonad in the *low* confidence 25- or 90-day inhalation studies in rats by [Glaser et al.](#)

1 [\(1985\)](#) and [Kim et al. \(2004\)](#) at concentrations up to 0.2 mg/m³ Cr(VI) or 1.25 mg/m³ Cr(VI),
2 respectively; or in the *low* confidence 4-week drinking water study by [Wang et al. \(2015\)](#) at
3 concentrations up to 106.1 mg/L Cr(VI). However, these four studies exposed adult rodents and
4 therefore did not expose rodents during critical gestational or developmental windows.

5 In contrast, a *high* confidence gestational exposure study ([Zheng et al., 2018](#)) and four *low*
6 confidence subchronic oral exposure studies ([Bashandy et al., 2021](#); [Navin et al., 2021](#); [Kumar et al.,](#)
7 [2017](#); [Rasool et al., 2014](#)) observed histopathological changes in the testis. [Zheng et al. \(2018\)](#)
8 reported altered Leydig cell distribution (increased single-cell clusters and decreased larger
9 clusters) and decreased Leydig cell size and cytoplasmic size in F1 male rat pups following
10 maternal exposure to 3–12 mg/kg-day Cr(VI) by oral gavage from GD 12–21, but no change in
11 Leydig cell number or proliferation. The number of Sertoli cells and the incidence of multinuclear
12 gonocytes in the pups was not affected. In adult F1 male rats exposed from GD 9–14, [Kumar et al.](#)
13 [\(2017\)](#) observed a statistically significant decrease in the diameter of the seminiferous tubules and
14 lumen, number of Sertoli cells, and testicular spermatocytes and spermatids at maternal doses of
15 17.7–70.7 mg/L Cr(VI) in drinking water. A study by the same group of authors ([Navin et al., 2021](#))
16 similarly observed shrunken tubules with increased interstitial space and sloughing of immature
17 germ cells from the basal compartment into the lumen at maternal doses of 35.4 – 70.7 mg/L Cr(VI)
18 in drinking water. In animals exposed for subchronic durations as adults, [Bashandy et al. \(2021\)](#)
19 and [Rasool et al. \(2014\)](#) observed damage to Leydig cells, germinal epithelium, and sperm cells in
20 rats exposed to 3.5 mg/kg-day Cr(VI) (gavage) and mice exposed to 1.77 mg/kg-day Cr(VI)
21 (unspecified method of oral administration), respectively. The studies by [Zheng et al. \(2018\)](#) and
22 [Kumar et al. \(2017\)](#) provided quantitative data on the incidence of effects, whereas the other three
23 studies reported only qualitative findings. Data in [Kumar et al. \(2017\)](#) was presented as the mean
24 of individual animals without accounting for potential litter effects, which has the potential to
25 overestimate statistical significance ([Haseman et al., 2001](#)).

26 Within the *high* confidence study by [Zheng et al. \(2018\)](#), the changes in Leydig cell
27 distribution may be coherent with the reported effects on testosterone in this study (see next
28 section). Histopathological changes were also coherent with effects on testosterone and sperm
29 parameters within *low* confidence studies, although the interpretation of those studies is more
30 limited.

31 *Hormones*

32 Effects on reproductive hormone levels were observed across all studies that evaluated this
33 outcome, which included one *high* confidence, one *medium* confidence, and four *low* confidence
34 studies. The *high* confidence study by [Zheng et al. \(2018\)](#) reported a nonmonotonic effect in which
35 serum testosterone was increased in F1 male rat pups following maternal exposure to 3 mg/kg-day
36 Cr(VI) by oral gavage from GD 12–21 but decreased in the 12 mg/kg-day Cr(VI) dose group. The
37 *medium* confidence study by [Bashandy et al. \(2021\)](#) reported decreased testosterone, decreased
38 luteinizing hormone (LH), and increased follicle stimulating hormone (FSH) in following an 8-week

1 exposure of adult male rats to 3.5 mg/kg-day Cr(VI) by oral gavage. Three *low* confidence studies
2 by the same group of authors ([Navin et al., 2021](#); [Shobana et al., 2020](#); [Kumar et al., 2017](#)) evaluated
3 F1 male rats that had been exposed during gestation via maternal drinking water and also reported
4 decreased serum testosterone levels. Effects on serum testosterone reached statistical significance
5 at a maternal dose of 17.7 mg/L Cr(VI) in males evaluated on PND 30 ([Shobana et al., 2020](#)) and
6 PND 60 ([Navin et al., 2021](#)) versus 70.7 mg/L Cr(VI) in males evaluated on PND 120 ([Kumar et al.,](#)
7 [2017](#)), although effects on testosterone in testicular interstitial fluid at PND 120 reached statistical
8 significance at 17.7 mg/L Cr(VI). [Shobana et al. \(2020\)](#) and [Navin et al. \(2021\)](#) also reported
9 increased estrogen, decreased prolactin, and increased LH and FSH, whereas [Kumar et al. \(2017\)](#)
10 reported decreased LH and FSH. Measurements in these three studies were presented as the mean
11 of individual animals without accounting for potential litter effects, which has the potential to
12 overestimate statistical significance ([Haseman et al., 2001](#)). Lastly, the *low* confidence study by
13 [Yousef et al. \(2006\)](#) reported a statistically significant decrease in plasma testosterone in rabbits
14 after a 12-week oral exposure to 3.6 mg/kg-day Cr(VI). Concerns about selective reporting and the
15 presentation of results were raised because authors stated that testosterone measurements were
16 performed biweekly but reported only a single mean value for serum testosterone.

17 These results suggest that Cr(VI) exposure has an anti-androgenic effect at higher dose
18 levels, although interpretation of results in the *low* confidence studies is limited. The *high*
19 confidence studies by NTP ([2007](#), [1997](#), [1996a](#), [b](#)) did not evaluate hormone levels, so a direct
20 comparison with those studies is not possible; however, one mouse strain in NTP's 3-month
21 drinking water study observed decreased testis weight ([NTP, 2007](#)), which is considered indicative
22 of changes in androgen levels ([Foster and Gray, 2013](#); [Evans and Ganjam, 2011](#)). The lack of effect
23 on male reproductive organ weights in the other studies by NTP suggests that there was minimal
24 effect on androgens on those studies.

25 *Organ weight*

26 Except for decreased testis weight observed in one mouse strain in the *high* confidence
27 study by [NTP \(2007\)](#), effects on male reproductive organ weights were only seen in *low* confidence
28 studies. The 3-month drinking water exposure study by [NTP \(2007\)](#) reported a statistically
29 significant 11% decrease in absolute testis weight in *am3-C57BL/6* mice in the highest dose group
30 (8.7 mg/kg-day Cr(VI); n = 5/group). No effects were observed in the two other mouse strains
31 (B6C3F1 and BALB/c) that were tested in this study at doses up to 8.7 mg/kg-day Cr(VI), or in
32 F344/N rats or B6C3F1 mice at doses up to 20.9 and 27.9 mg/kg-day Cr(VI), respectively ([NTP,](#)
33 [2007](#)). No effects on testis or accessory reproductive organ weights were observed in the other
34 *high* confidence RACB or 3-month dietary exposure studies in mice or rats by NTP at doses ranging
35 from 0.35–37.1 mg/kg-day Cr(VI) ([NTP, 1997](#), [1996a](#), [b](#)). There were also no effects on testis
36 weight in the *low* confidence studies by [Glaser et al. \(1986\)](#), [Kim et al. \(2004\)](#), [Al-Hamood et al.](#)
37 [\(1998\)](#), [Wang et al. \(2015\)](#), or [Kim et al. \(2012\)](#). [Kim et al. \(2012\)](#) also reported no effect on

1 epididymis weight, although the short exposure duration in this study (6 days) likely limited study
2 sensitivity.

3 In contrast, six *low* confidence subchronic oral exposure studies reported Cr(VI)-induced
4 changes in testis and accessory male reproductive organ weights. The most notable findings
5 consisted of a statistically significant decrease in absolute testis, seminal vesicle, and preputial
6 gland weights in rats after 12-week exposure to 350 mg/L Cr(VI) in drinking water ([Bataineh et al.
7 1997](#)); a statistically significant decrease in testis, vas deferens, epididymis, prostate, and seminal
8 vesicle weight (unclear whether absolute or relative to body weight) in rats after an 8-week
9 exposure to 3.5 mg/kg-day Cr(VI) by oral gavage ([Bashandy et al., 2021](#)); a statistically significant
10 decrease in relative testis and epididymis weights in rabbits after a 10-week exposure to 3.6
11 mg/kg-day Cr(VI) via oral gavage ([Yousef et al., 2006](#)); decreased absolute and relative testis
12 weights in F1 rats that had been exposed from GD 9–14 and were evaluated on PND 60, reaching
13 statistical significance at 70.7 mg/L Cr(VI); and a statistically significant decrease in relative testis
14 weight and absolute epididymal and seminal vesicle weights in adult F1 rats that had been exposed
15 from GD 9–14 to maternal doses of 17.7–70.7 mg/L Cr(VI) in drinking water ([Kumar et al., 2017](#)).
16 The measurements by [Navin et al. \(2021\)](#) and [Kumar et al. \(2017\)](#) were presented as the mean of
17 individual animals without accounting for potential litter effects, which has the potential to
18 overestimate statistical significance ([Haseman et al., 2001](#)). Additionally, the 12-week drinking
19 water exposure study in mice by [Elbetieha and Al-Hamood \(1997\)](#) reported a statistically
20 significant decrease in relative seminal vesicle and preputial gland weight in the 1770 mg/L Cr(VI)
21 group, but a statistically significant increase in relative testis weight in the 710 and 1770 mg/L
22 Cr(VI) groups; however, the increase in relative testis weight may have been an artifact of
23 decreased body weight in these animals. It has been shown that testis weights are not modeled
24 well by an organ-to-body weight ratio because testis and body weights are not proportional ([Bailey
25 et al., 2004](#)), so relative organ weights may be a less sensitive measure than absolute testis weight.
26 Decreased body weight was reported in all four studies, including those that reported relative
27 decreases in organ weights.

28 Overall, these results suggest that male reproductive organ weights can be decreased by
29 Cr(VI) exposure, which is consistent with decreased androgen levels as described above. However,
30 interpretation of these results is limited because effects were predominantly observed in *low*
31 confidence studies and were not observed in the majority of the *high* confidence studies by NTP.
32 Effects on testis weight observed by [Yousef et al. \(2006\)](#), [Kumar et al. \(2017\)](#), and [Navin et al.
33 \(2021\)](#) are coherent with the decreased testosterone observed in these studies.

34 *Sexual behavior*

35 Effects on sexual behavior were observed in two *low* confidence subchronic oral exposure
36 studies, which were the only studies that evaluated this outcome. Neither of these studies reported
37 that any steps were taken to reduce observational bias during outcome evaluation, which is a
38 concern since behavior can be a relatively subjective measurement. In rats, [Bataineh et al. \(1997\)](#)

1 reported a statistically significant decrease in mounts and percentage of males ejaculating, and
2 significant increase in ejaculation latency and post-ejaculatory interval following 12 weeks of
3 exposure to 350 mg/L Cr(VI) in drinking water. This assessment of sexual behavior was performed
4 on a separate cohort of animals than those used in the fertility assay by these authors (see earlier
5 section). In rabbits, [Yousef et al. \(2006\)](#) reported a statistically significant increase in the reaction
6 time to mounting following 10-week exposure to 3.6 mg/kg-day Cr(VI) by oral gavage. These
7 results are suggestive of effects on sexual behavior, but interpretation of the results is limited
8 because these studies are considered *low* confidence.

9 *Anogenital distance (AGD)*

10 The *low* confidence gestational exposure study by [Kumar et al. \(2017\)](#) reported a
11 dose-related decrease in AGD in F1 male rats that had been exposed during gestation from GD 9–14
12 to maternal doses of 17.7–70.7 mg/L Cr(VI) in drinking water. AGD was measured at multiple
13 timepoints between PNDs 1–30. AGD is a biomarker of androgen-dependent development, so this
14 effect is coherent with the decreased androgen levels observed in these animals as adults (see
15 earlier section). This measurement was presented as the mean of individual animals without
16 accounting for potential litter effects, which has the potential to overestimate statistical significance
17 ([Haseaman et al., 2001](#)). Overall, while this finding suggests that Cr(VI) exposure decreases AGD via
18 decreased androgen levels, interpretation of the results is limited because this study is considered
19 *low* confidence.

20 **3.2.7.3. Mechanistic Evidence**

21 The Cr(VI) literature provides evidence for potential mechanisms of Cr(VI)-induced male
22 reproductive toxicity; specifically, oxidative stress in male reproductive tissues, altered cell cycle
23 regulation and apoptosis in somatic and germ cells, alterations in steroid hormone signaling and
24 the hypothalamic-pituitary-gonadal (HPG) axis, and effects on Sertoli cells and the blood-testis
25 barrier. These studies support the biological plausibility that Cr(VI) may have the potential to act
26 as a male reproductive toxicant acting through several possible modes of action. Mechanistic
27 studies are tabulated in Appendix C.2.6 and summarized here.

28 The mechanistic studies reviewed here consisted of *in vivo* mechanistic data from several of
29 the included oral exposure studies discussed above (Table 3-41), as well as from intraperitoneal
30 (i.p.) injection studies that did not meet PECO criteria but were reviewed as informative for
31 mechanistic analysis. Dosing via i.p. injection is likely to result in higher tissue concentrations of
32 Cr(VI) compared to oral exposure due to the oral first-pass effect caused by the reduction of Cr(VI)
33 in the low pH environment of the stomach; less than 10–20% of an ingested dose may be absorbed
34 in the GI tract, and further reduction will occur in the liver prior to distribution to the rest of the
35 body (see Section 3.1 and Appendix C). Therefore, systemic effects are expected to be more likely
36 following i.p. injection or inhalation compared to oral exposure. Given their specific relevance to
37 the pattern of findings observed in a subset of the *in vivo* animal studies, *in vitro* studies that

1 evaluated Leydig, Sertoli, or male germ cells were also considered within this synthesis of
2 mechanistic evidence.

3 Oxidative stress

4 Decreased antioxidant enzyme activities [e.g., superoxide dismutase (SOD), catalase (CAT),
5 glutathione peroxidase (GPx), glutathione-S-transferase (GST), glucose-6-phosphate
6 dehydrogenase (G-6-PDH), γ -glutamyl transpeptidase (γ -GT)], decreased nonenzymatic
7 antioxidants (metallothionein, glutathione, vitamins A, C, E), and increased lipid peroxidation
8 [measured as malondialdehyde (MDA) or lipid peroxidation potential] were observed in serum or
9 in male reproductive tissues in rodents and monkeys concurrent with apical outcomes following
10 oral exposure ([Bashandy et al., 2021](#); [Shobana et al., 2020](#); [Rasool et al., 2014](#); [Kim et al., 2012](#);
11 [Subramanian et al., 2006](#); [Aruldhass et al., 2005](#)) or i.p. injection ([El-Demerdash et al., 2019](#);
12 [Marouani et al., 2015a](#); [Hfaiedh et al., 2014](#); [Acharya et al., 2006](#); [Acharya et al., 2004](#)). Similar
13 markers of oxidative stress were observed in vitro in cultured mouse Leydig cells, Sertoli cells, or
14 spermatogonial stem cells ([Lv et al., 2018](#); [Das et al., 2015](#)). Although antioxidant levels were
15 generally decreased across studies, increased GST or metallothionein were observed in some cases
16 ([Das et al., 2015](#); [Marouani et al., 2015a](#); [Aruldhass et al., 2005](#)), indicating an antioxidant response.

17 Several in vivo studies demonstrated that effects on sperm, testicular histopathology,
18 hormones, and male fecundity were attenuated following cotreatment with antioxidants ([Bashandy
19 et al., 2021](#); [El-Demerdash et al., 2019](#); [Lv et al., 2018](#); [Hfaiedh et al., 2014](#); [Kim et al., 2012](#);
20 [Subramanian et al., 2006](#)). This may imply that oxidative stress is a mechanism underlying these
21 effects, but interpretation is difficult because antioxidants can also decrease tissue Cr(VI) levels by
22 stabilizing lower Cr oxidation states. For instance, [Subramanian et al. \(2006\)](#) reported lower
23 plasma Cr levels with coadministration of Vitamin C. The authors hypothesized that the protective
24 effect of Vitamin C may be due to enhanced conversion of Cr(VI) to Cr(III).

25 Cell cycle regulation and apoptosis in somatic and germ cells

26 There is evidence that Cr(VI) exposure alters cell cycle regulation and promotes apoptosis
27 in male reproductive tissues following in vivo exposure. [Bashandy et al. \(2021\)](#) reported increased
28 p53 expression and decreased DNA content in spermatogenic cells of rats exposed to 3.5 mg/kg-
29 day Cr(VI) for 8 weeks via oral gavage, suggesting that DNA replication was inhibited in these
30 animals. Increased expression of the pro-apoptotic protein BAX and increased DNA fragmentation
31 (measured using DNA ladders or by the biomarker γ -H2AX) were observed in the testes of male
32 rats and mice following i.p. injection ([Lv et al., 2018](#); [Marouani et al., 2015a](#)). I.p. injection studies
33 have also reported degenerative histopathological changes in seminiferous tubules and
34 spermatogenic cells, absence of spermatocytes in the seminiferous tubules, and lower sperm counts
35 in rats, mice, and rabbits ([El-Demerdash et al., 2019](#); [Lv et al., 2018](#); [Acharya et al., 2004](#); [Behari et
36 al., 1978](#)).

1 In vitro studies using mouse Leydig, Sertoli, or spermatogonial stem cells provided
2 additional evidence of the activation of intrinsic (mitochondria-dependent) apoptotic pathways,
3 including increased staining in the TUNEL assay, decreased mitochondrial membrane potential,
4 decreased BAX/BCL-2 ratio, and increased cleavage of caspases 3 and 9 in all three of these cell
5 types ([Lv et al., 2018](#); [Das et al., 2015](#)). In vitro studies also found that biomarkers of extrinsic
6 apoptosis (caspase 8, Fas) were not activated, further supporting intrinsic apoptosis as the
7 mechanism of cell death ([Lv et al., 2018](#); [Das et al., 2015](#)). It was demonstrated both in vivo and in
8 vitro that effects on cell cycle regulation and cell death were attenuated following cotreatment with
9 an antioxidant ([Bashandy et al., 2021](#); [Lv et al., 2018](#); [Das et al., 2015](#)).

10 A single study provides evidence of an effect of Cr(VI) on meiosis, another potential
11 mechanism for effects on spermatogenesis. Using a bicameral culture chamber of rat Sertoli and
12 germ cells, [Geoffroy-Siraudin et al. \(2010\)](#) observed that Cr(VI) treatment decreased the number of
13 late spermatocytes and round spermatids and increased the percentage of cells with alterations in
14 meiotic prophase.

15 Altered steroidogenesis and effects on the HPG axis

16 As described above, hormonal effects in studies meeting PECO criteria included a
17 nonmonotonic effect on fetal testosterone in F1 male rats (increased at the lowest dose and
18 decreased at the highest dose) in the *high* confidence study by [Zheng et al. \(2018\)](#) and decreased
19 testosterone and effects on gonadotropin levels in *medium* and *low* confidence studies in rats
20 ([Bashandy et al., 2021](#); [Navin et al., 2021](#); [Shobana et al., 2020](#); [Kumar et al., 2017](#)) and rabbits
21 ([Yousef et al., 2006](#)). Decreased prolactin and increased estrogen were also reported in F1 rats
22 ([Navin et al., 2021](#); [Shobana et al., 2020](#)). Similarly, i.p. injection studies reported decreased
23 testosterone ([El-Demerdash et al., 2019](#); [Hfaiedh et al., 2014](#); [Marouani et al., 2012](#)), decreased LH,
24 and increased FSH ([El-Demerdash et al., 2019](#); [Marouani et al., 2012](#)) in adult male rats. Several of
25 these studies found that hormone changes were attenuated by cotreatment with an antioxidant
26 ([Bashandy et al., 2021](#); [El-Demerdash et al., 2019](#); [Hfaiedh et al., 2014](#)).

27 Findings at the molecular level provide supporting evidence that Cr(VI) affects
28 steroidogenesis, with inhibition occurring at higher dose levels. In Leydig cells of F1 male rats
29 exposed during gestation, [Zheng et al. \(2018\)](#) reported a nonmonotonic effect on genes/proteins in
30 the steroidogenesis pathway (increased at low dose and decreased at high dose) and [Navin et al.](#)
31 [\(2021\)](#) reported decreased expression of the steroidogenesis pathway. These changes are
32 consistent with the effects on testosterone in these two studies, although the molecular changes
33 reported by [Zheng et al. \(2018\)](#) were less consistent and often differed between the mRNA and
34 protein levels. Both studies reported decreased Leydig cell LH receptor (LHR) expression at high
35 dose levels, and [Navin et al. \(2021\)](#) also reported decreased expression of Leydig cell androgen
36 receptor (AR), prolactin receptor (PRLR), and estrogen receptor alpha (ER α). In Sertoli cells, which
37 are somatic cells that support germ cell development and play a role in HPG regulation, decreased
38 expression of FSH receptor (FSHR) and AR was reported in F1 rats by [Shobana et al. \(2020\)](#) and

1 [Kumar et al. \(2017\)](#), whereas [Zheng et al. \(2018\)](#) reported a low-dose increase in FSHR mRNA
2 expression but no change at the high dose level. [Zheng et al. \(2018\)](#) also reported that secretion of
3 the growth factors LIF and PDGFA by Sertoli cells was increased at low doses of Cr(VI) and may
4 have contributed to Leydig cell stimulation at the low dose level, whereas a high dose of Cr(VI)
5 caused a decrease in the secretion of insulin-like growth factor-1 (IGF-1) by Sertoli cells that may
6 have contributed to the suppression of Leydig cell androgen production at the high dose level.
7 These in vivo observations are supported by an in vitro study ([Das et al., 2015](#)), which reported that
8 Cr(VI) treatment decreased testosterone secretion and expression of genes in the steroidogenesis
9 pathway in cultured mouse Leydig cells, and decreased transcriptional expression of FSHR and AR
10 in cultured mouse Sertoli cells.

11 Another series of studies specifically suggested that the pituitary and hypothalamus were
12 targeted by Cr(VI). Male rats exposed to 73.05 mg/kg-day Cr(VI) for 30 days by drinking water
13 were found to have Cr accumulation in the pituitary and decreased serum prolactin, but no effect on
14 serum LH, with the same trend observed in primary rat anterior pituitary cells treated with Cr(VI)
15 in vitro ([Quinteros et al., 2007](#)). A follow-up study using the same experimental design but lower
16 dose [11.6 mg/kg-day Cr(VI)] reported accumulation of Cr and evidence of oxidative stress in the
17 pituitary and hypothalamus ([Nudler et al., 2009](#)). Oxidative stress and apoptosis were also
18 reported in primary anterior pituitary cells treated with Cr(VI) in vitro and were mitigated by
19 cotreatment with an antioxidant ([Quinteros et al., 2008](#); [Quinteros et al., 2007](#)).

20 Effects on Sertoli cells and the blood-testis barrier

21 Several studies reported that Cr(VI) exposure impaired the functionality of Sertoli cells,
22 including the dynamics of the blood-testis barrier. In F1 rats exposed to Cr(VI) during gestation,
23 [Shobana et al. \(2020\)](#) reported a decrease in Sertoli cell secretory products (lactate, pyruvate,
24 retinoic acid, inhibin, androgen binding protein, transferrin), and both [Shobana et al. \(2020\)](#) and
25 [Kumar et al. \(2017\)](#) reported decreased expression of the tight junction proteins claudin-11 and
26 occludin. These factors can affect germ cell development and organization of the blood-testis
27 barrier and are coherent with the histological changes reported in the testis by [Kumar et al. \(2017\)](#).
28 In rats exposed by i.p. injection, [Murthy et al. \(1991\)](#) observed leakage of Sertoli cell tight junctions
29 and adverse effects on late-stage spermatids using electron microscopy. In cultured mouse Sertoli
30 cells in vitro, Cr(VI) treatment decreased transcriptional expression of tight junction signaling
31 molecules ([Das et al., 2015](#)). Comparatively, in a bicameral chamber culture of rat primary Sertoli
32 and germ cells that maintains the blood-testis barrier, gap junction coupling was decreased and the
33 gap junction protein connexin 43 was delocalized from the membrane to the cytoplasm, but
34 adherins and tight junction proteins were not affected ([Carette et al., 2013](#)).

35 **3.2.7.4. Integration of Evidence**

36 Overall, the **evidence suggests** that Cr(VI) may cause male reproductive toxicity in humans.
37 This conclusion is based on coherent evidence of effects across human and animal studies.

1 Decreased testosterone and decreased sperm quantity and quality were observed in both human
2 and animal studies; however, interpretation of this evidence was limited because most studies that
3 observed these effects were considered *low* confidence and there was inconsistency with higher
4 confidence studies. Integrated evidence of the male reproductive effects of Cr(VI) exposure from
5 human, animal, and mechanistic studies is summarized in an evidence profile table (Table 3-42).

6 The evidence of an association between Cr(VI) exposure and male reproductive effects in
7 humans is *slight* and indicates an inverse association between occupational exposure to Cr(VI) and
8 several sperm parameters (concentration, morphology, and motility) and serum testosterone
9 concentrations. This is largely based on a single *medium* confidence study in welders ([Bonde and](#)
10 [Ernst, 1992](#); [Bonde, 1990](#)) and supported by some coherent findings from *low* confidence studies.
11 Evidence of a dose-response pattern in these associations further supports this conclusion. Though
12 some results did not reach statistical significance, this may be explained by the likely impact of
13 exposure misclassification on study sensitivity in all available studies.

14 Evidence from animal toxicology studies and supportive mechanistic data from in vivo and
15 in vitro studies provide *slight* evidence that Cr(VI) is a male reproductive toxicant. Findings from
16 *high* confidence drinking water and dietary exposure studies by NTP that exposed rats or mice as
17 adults ([NTP, 2007, 1996a, b](#)) or for multiple generations using an RACB design ([NTP, 1997](#)) indicate
18 that the male reproductive system is not responsive to Cr(VI)-induced toxicity following oral
19 exposure, with no observed effects on sperm parameters, histopathological outcomes, or male
20 fertility or fecundity. In contrast, a *high* confidence gestational exposure study in which maternal
21 rats were dosed by oral gavage⁴⁴ reported nonmonotonic alterations in testosterone and Leydig cell
22 size and distribution ([Zheng et al., 2018](#)), and a *medium* confidence study in which adult male rats
23 were dosed by oral gavage reported decreased testosterone levels, adverse effects on sperm
24 parameters and testis histopathology, and decreased reproductive organ weights ([Bashandy et al.,](#)
25 [2021](#)). The available *low* confidence developmental and subchronic oral exposure studies likewise
26 reported effects including decreased male fecundity (suggestive of dominant lethal mutations in
27 sperm), decreased sperm quantity and quality, decreased testosterone and gonadotropins,
28 decreased male reproductive organ weights, and altered mating behavior. The *low* confidence
29 drinking water exposure studies frequently did not provide sufficient information to support an
30 estimate of dose, which makes it difficult to compare the dose-response relationships with those
31 from the higher confidence studies. The doses (in mg/kg-d) of Cr(VI) at which effects were
32 observed could not be calculated for any of the *low* confidence drinking water studies because
33 drinking water consumption data was not reported, but the available information indicates that
34 some were higher and some were lower than doses used by NTP (both the drinking water studies
35 and the oral dietary studies). This makes it unlikely that the discrepancy in responses between
36 *high* and *low* confidence studies is due solely to a difference in the dose ranges tested. Support for

⁴⁴As previously noted, oral gavage administration is likely to achieve higher systemic absorption of un-reduced Cr(VI) than ad libitum drinking water or dietary administration.

1 biological plausibility of Cr(VI)-induced male reproductive toxicity is provided by mechanistic data
2 demonstrating evidence of oxidative stress in male reproductive tissues, altered cell cycle
3 regulation and apoptosis in somatic and germ cells, altered steroid hormone signaling, and
4 disruption of Sertoli cells and the blood-testis barrier, although much of this evidence was derived
5 from i.p. injection studies and in vitro studies that have unclear relevance for other routes of
6 exposure.

7 In the only human study that provided a quantitative measure of Cr(VI) exposure ([Bonde,](#)
8 [1990](#)), effects were observed at air mean (SD) concentrations of 3.6 (2.8) $\mu\text{g}/\text{m}^3$; these reported
9 concentrations may underestimate exposure in this study population due use of a cellulose fiber
10 filter during sampling, which can contribute to reduction of Cr(VI) to Cr(III). In animal toxicology
11 studies, the observation of decreased testis weight occurred at 8.7 mg/kg-day Cr(VI) in the 3-month
12 drinking water study in mice by [NTP \(2007\)](#), and effects were observed at doses of 3–12 mg/kg-day
13 Cr(VI) ([Zheng et al., 2018](#)), 3.5 mg/kg-day Cr(VI) ([Bashandy et al., 2021](#)), 0.353 mg/kg-day Cr(VI)
14 ([Marat et al., 2018](#)), or 3.6 mg/kg-day Cr(VI) ([Yousef et al., 2006](#)) in oral gavage studies. For the
15 other drinking water studies in animals, the doses of Cr(VI) at which effects were observed could
16 not be calculated because drinking water consumption data was not reported. Effects were not
17 observed in any of the three animal studies that evaluated inhalation exposure, but those studies
18 did not include specific measures of male reproductive structure and function, so were considered
19 insensitive. There is therefore inadequate information to evaluate the extent of effects in oral
20 versus inhalation exposure.

Table 3-42. Evidence profile table for male reproductive outcomes

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from studies of exposed humans					⊕⊖⊖
<p>SPERM PARAMETERS Medium confidence: Bonde et al. (1992; 1990) Low confidence: Danadevi et al. (2003) Hjollund et al. (1998) Jelnes and Knudsen (1988) Kumar et al. (2005)</p>	<p>Note: Sperm concentration was measured in all five studies considered; other endpoints were measured in some but not all of the studies.</p> <p>Decreased sperm motility in 1 <i>medium</i> study and 2 <i>low</i> confidence studies (1 statistically significant at $p < 0.001$, 1 no p-value or significance reported); a fourth study was uninformative for this measurement.</p> <p>Decreased % sperm with normal morphology in 2 <i>low</i> confidence studies (out of 4 studies), and decreased sperm concentration in 1 <i>low</i> confidence study (out of 5 studies).</p> <p>Decreased semen volume was reported in 1 <i>medium</i> confidence study, but no effect on volume was reported in 3 <i>low</i> confidence studies.</p>	<ul style="list-style-type: none"> • Coherence in direction of related parameters across studies • Exposure-response gradient in one <i>medium</i> confidence study • Detection of effects despite limitations to study sensitivity • Mechanistic evidence of oxidative stress, cell cycle dysregulation and impaired Sertoli cell function provides biological plausibility 	<ul style="list-style-type: none"> • High proportion of <i>low</i> confidence studies 	<p>⊕⊖⊖ <i>Slight</i></p> <p>Occupational (inhalation) Cr(VI) exposure is inversely associated with sperm concentration, normal sperm morphology, sperm motility, and serum testosterone.</p> <p>These findings are consistent and coherent across multiple studies and endpoints, but interpretation is limited because most studies evaluating sperm were considered <i>low</i> confidence.</p> <p>Evidence of the impact of Cr(VI) exposure on semen volume and serum LH and FSH concentrations in humans is unclear.</p>	<p>The evidence suggests that Cr(VI) may cause male reproductive toxicity in humans given sufficient exposure conditions.</p> <p>Effects on sperm parameters and testosterone were observed in both human and animal studies.</p> <p>Most human and animal studies were considered <i>low</i> confidence. Effects in <i>low</i> confidence animal studies or in <i>high</i> or <i>medium</i> confidence animal studies with gavage exposures were generally not seen in the <i>high</i> confidence RACB and subchronic studies by NTP.</p> <p>Mechanistic findings (animals and in vitro) provide evidence supportive of male reproductive toxicity.</p>

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>HORMONES Medium confidence: Bonde et al. (1992; 1990)</p>	<p>Exposure associated with decreased serum testosterone concentration in Danish stainless-steel welders. Decreases in serum LH or FSH concentrations that were not statistically significant were also reported.</p>	<ul style="list-style-type: none"> Exposure-response gradient Mechanistic evidence of alterations in steroidogenesis provides biological plausibility 	<ul style="list-style-type: none"> Uncertainty about exposure measurements due to multiple factors that impact exposure among welders; direction of bias is likely toward the null 		<p>These mechanisms are presumed relevant to humans.</p>
Evidence from animal studies					
<p>FERTILITY AND FECUNDITY High confidence: NTP (1997) Low confidence: Al-Hamood et al. (1998) Bataineh et al. (1997) Elbetieha and Al-Hamood (1997) Marat et al. (2018)</p>	<p>No effects on ability to impregnate females. Decreased fetal viability (indicative of dominant lethal effects) in two <i>low</i> confidence studies in rats and mice following paternal-only exposure; no effects on fetal viability in other three studies.</p>	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Effects observed only in <i>low</i> confidence studies 	<p>⊕⊖⊖ <i>Slight</i> Evidence of male reproductive effects was observed primarily in <i>low</i> confidence studies (drinking water or gavage) and in one <i>high</i> and one <i>medium</i> confidence gavage study.</p>	
<p>SPERM EVALUATION High confidence: NTP (1996a) NTP (1996b) NTP (1997) NTP (2007)</p>	<p>No effects on sperm parameters in four <i>high</i> confidence studies in rats or mice, including an RACB study (F0 and F1 males) and three 3-month exposure studies. A <i>medium</i> confidence study in adult rats and <i>low</i> confidence</p>	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Effects observed only in <i>low</i> confidence studies 	<p><i>High</i> confidence RACB and subchronic studies by NTP observed no male reproductive effects, aside from decreased testis weight in one mouse strain.</p>	

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>Medium confidence: Bashandy et al. (2021)</p> <p>Low confidence: Kim et al. (2012) Kumar et al. (2017) Yousef et al. (2006)</p>	<p>studies in rabbits and F1 rats report decreased sperm quality and quantity.</p>			<p>Evidence was insufficient to evaluate the extent of effects following inhalation exposure.</p>	
<p>HISTOPATHOLOGY</p> <p>High confidence: NTP (2007) Zheng et al. (2018)</p> <p>Low confidence: Bashandy et al. (2021) Kumar et al. (2017) Navin et al. (2021) Rasool et al. (2014)</p>	<p>No dose-related lesions in male reproductive tissues in a <i>high</i> confidence 3-month drinking water study in rats and a variety of mouse strains.</p> <p>A <i>high</i> confidence gestational exposure study in F1 rats reported Leydig cell alterations.</p> <p><i>Low</i> confidence studies in rats and mice observed histopathological changes in the testis and seminiferous tubules.</p>	<ul style="list-style-type: none"> • <i>High</i> confidence study showing Leydig cell alterations • Dose-response gradient • Coherent with effects on testosterone 	<ul style="list-style-type: none"> • Inconsistent findings in <i>high</i> confidence studies • Changes in testis and seminiferous tubules only observed in <i>low</i> confidence studies 		
<p>HORMONES</p> <p>High confidence: Zheng et al. (2018)</p> <p>Medium confidence: Bashandy et al. (2021)</p> <p>Low confidence: Kumar et al. (2017) Navin et al. (2021) (Shobana et al., 2020) Yousef et al. (2006)</p>	<p>Nonmonotonic effect on serum testosterone in a <i>high</i> confidence gestational exposure study in F1 rats.</p> <p>Decreased testosterone and effects on gonadotropins in a <i>medium</i> confidence study in adult rats and <i>low</i> confidence studies in adult rabbits and F1 rats.</p>	<ul style="list-style-type: none"> • <i>High</i> confidence study showing effects on serum testosterone • Coherent with effects on Leydig cells • Mechanistic evidence provides biological plausibility 	<ul style="list-style-type: none"> • Decreased testosterone and effects on gonadotropins only observed in <i>medium</i> and <i>low</i> confidence studies 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>ORGAN WEIGHT High confidence: NTP (1996a) NTP (1996b) NTP (1997) NTP (2007)</p> <p>Low confidence: Al-Hamood et al. (1998) Bashandy et al. (2021) Bataineh et al. (1997) Elbetieha and Al-Hamood (1997) Glaser et al. (1986) Kim et al. (2004) Kim et al. (2012) Kumar et al. (2017) Navin et al. (2021) Wang et al. (2015) Yousef et al. (2006)</p>	<p>Decreased testis weight in one mouse strain in the <i>high</i> confidence 3-month drinking water study by NTP (2007).</p> <p>Changes (typically, decrease) in testis and accessory male reproductive organ weights in <i>low</i> confidence studies in rabbits, rats, and mice.</p> <p>No effects observed in other mouse strains evaluated in NTP (2007), or in any of the remaining studies.</p>	<ul style="list-style-type: none"> Coherent with decreased testosterone within <i>low</i> confidence studies 	<ul style="list-style-type: none"> Unexplained inconsistency across <i>high</i> confidence studies 		
<p>SEXUAL BEHAVIOR Low confidence: Bataineh et al. (1997) Yousef et al. (2006)</p>	<p>Decreased mounts, increased ejaculation latency and post-ejaculation interval, and decreased percentage of males ejaculating in rats exposed as adults.</p> <p>Increased reaction time to mounting in rabbits.</p>	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> <i>Low</i> confidence studies 		
<p>ANOGENITAL DISTANCE Low confidence: Kumar et al. (2017)</p>	<p>Decreased AGD in developing F1 males.</p>	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> <i>Low</i> confidence study 		
Mechanistic evidence					

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Biological events or pathways	Summary of key findings and interpretations			Judgments and rationale	
Oxidative stress	<p><i>Interpretation:</i> In vivo and in vitro evidence of Cr(VI)-induced oxidative stress in male reproductive tissues or in serum concurrent with effects on sperm or testicular pathology.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> • Across most studies, decreased antioxidant activity or expression in male reproductive tissues or serum observed in animals exposed orally (Bashandy et al., 2021; Shobana et al., 2020; Rasool et al., 2014; Kim et al., 2012; Subramanian et al., 2006; Aruldas et al., 2005) or i.p. (El-Demerdash et al., 2019; Marouani et al., 2015a; Hfaiedh et al., 2014; Acharya et al., 2006) and in cultured mouse Leydig, Sertoli, and spermatogonial stem cells (Lv et al., 2018; Das et al., 2015) • Consistent observation of increased testicular or epididymal lipid peroxidation in animals exposed orally (Bashandy et al., 2021; Shobana et al., 2020; Rasool et al., 2014; Kim et al., 2012) or i.p. (El-Demerdash et al., 2019; Marouani et al., 2015a; Hfaiedh et al., 2014; Acharya et al., 2006; Acharya et al., 2004), and increased reactive oxygen species in vitro (Lv et al., 2018; Das et al., 2015) • Cotreatment of with antioxidants mitigated effects on sperm, testicular histopathology, male hormones, and male fecundity in Cr(VI)-exposed animals (Bashandy et al., 2021; Shobana et al., 2020; El-Demerdash et al., 2019; Lv et al., 2018; Hfaiedh et al., 2014; Kim et al., 2012; Subramanian et al., 2006), and decreased Cr(VI)-induced apoptosis in vitro (Lv et al., 2018; Das et al., 2015) 			<p>Observations of oxidative stress, altered cell cycle regulation and apoptosis, altered steroid hormone signaling/effects on the HPG axis, and effects on Sertoli cells and the blood-testis barrier.</p> <p>Oxidative stress was concurrent with apical outcomes in some animal studies.</p> <p>Testicular degeneration, decreased testosterone, and apoptosis are mitigated by cotreatment with antioxidants.</p> <p>Much of this evidence was derived from i.p. injection studies and in vitro studies that have unclear relevance for other routes of exposure.</p>	
Cell cycle regulation and apoptosis in somatic and germ cells	<p><i>Interpretation:</i> In vivo and in vitro evidence of Cr(VI)-induced apoptosis in male reproductive tissues.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> • Increased p53 and decreased DNA content of spermatogenic cells after oral gavage exposure (Bashandy et al., 2021) 				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<ul style="list-style-type: none"> In vivo expression of BAX and DNA fragmentation in testes following i.p. injection (Lv et al., 2018; Marouani et al., 2015a) Degenerative changes in testis and decreased sperm counts in animals after i.p. injection (El-Demerdash et al., 2019; Lv et al., 2018; Acharya et al., 2004; Behari et al., 1978) In vitro evidence of intrinsic apoptosis (TUNEL staining, decreased mitochondrial membrane potential, decreased BAX/BCL-2 ratio, and increased cleavage of caspases 3 and 9) in cultured Leydig, Sertoli, and spermatogonial stem cells (Lv et al., 2018; Das et al., 2015) Evidence of impaired meiotic prophase in a bicameral culture chamber model using rat primary Sertoli and germ cells (Geoffroy-Siraudin et al., 2010) 				
Altered steroid hormone signaling and effects on the HPG axis	<p><i>Interpretation:</i> Cr(VI) alters steroidogenesis in vivo and in vitro.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Biphasic effects on testosterone in one oral exposure study in rats (increased at lowest dose and decreased at highest dose) (Zheng et al., 2018), and decreased testosterone and altered gonadotropin levels in other animal studies following oral (subchronic and gestational) (Bashandy et al., 2021; Navin et al., 2021; Shobana et al., 2020; Kumar et al., 2017; Yousef et al., 2006) and i.p. exposures (El-Demerdash et al., 2019; Hfaiedh et al., 2014; Marouani et al., 2012) Changes in expression of steroidogenic genes and proteins in testis that are generally consistent with effect on testosterone (Navin et al., 2021; Zheng et al., 2018) Oxidative stress in pituitary and hypothalamus and decreased prolactin secretion in rats following 30-day oral exposure (Nudler et al., 2009; Quinteros et al., 2007) and in cultured rat primary anterior pituitary cells (Quinteros et al., 2008; Quinteros et al., 2007) 				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<ul style="list-style-type: none"> Decreased testosterone production and transcriptional expression of steroidogenic genes in cultured Leydig and Sertoli cells in vitro (Das et al., 2015) 				
Effects on Sertoli cells and the blood-testis barrier	<p><i>Interpretation:</i> In vivo and in vitro evidence of impaired Sertoli cell function and dynamics of the blood-testis barrier.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Decrease in Sertoli cell secretory products (lactate, pyruvate, retinoic acid, inhibin, androgen binding protein, transferrin) (Shobana et al., 2020) Leakage of Sertoli cell tight junctions and adverse effects on late-stage spermatids in rats exposed i.p. (Murthy et al., 1991) In vivo and in vitro changes in the expression of molecules that form the blood-testis barrier (Shobana et al., 2020; Kumar et al., 2017; Das et al., 2015; Carette et al., 2013) 				

1

3.2.8. Female Reproductive Effects

1 Female reproductive effects include endpoints related to the structure and function of
2 reproductive organs in pregnant and non-pregnant females, and the balance and cycling of
3 hormones from the HPG axis that regulate the development and function of these organs. This
4 section considers reproductive effects in females exposed to Cr(VI) at any life stage, including
5 exposures occurring preconception and for all stages of development. This is in accordance with
6 EPA's *Framework for Assessing Health Risk of Environmental Exposures to Children* ([U.S. EPA,](#)
7 [2006d](#)), which recommends that evidence for organ system toxicity be considered for all life stages
8 in order to identify populations or life stages that may be more susceptible to chemical-induced
9 toxicity. Exposure during pregnancy can affect both the mother and the fetus, and it is frequently
10 not possible to determine whether effects on the fetus are in response to or separate from maternal
11 toxicity in studies that report both. The maternal endpoints in animal toxicology studies described
12 in this section (maternal body weight gain and gestation length) must therefore be considered in
13 conjunction with the fetal endpoints (survival, growth, and structural alterations) that are
14 discussed in the Developmental Effects Section, 3.2.9.

3.2.8.1. Human Evidence

15 The majority of human studies with well-characterized exposure to Cr(VI) are conducted in
16 occupational studies where males predominate. Limited data are available on female reproductive
17 effects in either the occupational or general population settings. Two studies of female chromate
18 workers were identified that investigated outcomes on fertility, menstruation, pregnancy
19 complications, and pregnancy outcomes ([Ren et al., 2003](#); [Chen et al., 1997](#)), but were found to be
20 *uninformative* due to multiple deficiencies and thus were not further considered. A single ecologic
21 study ([Remy et al., 2017](#)) considered female reproductive effects of Cr(VI) exposure in a population
22 living near a factory that used Cr(VI) in their production processes and where there was
23 documented contaminated groundwater. This study was considered *low confidence* due to
24 potential for exposure misclassification from the ecologic design (exposure was based on location
25 of residence in relation to the factory), outcome misclassification, and confounding. This study
26 reported higher relative risk of reproductive organ neoplasm (RR 1.27, 95% CI: 1.08, 1.5), pelvic
27 inflammatory disease (1.31 (1.17,1.47)), endometriosis (1.19 (1.05, 1.36)), menstrual disorder
28 (1.15 (1.03, 1.29)), and ovarian cyst (1.43 (1.23, 1.65)) in the more exposed geographic area. Due
29 to concerns for potential bias, however, these data are difficult to interpret on their own.
30

3.2.8.2. Animal Evidence

Study evaluation summary

31 Table 3-43 summarizes the animal toxicology studies considered in the evaluation of the
32 effects of Cr(VI) on the female reproductive system. These consist of a two-generation reproductive
33
34

1 study with dietary exposure using NTP's Reproductive Assessment by Continuous Breeding (RACB)
2 protocol ([NTP, 1997](#)); subchronic oral exposure studies in adult animals ([Thompson et al., 2020](#);
3 [NTP, 2007](#); [Kanojia et al., 1998](#); [Elbetieha and Al-Hamood, 1997](#); [Murthy et al., 1996](#); [NTP, 1996a](#),
4 [b](#)); gestational exposure studies that were designed to evaluate offspring development but also
5 reported some F0 maternal outcomes, such as gestational weight gain ([Zheng et al., 2018](#); [Samuel et](#)
6 [al., 2012a](#); [Elsaieed and Nada, 2002](#); [Junaid et al., 1996b, 1995](#); [Trivedi et al., 1989](#)); and studies that
7 evaluated effects in F1 females from dams that had been exposed during gestation or lactation
8 ([Sivakumar et al., 2022](#); [Banu et al., 2016](#); [Banu et al., 2015](#); [Sivakumar et al., 2014](#); [Stanley et al.,](#)
9 [2014](#); [Stanley et al., 2013](#); [Samuel et al., 2012a](#); [Banu et al., 2008](#); [Al-Hamood et al., 1998](#)).

10 The RACB study ([NTP, 1997](#)) and subchronic exposure studies by NTP ([2007, 1996a, b](#))
11 were well-reported and well-designed to evaluate reproductive outcomes and were therefore rated
12 as *high* confidence for all reported outcomes (Table 3-43). The subchronic exposure study in mice
13 by [Thompson et al. \(2020\)](#) was also rated as *high* or *medium* confidence for most outcomes. The
14 remaining studies had reporting limitations and other substantial concerns raised during study
15 evaluation and were rated as *low* confidence across almost all outcomes. Endpoint-specific
16 concerns are discussed in the respective sections below. Two of the *low* confidence studies ([Al-](#)
17 [Hamood et al., 1998](#); [Elbetieha and Al-Hamood, 1997](#)) exposed animals to high concentrations
18 (350–1770 mg/L) of Cr(VI) in drinking water, which was considered a potential confounding
19 variable as it is not possible to determine whether reproductive effects may have been exacerbated
20 by reduced water consumption and/or systemic toxicity; for instance, drinking water
21 concentrations of 350 mg/L Cr(VI) have been associated in rats with decreased water consumption
22 and site of contact toxicity (80 and 100% incidence of ulcers in the glandular stomach of males and
23 females, respectively) ([NTP, 2007](#)). There were concerns about scientific integrity for two groups
24 of authors⁴⁵ ([Banu et al., 2016](#); [Banu et al., 2015](#); [Sivakumar et al., 2014](#); [Stanley et al., 2014](#); [Stanley](#)
25 [et al., 2013](#); [Samuel et al., 2012a](#); [Banu et al., 2008](#); [Kanojia et al., 1998](#); [Junaid et al., 1996b](#); [Murthy](#)
26 [et al., 1996](#); [Junaid et al., 1995](#); [Trivedi et al., 1989](#)), which reduces confidence in these studies and
27 led to exclusion of three datasets but does not necessarily discount the results.

⁴⁵Four studies demonstrating self-plagiarism—i.e., publication of identical data presented as separate and unique experiments—were considered *uninformative* and were excluded from the assessment. Specifically, 1) identical data were presented for rats by [Kanojia et al. \(1996\)](#) and for mice by [Junaid et al. \(1996a\)](#), despite these being presented as separate studies in different species; and 2) subsets of the data presented by Samuel et al. ([2012b](#); [2011](#)) were identical to that in an earlier publication by this laboratory group ([Banu et al., 2008](#)). Other studies by the same groups of authors, listed in the text above, were included in the assessment but considered *low* confidence.

Table 3-43. Summary of included studies for Cr(VI) female reproductive effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a [Click to see interactive graphic with ratings rationale.](#)

Author (year) ^b	Species (strain)	Exposure life stage and duration	Exposure route	Fertility, Fecundity	Maternal BW gain	Gestation length	Hormones	Estrous cyclicity	Timing of puberty	Organ weight	Oocytes/ovarian histopathology	Other histopathology
Al-Hamood et al. (1998)	Mice (BALBC)	F1 females; GD 12–PND 20	Drinking water	L	-	-	-	-	L	L	-	-
Banu et al. (2008)	Rat (Wistar)	F1 females; PND 1–21	Drinking water	-	-	-	L	L	L	-	L	-
Banu et al. (2015)	Rat (Sprague-Dawley)	F1 females; GD 9.5–14.5	Drinking water	-	-	-	-	-	-	-	L	-
Banu et al. (2016)	Rat (Sprague-Dawley)	F1 females; PND 1–21	Drinking water	-	-	-	L	-	-	-	L	-
Elbetieha and Al-Hamood (1997)	Mice (Swiss)	F0 dams; 12 weeks prior to mating	Drinking water	L	-	-	-	-	-	L	-	-
Elsaieed and Nada (2002)	Rat (Wistar)	F0 dams; GD 6–15	Drinking water	-	L	-	-	-	-	-	-	-
Junaid et al. (1995)	Mice (Swiss albino)	F0 dams; GD 14–19	Drinking water	-	L	-	-	-	-	-	-	-
Junaid et al. (1996b)	Mice (Swiss albino)	F0 dams; GD 6–14	Drinking water	-	L	-	-	-	-	-	-	-
Kanojia et al. (1998)	Rat (Druckrey)	F0 dams; 3 months prior to mating	Drinking water	L	L	-	-	L	-	-	L	-
Murthy et al. (1996)	Mice (Swiss)	Adult females; 20 or 90 days	Drinking water	-	-	-	-	L	-	-	L	-
NTP (1996a)	Mice (BALBC)	Adult females; 3, 6, or 9 weeks	Diet	-	-	-	-	-	-	-	H	H
NTP (1996b)	Rat (Sprague-Dawley)	Adult females; 3, 6, or 9 weeks	Diet	-	-	-	-	-	-	-	H	H
NTP (1997)	Mice (BALBC)	Reproductive Assessment by Continuous Breeding (F0 to F2)	Diet	H	H	H	-	H	-	H	H	H
NTP (2007)	Rats (F344/N); Mice (B6C3F1)	Adult females; 3 months	Drinking water	-	-	-	-	-	-	-	H	H
Samuel et al. (2012a)	Rat (Wistar)	<i>Study 1:</i> F0 dams and F1 females; GD 9–21 <i>Study 2:</i> F1 females; GD 9–PND 65	Drinking water	-	-	-	L	L	L	L	L	-

Toxicological Review of Hexavalent Chromium

Author (year) ^b	Species (strain)	Exposure life stage and duration	Exposure route	Fertility, Fecundity	Maternal BW gain	Gestation length	Hormones	Estrous cyclicity	Timing of puberty	Organ weight	Oocytes/ovarian histopathology	Other histopathology
Sivakumar et al. (2014)	Rat (strain not reported)	F1 females; GD 9.5–14.5	Drinking water	L	-	-	-	-	-	-	L	-
Sivakumar et al. (2022)	Rat (Sprague-Dawley)	F0 dams; GD 9.5-14.5	Drinking water	-	-	-	-	-	-	-	L	-
Stanley et al. (2013)	Rat (Sprague-Dawley)	F1 females; PND 1–21	Drinking water	-	-	-	L	-	-	-	L	-
Stanley et al. (2014)	Rat (Sprague-Dawley)	F1 females; PND 1–21	Drinking water	-	-	-	L	-	L	-	L	-
Thompson et al. (2020)	Mice (B6C3F1)	5-week-old females; 90 days	Drinking water	-	-	-	-	L	-	H	H	M
Trivedi et al. (1989)	Mice (albino)	F0 dams; GD 0–19	Drinking water	-	L	-	-	-	-	-	-	-
Zheng et al. (2018)	Rat (Sprague-Dawley)	F0 dams; GD 12–21	Gavage	-	L	-	-	-	-	-	-	-

BW = body weight; GD = gestation day; PND = postnatal day.

^aIn addition to these included studies, there were four animal toxicology studies reporting female reproductive effects that met PECO criteria but were found to be *uninformative* at the study evaluation stage: [Junaid et al. \(1996a\)](#), [Kanojia et al. \(1996\)](#), [Samuel et al. \(2011\)](#), and [Samuel et al. \(2012b\)](#).

^bData are available in HAWC for [NTP \(1997\) \(here\)](#), [NTP \(1996a\) \(here\)](#), [NTP \(1996b\) \(here\)](#).

1 Synthesis of evidence in animals

2 *Fertility and fecundity*

3 In the *high* confidence RACB study in mice ([NTP, 1997](#)), Cr(VI) exposure did not affect
 4 pregnancy index in F0 females at doses up to 50 mg/kg-day Cr(VI) via diet, and had no effect on
 5 mating index, pregnancy index, or fertility index in F1 females at doses up to 39 mg/kg-day Cr(VI)
 6 via diet. Additionally, no effects on pregnancy rate were observed in the *low* confidence study by
 7 [Elbetieha and Al-Hamood \(1997\)](#), in which mice were exposed to 707–1,770 mg/L Cr(VI)⁴⁶ in
 8 drinking water for 12 weeks prior to mating with untreated males.

⁴⁶For many of the oral studies presented here, it was not possible to estimate an average daily mg/kg dose due to lack of reporting. To estimate an average daily dose, paired records of body weight and daily intake of test article are required. This is particularly important for Cr(VI) reproductive and developmental studies, because rapid changes in maternal body weight are expected during pregnancy, and Cr(VI) affects palatability (which affects both Cr(VI) intake rate and body weight). Doses of Cr(VI) are presented where possible, however many cross-study comparisons are done on the basis of mg/L Cr(VI) in drinking water. Reporting and nomenclature related to exposure concentration units and water intakes for the studies by [Kanojia et al. \(1998\)](#), [Murthy et al. \(1996\)](#), and [Junaid et al. \(1995\)](#) were inconsistent with each other. This assessment assumes that the drinking water concentrations provided by these studies (from the same laboratory) were in units of mg/L potassium dichromate.

1 In contrast, the *low* confidence study by [Kanojia et al. \(1998\)](#) reported a decrease in mating
2 index and fertility index in female rats exposed to 88.4–265 mg/L Cr(VI) in drinking water for
3 3 months prior to mating with untreated males. Two *low* confidence gestational exposure studies
4 also observed decreased pregnancy rates in F1 females from dams exposed to 8.8 mg/L Cr(VI) in
5 drinking water from GD 9.5–14.5 (rats) ([Sivakumar et al., 2014](#)) or 353 mg/L Cr(VI) in drinking
6 water from GD 12–PND 20 (mice) ([Al-Hamood et al., 1998](#)). Both of the gestational exposure
7 studies evaluated the F1 animals as individuals without considering the effects of litter, which has
8 the potential to overestimate statistical significance ([Haseman et al., 2001](#)). Additionally, there is
9 uncertainty about how pregnancy rates were determined in the study by [Sivakumar et al. \(2014\)](#),
10 which bred the animals continuously for 8–10 months and presented data as the percentage of F1
11 females pregnant at various blocks of age (2–4, 4–6, 6–8, and 8–10 months old); the authors did not
12 indicate how many times the animals became pregnant within each of these 2-month windows or
13 provide any additional information on how these percentage were calculated. Overall, although
14 decreased fertility was observed across several studies, interpretation is limited because these
15 studies were considered *low* confidence.

16 *Maternal body weight gain*

17 Decreased maternal body weights at the time of delivery were observed for both F0 and F1
18 dams in the RACB study in mice ([NTP, 1997](#)), which was considered *high* confidence for this
19 outcome. For F0 dams, which were allowed to produce up to five litters, the trend was statistically
20 significant for the first four litters; dam body weights were statistically significantly 5% decreased
21 compared to controls at doses of 24.4 mg/kg-day Cr(VI) for the first litter and 5–7% decreased
22 compared to controls at 50.6 mg/kg-day Cr(VI) for the first, second, and third litters, but were not
23 statistically significantly different from the control group in the fourth or fifth litters. For F1 dams,
24 the trend towards decreased dam body weights was statistically significant but treated animals did
25 not differ significantly from controls in any dose group. This study also observed a trend towards
26 decreased F0 dam body weights during lactation for the final litter; this trend was statistically
27 significant at PNDs 1, 4, and 14, and dam body weights were statistically significantly different from
28 controls at doses of 24.4–50.6 mg/kg-day Cr(VI) at these timepoints.

29 Dose-dependent decreases in maternal gestational weight gain were also observed in five
30 *low* confidence studies in which F0 rats or mice were exposed to potassium dichromate in drinking
31 water and euthanized near the end of gestation. None of these studies adjusted for gravid uterine
32 weight, which is considered preferable in order to distinguish between maternal and fetal toxicity
33 ([U.S. EPA, 1991](#)), so the magnitude of decreased gestational weight gain in these *low* confidence
34 studies likely reflects a combination of maternal toxicity as well as the decreased fetal growth and
35 survival that was observed in these studies (see “Developmental effects” section). [Kanojia et al.](#)
36 [\(1998\)](#) exposed female rats for 90 days prior to mating and reported that gestational weight gain
37 was decreased by 10–22% compared to controls in the 88–265 mg/L dose groups, reaching
38 statistical significance at 177 mg/L Cr(VI). A 10–15% mortality rate and clinical signs of hair loss

1 and lethargy were also noted in females in the 177 and 265 mg/L dose groups in this study. In
2 three studies by the same group of authors that exposed mice for various durations during
3 pregnancy, gestational weight gain was decreased compared to controls by 11–26% ([Junaid et al.,
4 1995](#)), 8–24% ([Junaid et al., 1996b](#)), and 17–20% ([Trivedi et al., 1989](#)) following exposure from
5 GDs 14–19, 6–14, and 0–19, respectively, reaching statistical significance at 177 mg/L Cr(VI) in all
6 studies with no mortality or clinical signs of toxicity observed. The study by [Trivedi et al. \(1989\)](#)
7 included a high dose group of 354 mg/L Cr(VI) in which the dams lost weight during the treatment
8 period and did not produce any litters. [Elsaieed and Nada \(2002\)](#) exposed rat dams to 50 mg/L
9 Cr(VI) from GD 6–15 and observed a 40% decrease in maternal body weight gain.

10 Lastly, in the *low* confidence study by [Zheng et al. \(2018\)](#), no effect on maternal body weight
11 was observed in F0 rat dams exposed from GD 12–21 at oral gavage doses up to 12 mg/kg-day
12 Cr(VI); however, body weight measurements in this study were taken 10 days after the exposure
13 ended, so are potentially insensitive due to the lag time between the exposure and endpoint
14 evaluation.

15 *Gestation length*

16 The only study that evaluated effects on gestation length was the *high* confidence RACB
17 study in mice by [NTP \(1997\)](#). There was no effect on the cumulative days to litter for F0 dams over
18 the course of five litters at doses up to 50.6 mg/kg-day Cr(VI) via diet. “Cumulative days to litter” is
19 the number of days from cohabitation to the birth of each litter and is used as a metric for gestation
20 length in the RACB in lieu of checking for a copulatory plug. For F1 dams in this study, which were
21 only allowed to produce one litter and were checked for copulatory plugs to confirm mating, there
22 was likewise no effect on gestation length at doses up to 39 mg/kg-day Cr(VI) via diet.

23 *Hormones*

24 Statistically significant decreases in serum estrogen, testosterone, and progesterone were
25 observed in weanling and peripubertal F1 females in four *low* confidence studies in which F0 dams
26 were exposed to 17.7–70.7 mg/L Cr(VI) in drinking water during lactation (PND 1–21) ([Banu et al.,
27 2016](#); [Stanley et al., 2014](#); [Stanley et al., 2013](#); [Banu et al., 2008](#)). The same effects as well as
28 decreases in prolactin and growth hormone were observed in F1 females in the *low* confidence
29 study by [Samuel et al. \(2012a\)](#), in which F0 dams were exposed to 70.7 mg/L Cr(VI) in drinking
30 water from GD 9–PND 21 and F1 females were continued on the same dosing regimen from
31 weaning through PND 65. Three of these studies also evaluated gonadotropins and observed a
32 statistically significant increase in follicle stimulating hormone ([Stanley et al., 2013](#); [Samuel et al.,
33 2012a](#); [Banu et al., 2008](#)). Luteinizing hormone was statistically significantly increased in the study
34 by [Samuel et al. \(2012a\)](#), whereas it was not affected in the study by [Banu et al. \(2008\)](#). Across all
35 five studies, effects were observed at all tested doses and generally at all timepoints evaluated,
36 which ranged from PND 0–65. Although results were consistent across studies, it should be noted
37 that all five studies were performed by the same group of researchers, so it is unclear whether

1 results would be replicated by an outside research group or by higher confidence studies.
2 Measurements in all studies were presented as the mean of individual animals without accounting
3 for potential litter effects, which has the potential to overestimate statistical significance ([Haseman](#)
4 [et al., 2001](#)). [Samuel et al. \(2012a\)](#) reported that body weights were decreased in the F1 females,
5 whereas the other studies did not report whether there was an effect on body weight or other
6 evidence of overt toxicity coinciding with the hormonal effects. Overall, the results indicate that
7 Cr(VI) decreases sex steroid hormone levels in females exposed during development, but
8 interpretation is limited because all studies were considered *low* confidence.

9 *Estrous cyclicity*

10 There were no notable effects on estrous cycle length, number of cycles, relative time spent
11 in estrous stages, or number of females with regular cycles in F1 mice in the *high* confidence dietary
12 exposure RACB study by [NTP \(1997\)](#). The proportion of F1 females with irregular cycles increased
13 with dose from 0/20 in the control group to 3/20 in the 39 mg/kg-day Cr(VI) dose group, but this
14 effect was not statistically significant and the remaining females had regular cycles with lengths
15 between 4–5 days. There was also no apparent effect on estrous cyclicity in mice exposed to levels
16 up to 149.3 mg/L Cr(VI) in drinking water for 90-days in a study by [Thompson et al. \(2020\)](#);
17 however, the authors did not provide quantitative data and based their conclusion on a single
18 vaginal smear taken at study termination, so the study was considered *low* confidence for this
19 outcome.

20 Four *low* confidence studies reported statistically significant increases in estrous cycle
21 length. A direct comparison between results from these *low* confidence studies and [NTP \(1997\)](#) is
22 complicated by the difference in oral administration (feed vs. drinking water), and inadequate
23 reporting of body weights and/or drinking water consumption by the *low* confidence studies
24 (precluding estimates of the mg/kg-d doses⁴⁷). In adult rats exposed for 90 days, estrous cycle
25 duration was dose-dependently increased from a mean of 5.15 days in control animals to 8.66 days
26 at 265 mg/L Cr(VI) ([Kanojia et al., 1998](#)); however, effects above 88.4 mg/L Cr(VI) may be related
27 to overt toxicity, as there was a 10–15% mortality rate and decreased body weight among females
28 in the 177 and 265 mg/L dose groups. In another study in adult mice that used these same dose
29 levels but a 20-day exposure duration, there was a statistically significant increase in estrous cycle
30 duration from a mean of 4.4 days in control animals to 7.7 days at 265 mg/L Cr(VI) with no effects
31 at lower dose levels ([Murthy et al., 1996](#)). The authors did not report whether there was an effect
32 on body weights or clinical signs of toxicity, which are likely to occur at the 265-mg/L dose level
33 and limits the interpretation of this finding. The remaining two studies investigated estrous
34 cyclicity in F1 females that had been exposed during development. [Samuel et al. \(2012a\)](#) exposed

⁴⁷Based on the information available, the *ad libitum* drinking water doses from [Kanojia et al. \(1998\)](#) and [Murthy et al. \(1996\)](#) were higher than the dietary doses from [NTP \(1997\)](#), while the doses in [Banu et al. \(2008\)](#) and [Samuel et al. \(2012a\)](#) were lower than [NTP \(1997\)](#).

1 F0 dams to 70.7 mg/L Cr(VI) in drinking water during gestation and lactation (GD 9–PND 21) and
2 continued F1 females on the same dosing regimen through PND 65 and observed a statistically
3 significant increase in the number of hours spent in metestrous and diestrous by the F1 animals.
4 Similarly, [Banu et al. \(2008\)](#) reported a statistically significant increase in the number of hours
5 spent in diestrous for F1 females from dams exposed to 70.7 mg/L Cr(VI) in drinking water from
6 PND 1–21, but no change in other estrous phases. None of the available studies indicated whether
7 investigators were blinded to treatment groups during the evaluation of vaginal cytology, which
8 would be considered appropriate for reducing observational bias. Measurements in the
9 developmental exposure studies by [Samuel et al. \(2012a\)](#) and [Banu et al. \(2008\)](#) were presented as
10 the mean of individual F1 animals without accounting for potential litter effects, which has the
11 potential to overestimate statistical significance ([Haseman et al., 2001](#)). The finding of increased
12 estrous cycle duration is coherent with the decreased expression of sex steroid hormones within
13 the developmental studies by [Samuel et al. \(2012a\)](#) and [Banu et al. \(2008\)](#) (see “Hormones” section
14 above), but interpretation is limited because effects were observed only in *low* confidence studies.

15 *Timing of puberty*

16 Four *low* confidence studies that evaluated F1 females following developmental exposure
17 reported a statistically significant increase in the age at vaginal opening, which is a biomarker of
18 female puberty. In F1 mice from dams exposed to potassium dichromate in drinking water from GD
19 12–PND 20, [Al-Hamood et al. \(1998\)](#) observed a statistically significant increase in the mean age of
20 vaginal opening from 24.6 days in control animals to 27 days at 353 mg/L Cr(VI); however, the
21 authors did not report whether there was overt maternal toxicity, which would be expected at this
22 high dose level (see “Maternal body weight gain” section above) and could limit the interpretation
23 of this finding. In two studies that exposed rat dams to potassium dichromate in drinking water
24 from PND 1–21, there were statistically significant increases in the mean age of vaginal opening in
25 F1 females from 33 days in control animals to 55 days at 70.7 mg/L Cr(VI) ([Banu et al., 2008](#)), and
26 from 31 days in control animals to 42 days at 17.7 mg/L ([Stanley et al., 2014](#)). Another study in
27 developing rats by [Samuel et al. \(2012a\)](#) exposed F0 dams to 70.7 mg/L Cr(VI) in drinking water
28 during gestation and lactation (GD 9–PND 21) and continued F1 females on the same dosing
29 regimen through PND 65, and observed a statistically significant increase in the mean age of vaginal
30 opening from 42.3 days in control animals to 65 days at 70.7 mg/L Cr(V)⁴⁸. In all four of these
31 studies, results were presented as the mean of individual F1 animals without accounting for
32 potential litter effects, which has the potential to overestimate statistical significance ([Haseman et](#)
33 [al., 2001](#)).

34 Delayed puberty is coherent with decreased estrogen levels in three of these studies
35 ([Stanley et al., 2014](#); [Stanley et al., 2013](#); [Banu et al., 2008](#)) (see “Hormones” section above).

⁴⁸Numerical values in the study by [Samuel et al. \(2012a\)](#) were extracted from a figure using WebPlotDigitizer software: <https://automeris.io/WebPlotDigitizer/>.

1 Delayed puberty can also be closely tied to decreased body weight ([Greenspan and Lee, 2018](#)), so
2 examination of body weight may provide a means for separating direct effects on puberty from
3 those that are related to general delays in development. [Samuel et al. \(2012a\)](#) reported decreased
4 body weights in Cr(VI) treatment groups at multiple postnatal timepoints, whereas [Banu et al.](#)
5 [\(2008\)](#) and [Stanley et al. \(2014\)](#) did not report body weights. [Al-Hamood et al. \(1998\)](#) reported
6 that body weight of the F1 females was not affected by Cr(VI) exposure, but the study was not clear
7 about when the body weight measurements were taken. Thus, the delayed puberty could be
8 related either to decreases in reproductive hormones or body weight. Overall, interpretation of
9 these *low* confidence studies is limited.

10 *Organ weight*

11 Effects on female reproductive organ weight were inconsistent across studies. No effects on
12 absolute or relative ovary weights were observed in adult F0 or F1 females in the *high* confidence
13 RACB study in mice at doses up to 50.6 and 39 mg/kg-day Cr(VI) via diet, respectively ([NTP, 1997](#)).
14 The *high* confidence study by [Thompson et al. \(2020\)](#) reported no change in the absolute weight of
15 the ovaries or uterus following a 90-day exposure to 149.3 mg/L Cr(VI) in drinking water. No effect
16 on relative ovary or uterus weights were observed at PND 50 in F1 female mice exposed to
17 353 mg/L Cr(VI) in drinking water from GD 12–PND 20 in the *low* confidence developmental
18 exposure study by ([Al-Hamood et al., 1998](#)). In the *low* confidence study in adult mice by ([Elbetieha](#)
19 [and Al-Hamood, 1997](#)), relative ovary weight was statistically significantly increased following
20 exposure to 1770 mg/L Cr(VI) in drinking water for 12 weeks, while relative uterus weight was not
21 changed. Conversely, in the *low* confidence study in rats by [Samuel et al. \(2012a\)](#), there was a dose-
22 dependent decrease in absolute uterus and ovary weight in F0 rat dams exposed to potassium
23 dichromate in drinking water from GD 9–21 that reached statistical significance at 35.3 mg/L and
24 70.7 mg/L Cr(VI), respectively. The study by [Samuel et al. \(2012a\)](#) also evaluated F1 females that
25 were continued on the 70.7 mg/L Cr(VI) dosing regimen through PND 65, and observed a
26 statistically significant decrease in absolute ovary and uterus weight at multiple timepoints
27 measured between PND 3 and PND 65. [Samuel et al. \(2012a\)](#) evaluated F1 animals as individuals
28 without accounting for potential litter effects, which has the potential to overestimate statistical
29 significance ([Haseman et al., 2001](#)). Body weights were decreased in both studies that observed
30 effects, which could have contributed to the increase in relative organ weights and decrease in
31 absolute organ weights. Overall, interpretation is limited because effects were only observed in *low*
32 confidence studies and were not seen in *high* confidence studies, and the direction of effect was
33 inconsistent.

34 *Oocytes and ovarian histopathology*

35 The *high* confidence subchronic studies by NTP reported no gross or microscopic changes in
36 the ovary in adult rats or mice following up to 9 weeks of exposure to doses up to 8.5 or
37 32.5 mg/kg-day Cr(VI) via diet, respectively ([NTP, 1996a, b](#)); or in adult rats or mice following

1 3-month exposure to doses up to 20.9 or 27.9 mg/kg-day Cr(VI) via drinking water ([NTP, 2007](#)),
2 respectively. No gross changes were observed in the ovary in F0 or F1 females in the *high*
3 confidence RACB study in mice at doses up to 50.6 and 39 mg/kg-day Cr(VI) via diet, respectively
4 ([NTP, 1997](#)). The *high* confidence study by [Thompson et al. \(2020\)](#) likewise reported no change in
5 the numbers of small, medium, or large follicles and no change in the incidence of follicular atresia
6 in mice following 90-day exposure to levels up to 149.3 mg/L in drinking water.

7 In contrast, nine *low* confidence studies reported pathological effects in the ovary following
8 exposure to potassium dichromate in drinking water. [Kanojia et al. \(1998\)](#) reported a statistically
9 significant decrease in the number of corpora lutea in maternal female rats that had been exposed
10 to doses of 177 mg/L Cr(VI) and higher in drinking water for 3 months prior to mating; however,
11 there was a 10–15% mortality rate and clinical signs of toxicity among rats at these dose levels, so
12 this effect may be indicative of overt toxicity. Similarly, following exposure in adult mice for
13 20 days, [Murthy et al. \(1996\)](#) reported a dose-related statistically significant decrease in follicle
14 numbers at drinking water concentrations of 88.4 mg/L Cr(VI) and higher, and a statistically
15 significant decrease in the number of ova recovered when the animals were induced to
16 superovulate at concentrations of 177 mg/L Cr(VI) and higher. The remaining seven *low*
17 confidence studies evaluated ovarian histopathology in developing F1 females and were performed
18 by a single group of authors (Banu, Stanley, Sivakumar, Samuel, and coauthors). Following
19 gestational exposure (GD 9.5–14.5) of F0 dams to 8.8 mg/L Cr(VI), F1 female rat fetuses and
20 newborn pups were found to have decreased oocyte counts and accelerated breakdown of germ
21 cell nests into primordial follicles⁴⁹ ([Sivakumar et al., 2022](#); [Banu et al., 2015](#); [Sivakumar et al.,](#)
22 [2014](#)), with an increased number of primary and secondary follicles at PND 4 in treated animals
23 compared to the control group ([Banu et al., 2015](#)). Following lactational exposure (PND 1–21) of F0
24 dams to 8.8–70.7 mg/L Cr(VI), F1 female rats were found to have a dose-related increase in
25 incidence of follicular atresia⁵⁰ ([Banu et al., 2016](#); [Stanley et al., 2014](#); [Stanley et al., 2013](#)) and
26 decreased numbers of primordial, primary, secondary, and antral follicles ([Banu et al., 2008](#)) at
27 timepoints between PND 21 and PND 65. [Samuel et al. \(2012a\)](#) exposed F0 dams to 70.7 mg/L
28 Cr(VI) in drinking water during gestation and lactation (GD 9–PND 21) and continued F1 females
29 on the same dosing regimen through PND 65, and observed pyknotic nuclei and vacuolation in
30 oocytes, stunted or arrested ovarian follicle development, and abnormalities in thecal cells,
31 granulosa cells, and luteum in F1 females at various timepoints measured between PND 3–65, but
32 did not provide quantitative data. These ovarian effects are coherent with the effects on hormones
33 that were observed in some of these studies ([Banu et al., 2016](#); [Stanley et al., 2014](#); [Stanley et al.,](#)
34 [2013](#); [Samuel et al., 2012a](#); [Banu et al., 2008](#)) (see above section) since estrogens and

⁴⁹Germ cell nests are clusters of oogonia that are formed in the developing ovary during late gestation. Germ cell nests are present at birth, and then are broken down into primordial follicles during the final stage of early ovarian development ([Wear et al., 2016](#)).

⁵⁰Follicular atresia is defined as degenerative changes in the granulosa cell layers or oocyte.

1 gonadotropins play a critical role in the growth and development of oocytes. Biological plausibility
2 is also provided by molecular observations of increased oxidative stress, apoptosis, and effects on
3 the extracellular matrix in the ovary, which are discussed below as mechanistic evidence.
4 Interpretation of the histopathological changes in the ovary is limited, however, because effects
5 were observed only in *low* confidence studies and were not seen in the *high* confidence studies.

6 *Other histopathology of the female reproductive system*

7 The *high* confidence studies by NTP reported no effects on the incidence of gross or
8 microscopic lesions in the vagina, cervix, uterus, or clitoral gland in adult rats or mice following up
9 to 9 weeks of exposure to doses up to 8.5 or 32.5 mg/kg-day Cr(VI) via diet, respectively ([NTP,
10 1996a, b](#)); or in adult rats or mice following 3-month exposure to doses up to 20.9 or 27.9 mg/kg-
11 day Cr(VI) via drinking water ([NTP, 2007](#)), respectively. No treatment-related gross lesions were
12 observed in these organs in F0 or F1 females in the RACB study in mice at doses up to 50.6 and
13 39 mg/kg-day Cr(VI) via diet, respectively ([NTP, 1997](#)). The study by [Thompson et al. \(2020\)](#)
14 likewise reported no significant alterations in the gross and microscopic appearance of the corpus
15 and cervix uteri, vaginas, or mammary glands, but was considered *medium* confidence for this
16 outcome because no quantitative data was reported.

17 **3.2.8.3. Mechanistic Evidence**

18 The Cr(VI) literature provides evidence informing potential mechanisms of Cr(VI)-induced
19 female reproductive toxicity; specifically, oxidative stress and apoptosis in female reproductive
20 tissues, altered hormone signaling, and effects on the extracellular matrix. Mechanistic studies are
21 tabulated in Appendix C.2.7 and summarized here.

22 The mechanistic studies reviewed here consisted of *in vivo* mechanistic data from several of
23 the included oral exposure studies discussed above (Table 3-43), as well as from intraperitoneal
24 (i.p.) injection studies that did not meet PECO criteria but were reviewed as relevant to the
25 mechanistic synthesis. Dosing via i.p. injection is likely to result in higher tissue concentrations of
26 Cr(VI) compared to oral exposure, since an oral first-pass effect exists due to the reduction of Cr(VI)
27 in the low pH environment of the stomach; less than 10–20% of an ingested dose may be absorbed
28 in the GI tract, and further reduction will occur in the liver prior to distribution to the rest of the
29 body (see Section 3.1 and Appendix C.1). Therefore, systemic effects are expected to be more likely
30 following i.p. injection or inhalation compared to oral exposure. *In vitro* studies conducted in
31 relevant cell types, such as thecal and granulosa cells, were also considered for mechanistic
32 evidence.

33 Altered steroidogenesis

34 The effects on hormone levels (described in sections above) are supported by changes in
35 the ovarian expression of genes involved in steroidogenesis, which were observed in rats and rat
36 granulosa cells following exposure to potassium dichromate. In F1 rats, [Stanley et al. \(2013\)](#)

1 reported decreased ovarian FSH receptor gene expression and [Banu et al. \(2016\)](#) reported
2 decreased ovarian gene expression of steroidogenic acute regulatory protein (StAR),
3 β -hydroxysteroid dehydrogenase, and aromatase. [Banu et al. \(2016\)](#) also reported increased gene
4 expression of enzymes involved in the metabolic clearance of estradiol (Cyp1a1, Cyp1b1,
5 UDP-glucuronosyltransferases, Sult1a1, NAD(P)H quinone oxidoreductase 1). Similar effects were
6 observed in an immortalized rat granulosa cell line ([Stanley et al., 2011](#); [Banu et al., 2008](#)) and in
7 primary rat granulosa cells ([Stanley et al., 2013](#); [Stanley et al., 2011](#)), including decreased
8 expression of LH receptor, FSH receptor, estrogen receptors (ER α , ER β), StAR, steroidogenic factor
9 (SF)-1, and 17β -hydroxysteroid dehydrogenases -1 and -2. In all of these studies, these effects
10 (including steroid hormone measurements in the in vivo studies) were attenuated by cotreatment
11 with an antioxidant (vitamin C or resveratrol). [Stanley et al. \(2014\)](#) found that cotreatment of
12 potassium dichromate-exposed F1 female rats with estradiol restored the expression of several
13 antioxidant enzymes (Gpx1, catalase, Prdx3, and Txn2), also suggesting a relationship between
14 hormonal effects and oxidative stress.

15 Oxidative stress

16 Decreased antioxidant enzyme expression or activity [e.g., superoxide dismutase (SOD),
17 catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), peroxiredoxin (PRDX) 3,
18 and thioredoxin (TXN)], decreased nonenzymatic antioxidants (glutathione, metallothioneine,
19 vitamin C), and increased markers of oxidative stress (lipid peroxidation, superoxide anion, H₂O₂)
20 were observed in the ovary in several of the studies in F1 rats described above ([Banu et al., 2016](#);
21 [Stanley et al., 2014](#); [Stanley et al., 2013](#); [Samuel et al., 2012a](#)) and in adult mice ([Rao et al., 2009](#))
22 following oral exposure, as well as in the uterus of adult rats following intraperitoneal injection
23 ([Marouani et al., 2015b](#)). Increased ovarian glutathione-S-transferase (GST) ([Stanley et al., 2013](#))
24 and SOD expression ([Banu et al., 2016](#)) were observed in some cases. A similar spectrum of effects
25 was observed in vitro in primary granulosa and theca cells isolated from immature rats and in an
26 immortalized granulosa cell line ([Stanley et al., 2013](#)). [Sivakumar et al. \(2014\)](#) observed that
27 potassium dichromate exposure increased colocalization of p53/SOD-2 in the ovary of F1 rats and
28 hypothesized that this could be contributing to oxidative stress, as p53 has been demonstrated to
29 reduce SOD-2 antioxidant activity.

30 Several in vivo studies found that cotreatment of animals with antioxidants (vitamin C,
31 resveratrol, ginseng edaravone) mitigated apical outcomes including decreased maternal body
32 weight gain, follicular atresia, and effects on pubertal onset, estrous cyclicity, and hormone levels
33 ([Banu et al., 2016](#); [Stanley et al., 2014](#); [Stanley et al., 2013](#); [Banu et al., 2008](#); [Elsaieed and Nada, 2002](#)).
34 This may imply that oxidative stress is a mechanism underlying these effects, but
35 interpretation is difficult because antioxidants can also decrease tissue Cr(VI) levels by stabilizing
36 lower Cr oxidation states. For instance, ([Elsaieed and Nada, 2002](#)) reported lower plasma, placenta,
37 and fetus Cr levels with coadministration of ginseng, and ([Banu et al., 2008](#)) reported lower plasma
38 and ovarian Cr levels with coadministration of Vitamin C.

1 Apoptosis of somatic and germ cells

2 In a series of studies in F1 rat pups that reported accelerated breakdown of germ cell nests,
3 follicular atresia, and decreased follicle counts ([Sivakumar et al., 2022](#); [Banu et al., 2016](#); [Banu et al.,](#)
4 [2015](#); [Sivakumar et al., 2014](#); [Stanley et al., 2014](#); [Stanley et al., 2013](#)), these histopathological
5 changes were accompanied by increased apoptosis of follicular and germ cells. Evidence included
6 increased staining in the TUNEL assay, increased expression of pro-apoptotic markers [Bax,
7 cytochrome c, caspase-3, p53, p27, p53-upregulated modulator of apoptosis (PUMA)], decreased
8 expression of anti-apoptotic markers (Bcl-2, Bcl-XL, Bcl2l1, HIF-1 α), and decreased expression of
9 other signaling molecules that regulate cell survival [p-AKT, p-ERK, X-linked inhibitor of apoptosis
10 protein (XIAP)]. Increased apoptotic cells and protein expression of Bax in the uterus was also
11 reported in adult female rats following intraperitoneal injection with potassium dichromate,
12 accompanied by a decrease in the relative weight of the uterus and ovary ([Marouani et al., 2015b](#)).
13 In primary granulosa cells from immature rats, ([Banu et al., 2011](#)) similarly reported upregulation
14 of apoptotic markers and down-regulation of anti-apoptotic markers and further investigated the
15 role of signal transduction pathways that regulate cell survival, finding that apoptosis and p53
16 activity were decreased after treatment with an ERK1/2 inhibitor. Another study in primary and
17 immortalized rat granulosa cells reported that potassium dichromate induced cell cycle arrest,
18 decreased expression of proteins that regulate the progression of the cell cycle [cyclins, cyclin-
19 dependent kinases (CDKs), and proliferating cell nuclear antigen (PCNA)], and increased expression
20 of inhibitors of CDKs (p15, p16, and p27), although authors stated it was unclear whether these
21 disruptions to the cell cycle were a cause or a consequence of apoptosis ([Stanley et al., 2011](#)).

22 Effects on the ovarian extracellular matrix

23 [Banu et al. \(2015\)](#) proposed a mechanism by which Cr(VI) induces premature ovarian
24 failure by targeting the metalloenzyme X-propyl aminopeptidase (coded by the gene Xpnpep2),
25 leading to effects on the extracellular matrix. In F1 female rats from dams that were exposed to
26 25 mg/L potassium dichromate in drinking water from GD 9.5–14.5, the authors reported increased
27 ovarian expression of Xpnpep2 during late gestation and decreased ovarian expression of Xpnpep2
28 during early postnatal life. Levels of ovarian collagen expression (Col1, Col3, Col4) were inversely
29 proportional to Xpnpep2 at each of the sample time points. The authors hypothesized that Cr(VI)
30 accelerates the breakdown of germ cell nests by upregulating Xpnpep2 and decreasing the
31 distribution of collagen in the fetal ovary and alters the histoarchitecture of the ovary in postnatal
32 animals by downregulating Xpnpep2.

33 **3.2.8.4. Integration of Evidence**

34 Overall, the available **evidence is inadequate** to assess whether Cr(VI) may cause female
35 reproductive effects. Although an association with female reproductive toxicity was demonstrated
36 in a single *low* confidence epidemiology study and a series of *low* confidence animal toxicology
37 studies, effects were not observed in *medium* or *high* confidence studies aside from a moderate

1 decrease in maternal body weight ([NTP, 1997](#)). Integrated evidence of the female reproductive
2 effects of Cr(VI) exposure from human, animal, and mechanistic studies is summarized in an
3 evidence profile table (Table 3-44).

4 The evidence of an association between Cr(VI) exposure and female reproductive effects in
5 humans is *indeterminate*. A single *low* confidence study indicated higher risk of several female
6 reproductive conditions in a population that was estimated to have higher Cr(VI) exposure, but
7 there is too much uncertainty to draw conclusions regarding these associations.

8 Evidence of female reproductive effects from animal toxicology studies and supportive
9 mechanistic data from *in vivo* and *in vitro* studies was also found to be *indeterminate*. Across *high*
10 confidence studies in rats and mice ([Thompson et al., 2020](#); [NTP, 1997, 1996a, b](#)), the only notable
11 female reproductive effect was a 5–7% decrease in F0 and F1 maternal body weights at delivery in
12 the RACB study in mice ([NTP, 1997](#)); fertility, fecundity, and estrous cyclicity were not affected, and
13 effects on organ weights, follicle counts, and histopathology were not observed. In contrast,
14 profound effects on female fertility, estrous cyclicity, hormone levels, ovarian follicles and germ
15 cells, and reproductive development were observed across the other available studies, which were
16 all considered *low* confidence and many of which were from a single research group. The doses of
17 Cr(VI) at which effects were observed could not be calculated for any of the *low* confidence studies
18 because drinking water consumption data was not reported, but the available information indicates
19 that some were higher and some were lower than doses used by NTP; so, it is unlikely that the
20 discrepancy in responses between *high* and *low* confidence studies is simply due to a difference in
21 the dose ranges tested. Some of the *low* confidence studies used relatively high dose levels
22 associated with mortality or other overt toxicity, limiting the ability to interpret the female
23 reproductive findings. A strength of these *low* confidence studies is that they evaluated several
24 indicators of female reproductive toxicity that were not included in the NTP studies: specifically,
25 steroid hormone and gonadotropin levels, age at pubertal development, and ovarian histopathology
26 during early developmental stages. The interpretation of the *low* confidence studies is limited,
27 however, by deficiencies in study design, conduct, and reporting. Support for biological plausibility
28 of Cr(VI)-induced female reproductive effects comes from mechanistic data that was also largely
29 published by the same laboratory group, demonstrating altered expression of steroid hormone
30 signaling pathways in female rats and rat cells, as well as oxidative stress and apoptosis in rodent
31 ovarian and uterine tissues and cells. There were no animal studies that evaluated female
32 reproductive effects following inhalation exposure.

Table 3-44. Evidence profile table for female reproductive outcomes

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from studies of exposed humans					○○○
FEMALE REPRODUCTIVE EFFECTS Low confidence: Remy et al. (2017)	One ecologic study reported higher relative risk for reproductive organ neoplasm, pelvic inflammatory disease, endometriosis, menstrual disorder, and ovarian cysts in a higher exposed geographic area.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Low confidence study 	○○○ <i>Indeterminate</i> There is some indication of an association between Cr(VI) exposure and female reproductive effects, but the only evidence comes from a single, low confidence ecologic study so there is considerable uncertainty in the findings.	The evidence is inadequate to assess whether Cr(VI) causes female reproductive toxicity in humans. The single human study and most animal studies were considered <i>low</i> confidence. With the exception of decreased maternal body weight, effects in <i>low</i> confidence animal studies were not seen in the <i>high</i> confidence RACB and subchronic and studies.
Evidence from animal studies					
FERTILITY AND FECUNDITY High confidence: NTP (1997) Low confidence: Kanojia et al. (1998) Elbetieha and Al-Hamood (1997) Al-Hamood et al. (1998) Sivakumar et al. (2014)	No effects on mating or pregnancy rates in mice in the <i>high</i> confidence RACB study (NTP, 1997) or in a <i>low</i> confidence 12-week exposure study (Elbetieha and Al-Hamood, 1997). Decreased fertility or fecundity in female rats or mice after developmental or adult exposure was reported in 3 <i>low</i> confidence studies.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Effects observed only in <i>low</i> confidence studies 	○○○ <i>Indeterminate</i> Evidence of female reproductive effects was observed in multiple <i>low</i> confidence studies. Decreased F0 and F1 maternal body weights in a RACB study in mice (NTP, 1997) was the	Mechanistic findings (animals and in vitro) provide evidence supportive of female reproductive toxicity. These mechanisms are presumed relevant to humans.

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
<p>MATERNAL BODY WEIGHT GAIN High confidence: NTP (1997) Low confidence: Elsaieed and Nada (2002) Junaid et al. (1995) Junaid et al. (1996b) Kanojia et al. (1998) Trivedi et al. (1989) Zheng et al. (2018)</p>	<p>Decreased maternal body weight was reported in 6 out of 7 studies, including F0 and F1 animals in the <i>high</i> confidence RACB study.</p> <p>In <i>low</i> confidence studies, decreased maternal body weights during pregnancy were concurrent with decreased fetal survival and/or fetal body weight, and authors did not adjust for gravid uterine weight to distinguish between maternal and fetal effects.</p>	<ul style="list-style-type: none"> • <i>High</i> confidence study • Consistency • Dose-response gradient 	<ul style="list-style-type: none"> • <i>Low</i> confidence studies did not adjust for gravid uterine weight 	only notable effect in <i>high</i> confidence studies.	
<p>GESTATION LENGTH High confidence: NTP (1997)</p>	<p>No effects on cumulative days to litter (F0 dams) or gestation length (F1 dams) in a <i>high</i> confidence RACB study in mice.</p>	<ul style="list-style-type: none"> • No factors noted 	<ul style="list-style-type: none"> • No factors noted 		
<p>HORMONES Low confidence: Banu et al. (2008) Banu et al. (2016) Stanley et al. (2013) Stanley et al. (2014) Samuel et al. (2012a)</p>	<p>Decreased serum estrogen, testosterone, and progesterone and increased FSH and LH in F1 rats in five <i>low</i> confidence studies from a single laboratory group. Decreased prolactin and growth hormone also noted in one of these studies.</p>	<ul style="list-style-type: none"> • No factors noted 	<ul style="list-style-type: none"> • <i>Low</i> confidence studies, all from one research group 		
<p>ESTROUS CYCLICITY High confidence: NTP (1997) Low confidence: Kanojia et al. (1998) Murthy et al. (1996)</p>	<p>No notable effects on F1 estrous cyclicity in the <i>high</i> confidence RACB study in mice.</p> <p>Increased estrous cycle duration in four <i>low</i> confidence studies in rats or mice exposure during development or as adults.</p>	<ul style="list-style-type: none"> • No factors noted 	<ul style="list-style-type: none"> • Effects observed only in <i>low</i> confidence studies 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Banu et al. (2008) Samuel et al. (2012a) Thompson et al. (2020)					
TIMING OF PUBERTY Low confidence: Al-Hamood et al. (1998) Banu et al. (2008) Stanley et al. (2014) Samuel et al. (2012a)	Increase in the age at pubertal onset (vaginal opening) was reported in F1 female rats or mice in four <i>low</i> confidence studies.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Effects observed only in <i>low</i> confidence studies 		
ORGAN WEIGHT High confidence: NTP (1997) Thompson et al. (2020) Low confidence: Elbetieha and Al-Hamood (1997) Al-Hamood et al. (1998) Samuel et al. (2012a)	Increased relative ovary weight and decreased absolute ovary and uterus weight in 2 <i>low</i> confidence studies. Otherwise, no effects were observed.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Effects observed only in <i>low</i> confidence studies May be secondary to decreased body weight 		
OOCYTES AND OVARIAN HISTOPATHOLOGY High confidence: NTP (1996a) NTP (1996b) NTP (1997) NTP (2007) Thompson et al. (2020) Low confidence: Kanojia et al. (1998)	No gross or microscopic changes in the ovary across 5 <i>high</i> confidence studies. Decreased corpora lutea and decreased follicle numbers and ova following superovulation in <i>low</i> confidence studies. Degenerative effects on the ovary including accelerated breakdown of germ cell nests, follicular atresia, stunted or arrested follicle	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Effects observed only in <i>low</i> confidence studies, mostly from one research group 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Murthy et al. (1996) Banu et al. (2008) Banu et al. (2015) Banu et al. (2016) Sivakumar et al. (2022) Sivakumar et al. (2014) Stanley et al. (2013) Stanley et al. (2014) Samuel et al. (2012a)	development, and decreased follicle counts across 7 <i>low</i> confidence studies from a single laboratory group.				
OTHER HISTOPATHOLOGY OF THE FEMALE REPRODUCTIVE SYSTEM <i>High confidence:</i> NTP (1996a) NTP (1996b) NTP (1997) NTP (2007) <i>Medium confidence:</i> Thompson et al. (2020)	No gross or microscopic changes were observed in the vagina, cervix, uterus, and/or clitoral gland across 5 <i>high</i> or <i>medium</i> confidence studies.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> No factors noted 		
Mechanistic evidence					
Biological events or pathways	Summary of key findings and interpretations			Judgments and rationale	
Altered steroidogenesis	<i>Interpretation:</i> Cr(VI) alters steroidogenesis in vivo and in vitro. <i>Key findings:</i> <ul style="list-style-type: none"> Decreased estrogen, testosterone, and progesterone and increased FSH and LH in animals in F1 rats following gestational exposure (Banu et al., 2016; Stanley et al., 2014; Stanley et al., 2013; Samuel et al., 2012a; Banu et al., 2008). 			Observations of altered hormone signaling, oxidative stress, apoptosis, and effects on the ovarian extracellular matrix.	

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<ul style="list-style-type: none"> Decreased ovarian expression of gonadotropin receptors and/or steroidogenic genes in F1 rats (Banu et al., 2016; Stanley et al., 2013) and in cultured rat granulosa cells (Stanley et al., 2013; Stanley et al., 2011; Banu et al., 2008). Upregulation of genes involved in metabolic clearance of estradiol in F1 rats (Banu et al., 2016). 			<p>Oxidative stress was concurrent with apical outcomes in some animal studies.</p> <p>Effects on maternal body weight gain, follicular atresia, pubertal onset, estrous cyclicity, and hormones were mitigated by cotreatment of antioxidants.</p>	
Oxidative stress	<p><i>Interpretation:</i> In vivo and in vitro evidence of Cr(VI)-induced oxidative stress in female reproductive tissues concurrent with apical measurements of female reproductive toxicity.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Decreased antioxidant activity or expression in the ovary was observed in F1 rats (Banu et al., 2016; Stanley et al., 2014; Stanley et al., 2013; Samuel et al., 2012a), in orally exposed adult mice (Rao et al., 2009), in the rat uterus following i.p. injection (Marouani et al., 2015b), and in cultured rat granulosa and theca cells (Stanley et al., 2013). Cotreatment of with antioxidants mitigated effects on maternal body weight gain, follicular atresia, and effects on pubertal onset, estrous cyclicity, and hormone levels (Banu et al., 2016; Stanley et al., 2014; Stanley et al., 2013; Banu et al., 2008; Elsaieed and Nada, 2002). 				
Apoptosis of somatic and germ cells	<p><i>Interpretation:</i> In vivo and in vitro evidence of Cr(VI)-induced apoptosis in ovarian follicles and germ cells.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Increased TUNEL assay staining, increased expression of pro-apoptotic markers, decreased expression of anti-apoptotic markers, and/or decreased expression of other signaling molecules that regulate cell survival reported in ovarian tissue of F1 rats (Sivakumar et al., 2022; Banu et al., 2016; Banu et al., 2015; Sivakumar et al., 2014; Stanley et al., 2014; 				

Toxicological Review of Hexavalent Chromium

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<p>Stanley et al., 2013). Similar findings reported in adult female rats following i.p. injection (Marouani et al., 2015b).</p> <ul style="list-style-type: none"> In vitro evidence of cell cycle arrest in cultured rat granulosa cells (Stanley et al., 2011). 				
Ovarian extracellular matrix	<p><i>Interpretation:</i> In vivo evidence that Cr(VI) induces premature ovarian failure by altering the extracellular matrix.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Ovarian expression of the metalloenzyme X-propyl aminopeptidase was increased in F1 rats during late gestation and increased during early postnatal life and was inversely proportional to ovarian collagen expression (Banu et al., 2015). 				

3.2.9. Developmental Effects

1 Developmental toxicity encompasses effects that occur following pre- or postnatal exposure
2 of the developing organism. The major categories of developmental toxicity discussed in this
3 section are changes in survival, growth, structural alterations, and effects on the placenta.

4 Functional effects on specific organ systems following developmental exposures are considered in
5 their respective sections (e.g., “Male reproductive effects” and “Female reproductive effects”
6 sections) and are also summarized here. These endpoints are considered relevant for
7 developmental toxicity risk assessment per U.S. EPA guidelines ([U.S. EPA, 1991](#)).

8 This section considers both indirect (maternal or paternal) and direct routes of exposure to
9 the developing organism. As noted previously, it is frequently difficult to determine whether effects
10 on the fetus are in response to or separate from maternal toxicity in studies that report both, so the
11 fetal endpoints described in this section should be considered in conjunction with the maternal
12 endpoints described in the “Female reproductive effects” section. Developmental effects produced
13 at doses that cause minimal maternal toxicity are still considered to represent developmental
14 toxicity and should not be discounted as maternal toxicity ([U.S. EPA, 1991](#)). Less is known about
15 the potential impact of paternal exposures prior to conception, but it is thought that offspring
16 development can be affected by genetic or epigenetic changes in sperm or by direct exposure to
17 toxicant residues in the seminal fluid.

18 3.2.9.1. *Human Evidence*

19 Study evaluation summary

20 Table 3-45 summarizes the nine human epidemiology studies (eight publications)
21 considered in the evaluation of the developmental effects of Cr(VI). Four studies were found to be
22 *uninformative* due to critical deficiencies in one or more domains ([Xia et al., 2016](#); [Quansah and](#)
23 [Jaakkola, 2009](#); [Ren et al., 2003](#); [Chen et al., 1997](#)) and were not considered further. Of the six
24 included studies, three studies (four publications) from the same research group examined
25 paternally mediated effects on offspring, specifically resulting from paternal occupational
26 exposures to Cr(VI) from stainless-steel welding ([Hjollund et al., 2005](#); [Hjollund et al., 2000](#);
27 [Hjollund et al., 1995](#); [JP et al., 1992](#)). Exposure was measured in these studies using questionnaires.
28 Participants were asked about their past and current welding experiences including type of metal
29 (stainless or mild steel), welding methods, timing of welding exposures (years welding), and safety
30 precautions used (ventilation). In each study, exposure was analyzed in three categories (stainless-
31 steel welding, mild steel welding, and no welding). The questionnaires were not validated, and thus
32 all the studies were evaluated as *low* confidence due to concerns in the exposure measurement
33 domain. Spontaneous abortion was examined in all three studies, and one of these ([JP et al., 1992](#))
34 also examined preterm birth, fetal growth, infant death within one year of birth, and congenital
35 malformations. In addition to the three studies evaluating effects of paternal occupational
36 exposure, one general population pregnancy cohort ([Peng et al., 2018](#)) examined fetal growth

1 markers but was limited due to exposure measurement of total chromium in urine with no
 2 additional information to inform Cr(VI) exposure specifically. In addition, two ecologic studies
 3 examined associations based on proximity to a Cr(VI) contaminated site (kilometers from center of
 4 polluted area in [Eizaguirre-García et al. \(2000\)](#), primarily affected town vs. rest of county in [Remy
 et al. \(2017\)](#)). The developmental effects examined in these studies included spontaneous abortion,
 5 early pregnancy loss (not defined), pregnancy complications, and infant health ([Remy et al., 2017](#))
 6 and congenital malformations/anomalies ([Remy et al., 2017](#); [Eizaguirre-García et al., 2000](#)).
 7

Table 3-45. Summary of human studies for Cr(VI) developmental effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a
[Click to see interactive data graphic for rating rationales.](#)

Author (year)	Industry	Location	Study design	Spontaneous abortion	Preterm birth	Fetal growth	Other (infant death, congenital malformations)
Eizaguirre-García et al. (2000)	General population	Scotland	Ecologic	–	–	–	L
Hjollund et al. (1995), JP et al. (1992)^b	SS Welding	Denmark	Cohort (occupational)	L	L	L	L
Hjollund et al. (2000)	SS Welding	Denmark	Cohort (occupational)	L	–	–	–
Hjollund et al. (2005)	SS Welding	Denmark	Retrospective cohort	L	–	–	–
Peng et al. (2018)	General population	China	Pregnancy cohort	–	–	L	–
Remy et al. (2017)	General population	U.S.	Ecologic	L	L	–	L

SS = stainless steel.

^aIn addition to these included studies, four additional studies reported developmental outcomes that met PECO criteria but were found to be *uninformative* at the study evaluation stage: [Quansah and Jaakkola \(2009\)](#), [Xia et al. \(2016\)](#), [Chen et al. \(1997\)](#), and [Ren et al. \(2003\)](#).

^bOne study was described in two publications ([Hjollund et al., 1995](#); [JP et al., 1992](#)) that reported different but overlapping subsamples. Results from both are described in the text but their results are not considered independent of each other.

8 Synthesis of evidence in humans

9 *Spontaneous abortion*

10 Four studies examined associations between spontaneous abortion and Cr(VI) exposure.
 11 Spontaneous abortion is pregnancy loss occurring before approximately 28 weeks gestation and
 12 can be subdivided into early loss (loss before pregnancy is recognized) and clinical loss (loss after
 13 5 weeks gestation) ([Radke et al., 2019](#)). Methods of spontaneous abortion ascertainment can vary
 14 in their ability to identify early losses. When early losses are not detected, there is potential for bias
 15 if a true association with the exposure exists. This can even result in an apparent protective effect.

1 In the four available studies, two were designed to ascertain early losses. [Hjollund et al. \(2000\)](#)
2 used daily urine samples to identify pregnancy and early losses, which is the ideal approach.
3 [Hjollund et al. \(2005\)](#) used registry data from the Danish In Vitro Fertilization Register, which
4 includes information on clinical pregnancy identification. While this approach may not be as
5 sensitive as daily urine samples, it is likely that women were closely monitored and pregnancies
6 were identified early in this population. The other two studies ([Remy et al., 2017](#); [Hjollund et al.,](#)
7 [1995](#)) identified spontaneous abortions based on hospital discharge data, which would be limited
8 to clinical losses, and only those in women who sought medical attention.

9 [Hjollund et al. \(2000\)](#) reported a statistically significant increased risk of spontaneous
10 abortion with paternal stainless-steel welding (RR = 3.5, 95% CI: 1.3–9.1), which was specific to this
11 exposure group (i.e., no increase was observed with mild steel welding exposure)⁵¹. Conversely,
12 [Hjollund et al. \(2005\)](#) and [Hjollund et al. \(1995\)](#) reported inverse associations (statistically
13 significant in [Hjollund et al. \(2005\)](#)), although a different analysis of the population in the latter
14 study ([JP et al., 1992](#)) reported a positive association (OR = 1.9, 95% CI: 1.1–3.2). However, in this
15 latter analysis, spontaneous abortion was based on registry data providing the number of
16 spontaneous abortions preceding each birth recorded in the national registry, and this measure
17 was considered to be less sensitive than measures in other studies. In addition, in [JP et al. \(1992\)](#),
18 there were similarly higher odds for induced abortion (OR = 2.1, 95% CI: 1.2–3.4), which increases
19 uncertainty about the reliability of the estimate since there is limited plausibility for Cr(VI) to
20 influence induced abortions (currently limited data exists on the association between Cr(VI) and
21 birth defects, as described below). A low confidence ecologic study ([Remy et al., 2017](#)) also
22 reported higher relative risk of spontaneous abortion with higher exposure (RR 1.80, 95% CI: 1.20,
23 2.68). Overall, there is some indication that Cr(VI) exposure is associated with spontaneous
24 abortion, most notably in [Hjollund et al. \(2000\)](#), which had outcome ascertainment methods best
25 able to ascertain early losses. It is possible that the inverse associations observed in [Hjollund et al.](#)
26 [\(1995\)](#) were due to early losses missed by their outcome ascertainment methods, but there is not
27 adequate data to assess this. However, given the small number of studies and the limited nature of
28 the evidence there is considerable uncertainty.

29 *Fetal growth, preterm birth, and infant death*

30 Three studies ([Peng et al., 2018](#); [Remy et al., 2017](#); [JP et al., 1992](#)) examined associations
31 with fetal growth outcomes, though in [Remy et al. \(2017\)](#) the association was reported for a
32 combination of outcomes that also included preterm birth. [Peng et al. \(2018\)](#) examined birth
33 weight, length, and ponderal index, as well as fetal ultrasound measurements of head and
34 abdominal circumference and femur length in all three trimesters. There were statistically

⁵¹As noted in Section 3.1.1.2, highly soluble Cr(VI) may be more rapidly absorbed by the lungs and transported to the bloodstream than Cr(VI) compounds that are less soluble. Cr(VI) components of stainless steel welding fume are significantly more water soluble than for mild steel welding, and may cause more persistent and greater inflammatory responses ([Shoeb et al., 2017](#)).

1 significant decreases in ponderal index with increased exposure, and non-statistically significant
2 decreases in birth weight and fetal head and abdominal circumference and femur length (in the
3 third trimester only). [JP et al. \(1992\)](#) reported no association with low birthweight. [Remy et al.
4 \(2017\)](#) reported higher relative risk for preterm birth, low birthweight, and small for gestational
5 age combined (RR 1.14, 95% CI: 1.05, 1.25). Thus, there is some indication of fetal growth
6 restriction with Cr(VI) exposure, but there is considerable uncertainty as the exposure in [Peng et al.
7 \(2018\)](#) was total chromium and [Remy et al. \(2017\)](#) also included preterm birth, both of which
8 reduce the interpretability of the findings.

9 In addition, [JP et al. \(1992\)](#) reported on preterm birth and infant death within the first year.
10 They reported a non-statistically significant association between higher Cr(VI) exposure levels and
11 increased odds of preterm birth (OR = 1.3, 95% CI: 0.9–1.9). No association was observed for infant
12 mortality, but the lack of association could be due at least in part to poor sensitivity as above. In
13 addition to the preterm birth results already discussed, [Remy et al. \(2017\)](#) reported higher relative
14 risk for perinatal jaundice (RR 1.13, 95% CI: 1.06, 1.20) and some infant health conditions
15 (infectious/parasitic, nervous system). While both studies reported associations with preterm
16 birth, this was analyzed in a combined outcome in [Remy et al. \(2017\)](#), which again makes it difficult
17 to interpret. The other outcomes were observed in a single *low* confidence study.

18 *Congenital malformations*

19 Three studies examined the association between Cr(VI) exposure and congenital
20 malformations ([Remy et al., 2017](#); [Eizaguirre-García et al., 2000](#); [JP et al., 1992](#)). In [JP et al. \(1992\)](#),
21 there was no association between paternal occupational exposure and congenital malformations.
22 In [Eizaguirre-García et al. \(2000\)](#), risk of congenital malformations was lowest in areas closest to
23 the center of the polluted area. In [Remy et al. \(2017\)](#), there was higher relative risk of eye, ear, face,
24 neck, and cleft anomalies in the higher exposed geographic area (RR 1.19, 95% CI: 0.91, 1.56), but
25 this was only observed in one of the two time periods studied. No increase in genitourinary
26 anomalies was observed. Overall, there is limited evidence of an association between congenital
27 malformations and Cr(VI) exposure. However, all of the available studies had serious limitations
28 which limits interpretation of their results.

29 In summary, there are some indications of an association between Cr(VI) exposure and
30 spontaneous abortion, fetal growth, preterm birth, and congenital malformations, but the evidence
31 is limited in quality and quantity.

32 **3.2.9.2. *Animal Evidence***

33 Study evaluation summary

34 Table 3-46 summarizes the animal toxicology studies considered in the evaluation of the
35 developmental effects of Cr(VI). These consist of a continuous breeding study using NTP's
36 Reproductive Assessment by Continuous Breeding (RACB) protocol ([NTP, 1997](#)); studies that

1 evaluated effects in F1 offspring following maternal-only exposure ([Kanojia et al., 1998](#); [Elbetieha](#)
2 [and Al-Hamood, 1997](#)) or paternal-only exposure ([Marat et al., 2018](#); [Al-Hamood et al., 1998](#);
3 [Bataineh et al., 1997](#); [Elbetieha and Al-Hamood, 1997](#)) prior to mating; and studies that evaluated
4 F1 offspring from dams that were exposed during gestation ([Sivakumar et al., 2022](#); [Navin et al.,](#)
5 [2021](#); [Shobana et al., 2020](#); [Zheng et al., 2018](#); [Arshad et al., 2017](#); [Banu et al., 2017a](#); [Banu et al.,](#)
6 [2017b](#); [Kumar et al., 2017](#); [Shobana et al., 2017](#); [Banu et al., 2015](#); [Sivakumar et al., 2014](#); [Samuel et](#)
7 [al., 2012a](#); [Bataineh et al., 2007](#); [De Flora et al., 2006](#); [Elsaieed and Nada, 2002](#); [Junaid et al., 1996b,](#)
8 [1995](#); [Trivedi et al., 1989](#)) or lactation ([Sánchez and Ubios, 2021, 2020](#); [Banu et al., 2016](#); [Sánchez](#)
9 [et al., 2015](#); [Stanley et al., 2014](#); [Stanley et al., 2013](#); [Banu et al., 2008](#)). All studies were oral
10 exposures (diet, drinking water, or oral gavage), although exposure to offspring was indirect in all
11 studies except the RACB study.

12 The RACB study by [NTP \(1997\)](#) and the gestational exposure study by [Zheng et al. \(2018\)](#)
13 were well-reported and well-designed to evaluate effects in developing animals and therefore were
14 rated as *high* confidence for all reported outcomes. The studies by [De Flora et al. \(2006\)](#) and
15 [Shobana et al. \(2017\)](#) had minor concerns raised during study evaluation and were rated *medium*
16 confidence. The remaining studies had reporting limitations and other substantial concerns and
17 were rated as *low* confidence across all outcomes. Endpoint-specific concerns are discussed in the
18 respective sections below. Three of the *low* confidence studies ([Al-Hamood et al., 1998](#); [Bataineh et](#)
19 [al., 1997](#); [Elbetieha and Al-Hamood, 1997](#)) exposed animals to high concentrations (350–
20 1770 mg/L) of Cr(VI) in drinking water, which was considered a potential confounding variable as
21 it is not possible to determine whether developmental effects may have been exacerbated by
22 reduced water consumption and/or systemic toxicity; for instance, drinking water concentrations
23 of 350 mg/L Cr(VI) have been associated in rats with decreased water consumption and site of
24 contact toxicity (80 and 100% incidence of ulcers in the glandular stomach of males and females,
25 respectively) ([NTP, 2007](#)). There were concerns about scientific integrity for two groups of
26 authors⁵² ([Banu et al., 2017a](#); [Banu et al., 2017b](#); [Kumar et al., 2017](#); [Samuel et al., 2012a](#); [Kanojia et](#)
27 [al., 1998](#); [Junaid et al., 1996b, 1995](#)), which reduces confidence in these studies but does not
28 necessarily discount the results.

⁵²Four studies demonstrating self-plagiarism—i.e., publication of identical data presented as separate and unique experiments—were considered *critically deficient* and were excluded from the assessment. Specifically, 1) identical data were presented for rats by [Kanojia et al. \(1996\)](#) and for mice by [Junaid et al. \(1996a\)](#), despite these being presented as separate studies in different species; and 2) subsets of the data presented by Samuel et al. ([2012b](#); [2011](#)) were identical to that in an earlier publication by this laboratory group ([Banu et al., 2008](#)). Other studies by the same groups of authors, listed in the text above, were included in the assessment but considered *low* confidence.

Table 3-46. Summary of included studies for Cr(VI) developmental effects and overall confidence classification [high (H), medium (M), low (L)] by outcome.^a
[Click to see interactive graphic for ratings rationale.](#)

Author (year)	Species (strain)	Exposure life stage and duration	Exposure route	Survival	Growth	Structural alterations	Placenta	Functional effects
Al-Hamood et al. (1998)	Mice (BALBC)	F1 males or females exposed GD 12–PND 20 and mated with untreated animals	Drinking water	L	-	-	-	L
Arshad et al. (2017)	Mice (Swiss-Webster)	GD 6	Gavage	L	L	L	-	-
Banu et al. (2008)	Rat (Wistar)	F1 females; PND 1–21	Drinking water	-	-	-	-	L
Banu et al. (2015)	Rat (Sprague-Dawley)	F1 females; GD 9.5–14.5	Drinking water	-	-	-	-	L
Banu et al. (2016)	Rat (Sprague-Dawley)	F1 females; PND 1–21	Drinking water	-	-	-	-	L
Banu et al. (2017b)	Rat (Sprague-Dawley)	GD 9.5–14.5	Drinking water	-	L	-	-	-
Banu et al. (2017a)	Rat (Sprague-Dawley)	GD 9.5–14.5	Drinking water	-	-	-	L	-
Bataineh et al. (1997)	Rat (Sprague-Dawley)	F0 males exposed 12 weeks prior to mating with untreated females	Drinking water	L	-	-	-	-
Bataineh et al. (2007)	Rat (Sprague-Dawley)	GD 1–3 or 4–6	Gavage	L	-	-	-	-
De Flora et al. (2006)	Mice (Swiss albino)	“Duration of pregnancy”–GD 18	Drinking water	M	M	-	-	-
Elbetieha and Al-Hamood (1997)	Mice (Swiss)	F0 males or females exposed 12 weeks prior to mating with untreated animals	Drinking water	L	-	-	-	-
Elsaieed and Nada (2002)	Rat (Wistar)	GD 6–15	Drinking water	L	L	L	L	-
Junaid et al. (1995)	Mice (Swiss albino)	GD 14–19	Drinking water	L	L	L	L	-
Junaid et al. (1996b)	Mice (Swiss albino)	GD 6–14	Drinking water	L	L	L	L	-

Toxicological Review of Hexavalent Chromium

Author (year)	Species (strain)	Exposure life stage and duration	Exposure route	Survival	Growth	Structural alterations	Placenta	Functional effects
Kanojia et al. (1998)	Rat (Druckrey)	F0 females exposed 3 months prior to mating with untreated males	Drinking water	L	L	L	L	-
Kumar et al. (2017)	Rat (Wistar)	GD 9–14	Drinking water	-	L	-	-	L
Marat et al. (2018)	Rat (white outbred)	Adult males; 60 days	Gavage	L	-	-	-	-
Navin et al. (2021)	Rat (Wistar)	F1 offspring; GD 9-14	Drinking water	-	-	-	-	L
NTP (1997)	Mice (BALBC)	Reproductive Assessment by Continuous Breeding (F0 to F2)	Diet	H	H	-	-	H
Samuel et al. (2012a)	Rat (Wistar)	<i>Study 1:</i> GD 9–21 <i>Study 2:</i> GD 9–PND 65	Drinking water	L	L	-	-	L
Sánchez et al. (2015)	Rat (Wistar)	PND 4–19	Gavage	-	-	L	-	-
Sánchez and Ubios (2020)	Rat (Wistar)	PND 4–9, PND 4–15, or PND 4–23	Gavage	-	-	L	-	-
Sánchez and Ubios (2021)	Rat (Wistar)	PND 4–9 or PND 4–15	Gavage	-	-	L	-	-
Shobana et al. (2017)	Rat (Wistar)	GD 9–14	Drinking water	-	-	-	-	M
(Shobana et al., 2020)	Rat (Wistar)	F1 offspring; GD 9-14 or GD 15-21	Drinking water	-	-	-	-	L
Sivakumar et al. (2014)	Rat (strain not reported)	F0 dams; GD 9.5–14.5	Drinking water	-	-	-	-	L
Sivakumar et al. (2022)	Rat (Sprague-Dawley)	F0 dams; GD 9.5-14.5	Drinking water	-	-	-	-	L
Stanley et al. (2013)	Rat (Sprague-Dawley)	F1 females; PND 1–21	Drinking water	-	-	-	-	L
Stanley et al. (2014)	Rat (Sprague-Dawley)	F1 females; PND 1–21	Drinking water	-	-	-	-	L
Trivedi et al. (1989)	Mice (albino)	GD 0–19	Drinking water	L	L	L	L	-
Zheng et al. (2018)	Rat (Sprague-Dawley)	GD 12–21.5	Gavage	H	H	-	-	H

GD = gestation day; PND = postnatal day.

^aIn addition to these included studies, there were seven animal toxicology studies reporting female reproductive effects that met PECO criteria but were found to be *uninformative* at the study evaluation stage: [Junaid et al.](#)

[\(1996a\)](#), [Kanojia et al. \(1996\)](#), [Soudani et al. \(2011b\)](#), [Soudani et al. \(2011a\)](#), [Soudani et al. \(2013\)](#), [Zahid et al. \(1990\)](#), and [Borneff et al. \(1968\)](#).

1 Synthesis of evidence in animals^{53, 54}

2 *Fetal and postnatal survival*

3 Decreased offspring survival was observed only in *low* confidence studies. Statistically
4 significant effects occurred at the same dose or lower compared to decreased maternal body weight
5 gain or clinical signs of maternal toxicity within a subset of studies that reported both maternal and
6 fetal endpoints ([Elsaieed and Nada, 2002](#); [Kanojia et al., 1998](#); [Iunaid et al., 1996b, 1995](#); [Trivedi et
7 al., 1989](#)). Other *low* confidence studies provided little or no data on maternal toxicity, so the
8 relative sensitivity of maternal and offspring effects could not be compared in those cases.

9 In the *high* confidence RACB study in mice ([NTP, 1997](#)) there was no effect on the number
10 of live pups per litter or proportion of pups born alive across the F1 and F2 litters at dietary doses
11 up to 30.3 mg/kg-day Cr(VI) (F0 parental animals) and 37.1 mg/kg-day Cr(VI) (F1 parental
12 animals), and no effects on survival of F1 from birth until weaning at PND 21. The *high* confidence
13 gestational exposure study by [Zheng et al. \(2018\)](#) also reported no effects on rat pup numbers or
14 sex ratio (% male pups) following maternal exposure at doses up to 12 mg/kg-d Cr(VI) via oral
15 gavage from GD 12–21. The *medium* confidence gestational exposure study by [De Flora et al.
16 \(2006\)](#) reported no effect on the number of fetuses at GD 18 following maternal exposure to 5 or
17 10 mg/L Cr(VI) in drinking water throughout the duration of pregnancy.

18 In contrast to the findings in *high* and *medium* confidence studies, all *low* confidence studies
19 that exposed dams to Cr(VI) during pregnancy reported increased pre- or post-implantation loss.
20 Rat dams dosed with 25 mg/kg-day potassium dichromate via oral gavage from GD 1–3 had no
21 implantations [Bataneh et al. \(2007\)](#); and a dose-related increase in pre-implantation loss was
22 observed in mice exposed from GD 0–19, reaching statistical significance at 177 mg/L Cr(VI)
23 ([Trivedi et al., 1989](#)). Statistically significant increases in pre-implantation loss were also reported
24 in rats exposed to 50 mg/L potassium dichromate in drinking water from GD 6–15 ([Elsaieed and
25 Nada, 2002](#)), and a dose-related decrease in implantation index (number of implantation sites /
26 number of corpora lutea) was reported in rats exposed to 50–400 mg/L Cr(VI) from GD 9–21
27 ([Samuel et al., 2012a](#)); however, these exposures began around or after the time of implantation in
28 rats (generally GD 6) and therefore effects may not have been related to treatment ([U.S. EPA, 1991](#)).
29 Statistically significant dose-related increases in post-implantation loss (resorptions or dead
30 fetuses) were observed in mice following exposure from GD 0–19 ([Trivedi et al., 1989](#)), GD 6–14

⁵³Data are available in HAWC for [NTP \(1997\) here](#).

⁵⁴For many of the oral studies presented here, it was not possible to estimate an average daily mg/kg dose due to lack of reporting. To estimate an average daily dose, paired records of body weight and daily intake of test article are required. This is particularly important for Cr(VI) reproductive and developmental studies, because rapid changes in maternal body weight are expected during pregnancy, and Cr(VI) affects palatability (which affects both Cr(VI) intake rate and body weight). Doses of Cr(VI) are presented where possible, however many cross-study comparisons are done on the basis of mg/L Cr(VI) in drinking water.

1 ([Junaid et al., 1996b](#)), and GD 14–19 ([Junaid et al., 1995](#)), reaching statistical significance at 88 or
2 177 mg/L Cr(VI). In studies that tested a single dose level, post-implantation loss was increased in
3 rats following exposure to a maternal dose of 50 mg/L Cr(VI) in drinking water from GD 6–15
4 ([Elsaieed and Nada, 2002](#)), in rats given a maternal dose of 8.8 mg/kg-day Cr(VI) via oral gavage
5 from GD 4–6 ([Bataineh et al., 2007](#)), and in mice given a maternal dose of 3.9–16 mg/kg Cr(VI) via
6 oral gavage on GD 6 ([Arshad et al., 2017](#)). The studies by [Arshad et al. \(2017\)](#) and [Samuel et al.](#)
7 ([2012a](#)) presented results in terms of the number of individual fetuses affected without indication
8 of means or variance across litters, so there is greater uncertainty in the results of these studies.

9 Three *low* confidence studies reported decreased fetal survival when maternal animals
10 were exposed to Cr(VI) prior to mating. [Kanojia et al. \(1998\)](#) exposed rat dams to Cr(VI) via
11 drinking water for 3 months prior to mating with unexposed males and reported a dose-related 2-
12 to 3.1-fold increase in pre-implantation loss and a 2.2- to 4.2-fold increase in post-implantation loss,
13 reaching statistical significance at 88 mg/L Cr(VI). [Elbetieha and Al-Hamood \(1997\)](#) exposed adult
14 F0 female mice to Cr(VI) in drinking water for 12 weeks prior to mating with unexposed males, and
15 reported a 17–18% decrease in implantations, ~5–6 fold increase in the number of mice with
16 resorptions, and a 25–32% decrease in viable fetuses, all of which were statistically significant at
17 both of the tested doses [707 and 1,768 mg/L Cr(VI)]. ([Al-Hamood et al., 1998](#)) exposed F1 female
18 mice to maternal doses of 353 mg/L Cr(VI) in drinking water during development (from GD 12–
19 PND 20) and then mated these animals with unexposed males as adults, and reported a statistically
20 significant 12% decrease in implantations and 14% decrease in viable fetuses.

21 Male-mediated decreases in fetal survival were observed in two *low* confidence paternal-
22 only exposure studies. [Elbetieha and Al-Hamood \(1997\)](#) reported a statistically significant 16–23%
23 decrease in implantations and viable fetuses when adult F0 male mice were exposed to 707 or
24 1,414 mg/L Cr(VI) in drinking water for 12 weeks prior to mating with untreated females; these
25 effects were not observed at the 353 or 1,768 mg/L dose levels, although some resorptions or dead
26 fetuses were noted. [Marat et al. \(2018\)](#) exposed adult F0 male rats to 0.353 mg/kg-day Cr(VI) via
27 oral gavage for 60 days prior to mating with untreated females and reported a 1.8-fold increase in
28 pre-implantation loss, an 8.9-fold increase in post-implantation loss, and a dominant lethal
29 mutation frequency of 0.665. There were no effects on the number of implantation sites and viable
30 fetuses in two other *low* confidence paternal exposure studies, both of which exposed parental
31 males to a dose level of 353 mg/L Cr(VI) in drinking water during development ([Al-Hamood et al.](#)
32 [1998](#)) or as adults ([Bataineh et al., 1997](#)) and mated with unexposed females.

33 *Fetal and postnatal growth*

34 Decreased fetal or postnatal growth were observed to some extent in almost all studies that
35 evaluated these outcomes. Statistically significant effects occurred at the same dose or lower
36 compared to decreased maternal body weight gain or clinical signs of toxicity within a subset of
37 studies that reported both maternal and fetal endpoints ([Elsaieed and Nada, 2002](#); [Kanojia et al.](#)

1 [1998](#); [NTP, 1997](#); [Junaid et al., 1996b, 1995](#); [Trivedi et al., 1989](#)). Other *low* confidence studies
2 provided little or no data on maternal toxicity, so the relative sensitivity of maternal and offspring
3 effects could not be compared in those cases.

4 In the *high* confidence RACB study in mice, mean F1 male and female pup body weights in
5 the highest dose group [F0 dietary exposure of 30.3 mg/kg-day Cr(VI)] were similar to controls at
6 birth but were 9–15% lower than controls at PNDs 14 and 21, although this effect was not
7 statistically significant⁵⁵. By PND 74 ± 10, the effect on F1 body weights was statistically significant;
8 mean F1 male and female body weights in the highest dose group [37.1 mg/kg-day Cr(VI)] were
9 decreased by 9% compared to controls, and F1 females in the second highest dose group
10 [16.1 mg/kg-day Cr(VI)] were decreased by 4% compared to controls ([NTP, 1997](#)). Food
11 consumption was increased in the treated animals compared to controls, so the decrease in growth
12 does not seem to be attributable to palatability or changes in feed consumption. There was a
13 statistically significant 11% decrease in F2 female pup birth weights at 37.1 mg/kg-day Cr(VI),
14 although pup body weights in this group were not statistically significantly lower than controls
15 when adjusted for litter size. Otherwise, there were no effects on F2 pup birth weights, and F2
16 animals were not monitored further.

17 The remaining studies that observed decreased F1 growth were considered *low* confidence.
18 [Kanojia et al. \(1998\)](#) exposed rat dams via drinking water for 3 months prior to mating and
19 reported a dose-related 21–36% decrease in fetal body weight, reaching statistical significance at
20 88 mg/L Cr(VI). In drinking water studies that exposed pregnant dams, fetal body weights were
21 decreased in a dose-related manner compared to controls by 18–47% ([Junaid et al., 1995](#)), 3–19%
22 ([Junaid et al., 1996b](#)), and 32–44% ([Trivedi et al., 1989](#)) following exposure from GDs 14–19, 6–14,
23 and 0–19, respectively, reaching statistical significance at 88 or 177 mg/L Cr(VI). Two studies that
24 exposed pregnant dams to 50 mg/L Cr(VI) observed that fetal body weights were statistically
25 significantly decreased compared to controls by 33% following maternal exposure from GD 6–14
26 ([Elsaieed and Nada, 2002](#)) and by 31% following maternal exposure from GD 9.5–14.5 ([Banu et al.,](#)
27 [2017b](#))⁵⁶. One study that exposed pregnant mice on GD 6 via oral gavage reported that fetal body
28 weights were decreased by 17–27% compared to controls, reaching statistical significance at
29 22 ug/g potassium dichromate ([Arshad et al., 2017](#)). Three of the gestational exposure studies also
30 reported decreased crown-rump length ([Arshad et al., 2017](#); [Junaid et al., 1995](#); [Trivedi et al.,](#)
31 [1989](#)), and the study by [Arshad et al. \(2017\)](#) reported decreased morphometric parameters
32 including head and eye circumference, and fore limb, hind limb, and tail length. In two studies that
33 assessed postnatal growth, [Kumar et al. \(2017\)](#) reported a dose-related statistically significant
34 11–20% decrease in body weight at PND 120 in F1 male rats from dams that had been exposed to
35 35.3 or 70.7 mg/L Cr(VI) in drinking water from GD 9–14, and [Samuel et al. \(2012a\)](#) reported a

⁵⁵Data are available for males ([PND14](#) and [PND21](#)) and females ([PND14](#) and [PND21](#)).

⁵⁶Fetal body weights in [Banu et al. \(2017b\)](#) were reported graphically, but were estimated using WebPlotDigitizer to be 2.64 ± 0.01 g in the control group and 1.82 ± 0.14 g in the Cr(VI) exposure group.

1 statistically significant 33–41% decrease in body weights on PNDs 3, 7, 18, 45, and 65 in F1 female
2 rats that had been continuously exposed to 200 mg/L Cr(VI) in drinking water from GD 9–PND
3 65⁵⁷. The studies by [Banu et al. \(2017b\)](#), [Kumar et al. \(2017\)](#), and [Samuel et al. \(2012a\)](#) reported
4 body weights as the mean of individual offspring without accounting for litter effects, and it was not
5 clear whether results in the studies by [Elsaieed and Nada \(2002\)](#) or [Arshad et al. \(2017\)](#) were litter
6 means or the means of individual animals; this affects interpretation of the results in these studies,
7 as failure to consider litter effects has the potential to overestimate statistical significance
8 ([Haseaman et al., 2001](#)).

9 Three studies reported no effect on F1 growth. The *high* confidence study in rats by [Zheng](#)
10 [et al. \(2018\)](#) reported no change in newborn pup body weight following maternal exposure at doses
11 up to 12 mg/kg-d Cr(VI) via oral gavage from GD 12–21. The *medium* confidence study in mice by
12 [De Flora et al. \(2006\)](#) reported no change in fetal body weight at GD 18 following maternal
13 exposure to 5 or 10 mg/l Cr(VI) in drinking water throughout the duration of pregnancy. The *low*
14 *confidence* study by [Al-Hamood et al. \(1998\)](#) reported no effects on male or female body weight at
15 PND 50 in F1 mice that had been exposed to maternal doses of 353 mg/L Cr(VI) in drinking water
16 from GD 12–PND 20.

17 *Structural alterations*

18 A dose-related increase in structural alterations was reported in all studies that evaluated
19 these outcomes in fetuses or early postnatal animals, which consisted of *low* confidence studies.
20 Statistically significant effects occurred at the same dose or lower compared to decreased maternal
21 body weight gain or clinical signs of toxicity within a subset of studies that reported both maternal
22 and fetal endpoints ([Elsaieed and Nada, 2002](#); [Kanojia et al., 1998](#); [Junaid et al., 1996b, 1995](#);
23 [Trivedi et al., 1989](#)), whereas the other two studies did not provide data on maternal toxicity.
24 Within studies, reduced ossification occurred at doses concurrent with decreased fetal growth
25 (body weight or morphometric parameters) and was mostly observed in bones that undergo rapid
26 ossification at the end of gestation (e.g., parietals, interparietals, caudal, frontals). This may indicate
27 that the delay in ossification is indicative of a generalized growth delay ([Carney and Kimmel, 2007](#)).

28 Four *low* confidence studies by the same research group evaluated fetuses at GD 19.
29 Reduced skeletal ossification was observed when F0 rat dams were exposed to potassium
30 dichromate in drinking water for 3 months prior to mating ([Kanojia et al., 1998](#)) and when F0
31 mouse dams were exposed to potassium dichromate in drinking water from GD 0–19 ([Trivedi et al.,](#)
32 [1989](#)), GD 6–14 ([Junaid et al., 1996b](#)), or GD 14–19 ([Junaid et al., 1995](#)). Skeletal effects across
33 these studies reached statistical significance at levels as low as 88 mg/L Cr(VI). [Trivedi et al.](#)
34 [\(1989\)](#) also reported that fetuses had decreased number of ribs, which reached statistical

⁵⁷F1 body weights in [Kumar et al. \(2017\)](#) and [Samuel et al. \(2012a\)](#) were reported graphically and were estimated using WebPlotDigitizer. The difference in body weights between control and Cr(VI)-exposed animals on PND 3 in the study by [Samuel et al. \(2012a\)](#) could not be estimated using WebPlotDigitizer due to the scale of the figure, so the values shown are for PNDs 7, 18, 45, and 65.

1 significance at 177 mg/L Cr(VI). In addition to skeletal effects, these four studies each reported the
2 same gross abnormalities (drooping wrist, subdermal hemorrhagic patches, kinking tail, short tail)
3 and reported that the exposed animals did not have any visceral alterations. [Trivedi et al. \(1989\)](#)
4 also reported “enlarged gap between fingers.”

5 The remaining *low* confidence studies that evaluated fetal structural alterations have
6 greater uncertainty due to incomplete reporting of results. [Elsaieed and Nada \(2002\)](#) reported a
7 statistically significant increase in skeletal and visceral abnormalities in fetuses from F0 rat dams
8 that were exposed to 50 mg/L Cr(VI) in drinking water from GD 6–15 and euthanized on the day
9 before delivery, and noted that some animals had incomplete ossification of the skull bone and
10 increased renal dilation; however, data were reported as the average total skeletal and visceral
11 abnormalities per litter with no quantitative incidence data provided for specific alterations.
12 [Arshad et al. \(2017\)](#) reported numerous skeletal and visceral abnormalities in mouse fetuses from
13 dams that were dosed on GD 6 with 3.8–16 mg/kg Cr(VI) via oral gavage and euthanized on GD 18,
14 including reduced skeletal ossification; however, most of these abnormalities were described
15 qualitatively with no information provided on relative incidence. Quantitative incidence data was
16 provided for some abnormalities (anophthalmia, limb hyperextension, limb hyperflexion, limb
17 malrotation, limb micromelia, and spina bifida) but was reported as the total number of individual
18 fetuses affected without indication of potential litter effects. A series of studies by Sánchez and
19 coauthors evaluated periodontal bone development in rats dosed with 4.4 mg/kg-day Cr(VI) via
20 oral gavage during lactation and reported delayed tooth eruption, delayed mineralization,
21 decreased periodontal width and bone volume, and decreased bone resorption and formation
22 surfaces ([Sánchez and Ubios, 2021, 2020](#); [Sánchez et al., 2015](#)). The publications did not report pup
23 body weights, but the authors clarified via personal correspondence that pup weights were
24 decreased in the experimental groups compared to controls, which may suggest that the effects on
25 tooth development are related to a generalized growth delay. The authors provided quantitative
26 results for some histomorphometric parameters but concerns were raised due to the lack of
27 blinding in the analysis and the small sample size (one litter used per experimental group).

28 *Effects on the placenta*

29 Effects on the placenta were evaluated in several *low* confidence studies that exposed dams
30 to Cr(VI) prior to or during gestation. Placental effects occurred at the same doses as decreased
31 maternal body weight gain in three of these studies that provided both maternal and fetal data
32 ([Elsaieed and Nada, 2002](#); [Kanojia et al., 1998](#); [Junaid et al., 1995](#)), whereas the studies by [Junaid et](#)
33 [al. \(1996b\)](#) and [Trivedi et al. \(1989\)](#) reported decreased maternal body weight gain but no effect on
34 placenta weights.

35 Two *low* confidence studies evaluated placental histopathology. In rat dams exposed to 50
36 mg/L potassium dichromate in drinking water from GD 6–15, [Elsaieed and Nada \(2002\)](#) reported
37 histologic lesions in the placenta including necrosis in the chorionic villi and focal extravasation of

1 red blood cells in the decidua basalis. [Banu et al. \(2017a\)](#) reported histologic effects including
2 increased hypertrophy and hemorrhagic lesions in the basal zone in rat dams exposed to 17.7 mg/L
3 Cr(VI) in drinking water from GD 9.5–14.5. Neither of these studies provided quantitative data on
4 the incidence or severity of these lesions, so interpretation of these findings is limited.

5 Changes in placenta weight were also observed in *low* confidence studies, although the
6 direction of effect was inconsistent across studies. Rat dams exposed to potassium dichromate in
7 drinking water for 3 months prior to mating had statistically significantly decreased placenta
8 weights in the 177 and 265 mg/L Cr(VI) dose groups in the study by [Kanojia et al. \(1998\)](#), whereas
9 a statistically significant dose-related increase in placenta weight was observed at exposure levels
10 ≥ 88 mg/L Cr(VI) in mouse dams exposed from GD 14–19 in the study by [Junaid et al. \(1995\)](#). In
11 other *low* confidence studies, no effects on placenta weight were observed in mouse dams exposed
12 to levels up to 265 mg/L Cr(VI) in drinking water from GD 6–14 ([Junaid et al., 1996b](#)) or up to
13 177 mg/L Cr(VI) in drinking water from GD 0–19 ([Trivedi et al., 1989](#)).

14 *Functional effects (reproductive, endocrine)*

15 Effects on the developing reproductive system are described in the “Male reproductive
16 effects” and “Female reproductive effects” sections and summarized briefly here. Effects on F1
17 male and female fertility and histopathology were not observed in the *high* confidence RACB study
18 ([NTP, 1997](#)) at doses up to 37.1 mg/kg-day Cr(VI) via diet, but were documented in several other
19 studies. In F1 male rats, a nonmonotonic effect on testosterone (increased at 3 mg/kg-day,
20 decreased at 12 mg/kg-day) and altered Leydig cell distribution were observed following maternal
21 exposure by oral gavage from GD 12–21 in the *high* confidence study by [Zheng et al. \(2018\)](#). A
22 series of *low* confidence studies by one laboratory group reported effects including decreased
23 sperm quality, histopathological changes in the testis, decreased testosterone and gonadotropins,
24 and decreased reproductive organ weights in F1 males exposed from GD 9–14 ([Navin et al., 2021](#);
25 [Shobana et al., 2020](#); [Kumar et al., 2017](#)) or GD 15–21 ([Shobana et al., 2020](#)) to maternal doses of
26 17.7–70.7 mg/L Cr(VI) in drinking water. In F1 female rats, a series of *low* confidence studies by
27 one laboratory group reported pathological effects on oocyte development following gestational
28 and/or postnatal exposure to maternal doses of 8.8–70.7 mg/L Cr(VI) in drinking water, as well as
29 decreased sex steroid hormone levels, increased gonadotropin levels, delayed puberty, and changes
30 in estrous cyclicity ([Sivakumar et al., 2022](#); [Banu et al., 2016](#); [Banu et al., 2015](#); [Sivakumar et al.,](#)
31 [2014](#); [Stanley et al., 2014](#); [Stanley et al., 2013](#); [Samuel et al., 2012a](#); [Banu et al., 2008](#)). A *low*
32 confidence study in mice by [Al-Hamood et al. \(1998\)](#) likewise reported decreased pregnancy rates
33 and delayed puberty in F1 males that had been exposed to maternal doses of 353 mg/L Cr(VI) from
34 GD 12–PND 20. Interpretation of the *low* confidence studies is limited, due to the study design and
35 reporting concerns discussed in “Male reproductive effects” and “Female reproductive effects”
36 sections.

1 Other evidence of functional effects in developing animals comes from a *medium* confidence
2 study that evaluated insulin signaling in F1 rats following maternal exposure to potassium
3 dichromate in drinking water from GD 9–14 ([Shobana et al., 2017](#)). Serum insulin levels in pubertal
4 F1 rats evaluated on PND 59 were statistically significantly increased compared to controls at
5 maternal exposure levels ≥ 50 mg/L. Glucose uptake was increased in liver but decreased in
6 skeletal muscle, and glucose oxidation was increased in both liver and skeletal muscle at 50 mg/L
7 Cr(VI) but decreased at 100 and 200 mg/L Cr(VI). Despite these changes, there was no effect on
8 fasting blood glucose or oral glucose tolerance in these animals.

9 **3.2.9.3. Mechanistic Evidence**

10 Studies providing mechanistic evidence on the potential developmental effects of Cr(VI) are
11 tabulated in Appendix C.2.8 and summarized here. Together, these studies provide supporting
12 evidence that Cr(VI) may have adverse developmental effects if it were to reach the relevant target
13 tissues. The mechanistic studies reviewed here consisted of *in vivo* mechanistic data from several
14 oral exposure studies, most of which are discussed above (Table 3-46), as well as data from
15 intraperitoneal (i.p.) injection studies, *in vitro* studies in whole embryos, and *in vitro* studies in
16 trophoblast or osteoblast cell lines that did not meet PECO criteria but were reviewed as
17 informative to the mechanistic analysis. Dosing via i.p. injection is likely to result in higher tissue
18 concentrations of Cr(VI) compared to oral exposure, since an oral first-pass effect exists due to the
19 reduction of Cr(VI) in the low pH environment of the stomach; less than 10–20% of an ingested
20 dose may be absorbed in the GI tract, and further reduction will occur in the liver prior to
21 distribution to the rest of the body (see Section 3.1 and Appendix C). Therefore, systemic effects
22 are expected to be more likely following i.p. injection or inhalation compared to oral exposure.
23 Effects are also expected to be more likely in *in vitro* embryonic studies compared to *in vivo*
24 studies, since the *in vitro* studies incubated sperm or blastocytes directly with potassium
25 dichromate.

26 Fetal genotoxicity

27 One study assessed genotoxicity [measured as the frequency of micronucleated (MN)
28 polychromatic erythrocytes (PCE) in maternal bone marrow and fetal liver and peripheral blood] in
29 mice exposed to Cr(VI) salts during gestation via i.p. injection or oral exposure ([De Flora et al.,
30 2006](#)). Fetuses from dams dosed orally via drinking water with sodium dichromate dihydrate (5 or
31 10 mg/l) or potassium dichromate (10 mg/l) did not have any changes in the frequency of MN PCE
32 compared to controls. In contrast, fetuses from dams given a single i.p. injection of 50 mg/kg
33 potassium dichromate or sodium dichromate dihydrate on GD 17 had significantly increased
34 frequency of MN PCE frequency in the liver and peripheral blood. The same pattern was observed
35 in maternal bone marrow. This study suggests that Cr(VI) is genotoxic to fetuses when it reaches
36 target tissues, although bioavailability is poor through the oral route of exposure.

1 In vitro evaluations of embryo development

2 Three studies in whole embryos provided evidence that Cr(VI) impairs embryonic
3 development. One study incubated mouse sperm with potassium dichromate and used it to fertilize
4 eggs from untreated mice ([Yoisungnern et al., 2015](#)). It was found that the percentage of
5 unfertilized oocytes and embryos in the 2-cell stage increased while the percentage in the expanded
6 and hatching blastocyst stages and total number of blastocysts were decreased, suggesting delays in
7 embryonic development. These effects were observed at the lowest dose level (1.1 μM Cr(VI)), and
8 differences became more pronounced with increasing doses, although higher doses also produced
9 statistically significant decreases in sperm viability. Blastocysts in the low dose group also had a
10 decrease in the number of trophectoderm and inner cell mass cells and decreased expression of
11 pluripotent marker genes (*sox2*, *pou5f1*, and *klf4*), indicating impaired development of the embryo
12 and placenta. A second study that incubated mouse blastocysts with potassium dichromate ([Iijima
13 et al., 1983](#)) found a dose-dependent decrease in 2-layer inner cell masses after 6 days of exposure
14 to 0.088–0.71 μM Cr(VI), but statistically significant differences in hatching, attachment and
15 trophoblast outgrowths were not observed. Cultured embryos treated for 24 hours with
16 0.18–0.71 μM Cr(VI) showed statistically significant decreases in allantois fusion, beating hearts,
17 and blood islands. Decreased crown-rump length was also observed at doses of 0.35–0.71 μM
18 Cr(VI). Additionally, a third study that collected mouse embryos at the 2-cell stage and incubated
19 them in culture with potassium dichromate or calcium chromate reported that Cr(VI) salts
20 inhibited blastocyst formation and hatching in a dose-dependent manner, with the high dose of
21 potassium dichromate (7.1 μM Cr(VI)) arresting embryonic development at the 4-cell stage ([Jacquet
22 and Draye, 1982](#)).

23 Mechanisms affecting bone development

24 Several in vitro and in vivo studies identified mechanisms that are potentially relevant to
25 skeletal alterations and suggested oxidative stress as an underlying mechanism. In vitro studies
26 with immortalized rat osteoblasts show that Cr(VI) inhibits cell viability and decreases cellular
27 activity (protein, DNA, and RNA synthesis; production of collagen fibers) and found that effects
28 were mitigated by Vitamin C (ascorbic acid), which is an antioxidant ([Ning et al., 2002](#); [Ning and
29 Grant, 2000, 1999](#)).

30 Additionally, thyroid effects [decreased triiodothyronine (T3) and thyroxine (T4), and
31 follicle size and increased TSH concurrent with morphology changes] were observed in adult male
32 rats following injection with 21 $\mu\text{g}/\text{kg}$ Cr(VI) and were partially prevented when animals were
33 pretreated or cotreated with ascorbic acid ([Qureshi and Mahmood, 2010](#)). Thyroid function is
34 important for skeletal developmental and disruption can result in delays in skeletal ossification;
35 however, the relevance of this finding to developing animals is unclear since this study was
36 conducted in adults.

1 Mechanisms affecting insulin regulation

2 The gestational exposure study in rats by [Shobana et al. \(2017\)](#), described in the section
3 above, also provided mechanistic information relevant to insulin signaling. Insulin receptor protein
4 expression in liver and gastrocnemius muscle was decreased, suggesting negative feedback
5 resulting from increased insulin levels, and decreasing trends were observed in the expression of
6 insulin receptor substrate-1 (IRS-1) and its phosphorylated form (p-IRS-1^{tyr632}) in these tissues. In
7 liver, the expression of the downstream signaling molecule Akt was unchanged while the
8 phosphorylated form (p-Akt^{Ser473}) increased; whereas in gastrocnemius muscle, Akt expression
9 decreased and the effects on p-Akt^{Ser473} were nonmonotonic (increased at 50 mg/L Cr(VI) but
10 decreased at 100 mg/L Cr(VI)). GLUT 2 was increased in liver at 50 mg/L Cr(VI) and GLUT 4 was
11 decreased in gastrocnemius muscle at 200 mg/L, reflecting glucose uptake in these tissues. PPAR γ
12 expression in these tissues was increased, which the authors speculated may be involved in the
13 regulation of glucose transporters.

14 Oxidative stress and apoptosis in the placenta

15 Studies in humans, rats, and human cell lines provide supporting evidence for oxidative
16 damage and apoptosis in the placenta, as well as evidence that chromium reaches human placental
17 tissue. Placentae collected from healthy women in the general population showed average
18 chromium concentrations between 0.02 to 1.25 mg/L ([Banu et al., 2018](#)), although these were total
19 chromium concentrations and it was unclear whether the women were exposed to Cr(VI) or
20 another form of Cr. Two biomarkers of oxidative stress in the samples with the highest average
21 chromium concentrations were statistically significantly increased over the lowest concentration
22 group and differences were also noted in the mRNA and protein expression of some antioxidants,
23 but there are uncertainties in the interpretation of this data; several apoptotic markers
24 (e.g., cytochrome C, AIF, Bax and cleaved caspase-3) were elevated in addition to anti-apoptotic
25 markers Bcl-2 and Bcl-XL, and some results showed sexually dimorphic differences ([Banu et al.,
26 2018](#)).

27 Two studies evaluated placentae in rats administered 17.7 mg/L Cr(VI) in drinking water
28 during gestation. [Banu et al. \(2017b\)](#) performed immunohistochemical analysis demonstrating
29 decreased trophoblast cell populations and decreased expression of cyclin D1 in the placentas and
30 found that placentas of Cr(VI)-treated dams had increased biomarkers of oxidative stress (LPO and
31 H₂O₂) and decreased expression of antioxidant enzymes (SOD, Gpx, Prdx3, and Txn2). [Banu et al.
32 \(2017a\)](#) reported increases in apoptosis and caspase-3 in the maternal compartment (metrial
33 gland) and the caspase-3 independent apoptotic marker AIF in both the fetal and maternal
34 compartments. Increases in p53 and related signaling cascade molecules were also observed.

35 Two studies evaluated placental cells in vitro. [Banu et al. \(2018\)](#) evaluated the human
36 trophoblastic cell line BeWo and observed a dose-related decrease in the mRNA expression of
37 antioxidant enzymes (SOD, Gpx, Prdx3 and Txn2) following dosing with 1.8–11 μ M Cr(VI) for 12–

1 24 hours. Another in vitro study by [Sawicka and Długosz \(2017\)](#) observed increased lipid
2 peroxidation and decreased antioxidant enzyme activity (SOD, GST) in mitochondria isolated from
3 human placental tissue following treatment with 0.05–1 µg/mL Cr(VI). The increase in lipid
4 peroxidation and decrease in SOD were mitigated by cotreatment with an estradiol metabolite,
5 4-OHE2.

6 Gestational anemia

7 Pregnant women are at risk for developing gestational anemia due to the increased
8 production of blood that occurs during pregnancy ([American Pregnancy Association, 2021](#)).
9 Gestational anemia is associated with adverse developmental effects including low birth weight,
10 preterm birth, and perinatal and neonatal mortality ([Figueiredo et al., 2018](#); [Rahman et al., 2016](#)).
11 Because the **evidence suggests** that Cr(VI) may produce anemia-like effects such as reduced
12 hematocrit, hemoglobin, MCV, MCH, and MCHC (see Section 3.2.5), exposure to Cr(VI) may
13 exacerbate the risk of developing anemia, with pregnant women being a potentially susceptible
14 subpopulation (see Section 3.3.1.1). Gestational anemia is therefore a potential mechanism for the
15 low birth weight and preterm birth that are associated with Cr(VI) exposure, although the
16 relationship between Cr(VI) exposure and gestational anemia has not yet been investigated.

17 **3.2.9.4. Integration of Evidence**

18 Overall, the available **evidence indicates** that Cr(VI) likely causes developmental effects in
19 humans. This conclusion is primarily based on the observation of decreased offspring growth
20 across most animal studies, as evidenced by decreased fetal or postnatal body weights and
21 decreased skeletal ossification. Other outcomes in animal studies are more uncertain because they
22 were inconsistent among *high* and *medium* confidence studies or were evaluated only in *low*
23 confidence studies. Likewise, the available human data were of *low* confidence and difficult to
24 interpret. Integrated evidence of the developmental effects of Cr(VI) exposure from human, animal,
25 and mechanistic studies is summarized in an evidence profile table (Table 3-47). The exposure
26 conditions relevant to these effects are further defined in Section 4.

27 The evidence of an association between Cr(VI) exposure and developmental effects in
28 humans is *slight*, with an indication of higher rates of spontaneous abortion with higher exposure
29 levels in two of four *low* confidence paternal occupational exposure studies and an ecologic study
30 with exposure evaluated at the zip code level (representing both maternal and paternal exposure).
31 Results for other outcomes, including preterm birth, fetal growth, infant death, and congenital
32 malformations indicated no clear association. The available evidence was all considered *low*
33 confidence and the studies generally had poor sensitivity, so there is considerable uncertainty in
34 this judgment.

35 Animal toxicology studies and supportive mechanistic data provide *moderate* evidence that
36 Cr(VI) exposure leads to developmental effects. The strength of evidence was greatest for effects
37 on fetal and postnatal growth, which were observed to some extent in the *high* confidence RACB

1 study in mice by [NTP \(1997\)](#) as well as all *low* confidence studies that evaluated these outcomes.
2 The observation of reduced ossification within several *low* confidence studies appears to be
3 consistent with a generalized growth delay, although there is mechanistic evidence suggestive of
4 effects on osteoblasts or thyroid function that could also affect skeletal development. Many studies
5 reported decreased fetal survival and functional effects on the developing reproductive system, but
6 there is more uncertainty in these findings because effects were observed primarily in *low*
7 confidence studies and were not recapitulated in the *high* confidence RACB study by [NTP \(1997\)](#)
8 that evaluated effects through the F2 generation. Other outcomes had limited data available
9 (insulin regulation) or were only evaluated in *low* confidence studies (effects on the placenta) and
10 therefore also have greater uncertainty. Within studies that used a maternal route of exposure,
11 statistically significant effects on fetal development were observed at exposure levels the same or
12 lower than those that caused maternal toxicity. Most studies did not report maternal body weights
13 or other measures of overt toxicity, however, so maternal and fetal toxicity could not be compared
14 within those studies. Decreased fetal survival in paternal-only exposure studies in rats and mice
15 suggests dominant lethal mutations in sperm (as discussed in the “Male reproductive effects”
16 section) and is coherent with human paternal occupational exposure studies. There is more
17 uncertainty in these male-mediated findings because the human and animal studies were rated *low*
18 confidence and effects were not consistent across studies.

19 Postnatal growth in the RACB study by [NTP \(1997\)](#) was decreased in F1 animals at dose
20 levels of 16.1–37.1 mg/kg-day via diet, and birth weights in F2 females were decreased before
21 adjusting for litter size at 37.1 mg/kg-day Cr(VI). The doses of Cr(VI) at which effects were
22 observed in the *low* confidence drinking water studies in animal models could not be calculated
23 because drinking water consumption data was not reported, and none of the available human
24 studies provided a quantitative measure of exposure. There were no animal studies that evaluated
25 developmental effects following inhalation exposure.

Table 3-47. Evidence profile table for developmental effects of Cr(VI)

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Evidence from human studies					⊕⊕⊖
SPONTANEOUS ABORTION Low confidence Hjollund et al. (1995) JP et al. (1992) Hjollund et al. (2000) Hjollund et al. (2005) Remy et al. (2017)	Two studies reported higher rates of spontaneous abortion with higher Cr(VI) exposure and two studies reported lower rates (in one study, the effect varied by analysis).	<ul style="list-style-type: none"> Large effect size (RR = 3.5) in one study Left truncation of early losses could explain inconsistent results 	<ul style="list-style-type: none"> Low confidence studies 	⊕⊖⊖ <i>Slight</i> Based on associations with paternal occupational exposure and spontaneous abortion in the study with the most sensitive and specific outcome ascertainment (Hjollund et al., 2000).	The evidence indicates that Cr(VI) likely causes developmental effects in humans given sufficient exposure conditions. Decreased offspring growth was observed across most animal studies; other effects were inconsistent in higher confidence studies, had limited data available, or were only evaluated in <i>low</i> confidence animal studies. Coherence of spontaneous abortions after paternal occupation exposure in human studies with decreased fetal survival after paternal-only exposure in animal studies; however, only in <i>low</i> confidence studies, and effects were not consistent.
OTHER DEVELOPMENTAL EFFECTS Low confidence JP et al. (1992) Eizaguirre-García et al. (2000) Peng et al. (2018) Remy et al. (2017)	Two studies reported positive associations between Cr(VI) exposure and preterm birth and decreased birth size. Inconsistent associations reported for congenital malformations.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Low confidence studies 	⊕⊖⊖ <i>Moderate</i> Based primarily on the observation of decreased offspring growth	Mechanistic findings (animals and in vitro) provide supporting evidence of fetal genotoxicity, impaired embryo and fetal functional development, and oxidative stress and apoptosis in the placenta. These mechanisms
Evidence from animal studies					
FETAL AND POSTNATAL SURVIVAL High confidence: NTP (1997) Zheng et al. (2018) Medium confidence:	No effects on fetal survival (live pups) in 2 <i>high</i> and 1 <i>medium</i> confidence studies, including NTP's RACB study in mice. Increased pre- and/or post-implantation loss in 10 <i>low</i> confidence studies in which maternal animals were exposed before mating or during gestation.	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> Effects observed only in <i>low</i> confidence studies 	⊕⊕⊖ <i>Moderate</i> Based primarily on the observation of decreased offspring growth	Mechanistic findings (animals and in vitro) provide supporting evidence of fetal genotoxicity, impaired embryo and fetal functional development, and oxidative stress and apoptosis in the placenta. These mechanisms

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
De Flora et al. (2006) Low confidence: Al-Hamood et al. (1998) Arshad et al. (2017) Bataineh et al. (2007) Bataineh et al. (1997) Elbetieha and Al-Hamood (1997) Elsaieed and Nada (2002) Junaid et al. (1995) Junaid et al. (1996b) Kanojia et al. (1998) Marat et al. (2018) Samuel et al. (2012a) Trivedi et al. (1989)	<p>Effects were at doses same or lower than those that caused maternal toxicity.</p> <p>Increased pre- and/or post-implantation loss in 2 out of 4 <i>low</i> confidence studies in which only paternal animals were exposed to prior to mating.</p>			<p>across most studies, including within the <i>high</i> confidence RACB in mice by NTP (1997).</p>	are presumed relevant to humans.
FETAL AND POSTNATAL GROWTH High confidence: NTP (1997) Zheng et al. (2018) Medium confidence: De Flora et al. (2006) Low confidence: Al-Hamood et al. (1998) Arshad et al. (2017) Banu et al. (2017b) Elsaieed and Nada (2002) Junaid et al. (1995)	<p>Decreased F1 postnatal body weights in NTP's <i>high</i> confidence RACB study. Effects on F1 and F2 birth weights in this study were minimal.</p> <p>Decreased fetal or pup body weight and other morphometric parameters (e.g., crown-rump length) in 8 out of 9 <i>low</i> confidence studies.</p> <p>Within all studies, effects were at same or lower dose levels that those that caused decreased maternal body weight gain.</p>	<ul style="list-style-type: none"> • <i>High</i> confidence study • Consistency • Effect size • Dose-response gradient • Coherence with decreased ossification within <i>low</i> confidence studies 	<ul style="list-style-type: none"> • No factors noted 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Junaid et al. (1996b) Kanojia et al. (1998) Kumar et al. (2017) Samuel et al. (2012a) Trivedi et al. (1989)					
STRUCTURAL ALTERATIONS Low confidence: Arshad et al. (2017) Elsaieed and Nada (2002) Junaid et al. (1995) Junaid et al. (1996b) Kanojia et al. (1998) Trivedi et al. (1989) Sánchez et al. (2015)	<p>Decreased fetal skeletal ossification as well as some other structural abnormalities in <i>low</i> confidence studies, occurring at the same dose levels as decreased fetal growth.</p> <p>Decreased periodontal bone formation in rat pups exposed postnatally in three <i>low</i> confidence studies by the same group of authors, occurring at a dose level that also caused decreased body weight.</p>	<ul style="list-style-type: none"> Coherence of decreased ossification with decreased growth 	<ul style="list-style-type: none"> <i>Low</i> confidence studies 		
EFFECTS ON THE PLACENTA Low confidence: Banu et al. (2017a) Elsaieed and Nada (2002) Junaid et al. (1995) Junaid et al. (1996b) Kanojia et al. (1998) Trivedi et al. (1989)	<p>Histopathological changes in the placenta in 2 <i>low</i> confidence studies.</p> <p>Inconsistent effects on placenta weight across studies (increased, decreased or no effect).</p>	<ul style="list-style-type: none"> No factors noted 	<ul style="list-style-type: none"> <i>Low</i> confidence studies 		
FUNCTIONAL ENDPOINTS High confidence: NTP (1997)	<p>Effects on developing male reproductive system observed in 1 <i>high</i> confidence study, and effects on developing female reproductive system observed in</p>	<ul style="list-style-type: none"> Dose-response gradient 	<ul style="list-style-type: none"> Unexplained inconsistency across <i>high</i> 		

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
Zheng et al. (2018) Medium confidence: Shobana et al. (2017) Low confidence: Al-Hamood et al. (1998) Banu et al. (2008) Banu et al. (2015) Banu et al. (2016) Kumar et al. (2017) Navin et al. (2021) Samuel et al. (2012a) Shobana et al. (2020) Sivakumar et al. (2022) Sivakumar et al. (2014) Stanley et al. (2013) Stanley et al. (2014)	multiple <i>low</i> confidence studies. No effects in NTP’s RACB. Increased serum insulin levels and alterations in glucose uptake and glucose oxidation in F1 rats that had been exposed during gestation.	<ul style="list-style-type: none"> Mechanistic evidence provides biological plausibility 	confidence studies		
Mechanistic evidence					
Biological events or pathways	Summary of key findings and interpretations			Judgments and rationale	
Fetal genotoxicity	<i>Interpretation:</i> In vivo evidence of fetal genotoxicity. <i>Key findings:</i> <ul style="list-style-type: none"> Increased frequency of fetal micronucleated polychromatic erythrocytes when mouse dams were exposed via a single i.p. injection, but no effects following repeat dose oral exposure (De Flora et al., 2006). 			Observations of multiple mechanisms by which Cr(VI) can disrupt fetal structural and functional development.	
In vitro evaluations of embryo development	<i>Interpretation:</i> In vitro evidence that Cr(VI) impairs or arrests embryo development <i>Key findings:</i>				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	<ul style="list-style-type: none"> Impaired embryo development when Cr(VI)-treated mouse sperm were used to fertilize untreated eggs (Yoisungnern et al., 2015), or when mouse blastocysts were incubated in solutions of Cr(VI) (Iijima et al., 1983; Jacquet and Draye, 1982). 				
Mechanisms affecting bone development	<p><i>Interpretation:</i> In vitro evidence that Cr(VI) affects viability and activity of osteoblasts, and in vivo evidence that Cr(VI) decreases thyroid hormone levels.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Increased cytotoxicity (Ning et al., 2002; Ning and Grant, 2000, 1999) and decreased protein, DNA, RNA, and collagen fiber production (Ning et al., 2002) in an immortalized osteoblast cell line. Decreased thyroid hormone levels and follicle size in adult male rats exposed via i.p. injection (Qureshi and Mahmood, 2010); this mechanism could affect bone development, but the relevance to developing animals is unclear. 				
Mechanisms affecting insulin regulation	<p><i>Interpretation:</i> In vivo evidence that Cr(VI) affects insulin signaling in developing animals.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Decreased expression of insulin receptor protein and substrates in F1 offspring from dams exposed via drinking water from GD 9-14 (Shobana et al., 2017). 				
Oxidative stress and apoptosis in the placenta	<p><i>Interpretation:</i> In vivo and in vitro evidence that Cr(VI) increases oxidative stress and apoptosis in the placenta.</p> <p><i>Key findings:</i></p> <ul style="list-style-type: none"> Biomarkers of oxidative stress and apoptosis observed in human placenta samples with relatively high Cr levels (Banu et al., 2018), in rat placentas following in vivo oral exposure (Banu et al., 2017a; Banu et al., 2017b), and 				

Evidence summary and interpretation					Inferences and summary judgment
Studies, outcomes, and confidence	Summary of key findings	Factors that increase certainty	Factors that decrease certainty	Judgments and rationale	
	in placental cells (Banu et al., 2018) or placental mitochondria (Sawicka and Długosz, 2017) cultured in vitro.				
Gestational anemia	<i>Interpretation:</i> Evidence suggests that Cr(VI) causes anemia-like effects. Gestational anemia is a potential mechanism for low birth weight and preterm birth following Cr(VI) exposure, although this has not yet been investigated.				

1

3.3. SUMMARY OF HAZARD IDENTIFICATION AND CONSIDERATIONS FOR DOSE-RESPONSE ANALYSIS

3.3.1. Susceptible Populations and Life Stages

1 Susceptible populations and life stages refers to groups of people who may be at increased
 2 risk for negative health consequences following chemical exposures due to factors such as life stage,
 3 genetics, race/ethnicity, health status and disease, sex, lifestyle factors, and other coexposures.
 4 This discussion of susceptibility focuses on factors for which there are available Cr(VI) data and
 5 factors hypothesized to be important to Cr(VI). It should be noted that while evidence gaps exist
 6 regarding Cr(VI)-specific susceptibilities, it is generally understood that increased negative health
 7 consequences from exposure to pollutants in the air, soil, and groundwater can result from multiple
 8 interacting factors (Table 3-48).

Table 3-48. Individual and social factors that may increase susceptibility to exposure-related health effects (adapted from [U.S. EPA \(2020b\)](#))

Factor	Examples
Demographic	Sex, age, race/ethnicity, education, income, occupation, geography
Genetic variability	Polymorphisms in genes regulating cell cycle, DNA repair, cell division, cell signaling, cell structure, gene expression, apoptosis, and metabolism
Lifestage	In utero, childhood, puberty, pregnancy, women of child-bearing age, old age
Health status	Preexisting conditions or disease such as psychosocial stress, elevated body mass index, frailty, nutritional status, chronic disease
Behaviors or practices	Diet, mouthing, smoking, alcohol consumption, pica, subsistence, or recreational hunting and fishing
Social determinants	Income, socioeconomic status, neighborhood factors, health care access, and social, economic, and political inequality

9 For noncancer dose-response, the intraspecies UF (UF_H) is applied to account for variations
 10 in susceptibility within the human population (interhuman variability) and the possibility (given a
 11 lack of relevant data) that the database available is not representative of the dose/exposure-
 12 response relationship in the subgroups of the human population that are most sensitive to the
 13 health hazards of the chemical being assessed. This is described in greater detail in EPA's *A review
 14 of the reference dose and reference concentration processes* ([U.S. EPA, 2002](#)) and *Methods for
 15 Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry* ([U.S. EPA,
 16 1994](#)). This assessment will apply an UF_H to account for the anticipated broader variability in the
 17 general population, which are outlined in Table 3-48. Toxicokinetics considerations, and use of a
 18 PBPK model to account for some of the physiological human variabilities, will be considered when

1 selecting an appropriate UF_H . For cancer dose-response, slope factors generally represent an upper
2 bound on the average risk in a population or the risk for a randomly selected individual but not the
3 risk for a highly susceptible individual or group. Some individuals face a higher risk and some face a
4 lower risk. This is described in greater detail in EPA's *Guidelines for Carcinogen Risk Assessment*
5 ([U.S. EPA, 2005a](#)).

6 A number of different factors were identified that could predispose some populations of
7 humans to be more susceptible to Cr(VI) toxicity. These factors depend on the toxicity of concern
8 and route of exposure. For all endpoints following oral exposure (GI tract cancer and noncancer,
9 hepatic effects, developmental effects), conditions that elevate stomach pH would lower an
10 individual's ability to reduce Cr(VI) effectively and could lead to a higher rate of Cr(VI) absorption
11 (see Section 3.1). Stomach pH may vary according to health status and life stage. For respiratory
12 effects, preexisting respiratory conditions may be exacerbated by inhalation of Cr(VI). Preexisting
13 GI, liver, and hematologic conditions may be exacerbated by ingestion of Cr(VI).

14 **3.3.1.1. Health Status and Disease**

15 Low stomach acid

16 Individuals with chronically high stomach pH are expected to detoxify Cr(VI) less
17 effectively, leading to increased uptake of Cr(VI) in the GI tract (affecting the GI and other systemic
18 tissues). Individuals with hypochlorhydria (also known as achlorhydria) have consistently low
19 stomach acid, causing high stomach pH ([Kalantzi et al., 2006](#); [Feldman and Barnett, 1991](#);
20 [Christiansen, 1968](#)). This condition may be caused or exacerbated by multiple preexisting gastric
21 conditions, including *H. pylori* infection. Less than 1% of the adult population may exhibit
22 hypochlorhydria, whereas 10–20% of the elderly population (age 65 and up) may exhibit this
23 condition ([Russell et al., 1993](#)). In addition, individuals taking medication to treat gastroesophageal
24 reflux disease (GERD), including calcium carbonate-based acid reducers and proton pump
25 inhibitors, have an elevated stomach pH during treatment. Approximately 20% of the population
26 may be afflicted by GERD ([Lin and Triadafilopoulos, 2015](#)). Sensitivity analyses on high-pH
27 populations using the PBPK model were performed to inform the dose-response assessment (see
28 Appendix C.1.5).

29 In addition to those with medical conditions, there is a significant percentage of individuals
30 with high stomach pH due to population variability. Among adults without hypochlorhydria,
31 [Feldman and Barnett \(1991\)](#) estimated that 5% of men may exhibit basal pH exceeding 5, and 5%
32 of women may exhibit basal pH exceeding 6.8. In the healthy elderly population, the percentage of
33 individuals with pH > 5 may be higher than for younger adults ([Russell et al. \(1993\)](#) observed that
34 11% of elderly subjects had pH > 5).

1 GI tract diseases

2 Individuals with preexisting GI conditions may be at higher risk of Cr(VI)-induced health
3 effects in the GI tract. Cr(VI) contributes to oxidative stress and inflammation in the GI tract. As a
4 result, damage to the gastric and intestinal epithelia due to preexisting inflammatory GI conditions
5 may be exacerbated by oral Cr(VI) exposure. For stomach cancer, preexisting conditions known to
6 increase risk in humans include *H. pylori* bacterial infection ([Bessède et al., 2015](#); [Fox and Wang,](#)
7 [2014](#)) and Epstein-Barr virus ([CGARN, 2014](#)). Therefore, populations with these preexisting
8 conditions may also represent a population sensitive to Cr(VI)-induced gastrointestinal tract
9 cancer.

10 Liver diseases

11 Populations with preexisting liver disease represent a population susceptible to Cr(VI).
12 Cr(VI) contributes to oxidative stress in the liver, causes inflammation, increased fat storage
13 (histologically noted as vacuolation or fatty changes), and substantial increases in serum ALT and
14 AST, indicative of hepatocellular injury (see Section 3.2.4). The most common chronic liver disease
15 in western societies is nonalcoholic fatty liver disease (NAFLD), with an increasing prevalence in
16 line with obesity ([Younossi, 2019](#)). It is estimated that 25% of the US population has NAFLD. This
17 condition is characterized by excessive fat accumulation, especially triglycerides, in hepatocytes. If
18 untreated, NAFLD can progress to nonalcoholic steatohepatitis (NASH) and continue to fibrosis,
19 cirrhosis, and in some cases, hepatocellular carcinoma ([Monserrat-Mesquida et al., 2020](#)).
20 Increased oxidative stress/pro-inflammatory status is implicated in the pathogenesis of NAFLD
21 ([Videla et al., 2004](#)) and increased inflammation is associated with increased severity of NASH
22 ([Monserrat-Mesquida et al., 2020](#)). NAFLD is associated with type 2 diabetes, metabolic syndrome,
23 obesity and cardiovascular disease ([Younossi, 2019](#)), therefore, populations with these preexisting
24 conditions likely also represent a population sensitive to Cr(VI)-induced liver perturbation.

25 Respiratory diseases

26 Inhaled Cr(VI) exposure may exacerbate preexisting respiratory conditions such as asthma,
27 emphysema and chronic obstructive pulmonary disease (COPD). This is because preexisting
28 conditions which reduce lung capacity, inflame airways, or obstruct breathing could be
29 compounded by Cr(VI) exposure, which may induce similar effects. Additionally, respiratory
30 conditions induced by lifestyle factors (i.e., smoking) or coexposures (i.e., asbestos) may interact
31 with the effects induced by inhaled Cr(VI) exposure.

32 Anemia and other blood disorders

33 Because the **evidence suggests** that Cr(VI) may produce anemia-like effects such as
34 reduced hematocrit, hemoglobin, MCV, MCH, and MCHC (see Section 3.2.5), exposure to Cr(VI) may
35 exacerbate the condition in individuals with preexisting conditions such as anemia, iron deficiency
36 or bleeding disorders. Pregnant women are at increased risk of developing anemia ([American](#)

1 [Pregnancy Association, 2021](#); [O'Brien and Ru, 2017](#)), and should be considered a susceptible group
2 for this reason. The prevalence of gestational anemia is highest among women with lower
3 socioeconomic status ([O'Brien and Ru, 2017](#); [Rahman et al., 2016](#)). Gestational anemia is also a
4 risk factor for developmental toxicity, as noted below in Section 3.3.1.3.

5 **3.3.1.2. Genetic Factors**

6 Genetic polymorphisms

7 As summarized in Cancer MOA, Section 3.2.3.3, individuals with genetic polymorphisms
8 conveying deficiencies in DNA repair capacity may have increased susceptibility to Cr(VI)-induced
9 lung cancer. See Section 3.2.3.3 and Appendix C.3.5.1 for more details (see also [Urbano et al.](#)
10 [\(2012\)](#)).

11 Carriers of a mutated cystic fibrosis transmembrane conductance regulator (CFTR) allele

12 Suppression of the CFTR gene was shown to enhance intestinal tumorigenesis in animal
13 models ([Than et al., 2016](#)). An analysis of the toxicogenomic data reported in Kopec et al. ([2012b](#);
14 [2012a](#)) from mice exposed to Cr(VI) have identified a potential role for CFTR in the carcinogenic
15 effects of Cr(VI) (see Appendix C.3.4.2). Data from Kopec et al. ([2012b](#); [2012a](#)) indicate that CFTR
16 was inactivated in mice exposed to Cr(VI) in drinking water concentrations as low as 0.1 mg/L. In
17 the US, more than 10 million people are carriers of a mutated CFTR allele that confers an
18 approximately 50% reduction in CFTR expression levels; the deficit in CFTR function has been
19 shown to lead to an increased risk for several conditions associated with cystic fibrosis, including
20 colorectal cancer ([Miller et al., 2020](#); [Scott et al., 2020](#)). Thus, individuals with this preexisting
21 condition may suffer an even further reduction in CFTR expression levels following oral exposure to
22 Cr(VI).

23 Heritable adenomatous polyposis coli (APC) mutations cause most cases of familial
24 adenomatous polyposis (FAP), an inherited syndrome associated with a high risk of colorectal
25 cancers ([Jasperson et al., 2017](#); [Leoz et al., 2015](#)). Impaired CFTR activity was also shown to
26 enhance intestinal tumorigenesis in mice carrying the mutated tumor-suppressor gene
27 adenomatous polyposis coli (*Apc*). As a result, carriers of APC mutations may be more susceptible
28 to the tumorigenicity induced by events that inactivate CFTR, including Cr(VI) exposure, and there
29 could be additional risk for individuals carrying both the CFTR and APC mutations. Although 95%
30 of patients with classic FAP develop colorectal cancer by age 35 ([Leoz et al., 2015](#)), there are over
31 1000 different types of APC mutations, many associated with a milder variant of FAP, that would
32 also be affected by CFTR inactivation.

1 **3.3.1.3. Life Stage**

2 Developmental stages and pregnancy

3 Because the **evidence indicates** that Cr(VI) likely causes developmental effects in humans
4 given sufficient exposure conditions, pregnant women are considered a sensitive subpopulation. In
5 human studies of Cr(VI) focusing on this population, there are some indications of an association
6 between Cr(VI) exposure and spontaneous abortion, fetal growth, preterm birth, and congenital
7 malformations, but the evidence is limited in quality and quantity (see Section 3.2.9). Furthermore,
8 pregnant women, who are susceptible to developing iron-deficient anemia that is associated with
9 low birth weight, preterm birth, and perinatal and neonatal mortality ([Figueiredo et al., 2018](#);
10 [Rahman et al., 2016](#)) are expected to be more sensitive to the hematologic effects of Cr(VI)
11 exposure.

12 Early life stages

13 Neonates, infants, and young toddlers generally have neutral stomach pH for the first 20–30
14 months, which then lowers to the normal adult range of 1–2 ([Neal-Kluever et al., 2019](#); [Bai et al.,](#)
15 [2016](#)). Neonates also have delayed gastric emptying of milk, formula, and other caloric-containing
16 liquids ([Neal-Kluever et al., 2019](#)). Delayed stomach emptying combined with elevated stomach pH
17 would lead to a higher uptake of ingested Cr(VI) in the stomach. In addition, incomplete stomach
18 reduction would lead to increased uptake of Cr(VI) in the small intestine. For chronic noncancer
19 effects and derivation of the RfD, this short-term change in the potential for absorbed Cr(VI) does
20 not impact the total lifetime average daily absorbed dose (because it occurs during such a short
21 time period). It is possible that neonates, infants, and young toddlers may be more susceptible than
22 adults during the short-term. However, there are no data for Cr(VI) reduction in the gastric acid of
23 infants and toddlers, and there would be significant uncertainties in applying the adult-based PBPK
24 model to infant or child physiology. For cancer effects, incorporation of age-dependent adjustment
25 factors in accordance with the *Supplemental Guidance for Assessing Susceptibility from Early-Life*
26 *Exposure to Carcinogens* ([U.S. EPA, 2005b](#)) account for early-life (birth to 16 years) susceptibility by
27 using an adjustment to the slope factor.

28 Later life stages

29 In general, healthy elderly men and women (age 65 and older) have similar pH profiles as
30 adults ([Russell et al., 1993](#)), although they may have slightly lower stomach pH than adults, and
31 higher duodenal pH ([Bai et al., 2016](#)). The healthy elderly population has the same gastric
32 emptying rate as healthy adults, but slower transit time in the small and large intestine ([Bai et al.,](#)
33 [2016](#)). There are age-related changes in the liver affecting hepatic clearance of drugs ([Bai et al.,](#)
34 [2016](#)), but it is not clear how this may affect hepatic reduction of Cr(VI). As a result, it is uncertain
35 how Cr(VI) may affect the healthy elderly population differently from adults. However, elderly
36 populations are more likely to have preexisting health conditions that can lead to increased

1 susceptibility to the effects of ingested Cr(VI). The elderly have high prevalence of conditions
2 associated with hypochlorhydria such as *H. pylori* infection ([Bai et al., 2016](#); [Moriyama et al., 2001](#);
3 [Russell et al., 1993](#)). The elderly also have higher usage of proton pump inhibitors to treat acid
4 reflux diseases, leading to increased stomach pH ([Burdall et al., 2013](#)). As a result, it is possible
5 that the elderly are more susceptible to the health effects of ingested Cr(VI), but mostly due to
6 pre-existing conditions that are associated with aging.

7 **3.3.1.4. Sex**

8 Males and females can differ greatly in body composition, organ function, and many other
9 physiological parameters that may influence the pharmacokinetics of chemicals and their
10 metabolites in the body ([Gochfeld, 2007](#); [Gandhi et al., 2004](#)). On average, males and females are
11 expected to have the same stomach pH ([Shih et al., 2003](#); [Dressman et al., 1990](#)). The human
12 epidemiology studies do not support any specific sex susceptibilities for noncancer effects due to
13 Cr(VI) exposure. In animals, GI tract toxicity and hepatotoxicity may have been more severe in
14 females (see Sections 3.2.2 and 3.2.4), but it is unclear if the slight differences in results by sex in
15 rodents are applicable to humans.

16 **3.3.2. Effects Other Than Cancer**

17 The currently available **evidence indicates** that Cr(VI) is likely to cause GI, liver,
18 developmental, and lower respiratory toxicity in humans, given sufficient exposure conditions. The
19 **evidence suggests** that Cr(VI) may cause male reproductive, immune, and hematologic toxicity in
20 humans. The **evidence is inadequate** to assess whether Cr(VI) causes female reproductive toxicity
21 in humans. Because the totality of available evidence was sufficient to indicate that exposure to
22 Cr(VI) has the potential to cause GI, liver, developmental, and lower respiratory toxicity in humans,
23 organ/system-specific reference values were derived for those health effects, and not for most
24 health effects with evidence integration judgments of **evidence suggests** (i.e., male reproductive
25 effects and immune toxicity). Well-conducted studies for immune toxicity do not indicate chronic
26 hazards, and lack of sufficient dose-response data are available for male reproductive toxicity. It
27 was determined that a toxicity value derived for short-term/subchronic hematological effects may
28 be useful to protect susceptible populations (such as individuals with pre-existing anemia,
29 including pregnant women). More details are provided in Section 3.3.2.5.

30 The evidence base consisted of a wide array of animal and human studies (outlined in
31 greater detail by the health effect summary subsections below). A summary of the justifications for
32 the evidence integration conclusions for each of the main hazard sections is provided below and
33 organized by health effect. The strength of the evidence for each hazard differed by species and
34 route of exposure. As discussed in Section 3.1, differences in observed effects between routes of
35 exposure can be attributed to pharmacokinetics. There was a lack of sufficient dose-response data
36 for health hazards outside of the respiratory tract following inhalation exposure, and as a result,
derivation of the RfC only considered effects in the respiratory tract. Similarly, respiratory tract

1 effects were not observed following oral ingestion, and derivation of the RfD only considered effects
 2 observed following ingestion (GI, hepatic, and developmental effects). Additional considerations,
 3 decisions, and rationale are presented below in Table 3-49 and in Sections 4.1 and 4.4.

Table 3-49. Dose response considerations and rationale for specific routes of exposure and health effects

Dose response consideration	Decision	Rationale
Animal and human data for RfD derivation	RfD derivation used animal data only.	Quantitative dose-response data from <i>medium</i> and <i>high</i> confidence oral studies were only available for rodents.
Appropriate exposure data for RfD derivation	Gavage studies excluded. Studies not including a dose group below 20 mg/kg-d excluded.	Concern for frank-effect toxicity.
Health effects for RfC derivation	RfC derivation for respiratory tract effects only. Route-to-route extrapolation not performed.	Pharmacokinetic differences are significant between inhalation and oral exposure, particularly for portal-of-entry effects.
Animal and human data for RfC derivation	RfC derivation of nasal effects used human data only. RfC derivation of lower respiratory effects used animal data only.	Quantitative dose-response data from <i>medium</i> and <i>high</i> confidence studies were limited by species and effects.

4 **3.3.2.1. GI Tract Effects**

5 The judgment that the available **evidence indicates** that Cr(VI) likely causes GI toxicity in
 6 humans given sufficient exposure conditions is based on four *high* confidence toxicology studies.
 7 Two of these studies ([NTP, 2008, 2007](#)) contained multiple study arms, resulting in both chronic
 8 and subchronic data across multiple species, strains, and sexes (see Table 3-49). All four *high*
 9 confidence studies in rats and mice reported various histological effects in the GI tract associated
 10 with oral exposure to Cr(VI). These include diffuse epithelial hyperplasia or crypt cell hyperplasia,
 11 histiocytic cellular infiltration, squamous metaplasia, degenerative changes in the villi
 12 (vacuolization, atrophy, and apoptosis), and gastric ulceration ([Thompson et al., 2012b](#); [Thompson](#)
 13 [et al., 2011](#); [NTP, 2008, 2007](#)). The literature search for this assessment did not identify
 14 epidemiological studies with analyses of GI effects in humans that met PECO criteria.

15 Mechanistic evidence supports the GI tract effects observed in animals and suggests a
 16 possible MOA of Cr(VI)-induced GI toxicity involving the production of free radicals and reactive
 17 intermediates through intracellular Cr(VI) reduction resulting in oxidative stress, mitochondrial
 18 dysfunction, inflammation, and apoptosis. Degenerative changes to the cells lining the GI tract can
 19 manifest as necrosis, apoptosis, and subsequent villous stunting, resulting in crypt abscess and
 20 ulceration ([Betton, 2013](#)). Irreversible cytoplasmic vacuolization can be a marker of cell death and
 21 cytoprotective autophagy in response to stress ([Shubin et al., 2016](#)).

1 The histiocytic cellular infiltration endpoint was considered of unclear biological
 2 significance (see Sections 3.2.2.2 and 3.2.2.4) and therefore was not included for dose-response
 3 analysis. Endpoints observed in subchronic studies such as apoptosis, villous atrophy, and villous
 4 cytoplasmic vacuolization were not considered for dose-response assessment. Only the chronic
 5 data from [NTP \(2008\)](#) were considered for effects in the GI tract.

6 Diffuse epithelial hyperplasia only occurred in portions of the GI tract where other
 7 degenerative effects were observed. Diffuse epithelial hyperplasia, although predictive of more
 8 severe manifestations of toxicity, is considered minimally adverse. Data for this endpoint are
 9 available from both the chronic and subchronic studies (Table 3-50).

Table 3-50. Available animal studies showing histopathological changes in the duodenum

Reference	Study arms performed	Observations
NTP (2008)	F344 Rat, male and female (chronic)	Histiocytic cellular infiltration
	B6C3F1 mouse, male and female (chronic)	Diffuse epithelial hyperplasia, histiocytic cellular infiltration
NTP (2007)	F344 Rat, male and female (subchronic)	Histiocytic cellular infiltration
	B6C3F1 mouse, male and female (subchronic)	Epithelial hyperplasia, histiocytic cellular infiltration
	B6C3F1, BALB/c, and am-C57BL/6 mouse, male (subchronic strain comparison)	Epithelial hyperplasia, histiocytic cellular infiltration
Thompson et al. (2012b)	F344 Rat, female (subchronic)	Crypt cell hyperplasia, histiocytic infiltration, apoptosis, villus atrophy
Thompson et al. (2011)	B6C3F1 mouse, female (subchronic)	Crypt cell hyperplasia, histiocytic infiltration, apoptosis, villus atrophy, villous cytoplasmic vacuolization

10 **3.3.2.2. Hepatic Effects**

11 The judgment that the available **evidence indicates** that Cr(VI) likely causes hepatic
 12 toxicity in humans given sufficient exposure conditions is based on studies in animals that observed
 13 hepatic effects following drinking water exposure. Several studies in rats and mice reported
 14 various histological lesions in the liver associated with oral exposure to Cr(VI). These lesions
 15 include increased inflammation and infiltration of immune cells, fatty changes and vacuolation,
 16 indications of apoptosis and necrosis, and increased incidence of altered hepatic foci. [NTP \(2008\)](#)
 17 described chronic inflammation as “minimal to mild severity” in most dose groups, with “mild to

1 moderate” in the higher dose groups. The severity ratings were used to inform BMR selection (see
2 Section 4.1).

3 Many studies have examined serum indicators that are potentially informative for
4 predicting hepatotoxicity following exposure to Cr(VI). The most commonly reported indicators
5 included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase
6 (ALP), and sorbitol dehydrogenase (SDH). These changes were observed across multiple studies,
7 with ALT changes exceeding twofold which is an indicator of concern for hepatic injury ([Sawicka
8 and Dlugosz, 2017](#); [EMEA, 2010](#); [Boone et al., 2005](#)). The outcomes rated *medium* confidence
9 showing a response were available from chronic and subchronic studies across multiple species,
10 strains, and sexes (see Table 3-51). These are discussed further in Section 4.1.

11 The human evidence for Cr(VI)-induced liver effects is limited in terms of number and
12 confidence of studies. However, two of the available three studies (one occupational and one
13 general population study) provide some indication of exposure-related alterations of liver clinical
14 chemistry ([Sazakli et al., 2014](#); [Saraswathy and Usharani, 2007](#)).

15 Mechanistic evidence supports the hepatic effects observed in animals and humans and
16 suggests a possible MOA of Cr(VI)-induced liver toxicity involving the production of free radicals
17 and reactive intermediates through intracellular Cr(VI) reduction resulting in oxidative stress,
18 mitochondrial dysfunction, inflammation, and apoptosis.

Table 3-51. Available animal studies showing histopathological and clinical chemistry changes in the liver

Reference	Species/strain and sex	Observations ^a
NTP (2008)	F344 Rat, male and female (chronic)	Histopathology: histiocytic cellular infiltration, chronic inflammation, fatty change, basophilic focus Clinical chemistry (male rats only): ALT, ALP, SDH, bile acids
	B6C3F1 mouse, male and female (chronic)	Histopathology: histiocytic cellular infiltration, chronic inflammation
NTP (2007)	F344 Rat, male and female (subchronic)	Histopathology: histiocytic cellular infiltration, chronic focal inflammation Clinical chemistry: ALT, ALP, SDH, bile acids, cholesterol, triglycerides, 5’ nucleotidase
	B6C3F1, BALB/c, and am-C57BL/6 mouse, male (subchronic)	Clinical chemistry: ALT, ALP, SDH, bile acids, glycogen (B6C3F1 and am-C57BL/6 only)
Rafael et al. (2007)	Wistar rat, male (chronic)	Clinical chemistry: ALT, ALP, SDH, glucose, cholesterol, total protein
NTP (1996a)	BALB/c mouse, male and female (subchronic)	Histopathology: cytoplasmic vacuolation (fatty change)

Reference	Species/strain and sex	Observations ^a
NTP (1997)	BALB/c mouse, male and female (continuous breeding)	Histopathology: hepatocyte cytoplasmic vacuolation (fatty change), hepatocyte individual cell necrosis, necrosis, acute inflammation
Krim et al. (2013)	Wistar rat, male (subchronic)	Clinical chemistry: ALT, ALP, AST, cholesterol, total lipids, triglycerides, LDH
Wang et al. (2015)	Sprague-Dawley rat, male (subchronic)	Clinical chemistry: ALT, AST, cholesterol, triglycerides, glucose
Navya et al. (2017a)	Wistar rat, male (subchronic)	Clinical chemistry: ALT, ALP, AST

^aOnly endpoints rated *medium* or *high* confidence within each study are listed.

1 **3.3.2.3. Respiratory Tract Effects**

2 The judgment that the available **evidence indicates** that Cr(VI) likely causes respiratory
3 toxicity in humans given sufficient exposure conditions is based on studies in animals that observed
4 effects following inhalation exposure. Most animal inhalation studies of lower respiratory effects
5 contained data for lung histopathology, lung weight, and cellular responses. Because
6 histopathological and cellular changes occurred together, and in combination with serum
7 biomarkers indicating an inflammatory response ([Nikula et al., 2014](#)), these were considered
8 indicators of adverse responses and considered for dose-response analysis. Because lung weight is
9 a less specific endpoint for lung injury (e.g., lung weight increase in the only *medium* confidence
10 data by [Glaser et al. \(1985\)](#) may be related to accumulation of macrophages), this endpoint was not
11 considered for dose-response analysis. The available histopathological changes and cellular
12 response outcomes that were rated *medium* confidence are outlined in Table 3-52. These are
13 discussed further in Section 4.2.

14 The human evidence for Cr(VI)-induced lower respiratory effects is limited in terms of
15 number and confidence of studies. However, three of the available five studies provide some
16 indication of exposure-related decrements in lung function assessed using spirometry ([Zhang et al.,
17 2022](#); [Li et al., 2015b](#); [Kuo et al., 1997b](#)).

18 Mechanistic evidence supports the respiratory tract effects observed in animals and
19 suggests a possible MOA of Cr(VI)-induced toxicity involving the production of free radicals and
20 reactive intermediates through intracellular Cr(VI) reduction resulting in oxidative stress.

Table 3-52. Available animal studies showing histopathological changes and cellular responses in the lung

Reference	Species/ strain and sex	Observations ^a
Glaser et al. (1990)	Wistar rat, male (subchronic)	Histopathology: Histiocytosis, bronchioalveolar hyperplasia, fibrosis

Reference	Species/ strain and sex	Observations ^a
		BALF: LDH, ALB, total protein, macrophage effects
Glaser et al. (1985)	Wistar rat, male (subchronic)	BALF: Macrophage effects
Johansson et al. (1986a)	Rabbit, male (subchronic)	Histopathology: Histiocytosis
Cohen et al. (2003)	F344 Rat, male (chronic)	BALF: Total cells, total macrophages
Johansson et al. (1986b)	Rabbit, male (subchronic)	BALF: Total macrophages, macrophage effects
Kim et al. (2004)	Sprague-Dawley Rat, male (subchronic)	Histopathology: Inflammatory markers (qualitative)

^aOnly endpoints rated *medium* or *high* confidence within each study are listed.

1 **3.3.2.4. *Developmental Effects***

2 The judgment that the available **evidence indicates** that Cr(VI) likely causes developmental
3 toxicity in humans given sufficient exposure conditions is based on the observation of decreased
4 offspring growth across most animal studies, as evidenced by decreased fetal or postnatal body
5 weights and decreased skeletal ossification. The only data suitable for dose-response analysis were
6 for fetal and postnatal growth, which were observed to some extent in the *high* confidence RACB
7 study in mice by [NTP \(1997\)](#) (all other studies were *low* confidence and not considered for dose-
8 response assessment). Within the animal studies, statistically significant effects on fetal
9 development were observed at doses the same or lower than those that caused decreased maternal
10 body weight. According to EPA Guidelines, developmental effects at doses that cause minimal
11 maternal toxicity are still considered to represent developmental toxicity and should not be
12 discounted as maternal toxicity ([U.S. EPA, 1991](#)). Because of the correlation between maternal dam
13 weight and offspring body weight, the maternal dose was used as the basis for dose-response
14 modeling instead of the averaged F0 male and female dose.

15 **3.3.2.5. *Hematological Effects***

16 Although toxicity values are not typically developed for hazards with suggestive conclusions
17 (e.g., **evidence suggests** for noncancer hazards and “suggestive evidence of carcinogenic
18 potential”), it may be useful to develop values for some purposes. For example, providing a sense of
19 the magnitude and uncertainty of potential risks, ranking potential hazards, or setting research
20 priorities ([U.S. EPA, 2005a](#)). A value may be useful for some purposes when the evidence includes a
21 well-conducted study (particularly when that study may also demonstrate a credible concern for
22 greater toxicity in a susceptible population or lifestage) [U.S. EPA \(2020b\)](#). Pregnant women are
23 more susceptible to developing iron-deficient anemia, making them more susceptible to the
24 hematological effects of Cr(VI), and hematological effects have been correlated to low birthweight.
25 Because these factors demonstrate a credible concern for greater toxicity in a susceptible

1 population and life stage, organ/system-specific reference doses were derived for hematological
2 effects. Hematological markers affected by Cr(VI) exposure include MCV, MCH, MCHC, Hgb, and Hct
3 (see Section 3.2.5). Of the available studies collecting complete blood count data, the [NTP \(2008\)](#)
4 and [NTP \(2007\)](#) bioassays provided the most comprehensive data set considering multiple
5 timepoints and related hematological endpoints in both sexes, and were therefore considered for
6 dose-response. Additional discussion is provided in Section 4.1.1.

3.3.3. Cancer

7 Under the 2005 Guidelines for Carcinogen Risk Assessment, Cr(VI) is “carcinogenic to
8 humans” via the inhalation route of exposure and is “likely to be carcinogenic to humans” via the
9 oral route of exposure.

10 In 1998, the EPA IRIS Toxicological Review of Hexavalent Chromium classified Cr(VI) as a
11 “known human carcinogen by the inhalation route of exposure” based on consistent evidence that
12 inhaled Cr(VI) causes lung cancer in humans and supporting evidence of carcinogenicity in animals
13 ([U.S. EPA, 1998c](#)). The same conclusion has since been reached by other authoritative federal and
14 state health agencies and international organizations and the carcinogenicity of Cr(VI) is
15 considered to be well-established for inhalation exposures ([TCEQ, 2014](#); [IPCS, 2013](#); [NIOSH, 2013](#);
16 [IARC, 2012](#); [CalEPA, 2011](#); [NTP, 2011](#); [OSHA, 2006](#)). As stated in the 2014 preliminary packages
17 ([U.S. EPA, 2014b, c](#)) and the Systematic Review Protocol (Appendix A), the review of cancer by the
18 inhalation route focused on data that may improve the quantitative exposure-response analysis
19 conducted in EPA’s 1998 IRIS assessment; EPA did not reperform a carcinogenicity determination
20 for inhalation exposure. An overview of the literature screening for exposure-response data is
21 contained in Section 4.4.

22 Determination that Cr(VI) is likely to be carcinogenic to humans by the oral route of
23 exposure was made based on 1) a *high* confidence study in rodents showing a clear dose-response
24 relationship between oral Cr(VI) exposure and incidence of GI tract tumors ([NTP, 2008](#)); and 2)
25 robust evidence that a mutagenic MOA has a key role in Cr(VI)-induced cancer via inhalation and
26 oral exposures (see Section 3.2.3).

27 Because a mutagenic MOA for Cr(VI) carcinogenicity (see Section 3.2.3) is “sufficiently
28 supported in (laboratory) animals” and “relevant to humans,” for both routes of exposure, EPA uses
29 a linear low dose extrapolation from the POD in accordance with Guidelines for Carcinogen Risk
30 Assessment ([U.S. EPA, 2005a](#)). Furthermore, in the absence of chemical-specific data to evaluate
31 differences in age-specific susceptibility, increased early-life susceptibility to Cr(VI) is assumed and
32 EPA applies ADAFs in accordance with the *Supplemental Guidance for Assessing Susceptibility from*
33 *Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)). Linear low dose extrapolation and ADAFs are

1 applied for both the inhalation and oral routes of exposure⁵⁸. The 2-year drinking water bioassay
2 by [NTP \(2008\)](#) provides the datasets for dose-response modeling of tumors in the GI tract (tumors
3 of the oral cavity in male and female F344 rats, and tumors of the small intestine in male and female
4 B6C3F1 mice).

5 Due to reduction (detoxification) of Cr(VI) in the stomach compartment prior to transit to
6 the small intestine, dose-response modeling of tumors in the mouse small intestine incorporates
7 adjustments by a PBPK model when performing animal-to-human extrapolation. For tumors of the
8 rat oral cavity, PBPK modeling is not applied, because Cr(VI) in drinking water exposes the
9 epithelium of the tongue and oral mucosa prior to detoxification in the stomach.

⁵⁸Because carcinogenicity determination was not reperformed for lung cancer, this section focuses only on cancer of the GI tract. A discussion of the considerations for dose-response of lung cancer is contained in Section 4.4.

4. DOSE-RESPONSE ANALYSIS

4.1. ORAL REFERENCE DOSE FOR EFFECTS OTHER THAN CANCER

1 The RfD (expressed in units of mg/kg-day) is defined as an estimate (with uncertainty
2 spanning perhaps an order of magnitude) of a daily exposure to the human population (including
3 sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a
4 lifetime. It can be derived from points of departure (PODs) such as a no-observed-adverse-effect
5 level (NOAEL), lowest-observed-adverse-effect level (LOAEL), or the 95% lower bound on the
6 benchmark dose (BMDL), with uncertainty factors (UFs) generally applied to reflect limitations of
7 the data used.

8 As discussed in Sections 3.2.2, 3.2.4, 3.2.5, and 3.2.9, based on findings in experimental
9 animals, the **evidence indicates** that exposure to Cr(VI) is likely to cause GI, liver, and
10 developmental toxicity in humans. Because the totality of available evidence was sufficient to
11 indicate that exposure to Cr(VI) has the potential to cause these health effects, organ/system-
12 specific reference values were derived for GI, liver, and developmental toxicity, and not for most
13 health effects with evidence integration judgments of **evidence suggests** (i.e., male reproductive
14 effects and immune toxicity). However, for hematologic effects, it was determined that a toxicity
15 value derived for short-term/subchronic exposures may be useful to protect susceptible
16 populations (such as individuals with pre-existing anemia, including pregnant women). More
17 details are provided in Section 3.3.2.5. An overview of the process for deriving candidate values,
18 osRfDs and osRfCs and overall RfDs and RfCs is provided in Appendix Figure D-1.

4.1.1. Identification of Studies for Dose-Response Analysis of Selected Effects

19 In order to identify the studies for dose-response analysis, key attributes of the studies
20 reporting the endpoints selected for each hazard were reviewed (i.e., study size and design,
21 relevance of the exposure paradigm, and measurement of the endpoints of interest). Exposure
22 paradigms including a relevant route of human environmental exposure are preferred. When
23 developing a chronic reference value, chronic or subchronic studies are preferred over studies of
24 acute exposure durations (with the exception of developmental studies, where exposures only need
25 to occur during susceptible periods). Studies with a broad exposure range and multiple exposure
26 levels are preferred to the extent that they can provide information about the shape of the
27 exposure-response relationship.

28 Human studies are generally preferred over animal studies as the basis for a reference value
29 when quantitative measures of exposure are reported, and the reported effects are determined to
30 be associated with exposure. The available epidemiological studies of worker populations exposed
31 to Cr(VI) examined the relationship between certain health endpoints and inhalation exposure;

1 however, no sufficient epidemiological studies of ingested Cr(VI) are available and route-to-route
2 extrapolation was not considered for this assessment (see Protocol, Appendix A). In the absence of
3 human data, the animal studies were considered for dose-response analysis.

4 Experimental animal studies considered for each health effect were evaluated using general
5 study evaluation considerations discussed in the Protocol (Appendix A). The oral animal
6 toxicological evidence base for Cr(VI) consists of chronic and subchronic studies. Because *medium*
7 and *high* confidence studies were available, *low* confidence studies were not considered for toxicity
8 value derivation.

9 Cr(VI) can induce frank effects in rodents at high doses, which raises considerations of
10 exposures and study designs appropriate for dose-response analysis. Because Cr(VI) gavage
11 exposure has been shown to induce frank effects and high mortality in rodents (gut detoxification is
12 much less effective for gavage exposure), these studies were not considered for dose-response
13 assessment. This criterion resulted in the omission of one *high* confidence study ([Zheng et al.,
14 2018](#)) from consideration of dose-response analysis for developmental effects. High dose exclusion
15 criteria for drinking water and oral feed studies were also considered. At approximately
16 20 mg/kg-d *ad libitum*, [NTP \(2007\)](#) reported reduced body weight, chemical-induced stomach
17 ulcers (80–100% incidence), and reduced water consumption in rats exposed for 90 days. The
18 study also reported 10–20% decreases in final body weight relative to controls in mice exposed for
19 90 days at the high doses (approximately 15–25 mg/kg-d). In order to focus on chronic effects
20 observed in the low dose region (defined here as around 1 mg/kg-d *ad libitum* based on results
21 observed by the chronic 2-year [NTP \(2008\)](#) drinking water bioassay), studies which did not include
22 an exposed group below 20 mg/kg-d were not considered for RfD derivation. This criterion
23 ultimately did not impact any decisions regarding dose-response, because all such studies were
24 rated *low* confidence.




Figure 4-1. Evaluation of studies from the Cr(VI) hazard identification for derivation of toxicity values. For endpoints where *medium* or *high* confidence studies were available, *low* confidence studies were not considered.

1 **4.1.1.1. GI Tract Toxicity**

2 Small intestine histopathology was considered for dose-response analysis of the GI tract
 3 effects of oral exposure to Cr(VI). Chronic data from the [NTP \(2008\)](#) 2-year bioassay were used for
 4 the dose-response assessment. The chronic 2-year [NTP \(2008\)](#) bioassay analyzed many of the
 5 same endpoints as other shorter term studies (which had smaller sample sizes and typically used
 6 higher doses). Thompson et al. ([2012b](#); [2011](#)) were subchronic studies which incorporated lower
 7 doses than [NTP \(2008\)](#). However, these studies used smaller sample sizes and shorter exposure

1 durations than [NTP \(2008\)](#), and only examined females (Table 4-1). An overview of design features
 2 of the *high* confidence animal studies containing data for the GI tract is provided below in Table 4-1.

Table 4-1. Design features of *high* confidence studies that examined GI tract effects (histopathology) via the oral route of exposure

Study reference	Species/strain and sex	Exposure duration	Number of dose groups ^b	Number of animals/group	Dose range (mg/kg-d)
NTP (2008) ^a	B6C3F1 mouse, male and female	2 years	4	50	0.3–8.9
NTP (2008)	F344 Rat, male and female	2 years	4	50	0.2–7.1
NTP (2007)	F344 Rat, male and female	90 days	5	10	1.7–21
NTP (2007)	B6C3F1 mouse, male and female	90 days	5	10	3.1–27.9
NTP (2007)	B6C3F1 mouse, male	90 days	3	5	2.8–8.7
NTP (2007)	BALB/c mouse, male	90 days	3	5	2.8–8.7
NTP (2007)	am-C57BL/6 mouse, male	90 days	3	5	2.8–8.7
Thompson et al. (2012b)	F344 Rat, female	90 days ^c	5	10	0.015–20
Thompson et al. (2011)	B6C3F1 mouse, female	90 days ^c	6	10	0.024–31.1

^aPreferred data for dose-response.

^bNumber does not include control group.

^cNote: [Thompson et al. \(2012b\)](#) and [Thompson et al. \(2011\)](#) also performed an 8-day sacrifice on 5 animals/group.

3 The most sensitive GI effect in mice, diffuse epithelial hyperplasia, was consistently
 4 observed at statistically significant incidence levels in mice in all exposure groups (≥ 0.3 mg/kg-d
 5 Cr(VI)) of males and females of multiple strains in three *high* confidence subchronic and chronic
 6 studies ([Thompson et al., 2011](#); [NTP, 2008, 2007](#)). The hyperplastic duodenal lesions were
 7 described as being suggestive of tissue regeneration following degenerative changes to the
 8 intestinal villi. In rats, it was observed less consistently and at higher doses compared to mice
 9 ([Cullen et al., 2015](#); [Thompson et al., 2012b](#); [Thompson et al., 2011](#)). Dose-response modeling was
 10 performed on the chronic 2-year data for male and female mice exhibiting diffuse epithelial
 11 hyperplasia of the proximal small intestine (duodenum).

1 **4.1.1.2. Hepatic Toxicity**

2 Liver histopathology changes and serum biomarkers of liver injury were considered for
3 dose-response analysis of the hepatic effects of oral exposure to Cr(VI). These were considered the
4 most representative indicators of hepatic toxicity in the database. Fatty liver changes (cytoplasmic
5 vacuolation) and increased ALT are also clinical markers used in diagnosis of human liver diseases
6 (see Section 3.3). Dose-response modeling was not performed on liver weight because only
7 moderate changes were observed (see Section 3.2.4), and changes in liver histopathology and
8 serum biomarkers were more consistently observed and more sensitive than liver weight changes.

9 Generally consistent elevations of ALT (biomarkers of liver injury) were seen across various
10 multiple well-conducted studies in both rats and mice, with the magnitude of change considered to
11 be biologically significant and a specific indication of liver damage. For dose-response modeling of
12 clinical chemistry changes, [NTP \(2008\)](#) observed increased alanine aminotransferase (ALT) in male
13 F344 rats at all three data collection time points (3, 6, and 12 months). Dose-response modeling
14 was performed on the clinical chemistry endpoint ALT in male F344 rats⁵⁹ at the 12-month and
15 90-day collection periods of the [NTP \(2008\)](#) bioassay. ALT changes in male and female rats from
16 the 90-day [NTP \(2007\)](#) study were also modeled⁶⁰. ALT changes in male rats at the 90-day
17 timepoint from the 2-year [NTP \(2008\)](#) study were modeled to provide a comparison with the
18 90-day [NTP \(2007\)](#) data. In mice, changes in ALT only occurred at high doses during the 90-day
19 [NTP \(2007\)](#), and there were no changes in the other clinical chemistry parameters like there were
20 in rats. Therefore, this endpoint was not modeled in mice.

21 For histopathological changes, increased incidence of chronic liver inflammation was
22 observed in rodents during the 2-year [NTP \(2008\)](#) bioassay, but this endpoint exhibited a
23 monotonic dose-response relationship for female rats and mice. In male rats, the increased
24 inflammation was nonmonotonic and only significantly increased for one dose group. In male mice,
25 no effect was observed. Fatty liver changes were also observed in female rats during the 2-year
26 [NTP \(2008\)](#) bioassay. Similar to the chronic inflammation endpoint, this effect was not consistently
27 observed across species or sex. Dose-response modeling was performed on the incidence data for
28 chronic liver inflammation and fatty liver changes in female rats from [NTP \(2008\)](#), and chronic
29 inflammation in female mice from [NTP \(2008\)](#).

30 An overview of design features of the *medium* and *high* confidence animal studies
31 containing data for hepatic effects considered for oral dose-response is provided below in Table 4-
32 2. Because there were studies that were rated *high* and *medium* for endpoints within this domain
33 (see Section 3.2.4), *low* confidence studies were not considered for dose-response assessment.

⁵⁹The [NTP \(2008\)](#) 2-year study did not obtain clinical chemistry data in mice or female rats, whereas the 90-day [NTP \(2007\)](#) study contained data for both male and female F344 rats and mice. While chronic data are still preferred, subchronic data were evaluated to assess differences between sexes.

⁶⁰Note: the lowest dose (in mg/kg-d Cr(VI)) was the same in males and females for the subchronic study. When taking into consideration differences in body weight in the pharmacokinetic model, the daily absorbed dose in males was slightly higher than females (see Appendix C.1.5).

Table 4-2. Design features of studies that examined hepatic effects (clinical chemistry and histopathology) via the oral route of exposure

Study reference (quality)	Species/strain and sex	Exposure duration	Number of dose groups ^b	Number of animals/group	Dose range (mg/kg-d)
NTP (2008) (high) ^a	F344 Rat, male and female	2 years	4	50	0.2–7.1
NTP (2008) (high) ^a	B6C3F1 mouse, male and female	2 years	4	50	0.3–8.9
NTP (2007) (high) ^a	F344 Rat, male and female	90 days	5	10	1.7–21
NTP (2007) (high)	B6C3F1 mouse, male and female	90 days	5	10	3.1–27.9
NTP (2007) (high)	B6C3F1 mouse, male	90 days	3	5	2.8–8.7
NTP (2007) (high)	BALB/c mouse, male	90 days	3	5	2.8–8.7
NTP (2007) (high)	am-C57BL/6 mouse, male	90 days	3	5	2.8–8.7
Navya et al. (2017a) (medium)	Wistar rat, male	28 days	1	6	10.6
Rafael et al. (2007) (medium)	Wistar rat, male	10 weeks	1	9 control, 19 exposed	2.96
NTP (1996a) (high)	BALB/c mouse, male and female	9 weeks	4	24 males, 48 females (5–6 males, 12 females/group per timepoint)	1.1–48.4
NTP (1997) (high)	BALB/c mouse, male and female	13-week continuous breeding	3	20 (F0), 5–10 (offspring)	6.8–50
Krim et al. (2013) (medium)	Wistar rat, male	30	1	10	5.3
NTP (1996b) (high)	Sprague-Dawley rat, male and female	9 weeks	4	5	0.35–9.90
Wang et al. (2015) (medium)	Sprague-Dawley rat, male	4 weeks	3	8	2.5–7.6

^aPreferred data for dose-response.

^bNumber does not include control group.

- 1 In summary, dose-response modeling was performed on the following hepatic datasets:
- 2 • Increased ALT in male rats from [NTP \(2008\)](#) at the 90-day timepoint and 12-month
- 3 timepoint

- 1 • Increased ALT in male and female rats from [NTP \(2007\)](#) (90 days)⁶¹
- 2 • Increased chronic liver inflammation in female rats from [NTP \(2008\)](#) (2 years)
- 3 • Increased chronic liver inflammation in female mice from [NTP \(2008\)](#) (2 years)
- 4 • Fatty liver change in female rats from [NTP \(2008\)](#) (2 years)

5 **4.1.1.3. Developmental Toxicity**

6 As noted in Section 3.2.9, decreases in fetal and postnatal growth were the only consistently
7 observed effects observed in exposed animals. The two *medium to high* confidence studies that
8 observed this effect were [NTP \(1997\)](#) and [Zheng et al. \(2018\)](#). [De Flora et al. \(2006\)](#) did not
9 observe this effect. The *high* confidence study by [Zheng et al. \(2018\)](#) was not considered for dose-
10 response assessment because it was a gavage study; Cr(VI) gavage exposure has been shown to
11 induce frank effects and high mortality in rodents due to less effective gut detoxification compared
12 to drinking water exposure. Dose-response modeling was performed on fetal and postnatal growth
13 outcomes in the F1 generation observed by [NTP \(1997\)](#). Data are available for males ([PND14](#) and
14 [PND21](#)) and females ([PND14](#) and [PND21](#)).

15 **4.1.1.4. Hematological Toxicity**

16 The database of hematological endpoints is extensive due to the number of studies
17 reporting these endpoints and the comprehensive measures available for multiple markers from
18 complete blood counts (i.e., MCV, MCH, MCHC, Hgb, and Hct) (see Section 3.2.5). There are eleven
19 datasets from six *high* confidence National Toxicology Program studies, and five *medium* confidence
20 datasets from NTP and other sources. Data from [NTP \(2008\)](#) and [NTP \(2007\)](#) were particularly
21 useful because they collected data at multiple timepoints. An overview of the design features of
22 these studies is presented above in Table 4-2. Because hemoglobin (Hgb) is essential for the
23 transport of oxygen molecules, it is the marker most closely associated with adverse outcomes
24 caused by iron-deficient anemia. Because the hematological effects ameliorated over time, the
25 dose-response will focus on subchronic and short-term data (90 days and 22 days), with chronic
26 data at 12 months used as a comparison. Only the rat data were modeled, since little or no effects
27 were observed in mice. While the most sensitive low-dose data were at 22 days from [NTP \(2008\)](#)
28 (which used lower doses than [NTP \(2007\)](#)), dose response data from the 2007 study were still
29 evaluated to assess possible sex differences (the 2008 study only collected hematological data in
30 male rats and female mice). The use of 22-day data for the POD (as opposed to the 12-month data
31 when effects ameliorated) was determined to be appropriate in order to protect susceptible

⁶¹While chronic data are preferred for dose-response, only chronic male data were available for this endpoint. Subchronic data from both the 90-day study and 2-year study were modeled to evaluate possible difference between sexes.

1 subpopulations (such as individuals with pre-existing anemia, including pregnant women; see
2 Section 3.3.1) from both short-term and chronic health effects.

3 In summary, dose-response modeling was performed on the following hematological
4 datasets:

- 5 • Decreased Hgb in male rats from [NTP \(2008\)](#) at 22 days, 90 days, and 12 months
- 6 • Decreased Hgb in male and female rats from [NTP \(2007\)](#) at 23 days, and 90 days

4.1.2. Methods of Analysis

7 Biologically based dose-response models are not available for Cr(VI). In this situation, EPA
8 evaluates a range of dose-response models thought to be consistent with underlying biological
9 processes to determine how best to empirically model the dose-response relationship in the range
10 of the observed data. Consistent with this approach, EPA evaluated dose-response information
11 with the models⁶² available in EPA's Benchmark Dose Software (BMDS, Version 3.2). EPA
12 estimated the benchmark dose (BMD) and the 95% lower confidence limit on the BMD (BMDL)
13 using a benchmark response (BMR) that represents a minimal, biologically significant level of
14 change ([U.S. EPA, 2012b](#)). Endpoint-specific BMRs are described below. Where modeling was
15 feasible, the estimated BMDLs were used as points of departure (PODs); the PODs are summarized
16 in Table 4-3. Further details including the modeling output and graphical results for the model
17 selected for each endpoint can be found in Appendix D.1 and U.S. EPA ([2021a](#)). Where
18 dose-response modeling was not feasible, no-observed-adverse-effect levels (NOAELs) or
19 lowest-observed-adverse-effect levels (LOAELs) were identified; NOAELs and LOAELs are also
20 summarized in Table 4-3.

4.1.2.1. *PBPK Modeling and Animal-to-Human Extrapolation*

21 Following ingestion, extracellular reduction of Cr(VI) to Cr(III) in the stomach is a major
22 pathway for detoxification in both rodents and humans, and may have a significant impact on the
23 amount of Cr(VI) available for absorption and distribution. Uptake of Cr(VI) into tissues and
24 intracellular reduction occurs rapidly (see Section 3.1.1 and Appendix C.1.1 for overview). While GI
25 tract PBPK models are capable of estimating the extent of extracellular reduction in the stomach,
26 the in vivo estimates of localized uptake and reduction of Cr(VI) in GI and systemic tissues exhibit
27 high uncertainties (particularly for the distal GI). Thus, all unreduced Cr(VI) that escapes stomach
28 reduction and enters the small intestine (estimated by PBPK modeling) is assumed to have the
29

⁶²Some statistical models (Gamma, Dichotomous Hill, Weibull, and LogLogistic) were run with constrained slope or power parameters (≥ 1) ([U.S. EPA, 2012b](#)). As noted in *Benchmark Dose Software (BMDS) version 3.2 user guide* ([U.S. EPA, 2020a](#)), some models with unrestricted coefficients can give complicated shapes, in particular high-degree polynomial models (which produce unrealistic 'wavy' results with negative response rates). While Bayesian model averaging is an available feature of BMDS 3.2, only frequentist models were run in this assessment.

1 potential for absorption into epithelial cells. The unreduced mg/kg-d Cr(VI) dose escaping stomach
2 reduction in the rodent can be adjusted to an internal dose⁶³ by allometric scaling consistent with
3 *Recommended Use of Body Weight^{3/4} as the Default method in derivation of the oral reference dose*
4 ([U.S. EPA, 2011c](#)). This assumes that absorbed Cr(VI) is rapidly cleared (reduced or excreted), with
5 interspecies differences following allometry. While there is some uncertainty in how much of the
6 unreduced Cr(VI) escaping the stomach is reduced and absorbed by the GI tissue prior to systemic
7 distribution, the interspecies difference in this amount is likely to be low in relation to the
8 interspecies difference in gastric reduction (which is driven by differences in stomach pH and
9 Cr(VI) reduction capacity).

10 PBPK modeling revealed that the Cr(VI) dose escaping stomach reduction (and therefore
11 the internal dose) increased linearly with oral dose for rats and mice (Appendix C.1.5). Therefore,
12 performing BMD modeling on the orally administered doses and performing PK conversions at a
13 later step would ultimately produce the same POD as if BMD modeling was performed on the basis
14 of internal PK-derived rodent doses. For humans, gastric reduction is nonlinear with respect to
15 ingested dose (Appendix C.1.5).

16 The steps for candidate value derivation are outlined below and in Figure 4-2:

- 17 • Dose-response modeling was performed on the basis of mg/kg-d Cr(VI) ingested to
18 determine a BMDL or LOAEL/NOAEL. Where possible, time-weighted average daily doses
19 calculated from time-course data (through the time of data collection) were used. For
20 example, for endpoints only measured at the 12-month time point in a 2-year study, the
21 time-weighted average daily doses over 12 months were used for dose-response (as
22 opposed to the average daily doses over the full 2-year study).
- 23 • The BMDL or LOAEL/NOAEL (in units of mg/kg-d Cr(VI)) was converted to an internal dose
24 using the PK model. The internal dose was the average rodent dose escaping reduction (in
25 mg/kg-d) multiplied by $(BW_A/BW_H)^{1/4}$ in accordance with *Recommended Use of Body*
26 *Weight^{3/4} as the Default Method in Derivation of the Oral Reference Dose* ([U.S. EPA, 2011c](#)).
27 Study-specific time-weighted average body weights relevant to the data collection time
28 were used in the model and for the BW scaling step.
- 29 • The adult-based human PBPK model was used to estimate the daily mg/kg Cr(VI) dose that
30 must be ingested to achieve the internal dose calculated in step (2). To account for
31 interindividual variability, the human equivalent dose was determined by Monte Carlo
32 analysis. The lower 1% value of 20000 Monte Carlo PK simulations needed to achieve the
33 internal dose POD was used. As a result, the intraspecies uncertainty factor (UF_H) was
34 lowered from 10 to 3 (the pharmacokinetic component of the uncertainty factor was
35 removed as it was accounted for with this analysis). See Appendix C.1.5.

⁶³Alternatively for the small intestine, an internal dose to the small intestine may be derived by scaling the un-reduced daily Cr(VI) intake rate by intestinal tissue volume (defined as pyloric flux, mg/L-d, by [Thompson et al. \(2014\)](#)). Because organ volumes vary between species by allometric relationships, using the pyloric flux internal dose metric produces similar results as $BW^{3/4}$ scaling of the un-reduced Cr(VI) dose.

- 1 • The uncertainty factors are applied to derive the candidate values.




Figure 4-2. Process for calculating the human equivalent dose for Cr(VI).

2 4.1.2.2. GI Tract Effects

3 Incidence data of diffuse epithelial hyperplasia of the duodenum in male mice from [NTP](#)
 4 [\(2008\)](#) were amenable to BMD modeling with the highest dose omitted. A BMR of 10% extra risk
 5 (ER) was applied under the assumption that it represents a minimally biologically significant level
 6 of change in the absence of a biologically based BMR ([U.S. EPA, 2012b](#)). Diffuse epithelial
 7 hyperplasia, although predictive of more severe manifestations of toxicity, is considered minimally
 8 adverse and does not support using a lower BMR. Incidence data for male mice (all doses included)
 9 are contained in [HAWC](#).

10 Diffuse epithelial hyperplasia was not amenable to BMD modeling for [female mice](#) because
 11 there was too much uncertainty in estimating the BMDL (see Appendix D.1.1). There were three
 12 models which adequately fit the data in accordance with EPA's *Benchmark Dose Technical Guidance*
 13 ([U.S. EPA, 2012b](#)). However, they produced significantly different BMDs and BMDLs, and one
 14 model did not produce useful results due to an extremely low BMDL estimate and high BMD:BMDL
 15 ratio. This is an indication that there was some model dependence of the estimates, and
 16 uncertainty in the estimates was too great to be able to rely on the modeling results. The
 17 uncertainty was primarily caused by the fact that the observed percent incidence at the lowest dose
 18 (38%) was much higher than the BMR (10%). Because there are no data near where the true 10%
 19 response occurs, estimating the BMD₁₀ and the 95% lower confidence limit on the BMD₁₀ is highly
 20 uncertain. Alternative modeling approaches were explored; however, they could not address the
 21 lack of low dose data near the target 10% extra risk response level. As a result, the LOAEL
 22 approach was used (the LOAEL for hyperplasia in female mice was 0.302 mg/kg-d). Incidence data
 23 for female mouse hyperplasia in the duodenum are available in [HAWC](#).

1 **4.1.2.3. Hepatic Effects**

2 For the liver, data for [chronic liver inflammation](#) in female mice from [NTP \(2008\)](#) were
3 amenable to BMD modeling. A BMR of 10% extra risk (ER) was applied under the assumption that
4 it represents a minimally biologically significant level of change. [NTP \(2008\)](#) described these
5 lesions as “minimal to mild severity”, with “mild to moderate” in the higher dose groups. As a
6 result, a BMR lower than 10% was not considered.

7 Changes in the [liver enzyme alanine aminotransferase \(ALT\)](#) at 12 months in male rats from
8 [NTP \(2008\)](#) were amenable to BMD modeling. Several expert organizations, particularly those
9 concerned with early signs of drug-induced hepatotoxicity, have identified an increase in liver
10 enzymes compared with concurrent controls of two to fivefold as an indicator of concern for
11 hepatic injury ([Sawicka and Długosz, 2017](#); [EMEA, 2010](#); [Boone et al., 2005](#); [Group, 2000](#)). For this
12 assessment, a twofold increase in ALT is considered indicative of liver injury in experimental
13 animals. Thus, a BMR of 100% change from control (1 relative deviation from control) was applied.
14 Data for male and female rats in the subchronic study by [NTP \(2007\)](#) were not amenable to BMD
15 modeling⁶⁴, and the lowest dose was identified as the LOAEL. The chronic study by [NTP \(2008\)](#)
16 also provides [subchronic data for ALT](#) in male rats at 90 days. Because the chronic study used
17 lower doses, it was possible to identify a NOAEL⁶⁵ of 1.58 mg/kg-d, and a LOAEL of 4.16 mg/kg-d
18 for increased ALT in male rats at 90 days (see Appendix C.1.5 for time-weighted average daily doses
19 of the first 90 days of exposure during the [NTP \(2008\)](#) 2-year study).

20 [Fatty liver change](#) in female rats from [NTP \(2008\)](#) was not amenable to BMD modeling.
21 Similar to hyperplasia in the female mouse duodenum, uncertainty in estimating the BMDL was too
22 high (see Appendix D.1.1). As a result, the NOAEL (the lowest dose level, 0.248 mg/kg-d, which
23 exhibited less than 10% extra risk) was used as the POD for this dataset. Similarly, [chronic liver](#)
24 [inflammation](#) in female rats from [NTP \(2008\)](#) was not amenable to BMD modeling and the LOAEL
25 (0.248 mg/kg-d, which exhibited greater than 10% extra risk) was used as the POD.

26 **4.1.2.4. Developmental Effects**

27 For [NTP \(1997\)](#), doses reported for the F0 dams⁶⁶ were 11.6, 24.4, and 50.6 mg/kg-d Cr(VI)
28 (via feed). Decreased postnatal growth in the F1 generation was observed beginning at
29 24.4 mg/kg-d. Data are available for males ([PND14](#) and [PND21](#)) and females ([PND14](#) and [PND21](#)).
30 For postnatal growth in the F2 generation, effects were observed at the highest dose only (maternal
31 doses for females in the F1 generation were 7.27, 17.19, 39.15 mg Cr(VI)/kg-d). Datasets for

⁶⁴For female rats, the first nonzero dose had a very high response relative to other dose levels ([click here](#) to see dose-response data). For male rats, the goodness-of-fit p-values were less than 0.1 for all statistical models (even when removing the highest dose, which had a low response relative to other exposure levels). [Click here](#) to see dose-response data for male rats.

⁶⁵Data were not amenable to BMD modeling. No change from control was observed at the first nonzero dose.

⁶⁶Maternal dam weight is highly correlated to offspring body weight. Because maternal body weight in this study was also decreased, maternal dose is examined here instead of the averaged F0 male and female dose.

1 postnatal growth were not amenable to BMD modeling because study statistics reported by the
 2 authors were inadequate for use in multi-generational modeling⁶⁷. A NOAEL of 11.6 mg/kg-d was
 3 used based on outcomes observed in the F1 generation (see Section 3.2.9).

4 **4.1.2.5. Hematological Effects**

5 [Male rat data of decreased Hgb at 22 days](#) from [NTP \(2008\)](#) was amenable to BMD modeling
 6 using a BMR of 1 standard deviation from the mean⁶⁸. These data exhibited the most sensitive
 7 response, and also contained the lowest dose range. With the exception of male rat data at 90 days
 8 from [NTP \(2007\)](#) (which was also amenable to BMD modeling), all other datasets required a
 9 LOAEL/NOAEL analysis. All available hematological data considered for dose-response modeling
 10 are available in Appendix D.1.

4.1.3. Derivation of Candidate Values

11 This section describes the data and rationale for the selection of uncertainty factors and
 12 derivation of candidate values for each identified human health hazard. The dose-response
 13 modeling results and rodent-to-human extrapolations are summarized in Table 4-3. Further
 14 details, including the BMDS modeling output and graphical results for the model selected for each
 15 endpoint, can be found in Appendix D.1.

Table 4-3. Summary of derivation of points of departure following oral exposure

Species/ sex	Model	BMR	BMD mg/kg-d	BMDL or LOAEL/ NOAEL mg/kg-d	Internal dose ^a mg/kg-d	TWA BW kg	BW ^{3/4} adjust ^b	POD _{HED} mg/kg- day ^c
Diffuse epithelial hyperplasia of the duodenum at two years (NTP, 2008)								
Mice/M	Quantal linear ^d	10% ER	0.148	0.121	0.0182	0.05	2.88 × 10 ⁻³	0.0443
Mice/F	LOAEL	--	--	0.302	0.0463	0.05	7.32 × 10 ⁻³	0.0911
Increase in the liver enzyme alanine aminotransferase (ALT) (NTP, 2008)								
Rat/M 12 mo	Expon.2 ^d	1RD	1.83	1.56	0.170	0.395	0.0451	0.204
Rat/M 3 mo	NOAEL	--	--	1.58	0.165	0.246	0.0389	0.191
Increase in the liver enzyme alanine aminotransferase (ALT) at 90 days (NTP, 2007)								
Rat/M	LOAEL	--	--	1.74	0.188	0.232	0.0436	0.203

⁶⁷It was unclear whether standard errors reported for dose groups are based on variation among litters or among pups across litters, and individual-level data are not available.

⁶⁸When no biological information is readily available that allows for determining a minimally biological significant response, the BMD Technical Guidance ([U.S. EPA, 2012b](#)) recommends a BMR based on one standard deviation (SD).

Toxicological Review of Hexavalent Chromium

Species/ sex	Model	BMR	BMD mg/kg-d	BMDL or LOAEL/ NOAEL mg/kg-d	Internal dose ^a mg/kg-d	TWA BW kg	BW ^{3/4} adjust ^b	POD _{HED} mg/kg- day ^c
Rat/F	LOAEL	--	--	1.74	0.181	0.160	0.0383	0.190
Chronic liver inflammation at two years (NTP, 2008)								
Rat/F	LOAEL	--	--	0.248	0.0195	0.260	4.66 × 10 ⁻³	0.0669
Mice/F	Log- logistic	10% ER	3.70	1.33	0.225	0.05	0.0356	0.182
Liver fatty change at two years (NTP, 2008)								
Rat/F	NOAEL	--	--	0.248	0.0195	0.260	4.66 × 10 ⁻³	0.0669
Decreased offspring growth (NTP, 1997)								
Mouse/F	NOAEL	--	--	11.6	3.09	0.0240	0.407	0.700
Decrease in hemoglobin (Hgb) NTP (2008)								
Rat/M 22 d	Exp-4	1SD	1.07	0.816	0.0705	0.138	0.0144	0.126
Rat/M 3 mo	NOAEL	--	--	1.58	0.165	0.246	0.0389	0.191
Rat/M 12 mo	NOAEL	--	--	2.49	0.336	0.395	0.0891	0.286
Decrease in hemoglobin (Hgb) NTP (2007)								
Rat/M 90d	Exp-3	1SD	2.99	2.09	0.243	0.232	0.0564	0.227
Rat/M 23d	LOAEL	--	--	2.92	0.367	0.120	0.0722	0.259
Rat/F 90d	NOAEL	--	--	3.50	0.500	0.160	0.106	0.312
Rat/F 23d	LOAEL	--	--	2.97	0.370	0.105	0.0704	0.187

^aDose escaping stomach reduction in rodent (mg/kg-d) estimated by PK modeling. Animal BW set to study/sex-specific time-weighted average values for PK modeling. This explains the discrepancy in internal doses between male and female rats having the same external-dose LOAEL for ALT changes at 90 days, and differences between male rats at 3 months and 12 months.

^bBW^{3/4} scaling adjustment: mg/kg-d multiplied by (BW_A/80)^{1/4}. Animal BW set to study/sex-specific time-weighted average values for both BW^{3/4} scaling and bioassay PK simulation.

^cPOD_{HED} in units of mg/kg-d Cr(VI) oral dose ingested by humans (lower 1% value of 20000 Monte Carlo PK simulations needed to achieve the internal dose POD). See Appendix C.1.5 for details.

^dData were amenable to BMD modeling with the highest dose omitted.

1
2 For BW^{3/4} scaling adjustment and PBPK modeling applied above, the mean body weight
3 recommended by EPA's *Exposure Factors Handbook* (U.S. EPA, 2011a) (80 kg) was used. There is a
4 negligible difference in the PODs when using 70 kg (U.S. EPA, 1988) or 80 kg, and the final reference
5 value would be the same under either assumption.

6 Consistent with EPA's *A Review of the Reference Dose and Reference Concentration Processes*
7 (U.S. EPA, 2002), a series of five UFs were applied to the POD developed for each endpoint/study,
8 specifically addressing the following areas of uncertainty: interspecies uncertainty (UF_A) to account
9 for animal-to-human extrapolation, and consisting of equal parts representing pharmacokinetic and
10 pharmacodynamic differences; intraspecies uncertainty (UF_H) to account for variation in

1 susceptibility across the human population, and the possibility that the available data may not be
2 representative of individuals who are most susceptible to the effect; LOAEL-to-NOAEL uncertainty
3 (UF_L) to infer an exposure level where effects are not expected when a POD is based on a
4 lowest-observed-adverse-effect level (LOAEL); subchronic-to-chronic uncertainty (UF_S) to account
5 for the uncertainty in using subchronic studies to make inferences about lifetime exposure, and to
6 consider whether lifetime exposure would have effects at lower levels (e.g., for studies other than
7 subchronic studies); and database uncertainty (UF_D) to account for database deficiencies if an
8 incomplete database raises concern that further studies might identify a more sensitive effect,
9 organ system, or life stage. An explanation of the five possible areas of uncertainty and variability
10 follows:

- 11 • An intraspecies uncertainty factor, UF_H , of 3 was applied to account for variability and
12 uncertainty in pharmacodynamic susceptibility in extrapolating to subgroups of the human
13 population most sensitive to the health hazards of Cr(VI) ([U.S. EPA, 2002](#)). In the case of
14 Cr(VI), the PODs were derived from studies in inbred animal strains and are not considered
15 sufficiently representative of the exposure and dose-response of the most susceptible
16 human subpopulations (see Section 3.3.1). In certain cases, the pharmacokinetic
17 component of this factor may be replaced when a PK model is available that incorporates
18 the best available information on variability in pharmacokinetic disposition in the human
19 population (including sensitive populations). In the case of Cr(VI), a Monte Carlo analysis
20 using PBPK modeling (see Appendix Section C.1.5) was applied to account for
21 pharmacokinetic variability, and 3 was retained for pharmacodynamic variability.
- 22 • An interspecies uncertainty factor, UF_A , of 3 ($10^{1/2} = 3.16$, rounded to 3) was applied to all
23 PODs to account for uncertainty in characterizing the pharmacokinetic and
24 pharmacodynamic differences between rodents and humans. For all datasets used in this
25 assessment, a PBPK model or $BW^{3/4}$ scaling was used to convert doses in rodents to
26 equivalent doses in humans (see rationale in Section 4.1.2.1—Human Extrapolation). This
27 reduces pharmacokinetic uncertainty in extrapolating from the rodents to humans, but does
28 not account for interspecies differences due to pharmacodynamics. An UF_A of 3 was applied
29 to account for this remaining pharmacodynamic and any residual pharmacokinetic
30 uncertainty not accounted for by the PBPK model.
- 31 • A subchronic-to-chronic uncertainty factor, UF_S , of 1 was applied to all endpoints (GI tract
32 and liver effects) from the chronic 2-year (lifetime) study in rodents ([NTP, 2008](#)) where
33 exposure occurred for one year or more. For example, ALT changes in rats measured at one
34 year (12 months) were assigned an UF_S of 1. An UF_S of 1 was applied to the developmental
35 endpoint from [NTP \(1997\)](#), because exposure occurred during the critical window. An UF_S
36 of 1 was applied to decreased Hgb measured at subchronic timepoints from NTP ([2008](#),
37 [2007](#)) because this effect is known to ameliorate over time, and therefore subchronic-
38 derived PODs will be health-protective for chronic exposure. An UF_S of 3 was applied to
39 ALT changes from the 90-day study in rodents ([NTP, 2007](#)), and ALT changes reported at 3
40 months during the chronic [NTP \(2008\)](#) study. An $UF_S = 3$ (rather than 10) was applied to
41 90-day data for ALT because data collected at multiple time points from [NTP \(2008\)](#)
42 showed that these effects did not increase in severity between 90 days and 1 year. A value
43 of 3 was retained to account for the possibility that longer exposure may induce these
44 effects at a lower exposures ([U.S. EPA, 2002](#)), even if the effects themselves do not increase

1 in severity. Also, there were no chronic ALT data for female rats, and females may be more
2 susceptible (based on the observed chronic liver inflammation at 2 years).

- 3 • A LOAEL-to-NOAEL uncertainty factor, UF_L , of 1 was applied to PODs based on either a
4 NOAEL or a BMDL. An UF_L of 10 (rather than 3) was applied to PODs based on the LOAEL of
5 ALT changes in rats observed from the 90-day study ([NTP, 2007](#)), because the magnitude of
6 change from control at the lowest dose was very high (180% for males and 585% for
7 females). These measurements were somewhat volatile (for example, the changes were
8 typically very large, and the magnitude of changes varied greatly between studies, even
9 among the NTP studies in the same species and sex which were conducted under very
10 similar conditions). As a result, the higher UF_L was applied. Similarly, an UF_L of 10 was
11 applied to the LOAELs of hyperplasia in the female mouse duodenum and chronic liver
12 inflammation in female rats from [NTP \(2008\)](#) because responses were high (>20% extra
13 risk) at the lowest dose. Thus, an UF_L of 10 was applied to all PODs that were based on a
14 LOAEL.
- 15 • A database uncertainty factor, UF_D , value of 1 was applied for all endpoints. The
16 toxicological database for oral exposure to Cr(VI) includes several occupational health
17 studies, and subchronic and chronic toxicity studies in multiple laboratory species. The
18 database also contains prenatal, multi-generational, and gestational oral studies in rodents.

19 Table 4-4 is a continuation of Table 4-3 and summarizes the application of UFs to each POD
20 to derive a candidate value for each endpoint, preliminary to the derivation of the
21 organ/system-specific reference values. These candidate values are considered individually in the
22 selection of a representative oral reference value for a specific hazard and subsequent overall RfD
23 for Cr(VI).

Table 4-4. Effects and corresponding derivation of candidate values

Endpoint and Reference	POD _{HED} (mg/kg-day)	POD Type	UF _A	UF _H	UF _L	UF _S	UF _D	Composite UF	Candidate value (mg/kg-d)
GI tract									
Mouse (M) hyperplasia (2 years) (NTP, 2008)	0.0443	BMDL _{10%} _R	3	3	1	1	1	10	4.43 × 10 ⁻³
Mouse (F) hyperplasia (2 years) (NTP, 2008)	0.0911	LOAEL	3	3	10	1	1	100	9.11 × 10 ⁻⁴
Liver									
Rat (M) liver ALT (12 months) (NTP, 2008)	0.204	BMDL _{1RD}	3	3	1	1	1	10	0.0204
Rat (M) liver ALT (3 months) (NTP, 2008)	0.191	NOAEL	3	3	1	3	1	30	6.37 × 10 ⁻³
Rat (M) liver ALT (90 days) (NTP, 2007)	0.203	LOAEL	3	3	10	3	1	300	6.77 × 10 ⁻⁴
Rat (F) liver ALT (90 days) (NTP, 2007)	0.190	LOAEL	3	3	10	3	1	300	6.33 × 10 ⁻⁴
Rat (F) liver chronic inflammation (2 years) (NTP, 2008)	0.0669	LOAEL	3	3	10	1	1	100	6.69 × 10 ⁻⁴
Mouse (F) liver chronic inflammation (2 years) (NTP, 2008)	0.182	BMDL _{10%} _R	3	3	1	1	1	10	0.0182
Rat (F) liver fatty change (2 years) (NTP, 2008)	0.0669	NOAEL	3	3	1	1	1	10	6.69 × 10 ⁻³
Developmental									
Mouse (F) Decreased F1 postnatal growth (NTP, 1997)	0.700	NOAEL	3	3	1	1	1	10	0.0700
Hematological									
Rat (M) Hgb (22d) (NTP, 2008)	0.126	BMDL _{1SD}	3	3	1	1	1	10	0.0126
Rat (M) Hgb (3mo) (NTP, 2008)	0.191	NOAEL	3	3	1	1	1	10	0.0191

Toxicological Review of Hexavalent Chromium

Endpoint and Reference	POD _{HED} (mg/kg-day)	POD Type	UF _A	UF _H	UF _L	UF _S	UF _D	Composite UF	Candidate value (mg/kg-d)
Rat (M) Hgb (12mo) (NTP, 2008)	0.286	NOAEL	3	3	1	1	1	10	0.0286
Rat (M) Hgb (90d) (NTP, 2007)	0.227	BMDL _{1SD}	3	3	1	1	1	10	0.0227
Rat (M) Hgb (23d) (NTP, 2007)	0.259	LOAEL	3	3	10	1	1	100	2.59×10 ⁻³
Rat (F) Hgb (90d) (NTP, 2007)	0.312	NOAEL	3	3	1	1	1	10	0.0312
Rat (F) Hgb (23d) (NTP, 2007)	0.187	LOAEL	3	3	10	1	1	100	1.87×10 ⁻³




Figure 4-3. Candidate values with corresponding POD and composite UF.

4.1.4. Derivation of Organ/System-Specific Reference Doses

1 Table 4-5 distills the candidate values from Table 4-4 into a single value for each organ or
2 system (organ/system-specific RfDs, or osRfDs). These organ or system-specific reference values
3 may be useful for subsequent cumulative risk assessments that consider the combined effect of
4 multiple agents acting at a common site.

5 Each candidate value was evaluated with respect to multiple considerations, including
6 strength of evidence, basis of the POD (i.e., BMD vs. NOAEL vs. LOAEL), and dose-response model
7 uncertainties. The confidence rating of each osRfD is based on three factors: the level of confidence
8 in the primary study, the health effect database associated with that reference value, and the
9 quantification of the POD.

10 4.1.4.1. *GI tract Toxicity*

11 The osRfD for GI effects was based on the incidence of diffuse epithelial hyperplasia of the
12 duodenum in female B6C3F1 mice reported in [NTP \(2008\)](#). Data in both males and females
13 indicated that females may be more sensitive to this effect. While the result in males may have
14 higher certainty in quantification (since it is a BMDS-derived result with a lower uncertainty
15 factor), there is still significant uncertainty for females (the more sensitive group). Because the RfD
16 is intended to protect the population as a whole including potentially susceptible subgroups ([U.S.
17 EPA, 2002](#)), female data were selected for this osRfD. The hyperplasia in the GI tract following oral
18 exposures is considered to be representative of the constellation of histopathological observations
19 that together result in a change in tissue function that is considered an adverse noncancer effect.
20 An osRfD of 9×10^{-4} mg/kg-d (rounded from 9.11×10^{-4}) was derived. There is high confidence in
21 this osRfD because it is based on chronic 2-year data from a *high* confidence study, and a strong
22 dose-response was exhibited in both male and female mice. *High* confidence subchronic studies
23 (click the [HAWC link](#) for study evaluation details) and mechanistic studies were supportive of these
24 effects.

25 4.1.4.2. *Hepatic Toxicity*

26 The osRfD for hepatic effects was based on the lowest candidate toxicity value from the
27 chronic data: chronic inflammation in female F344 rats reported in [NTP \(2008\)](#). Histological
28 changes were primarily observed in female rats and were less severe in male rats and mice.
29 Therefore, female rats may be the most sensitive group. Chronic hepatic inflammation can lead to
30 fibrosis ([Koyama and Brenner, 2017](#)), and the candidate value is also protective of the other
31 endpoints evaluated using chronic data (increased fatty changes and ALT). An osRfD of 7×10^{-4}
32 mg/kg-d (rounded from 6.69×10^{-4}) was derived. There is high confidence in this osRfD. It is
33 based on a [high confidence](#) chronic study in rats and there are other subchronic data and
34 mechanistic evidence to support the liver endpoints.

1 4.1.4.3. Developmental Toxicity

2 The osRfD for developmental toxicity was based on the only candidate value: decreased F1
 3 offspring postnatal growth from the continuous breeding study in BALBC mice ([NTP, 1997](#)). The
 4 osRfD was 0.07 mg/kg-d. There is low confidence in this osRfD. While it is based on a *high*
 5 confidence continuous breeding study and similar effects on decreased offspring growth observed
 6 in multiple other studies (see Section 3.2.9, click the [HAWC link](#) for study evaluation details), this
 7 effect only occurred in high dose groups where other toxicological effects (as indicated by the lower
 8 points of departure in this section) may be occurring. For example, female mice in the F0
 9 generation (dams) were exposed to 11.6, 24.4, 50.6 mg/kg-d Cr(VI) ([NTP, 1997](#)). The decreased F1
 10 offspring growth effect was observed at maternal dose of 24.4 mg/kg-d, which is a relatively high
 11 dose ([NTP \(2007\)](#) observed high incidence of stomach ulcers in rats at approximately 20 mg/kg-d).
 12 Other studies in the database observing similar effects were lower confidence and used higher (or
 13 unknown) doses. A lower osRfD confidence was assigned due to: 1) a weak health effects database
 14 for this endpoint (most studies were rated *low* confidence), and 2) the possibility that other
 15 unknown toxicities could be affecting the animals at the high dose. Thus, there was lowered
 16 confidence due to the database of studies examining this endpoint, and lowered confidence in
 17 quantification of the POD.

18 4.1.4.4. Hematological Toxicity

19 The osRfD for hematological toxicity was based on decreased Hgb in male F344 rats at 22
 20 days reported in [NTP \(2008\)](#). This effect was observed to have the highest magnitude at short time
 21 periods, and other short-term data (such as 23-day data from [NTP \(2007\)](#)) were not as applicable
 22 for low-dose extrapolation due to the higher dose ranges used. An osRfD of 0.01 mg/kg-d (rounded
 23 from 0.0126 mg/kg-d) was derived. There is high confidence in this osRfD. It is based on a [high](#)
 24 [confidence](#) study in rats that measured data at multiple time points (1 week, 22 days, 3 months, 6
 25 months, 12 months). There are other subchronic datasets, mechanistic evidence, as well as
 26 multiple hematological markers (such as MCV, MCH, MCHC, Hct) that also support this endpoint.

Table 4-5. Organ/system-specific RfDs and proposed overall RfD for Cr(VI)

Effect	Basis	osRfD (mg/kg-day)	Exposure Description	Confidence
GI tract toxicity	Diffuse epithelial hyperplasia in small intestine (female mice)	9×10^{-4}	Chronic	High
Hepatic toxicity	Chronic inflammation (female rats)	7×10^{-4}	Chronic	High
Developmental toxicity	Decreased F1 offspring postnatal growth (mice)	0.07	Continuous breeding	Low
Hematological toxicity	Decreased Hgb (male rats)	0.01	Subchronic	High

Effect	Basis	osRfD (mg/kg-day)	Exposure Description	Confidence
Overall RfD	GI tract effects	9×10^{-4}	Chronic	High

4.1.5. Selection of the Overall Reference Dose

1 Choice of the overall RfD involved consideration of both the level of certainty in the
 2 estimated organ/system-specific values, as well as the level of confidence in the observed effect(s).
 3 An overall confidence level was assigned to the RfD to reflect an interpretation regarding
 4 confidence in the collection of studies used to determine the hazard(s) and derive the RfD, the RfD
 5 calculation itself, as well as the overall completeness of the database on the potential health effects
 6 of hexavalent chromium exposure.

7 To estimate an exposure level below which noncancer effects from lifetime oral Cr(VI)
 8 exposure are not expected to occur, the osRfD for GI effects, 9×10^{-4} mg/kg-d, is selected as the
 9 overall RfD for Cr(VI). This was a high confidence value derived from chronic exposure data. The
 10 overall RfD is derived to be protective of all types of noncancer effects for lifetime exposure and is
 11 intended to protect the population as a whole including potentially susceptible subgroups ([U.S.
 12 EPA, 2002](#)). While the osRfD for liver was slightly lower, the osRfD for GI effects is still lower than
 13 most other candidate values considered for the liver osRfD (see Figure 4-3). With the exception of
 14 chronic liver inflammation in female rats, candidate values for the osRfD for liver effects that were
 15 based on chronic exposure data (12 months or 2 years; see Figure 4-3) were above 9×10^{-4} mg/kg-
 16 d. Candidate liver values derived from subchronic data that were lower than 9×10^{-4} mg/kg-d had
 17 cumulative uncertainty factors of 300, whereas other candidate values had uncertainty factors of
 18 100 or less. Because the GI tract is exposed to higher concentrations of un-reduced Cr(VI) than the
 19 liver, it is likely to be more susceptible to the effects of ingested Cr(VI). Thus, the osRfD for GI
 20 effects was selected as the overall RfD.

21 This value (9×10^{-4} mg/kg-d) should be applied in general population risk assessments.
 22 However, decisions concerning averaging exposures over time for comparison with the RfD should
 23 consider the types of toxicological effects and specific life stages of concern. For example,
 24 fluctuations in exposure levels that result in elevated exposures during various life stages could
 25 potentially lead to an appreciable risk, even if average levels over the full exposure duration were
 26 less than or equal to the RfD.

4.1.6. Uncertainties in the Derivation of Reference Dose

27 The RfD was derived based on GI effects (diffuse epithelial hyperplasia in the duodenum) of
 28 female mice exposed to Cr(VI) in drinking water for two years ([NTP, 2008](#)). Some of the
 29 uncertainty considerations related to the RfD derivation are outlined below and in Section 3.3.

1 **4.1.6.1. Site Concordance and Human Relevance**

2 The GI tract reference value was based on an effect observed in the small intestine of mice,
3 however it is possible that the effect may be exhibited in different sections of the alimentary tract in
4 the human (specifically, the oral cavity, esophagus, and stomach). Estimated Cr(VI) exposure to the
5 stomach epithelium may be similar to exposure to the small intestine epithelium, since both would
6 be strong functions of gastric pH, Cr(VI) concentration and reduction rate. There are differences in
7 morphologies between the small intestine and stomach that could potentially impact the tissue
8 susceptibility. Effects in the rodent stomach only occurred at the high doses of the 90-day [NTP](#)
9 [\(2007\)](#) study. Rodents exposed to Cr(VI) during the 2-year [NTP \(2008\)](#) study did not exhibit effects
10 in the stomach.

11 Exposure to the oral cavity and esophagus occurs prior to Cr(VI) reduction in the stomach.
12 However, no noncancer effects were observed in these tissues during the [NTP \(2008\)](#) or [NTP](#)
13 [\(2007\)](#) bioassays (aside from mild salivary gland atrophy in rats during the 2-year study).

14 **4.1.6.2. Susceptible Populations**

15 A significant fraction of the human population may be highly susceptible to Cr(VI)-induced
16 effects in the GI tract due to high stomach pH. Individuals with hypochlorhydria (low stomach acid)
17 have consistently high stomach pH that may exceed 8 ([Feldman and Barnett, 1991](#)). Less than 1%
18 of the adult population may exhibit hypochlorhydria, whereas 10–20% of the elderly population
19 (aged 65 and up) may exhibit this condition ([Russell et al., 1993](#)). For individuals without this
20 medical condition, there is still high variability ([Feldman and Barnett \(1991\)](#) estimated that 5% of
21 men may exhibit basal pH exceeding 5, and 5% of women may exhibit basal pH exceeding 6.8). Gut
22 microbiota and gastric juice chemistry in individuals with high gastric pH may differ from those in
23 the general population. It is not known how effective Cr(VI) can reduce to Cr(III) in this type of
24 gastric environment. Data by [Kirman et al. \(2016\)](#), which included some groups with high stomach
25 pH, were highly variable.

26 Individuals taking medication to treat gastroesophageal reflux disease (GERD), including
27 calcium carbonate-based acid reducers and proton pump inhibitors, have an elevated stomach pH
28 during treatment. This is known to be a significant fraction of the population since up to 20% of the
29 population may be afflicted by GERD, and the gastric pH for these individuals may be above 4
30 throughout the day during successful treatment ([Delshad et al., 2020](#); [GBD 2017, 2020](#); [Lin and](#)
31 [Triadafilopoulos, 2015](#); [Burdall et al., 2013](#); [Atanassoff et al., 1995](#)). A sensitivity analysis was
32 performed on the human model (Appendix C.1.5), assuming a baseline stomach pH = 4 (as opposed
33 to 1.3). It was found that for internal PODs above 0.001 mg/kg-d (which apply to all the PODs), the
34 current Monte Carlo approach (taking the lower 1% of 20,000 simulations of the standard
35 population with baseline stomach pH = 1.3) was protective for the population with baseline pH = 4.
36 For populations with baseline pH higher than 4, candidate values derived using the
37 pharmacokinetic approach would not be health-protective. Appendix D.3 contains candidate values

1 calculated by default approaches without adjustment for gastric reduction, which may be health-
2 protective at low doses for the pH > 4 population (since those results implicitly assume gastric pH
3 and reduction capacity in rodents and humans are equivalent).

4 Uncertainties related to extremely high gastric pH, as well as other conditions that could
5 lead to pharmacokinetic susceptibility (*H. pylori* infection, gastric bypass, gastrectomy) cannot be
6 accounted for quantitatively. High interindividual variation was observed in ex vivo data by
7 [Kirman et al. \(2016\)](#), both in health individuals with high stomach pH and individuals taking proton
8 pump inhibitors. Additionally, no data are available studying Cr(VI) reduction in the gastric
9 environments of children, toddlers, or infants. As a result, PBPK modeling was not performed for
10 these groups, and there may be some residual pharmacokinetic uncertainty not accounted for by
11 the UF_H.

12 **4.1.6.3. Rodent Gastric Modeling Uncertainties**

13 Stomach reduction in the mouse may be impacted by a number of factors. Higher reduction
14 efficiency may occur during the ingestion of a solid meal, since gastric emptying is delayed, and pH
15 is decreased (for the mouse, glandular stomach pH is decreased by the fasted state, while the
16 opposite is true for humans). However, this effect may be counteracted by kinetics in the
17 forestomach, which humans do not have. The forestomach may not follow the same fed/fasted
18 pattern as the glandular stomach ([Ward and Coates, 1987](#)).

19 The rodent glandular stomach actively secretes digestive enzymes shortly before, during,
20 and after a solid meal. The precise dynamics of gastric changes are uncertain, and the “well-mixed”
21 PBPK model assumption may not be accurate due to ongoing food consumption. In addition, the
22 rodent forestomach contents may have an elevated pH relative to the glandular stomach ([Kohl et](#)
23 [al., 2013](#); [Browning et al., 1983](#); [Kunstyr et al., 1976](#)), and ingested drinking water passes through
24 both of these stomach regions.

25 There are also uncertainties related to the pH-kinetic relationship. The dose-response
26 analysis for this assessment applied rodent pH of greater than 4.0, setting pH to values at which the
27 rodent ex vivo reduction experiments were performed. Prior to dilution with water, [Proctor et al.](#)
28 [\(2012\)](#) estimated the rodent stomach pH to be approximately 4, but it was increased to
29 approximately 4.5 after dilution with water for the experiments. The precise relationship between
30 pH and reduction kinetics in the rodent at lower pH is uncertain, and therefore it was desirable to
31 perform simulations assuming rodent pH of 4.0 or higher. If the true rodent stomach pH is lower,
32 or if the reduction kinetics are faster than estimated by the current model, this would ultimately
33 lead to a decreased RfD. On the other hand, the model already estimates a low percentage of Cr(VI)
34 escaping the rodent stomach (5–10%). If the true percentage was lower than this, it would mean
35 that a negligible amount of Cr(VI) enters the mouse small intestine following ingestion. It has been
36 confirmed by multiple pharmacokinetic studies that Cr(VI) is absorbed systemically in rodents
37 following exposure via drinking water. Data by [Kirman et al. \(2012\)](#) show chromium
38 concentrations in the duodenum increasing with a linear or supralinear relationship with respect to

1 dose in mice exposed to Cr(VI) in drinking water for 90 days. Data by [NTP \(2008\)](#) show elevated
2 tissue chromium for all chronically-exposed groups. Therefore, assuming that in vivo rodent
3 gastric reduction occurs very effectively (i.e., 99% reduction) would not be consistent with the
4 available pharmacokinetic data.

5 **4.1.6.4. Human Gastric Modeling Uncertainties**

6 As with the rodent gastric system, there are uncertainties in modeling the human stomach.
7 There exist complex gastric and intestinal kinetic models, and many of the parameters are highly
8 variable ([Paixão et al., 2018](#); [Talattof and Amidon, 2018](#); [Yu et al., 2017](#); [Hens et al., 2014](#); [Mudie et](#)
9 [al., 2010](#); [ICRP, 2006](#)). While the PBPK model in this assessment adopts some parameters and
10 concepts from literature, and incorporates Monte Carlo analysis, it may not account for all
11 uncertainty and variability. Ex vivo data for Cr(VI) reduction in gastric juices show high
12 interindividual variability ([De Flora et al. \(2016\)](#); [Kirman et al. \(2016\)](#)). Interindividual variability in
13 gastric contents and microbiota likely introduces variation in Cr(VI) reduction. Variability in
14 reduction kinetic parameters (with the exception of the reducing capacity parameter) was not
15 incorporated into the model. Furthermore, there are no data for Cr(VI) reduction in the gastric acid
16 of infants and toddlers, and there would be significant uncertainties in applying the adult-based
17 PBPK model to infant or child physiology.

18 **4.1.6.5. Uncertainty in Systemic Pharmacokinetics**

19 The current approach uses a PBPK model of the stomach lumen to adjust the average daily
20 oral Cr(VI) dose to account for detoxification in the stomach compartment. It does not explicitly
21 model systemic whole-body pharmacokinetics. While whole-body PBPK models are available for
22 Cr(VI), the uncertainties related to the systemic pharmacokinetics in rodents and humans are high,
23 especially at low doses. However, most endpoints observed following oral ingestion were in or
24 near the GI tract, and therefore may not require an accounting of systemic chromium. Cr(VI) which
25 enters the intestinal lumen may expose the systems in which effects were observed (the small
26 intestine, and the liver by first-pass effect) prior to distribution to systemic circulation. Reduction
27 of Cr(VI) in the blood and other tissues is rapid, and this assessment neglects the impact that re-
28 circulating Cr(VI) may have on the liver and small intestine. It is health-protective to assume that
29 any unreduced Cr(VI) emptying into the human small intestine is absorbed.

30 For systemic effects, there is some residual pharmacokinetic uncertainty. The modeling
31 does not take into account how much Cr(VI) may remain in the GI epithelium (or be reduced by the
32 G.I. tissues, liver, and blood). This loss of Cr(VI) available to absorb into systemic tissues is
33 neglected in both animals and humans.

1 **4.1.6.6. Uncertainty in Dose-response Modeling**

2 For the two osRfDs (diffuse epithelial hyperplasia in female mice, and chronic liver
3 inflammation in female rats from [NTP \(2008\)](#)), there was uncertainty related to the dose-response
4 modeling. Thus a NOAEL/LOAEL approach was used.

5 As noted in Section 4.1.6, diffuse epithelial hyperplasia was not amenable to BMD modeling
6 for female mice because there was too much uncertainty in estimating the BMDL. Estimates of the
7 epithelial hyperplasia RfD from female mice using BMD modeling (without dropping doses) span
8 from 7.95×10^{-5} mg/kg-d to 2.04×10^{-3} mg/kg-d (see Appendix D.1.1). The GI tract osRfD (derived
9 by a LOAEL, which resulted in a higher uncertainty factor) falls within this span and differs by
10 approximately 15% from both the mean and median value of the three adequately fit models (1.06
11 $\times 10^{-3}$ mg/kg-d). If dropping the two highest doses (as was done by ATSDR ([2012](#))) and
12 performing BMD modeling, the resulting RfD would be 2.6×10^{-3} mg/kg-d (and rounded to 3
13 $\times 10^{-3}$ mg/kg-d). EPA's *Benchmark Dose Technical Guidance* ([U.S. EPA, 2012b](#)) states dropping dose
14 groups should only be done when an adequate model fit cannot be achieved. This situation did not
15 apply to female mouse hyperplasia, because multiple adequate fits were achieved when including
16 all dose groups, but there was too much uncertainty in the BMD estimate to use these model results
17 for determining the POD.

18 Similarly, chronic liver inflammation in female rats from [NTP \(2008\)](#) was not amenable to
19 BMD modeling. Estimates of the candidate values for this endpoint span from 1.00×10^{-4} to 4.02
20 $\times 10^{-3}$ (see Appendix D.1.1). The liver osRfD (derived by a LOAEL, which resulted in a higher
21 uncertainty factor) falls within this span and is about 2x lower than the mean and median values of
22 the three adequately fit models (mean: 1.80×10^{-3} mg/kg-d, median: 1.28×10^{-3} mg/kg-d).

4.1.7. Confidence Statement

23 An overall confidence level of **High**, **Medium**, or **Low** was assigned to reflect the level of
24 confidence in the study(ies) and hazard(s) used to derive the RfD, the overall database, and the RfD
25 itself, as described in EPA's *Methods for Derivation of Inhalation Reference Concentrations and*
26 *Application of Inhalation Dosimetry* §4.3.9.2 ([U.S. EPA, 1994](#)).

27 The confidence in the overall chronic RfD is **high**. The RfD is based on a *high* confidence
28 chronic 2-year drinking water study by [NTP \(2008\)](#) which exposed rats and mice of both sexes to
29 Cr(VI) as sodium dichromate dihydrate at drinking water concentrations from 5 mg/L to 180 mg/L
30 (approximately 0.2 mg/kg-d to 10 mg/kg-d). Multiple *high* confidence subchronic studies also
31 support these data (click the [HAWC link](#) for study evaluation details), and mechanistic studies
32 support oxidative stress as a mechanism of Cr(VI) toxicity in a variety of tissues, including the GI
33 tract. Although the value is based on a LOAEL, the final result is supported by BMD modeling
34 results for hyperplasia in the duodenum of male mice from the same study, and is within the range
35 of adequately fit models that could not be utilized (see above in Section 4.1.6.6). The osRfD for the
36 liver is also supportive of the GI tract RfD, because the GI tract and liver are exposed on first-pass

1 following oral ingestion (so both should get the highest internal dose). While the human database
2 for Cr(VI)-induced GI toxicity was *indeterminate*, this did not warrant changing the overall
3 confidence from *high*.

4.1.8. Previous IRIS Assessment: Oral Reference Dose

4 The previous RfD assessment for Cr(VI) was completed in September 1998. The previous
5 RfD was based on a NOAEL identified from a 1-year drinking water study in rats in which animals
6 were exposed to Cr(VI) ([MacKenzie et al., 1958](#))⁶⁹. [MacKenzie et al. \(1958\)](#) monitored body weight,
7 gross external conditions, histopathology and blood chemistry and did not observe any effects at
8 any level of treatment. A NOAEL of 2.5 mg/kg-day was identified. A composite uncertainty factor
9 of 300 (10 for interspecies extrapolation, 10 for intraspecies extrapolation, and 3 for subchronic-to-
10 chronic extrapolation) and a modifying factor of 3 (to account for concerns raised by the
11 epidemiology study of [Zhang and Li \(1987a\)](#)) were applied to this POD to yield an oral RfD of 3
12 $\times 10^{-3}$ mg/kg-d.

4.2. INHALATION REFERENCE CONCENTRATION FOR EFFECTS OTHER THAN CANCER

13 The reference concentration (RfC, expressed in units of mg/m³) is defined as an estimate
14 (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to
15 the human population (including sensitive subgroups) that is likely to be without an appreciable
16 risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or the 95%
17 lower bound on the benchmark concentration (BMCL), with uncertainty factors generally applied to
18 reflect limitations of the data used. As noted in Section 3.3.2, derivation of the RfC was limited to
19 effects in the respiratory tract.

20 Upper respiratory toxicity in the form of nasal effects in humans has been determined
21 previously (see Protocol Section 3.1.2, Appendix A), and a set of human studies were evaluated for
22 data that may inform the quantitative dose-response analysis (this will be discussed in Section
23 4.2.1). Data suitable for RfC derivation of upper respiratory effects were only available from human
24 studies (and these were limited to effects in the nasal airways). Data from animals of effects in the
25 upper respiratory tract (such as reported nosebleeds and other qualitative effect descriptions)
26 were not considered due to the availability of quantitative dose-response data in humans.

27 Based on findings from inhalation studies in experimental animals and occupational studies
28 in humans, evidence indicates that Cr(VI) is likely to cause lower respiratory toxicity in humans
29 (see Section 3.2.1). Data suitable for RfC derivation of lower respiratory effects were only available

⁶⁹This study was determined to meet PECO criteria in the current assessment; however, the overall confidence was rated *uninformative* due to insufficient reporting of the outcomes, survival, and sample sizes of evaluated animals. Normally in situations concerning poor reporting, authors may be contacted for clarifications that may result in upgraded confidence ratings, but this was not possible due to the age of the publication.

1 from animal studies. All human studies of these effects were *low* confidence and only provided
2 information on associations (and did not provide dose-response data).

4.2.1. Identification of Studies for Dose-Response Analysis of Selected Effects

3 4.2.1.1. *Upper Respiratory Tract Effects*

4 Effects in the nasal cavity of humans are well-established hazards of inhaled Cr(VI)
5 exposure, and this review focused on data that may improve the quantitative dose-response
6 analysis conducted in EPA's 1998 IRIS assessment (see Protocol Section 3.2, Appendix A)⁷⁰.
7 Quantitative animal data for effects in the upper respiratory tract were not available. Qualitative
8 findings in rodents such as obstructive respiratory dyspnea ([Glaser et al., 1990](#)), or "peculiar sound
9 during respiration" and periodic nose bleeds ([Kim et al., 2004](#)) were not considered for dose-
10 response assessment due to the availability of human data. No other effects in the upper
11 respiratory tract outside of the nasal cavity were identified during hazard identification (Section
12 3.2.1).

13 The epidemiological database for inhalation of Cr(VI) mainly consists of observational
14 studies of workers exposed in occupational settings. Human studies were considered suitable for
15 dose-response analysis and toxicity value derivation if they met the criteria listed below.
16 Furthermore, preference was given to studies with *medium* or *high* overall confidence ratings based
17 on study evaluation and to studies with larger sample sizes and exposures in the lower range of
18 human exposures, as these are most likely to represent the relationship between inhalation
19 exposure to Cr(VI) and adverse effects in the general population.

20 The following considerations were made during evaluation of studies for derivation of
21 inhalation toxicity values from human data:

- 22 • The study population must be exposed to Cr(VI) (as opposed to Cr(III)) based on air
23 measurements or job history and industry
- 24 • Quantitative estimates relating exposure (or dose) to the core outcomes considered
- 25 • Concentration of Cr(VI) in air must be measured at the study site
- 26 • Quality of measurements will depend on: type of sampling (personal, stationary, or both);
27 frequency of sampling; sampling duration; number of samplers; sampling methods
- 28 • Exposure to Cr(VI) for individuals or groups of individuals must be estimated with
29 reasonable accuracy and precision in units of air concentration

⁷⁰A large literature database exists presenting qualitative evidence for an association between inhalation Cr(VI) exposure and nasal effects (see [ATSDR \(2012\)](#)). These qualitative studies, which presumably would have varying confidence ratings, were not evaluated in this assessment. Study confidence ratings for the quantitative data in this assessment do not impact EPA's determination that nasal effects are well established hazards of inhalation Cr(VI) exposure.

- 1 • If exposure is categorical, it must have corresponding air concentration estimates for each
2 category
- 3 • Exposure is not solely quantified in units of concentration in a biological sample such as
4 urine or blood

5 The core outcomes for nasal effects in humans considered for evaluation of dose response
6 included the following clinical outcomes diagnosed by a trained examiner (e.g., physician,
7 otolaryngologist, or trained researcher): atrophy of the nasal mucosa, ulceration of the nasal
8 mucosa or septum, perforation of the septum, and bleeding nasal septum. The development of
9 these outcomes is highly specific to exposure to Cr(VI) and occurrence outside this exposure
10 scenario is extremely rare. Consistent with this specificity of outcome, perforation of the septum
11 has been known as “chrome hole” since the early days of chromium-related industries (including
12 chromate production and electroplating ([Bloomfield and Blum, 1928](#))). Furthermore, the presence
13 of nasal pathologies considered here are occasionally used as supplemental information to confirm
14 exposure to chromium in studies of non-nasal outcomes ([Ciminera et al., 2016](#); [Gibb et al., 2015](#);
15 [Machle and Gregorius, 1948](#)). The specificity of this outcome to Cr(VI) exposure makes it ideal for
16 the estimation of the dose-response relationship for noncancer effects in humans.

17 There were over 20 peer-reviewed studies of nasal effects that contained information
18 related to endpoints in the nasal cavity, but these did not meet all criteria for dose-response
19 analysis outlined above and were therefore not evaluated. There were also five non-peer-reviewed
20 reports examining effects in the nasal cavity available from the National Institute for Occupational
21 Safety and Health (NIOSH). These include [Ceballos et al. \(2017\)](#), [Zey and Lucas \(1985\)](#), [Lucas](#)
22 [\(1976\)](#), [Lucas and Kramkowski \(1975\)](#), [Cohen and Kramkowski \(1973\)](#) and [Almaguer and](#)
23 [Kramkowski \(1983\)](#)⁷¹. Many of these studies did not have multiple exposure groups (either a
24 referent or low/high concentration groups). Exposure and health effect data from these studies
25 were only available for short time periods, and data were only collected after health effects were
26 reported for the purpose of evaluating plant industrial hygiene practices (potentially leading to
27 bias). As a result, most of these were excluded for dose-response consideration. Only data from
28 [Cohen and Kramkowski \(1973\)](#) and its related peer-reviewed study ([Cohen et al., 1974](#)) were
29 considered since this study contained a referent group. All studies excluded based on criteria above
30 are listed at the bottom of Table 4-6, and detailed rationale for why each of these were not
31 considered is provided in Appendix D.4 Table D-25.

32 Four peer-reviewed studies (some of which were associated with additional related studies
33 containing exposure or study design information) initially met the criteria to be considered for
34 toxicity value derivation and underwent formal study evaluation using HAWC. These were [Gibb et](#)
35 [al. \(2000a\)](#), [Lindberg and Hedenstierna \(1983\)](#), [Cohen et al. \(1974\)](#), and [Hanslian et al. \(1967\)](#). All
36 were conducted in occupational settings and the study populations were workers in either the

⁷¹The cited reports were published by the National Institute for Occupational Safety and Health (NIOSH). Author names listed in these citations are the NIOSH investigators.

1 chromate production or chrome electroplating industries. One study of 2,307 chromate production
2 workers [Gibb et al. \(2000a\)](#), though retrospective in design, utilized company records of air
3 concentration data, individual job and task data, and data from regular medical examinations, to
4 construct a dataset that included individual exposure estimates for each worker as well as the time
5 from baseline exposure to the incident event of the health outcome (see Table 4-23 in Section
6 4.4.5). The other three studies ([Lindberg and Hedenstierna, 1983](#); [Cohen et al., 1974](#); [Hanslian et
7 al., 1967](#)) were cross-sectional in design and were conducted in smaller study populations
8 composed of chrome electroplating workers. The populations were adults, and the largest cohort
9 ([Gibb et al. \(2000a\)](#), which had a population size of 2307) only had male workers.

10 Three studies were classified as *medium* confidence ([Gibb et al., 2000a](#); [Lindberg and
11 Hedenstierna, 1983](#); [Cohen et al., 1974](#)), and one study was *low* confidence ([Hanslian et al., 1967](#)).
12 Because of the availability of *medium* confidence studies, data from [Hanslian et al. \(1967\)](#) were no
13 longer considered for dose-response. In addition to the usual factors considered during study
14 evaluation, diagnosis of nasal outcomes after physical examination of the nasal cavity by a trained
15 examiner was considered when determining confidence ratings for nasal effects studies. Additional
16 study details, including the reported endpoint data, are provided in Table 4-7.

Table 4-6. Evaluation of epidemiology studies on Cr(VI) and nasal effects. [Click to see interactive data graphic for rating rationales.](#)

	Reference	Study description	Study evaluation							
			Exposure	Outcome	Selection	Confounding	Analysis	Sensitivity	Sel. reporting	Overall confidence
Included	Gibb et al. (2000a) related: Gibb et al. (2015) Braver et al. (1985) ; Hayes et al. (1979)	Occupational longitudinal study. Male workers in a chromate production plant in Baltimore, MD (n = 2307).	A	A	A	A	A	G	A	MED
	Lindberg and Hedenstierna (1983)	Cross-sectional study. Male and female employees in chrome-plating industry (n = 104). Office employees (n = 19) as reference group	A	A	A	A	A	A	A	MED
	Cohen et al. (1974) Related: Cohen and Kramkowski (1973)	Cross-sectional study. White male and female electroplating workers in nickel-chrome department (n = 37) Randomly-chosen workers employed in other areas of the plant not significantly exposed to chromic acid as reference group (n = 15)	A	G	A	A	A	A	A	MED
Excluded	Hanslian et al. (1967)	Cross-sectional study. Male and female chrome-plating workers (n = 77). 53 working directly with baths, 23 working directly with chromium. No reference group.	D	A	D	A	A	A	A	LOW
Not suitable ^a	Almaguer and Kramkowski (1983) , Armienta-Hernández and Rodríguez-Castillo (1995) , Bloomfield and Blum (1928) , Ceballos et al. (2019, 2017) , Dornan (1981) , Elhosary et al. (2014) , Fagliano et al. (1997) , Gomes (1972) , Horiguchi et al. (1990) , Huvinen et al. (2002a) , Kleinfeld and Rosso (1965) , Kitamura et al. (2003) , Korallus et al. (1982) , Lee and Goh (1988) , Lin et al. (1994) , Lucas et al. (1976; 1975) , Machle and Gregorius (1948) , Mancuso (1951) , PHS (1953) , Royle (1975) , Singhal et al. (2015) , Sorhan et al. (1998; 1987) , Vigliani and Zurlo (1955) , Wang et al. (1994) , Yuan et al. (2016) , Zey and Lucas (1985)									

G = good; A = adequate; P = poor.

^aStudies that may have contained data for effects in the nasal cavity, but were determined not to meet PECO within the scope of derivation of nasal toxicity values, or were not suitable for dose-response analysis for other reasons. Rationale for excluding individual studies is available in Appendix D4 Table D-27.

Table 4-7. Dose-response data for effects in the nasal cavity of humans (*medium* confidence studies)

Study	Exposure	Conf	Result Format	Effects		
Lindberg and Hedenstierna (1983)	Chrome plating	MED	Number of cases	Ulceration 8-hr mean air $\mu\text{g Cr(VI)}/\text{m}^3$ Group n cases (%) ≤1.9 19 0 2–20 24 8 (33) Highest air $\mu\text{g Cr(VI)}/\text{m}^3$ Group n cases 0.2–1.2 10 0 2.5–11 12 0 20–46 14 7 (50)	Atrophy 8-hr mean air $\mu\text{g Cr(VI)}/\text{m}^3$ Group n cases (%) ≤1.9 19 4 (21) 2–20 24 8 (33) Highest air $\mu\text{g Cr(VI)}/\text{m}^3$ Group n cases 0.2–1.2 10 1 (10) 2.5–11 12 8 (67) 20–46 14 0	Perforation only* 8-hr mean air $\mu\text{g Cr(VI)}/\text{m}^3$ Group n cases ≤1.9 19 0 2–20 24 3 (13) Highest air $\mu\text{g Cr(VI)}/\text{m}^3$ Group n cases 0.2–1.2 10 0 2.5–11 12 0 20–46 14 3 (21) *2 w/ulceration also had perforation (total w/ perforation = 5)
Gibb et al. (2000a)	Chromate production	MED	Cumulative incidence (%) (n = 2307), onset time, and relative risk (ulceration only)	Ulcerated nasal septum Effect: 62.9% Mean (median) exposure: 0.054 (0.020) mg CrO ₃ /m ³ or 28 (10) $\mu\text{g Cr(VI)}/\text{m}^3$ Mean (median) time on job (days) from date first hired to date of first diagnosis: 86 (22)	Perforated nasal septum Effect: 17.3% Mean (median) exposure: 0.063 (0.021) mg CrO ₃ /m ³ or 33 (11) $\mu\text{g Cr(VI)}/\text{m}^3$ Mean (median) time on job (days) from date first hired to date of first diagnosis: 313 (172)	Ulcerated septum relative risk Adjusted relative risk for a 0.1 mg CrO ₃ /m ³ increase (in ambient air) = 1.2 (by Cox proportional hazards model adjusted for calendar year at hire and age at hire, p = 0.0001).
Cohen et al. (1974)	Chrome plating	MED	Prevalence (%) (with grading by severity)	Nasal ulceration parameter cases, number (%) nasal mucosa (grade 0) shallow erosion of septal mucosa (grade 1) ulceration and crusting of septal mucosa (grade 2) avascular, scarified areas of septal mucosa w/o erosion or ulceration (grade 3) perforation of septal mucosa (grade 4)	non-exposed (n = 15) exposed (n = 37) 14 (93) 2 (5) 0 8 (22) 0 12 (32) 0 11 (30) 1 (7) 4 (11)	Exposed group area breathing zone: mean = 2.9 (ND–9.1) $\mu\text{g Cr(VI)}/\text{m}^3$ Referent area breathing zone: 0.3 (0.1–0.4) $\mu\text{g Cr(VI)}/\text{m}^3$

1 mg CrO₃ = 0.52 mg Cr(VI).

1 **4.2.1.2. Lower Respiratory Tract Effects**

2 The inhalation animal toxicological database for Cr(VI) consists of studies with chronic,
3 subchronic, and/or acute data. Many of these studies analyzed similar or identical toxicological
4 endpoints, particularly for the respiratory system. Within the endpoint-specific databases for
5 hazard identification, a subset of these studies were considered for toxicity value derivation based
6 on factors outlined in Section 4.1.1. Preference was given to studies with larger sample sizes and
7 low concentrations, to facilitate extrapolation to levels typical of environmental human exposure
8 ([U.S. EPA, 2012b](#)). For inhalation studies of particulates, studies that provided measures of particle
9 size and distribution were preferred. Because of the availability of studies that were rated *medium*
10 confidence for lower respiratory tract endpoints, *low* confidence studies were not considered for
11 candidate value derivation. An outline of the process used to select candidate animal datasets for
12 dose-response analysis and candidate value derivation is provided in Figure 4-4.




Figure 4-4. Evaluation of animal studies from the Cr(VI) hazard identification for derivation of toxicity values. *Low confidence studies were not considered.*

Table 4-8. Design features of inhalation studies that examined effects in animals

Study reference	Species/ strain and sex	Exposure duration	Dose groups ^a	Animals/ group	Chemical and particle size	Concentration range (mg/m ³ Cr[VI])
Glaser et al. (1990)	Wistar Rat, Male	30/90 days (22 hr/day, 7 d/wk)	4	10	Sodium dichromate MMAD 0.28 (±1.63) µm bottom two dose groups 0.39 (±1.72) µm high groups	0.05–0.4
Glaser et al. (1985)	Wistar Rat, Male	28/90 days (22 hr/day, 7 d/wk)	3	10	Sodium dichromate MMD 0.2 (±1.5) µm	0.025–0.2
Johansson (1986b ; 1986a)	Rabbit, Male	4–6 weeks (inexact), 6 hr/day, 5 d/wk	1	8	Sodium dichromate MMAD 1 µm (approx.)	0.9
Cohen et al. (2003)	F344 Rat, Male	48 weeks, 5 hr/day, 5 d/wk	1	30	Calcium chromate MMAD 0.6 (±1.7) µm	0.36
Kim et al. (2004)	Sprague- Dawley Rat, Male	90 days, 6 hr/day, 5 d/wk	3	5	Chromium trioxide (size not reported)	0.2–1.25

^aNumber does not include control group.

1 Table 4-4 outlines the inhalation studies rated *medium* or higher confidence for respiratory
2 tract endpoints (all were rated *medium* confidence for lung histopathology cellular responses; see
3 Section 3.2.1). Of the studies listed in Table 4-8 the Glaser et al. ([1990](#); [1985](#)) studies were
4 preferred for candidate value derivation due to the number of exposure groups, sample sizes, and
5 reporting of endpoints, methods, and particle sizes. [Kim et al. \(2004\)](#) did not report quantitative
6 data for effects or chromium particle size, and effects, and Johansson ([1986b](#); [1986a](#)) and [Cohen et](#)
7 [al. \(2003\)](#) only used a single high exposure group.

8 Lung histiocytosis, bronchioalveolar hyperplasia, and increased total protein and albumin
9 in BAL fluid were observed by [Glaser et al. \(1990\)](#) after 90 days of exposure, and these measures
10 remained slightly elevated after a 30-day recovery period (see Section 3.2.1). Although lactate
11 dehydrogenase (LDH) in BAL fluid returned to normal following the 30-day recovery period, LDH is
12 considered a sensitive indicator of cellular injury ([Henderson et al., 1985](#)), and there was a clear
13 dose-response relationship. Dose-response data from [Glaser et al. \(1990\)](#) following 90 days of
14 exposure (with and without the 30-day recovery period) are presented in Figures 4-5 and 4-6.
15 Because histopathological and cellular changes occurred together, and in combination with serum
16 biomarkers indicating an inflammatory response ([Nikula et al., 2014](#)), all exposure levels were
17 considered to have induced adverse responses.




Figure 4-5. Dose-response relationship for lung histopathological in male rats using data from [Glaser et al. \(1990\)](#). Data are for 90-day observation time immediately following exposure, and 120-day observation time (90 days of exposure followed by a 30-day period of no exposure). N = 10/group. [Click here for interactive graphic.](#)




Figure 4-6. Dose-response relationship for selected endpoints in male rats using data from Glaser et al. (1990). Data (\pm 95% confidence interval) are for 90-day observation time immediately following exposure, and 120-day observation time (90 days of exposure followed by a 30-day period of no exposure). N = 10/group. [Click here for interactive graphic.](#)

- 1 The endpoints and datasets used for dose-response of lower respiratory tract effects were:
- 2 • BAL fluid measurements of total protein, albumin, and LDH from [Glaser et al. \(1990\)](#) at
- 3 90 days
- 4 • Lung histopathological findings of histiocytosis and bronchioalveolar hyperplasia [Glaser et](#)
- 5 [al. \(1990\)](#) at 90 days
- 6 These endpoints were preferred because they are the most direct and sensitive indicators of
- 7 cellular lung injury ([Nikula et al., 2014](#); [Henderson et al., 1985](#)).

1 **4.2.1.3. Other Effects**

2 Inhalation data for effects outside the respiratory system are limited. The only animal
3 inhalation studies reporting effects outside the respiratory tract were rated *low* confidence for
4 these outcomes. No effects were observed in studies rating *medium* confidence for outcomes
5 outside the respiratory tract that were determined to be a hazard in Section 3.2, including [Kim et al.](#)
6 [\(2004\)](#) (liver weight and clinical chemistry) and [Glaser et al. \(1985\)](#) (liver histopathology). As a
7 result, candidate values were not derived for effects outside of the respiratory tract.

4.2.2. Methods of Analysis

8 **4.2.2.1. Analysis of Animal Data**

9 Animal data by [Glaser et al. \(1990\)](#) were used to derive candidate values for lower
10 respiratory tract effects. As noted earlier, the candidate endpoints were 1) BAL fluid measurements
11 of total protein, albumin, and LDH; and 2) Lung histopathological findings of histiocytosis and
12 bronchioalveolar hyperplasia.

13 Biologically based dose-response models are not available for respiratory effects of Cr(VI).
14 In this situation, EPA evaluates a range of dose-response models thought to be consistent with
15 underlying biological processes to determine how best to empirically model the dose-response
16 relationship in the range of the observed data. Consistent with this approach, EPA evaluated
17 dose-response information with the models available in EPA's Benchmark Dose Software (BMDS,
18 Version 3.2). However, data for lung histiocytosis, and for LDH, albumin, and total protein in BAL
19 fluid at the 90-day observation from the [Glaser et al. \(1990\)](#) study in rats, were not amenable to
20 BMD modeling (see Appendix Section D.1.1.4 for details). As a result, no-observed-adverse-effect
21 level (NOAEL) and lowest-observed-adverse-effect level (LOAEL) approaches were used for these
22 effects. Because the lung histopathological changes and cellular responses in BAL fluid occurred
23 together at the lowest exposure level, and in combination with serum biomarkers indicating an
24 inflammatory response ([Nikula et al., 2014](#)), all exposure levels were considered to have induced
25 adverse responses. Therefore, a LOAEL of 0.054 mg/m³ was chosen as the POD for these endpoints.
26 Data for bronchioalveolar hyperplasia, however, were amenable to BMD modeling. Because the
27 BMD Technical Guidance ([U.S. EPA, 2012b](#)) recommends a BMR based on one standard deviation
28 (SD) when no biological information is readily available that allows for determining a minimally
29 biological significant response, a BMR of 1 standard deviation change from the control mean was
30 applied.

31 Animal-to-human extrapolation

32 In accordance with EPA's *Methods for Derivation of Inhalation Reference Concentrations and*
33 *Application of Inhalation Dosimetry* ([U.S. EPA, 1994](#)), duration adjustments and dosimetric
34 adjustment factors (DAFs) were used for extrapolating the selected/candidate PODs from animals
35 to humans in order to calculate human equivalent concentrations (HECs). Because the RfC is

1 intended to apply to continuous lifetime exposures for humans ([U.S. EPA, 1994](#)), a duration
 2 adjustment was made to convert study-specific rodent bioassay exposure regimens to continuous
 3 exposures. Next, a dosimetric adjustment factor was applied to account for differences in particle
 4 lung dosimetry between species. Unlike for the RfD, extracellular reduction of Cr(VI) to Cr(III) was
 5 assumed negligible for the inhalation route of exposure, and no additional dosimetric factors were
 6 applied for pharmacokinetics.

7 The PODs identified from [Glaser et al. \(1990\)](#) were adjusted to account for discontinuous
 8 daily exposure regimens as follows:

9
$$\text{POD}_{\text{ADJ}} = \text{POD} \times (\text{hours exposed per day}/24 \text{ hours}) \times (\text{days exposed per week}/7 \text{ days})$$

10 Where POD is the external exposure concentration rodent POD (mg/m³, determined by
 11 dose-response modeling of rodent data or from the study NOAEL or LOAEL) and POD_{ADJ} is the
 12 duration-adjusted experimental exposure concentration (mg/m³).

13 Next, the POD_{HEC} (human equivalent concentration POD) was calculated from the POD_{ADJ} by
 14 multiplying by a DAF, which in this case was the regional deposited dose ratio (RDDR_r) for
 15 respiratory tract region *r* of interest as described in *Methods for Derivation of Inhalation Reference*
 16 *Concentrations and Application of Inhalation Dosimetry* ([U.S. EPA, 1994](#)).

17
$$\text{POD}_{\text{HEC}} = \text{POD}_{\text{ADJ}} \times \text{RDDR}_r$$

18 The RDDR_r can be calculated based on the physiology and respiratory parameters of
 19 rodents and humans, and predicted fractional deposition in each respiratory tract region for each
 20 species:

21
$$\text{RDDR}_r = \frac{(\text{SA}_r)_H}{(\text{SA}_r)_A} \times \frac{(\text{V}_E)_A}{(\text{V}_E)_H} \times \frac{(\text{F}_r)_A}{(\text{F}_r)_H}$$

22 where:

23
 24 SA_r = surface area of respiratory tract region *r* (m² or cm²)

25 V_E = ventilation rate (L/minute)

26 F_r = fractional deposition in respiratory tract region *r*

27
 28 Since most effects in the BAL fluid may be indicative of effects due to deposition in the
 29 entire lung (with the exception of the upper airways), the total of the pulmonary (PU) and
 30 tracheobronchial (TB) surface areas and fractional depositions in these regions were used to
 31 calculate an RDDR_{TB+PU} :

32
$$\text{RDDR}_{\text{T B+P U}} = \frac{(\text{SA}_{\text{T B+P U}})_H}{(\text{SA}_{\text{T B+P U}})_A} \times \frac{(\text{V}_E)_A}{(\text{V}_E)_H} \times \frac{(\text{F}_{\text{T B+P U}})_A}{(\text{F}_{\text{T B+P U}})_H}$$

1 The factor $RDDR_{TB+PU}$ was employed for all BAL fluid endpoints (except albumin) because
2 these effects were believed to be induced by exposure in the conducting airways and deep lung. For
3 albumin in BAL fluid, $RDDR_{PU}$ was applied, because this effect is believed to be induced by exposure
4 in the deep lung only.

5 Fractional depositions in the pulmonary region (F_{PU}) and tracheobronchial region (F_{TB}) for
6 both rats and humans were calculated using the Multi-Path Particle Dosimetry (MPPD) model
7 version 2.11⁷², a computational model that can be used for estimating airway particle deposition
8 and clearance (ARA (2009)).

9 For the model runs, the Yeh-Schum 5-lobe model was used for the human and the
10 asymmetric multiple path model was used for the rat (see Appendix D.1.2). Both models were run
11 under nasal breathing scenarios with the inhalability adjustment selected. The aerosol Cr(VI)
12 concentrations reported by [Glaser et al. \(1990\)](#) were converted to aerosol sodium dichromate
13 concentrations by molecular weight conversion (see Appendix D.1.2). It was determined that
14 aerosol concentration did not affect the predicted fractional lung depositions (human F_r values
15 were identical if aerosol concentration was set to either 1 or 136 mg/m³). Thus, the aerosol
16 concentration at the lowest Cr(VI) concentration was applied for rodent-human extrapolation
17 (reported concentration of 54 mg/m³ Cr(VI) is equivalent to 136 mg/m³ sodium dichromate
18 aerosol). Mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD)
19 reported by [Glaser et al. \(1990\)](#) varied slightly with concentration, however this had a negligible
20 effect on the RDDR (see Appendix Section D.1.2). For MPPD simulations, the particle MMAD ± GSD
21 (0.28 ± 1.63 μm), which reported for the lower Cr(VI) concentrations, was applied. The density of
22 sodium dichromate was input as 2.52 g/cm³.

23 The inhalation parameters used for the rat were: breathing frequency, 102 per minute
24 (default); tidal volume, 2.1 mL (default); V_E , 0.214 L/minute (calculated); functional residual
25 capacity, 4 mL (default); and upper respiratory tract volume, 0.42 mL (default). Adult human lung
26 physiology was: functional residual capacity, 3,300 mL (default); and upper respiratory tract
27 volume, 50 mL (default). Since human breathing frequency and tidal volume have a significant
28 impact on the estimated F_r , and these parameters are a strong function of human activity, multiple
29 different scenarios were simulated: resting, light work, heavy work, and maximal work. Values
30 defined by EPA's *Exposure Factors Handbook* ([U.S. EPA, 2011a](#)) are contained in Appendix Table D-
31 17 and range from 40 breaths/min at a tidal volume of 3050 mL (maximal work) to 12 breaths/min
32 at a tidal volume of 500 mL (resting). All other parameters (rodent and human) were set to the
33 default MPPD software values (see Appendix D.1.2).

34 For the human, regional-specific surface areas for the respiratory tract (used as normalizing
35 factors) were 200 cm² for extrathoracic (ET), 3200 cm² for tracheobronchial (TB), and 54 m² for

⁷²EPA has since released newer version of the model. The differences in RDDR between MPPD v2.11 (released by Applied Research Associates) and draft MPPD v1.01 (released by EPA) are less than 10% (see Appendix D.1.2).

1 pulmonary (PU) ([U.S. EPA, 1994](#)). For the rat, respiratory tract surface areas were 15 cm² for ET,
 2 22.5 cm² for TB, and 0.34 m² for PU ([U.S. EPA, 1994](#)). The calculated RDDR values for TB/PU
 3 regions ranged from 2.12/7.00 (resting scenario) to 0.12/0.47 (maximal work scenario). Since the
 4 maximal and heavy work scenarios would not be representative of average daily lifetime inhalation
 5 rates and volumes, the RDDR values were taken to be the average of the mean adult resting and
 6 mean light work RDDRs. Values of RDDR were calculated as:

RDDR _{PU} : 3.435
RDDR _{TB+PU} : 2.685

7
 8 Table 4-9 summarizes the sequence of calculations leading to the derivation of a
 9 human-equivalent point of departure for each data set discussed above.

Table 4-9. Summary of derivation of points of departure following inhalation exposure to Cr(VI). Data for male Wistar rats from [Glaser et al. \(1990\)](#)

Endpoint	% extra risk at LOAEL (mg/m ³) ^a	BMC (mg/m ³)	POD (mg/m ³) (LOAEL or BMCL)	POD _{ADJ} (mg/m ³)	RDDR	POD _{HEC} (mg/m ³)
Histopathology: histiocytosis	87.5%	N/A	0.054	0.0495	2.685 (TB+PU)	0.133
Histopathology: bronchioalveolar hyperplasia	30%	BMC _{1SD} = 0.0294 ^b	BMCL _{1SD} = 0.0168	0.0154	2.685 (TB+PU)	0.0413
Cell responses: LDH in BALF	17%	N/A	0.054	0.0495	2.685 (TB+PU)	0.133
Cell responses: Albumin in BALF	49%	N/A	0.054	0.0495	3.435 (PU)	0.170
Cell responses: Total protein in BALF	75%	N/A	0.054	0.0495	2.685 (TB+PU)	0.133

^a%ER = (% incidence at LOAEL – % incidence at control)/(100 – % incidence at control) × 100

POD_{ADJ} = (BMCL or NOAEL or LOAEL) × (22/24) × (7/7), since rodents in the Glaser et al. studies were unexposed for 2 hours each day.

POD_{HEC} is the human equivalent concentration POD based on the regional deposited dose ratio (RDDR) accounting for interspecies differences in lung particle deposition. PU+TB: POD_{HEC} = (POD_{ADJ}) × RDDR_{TB+PU} = (POD_{ADJ}) × 2.685.

PU: POD_{HEC} = (POD_{ADJ}) × RDDR_{PU} = (POD_{ADJ}) × 3.435.

^bLog-logistic model selected.

1 **4.2.2.2. Analysis of Human Data**

2 Human data by [Gibb et al. \(2000a\)](#), [Lindberg and Hedenstierna \(1983\)](#), and [Cohen et al.](#)
 3 [\(1974\)](#) were used to derive candidate values of upper respiratory tract effects. However, these
 4 effects could not be modeled by Benchmark Dose Software (BMDS) models or other specialized
 5 models. As noted in the analysis of nasal effects by [OSHA \(2006\)](#), the available human data were
 6 insufficient to relate exposures and incidence. Studies either did not have the proper study design
 7 for a quantitative analysis, or lacked short-term airborne Cr(VI) exposure data over an entire
 8 employment period ([OSHA, 2006](#)). Because none of the available studies provided data for a no-
 9 observed-adverse-effect-level (NOAEL), PODs were derived using lowest-observed-adverse-effect-
 10 levels (LOAELs). How these uncertainties were accounted for in the quantitative derivation of the
 11 candidate values are described later in this section.

12 The adjustment factors to account for differences between occupational exposures and
 13 non-occupational exposure follow EPA guidelines ([U.S. EPA, 2009](#)) that acknowledges there are
 14 differences in breathing rates between workers (10 m³ per 8-hour day) and non-workers
 15 (20 m³ per 24-hour day) and that workers are exposed 240 days per year while non-workers are
 16 exposed 365 days per year ([U.S. EPA, 2016b, 2014e, 2012d, 2011d](#)). If workplace exposure is
 17 assumed to occur 240 workdays/year:

18
$$\text{LOAEL}_{\text{HEC}} = \text{LOAEL} (\mu\text{g}/\text{m}^3) \times (\text{VE}_{\text{ho}}/\text{VE}_{\text{h}}) \times 240 \text{ days} / 365 \text{ days}$$

19 where:

20 $\text{LOAEL}_{\text{HEC}}$ = the LOAEL dosimetrically adjusted to an ambient human equivalent
 21 concentration;

22 LOAEL = occupational exposure level (time-weighted average);

23 VE_{ho} = human occupational default minute volume (10 m³/8 h); and

24 VE_{h} = human ambient default minute volume (20 m³/24 h).

Table 4-10. Summary of derivation of points of departure following human inhalation exposure to Cr(VI)

Study	POD rationale	Notes and conversions	LOAEL (µg/m ³)	% incidence at LOAEL	POD HEC (µg/m ³)
Lindberg and Hedenstierna (1983)	Ulceration of the nasal septum. The lowest concentration for the 2–20 µg Cr(VI)/m ³ group. There is high uncertainty in the exposure concentrations.	Table 3	2	33%	0.66
Gibb et al. (2000a)	Ulceration of the nasal septum. The median exposure at first diagnosed nasal ulceration.	Table 1 20 µg CrO ₃ /m ³ = 10.4 µg Cr(VI)/m ³	10.4	63%	3.4

Toxicological Review of Hexavalent Chromium

Study	POD rationale	Notes and conversions	LOAEL ($\mu\text{g}/\text{m}^3$)	% incidence at LOAEL	POD HEC ($\mu\text{g}/\text{m}^3$)
Gibb et al. (2000a)	Ulceration of the nasal septum. The mean exposure at first diagnosed nasal ulceration	Table 1 $54 \mu\text{g CrO}_3/\text{m}^3 = 28 \mu\text{g Cr(VI)}/\text{m}^3$	28	63%	9.2
Cohen et al. (1974) (related study: Cohen and Kramkowski (1973))	Ulceration of the nasal septum. Mean air concentration for exposed groups.	Table 6 $0.0029 \text{ mg Cr(VI)}/\text{m}^3$ ($2.9 \mu\text{g Cr(VI)}/\text{m}^3$)	2.9	32%	0.95

Exposure adjustment for all study concentrations to obtain POD HEC used the following occupational/non-occupational factor: $(10/20) \times (240/365)$.

1
2 For ulceration of the nasal septum from [Gibb et al. \(2000a\)](#), the mean exposure
3 concentration was over 2x the median concentration, indicating that the data are skewed. Figure 1
4 in [Gibb et al. \(2000a\)](#) indicates that certain job titles were exposed to higher Cr(VI) concentrations
5 early in the study period, and that these job titles experienced lower exposure for most of the later
6 years in the timeline. The median result was chosen instead of the mean for this dataset, because
7 the median is a better estimate of the central tendency for these data.

4.2.3. Derivation of Candidate Values

8 The reference concentration (RfC) is the inhalation concentration likely to be without an
9 appreciable risk of deleterious noncancer health effects during a lifetime ([U.S. EPA, 1994](#)).

10 Under EPA's *A Review of the Reference Dose and Reference Concentration Processes* [([U.S.](#)
11 [EPA, 2002](#)); Section 4.4.5], five possible areas of uncertainty and variability were considered. An
12 explanation of the five possible areas of uncertainty and variability follows.

13 For animal-derived PODs using data for lower respiratory effects from [Glaser et al. \(1990\)](#):

- 14 • An intraspecies uncertainty factor, UF_H , of 10 was applied to account for variability and
15 uncertainty in pharmacokinetic and pharmacodynamic susceptibility within the human
16 population. The PODs were derived from studies in inbred animal strains, and data were
17 only available for males. This is not considered sufficiently representative of the exposure
18 and dose-response of the most susceptible human subpopulations. In the case of inhaled
19 Cr(VI), insufficient information is available to quantitatively estimate variability in human
20 susceptibility; therefore, the value of 10 for the intraspecies UF was selected.
- 21 • An interspecies uncertainty factor, UF_A , of 3 was applied to account for residual uncertainty
22 in the extrapolation from laboratory animals to humans in the absence of information to
23 characterize pharmacodynamic differences between rats and humans after inhalation
24 exposure to Cr(VI). This value is adopted when an adjustment from animal to a human
25 equivalent concentration has been performed as described in EPA's *Methods for Derivation*
26 *of Inhalation Reference Concentrations and Application of Inhalation Dosimetry* ([U.S. EPA,](#)

1 [1994](#)). For these animal endpoints, an RDDR factor was used to estimate a human
2 equivalent concentration from animal data.

- 3 • A subchronic-to-chronic uncertainty factor, UF_S , of 3 was incorporated to account for the
4 less-than-lifetime exposure in [Glaser et al. \(1990\)](#) (which was a 90-day study). A value of 3
5 accounts for the potential that longer exposure may induce effects at a lower concentrations
6 ([U.S. EPA, 2002](#)).
- 7 • A LOAEL-to-NOAEL uncertainty factor, UF_L , of 3 was applied to LOAELs that were based on
8 lung cellular and histopathological responses in BAL fluid. A value less than 10 was applied
9 because these responses were highly sensitive indicators of lung injury and inflammation
10 ([Nikula et al., 2014](#); [Henderson et al., 1985](#)). Additionally, effects began to resolve after a
11 short recovery time (see Figures 4-5 and 4-6). Considering these characteristics, the
12 changes were interpreted to approximate adverse responses, albeit with some residual
13 uncertainty, which do not support application of a $UF_L = 10$.

14 For human-derived PODs using occupational data for effects in the nasal cavity:

- 15 • An intraspecies uncertainty factor, UF_H , of 3 to account for variation in susceptibility across
16 the human population and the potential that the available data may not be representative of
17 individuals who are most susceptible to the effect. The populations evaluated were mostly
18 adult male workers, which is not representative of individuals who may be most susceptible
19 to the effect. A value of $UF_H = 3$ (as opposed $UF_H = 10$) was applied because this is a portal-
20 of-entry effect of a direct-acting corrosive, and therefore the response by different
21 subpopulations from anatomic or pharmacokinetic/pharmacodynamic variability is
22 unlikely to differ ([NRC, 2001](#)).
- 23 • An interspecies uncertainty factor, UF_A , of 1 was applied because results were derived from
24 studies in humans.
- 25 • A subchronic-to-chronic uncertainty factor, UF_S , of 3 was applied. While data were not from
26 chronic lifetime exposures, the nasal effects were observed to have a short onset time ([Gibb
27 et al. \(2000a\)](#) estimated a median onset time of 22 days for ulcerated nasal septum, and
28 172 days for perforated nasal septum). Studies were generally consistent in showing that
29 these effects occur after 1–6 months of exposure. This may indicate that nasal effects occur
30 following short-term occupational exposures to high concentrations of Cr(VI), when
31 significant impaction of large particulates or mists containing Cr(VI) occurs along the nasal
32 passages. As noted in [U.S. EPA \(2020b\)](#), if a POD is based on subchronic evidence, the
33 assessment considers whether lifetime exposure could have effects at lower levels of
34 exposure. A factor of up to 10 is applied when using subchronic studies to make inferences
35 about lifetime exposure. However, a factor other than 10 may be used depending on the
36 magnitude and nature of the response and the shape of the dose-response curve ([U.S. EPA,
37 2002, 1998a, 1996a, 1994, 1991](#)). Based on the available evidence, it is considered less
38 likely that exposure to Cr(VI) outside of occupational settings (where particulates are
39 larger) would induce nasal perforations/ulcerations at much lower concentrations and
40 smaller particle sizes. (Note: the high response levels at the lowest concentration groups
41 were already accounted for in the LOAEL-to-NOAEL UF selection; the rate of the effect at
42 short onset time shows that there cannot be 10x higher incidence due to prolonged
43 exposure). As a result, a factor of $UF_S < 10$ was applied. Because it is possible that

1 prolonged exposures to high concentrations may increase the severity of existing nasal
2 lesions after they occur, a value of $UF_S = 3$ (as opposed to $UF_S = 1$) was applied.

- 3 • A LOAEL-to-NOAEL uncertainty factor, UF_L , of 10 was applied because this endpoint had a
4 high incidence at the lowest concentration across multiple studies. As a result, there was
5 higher uncertainty in the exposure-response relationship at lower concentrations.

6 For PODs derived using either animal (lower respiratory) or human (nasal effect) data:

- 7 • A database uncertainty factor, UF_D , value of 3 was applied. A value of less than 10 was
8 applied because respiratory tract effects of inhaled Cr(VI) are considered portal-of-entry
9 effects, and are therefore likely to be amongst the most sensitive based on current
10 understanding of pharmacokinetics and mechanisms following inhalation. A value of
11 $UF_D = 3$ (as opposed to $UF_D = 1$) was applied because many of the inhalation studies were
12 low confidence (particularly for noncancer effects outside the portal of entry) and limited in
13 scope (working-age and mostly male humans, and only male rodents). Due to
14 pharmacokinetic differences from oral exposure (Cr(VI) is detoxified in the gut and liver on
15 first-pass), the stronger oral database could not be used to inform the UF_D for inhalation
16 effects beyond the respiratory tract⁷³.

17 Because of the non-uniform distribution of particulates in the lung, extracellular reduction
18 of Cr(VI) by epithelial lining fluid and BAL fluid was not modeled. Inhaled particles may accumulate
19 in susceptible areas such as airway bifurcation sites ([Balashazy et al., 2003](#); [Schlesinger and
20 Lippmann, 1978](#)). Localized dosimetry of inhaled particulates in susceptible regions could be
21 significantly higher than the average regional dosimetry estimated by MPPD (ARA ([2009](#))). This
22 assessment assumes that the capacity to reduce Cr(VI) extracellularly in the lung fluid is exceeded
23 in both rodents and humans at all concentrations. Thus, uncertainty factor selections for potential
24 interspecies (UF_A) or intraspecies (UF_H) differences were not influenced by consideration of
25 differences in extracellular lung reduction at concentrations lower than those examined in the
26 available studies.

27 Table 4-11 is a continuation of Tables 4-9 and 4-10 and summarizes the application of UFs
28 to each POD to derive a candidate value for each data set. The candidate values presented in the
29 tables below are preliminary to the derivation of the organ/system-specific reference values. These
30 candidate values are considered individually in the selection of a representative inhalation
31 reference value for a specific hazard and subsequent overall RfC for Cr(VI).

⁷³The database UF is intended to account for the potential for deriving an underprotective RfD/RfC as a result of an incomplete characterization of the chemical's toxicity ([U.S. EPA, 2002](#)). While the database for respiratory tract effects following inhalation is strong, toxicity information is lacking with respect to effects outside the respiratory tract following inhalation.

Table 4-11. Effects in the lower respiratory tract and corresponding derivation of candidate values for Cr(VI)

Endpoint	POD _{HEC} (µg/m ³)	POD type	UF _A	UF _H	UF _L	UF _S	UF _D	Composite UF	Candidate value (µg/m ³)
Data for lower respiratory tract effects in male Wistar rats by Glaser et al. (1990)									
Histopathology: histiocytosis	133	LOAEL	3	10	3	3	3	1000	0.13
Histopathology: bronchioalveolar hyperplasia	41.3	BMCL _{15D}	3	10	1	3	3	300	0.14
Cell responses: LDH in BALF	133	LOAEL	3	10	3	3	3	1000	0.13
Cell responses: Albumin in BALF	170	LOAEL	3	10	3	3	3	1000	0.17
Cell responses: Total protein in BALF	133	LOAEL	3	10	3	3	3	1000	0.13
Data for effects in the nasal cavity in humans									
Ulceration of the nasal septum (median) (Gibb et al., 2000a)	3.4	LOAEL	1	3	10	3	3	300	1.1 × 10 ⁻²
Nasal mucosal pathology (Cohen et al., 1974)	0.95	LOAEL	1	3	10	3	3	300	3.2 × 10 ⁻³
Ulceration of the nasal septum (Lindberg and Hedenstierna, 1983)	0.66	LOAEL	1	3	10	3	3	300	2.2 × 10 ⁻³




Figure 4-7. Candidate values with corresponding POD and composite UF.

4.2.4. Derivation of Organ/System-Specific Reference Concentrations

1 Selection of organ/system-specific toxicity values can be based on the most sensitive
 2 outcome, a clustering of values, or a combination. Each candidate value was evaluated with respect
 3 to multiple considerations, including strength of evidence, basis of the POD (i.e., BMC vs. NOAEL vs.
 4 LOAEL), and dose-response model uncertainties. A confidence level of high, medium, or low was
 5 assigned to each osRfC based on the study(ies) used to derive the candidate value, and the
 6 reliability of the associated POD and candidate value calculation(s). Confidence in the POD and
 7 candidate value calculation(s) included considerations of the quality and variability of the exposure
 8 assessment in an epidemiology study or the exposure protocols in an animal study. Moreover,
 9 higher confidence was placed in the osRfC when the POD was identified close to the range of the
 10 observed data and the magnitude of exposure was relevant to those experienced in the general U.S.
 11 population.

12 4.2.4.1. Lower Respiratory Toxicity

13 Cr(VI)-induced cytotoxicity has been observed in epithelial tissues following both inhalation
 14 and oral exposures (see Sections 3.2.1 and 3.2.2). Inhaled Cr(VI) in particles, dust, or mists of
 15 respirable size may be absorbed into epithelial cells in the lung and lung airways. The osRfC for
 16 lower respiratory tract effects was derived from data in [Glaser et al. \(1990\)](#). Endpoints included
 17 lung cellular responses (LDH, albumin, and total protein in BAL fluid), and changes in lung
 18 histopathology (histiocytosis and bronchioalveolar hyperplasia). Because most of these endpoints
 19 had the same LOAEL and uncertainty factors, they produced essentially the same candidate value

1 (note: albumin in BAL fluid differed from the others slightly due to selection of a different RDDR
2 extrapolation region for animal-to-human extrapolation). BMD modeling was performed on data of
3 bronchioalveolar hyperplasia, and the resulting candidate value (which used a lower uncertainty
4 factor) supported the NOAEL-derived candidate values. The osRfC for lower respiratory system
5 effects was taken as the value of the candidates for cellular responses (total protein and LDH in BAL
6 fluid) and histopathology findings (histiocytosis and bronchioalveolar hyperplasia) resulting in an
7 osRfC of 0.1 µg/m³ (rounded from 0.13 µg/m³), or 1 × 10⁻⁴ mg/m³.

8 The relatively small number of *medium* confidence studies evaluating noncancer lower
9 respiratory effects decreases the confidence of this osRfC. In addition, the endpoint was derived
10 from subchronic rodent data. Human data for noncancer lower respiratory tract effects of Cr(VI)
11 are scarce because studies published prior to the availability of standardized spirometry guidelines
12 from the American Thoracic Society (first developed in 1979) ([ATS/ERS, 2019](#)) were considered
13 uninformative for pulmonary function. A factor that increased confidence was the clear dose-
14 response observed for multiple lower respiratory endpoints in rodents.

15 **4.2.4.2. Upper Respiratory Toxicity**

16 As noted earlier, Cr(VI) is cytotoxic and there is high confidence that Cr(VI) induces effects
17 at the portals of entry. Furthermore, effects in the nasal cavity of humans are well documented by
18 occupational studies ([OSHA, 2006](#)). The osRfC for effects in the upper respiratory tract were based
19 on ulcerated nasal septum observed by the [Gibb et al. \(2000a\)](#) occupational study. While the study
20 reported multiple other nasal endpoints (irritated, perforated, and bleeding nasal septum),
21 ulcerated nasal septum was chosen because of its severity and high incidence (63% of the cohort
22 having the clinical finding). [Gibb et al. \(2000a\)](#) had higher sample sizes and better exposure data
23 than the alternative studies by [Cohen et al. \(1974\)](#), and [Lindberg and Hedenstierna \(1983\)](#).

24 The Baltimore plant studied by [Gibb et al. \(2000a\)](#) had a rigorous personal and air
25 monitoring system that spanned a period of decades (see Table 4-23 in Section 4.4.5). This greatly
26 increased confidence in the reported air concentrations and worker exposures. While the [Lindberg
27 and Hedenstierna \(1983\)](#) used both area and personal air samplers, the recorded data only
28 spanned 13 days. Furthermore, the defined concentration ranges (<2–20 µg Cr(VI)/m³) by
29 [Lindberg and Hedenstierna \(1983\)](#) only constituted average workday concentrations (peak values
30 were noted to be higher, but only limited concentration data are presented). Characterization of
31 the nasal endpoints by [Cohen et al. \(1974\)](#) were highly detailed, and the study employed only air
32 measurements consistent with current NIOSH recommendations ([Andrews and O'Connor, 2020](#);
33 [NIOSH, 2013](#))⁷⁴. However, the sample size was small, and the breathing-zone air samples
34 represented only a snapshot in time (and not the long-term exposure of the workers over time).
35 The osRfC for upper respiratory tract effects is based on the LOAEL for ulcerated nasal septum in

⁷⁴This manual chapter ([Andrews and O'Connor, 2020](#)) was published by the National Institute for Occupational Safety and Health (NIOSH). Author names listed for this citation are the NIOSH editors.

1 humans reported by [Gibb et al. \(2000a\)](#), resulting in an osRfC of $1 \times 10^{-2} \mu\text{g}/\text{m}^3$ (rounded from
 2 $1.1 \times 10^{-2} \mu\text{g}/\text{m}^3$), or $1 \times 10^{-5} \text{mg}/\text{m}^3$. Because only LOAELs could be obtained from the datasets,
 3 and because the estimated effect incidences were high at the LOAEL (63%), there is uncertainty in
 4 the dose-response relationship at lower concentrations. For the [Gibb et al. \(2000a\)](#) study, effects in
 5 the nasal cavity were observed after a few months of exposure (median time on the job of 86–418
 6 days), and it is unknown how the effect severity may increase over a lifetime of exposure. These
 7 factors decrease confidence in the osRfC for upper respiratory tract effects. Additional
 8 uncertainties relevant to upper respiratory tract effects are described in detail in Section 4.2.6.
 9 Factors that increase confidence in the osRfC for upper respiratory tract effects include the
 10 consistency at which this effect was observed (generally between 2–20 $\mu\text{g Cr(VI)}/\text{m}^3$ with early
 11 onset time), and the thorough air sampling programs implemented for the Baltimore Cohort (see
 12 Table 4-23) ([Gibb et al., 2000a](#)).

Table 4-12. Organ/system-specific reference concentrations (RfCs) and overall RfC for Cr(VI)

Effect	Basis	osRfC mg/m ³	Exposure description	Confidence
Lower respiratory	Increase in total protein and LDH in BAL fluid, and histiocytosis and bronchioalveolar hyperplasia in male rats Glaser et al. (1990)	1×10^{-4}	90-day rat study	Medium
Upper respiratory	Ulcerated nasal septum of humans Gibb et al. (2000a)	1×10^{-5}	Occupational exposure	Medium
Overall RfC	Ulcerated nasal septum	1×10^{-5}	Occupational exposure	Medium

13 As noted in Section 4.2.8, the prior IRIS assessment developed separate RfCs for “chromic
 14 acid mists and dissolved hexavalent chromium aerosols,” and for “hexavalent chromium dusts.”
 15 The RfC for chromic acid mists was based on human occupational exposure to chromic acid
 16 (H_2CrO_4) at a chrome-plating facility by [Lindberg and Hedenstierna \(1983\)](#), while the RfC for dusts
 17 was based on data for rodent exposure to sodium dichromate ($\text{Na}_2\text{Cr}_2\text{O}_7$) aerosols by Glaser et al.
 18 ([1990; 1985](#)). The current database now includes noncancer data from the Baltimore chromate
 19 production plant ([Gibb et al., 2000a](#)), which studied effects in humans occupationally exposed to a
 20 variety of chromium species in dust form, including sodium chromates (Na_2CrO_4) and dichromates
 21 ($\text{Na}_2\text{Cr}_2\text{O}_7$) ([Hayes et al., 1979](#)). Human nasal effects were observed by both the [Gibb et al. \(2000a\)](#)
 22 study (chromium dusts) and the [Lindberg and Hedenstierna \(1983\)](#) study (chromic acid mists).
 23 [Lindberg and Hedenstierna \(1983\)](#) observed that ulceration of the nasal septum occurred only in
 24 the highest peak exposure group (20–48 $\mu\text{g Cr(VI)}/\text{m}^3$) and the highest daily exposure group (>2–
 25 20 $\mu\text{g Cr(VI)}/\text{m}^3$). This is supportive of [Gibb et al. \(2000a\)](#), which reported ulceration of the nasal
 26 septum at a median concentration of 10 $\mu\text{g Cr(VI)}/\text{m}^3$, and a mean concentration of 28 μg

1 Cr(VI)/m³. Therefore, the RfC for upper respiratory tract effects is applicable to both forms of
2 Cr(VI) (mists and dusts). EPA also considers the RfC for lower respiratory tract effects applicable to
3 both forms of Cr(VI).

4 The previous distinction in RfCs drawn between mists and dusts is no longer supported.
5 However, distinctions are presented via the osRfCs (upper vs. lower respiratory tracts), and these
6 are a function of particle or droplet size. It is generally known that large inhaled particles (with
7 diameter >5 µm) will deposit in the extrathoracic region, particles greater than 2.5 µm are generally
8 deposited in the tracheobronchial regions, and particles less than 2.5 µm are generally deposited in
9 the pulmonary region ([OSHA, 2006](#)). The rodent study of Na₂Cr₂O₇ aerosols by Glaser et al. ([1990](#);
10 [1985](#)) likely induced effects in the lower respiratory tract due to the small particle sizes achieved
11 by the experiment (MMAD < 0.4 µm). For the human occupational studies, particle and droplet
12 sizes may have been larger, causing a larger proportion of Cr(VI) to impact in the nasal airways.

4.2.5. Selection of the Overall Reference Concentration

13 An overall RfC of 1 × 10⁻⁵ mg/m³ was selected. The overall RfC was based on effects in the
14 upper respiratory tract (ulceration of the nasal septum), because of the two endpoints
15 representative of respiratory tract effects it is the more sensitive effect and will be protective of
16 noncancer lower respiratory tract effects and systemic effects. Additional considerations of
17 uncertainty associated with this RfC are noted here and below in section 4.2.6. It was derived using
18 a LOAEL, where the incidence of the effect was high and the time of onset relatively short. The
19 occupational cohort ([Gibb et al., 2000a](#)) consisted of a population of mostly adult males and may
20 not have included sensitive individuals. It is uncertain if or how the endpoint severity may be
21 affected by lifetime chronic exposures.

4.2.6. Uncertainties in the Derivation of Reference Concentration

4.2.6.1. Onset Time for Nasal Effects

22 The time between first exposure and development of nasal effects varies depending on the
23 severity of the effect, but nasal effects generally occur within 1 year of initial exposure for more
24 severe effects, and 1–3 months for less severe effects. [Gibb et al. \(2000a\)](#), the only prospective
25 study of the development of nasal effects reported the time to event in days (mean [median]) for
26 irritation (89 [20]), ulceration (86 [22]), perforation of the septum (313 [172]), and bleeding nasal
27 septum (418 [92]) ([Gibb et al., 2000a](#)). Cross-sectional studies reported a similar time to event
28 periods based on self-reported interview data ([Lindberg and Hedenstierna, 1983](#); [Cohen et al.,](#)
29 [1974](#)). [Cohen et al. \(1974\)](#) reported that severity of pathology increased with longer exposure
30 times and prevalence of ulceration or perforation in the study population was higher at 94% in
31 workers who had worked at the plant for more than 1 year at the time data were collected
32 compared to 57% among workers who had worked for less than a year at the same plant. More
33 recently, [Singhal et al. \(2015\)](#) showed that severity of nasal outcomes increased with years of
34

1 exposure in both chromate manufacturing and chrome electroplating workers. The early
2 onset-time, combined with the fact that incidences were high at the lowest concentration (the
3 lowest concentration in this occupational setting is still high relative to environmental levels) leads
4 to uncertainty in the extrapolation from occupational exposure to continuous lifetime exposure.

5 **4.2.6.2. Hand-to-Nose Transfer**

6 Only one of the candidate value studies reported hand-to-nose transfer of Cr(VI) originating
7 from surface touching ([Cohen et al., 1974](#)). Surface contamination of Cr(VI) throughout workplace
8 environments (including on gloves and other personal protective equipment), and detection of
9 Cr(VI) on the hands of employees have been documented ([Ceballos et al., 2017](#); [Lucas and](#)
10 [Kramkowski, 1975](#); [Cohen and Kramkowski, 1973](#)). However, no quantitative data were available
11 to adjust for this potential route of exposure.

12 **4.2.6.3. Susceptible Populations**

13 Quantitative analysis of effects in the lower respiratory tract were based on animal data,
14 while analysis of effects in the upper respiratory tract were based on occupational studies of adult
15 humans. Data for these effects were not available in susceptible populations, such as children or
16 those with preexisting respiratory conditions.

4.2.7. Confidence Statement

17 An overall confidence level of **High**, **Medium**, or **Low** was assigned to reflect the level of
18 confidence in the study(ies) and hazard(s) used to derive the RfC, the overall database, and the RfC
19 itself, as described in Section 4.3.9.2 of EPA's *Methods for Derivation of Inhalation Reference*
20 *Concentrations and Application of Inhalation Dosimetry* ([U.S. EPA, 1994](#)).

21 The confidence in the overall chronic RfC is **medium**. The RfC for upper respiratory tract
22 effects is based on the LOAEL for ulcerated nasal septum in humans reported by [Gibb et al. \(2000a\)](#),
23 resulting in an RfC of 1×10^{-5} mg/m³. While there is high confidence that inhaled Cr(VI) can induce
24 effects in the nasal cavity of humans, quantitative characterization of these endpoints have
25 uncertainties. The available studies did not have enough exposure groups or individual-level data
26 adequate for a dose-response analysis, and only LOAELs could be obtained from all the available
27 datasets. For the [Gibb et al. \(2000a\)](#) study, effects in the nasal cavity were observed after a few
28 months of exposure (median time on the job of 86–418 days), and it is unknown how the effect
29 severity may increase over a lifetime of exposure. Because the estimated effect incidences were
30 high at the LOAEL (63%), there is uncertainty in the dose-response relationship at lower
31 concentrations. As a result, the confidence in the RfC for upper respiratory effects is medium.

4.2.8. Previous IRIS Assessment: Inhalation Reference Concentration

32 The previous IRIS assessment contained two RfCs for Cr(VI). An RfC for “chromic acid mists
33 and dissolved hexavalent chromium aerosols” and an RfC for “hexavalent chromium dusts” were

1 posted on the IRIS database in 1998. As noted in Section 4.2.4, health effects induced by inhalation
2 exposure to Cr(VI) are expected to differ due to particle size distribution. These differences are
3 now reflected in the derivation of osRfCs, which are strongly dependent on particle sizes rather
4 than other chemical properties. Larger particles are more likely to affect the nasal airways, while
5 smaller particles can affect the lower airways.

6 The 1998 RfC for Cr(VI) acid mists and dissolved aerosols was based on the human study by
7 [Lindberg and Hedenstierna \(1983\)](#). A LOAEL for nasal septum atrophy of 2 µg/m³ was identified
8 based on the lower bound of the 2-20 µg/m³ range, and this value was adjusted using a continuous
9 exposure adjustment factor, and an adjustment factor for occupational and 24-hour average
10 breathing rates. This resulted in a LOAEL for continuous exposure of 0.714 µg/m³. A total
11 uncertainty factor of 90 was applied: 3-fold for extrapolation from a subchronic to a chronic
12 exposure, 3-fold for extrapolation from a LOAEL to a NOAEL, and 10-fold for interhuman variation.
13 This resulted in an RfC of 0.008 µg/m³ (8 × 10⁻⁶ mg/m³) for hexavalent chromic acid mists and
14 dissolved hexavalent chromium aerosols. The current assessment derived a different LOAEL for
15 the [Lindberg and Hedenstierna \(1983\)](#) study, because most cases (7/8) of nasal ulceration in the 2-
16 20 µg/m³ group had peak exposure levels at or above 20 µg/m³.

17 The previous RfC for Cr(VI) dusts was based on the studies by Glaser et al. ([1990](#); [1985](#)) and
18 used the modeling and data analysis of this dataset published by [Malsch et al. \(1994\)](#). [Malsch et al.](#)
19 [\(1994\)](#) developed BMCs for lung weight, lactate dehydrogenase (LDH) in BAL fluid, protein in BAL
20 fluid, albumin in BAL fluid, and spleen weight. The [Malsch et al. \(1994\)](#) analysis defined the
21 benchmark concentration as the 95% lower confidence limit on the dose corresponding to a 10%
22 relative change in the endpoint compared to the control. A continuous exposure adjustment factor
23 was applied, and the maximum likelihood model was used to fit continuous data to a polynomial
24 mean response regression, yielding maximum likelihood estimates of 36–78 µg/m³ and BMCs of
25 16–67 µg/m³. LDH was the most sensitive endpoint (BMC of 16 µg/m³) and was the basis of the
26 1998 IRIS assessment RfC for Cr(VI) dusts. An RDDR of 2.1576, derived by methods outlined in [U.S.](#)
27 [EPA \(1994\)](#), was applied to this value to extrapolate a human equivalent concentration. A total
28 uncertainty factor of 300 was applied: 10-fold for the less-than-lifetime exposure, 10-fold for
29 variation in the human population, and 3-fold to account for pharmacodynamic differences not
30 accounted for by the RDDR. This resulted in an RfC of 1 × 10⁻⁴ mg/m³ for hexavalent chromium
31 dusts, which is the same as the value derived in this assessment for lower respiratory tract effects
32 (using the same study and similar methods).

4.3. ORAL SLOPE FACTOR FOR CANCER

33 The oral slope factor (OSF) is a plausible upper bound on the estimate of risk per
34 mg/kg-day of oral exposure. The OSF can be multiplied by an estimate of lifetime exposure (in
35 mg/kg-day) to estimate the lifetime cancer risk. EPA determined under the 2005 Guidelines for

1 Carcinogen Risk Assessment, Cr(VI) is “likely to be carcinogenic to humans” via the oral route of
2 exposure.

4.3.1. Analysis of Carcinogenicity Data

3 The animal database for cancer consisted of a chronic 2-year drinking water bioassay which
4 found “clear evidence of carcinogenic activity” of Cr(VI) in male and female rats and mice ([NTP,
5 2008](#)). These results were based on increased incidences of squamous cell neoplasms in the oral
6 cavity of rats, and increased incidences of neoplasms in the small intestine of mice. The data from
7 [NTP \(2008\)](#) indicate a dose-response relationship in both species.

8 Human dose-response data for cancer via the oral route were not suitable for dose-
9 response analysis. The lack of individual estimates of exposure, the uncertain nature of the
10 mortality data, and the potential impact of confounding made it difficult to draw conclusions (see
11 Section 3.2.3). Human cancer data via the inhalation route of exposure were not used for oral slope
12 factor derivation because route-to-route extrapolations were not considered in this assessment
13 (see Protocol, Appendix A).

4.3.2. Dose-Response Analysis—Adjustments and Extrapolations Methods

14 A benchmark dose (BMD) approach was used to model the dose-response data. This
15 method is described in detail in Section 4.1.2. Because a mutagenic mode-of-action for Cr(VI)
16 carcinogenicity via the oral route of exposure (see Section 3.2.3) is “sufficiently supported in
17 (laboratory) animals” and “relevant to humans,” EPA used a linear low dose extrapolation from the
18 POD in accordance with *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)). The
19 multistage model was selected for dose-response analysis because it is consistent with low dose
20 linearity, it is sufficiently flexible for most cancer bioassay data, and its use provides consistency
21 across cancer dose-response analyses ([Gehlhaus et al., 2011](#)). Graphical results are provided in
22 Figure 4-8 below. Further details, including the modeling outputs, can be found in U.S. EPA
23 ([2021a](#)).




Figure 4-8. BMD5 3.2 graphical output of selected models for dose-response of cancer data in male and female rats and mice from [NTP \(2008\)](#).

1 For tumors of the small intestine of mice, a PBPK model was used to extrapolate the rodent
 2 dose-response model results to a human equivalent dose, using the same methodology applied for
 3 noncancer effects (Section 4.1.2). The internal dose used for mouse-to-human extrapolation was
 4 the $BW^{3/4}$ -adjusted Cr(VI) dose that is estimated to escape gastric reduction. The mean result from
 5 Monte Carlo analysis was used as the POD for the OSF, as opposed to the lower 1% value (which
 6 was used for the POD of the RfD). This is because intraspecies variability in pharmacokinetics and
 7 pharmacodynamics is not incorporated into cancer risk assessment ([U.S. EPA, 2006c](#)), with the
 8 exception for early-life considerations noted in the *Supplemental Guidance for Assessing*
 9 *Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)). Uncertainty factors are not
 10 applied during rodent-to-human extrapolation of cancer dose-response data. For comparative
 11 purposes, the $BW^{3/4}$ scaling approach without Cr(VI) gastric reduction modeling or Monte Carlo
 12 analysis is also presented. This can be interpreted as the result for a susceptible subpopulation
 13 having high gastric pH (>4.0) and Cr(VI) gastric juice reduction capacity equivalent to rodents (see
 14 Appendix C.1.5).

15 For tumors in the oral cavity of rats, there is uncertainty regarding the appropriate internal
 16 dose metric. Mice did not exhibit tumors of the oral cavity, but in a separate bioassay were

1 observed to have higher oral tissue chromium levels than rats following 90-day drinking water
 2 exposure ([Kirman et al., 2012](#)). Mice rarely exhibit oral tumors from NTP bioassays, even for
 3 chemicals inducing oral tumors in rats ([Ibrahim et al., 2021](#); [NTP, 2008](#))⁷⁵. Thus, mice may be less
 4 susceptible to tumors of the oral cavity due to factors that cannot be accounted for using PBPK
 5 modeling. There were no observed nonneoplastic lesions in the oral mucosa of rats or mice
 6 following either the chronic or subchronic high dose NTP Cr(VI) drinking water bioassays ([Witt et
 7 al., 2013](#)). Unlike for the mouse, where tumors were observed in GI organs posterior to the
 8 stomach (where most Cr(VI) reduction occurs), tumors of the rat oral cavity occur in tissues where
 9 Cr(VI) exposure is not mitigated by extracellular reduction in the stomach. As a result, species
 10 differences in Cr(VI) reduction in the stomach are not relevant for the dose-response analysis of rat
 11 oral tumors. Site-specific PBPK models of Cr(VI) kinetics in the oral cavity epithelium are not
 12 available. In the absence of an adequately developed theory or information to develop and
 13 characterize an oral portal-of-entry dosimetric adjustment factor, application of BW^{3/4} scaling is
 14 recommended ([U.S. EPA, 2011c, 2005a](#)).

4.3.3. Derivation of the Oral Slope Factor

15 The lifetime oral cancer slope factor for humans is defined as the slope of the line from the
 16 lower 95% bound on the exposure at the POD to the control response (slope factor = 0.1/BMDL₁₀).
 17 This slope, a 95% upper confidence limit represents a plausible upper bound on the true risk.
 18 Using linear extrapolation from the BMDL₁₀, human equivalent oral slope factors were derived for
 19 each sex/tumor site combination. Results for all tumor types are listed in Table 4-13.

Table 4-13. Summary of the oral slope factor derivations

Species/ sex	Model	BMR	BMD mg/kg-d ^a	BMDL mg/kg-d ^a	Extrapolation Method	Internal rodent dose mg/kg-d ^b	Internal dose POD mg/kg-d ^c	POD _{HED} mg/kg-d ^d	OSF Per mg/kg- d
Adenomas or Carcinomas in the mouse small intestine (NTP, 2008)									
Mice (M)	1° MS	10	1.44	1.05	PK	0.173	0.0274	0.319	0.313
					BW ^{3/4}	N/A	N/A	0.166	0.602
Mice (F)	1° MS	10	1.34	1.03	PK	0.169	0.0267	0.316	0.317
					BW ^{3/4}	N/A	N/A	0.163	0.613

⁷⁵Of the 24 test articles associated with site-specific neoplasia that produced positive, clear or some evidence of carcinogenicity in the oral cavity ([NTP, 2020](#)), only one (1,2,3-trichloropropane) induced tumors of the oral cavity in mice. All other test articles induced tumors in the oral cavity of male or female rats. With the exception of Cr(VI), three chemicals were found to induce both oral and small intestinal tumors (2,2-bis(Bromomethyl)-1,3-propanediol, C.I. Direct blue 15, C.I. Acid red 114), although they only induced these effects in rats. In general, tumors of the small intestine are more rare in rats (compared to mice), and tumors of the oral cavity are more rare in mice (compared to rats) (see Appendix D.2).

Species/ sex	Model	BMR	BMD mg/kg-d ^a	BMDL mg/kg-d ^a	Extrapolation Method	Internal rodent dose mg/kg-d ^b	Internal dose POD mg/kg-d ^c	POD _{HED} mg/kg-d ^d	OSF Per mg/kg- d
Squamous cell carcinoma or squamous cell papilloma in oral mucosa or tongue (NTP, 2008)									
Rats (M)	1° MS	10	6.04	3.37	BW ^{3/4}	N/A	N/A	0.923	0.108
Rats (F)	1° MS	10	4.25	2.70	BW ^{3/4}	N/A	N/A	0.645	0.155

^aUnits of administered mg/kg-d Cr(VI) dose.

^bDose escaping stomach reduction in rodent (mg/kg-d) estimated by PK modeling.

^cBW^{3/4} scaling adjustment of the internal rodent dose (dose escaping reduction multiplied by (BWA/BWH)^{1/4}, where BWH = 80 kg and BWA is set to study-specific time-weighted average (TWA) values (these same study-specific BW values were also used in the PK modeling). TWA BWA = 0.450 kg for male rats, and TWA BWA = 0.260 kg for female rats at the 2-year time period in [NTP \(2008\)](#). TWA BWA = 0.05 kg for male and female mice at the 2-year time period in [NTP \(2008\)](#).

^dPOD_{HED} in units of mg/kg-d Cr(VI) oral dose ingested by humans. For the PK method, this is the mean value of 20000 Monte Carlo PK simulations needed to achieve the internal dose POD (see Appendix C.1.5 for details). For the standard BW^{3/4} method, no additional adjustments beyond BW^{3/4} scaling of the rodent dose are applied.

1 The OSF for Cr(VI) was derived from small intestine tumors in male and female mice using
2 PBPK modeling, 0.3 (mg/kg-d)⁻¹.

3 For BW^{3/4} scaling adjustment and PBPK modeling applied above, the mean body weight
4 recommended by EPA's *Exposure Factors Handbook* ([U.S. EPA, 2011a](#)) (80 kg) was used. There is a
5 negligible difference in the PODs when using 70 kg ([U.S. EPA, 1988](#)) or 80 kg, and the final OSF
6 would be the same under either assumption.

4.3.4. Application of Age-Dependent Adjustment Factors

7 Because a mutagenic mode-of-action for Cr(VI) carcinogenicity is sufficiently supported in
8 laboratory animals and is relevant to humans (see Section 3.2.3), and in the absence of chemical-
9 specific data to evaluate differences in age-specific susceptibility, increased early-life susceptibility
10 to Cr(VI) is assumed and ADAFs should be applied, as appropriate, in accordance with the
11 *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA,](#)
12 [2005b](#)). The oral slope factor of 0.3 (mg/kg-day)⁻¹, calculated from data applicable to adult
13 exposures, does not reflect presumed early-life susceptibility to this chemical. Example calculations
14 for estimating cancer risks based on age at exposure are provided in Section 6 of the *Supplemental*
15 *Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)).

16 The *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to*
17 *Carcinogens* establishes ADAFs for three specific age groups. The current ADAFs and their
18 corresponding age groups are 10 for exposed individuals <2 years old, 3 for exposed individuals 2
19 to <16 years old, and 1 for exposed individuals ≥16 years old ([U.S. EPA, 2005b](#)). The 10- and 3-fold
20 adjustments to the slope factor are to be combined with age-specific exposure estimates when
21 estimating cancer risks from early-life (<16 years of age) exposures to Cr(VI).

1 To illustrate the use of the ADAFs established in the *Supplemental Guidance for Assessing*
 2 *Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)), OSF calculations are
 3 presented for three exposure duration scenarios, including full lifetime. For oral exposures
 4 assuming Cr(VI) exposure-response equivalence across age groups (i.e., equivalent risk from
 5 equivalent exposure levels, independent of body size), the ADAF calculation is fairly
 6 straightforward. The partial and lifetime risks (per mg/kg-d) are presented below in Table 4-14.

Table 4-14. Application of ADAFs for 70-year exposure to Cr(VI) from ages 0 to 70

Age group	ADAF	Slope factor (per mg/kg-d)	Duration adjustment	Partial risk (per mg/kg-d)
0–<2 yrs	10	0.3	2 yrs/70 yrs	0.0857
2–<16 yrs	3	0.3	14 yrs/70 yrs	0.180
≥16 yrs	1	0.3	54 yrs/70 yrs	0.231
Total risk				0.497

7
 8 Note that the partial risk for each age group is the product of the values in columns 2–4
 9 (e.g., $10 \times 0.3 \times 2/70 = 0.0857$ for exposures from age 0 to <2 years), and the total risk is the sum of
 10 the partial risks. Thus, a lifetime estimate for the OSF for exposure starting at birth is 0.5 (per
 11 mg/kg-d).

12 If calculating the cancer risk for a 30-year exposure to a constant average daily dose of
 13 0.0001 mg Cr(VI)/kg-day from ages 0 to 30 years, the duration adjustments would be 2/70, 14/70,
 14 and 14/70, and the partial risks would be ($10 \times 0.3 \times 0.0001 \times 2/70 = 8.6 \times 10^{-6}$), ($3 \times 0.3 \times 0.0001 \times$
 15 $14/70 = 1.8 \times 10^{-5}$), and ($1 \times 0.3 \times 0.0001 \times 14/70 = 6 \times 10^{-6}$), resulting in a total risk estimate of 3.3
 16 $\times 10^{-5}$.

17 If calculating the cancer risk for a 30-year exposure to a constant average daily dose of
 18 0.0001 mg Cr(VI)/kg-day from ages 20 to 50 years, the duration adjustments would be 0/70, 0/70,
 19 and 30/70, and the partial risks would be 0, 0, and ($1 \times 0.3 \times 0.0001 \times 30/70 = 1.3 \times 10^{-5}$), resulting
 20 in a total risk estimate of 1.3×10^{-5} .

4.3.5. Uncertainties in the Derivation of the Oral Slope Factor

21 Because the studies and pharmacokinetics methods used to derive the OSF are the same as
 22 those used to derive the RfD, the major uncertainties related to OSF derivation are outlined in
 23 Section 3.3 and Section 4.1.6. Additional information on susceptible populations is provided in
 24 Section 3.3.1. Briefly,

- 25 • Uncertainties persists in the PBPK models of the human and mouse stomach. Population
 26 variability in kinetic parameters is unknown, and it is likely that gastric contents and
 27 microbiota contribute to interindividual variation.

- 1 • Uncertainty in the choice of the tumor type and internal dose metric for cross-species
2 extrapolation.
- 3 • Cr(VI) detoxification in the stomach for populations with elevated stomach pH (consumers
4 of medicine to treat acid reflux, hypochlorhydria individuals) may differ from standard
5 health individuals.
- 6 • There may be higher susceptibility for carriers of mutated cystic fibrosis transmembrane
7 conductance regulator (CFTR) gene (see Sections 3.2.3.4 and 3.3.1).

8 Individuals taking medication to treat gastroesophageal reflux disease (GERD), including
9 calcium carbonate-based acid reducers and proton pump inhibitors, have an elevated stomach pH
10 during treatment. This is known to be a significant fraction of the population since up to 20% of the
11 population is afflicted by GERD, and the gastric pH for these individuals may be above 4 throughout
12 the day during successful treatment ([Delshad et al., 2020](#); [GBD 2017, 2020](#); [Lin and
13 Triadafilopoulos, 2015](#); [Burdshall et al., 2013](#); [Atanassoff et al., 1995](#)). A sensitivity analysis was
14 performed on the human model (Appendix C.1.5), assuming a baseline stomach pH = 4 (as opposed
15 to 1.3). It was found that for internal doses near those of the cancer PODs for mice, the mean⁷⁶
16 human equivalent dose for a population with baseline gastric pH = 4 would be approximately ½
17 that of the standard population with baseline pH = 1.3. As a result, the OSF for this population
18 would be 2x more stringent. Similarly, the OSF estimated by default approaches (BW^{3/4} scaling and
19 no adjustment for gastric reduction) would be health-protective for this population, since that
20 method implicitly assumes that humans and rodents have the same gastric pH (>4) and reduction
21 capacity. After rounding, the adult-based OSF for BW^{3/4} scaling (0.6 per mg/kg-d) is exactly 2x the
22 adult-based OSF estimated by PBPK modeling (0.3 per mg/kg-d). Under the BW^{3/4} scaling
23 assumption, the lifetime ADAF-adjusted value would also be exactly 2x more stringent (1.2 per
24 mg/kg-d). The infant and neonatal gastric environments and the lack of data on Cr(VI) reduction
25 during early life stages are also significant uncertainties, and are not fully addressed by the ADAF or
26 the adult-based sensitivity analyses.

27 Table 4-15 provides an overview summarizing the uncertainties and their impact on the
28 OSF.

⁷⁶Additional characteristics of the probability distributions can be found in Appendix C.1.5 and Appendix D.6.2. According to U.S. EPA *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)): “Slope factors generally represent an upper bound on the average risk in a population or the risk for a randomly selected individual but not the risk for a highly susceptible individual or group. Some individuals face a higher risk and some face a lower risk.” As a result, mean PBPK results are presented in the quantitative cancer assessment.

Table 4-15. Summary of uncertainties in the derivation of oral slope factor values for Cr(VI)

Consideration	Impact on unit risk	Decision	Justification
Target organ	↓ OSF, 3-fold, if oral tumors selected	Small intestine tumors (adenomas or carcinomas of the duodenum or jejunum or ileum in mice)	Tumor site is concordant across rats and mice in the GI tract as a whole (small intestine and mouth), increasing support for its relevance to humans. As there are no data to support any one result as most relevant for extrapolating to humans, the most sensitive result for GI tract tumors was used to derive the oral slope factor.
Data set	None	NTP (2008)	NTP (2008) is a <i>high</i> confidence study and the only to evaluate potential carcinogenicity in multiple organs and multiple species following chronic drinking water exposure.
Cross-species scaling dose metric	Alternatives could ↓ or ↑ slope factor	mg/kg-d Cr(VI) emptied from stomach, adjusted by BW ^{3/4} scaling	The amount of Cr(VI) available for absorption into the small intestine is a function of how much Cr(VI) will escape the stomach unreduced. Applying the pyloric flux dose metric defined in Thompson et al. (2014) (daily mg Cr(VI) emptied from stomach, per L small intestine) would slightly decrease the OSF (BW ^{3/4} scaling is similar as scaling by small intestine volume). Applying BW ^{3/4} scaling without taking into account interspecies differences in gastric reduction would increase the OSF by 2x.
Low dose extrapolation	↓ cancer risk estimate would be expected with the application of nonlinear low dose extrapolation	Linear extrapolation from POD (based on mutagenic MOA)	Available MOA data support linearity (mutagenicity is a primary MOA of Cr(VI)). See Appendix D.3 for an uncertainty analysis of the low dose extrapolation method
Statistical uncertainty at POD	↓ OSF 1.4-fold if BMD used as the POD rather than BMDL	BMDL (preferred approach for calculating plausible upper-bound slope factor)	Limited size of bioassay results in sampling variability; lower bound is 95% confidence interval on administered exposure at 10% extra risk of alimentary tract tumors.
Dose-response modeling	Alternatives could ↓ or ↑ slope factor	Multistage-model	No biologically based models for Cr(VI) were available. Multistage models are sufficiently flexible for most cancer bioassay data, and their use provides consistency across cancer dose-response analyses. See Appendix Section C.1.5 for additional details on the impact of alternative dose metrics.
Sensitive subpopulations	↑ OSF to unknown extent	ADAFs are recommended for early-life exposures	No chemical-specific data are available to determine the range of human pharmacodynamic variability or sensitivity. Deriving an OSF from populations with high baseline gastric pH would lead to a significantly higher OSF (over 2x higher).

4.3.6. Previous IRIS Assessment: Oral Slope Factor

1 The previous IRIS assessment for Cr(VI) was posted to the IRIS database in 1998. In that
2 assessment, EPA concluded that the oral carcinogenicity of Cr(VI) could not be determined (and
3 was thus classified as Group D under the 1986 classification guidelines). At the time, only one study
4 in humans suggested an association with stomach cancer, but other human and animal studies did
5 not report similar effects. Therefore, no oral slope factor was derived.

4.4. INHALATION UNIT RISK FOR CANCER

6 The inhalation unit risk (IUR) is a plausible upper bound on the estimate of risk per $\mu\text{g}/\text{m}^3$
7 air breathed. The IUR can be multiplied by an estimate of lifetime exposure (in $\mu\text{g}/\text{m}^3$) to estimate
8 cancer risks over a lifetime or partial lifetime.

9 In 1998, the EPA IRIS Toxicological Review of Hexavalent Chromium classified Cr(VI) as a
10 "known human carcinogen by the inhalation route of exposure" based on consistent evidence that
11 inhaled Cr(VI) causes lung cancer in humans and supporting evidence of carcinogenicity in animals
12 ([U.S. EPA, 1998c](#)). The same conclusion has since been reached by other authoritative federal and
13 state health agencies and international organizations and the carcinogenicity of Cr(VI) is
14 considered to be well-established for inhalation exposures ([TCEQ, 2014](#); [IPCS, 2013](#); [NIOSH, 2013](#);
15 [IARC, 2012](#); [CalEPA, 2011](#); [NTP, 2011](#); [OSHA, 2006](#)).

4.4.1. Analysis of Carcinogenicity Data

16 This section focuses on identifying additional appropriate studies to update the quantitative
17 exposure-response analysis and the derivation of the IUR. More recent epidemiologic studies have
18 been identified in the peer-reviewed literature which include higher quality exposure data, longer
19 follow-up times, larger sample sizes, and more sophisticated analyses than were available in 1998.
20 While the focus of the updated cancer analysis was evaluation of new information and other studies
21 that were not evaluated in the 1998 IRIS assessment, EPA did not exclude studies published prior to
22 1998. Having judged the evidence of hazard for carcinogenicity of inhaled Cr(VI) to be
23 well-established, EPA focused on studies that could inform estimation of the exposure-response
24 function which could be used to derive an IUR.

4.4.1.1. *Identification of Studies for the Derivation of a Cr(VI) Inhalation Unit Risk*

Study selection

27 A title and abstract screening of human health studies obtained from the literature searches
28 described in Sections 1.2 and 2.1, and backwards searching using reference lists of screened
29 studies, identified 64 human lung and respiratory cancer references. These studies then underwent
30 full-text screening for exposure-response data that may be informative for derivation of a revised
31 inhalation unit risk. Studies needed to be epidemiological analyses examining quantitative
32 measures of chromium exposure in relation to lung cancer incidence or mortality risk. Studies

1 were excluded if Cr(VI) measurements in air, or convertible equivalents such as CrO₃, were not
2 presented, or if group-level exposure assignments were based on job title (and not chromium
3 measurements) (see Table D-26 in Appendix D.4). Applying these criteria, there were 22 lung
4 cancer references identified as potentially informative for exposure-response analysis.

5 All 22 studies were based on occupational cohorts, and many followed the same worksites
6 or worker populations over time. For cohorts with multiple follow-up studies, EPA included only
7 the most recent follow-up, and used the prior studies to obtain information relevant to analysis of
8 data and study evaluation (see Table D-27 in Appendix D.4). Of the 22 studies, five independent
9 cohort studies evaluating Cr(VI) exposure and the risk of lung cancer were obtained after
10 restricting to the most recent cohort follow-up data (Figure 4-9 and Table 4-16). These were: (1) a
11 chromate facility in Baltimore, MD ([Gibb et al., 2020](#); [Gibb et al., 2015](#); [Gibb et al., 2000b](#)); (2) a
12 chromate facility in Painesville, OH ([Proctor et al., 2016](#)); (3) two chromate facilities in Germany
13 (Leverkusen and Uerdingen) ([Birk et al., 2006](#)); (4) the IARC multicenter cohort of welders in the
14 European Union ([Gerin et al., 1993](#)); and (5) two chromate facilities in the United States (Corpus
15 Christi TX and Castle Hayne NC) ([Luippold et al., 2005](#)). A sixth study ([AEI, 2002](#)) did not include
16 new data, but was a pooled analysis of the four plants evaluated in [Birk et al. \(2006\)](#) and [Luippold](#)
17 [et al. \(2005\)](#).




Figure 4-9. Literature screening results for studies containing exposure-response data of Cr(VI) and lung cancer.

1 The next step was to evaluate the quantitative methods used in each of the analyses. It was
 2 preferred that exposure-response analyses were conducted using estimated airborne
 3 concentrations of speciated Cr(VI) compounds from which a slope⁷⁷ and its standard error could be
 4 obtained. Studies were available that presented results from models using a continuous measure of

⁷⁷The beta coefficient describing the function of exposure-response relationship between exposure to Cr(VI) in air, on a continuous scale, and the risk of lung cancer.

1 exposure, so the two that did not (e.g., studies that only presented an overall SMR) were excluded:
 2 [Luippold et al. \(2005\)](#) and [AEI \(2002\)](#). An overview of all studies excluded for exposure-response
 3 analysis of lung cancer in humans is provided in Appendix D.4 Tables D-26 through D-28. The
 4 remaining four studies were then evaluated for risk of bias and sensitivity. Study evaluation
 5 included consideration of exposure assessment, outcome ascertainment, population selection,
 6 confounding, selective reporting, sensitivity, and data analysis [see Protocol Section 6.2 (Appendix
 7 A) for more details]. Considerable focus was placed on factors that could notably affect the
 8 magnitude and direction of the effect estimates, including potential for exposure measurement
 9 error, confounding, missing data, and the specific statistical analyses conducted. Summaries of the
 10 study evaluations are presented in Table 4-16 along with the overall confidence rating. Details of
 11 those evaluations are presented in HAWC ([click here](#)).

Table 4-16. Summary of included studies considered for the derivation of an inhalation unit risk for Cr(VI) and overall confidence classification. [Click to see interactive data graphic for rating rationales.](#)

	Reference	Study description	Study evaluation							
			Exposure	Outcome	Selection	Confounding	Analysis	Sensitivity	Sel. reporting	Overall confidence
Included	Gibb et al., (2020; 2015; 2000b)^a	Occupational cohort (<i>n</i> = 2,354 male workers) in the U.S. exposed 1950–1985 and followed until 2011.	G	G	A	A	G	A	A	High
	Proctor et al. (2016)	Occupational cohort (<i>n</i> = 714 male workers) in the U.S. exposed 1940–1972 and followed until 2011.	A	A	G	D	G	A	A	Medium
	Birk et al. (2006)	Occupational cohort (<i>n</i> = 901 male workers) in Germany exposed 1958–1998 and followed until 1998.	D	A	A	A	A	D	A	Low
	Gerin et al. (1993)	Pooled IARC multicenter occupational cohorts (<i>n</i> = 11,092 male welders) across 135 companies in 9 EU countries exposed during various periods 1946–1986.	D	A	A	D	A	A	A	Low

^aThree studies were used to represent the Baltimore, MD cohort, as they had essentially the same worker population.

12 Three studies describing one cohort were classified as *high* confidence: Gibb et al., ([2020;](#)
 13 [2015; 2000b](#)) (the Baltimore MD cohort); and one was classified as *medium* confidence: [Proctor et](#)
 14 [al. \(2016\)](#) (the Painesville OH cohort). The remaining studies were *low* confidence. The *high* and
 15 *medium* confidence studies were advanced for further consideration in the derivation of the IUR for

1 Cr(VI). Overviews of the two cohorts and their analyses are provided below followed by an analysis
2 of the preferred characteristics for candidate principal studies for IUR development from
3 occupational cohorts are described in Table 4-17.

4 Overview of the Baltimore, MD cohort

5 Chromate production at the Baltimore, MD site began in 1845 and ultimately ceased in 1985
6 ([Gibb et al., 2000b](#); [Hayes et al., 1979](#)). The original Baltimore cohort included workers who were
7 newly employed between 1945 and 1974 ([Hayes et al., 1979](#)). The current cohort was defined by
8 [Gibb et al. \(2000b\)](#) and excluded most workers who began work before August 1, 1950. This cutoff
9 date coincided with when a new chromite ore mill and roasting plant were constructed, exposure
10 mitigation measures were implemented, and extensive exposure information collection began
11 ([Gibb et al., 2015](#); [Hayes et al., 1979](#)). The vital status of 2357 workers were initially followed up
12 through death or the end of 1992 ([Gibb et al., 2000b](#)) and then extended through 2011 for 2354
13 workers ([Gibb et al., 2015](#)) for a total of 91,186 person-years at risk. The mean duration of
14 employment for the 2011 update of the cohort was 3.1 years and the mean number of years of
15 follow-up was 38.9 years. The median duration of employment for the cohort was 0.4 years and the
16 median number of years of follow-up was 39.9 years.

17 [Gibb et al. \(2000b\)](#) estimated Cr(VI) exposures for each person in each year based on job
18 titles, the time spent in each sampling zone and exposure estimates based on ~70,000
19 contemporary measurements of Cr(VI) concentration in air during the study period. Samples
20 included short-term air sampling in the workers' breathing zones from 1950–1961 followed by
21 24-hour routine measurements taken by 20 air samplers rotated through 154 fixed sites
22 throughout the facility, and personal air sampling beginning in 1977. Exposure estimates were
23 merged with work history data to estimate each workers' cumulative exposures during
24 employment. All air measurements of Cr(VI) were converted to units of mg CrO₃/m³ as a common
25 basis in [Gibb et al. \(2000b\)](#) because the prevailing regulatory standard was from the metric used by
26 the U.S. Occupational Safety and Health Administration in its past Permissible Exposure Limits for
27 chromic acid and chromates. The mean cumulative exposure⁷⁸ to CrO₃ reported in [Gibb et al.](#)
28 [\(2015\)](#) Table 2 was 0.14 mg/m³-years which converts to 72.8 µg/m³-years of Cr(VI).⁷⁹ The 25th,
29 50th, and 75th percentiles were 0.52, 5.2, and 41.6 µg/m³-years of Cr(VI). Company medical
30 records provided smoking status at the beginning of employment for 91% of the cohort
31 (Yes/No/Unknown); 74% smoked cigarettes, 16% did not smoke, and smoking status was
32 unknown for 9%. No information on pack-years of smoking or how smoking status may have
33 changed over time was available.

⁷⁸Here the cumulative exposure is unlagged and untransformed.

⁷⁹Conversion of mass of CrO₃ to mass of Cr(VI) is based on the contribution of the molecular weight (MW) of Cr to MW of CrO₃. Since the MW of Cr is 51.996 g/mol and the MW of CrO₃ is 99.99 g/mol, the conversion factor is 51.996/99.99 = 0.52. Units are further converted to µg/m³ from mg/m³ by multiplying by 1000 µg/mg.

1 [Gibb et al. \(2015\)](#) reported 217 deaths from lung cancer in this cohort compared to 133
2 expected deaths based on Maryland vital statistics for a SMR of 1.63 (95% CI: 1.42–1.86). The risk
3 of lung cancer mortality was analyzed using a Cox proportional hazards model with age as the time
4 variable and cumulative exposure as a time-varying covariate. In a model adjusted for smoking and
5 age⁸⁰, each unit increase in log₁₀ cumulative Cr(VI) exposure, lagged by 5 years, was associated with
6 a 1.255-fold ($p < 0.001$) increase in the hazard ratio.

7 [Gibb et al. \(2020\)](#) re-analyzed this cohort with the same exposure and outcome data using a
8 Cox proportional hazards model adjusted for smoking and age, but without log-transforming
9 cumulative Cr(VI) exposure. In this analysis, untransformed cumulative Cr(VI) exposure, lagged by
10 5 years, was associated with a 1.64-fold (95% CI: 1.30, 2.04) increase in the hazard ratio. [Gibb et al.](#)
11 [\(2020\)](#) also reported analyses of the untransformed cumulative Cr(VI) exposure using a conditional
12 Poisson regression approach ([Richardson and Langholz, 2012](#)) to estimate the relative risk per unit
13 of cumulative exposure (controlling for age and smoking) showing that cumulative Cr(VI) exposure,
14 lagged by 15 years, was associated with a 1.82-fold (95% CI: 1.35, 2.45) increase in the hazard ratio.

15 Overview of the Painesville, OH cohort

16 The Painesville, OH chromate production plant was in operation from 1931–1972, with
17 major renovations occurring in 1949–1950 and 1962–1964 to mitigate exposure and modernize
18 plant operations ([Proctor et al., 2004](#)). Previous analyses of the Painesville plant relied on indirect
19 measures of Cr(VI) in air, using measures of air total chromium and soluble/insoluble chromium
20 dust measurements, and only studied workers employed prior to 1940 ([Mancuso, 1997, 1975](#)). The
21 current cohort was defined by [Proctor et al. \(2016\)](#) to include workers employed after December
22 31, 1939. The vital statistics of 714 workers were followed up through death or the end of 2011 for
23 a total of 24,535 person-years at risk. The mean duration of employment for the cohort was not
24 explicitly reported but falls within the interval of five to nine years (see Table 1 in [Proctor et al.](#)
25 [\(2016\)](#) and the mean number of years of follow-up was 34.4 years.

26 The Proctor et al. ([2016; 2004](#)) studies obtained 800 measurements of airborne Cr(VI) from
27 23 historical industrial hygiene surveys for workers employed from 1940–1972. Using historical
28 records of worker job histories over time and industrial hygiene data (which included Cr(VI)
29 measurements), a job-exposure matrix (JEM) was constructed ([Proctor et al., 2004](#)). Usable data
30 were available for 1943, 1945, 1948, 1957, and 1959–1971 (excluding 1962). Exposure estimates
31 were merged with work history data to estimate each workers' cumulative exposures during
32 employment. All Cr(VI) cumulative exposure estimates were reported in mg/m³-years. The mean
33 cumulative exposure to Cr(VI) was 1.1 mg/m³-years ([Proctor et al., 2016](#)) which converts to
34 $1.1 \times 10^3 \mu\text{g}/\text{m}^3\text{-years}$ with a range of $0.2 \times 10^3 \mu\text{g}/\text{m}^3\text{-years}$ to $22.1 \times 10^3 \mu\text{g}/\text{m}^3\text{-years}$. Employee
35 records provided smoking status for 29% of the cohort (Yes/No/Unknown); of those, 22% smoked

⁸⁰In this Cox proportional hazards regression, the time scale used was age and this controls for age in the model.

1 cigarettes, 7% did not smoke, and smoking status was unknown for 72%. No information on pack-
 2 years of smoking or how smoking status may have changed over time was available.

3 [Proctor et al. \(2016\)](#) reported 77 deaths from lung cancer in this cohort which yielded a
 4 SMR of 1.86 (95% CI: 1.45–2.28) compared to lung cancer mortality in Ohio and a SMR of 2.05
 5 (95% CI: 1.59–2.50) compared to the U.S. population. [Proctor et al. \(2016\)](#) fit several models
 6 within the cohort and concluded that the linear Cox model with age as the time variable and
 7 controlling for smoking and age at hire had the best fit and reported a hazard ratio of 1.19 per
 8 mg/m³-years increase in Cr(VI) exposure based on a regression coefficient of 0.17 per mg/m³-years
 9 (95% CI: 1.11–1.27; *p* = 0.0006).

Table 4-17. Details of rationale for selecting a principal study on Cr(VI) for IUR derivation

Attribute	Preferred characteristics for candidate principal studies for the Cr(VI) IUR	Baltimore, MD Cohort	Painesville, OH Cohort
Study design characteristics	<p>Sufficient follow-up time for outcomes to develop (this can depend on the health outcome being addressed).</p> <p>Study size and participation rates that are adequate to detect and quantify health outcomes being studied (without influential biases in study population selection) are preferred.</p> <p>Use of a study design or analytic approach that adequately addresses the relevant sources of potential confounding, including age, sex, and exposures to other risk factors for the outcome of interest.</p>	<p>Total person-time at risk: 91,186 person-years</p> <p>Size of cohort: 2354 workers</p> <p>Mean follow-up time: 38.7 years</p> <p>Confounding potential: Controlled for age and smoking; no mesothelioma deaths</p> <p>Effect modification potential: No known asbestos exposure and no mesothelioma deaths.</p>	<p>Total person-time at risk: 24,535 person-years</p> <p>Size of cohort: 714 workers</p> <p>Mean follow-up time: 34.4 years</p> <p>Confounding potential: Controlled for age and smoking; six mesothelioma deaths</p> <p>Effect modification potential: asbestos exposure is strongly indicated with six mesothelioma deaths.</p>

Toxicological Review of Hexavalent Chromium

Attribute	Preferred characteristics for candidate principal studies for the Cr(VI) IUR	Baltimore, MD Cohort	Painesville, OH Cohort
Relevance of exposure paradigm	<p>Studies of chronic duration are preferred over studies of shorter exposure duration because they are most relevant to environmental exposure scenarios (potentially including both continuous exposure from ambient conditions and episodic activity-related exposures).</p> <p>When available studies observe effects across different ranges of exposures, studies that include relatively low exposure intensities that may represent conditions more similar to environmental exposures are preferred as there may be less uncertainty in extrapolation of those results to lower exposure levels.</p>	<p>Chronic duration</p> <p>Mean exposure Cr(VI): 72.8 $\mu\text{g}/\text{m}^3\text{-years}$. The 25th, 50th, and 75th% were 0.52, 5.2, and 41.6 $\mu\text{g}/\text{m}^3\text{-years}$</p>	<p>Chronic duration</p> <p>Mean exposure Cr(VI): $1.1 \times 10^3 \mu\text{g}/\text{m}^3\text{-years}$. Range from 0.2 $\mu\text{g}/\text{m}^3\text{-years}$ to $22.1 \times 10^3 \mu\text{g}/\text{m}^3\text{-years}$</p>
Measurement of exposure	<p>Emphasis is placed on the specificity of exposure assessment in time and place with a preference for greater detail where possible. Exposure measurements that are site and task specific provide generally preferred exposure information. Where available, individual-level measurements are generally preferred. Measurement techniques that are more specific to the agent of concern are preferred over less specific analytical methods. Better characterization of airborne concentrations is preferred.</p> <p>Stronger studies will often be based upon knowledge of individual work histories (job titles/tasks with consideration of changes over time); however, appropriate group-based exposure estimates may also be relevant.</p> <p>Exposure reconstruction and estimating exposures based on air sampling from other time periods and/or operations are less preferred methods of exposure estimation.</p>	<p>~70,000 measurements during 1950–1974.</p> <p>Early samples were short-term air samples in the workers’ breathing zones, later 24-hours samples from 154 fixed sites, and full-shift personal air sampling began in 1977.</p> <p>Sampling records for 9 years could not be located (1950–56, 1960–61) and those values were imputed based on existing data to model those job-specific exposure values.</p> <p>Individual work histories matched to job-specific exposure estimates based on sampling measurements.</p>	<p>800 measurements during 1940–1972.</p> <p>No personal samples.</p> <p>Uncertainty in short-term workers’ exposures: Proctor et al. (2004) “company records lacked sufficient information on these individuals to reconstruct their work histories.”</p> <p>Individual work histories matched to job-specific exposure estimates based on sampling measurements.</p>
Measurement of covariates	<p>Studies that considered the potential effects of confounding by relevant covariates are preferred over those without such consideration—unless confounding is not a major concern.</p>	<p>Age is well measured.</p> <p>Smoking status was identified for 93% of the cohort.</p>	<p>Age is well measured.</p> <p>Smoking status was identified for 28% of the cohort.</p>

Attribute	Preferred characteristics for candidate principal studies for the Cr(VI) IUR	Baltimore, MD Cohort	Painesville, OH Cohort
Measurement of effect(s)	Cancer incidence data are generally preferred over cancer mortality data (U.S. EPA, 2005a). In the absence of cancer incidence data, cancer mortality data are appropriate with preference for cause of death classified using international classification disease (ICD) codes at time of death.	Lung cancer data were obtained from death certificates. 217 lung cancer cases. No deaths from mesothelioma and no evidence of outcome misclassification.	Lung cancer data were obtained from death certificates. 77 lung cancer cases. 3 deaths from mesothelioma (of 6 total) were initially classified as lung cancer deaths
Analysis methodology	Studies conducting and reporting regression results of within cohort comparisons and those with β and $SE(\beta)$ are preferred over standardized mortality ratio (SMR) results. Occasionally studies reporting standardized rate ratio (SRR) or SMR results with sufficient specificity by exposure category may allow for post hoc estimation of β and $SE(\beta)$ —although if the lowest exposure category is defined by the lowest quantile/category of exposure, such estimates may be biased towards the null.	Analyses included multiple model forms (types of regression) with multiple parameterizations of covariates and lags for exposure.	Analyses included multiple model forms (types of regression) with multiple parameterizations of covariates and lags for exposure.

1 Table 4-17 summarizes key considerations related to study attributes that were considered
2 in the rationale for identifying the principal cohort. The Baltimore, MD cohort was (1) larger than
3 the Painesville cohort, (2) had longer follow-up time, (3) had more deaths from lung cancer, (4) had
4 no deaths from mesothelioma, despite having 66,651 additional years of person-time at risk than in
5 the Painesville cohort, suggesting lower potential for confounding by asbestos exposure, (5) had
6 more than an order of magnitude lower average exposures which can be more relevant to
7 estimating effects at lower exposures and requires less extrapolation, (6) had more air samples to
8 estimate exposures, and (7) had more complete data on smoking. EPA selected the Baltimore, MD
9 cohort as the basis for deriving the IUR.

4.4.2. Dose-Response Analysis—Adjustments and Extrapolations Methods

10 The first step towards deriving an inhalation unit risk for lung cancer was to identify
11 candidate effect estimates (i.e., beta coefficients from the regression analyses) from studies of the
12 principal cohort. Once the lung cancer effect estimates have been obtained, they are adjusted for
13 differences in air volumes between workers and other populations due to exposure frequency and
14 breathing rates. Conversions between occupational Cr(VI) exposures and continuous
15 environmental exposures were made to account for differences in the number of days exposed per
16 year, and in the amount of air inhaled per day. Those adjusted values can be applied to the U.S.
17 population as a whole in EPA life-table analyses. These life-table analyses allow for the estimation
18 of an exposure concentration associated with a specific extra risk of cancer incidence caused by

1 inhalation of Cr(VI); the specific extra risk is called the benchmark response (BMR) and a value of
2 1% is standard for cancer outcomes in people. Those exposure concentrations serve as points of
3 departure (POD) from which IURs can be extrapolated. Non-occupational exposure adjustment and
4 methods applied for the life-table analysis are described in detail in Section 4.4.3.

5 Because a mutagenic mode of action for Cr(VI) carcinogenicity (see Section 3.2.3) is
6 “sufficiently supported in (laboratory) animals” and “relevant to humans,” EPA used a linear low
7 dose extrapolation from the POD in accordance with Guidelines for Carcinogen Risk Assessment
8 ([U.S. EPA, 2005a](#)).

9 **4.4.2.1. Cancer Risk Models for Cr(VI) Inhalation Exposures**

10 A cancer risk model predicts the probability of cancer in an individual with a specified
11 history of exposure to a cancer-causing agent. In the case of inhalation exposure to Cr(VI), the lung
12 cancer effects are of chief concern, and workers’ individual cumulative exposure to Cr(VI) are used
13 to predict cancer risk. Different types of regression analyses were used to model the lung cancer
14 effect of Cr(VI) in the Baltimore, MD cohort. The model forms are described below.

15 The Cox proportional hazards model ([Cox, 1972](#)) is one of the most commonly used
16 statistical models for the epidemiologic analysis of survival and mortality in cohort studies with
17 extensive follow-up, including studies of the Baltimore, MD cohort ([Gibb et al., 2020](#); [Gibb et al.,
18 2015](#); [Gibb et al., 2000b](#)). The Cox proportional hazards model assumes that a function of
19 covariates (e.g., exposures) result in hazard functions that are a constant proportion of the baseline
20 hazard function in unexposed individuals over some timescale, typically calendar time or age
21 (e.g., the background age-specific rates of lung cancer in the population). One of the strengths of
22 this model is that knowledge of the baseline hazard function is not necessary, and no particular
23 shape is assumed for the baseline hazard; rather, it is estimated nonparametrically.

24 Another methodology used to analyze the Baltimore, MD cohort ([Gibb et al., 2020](#)) was the
25 conditional Poisson regression approach proposed by Richardson and Langholz (R&L) to estimate
26 the relative risk per unit of cumulative exposure ([Richardson and Langholz, 2012](#)). The R&L
27 approach maximizes a conditional likelihood expression that allows for covariates like age and
28 smoking to be included in the model, but avoids estimation of all the stratum-specific parameters
29 by treating them as nuisance terms. This property is made possible by separating and then
30 cancelling the nuisance terms in the likelihood function. Thus, the R&L approach models the effects
31 of age and smoking when estimating the effect of Cr(VI), but does not yield the specific effect
32 estimates for age and smoking.

33 **4.4.2.2. Cancer Risk Parameters**

34 The Cox regression results from the Baltimore, MD cohort are shown in Table 4-18.

Table 4-18. Results of Cox proportional hazards modeling of cumulative chromium exposure (mg CrO₃/m³-years) by different lag periods (age and smoking are included in model). Table adapted from Table 1 of [Gibb et al. \(2020\)](#).

Lag period (y)	β per mg CrO ₃ /m ³ -year	SE(β)	Hazard ratio Exp(β)	95% CI (β)	-2 log(L)
0	0.4712	0.1133	1.60	1.28-2.00	2830.23
5	0.4868	0.1145	1.63	1.30-2.04	2829.80
10	0.4939	0.1197	1.64	1.30-2.07	2830.52
15	0.4812	0.1333	1.62	1.25-2.10	2833.03

Note: 1 mg CrO₃ = 0.520 mg Cr(VI); CrO₃/m³-year = (CrO₃/m³)(year).

1 The measure of fit (-2 Log(L)) of the Cox proportional hazards models of the lung cancer
 2 risk adjusted for age and smoking were very similar for all lag periods, although the fit for the
 3 5-year lag was slightly better than for the other lags—although not statistically better. The
 4 rationale for the lag period is that there is often a latency period for cancer beginning with the
 5 initial incidence of cancer and extending to the time of cancer mortality. In this conceptual model,
 6 the exposures that are experienced by the individual after cancer has begun are no longer expected
 7 to cause lung cancer, and thus those exposures may not be etiologically relevant. Here the results
 8 show little difference in effect size across the different lag times. This is likely due to the fact that
 9 exposures ceased in 1982 and follow-up continued until 2011 so there was little difference in
 10 lagged and unlagged exposures. Section 4.4.5 provides a sensitivity analysis across the different lag
 11 lengths.

12 The lung cancer effect estimate for the 5-year lag in Table 4-18 above ([Gibb et al., 2020](#)) is
 13 in units of per mg CrO₃/m³-year and was converted to unit of per μg Cr(VI)/m³-year as follows:

$$\begin{aligned}
 & 1 \text{ mg CrO}_3/\text{m}^3\text{-year} \cdot [0.52 \text{ mg Cr(VI)}/\text{mg CrO}_3] \cdot [1000 \text{ } \mu\text{g}/\text{mg}] = 520 \text{ } \mu\text{g Cr(VI)}/\text{m}^3\text{-year} \\
 & 5\text{-year lag } \beta_{\text{Cr(VI)}} = 0.4868 \text{ per mg CrO}_3/\text{m}^3\text{-year} = 0.4868/(1 \text{ mg CrO}_3/\text{m}^3\text{-year}) \\
 & = 0.4868/(520 \text{ } \mu\text{g Cr(VI)}/\text{m}^3\text{-year}) \\
 & = 9.362 \times 10^{-4} \text{ per } \mu\text{g Cr(VI)}/\text{m}^3\text{-year}
 \end{aligned}$$

18 The inhalation unit risk is derived from the one-sided 95th% upper bound of β. [Gibb et al.](#)
 19 [\(2020\)](#) reported a two-sided 95% confidence interval as is the standard practice in the
 20 epidemiologic literature (i.e., from the 2.5th% to the 97.5th% bounds). EPA estimated the
 21 one-sided 95th% upper bound (UB) of β by assuming the distribution of β was normally distributed
 22 (which is appropriate for the Cox Proportional Hazards model) as follows:

$$\begin{aligned}
 & \text{One-sided 95th\% UB of } \beta = \beta + 1.645(\text{se}(\beta)) \\
 & = 0.4868 \text{ per mg CrO}_3/\text{m}^3\text{-year} + 1.645 \cdot (0.1145 \text{ per mg CrO}_3/\text{m}^3\text{-year})
 \end{aligned}$$

1 = 0.6752 per mg CrO₃/m³-year
 2 = (0.6752 per mg CrO₃/m³-year) / (520 µg Cr(VI)/m³-year)
 3 = 1.298 × 10⁻³ per µg Cr(VI)/m³

4
 5 This one-sided 95th% upper bound of β from the Cox Proportional Hazards analysis in [Gibb](#)
 6 [et al. \(2020\)](#) will be used to derive an estimate of the IUR using a life-table analysis.
 7 R&L regression results from the Baltimore, MD cohort are shown in Table 4-19.

Table 4-19. Results for relative exponential exposure-response (R&L) model adjusted for age and smoking. Table adapted from Table 2 of [Gibb et al. \(2020\)](#).

# Age groups ^a	Lag period (y)	β	SE(β)	RR = exp(β)	95% CI(β)	-2 log(L)
1	0	0.454	0.098	1.57	1.30–1.91	9283.51
	5	0.454	0.098	1.57	1.30–1.91	9283.62
	10	0.451	0.101	1.55	1.29–1.91	9286.50
	15	0.414	0.108	1.51	1.22–1.87	9291.89
2	0	0.454	0.098	1.57	1.30–1.91	9283.50
	5	0.461	0.098	1.59	1.31–1.92	9282.79
	10	0.463	0.100	1.59	1.31–1.93	9284.08
	15	0.474	0.107	1.60	1.30–1.98	9286.46
3	0	0.915	0.047	2.50	2.28–2.74	8854.75
	5	0.933	0.048	2.59	2.31–2.79	8846.57
	10	0.982	0.050	2.67	2.42–2.94	8845.78
	15	1.088	0.056	2.97	2.66–3.31	8848.71
4	0	0.506	0.133	1.66	1.28–2.15	4327.08
	5	0.522	0.133	1.69	1.30–2.19	4326.07
	10	0.548	0.139	1.73	1.32–2.27	4325.97
	15	0.599	0.152	1.82	1.35–2.45	4325.95
5	0	1.179	0.036	3.25	3.03–3.49	8153.85
	5	1.246	0.036	3.48	3.24–3.73	8091.17
	10	1.387	0.040	4.00	3.70–4.33	8035.39
	15	1.559	0.044	4.75	4.36–5.18	8030.41
6	0	1.142	0.036	3.13	2.92–3.36	8253.33
	5	1.164	0.036	3.20	2.98–3.44	8235.51
	10	1.200	0.038	3.39	3.08–3.58	8238.56
	15	1.375	0.043	3.95	3.64–4.30	8223.38

Note: 1 mg CrO₃ = 0.520 mg Cr(VI).

^aOne age group (all ages, 15-96); two age groups (≥15 to 65 and ≥65); three age groups (ages ≥15 to 60, ≥60 to ≥70); four age groups (≥15 to 60, ≥60 to 65, ≥65 to 75, and ≥75); five age groups (ages ≥15 to 60, ≥60 to 65, ≥65 to 70, ≥70 to 75, and ≥75); six age groups (ages ≥15 to 55, ≥55 to 60, ≥60 to 65, ≥65 to 70, ≥70 to 75, and ≥75).

8 The R&L analysis based on four age groups fit the Baltimore, MD cohort better than the
 9 analyses based on other numbers of age groups as evidenced by the lower fit statistics, and within
 10 the 4-age group analysis, the fits were very similar for all lag periods, although the fit for the

1 15-year lag was slightly better than for the other lags—although not statistically better. Section
2 4.4.5 provides a sensitivity analysis across the different lag lengths.

3 The lung cancer effect estimate for the 15-year lag in Table 2 from [Gibb et al. \(2020\)](#) is
4 0.599 per mg CrO₃/m³-year and was converted to unit of per μg Cr(VI)/m³-year as follows:

$$5 \quad 1 \text{ mg CrO}_3/\text{m}^3\text{-year} \cdot [0.52 \text{ mg Cr(VI)}/\text{mg CrO}_3] \cdot [1000 \text{ } \mu\text{g}/\text{mg}] = 520 \text{ } \mu\text{g Cr(VI)}/\text{m}^3\text{-year}$$
$$6 \quad 5\text{-year lag } \beta_{\text{Cr(VI)}} = 0.599 \text{ per mg CrO}_3/\text{m}^3\text{-year} = 0.599/(1 \text{ mg CrO}_3/\text{m}^3\text{-year})$$

$$7 \quad = 0.599/(520 \text{ } \mu\text{g Cr(VI)}/\text{m}^3\text{-year})$$

$$8 \quad = 1.152 \times 10^{-3} \text{ per } \mu\text{g Cr(VI)}/\text{m}^3\text{-year}$$

$$9 \quad \text{One-sided 95th\% UB of } \beta = \beta + 1.645(\text{se}(\beta))$$

$$10 \quad = 0.599 \text{ per mg CrO}_3/\text{m}^3\text{-year} + 1.645 \cdot (0.152 \text{ per mg CrO}_3/\text{m}^3\text{-year})$$

$$11 \quad = 0.849 \text{ per mg CrO}_3/\text{m}^3\text{-year}$$

$$12 \quad = (0.849 \text{ per mg CrO}_3/\text{m}^3\text{-year}) / (520 \text{ } \mu\text{g Cr(VI)}/\text{m}^3)$$

$$13 \quad = 1.633 \times 10^{-3} \text{ per } \mu\text{g Cr(VI)}/\text{m}^3$$

14 This one-sided 95th% upper bound of β from the R&L analysis in [Gibb et al. \(2020\)](#) will be
15 used to derive an estimate of the IUR using a life-table analysis.

4.4.3. Inhalation Unit Risk Derivation

16 4.4.3.1. Life-Table Analysis to Derive an IUR

17 The β coefficients (slopes) for lung cancer risks attributable to cumulative exposures to
18 Cr(VI) from the [Gibb et al. \(2020\)](#) are used in life-table analyses to predict the risk of cancer as a
19 result of the exposure over a lifetime. The life-table analysis divides a lifetime into small
20 age-specific intervals and sums the risks of lung cancer incidence in each age group in the presence
21 and absence of Cr(VI) exposure. This is done to assess the age-specific risk of lung cancer incidence
22 while accounting for competing causes of death. The lung cancer risk in a particular year of life is
23 conditional on the assumption that the individual is alive, and at risk of incident lung cancer, at the
24 start of the year for each age-specific interval. Consequently, the risk of a Cr(VI)-related lung cancer
25 within a specified year of life is calculated as a function of (1) the probability of being alive at the
26 start of the year, (2) the background probability of getting lung cancer, and (3) the increased risk of
27 getting lung cancer from Cr(VI) exposure within the specified year. The lifetime risk is then the
28 sum of all the yearly risks. This procedure is performed to calculate the lifetime risk both for an
29 unexposed individual (R0) and for an individual with exposure to Cr(VI) (Rx).

30 “Extra risk” for lung cancer is a calculation of risk which adjusts for background incidence
31 rates of lung cancer, by estimating risk at a specified exposure level and is calculated as follows
32 ([U.S. EPA, 2012a](#)):

1 risk; and (4) adding a macro to solve for the EC₀₁ or the LEC₀₁. The SAS codes for performing the
2 lung cancer life-table calculations are provided in Appendix E.

3 The adjustment factors to account for differences between occupational exposures and non-
4 occupational exposure follow EPA guidance ([U.S. EPA, 2009](#)) that acknowledges there are
5 differences in breathing rates between workers (10 m³ per 8-hour day) and non-workers (20 m³
6 per 24-hour day) and that workers are exposed 240 days per year while non-workers are exposed
7 365 days per year ([U.S. EPA, 2016b, 2014e, 2012d, 2011d](#)). Thus, a worker is assumed to inhale
8 2,400 m³ of workplace air per year while a non-worker is assumed to inhale 7,300 m³ of air per
9 year. Since the effect estimates for Cr(VI) effects on lung cancer risks are in terms of ‘per
10 occupational year’, the life-table procedure adjusts for the differences in air volume breathed per
11 year to represent non-occupational exposures.

12 **4.4.3.2. Summary of Lifetime Unit Risk Estimates—Not Accounting for Assumed**
13 **Increased Early-Life Susceptibility**

14 The derivation of the unit risk—not accounting for assumed increased early-life
15 susceptibility—is based upon the two main regression modeling results in [Gibb et al. \(2020\)](#):
16 (1) the Cox Proportional Hazard model with exposure lagged by 5 years, and (2) the R&L model
17 with four age groups and exposure lagged by 15 years. Note that this estimate of the unit risk is
18 based on the assumption that the relative risks or hazard ratios are independent of age.

**Table 4-20. Calculation of lifetime cancer unit risk estimate not accounting for
assumed increased early-life susceptibility**

Source	Table in original publication	β (Slope) per mg CrO ₃ /m ³		β (Slope) per μg Cr(VI)/m ³		Exposure Concentration associated with BMR (1% Extra Risk) [μg Cr(VI)/m ³]		Lifetime Unit Risk [per μg Cr(VI)/m ³]	
		MLE	95% UB	MLE	95% UB	EC ₀₁ MLE	LEC ₀₁ 5% LB	MLE	95% UB
		Gibb et al. (2020) Cox PH Model	Table 1 5-year lag	0.487	0.675	9.36 x 10 ⁻⁴	1.30 x 10 ⁻³	1.25	0.899
Gibb et al. (2020) R&L Model	Table 2 4 age groups 15-year lag	0.599	0.849	1.15 x 10 ⁻³	1.63 x 10 ⁻³	1.35	0.952	7.41 x 10 ⁻³	1.05 x 10 ⁻²

19 The results from the Cox model yielded an estimate of the lifetime unit risk of 1.11 x 10⁻²
20 per μg Cr(VI)/m³ while the results from the R&L model yielded an estimate of the lifetime unit risk
21 of 1.05 x 10⁻² per μg Cr(VI)/m³. These two estimates are very close to each other and thus mutually
22 support one another. EPA advanced the estimate of the lifetime unit risk derived from the Cox
23 proportional hazards models with an exposure lag of 5 years for the following reasons: (1) the Cox

1 proportional hazards model is a well-established method for epidemiological analyses that is
2 commonly used in cohort studies, and (2) the results from this type of model have been used as the
3 basis for EPA IRIS IUR derivations for lung cancer ([U.S. EPA, 2014e](#)), breast cancer ([U.S. EPA,](#)
4 [2016b](#)) and lymphohematopoietic cancer ([U.S. EPA, 2016b](#)). In the absence of evidence of early-life
5 susceptibility, the lifetime unit risk for lung cancer caused by inhalation exposure to Cr(VI) is
6 considered to be best estimated as 1.11×10^{-2} per $\mu\text{g Cr(VI)}/\text{m}^3$.

7 Because a mutagenic mode of action for Cr(VI) carcinogenicity (see Section 3.2.3) is
8 “sufficiently supported in (laboratory) animals” and “relevant to humans,” and as there are no
9 chemical-specific data to evaluate the differences between adults and children, increased early-life
10 susceptibility should be assumed. If there is early-life exposure, age-dependent adjustment factors
11 (ADAFs) are applied, as appropriate, in accordance with the EPA’s *Supplemental Guidance for*
12 *Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)). See Section 4.4.4
13 below for more details on the application of ADAFs.

4.4.4. Application of Age-Dependent Adjustment Factors

14 The derivation of the IUR when increased early-life susceptibility should be assumed is
15 based on the same main Cox proportional hazards regression modeling results with exposure
16 lagged by 5 years ([Gibb et al., 2020](#)). The process for deriving an IUR when increased early-life
17 susceptibility should be assumed involves an initial estimation of a unit risk based only on
18 adult-only exposures ([U.S. EPA, 2016b](#)), followed by the application of age-dependent adjustment
19 factors to age-specific risks for children under age 16 years, and a summary of risks across all ages
20 weighted by the age-dependent adjustment factors. This is accomplished with several steps.

- 21 • The first step is to apply the effect estimate (i.e., the MLE β) from the Baltimore, MD cohort
22 and the 95% UB in a life-table initiating exposures at 16 years of age—instead of at birth.
23 This process estimates the unit risks for the 54-year period between age 16 years and age
24 70 years (IRIS’ assumption of a lifetime).
- 25 • The values of the EC01 and LEC01 are derived in the same way using the life-table
26 procedure.
- 27 • These EC01 and LEC01 values are then divided into the benchmark response of 1% to
28 compute the ‘adult-exposure-only’ unit risk estimates.
- 29 • The ‘adult-exposure-only’ unit risk estimates are multiplied by 70/54 to rescale the 54-year
30 adult period to 70 years. This yields the ‘adult-based’ lifetime unit risk.
- 31 • The last step is to apply the ADAFs which adjust the ‘adult-based’ lifetime age-specific unit
32 risk for children ages less than two years upwards by 10-fold during those years of life, and
33 the unit risk for children ages 2–15 upwards by 3-fold during those years of life, and then
34 applies the unadjusted ‘adult-based’ lifetime unit risk for people aged 16–70 during those
35 years of life. The weighted sum of these three partial unit risks is the ADAF-adjusted
36 lifetime IUR.

Table 4-21. Calculation of total cancer unit risk estimate from adult-only exposure

Source	β (Slope) per μg Cr(VI)/m ³		Exposure concentration associated with BMR (1% Extra Risk) Starting exposure at age 16 years [μg Cr(VI)/m ³]		Adult-exposure-only unit risk [per μg Cr(VI)/m ³] (54 years)		Adult-based unit risk [per μg Cr(VI)/m ³] (70 years)	
	MLE	95% UB	EC ₀₁ (16+)	LEC ₀₁ (16+)	MLE	95% UB	MLE	95% UB
			MLE	5% LB				
Gibb et al. (2020) Cox PH Model 5-year lag	9.36 × 10 ⁻⁴	1.30 × 10 ⁻³	1.64	1.18	6.12 × 10 ⁻³	8.48 × 10 ⁻³	7.93 × 10 ⁻³	1.10 × 10 ⁻²

1 The results from the Cox model yielded an estimate of the ‘adult-based’ unit risk of 1.10 ×
 2 10⁻² per μg Cr(VI)/m³. Application of the ADAFs to the ‘adult-based’ (rescaled as discussed above)
 3 unit risk estimate for Cr(VI) for a lifetime inhalation exposure scenario is presented below. The
 4 unit risk for each age group is the product of the values for the ADAF, the adult-based unit risk, and
 5 the duration adjustment in columns 2–4 [e.g., 10 × (1.10 × 10⁻²) × 2/70 = 3.14 × 10⁻³], and the total
 6 risk is the sum of the partial risks. This lifetime inhalation unit risk estimate for a constant
 7 exposure of 1 μg Cr(VI)/m³ is adjusted for potential increased early-life susceptibility, assuming a
 8 70-year lifetime.

Table 4-22. Total cancer risk from exposure to constant Cr(VI) exposure level of 1 μg/m³ from ages 0–70 years, adjusted for potential increased early-life susceptibility

Age group	ADAF	Adult-based unit risk (per μg Cr(VI)/m ³)	Duration adjustment	Unit risk [per μg Cr(VI)/m ³]
0–<2 years	10	1.10 × 10 ⁻²	2 years/70 years	3.14 × 10 ⁻³
2–<16 years	3	1.10 × 10 ⁻²	14 years/70 years	6.60 × 10 ⁻³
≥16 years	1	1.10 × 10 ⁻²	54 years/70 years	8.49 × 10 ⁻³
Total Lifetime Risk				1.82 × 10⁻²

The lifetime inhalation unit risk for Cr(VI) is 1.82 × 10⁻² per μg Cr(VI)/m³. This value is rounded to 2 × 10⁻² per μg Cr(VI)/m³.

9
 10 If calculating the cancer risk for a 30-year exposure to a constant average concentration of
 11 0.01 μg Cr(VI)/m³ from ages 0 to 30 years, the duration adjustments would be 2/70, 14/70, and
 12 14/70, and the partial risks would be (10 × 0.011 × 0.01 × 2/70 = 3.1 × 10⁻⁵), (3 × 0.011 × 0.01 ×

1 14/70= 6.6×10^{-5}), and ($1 \times 0.011 \times 0.01 \times 14/70 = 2.2 \times 10^{-5}$), resulting in a total risk estimate of
2 1.2×10^{-4} .

3 If calculating the cancer risk for a 30-year exposure to a constant average average
4 concentration of $0.01 \mu\text{g Cr(VI)}/\text{m}^3$ from ages 20 to 50 years, the duration adjustments would be
5 0/70, 0/70, and 30/70, and the partial risks would be 0, 0, and ($1 \times 0.011 \times 0.01 \times 30/70 = 4.7 \times 10^{-5}$),
6 resulting in a total risk estimate of 4.7×10^{-5} .

4.4.5. Uncertainties in the Derivation of the Inhalation Unit Risk

7 Several potential sources of uncertainty were identified in the derivation of the Cr(VI)
8 inhalation unit risks. As discussed below, these were not found to be major influences in this
9 evaluation—including two potential sources of uncertainties generally associated with larger
10 uncertainty (model uncertainty and low dose extrapolations). Uncertainties related to genetics,
11 physiological differences, and particle deposition have been discussed previously in this
12 assessment (see Sections 3.1.1.2 and 3.3.1), and the inhalation unit risk represents an upper bound
13 on the average risk in a population ([U.S. EPA, 2005a](#)).

14 Sources of uncertainty in this assessment are outlined below.

4.4.5.1. Uncertainty in Exposure Assessment

15 Routine air sampling was initiated after construction of the new Baltimore, MD facility in
16 1950 and followed written documentation specifying strategies for air sampling. Sampling was
17 intended to represent the “typical/usual exposures” to workers ([Gibb et al., 2000b](#)). Table 4-23
18 below details the sampling regimen over time. In constructing the job-exposure-matrix to assign
19 individual exposure for each worker, [Gibb et al. \(2000b\)](#) relied on approximately 70,000
20 measurements across the study period. While the sampling regimes changed over time and can
21 reasonably be expected to have improved in quantity and specificity, the samples were collected
22 methodically and used the same analytical method for assessing Cr(VI) concentration in dust over
23 the study period ([Gibb et al., 2000b](#)).

24 These exposure estimates were used to construct a job-exposure-matrix (JEM) for each of
25 the 114 job titles in each of the 36 years of the study period. According to [Gibb et al. \(2000b\)](#), the
26 JEM was “virtually complete” for the later years (1971–1985) and “fairly complete” for the early
27 years from 1950–1956 and 1960–1961. While the sampling records for nine years could not be
28 located, those values were imputed based on existing data to model those job-specific exposure
29 values. EPA considered uncertainty to be low for the 24 out of 36 years when sampling records was
30 available and low-to-medium for the missing years that were bookended by actual sampling values.
31 As exposures may reasonably be assumed to have decreased over the study period as industrial
32 hygiene practices improved, the interpolation between higher and lower exposure periods was
33 likely to have captured those interim exposure concentrations.
34

Table 4-23. Overview of air sampling program for the Baltimore cohort evaluated by Gibb et al., (2015; 2000b)

Exposure measurement system	Years implemented	Frequency and duration
Airborne dust via high-volume air sampling pumps and impingers, with sampling wand held in worker breathing zone.	1950–1961	Short-term samples (tens of minutes).
24-hour routine measurements (fixed-site monitors) using 20 tape air samplers (Research Appliance Co., Allison Park, PA). Observation of how much workers spent in the vicinity of each of these monitors.	Mid-1960s–1979	24 1-hour samples. Samplers rotated through 154 fixed sites representing exposure zones.
	1979–1985	After 1979, frequency reduced to 8 3-hour samples, and number of fixed sites reduced to 27.
Routine personal sample collection using NIOSH standard method P and CAM 169 (NIOSH, 1972).	1977–1985	Full-shift sampling.

1 **4.4.5.2. Uncertainty in the Exposure Metric**

2 [Gibb et al. \(2000b\)](#) fit multiple models of lung cancer risks using untransformed and
3 transformed cumulative exposure to Cr(VI) with log base-10 transformed Cr(VI) providing the
4 better overall model fit. [Gibb et al. \(2015\)](#) also reported updated lung cancer results based on log
5 base-10 of cumulative exposure to Cr(VI). While log transformation of concentration-based
6 cumulative exposure is commonplace in epidemiological analyses because those concentrations are
7 often log-normally distributed, risk calculation based on log-transformed exposure suffer from
8 exposure-response irregularities such as zero risk whenever the exposure has a numerical value of
9 one (in any units) [i.e., $\log_{10}(1) = 0$ or $\ln(1) = 0$], and when risks are extrapolated below one unit of
10 exposure, the sign of the risk estimate flips from positive to negative such that lower exposure
11 appears to be health protective as an artifact of the transformation. For the purpose of estimating
12 an IUR, exposure-response results in terms of untransformed cumulative exposures to Cr(VI) can
13 be more useful than log-transformed exposures. [Gibb et al. \(2020\)](#) reported risks of lung cancer
14 associated with untransformed cumulative Cr(VI). While a transformed exposure may provide a
15 better overall model across the entire range of exposures in a study, as in the case of [Gibb et al.](#)
16 [\(2020\)](#), those model results did not meet the needs for estimating an IUR based on a POD in the low
17 exposure range, and thus EPA selected the results from the models based on untransformed
18 cumulative Cr(VI)—even if there is some uncertainty concerning the relative fits of different
19 exposure metrics.

20 The two candidate IUR’s are based on the same cohort that was most highly rated and
21 preferred on the majority of additional considerations for exposure-response, there are some
22 aspects of the specific modeling details that were further considered in order to judge their
23 potential impact on the IUR. Specifically, the exposure lags and the number of age groups that

1 yielded the better overall fits, often the fit differences were small enough so as to be essentially
 2 equal in fit. Three additional sets of candidate unit risks were derived to show the differences in
 3 those values had those combinations been selected instead, and to allow for comparison between
 4 the two candidate IURs on a common basis of exposure lag length.

Table 4-24. Variation in unit risks among the Cox Proportional Hazards model results by lag length

Cox proportional hazards	Lag period (y) in Gibb et al. (2020) matched in life-table	
Lag period (y) in Gibb et al. (2020)	Lifetime unit risk (95%UB) without ADAFs [per $\mu\text{g Cr(VI)}/\text{m}^3$]	Lifetime unit risk (95%UB) with ADAFs [per $\mu\text{g Cr(VI)}/\text{m}^3$]
0	1.16×10^{-2}	2.00×10^{-2}
5	1.11×10^{-2}	1.82×10^{-2}
10	1.05×10^{-2}	1.64×10^{-2}
15	9.82×10^{-3}	1.47×10^{-2}

5 **4.4.5.3. Uncertainty in the Outcome Metric**

6 Lung cancer mortality was ascertained from death certificates according to specific codes
 7 from the International Classification of Diseases—eighth edition, and this coding system and those
 8 of previous editions have been stable over time. Uncertainty is considered to be very low for lung
 9 cancer mortality.

10 **4.4.5.4. Uncertainty Due to Length of Follow-up**

11 There is little potential uncertainty regarding the length of follow-up for cancer mortality.
 12 The hire dates among this cohort ranged from August 1, 1950 to December 31, 1974 (the mean date
 13 of hire was mid-1957) ([Gibb et al., 2000b](#)). Follow-up continued until the date of death, age
 14 96 years, or December 31, 2011, whichever occurred first. Therefore, the range of follow-up was
 15 from 37 to 61 years, with a mean of more than 38 years.

16 **4.4.5.5. Uncertainty in Model Form**

17 For lung cancer mortality, the Cox proportional hazards model is a well-established method
 18 for epidemiological analyses that is commonly used in cohort studies because this type of survival
 19 analysis takes into account differences in follow-up time among the cohort and is approximately
 20 linear at low exposures. This model form allows for the evaluation and control of important
 21 potential confounding factors such as age and smoking, and for the modeling of exposure as a
 22 continuous variable. There is little uncertainty in the choice of model form. Additionally, the R&L
 23 model is an alternative approach to the Poisson model and results from this modeling yielded
 24 similar results which further reduces the uncertainty in the choice of model form.

1 **4.4.5.6. *Uncertainty in Control of Potential Confounding in Modeling Lung Cancer***
2 ***Mortality***

3 It is well known that smoking is a strong independent risk factor for lung cancer.
4 Additionally, tobacco smoke contains chromium ([Fresquez et al., 2013](#)), and therefore smokers are
5 expected to be exposed to higher levels of total chromium than nonsmokers. Company medical
6 records provided smoking status at the beginning of employment for 91% of the cohort
7 (Yes/No/Unknown); 74% smoked cigarettes, 16% did not smoke, and smoking status was
8 unknown for 9% ([Gibb et al., 2000b](#)). No information on pack-years of smoking or how smoking
9 status may have changed over time was available. As an important potential confounder of the lung
10 cancer mortality analysis, smoking was controlled for in the analyses of lung cancer mortality
11 associated with exposure Cr(VI) ([Gibb et al., 2020; 2015; 2000b](#)). Each of the Cox proportional
12 hazards analyses showed that smoking at the beginning of employment was a strong predictor of
13 lung cancer risk. While additional information on the cumulative exposure to smoking may have
14 been helpful to more completely control for smoking, it is clear that as measured, smoking was a
15 strong independent predictor of lung cancer risks and was independent of cumulative Cr(VI)
16 exposure as it was measured at the beginning of employment. There remains some uncertainty as
17 to any potential residual confounding that might be attributed to lack of smoking data on 9% of the
18 cohort and the lack of information on any changes in smoking over time. However, the Baltimore
19 cohort had much better data on smoking compared to the Painesville cohort, and thus the selection
20 of the Baltimore cohort minimizes the potential for confounding by smoking among the available
21 cohorts.

22 **4.4.5.7. *Uncertainty Due to Potential Effect Modification***

23 Among the 217 deaths from lung cancer in workers, only four were among nonsmokers
24 ([Gibb et al., 2015](#)) and the investigators were unable to evaluate any potential statistical interaction
25 between smoking and Cr(VI) exposure. It is theoretically possible that the risk of lung cancer
26 mortality estimated in this current assessment is a reflection of a positive synergy between
27 smoking and Cr(VI), and that the adverse effect of Cr(VI) among nonsmokers has been
28 overestimated. However, this possibility cannot be assessed and remains an uncertainty. The unit
29 risk of the lung cancer risk herein would be health protective for any population that had a lower
30 prevalence of smoking than that of the Baltimore cohort.

31 **4.4.5.8. *Uncertainty in Low Dose Extrapolation***

32 A common source of uncertainty in quantitative cancer risk assessments generally derives
33 from extrapolating from high doses in animals to low doses in humans. Compared to assessments
34 based on animal data, the uncertainty from low-dose extrapolation in this assessment, which uses
35 occupational epidemiology data, is considered to be low because the POD was well within the range
36 of observed exposure data. The POD for lung cancer was based on 1% extra risk and yielded an
37 LEC₀₁ of 0.899 µg Cr(VI)/m³ from the Cox analysis and 0.951 µg Cr(VI)/m³ from the R&L analysis.

1 Table 2 of [Gibb et al. \(2015\)](#) shows that the median cumulative exposure to CrO₃ was 0.01 mg
2 CrO₃/m³-years and the 25%-tile of CrO₃ was 0.001 mg CrO₃/m³-years, and the minimum was zero.
3 Converting to µg Cr(VI)/m³, the median was 52 µg Cr(VI)/m³ and the 25%-tile was 5.2 µg
4 Cr(VI)/m³. Here the PODs appear to be between the minimum and the 25%-tile and thus not
5 outside the range of observed exposures. Thus, there is little uncertainty in extrapolation of the
6 risk function below the POD associated with a 1% BMR.

7 **4.4.5.9. Uncertainty in Extrapolation of Findings in Adults to Children.**

8 The analysis of lung cancer mortality using the Cox proportional hazards model assumed
9 that the effect was independent of age, while the analysis using the R&L approach allowed for
10 effects to be different by age group—although this analysis did not provide any estimates of what
11 the age effect was beyond showing that the relatively younger cohort members appeared to be at
12 higher risk of lung cancer mortality than the older cohort members. Given that both of these
13 analyses yielded approximately the same estimate of the IUR, it appears that while there may be an
14 age-related effect of Cr(VI) exposure on the risk of lung cancer, two different analyses that treated
15 age differently yielded essentially the same unit risk when the life-table analysis assumed that the
16 effect was independent of age.

17 However, Cr(VI) was found to cause cancer by a mutagenic mode of action, and chemical-
18 specific data are not available to address early-life exposure. According to EPA's *Supplemental*
19 *Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)),
20 ADAF are applied for children and risks were based on application of age-dependent risk modifiers
21 of an "adult-only" unit risks such that effect were independent of age among people age 16 years
22 and older. There is some uncertainty that these default ADAF would be health-protective of
23 children although this uncertainty is considered to be low.

24 The inhalation unit risk (IUR) is a plausible upper bound on the estimate of risk per µg/m³
25 air breathed. The IUR can be multiplied by an estimate of lifetime exposure (in µg/m³) to estimate
26 the lifetime cancer risk.

4.4.6. Previous IRIS Assessment: Inhalation Unit Risk

27 The previous IRIS assessment for Cr(VI) was posted to the IRIS database in 1998. EPA's
28 1998 IRIS assessment classified Cr(VI) as "Group A—known human carcinogen by the inhalation
29 route of exposure" under the 1986 guidelines ([U.S. EPA, 1986b](#)). This was based on evidence of a
30 causal relationship between inhalation of Cr(VI) and increased incidence of lung cancer in humans
31 in occupational settings. An inhalation unit risk (IUR) for Cr(VI) of 1.2×10^{-2} per µg/m³ was
32 calculated based on increased incidence of lung cancer in chromate workers from the Painesville
33 OH cohort ([Mancuso, 1997, 1975](#)). Because Mancuso et al. ([1997, 1975](#)) only provided total
34 chromium data and contained fewer employee records for smoking status, there was higher
35 uncertainty in the 1998 IUR. The lack of Cr(VI) data would have led to an underestimation of risk
36 (because the true Cr(VI) exposure rates were lower relative to total chromium exposure rates),

Toxicological Review of Hexavalent Chromium

- 1 while the lack of smoking data would have led to an overestimation of risk (due to the high
- 2 prevalence of smoking during this time period).

REFERENCES

- 1
2
3 [Abbaspour, N; Hurrell, R; Kelishadi, R.](#) (2014). Review on iron and its importance for human health
4 [Review]. *J Res Med Sci* 19: 164-174.
- 5 [ACC](#) (American Chemistry Council). (2015). Pathology peer slide review of non-neoplastic
6 findings in the duodenum of mice and rats treated with sdd in acc-ts and ntp
7 studies.
- 8 [Acharya, S; Mehta, K; Krishnan, S; Rao, CV.](#) (2001). A subtoxic interactive toxicity study of ethanol
9 and chromium in male Wistar rats. *Alcohol* 23: 99-108. [http://dx.doi.org/10.1016/S0741-
10 8329\(00\)00139-7](http://dx.doi.org/10.1016/S0741-8329(00)00139-7)
- 11 [Acharya, UR; Mishra, M; Mishra, I; Tripathy, RR.](#) (2004). Potential role of vitamins in chromium
12 induced spermatogenesis in Swiss mice. *Environ Toxicol Pharmacol* 15: 53-59.
13 <http://dx.doi.org/10.1016/j.etap.2003.08.010>
- 14 [Acharya, UR; Mishra, M; Tripathy, RR; Mishra, I.](#) (2006). Testicular dysfunction and antioxidative
15 defense system of Swiss mice after chromic acid exposure. *Reprod Toxicol* 22: 87-91.
16 <http://dx.doi.org/10.1016/j.reprotox.2005.11.004>
- 17 [Adachi, S.](#) (1987). [Effects of chromium compounds on the respiratory system: Part 5. Long term
18 inhalation of chromic acid mist in electroplating by C57BL female mice and recapitulation of
19 our experimental studies]. *Sangyo Igaku* 29: 17-33.
20 <http://dx.doi.org/10.1539/joh1959.29.17>
- 21 [Adachi, S; Yoshimura, H; Katayama, H; Takemoto, K.](#) (1986). [Effects of chromium compounds on
22 the respiratory system: Part 4. Long term inhalation of chromic acid mist in electroplating
23 to ICR female mice]. *Sangyo Igaku* 28: 283-287. <http://dx.doi.org/10.1539/joh1959.28.283>
- 24 [Adachi, S; Yoshimura, H; Miyayama, R; Katayama, H; Takemoto, K; Kawai, H.](#) (1981). [Effects of
25 chromium compounds to the respiratory system: Part 1. An experimental study of
26 inhalation of chromic acid mist in electroplating]. *Sangyo Igaku* 23: 294-299.
27 <http://dx.doi.org/10.1539/joh1959.23.294>
- 28 [AEI](#) (Applied Epidemiology Inc). (2002). Collaborative cohort mortality study of four chromate
29 production facilities, 1958-1998: Final report. (8EHQ-0810-18050; OSHA Docket H054A Ex.
30 48-1-2). Pittsburgh, PA: Industrial Health Foundation.
31 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0602411.xhtml>
- 32 [Ahmad, MK; Syma, S; Mahmood, R.](#) (2011). Cr(VI) Induces Lipid Peroxidation, Protein Oxidation and
33 Alters the Activities of Antioxidant Enzymes in Human Erythrocytes. *Biol Trace Elem Res*
34 144: 426-435. <http://dx.doi.org/10.1007/s12011-011-9119-5>
- 35 [Akbar, M; Brewer, JM; Grant, MH.](#) (2011). Effect of chromium and cobalt ions on primary human
36 lymphocytes in vitro. *J Immunotoxicol* 8: 140-149.
37 <http://dx.doi.org/10.3109/1547691X.2011.553845>
- 38 [Al-Hamood, MH; Elbetieha, A; Bataineh, H.](#) (1998). Sexual maturation and fertility of male and
39 female mice exposed prenatally and postnatally to trivalent and hexavalent chromium
40 compounds. *Reprod Fertil Dev* 10: 179-183.
- 41 [Alexander, J; Aaseth, J.](#) (1995). Uptake of chromate in human red blood cells and isolated rat liver
42 cells: the role of the anion carrier. *Analyst* 120: 931-933.
43 <http://dx.doi.org/10.1039/AN9952000931>

- 1 [Alexander, J; Aaseth, J; Norseth, T.](#) (1982). Uptake of chromium by rat liver mitochondria.
2 Toxicology 24: 115-122. [http://dx.doi.org/10.1016/0300-483X\(82\)90050-6](http://dx.doi.org/10.1016/0300-483X(82)90050-6)
- 3 [Alexander, J; Mikalsen, A; Ryberg, D.](#) (1986). Microsomal reduction of Cr VI. Acta Pharmacol Toxicol
4 59: 267-269. <http://dx.doi.org/10.1111/j.1600-0773.1986.tb02759.x>
- 5 [Alexopoulos, EC; Cominos, X; Trougakos, IP; Lourda, M; Gonos, ES; Makropoulos, V.](#) (2008).
6 Biological monitoring of hexavalent chromium and serum levels of the senescence
7 biomarker Apolipoprotein J/Clusterin in welders. Bioinorganic Chemistry and Applications
8 2008: 420578. <http://dx.doi.org/10.1155/2008/420578>
- 9 [Ali, AH; Kondo, K; Namura, T; Senba, Y; Takizawa, H; Nakagawa, Y; Toba, H; Kenzaki, K; Sakiyama, S;](#)
10 [Tangoku, A.](#) (2011). Aberrant DNA methylation of some tumor suppressor genes in lung
11 cancers from workers with chromate exposure. Mol Carcinog 50: 89-99.
12 <http://dx.doi.org/10.1002/mc.20697>
- 13 [Almaguer, D; Kramkowski, R.](#) (1983). Health hazard evaluation report no. HETA-82-116-1319,
14 Modine Manufacturing, McHenry, Illinois. Cincinnati, OH: National Institute for Occupational
15 Safety and Health.
- 16 [American Pregnancy Association.](#) (2021). Anemia during pregnancy. Available online at
17 [https://americanpregnancy.org/healthy-pregnancy/pregnancy-concerns/anemia-during-](https://americanpregnancy.org/healthy-pregnancy/pregnancy-concerns/anemia-during-pregnancy/)
18 [pregnancy/](https://americanpregnancy.org/healthy-pregnancy/pregnancy-concerns/anemia-during-pregnancy/) (accessed August 10, 2022).
- 19 [Andersen, A; Barlow, L; Engeland, A; Kjaerheim, K; Lynge, E; Pukkala, E.](#) (1999). Work-related
20 cancer in the Nordic countries [Supplemental Data]. Scand J Work Environ Health 25: 1-116.
- 21 [Andrews, R; O'Connor, PE.](#) (2020). NIOSH manual of analytical methods (NMAM), 5th edition.
22 Washington, DC: National Institute for Occupational Safety and Health.
23 <https://www.cdc.gov/niosh/nmam/default.html>
- 24 [Anger, G; Halstenberg, J; Hochgeschwender, K; Scherhag, C; Korallus, U; Knopf, H; Schmidt, P;](#)
25 [Ohlinger, M.](#) (2005). Chromium compounds. In B Elvers (Ed.), Ullmann's Encyclopedia of
26 Industrial Chemistry (7th ed., pp. 1-36). Hoboken, NJ: Wiley-VCH Verlag GmbH & Co.
27 http://dx.doi.org/10.1002/14356007.a07_067
- 28 [Antonini, JM; Lawryk, NJ; Murthy, GG; Brain, ID.](#) (1999). Effect of welding fume solubility on lung
29 macrophage viability and function in vitro. J Toxicol Environ Health A 58: 343-363.
30 <http://dx.doi.org/10.1080/009841099157205>
- 31 [Antonini, JM; Roberts, JR; Chapman, RS; Soukup, JM; Ghio, AJ; Sriram, K.](#) (2010a). Pulmonary toxicity
32 and extrapulmonary tissue distribution of metals after repeated exposure to different
33 welding fumes. Inhal Toxicol 22: 805-816.
34 <http://dx.doi.org/10.3109/08958371003621641>
- 35 [Antonini, JM; Taylor, MD; Zimmer, AT; Roberts, JR.](#) (2010b). Pulmonary responses to welding
36 fumes: Role of metal constituents [Review]. J Toxicol Environ Health A 67: 233-249.
37 <http://dx.doi.org/10.1080/15287390490266909>
- 38 [Anwar, RA; Langham, RF; Hoppert, CA; Alfredson, BV; Byerrum, RU.](#) (1961). Chronic toxicity
39 studies: III. Chronic toxicity of cadmium and chromium in dogs. Arch Environ Health 3: 456-
40 460.
- 41 [Aoki, Y; Matsumoto, M; Matsumoto, M; Masumura, K; Nohmi, T.](#) (2019). Mutant frequency is not
42 increased in mice orally exposed to sodium dichromate. Food Saf 7: 2-10.
43 <http://dx.doi.org/10.14252/foodsafetyfscj.2018014>
- 44 [Apte, AD; Tare, V; Bose, P.](#) (2006). Extent of oxidation of Cr(III) to Cr(VI) under various conditions
45 pertaining to natural environment. J Hazard Mater 128: 164-174.
46 <http://dx.doi.org/10.1016/j.jhazmat.2005.07.057>
- 47 [Arakawa, H; Ahmad, R; Naoui, M; Tajmir-Riahi, HA.](#) (2000). A comparative study of calf thymus DNA
48 binding to Cr(III) and Cr(VI) ions. Evidence for the guanine N-7-chromium-phosphate
49 chelate formation. J Biol Chem 275: 10150-10153.

- 1 [Arakawa, H; Weng, MW; Chen, WC; Tang, MS.](#) (2012). Chromium (VI) induces both bulky DNA
2 adducts and oxidative DNA damage at adenines and guanines in the p53 gene of human lung
3 cells. *Carcinogenesis* 33: 1993-2000. <http://dx.doi.org/10.1093/carcin/bgs237>
- 4 [Arias, E; Heron, M; Xu, J.](#) (2017). United States life tables, 2013. National Vital Statistics Reports; vol
5 66 no 3. Hyattsville, MD: National Center for Health Statistics.
- 6 [Armienta-Hernández, MA; Rodríguez-Castillo, R.](#) (1995). Environmental exposure to chromium
7 compounds in the valley of León, México. *Environ Health Perspect* 103 Suppl 1: 47-51.
- 8 [Arshad, M; Ahmad, N; Khalid, M; Asmatullah; Tahir, M; Naveed, K; Iqbal, A.](#) (2017). Exposure of
9 pregnant mice to hexavalent chromium causes fetal defects. *Pakistan J Zool* 49: 1383-1389.
10 <http://dx.doi.org/10.17582/journal.pjz/2017.49.4.1383.1389>
- 11 [Aruldhas, MM; Subramanian, S; Sekar, P; Vengatesh, G; Chandrahasan, G; Govindarajulu, P;
12 Akbarsha, MA.](#) (2005). Chronic chromium exposure-induced changes in testicular
13 histoarchitecture are associated with oxidative stress: study in a non-human primate
14 (*Macaca radiata* Geoffroy). *Hum Reprod* 20: 2801-2813.
15 <http://dx.doi.org/10.1093/humrep/dei148>
- 16 [Aruldhas, MM; Subramanian, S; Sekhar, P; Hasan, GC; Govindarajulu, P; Akbarsha, MA.](#) (2004).
17 Microcanalization in the epididymis to overcome ductal obstruction caused by chronic
18 exposure to chromium - a study in the mature bonnet monkey (*Macaca radiata* Geoffroy).
19 *Reproduction* 128: 127-137. <http://dx.doi.org/10.1530/rep.1.00067>
- 20 [Aruldhas, MM; Subramanian, S; Sekhar, P; Vengatesh, G; Govindarajulu, P; Akbarsha, MA.](#) (2006). In
21 vivo spermatotoxic effect of chromium as reflected in the epididymal epithelial principal
22 cells, basal cells, and intraepithelial macrophages of a nonhuman primate (*Macaca radiata*
23 Geoffroy). *Fertil Steril* 86: 1097-1105. <http://dx.doi.org/10.1016/j.fertnstert.2006.03.025>
- 24 [Asatiani, N; Abuladze, M; Kartvelishvili, T; Kulikova, N; Asanishvili, L; Holman, HY; Sapojnikova, N.](#)
25 (2010). Response of antioxidant defense system to chromium (VI)-induced cytotoxicity in
26 human diploid cells. *Biometals* 23: 161-172. [http://dx.doi.org/10.1007/s10534-009-9276-](http://dx.doi.org/10.1007/s10534-009-9276-6)
27 [6](#)
- 28 [Asatiani, N; Kartvelishvili, T; Abuladze, M; Asanishvili, L; Sapojnikova, N.](#) (2011). Chromium (VI) can
29 activate and impair antioxidant defense system. *Biol Trace Elem Res* 142: 388-397.
30 <http://dx.doi.org/10.1007/s12011-010-8806-y>
- 31 [Asatiani, N; Sapojnikova, N; Abuladze, M; Kartvelishvili, T; Kulikova, N; Kiziria, E; Namchevadze, E;
32 Holman, HY.](#) (2004). Effects of Cr(VI) long-term and low-dose action on mammalian
33 antioxidant enzymes (an in vitro study). *J Inorg Biochem* 98: 490-496.
34 <http://dx.doi.org/10.1016/j.jinorgbio.2003.12.014>
- 35 [Asgharian, B; Price, O.](#) (2009). Multiple-path particle dosimetry model (MPPD v 2.11) (Version 2.11)
36 [Computer Program]. Albuquerque, NM: Applied Research Associates. Retrieved from
37 <https://www.ara.com/mppd/>
- 38 [Asmatullah; Noreen, MA.](#) (1999). Effect of oral administration of hexavalent chromium on total
39 body weight, chromium uptake and histological structure of mouse liver. *Punjab Univ J Zool*
40 14: 53-63.
- 41 [Atanassoff, PG; Brull, SJ; Weiss, BM; Landefeld, K; Alon, E; Rohling, R.](#) (1995). The time course of
42 gastric pH changes induced by omeprazole and ranitidine: A 24-hour dose-response study.
43 *Anesth Analg* 80: 975-979. <http://dx.doi.org/10.1097/0000539-199505000-00021>
- 44 [ATS/ERS](#) (American Thoracic Society and European Respiratory Society). (2019). Standardization
45 of spirometry 2019 update. *Am J Respir Crit Care Med* 200: e70-e88.
46 <http://dx.doi.org/10.1164/rccm.201908-1590ST>
- 47 [ATSDR](#) (Agency for Toxic Substances and Disease Registry). (2005). Toxicological profile for nickel
48 [ATSDR Tox Profile]. Atlanta, GA: U.S. Department of Health and Human Services, Public
49 Health Service. <http://www.atsdr.cdc.gov/toxprofiles/tp15.pdf>

- 1 [ATSDR](#) (Agency for Toxic Substances and Disease Registry). (2012). Toxicological profile for
2 chromium. Atlanta, GA: US Department of Health and Human Services, Public Health
3 Service. <http://www.atsdr.cdc.gov/ToxProfiles/tp.asp?id=62&tid=17>
- 4 [Azad, N; Iyer, AK; Manosroi, A; Wang, L; Rojanasakul, Y.](#) (2008). Superoxide-mediated proteasomal
5 degradation of Bcl-2 determines cell susceptibility to Cr(VI)-induced apoptosis.
6 *Carcinogenesis* 29: 1538-1545. <http://dx.doi.org/10.1093/carcin/bgn137>
- 7 [Bach, SP; Renehan, AG; Potten, CS.](#) (2000). Stem cells: the intestinal stem cell as a paradigm
8 [Review]. *Carcinogenesis* 21: 469-476. <http://dx.doi.org/10.1093/carcin/21.3.469>
- 9 [Badding, MA; Fix, NR; Antonini, JM; Leonard, SS.](#) (2014). A Comparison of Cytotoxicity and Oxidative
10 Stress from Welding Fumes Generated with a New Nickel-, Copper-Based Consumable
11 versus Mild and Stainless Steel-Based Welding in RAW 264.7 Mouse Macrophages. *PLoS*
12 *ONE* 9: e101310. <http://dx.doi.org/10.1371/journal.pone.0101310>
- 13 [Bagchi, D; Bagchi, M; Stohs, SJ.](#) (2001). Chromium (VI)-induced oxidative stress, apoptotic cell death
14 and modulation of p53 tumor suppressor gene. *Mol Cell Biochem* 222: 149-158.
15 <http://dx.doi.org/10.1023/A:1017958028256>
- 16 [Bagchi, D; Balmoori, J; Bagchi, M; Ye, X; Williams, CB; Stohs, SJ.](#) (2000). Role of p53 tumor
17 suppressor gene in the toxicity of TCDD, endrin, naphthalene, and chromium (VI) in liver
18 and brain tissues of mice. *Free Radic Biol Med* 28: 895-903.
19 [http://dx.doi.org/10.1016/S0891-5849\(00\)00173-8](http://dx.doi.org/10.1016/S0891-5849(00)00173-8)
- 20 [Bagchi, D; Balmoori, J; Bagchi, M; Ye, X; Williams, CB; Stohs, SJ.](#) (2002). Comparative effects of TCDD,
21 endrin, naphthalene and chromium (VI) on oxidative stress and tissue damage in the liver
22 and brain tissues of mice. *Toxicology* 175: 73-82. [http://dx.doi.org/10.1016/S0300-](http://dx.doi.org/10.1016/S0300-483X(02)00062-8)
23 [483X\(02\)00062-8](http://dx.doi.org/10.1016/S0300-483X(02)00062-8)
- 24 [Bagchi, D; Hassoun, EA; Bagchi, M; Muldoon, DF; Stohs, SJ.](#) (1995a). Oxidative stress induced by
25 chronic administration of sodium dichromate [Cr(VI)] to rats. *Comp Biochem Physiol C*
26 *Pharmacol Toxicol Endocrinol* 110: 281-287. [http://dx.doi.org/10.1016/0742-](http://dx.doi.org/10.1016/0742-8413(94)00103-H)
27 [8413\(94\)00103-H](http://dx.doi.org/10.1016/0742-8413(94)00103-H)
- 28 [Bagchi, D; Hassoun, EA; Bagchi, M; Stohs, SJ.](#) (1995b). Chromium-induced excretion of urinary lipid
29 metabolites, DNA damage, nitric oxide production, and generation of reactive oxygen
30 species in Sprague-Dawley rats. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol*
31 *110*: 177-187. [http://dx.doi.org/10.1016/0742-8413\(94\)00093-P](http://dx.doi.org/10.1016/0742-8413(94)00093-P)
- 32 [Bagchi, D; Vuchetich, PJ; Bagchi, M; Hassoun, EA; Tran, MX; Tang, L; Stohs, SJ.](#) (1997). Induction of
33 oxidative stress by chronic administration of sodium dichromate [chromium VI] and
34 cadmium chloride [cadmium II] to rats. *Free Radic Biol Med* 22: 471-478.
35 [http://dx.doi.org/10.1016/s0891-5849\(96\)00352-8](http://dx.doi.org/10.1016/s0891-5849(96)00352-8)
- 36 [Bai, JPF; Burckart, GJ; Mulberg, AE.](#) (2016). Literature review of gastrointestinal physiology in the
37 elderly, in pediatric patients, and in patients with gastrointestinal diseases [Review]. *J*
38 *Pharm Sci* 105: 476-483. <http://dx.doi.org/10.1002/jps.24696>
- 39 [Bailey, SA; Zidell, RH; Perry, RW.](#) (2004). Relationships between organ weight and body/brain
40 weight in the rat: What is the best analytical endpoint? *Toxicol Pathol* 32: 448-466.
41 <http://dx.doi.org/10.1080/01926230490465874>
- 42 [Balachandar, V; Arun, M; Mohana Devi, S; Velmurugan, P; Manikantan, P; Karthick Kumar, A;](#)
43 [Sasikala, K; Venkatesan, C.](#) (2010). Evaluation of the genetic alterations in direct and
44 indirect exposures of hexavalent chromium [Cr(VI)] in leather tanning industry workers
45 North Arcot District, South India. *Int Arch Occup Environ Health* 83: 791-801.
46 <http://dx.doi.org/10.1007/s00420-010-0562-y>
- 47 [Balashazy, I; Hofmann, W; Heistracher, T.](#) (2003). Local particle deposition patterns may play a key
48 role in the development of lung cancer. *J Appl Physiol* (1985) 94: 1719-1725.
49 <http://dx.doi.org/10.1152/jappphysiol.00527.2002>

- 1 [Ban, M; Langonné, I; Goutet, M; Huguet, N; Pépin, E.](#) (2010). Simultaneous analysis of the local and
2 systemic immune responses in mice to study the occupational asthma mechanisms induced
3 by chromium and platinum. *Toxicology* 277: 29-37.
4 <http://dx.doi.org/10.1016/j.tox.2010.08.010>
- 5 [Banu, SK; Samuel, JB; Arosh, JA; Burghardt, RC; Aruldas, MM.](#) (2008). Lactational exposure to
6 hexavalent chromium delays puberty by impairing ovarian development, steroidogenesis
7 and pituitary hormone synthesis in developing Wistar rats. *Toxicol Appl Pharmacol* 232:
8 180-189. <http://dx.doi.org/10.1016/j.taap.2008.06.002>
- 9 [Banu, SK; Stanley, JA; Lee, J; Stephen, SD; Arosh, JA; Hoyer, PB; Burghardt, RC.](#) (2011). Hexavalent
10 chromium-induced apoptosis of granulosa cells involves selective sub-cellular translocation
11 of Bcl-2 members, ERK1/2 and p53. *Toxicol Appl Pharmacol* 251: 253-266.
12 <http://dx.doi.org/10.1016/j.taap.2011.01.011>
- 13 [Banu, SK; Stanley, JA; Sivakumar, KK; Arosh, JA; Barhoumi, R; Burghardt, RC.](#) (2015). Identifying a
14 novel role for X-prolyl aminopeptidase (Xpnpep) 2 in CrVI-induced adverse effects on germ
15 cell nest breakdown and follicle development in rats. *Biol Reprod* 92: 67.
16 <http://dx.doi.org/10.1095/biolreprod.114.125708>
- 17 [Banu, SK; Stanley, JA; Sivakumar, KK; Arosh, JA; Burghardt, RC.](#) (2016). Resveratrol protects the
18 ovary against chromium-toxicity by enhancing endogenous antioxidant enzymes and
19 inhibiting metabolic clearance of estradiol. *Toxicol Appl Pharmacol* 303: 65-78.
20 <http://dx.doi.org/10.1016/j.taap.2016.04.016>
- 21 [Banu, SK; Stanley, JA; Sivakumar, KK; Arosh, JA; Taylor, RJ; Burghardt, RC.](#) (2017a). Chromium VI -
22 Induced developmental toxicity of placenta is mediated through spatiotemporal
23 dysregulation of cell survival and apoptotic proteins. *Reprod Toxicol* 68: 171-190.
24 <http://dx.doi.org/10.1016/j.reprotox.2016.07.006>
- 25 [Banu, SK; Stanley, JA; Sivakumar, KK; Taylor, RJ; Arosh, JA; Burghardt, RC.](#) (2017b). Editor's
26 highlight: Exposure to CrVI during early pregnancy increases oxidative stress and disrupts
27 the expression of antioxidant proteins in placental compartments. *Toxicol Sci* 155: 497-511.
28 <http://dx.doi.org/10.1093/toxsci/kfw231>
- 29 [Banu, SK; Stanley, JA; Taylor, RJ; Sivakumar, KK; Arosh, JA; Zeng, L; Pennathur, S; Padmanabhan, V.](#)
30 (2018). Sexually Dimorphic Impact of Chromium Accumulation on Human Placental
31 Oxidative Stress and Apoptosis. *Toxicol Sci* 161: 375-387.
32 <http://dx.doi.org/10.1093/toxsci/kfx224>
- 33 [Baresic, M; Gornik, I; Radonic, R; Zlopasa, O; Gubarev, N; Gasparovic, V.](#) (2009). Survival after severe
34 acute chromic acid poisoning complicated with renal and liver failure. *Intern Med* 48: 711-
35 715.
- 36 [Barnhart, J.](#) (1997). Chromium chemistry and implications for environmental fate and toxicity.
37 *Journal of Soil Contamination* 6: 561-568. <http://dx.doi.org/10.1080/15320389709383589>
- 38 [Basak, O; van de Born, M; Korving, J; Beumer, J; van der Elst, S; van Es, IH; Clevers, H.](#) (2014).
39 Mapping early fate determination in Lgr5+ crypt stem cells using a novel Ki67-RFP allele.
40 *EMBO J* 33: 2057-2068. <http://dx.doi.org/10.15252/embj.201488017>
- 41 [Bashandy, SAE; Ebaid, H; Al-Tamimi, J; Ahmed-Farid, OA; Omara, EA; Alhazza, IM.](#) (2021). Melatonin
42 Alleviated Potassium Dichromate-Induced Oxidative Stress and Reprotoxicity in Male Rats.
43 *BioMed Res Int* 2021: 3565360. <http://dx.doi.org/10.1155/2021/3565360>
- 44 [Basketter, DA; Scholes, EW; Kimber, I.](#) (1994). The performance of the local lymph node assay with
45 chemicals identified as contact allergens in the human maximization test. *Food Chem*
46 *Toxicol* 32: 543-547.
- 47 [Bataineh, H; Al-Hamood, MH; Elbetieha, A; Bani Hani, I.](#) (1997). Effect of long-term ingestion of
48 chromium compounds on aggression, sex behavior and fertility in adult male rat. *Drug*
49 *Chem Toxicol* 20: 133-149. <http://dx.doi.org/10.3109/01480549709003875>

- 1 [Bataineh, HN; Bataineh, ZM; Daradka, H.](#) (2007). Short-term exposure of female rats to industrial
2 metal salts: Effect on implantation and pregnancy. *Reproductive Medicine and Biology* 6:
3 179-183. <http://dx.doi.org/10.1111/j.1447-0578.2007.00183.x>
- 4 [Beaumont, JJ; Sedman, RM; Reynolds, SD; Sherman, CD; Li, LH; Howd, RA; Sandy, MS; Zeise, L;
5 Alexeeff, GV.](#) (2008). Cancer mortality in a Chinese population exposed to hexavalent
6 chromium in drinking water. *Epidemiology* 19: 12-23.
7 <http://dx.doi.org/10.1097/EDE.0b013e31815cea4c>
- 8 [Bedinger, GM.](#) (2015). 2014 Minerals yearbook. Arsenic [advance release]. Reston, VA: U.S.
9 Geological Survey.
- 10 [Bednar, CM; Kies, C.](#) (1991). Inorganic contaminants in drinking water correlated with disease
11 occurrence in Nebraska. *J Am Water Resour Assoc* 27: 631-635.
12 <http://dx.doi.org/10.1111/j.1752-1688.1991.tb01464.x>
- 13 [Behari, J; Chandra, SV; Tandon, SK.](#) (1978). Comparative toxicity of trivalent and hexavalent
14 chromium to rabbits III Biochemical and histological changes in testicular tissue. *Biomed
15 Biochim Acta* 37: 463-468.
- 16 [Ben-David, U; Amon, A.](#) (2020). Context is everything: aneuploidy in cancer [Review]. *Nat Rev Genet*
17 21: 44-62. <http://dx.doi.org/10.1038/s41576-019-0171-x>
- 18 [Benova, D; Hadjidekova, V; Hristova, R; Nikolova, T; Boulanova, M; Georgieva, I; Grigorova, M;
19 Popov, T; Panev, T; Georgieva, R; Natarajan, AT; Darroudi, F; Nilsson, R.](#) (2002). Cytogenetic
20 effects of hexavalent chromium in Bulgarian chromium platers. *Mutat Res* 514: 29-38.
- 21 [Bessède, E; Dubus, P; Mégraud, F; Varon, C.](#) (2015). *Helicobacter pylori* infection and stem cells at
22 the origin of gastric cancer [Review]. *Oncogene* 34: 2547-2555.
23 <http://dx.doi.org/10.1038/onc.2014.187>
- 24 [Betton, GR.](#) (2013). A review of the toxicology and pathology of the gastrointestinal tract [Review].
25 *Cell Biol Toxicol* 29: 321-338. <http://dx.doi.org/10.1007/s10565-013-9257-y>
- 26 [Bick, RL; Girardi, TV; Lack, WJ; Costa, M; Titelbaum, D.](#) (1996). Hodgkin's disease in association with
27 hexavalent chromium exposure. *Int J Hematol* 64: 257-262.
- 28 [Birk, T; Mundt, KA; Dell, LD; Luippold, RS; Miksche, L; Steinmann-Steiner-Haldenstaett, W; Mundt,
29 DJ.](#) (2006). Lung cancer mortality in the German chromate industry, 1958 to 1998. *J Occup
30 Environ Med* 48: 426-433. <http://dx.doi.org/10.1097/01.jom.0000194159.88688.f8>
- 31 [Bitterman, PB; Saltzman, LE; Adelberg, S; Ferrans, VJ; Crystal, RG.](#) (1984). ALVEOLAR
32 MACROPHAGE REPLICATION - ONE MECHANISM FOR THE EXPANSION OF THE
33 MONONUCLEAR PHAGOCYTE POPULATION IN THE CHRONICALLY INFLAMED LUNG. *J Clin
34 Invest* 74: 460-469. <http://dx.doi.org/10.1172/JCI111443>
- 35 [Blaser, H; Dostert, C; Mak, TW; Brenner, D.](#) (2016). TNF and ROS Crosstalk in Inflammation
36 [Review]. *Trends Cell Biol* 26: 249-261. <http://dx.doi.org/10.1016/j.tcb.2015.12.002>
- 37 [Bloomfield, JJ; Blum, W.](#) (1928). Health hazards in chromium plating. *Public Health Rep* 43: 527-
38 528. <http://dx.doi.org/10.2307/4578958>
- 39 [Boland, CR; Goel, A.](#) (2010). Microsatellite instability in colorectal cancer [Review].
40 *Gastroenterology* 138: 2073-2087.e2073. <http://dx.doi.org/10.1053/j.gastro.2009.12.064>
- 41 [Bonassi, S; Coskun, E; Ceppi, M; Lando, C; Bolognesi, C; Burgaz, S; Holland, N; Kirsh-Volders, M;
42 Knasmueller, S; Zeiger, E; Carnesoltas, D; Cavallo, D; da Silva, J; de Andrade, VM; Demircigil,
43 GC; Domínguez Odio, A; Donmez-Altuntas, H; Gattas, G; Giri, A; Giri, S; Gómez-Meda, B;
44 Gómez-Arroyo, S; Hadjidekova, V; Haveric, A; Kamboj, M; Kurteshi, K; Martino-Roth, MG;
45 Montero Montoya, R; Nersesyan, A; Pastor-Benito, S; Favero Salvadori, DM; Shaposhnikova,
46 A; Stopper, H; Thomas, P; Torres-Bugarín, O; Yadav, AS; Zúñiga González, G; Fenech, M.](#)
47 (2011a). The HUman MicroNucleus project on eXfoLiated buccal cells (HUMN(XL)): the role
48 of life-style, host factors, occupational exposures, health status, and assay protocol
49 [Review]. *Mutat Res* 728: 88-97. <http://dx.doi.org/10.1016/j.mrrev.2011.06.005>

- 1 [Bonassi, S; El-Zein, R; Bolognesi, C; Fenech, M.](#) (2011b). Micronuclei frequency in peripheral blood
2 lymphocytes and cancer risk: evidence from human studies [Review]. *Mutagenesis* 26: 93-
3 100. <http://dx.doi.org/10.1093/mutage/geq075>
- 4 [Bonassi, S; Norppa, H; Ceppi, M; Stromberg, U; Vermeulen, R; Znaor, A; Cebulka-Wasilewska, A;](#)
5 [Fabianova, E; Fucic, A; Gundy, S; Hansteen, IL; Knudsen, LE; Lazutka, J; Rossner, P; Sram, RJ;](#)
6 [Boffetta, P.](#) (2008). Chromosomal aberration frequency in lymphocytes predicts the risk of
7 cancer: results from a pooled cohort study of 22 358 subjects in 11 countries.
8 *Carcinogenesis* 29: 1178-1183. <http://dx.doi.org/10.1093/carcin/bgn075>
- 9 [Bonassi, S; Znaor, A; Ceppi, M; Lando, C; Chang, WP; Holland, N; Kirsch-Volders, M; Zeiger, E; Ban, S;](#)
10 [Barale, R; Bigatti, MP; Bolognesi, C; Cebulka-Wasilewska, A; Fabianova, E; Fucic, A; Hagmar,](#)
11 [L; Joksic, G; Martelli, A; Migliore, L; Mirkova, E; Scarfi, MR; Zijno, A; Norppa, H; Fenech, M.](#)
12 (2007). An increased micronucleus frequency in peripheral blood lymphocytes predicts the
13 risk of cancer in humans. *Carcinogenesis* 28: 625-631.
14 <http://dx.doi.org/10.1093/carcin/bgl177>
- 15 [Bonde, JP.](#) (1990). Semen quality and sex hormones among mild steel and stainless steel welders: A
16 cross sectional study. *Br J Ind Med* 47: 508-514.
- 17 [Bonde, JP; Ernst, E.](#) (1992). Sex hormones and semen quality in welders exposed to hexavalent
18 chromium. *Hum Exp Toxicol* 11: 259-263.
- 19 [Boone, L; Meyer, D; Cusick, P; Ennulat, D; Bolliger, AP; Everds, N; Meador, V; Elliott, G; Honor, D;](#)
20 [Bounous, D; Jordan, H.](#) (2005). Selection and interpretation of clinical pathology indicators
21 of hepatic injury in preclinical studies [Review]. *Vet Clin Pathol* 34: 182-188.
22 <http://dx.doi.org/10.1111/j.1939-165X.2005.tb00041.x>
- 23 [Boorman, G; Dixon, D; Elwell, M; Kerlin, R; Morton, D; Peters, T; Regan, K; Sullivan, J; Group, SHW.](#)
24 (2003). Assessment of hyperplastic lesions in rodent carcinogenicity studies. *Toxicol Pathol*
25 31: 709-710.
- 26 [Borella, P; Bargellini, A.](#) (1993). Effects of trace elements on immune system: results in cultured
27 human lymphocytes. *J Trace Elem Med Biol* 7: 231-233.
- 28 [Borges, KM; Boswell, JS; Liebross, RH; Wetterhahn, KE.](#) (1991). Activation of chromium(VI) by thiols
29 results in chromium(V) formation, chromium binding to DNA and altered DNA
30 conformation. *Carcinogenesis* 12: 551-561. <http://dx.doi.org/10.1093/carcin/12.4.551>
- 31 [Borneff, J; Engelhardt, K; Griem, W; Kunte, H; Reichert, J.](#) (1968). Kanzerogene substanzen in wasser
32 und boden. XXII. Mäusentränkversuch mit 3,4-benzpyren und kaliumchromat.
33 [Kanzerogene substanzen in wasser und boden. XXII. Mäusentränkversuch mit 3,4-
34 benzpyren und kaliumchromat]. *Archiv fuer Hygiene und Bakteriologie* 152: 45-53.
- 35 [Boscolo, P; Di Gioacchino, M; Bavazzano, P; White, M; Sabbioni, E.](#) (1997). Effects of chromium on
36 lymphocyte subsets and immunoglobulins from normal population and exposed workers.
37 *Life Sci* 60: 1319-1325. [http://dx.doi.org/10.1016/S0024-3205\(96\)00669-8](http://dx.doi.org/10.1016/S0024-3205(96)00669-8)
- 38 [Bovet, P; Lob, M; Grandjean, M.](#) (1977). Spirometric alterations in workers in the chromium
39 electroplating industry. *Int Arch Occup Environ Health* 40: 25-32.
40 <http://dx.doi.org/10.1007/BF00435514>
- 41 [Brandt-Rauf, P.](#) (2006). Editorial retraction. Cancer mortality in a Chinese population exposed to
42 hexavalent chromium in water. *J Occup Environ Med* 48: 749.
43 <http://dx.doi.org/10.1097/00043764-200607000-00019>
- 44 [Braver, ER; Infante, P; Chu, K.](#) (1985). An analysis of lung cancer risk from exposure to hexavalent
45 chromium. *Birth Defects Res B Dev Reprod Toxicol* 5: 365-378.
- 46 [Bridgewater, LC; Manning, FC; Patierno, SR.](#) (1994). Base-specific arrest of in vitro DNA replication
47 by carcinogenic chromium: relationship to DNA interstrand crosslinking. *Carcinogenesis* 15:
48 2421-2427. <http://dx.doi.org/10.1093/carcin/15.11.2421>
- 49 [Bright, P; Burge, PS; O'Hickey, SP; Gannon, PF; Robertson, AS; Boran, A.](#) (1997). Occupational
50 asthma due to chrome and nickel electroplating. *Thorax* 52: 28-32.

- 1 [Brilliant, MH; Gondo, Y; Eicher, EM.](#) (1991). Direct molecular identification of the mouse pink-eyed
2 unstable mutation by genome scanning. *Science* 252: 566-569.
3 <http://dx.doi.org/10.1126/science.1673574>
- 4 [Brito, F; Ascanio, J; Mateo, S; Hernández, C; Araujo, L; Gili, P; Martín-Zarza, P; Domínguez, S;
5 Mederos, A.](#) (1997). Equilibria of chromate(VI) species in acid medium and ab initio studies
6 of these species. *Polyhedron* 16: 3835-3846. [http://dx.doi.org/10.1016/S0277-
8 5387\(97\)00128-9](http://dx.doi.org/10.1016/S0277-
7 5387(97)00128-9)
- 9 [Browning, CL; Qin, Q; Kelly, DF; Prakash, R; Vanoli, F; Jasin, M; Wise, JP.](#) (2016). Prolonged
10 Particulate Hexavalent Chromium Exposure Suppresses Homologous Recombination Repair
11 in Human Lung Cells. *Toxicol Sci* 153: 70-78. <http://dx.doi.org/10.1093/toxsci/kfw103>
- 12 [Browning, CL; Wise, JP.](#) (2017). Prolonged exposure to particulate chromate inhibits RAD51 nuclear
13 import mediator proteins. *Toxicol Appl Pharmacol* 331: 101-107.
14 <http://dx.doi.org/10.1016/j.taap.2017.05.030>
- 15 [Browning, J; Gannon, BJ; O'Brien, P.](#) (1983). The microvasculature and gastric luminal pH of the
16 forestomach of the rat: A comparison with the glandular stomach. *Int J Microcirc Clin Exp* 2:
17 109-118.
- 18 [Bryant, HE; Ying, S; Helleday, T.](#) (2006). Homologous recombination is involved in repair of
19 chromium-induced DNA damage in mammalian cells. *Mutat Res* 599: 116-123.
20 <http://dx.doi.org/10.1016/j.mrfmmm.2006.02.001>
- 21 [Buerge, JJ; Hug, SJ.](#) (1997). Kinetics and pH dependence of chromium(VI) reduction by iron(II).
22 *Environ Sci Technol* 31: 1426-1432.
- 23 [Burdsall, DP; Flores, HC; Krueger, J; Garretson, S; Gorbien, MJ; Iacch, A; Dobbs, V; Homa, T.](#) (2013).
24 Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US
25 skilled nursing facilities. *J Am Med Dir Assoc* 14: 429-432.
26 <http://dx.doi.org/10.1016/j.jamda.2013.01.021>
- 27 [Burke, T; Fagliano, J; Goldoft, M; Hazen, RE; Iglewicz, R; Mckee, T.](#) (1991). Chromite ore processing
28 residue in Hudson County, New Jersey. *Environ Health Perspect* 92: 131-137.
- 29 [Burton, ED; Choppala, G; Karimian, N; Johnston, SG.](#) (2019). A new pathway for hexavalent
30 chromium formation in soil: Fire-induced alteration of iron oxides. *Environ Pollut* 247: 618-
31 625. <http://dx.doi.org/10.1016/j.envpol.2019.01.094>
- 32 [Caglieri, A; Goldoni, M; De Palma, G; Mozzoni, P; Gemma, S; Vichi, S; Testai, E; Panico, F; Corradi, M;
33 Tagliaferri, S; Costa, LG.](#) (2008). Exposure to low levels of hexavalent chromium: target
34 doses and comparative effects on two human pulmonary cell lines. *Acta Biomed* 79 Suppl 1:
35 104-115.
- 36 [Calder, L.](#) (1988). Chromium contamination of groundwater. In JO Nriagu; E Nieboer (Eds.),
37 *Chromium in the natural and human environments* (pp. 215-229). New York, NY: Wiley.
38 [https://www.wiley.com/en-us/Chromium+in+the+Natural+and+Human+Environments+-+
39 p-9780471856436](https://www.wiley.com/en-us/Chromium+in+the+Natural+and+Human+Environments+-+p-9780471856436)
- 40 [CalEPA](#) (California Environmental Protection Agency). (2003). Ambient air monitoring for
41 hexavalent chromium and metals in Barrio Logan: May 2001 through May 2002. (Report:
42 2003-10-14). Sacramento, CA.
- 43 [CalEPA](#) (California Environmental Protection Agency). (2004). Barrio Logan report: A compilation
44 of air quality studies in Barrio Logan. November 2004. (Report: 2005-11-00). Sacramento,
45 CA.
- 46 [CalEPA](#) (California Environmental Protection Agency). (2011). Public health goal for Hexavalent
47 Chromium (Cr VI) in drinking water. Sacramento, CA: Pesticide and Environmental
48 Toxicology Branch, Office of Environmental Health Hazard Assessment.
49 <http://oehha.ca.gov/media/downloads/water/public-health-goal/cr6phg072911.pdf>
- 50 [CARB](#) (California Air Resources Board). (2004). Neighborhood scale monitoring in Barrio Logan.
(Paper 70255). Sacramento, CA.

- 1 [Carette, D; Perrard, MH; Prisant, N; Gilleron, J; Pointis, G; Segretain, D; Durand, P.](#) (2013).
2 Hexavalent chromium at low concentration alters Sertoli cell barrier and connexin 43 gap
3 junction but not claudin-11 and N-cadherin in the rat seminiferous tubule culture model.
4 *Toxicol Appl Pharmacol* 268: 27-36. <http://dx.doi.org/10.1016/j.taap.2013.01.016>
- 5 [Carlisle, DL; Pritchard, DE; Singh, J; Owens, BM; Blankenship, LJ; Orenstein, JM; Patierno, SR.](#) (2000).
6 Apoptosis and P53 induction in human lung fibroblasts exposed to chromium (VI): Effect of
7 ascorbate and tocopherol. *Toxicol Sci* 55: 60-68. <http://dx.doi.org/10.1093/toxsci/55.1.60>
- 8 [Carney, EW; Kimmel, CA.](#) (2007). Interpretation of skeletal variations for human risk assessment:
9 Delayed ossification and wavy ribs. *Birth Defects Res B Dev Reprod Toxicol* 80: 473-496.
10 <http://dx.doi.org/10.1002/bdrb.20133>
- 11 [Casadevall, M; da Cruz Fresco, P; Kortenkamp, A.](#) (1999). Chromium(VI)-mediated DNA damage:
12 oxidative pathways resulting in the formation of DNA breaks and abasic sites. *Chem Biol*
13 *Interact* 123: 117-132.
- 14 [Casteleyn, C; Rekecki, A; Van der Aa, A; Simoens, P; Van den Broeck, W.](#) (2010). Surface area
15 assessment of the murine intestinal tract as a prerequisite for oral dose translation from
16 mouse to man. *Lab Anim* 44: 176-183. <http://dx.doi.org/10.1258/la.2009.009112>
- 17 [Ceballos, D; West, C; Methner, M; Gong, W.](#) (2017). Health hazard evaluation report: HHE-2013-
18 0011-3278, May 2017. Evaluation of chromium, hexavalent chromium, cadmium, and
19 isocyanate exposures in an African refinishing plant. (HHE-2013-0011-3278). National
20 Institute for Occupational Safety and Health.
21 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB2017102698.xhtml>
- 22 [Ceballos, D; West, C; Methner, M; Gong, W.](#) (2019). Hexavalent Chromium Exposure and Nasal
23 Tissue Effects at a Commercial Aircraft Refinishing Facility. *J Occup Environ Med* 61: e69-
24 e73. <http://dx.doi.org/10.1097/JOM.0000000000001510>
- 25 [CGARN](#) (Cancer Genome Atlas Research Network). (2014). Comprehensive molecular
26 characterization of gastric adenocarcinoma. *Nature* 513: 202-209.
27 <http://dx.doi.org/10.1038/nature13480>
- 28 [CGARN](#) (Cancer Genome Atlas Research Network). (2018a). Comparative molecular analysis of
29 gastrointestinal adenocarcinomas. *Cancer Cell* 33: 721-735.
30 <http://dx.doi.org/10.1016/j.ccell.2018.03.010>
- 31 [CGARN](#) (Cancer Genome Atlas Research Network). (2018b). The immune landscape of cancer.
32 *Immunity* 48: 812-830.e814. <http://dx.doi.org/10.1016/j.immuni.2018.03.023>
- 33 [Chandra, SA; Nolan, MW; Malarkey, DE.](#) (2010). Chemical carcinogenesis of the gastrointestinal
34 tract in rodents: an overview with emphasis on NTP carcinogenesis bioassays [Review].
35 *Toxicol Pathol* 38: 188-197. <http://dx.doi.org/10.1177/0192623309356452>
- 36 [Chappell, GA; Wolf, JC; Thompson, CM.](#) (2022). Crypt and villus transcriptomic responses in mouse
37 small intestine following oral exposure to hexavalent chromium. *Toxicol Sci* 186: 43-57.
38 <http://dx.doi.org/10.1093/toxsci/kfab152>
- 39 [Chatterjee, N; Walker, GC.](#) (2017). Mechanisms of DNA damage, repair, and mutagenesis [Review].
40 *Environ Mol Mutagen* 58: 235-263. <http://dx.doi.org/10.1002/em.22087>
- 41 [Chebeir, M; Liu, H.](#) (2016). Kinetics and mechanisms of Cr(VI) formation via the oxidation of Cr(III)
42 solid phases by chlorine in drinking water. *Environ Sci Technol* 50: 701-710.
43 <http://dx.doi.org/10.1021/acs.est.5b05739>
- 44 [Chen, Q; Li, H; Chen, W; Yao, W; Li, S; Xu, Y; Meng, A.](#) (1997). [Impact of chromium compounds on
45 female reproductive function]. *Gongye Weisheng yu Zhiyebin* 23: 180-182.
- 46 [Chen, QY; Murphy, A; Sun, H; Costa, M.](#) (2019). Molecular and epigenetic mechanisms of Cr(VI)-
47 induced carcinogenesis [Review]. *Toxicol Appl Pharmacol* 377: 114636.
48 <http://dx.doi.org/10.1016/j.taap.2019.114636>

- 1 [Cheng, L; Liu, S; Dixon, K.](#) (1998). Analysis of repair and mutagenesis of chromium-induced DNA
2 damage in yeast, mammalian cells, and transgenic mice. *Environ Health Perspect* 106: 1027-
3 1032.
- 4 [Cheng, L; Sonntag, DM; de Boer, J; Dixon, K.](#) (2000). Chromium(VI)-induced mutagenesis in the
5 lungs of big blue transgenic mice. *J Environ Pathol Toxicol Oncol* 19: 239-249.
- 6 [Chiba, T; Marusawa, H; Ushijima, T.](#) (2012). Inflammation-associated cancer development in
7 digestive organs: mechanisms and roles for genetic and epigenetic modulation [Review].
8 *Gastroenterology* 143: 550-563. <http://dx.doi.org/10.1053/j.gastro.2012.07.009>
- 9 [Chopra, A; Pereira, G; Gomes, T; Pereira, J; Prabhu, P; Krishnan, S; Rao, CV.](#) (1996). A study of
10 chromium and ethanol toxicity in female Wistar rats. *Toxicol Environ Chem* 53: 91-106.
11 <http://dx.doi.org/10.1080/02772249609358274>
- 12 [Chowdhury, AR; Mitra, C.](#) (1995). Spermatogenic and steroidogenic impairment after chromium
13 treatment in rats. *Indian J Exp Biol* 33: 480-484.
- 14 [Christensen, MM; Ernst, E; Ellermann-Eriksen, S.](#) (1992). Cytotoxic effects of hexavalent chromium
15 in cultured murine macrophages. *Arch Toxicol* 66: 347-353.
- 16 [Christensen, OB; Christensen, MB; Maibach, HI.](#) (1984). Flare-up reactions and desensitization from
17 oral dosing in chromate-sensitive guinea pigs. *Contact Derm* 10: 277-279.
- 18 [Christiansen, PM.](#) (1968). The incidence of achlorhydria and hypochlorhydria in healthy subjects
19 and patients with gastrointestinal diseases. *Scand J Gastroenterol* 3: 497-508.
20 <http://dx.doi.org/10.3109/00365526809179909>
- 21 [Cid, MG; Loria, D; Vilensky, M; Miotti, JL; Matos, E.](#) (1991). Leather tanning workers: chromosomal
22 aberrations in peripheral lymphocytes and micronuclei in exfoliated cells in urine. *Mutat*
23 *Res* 259: 197-201. [http://dx.doi.org/10.1016/0165-1218\(91\)90053-0](http://dx.doi.org/10.1016/0165-1218(91)90053-0)
- 24 [Cieślak-Golonka, M.](#) (1996). Toxic and mutagenic effects of chromium(VI). A review. *Polyhedron* 15:
25 3667-3689. [http://dx.doi.org/10.1016/0277-5387\(96\)00141-6](http://dx.doi.org/10.1016/0277-5387(96)00141-6)
- 26 [Ciminera, P; Superior, MJ; Bullman, T.](#) (2016). Findings from the Department of Veterans Affairs
27 Qarmat Ali Medical Surveillance Program. *Mil Med* 181: 307-310.
28 <http://dx.doi.org/10.7205/MILMED-D-15-00278>
- 29 [Clementino, M; Kim, D; Zhang, Z.](#) (2019). Constitutive Activation of NAD-Dependent Sirtuin 3 Plays
30 an Important Role in Tumorigenesis of Chromium(VI)-Transformed Cells. *Toxicol Sci* 169:
31 224-234. <http://dx.doi.org/10.1093/toxsci/kfz032>
- 32 [Coelho, P; García-Lestón, J; Costa, S; Costa, C; Silva, S; Dall'Armi, V; Zoffoli, R; Bonassi, S; de Lima, JP;](#)
33 [Gaspar, JF; Pásaro, E; Laffon, B; Teixeira, JP.](#) (2013). Genotoxic effect of exposure to
34 metal(loid)s. A molecular epidemiology survey of populations living and working in
35 Panasqueira mine area, Portugal. *Environ Int* 60: 163-170.
36 <http://dx.doi.org/10.1016/j.envint.2013.08.014>
- 37 [Coffing, S; Engel, M; Dickinson, D; Thiffeault, C; Spellman, R; Shutsky, T; Schuler, M.](#) (2011). The rat
38 gut micronucleus assay: a good choice for alternative in vivo genetic toxicology testing
39 strategies. *Environ Mol Mutagen* 52: 269-279. <http://dx.doi.org/10.1002/em.20616>
- 40 [Cohen, MD; Prophete, C; Sisco, M; Chen, LC; Zelikoff, JT; Smee, JJ; Holder, AA; Crans, DC.](#) (2006).
41 Pulmonary immunotoxic potentials of metals are governed by select physicochemical
42 properties: chromium agents. *J Immunotoxicol* 3: 69-81.
43 <http://dx.doi.org/10.1080/15476910600718434>
- 44 [Cohen, MD; Sisco, M; Baker, K; Bowser, D; Chen, LC; Schlesinger, RB.](#) (2003). Impact of coexposure
45 to ozone on the carcinogenic potential of inhaled chromium. 1. Effects on retention and on
46 extra- and intracellular distribution. *J Toxicol Environ Health A* 66: 39-55.
47 <http://dx.doi.org/10.1080/15287390306459>
- 48 [Cohen, MD; Sisco, M; Prophete, C; Yoshida, K; Chen, LC; Zelikoff, JT; Smee, J; Holder, AA;](#)
49 [Stonehuerner, J; Crans, DC; Ghio, AJ.](#) (2010). Effects of metal compounds with distinct
50 physicochemical properties on iron homeostasis and antibacterial activity in the lungs:

- 1 Chromium and vanadium. *Inhal Toxicol* 22: 169-178.
2 <http://dx.doi.org/10.3109/08958370903161232>
- 3 [Cohen, MD; Zelikoff, JT; Chen, LC; Schlesinger, RB.](#) (1998). Immunotoxicologic effects of inhaled
4 chromium: role of particle solubility and co-exposure to ozone. *Toxicol Appl Pharmacol*
5 152: 30-40. <http://dx.doi.org/10.1006/taap.1998.8502>
- 6 [Cohen, RE; Neiders, ME; Bedi, GS; Comeau, R.](#) (1993). Induction of type 2 cystatin in rat
7 submandibular glands by systemically administered agents. *Arch Oral Biol* 38: 319-325.
- 8 [Cohen, SR; Davis, DM; Kramkowski, RS.](#) (1974). Clinical manifestations of chromic acid toxicity:
9 Nasal lesions in electroplate workers. *Cutis* 13: 558-568.
- 10 [Cohen, SR; Kramkowski, RS.](#) (1973). Health hazard evaluation/toxicity determination. Marsh
11 Plating Corporation, Ypsilanti, Michigan. (HHE-72-118-104). Cincinnati, OH: National
12 Institute for Occupational Safety and Health.
13 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults.xhtml?searchQuery=PB232740>
- 14 [Cole, P; Rodu, B.](#) (2005). Epidemiologic studies of chrome and cancer mortality: a series of meta-
15 analyses. *Regul Toxicol Pharmacol* 43: 225-231.
16 <http://dx.doi.org/10.1016/j.yrtph.2005.06.009>
- 17 [Collins, BJ; Stout, MD; Levine, KE; Kissling, GE; Melnick, RL; Fennell, TR; Walden, R; Abdo, K;](#)
18 [Pritchard, JB; Fernando, RA; Burka, LT; Hooth, MJ.](#) (2010). Exposure to hexavalent
19 chromium resulted in significantly higher tissue chromium burden compared with trivalent
20 chromium following similar oral doses to male F344/N rats and female B6C3F1 mice.
21 *Toxicol Sci* 118: 368-379. <http://dx.doi.org/10.1093/toxsci/kfq263>
- 22 [Cotton, FA; Wilkinson, G; Murillo, CA; Bochmann, M.](#) (1999). The elements of the first transition
23 series. In *Advanced Inorganic Chemistry*. New York: Wiley.
- 24 [Cox, DR.](#) (1972). Regression models and life-tables. *J R Stat Soc Ser B* 34: 187-220.
- 25 [Creasy, DM; Chapin, RE.](#) (2018). Chapter 17 - Male reproductive system. In *Fundamentals of*
26 *Toxicologic Pathology (Third Edition)*. London, UK: Academic Press of Elsevier.
27 <http://dx.doi.org/10.1016/B978-0-12-809841-7.00017-4>
- 28 [Crew, KD; Neugut, AI.](#) (2004). Epidemiology of upper gastrointestinal malignancies. *Semin Oncol*
29 31: 450-464. <http://dx.doi.org/10.1053/j.seminoncol.2004.04.021>
- 30 [Crissman, JW; Goodman, DG; Hildebrandt, PK; Maronpot, RR; Prater, DA; Riley, JH; Seaman, WJ;](#)
31 [Thake, DC.](#) (2004). Best practices guideline: Toxicologic histopathology. *Toxicol Pathol* 32:
32 126-131. <http://dx.doi.org/10.1080/01926230490268756>
- 33 [Cullen, JM; Ward, JM; Thompson, CM.](#) (2015). Reevaluation and Classification of Duodenal Lesions
34 in B6C3F1 Mice and F344 Rats from 4 Studies of Hexavalent Chromium in Drinking Water.
35 *Toxicol Pathol* 44: 279-289. <http://dx.doi.org/10.1177/0192623315611501>
- 36 [Cummings, DE; Fendorf, S; Singh, N; Sani, RK; Peyton, BM; Magnuson, TS.](#) (2007). Reduction of
37 Cr(VI) under acidic conditions by the facultative Fe(III)-reducing bacterium *Acidiphilium*
38 *cryptum*. *Environ Sci Technol* 41: 146-152. <http://dx.doi.org/10.1021/es061333k>
- 39 [D'Agostini, F; Izzotti, A; Bennicelli, C; Camoirano, A; Tampa, E; De Flora, S.](#) (2002). Induction of
40 apoptosis in the lung but not in the liver of rats receiving intra-tracheal instillations of
41 chromium(VI). *Carcinogenesis* 23: 587-593. <http://dx.doi.org/10.1093/carcin/23.4.587>
- 42 [Dai, L; Xu, W; Li, H; Frank, JA; He, C; Zhang, Z; Chen, G.](#) (2017). Effects of hexavalent chromium on
43 mouse splenic T lymphocytes. *Toxicol In Vitro* 45: 166-171.
44 <http://dx.doi.org/10.1016/j.tiv.2017.09.006>
- 45 [Danadevi, K; Rozati, R; Banu, BS; Grover, P.](#) (2004). Genotoxic evaluation of welders occupationally
46 exposed to chromium and nickel using the Comet and micronucleus assays. *Mutagenesis* 19:
47 35-41. <http://dx.doi.org/10.1093/mutage/geh001>
- 48 [Danadevi, K; Rozati, R; Reddy, PP; Grover, P.](#) (2003). Semen quality of Indian welders
49 occupationally exposed to nickel and chromium. *Reprod Toxicol* 17: 451-456.

- 1 [Das, J; Kang, MH; Kim, E; Kwon, DN; Choi, YJ; Kim, JH.](#) (2015). Hexavalent chromium induces
2 apoptosis in male somatic and spermatogonial stem cells via redox imbalance. *Sci Rep* 5:
3 13921. <http://dx.doi.org/10.1038/srep13921>
- 4 [Davidson, T; Kluz, T; Burns, F; Rossman, T; Zhang, Q; Uddin, A; Nadas, A; Costa, M.](#) (2004). Exposure
5 to chromium (VI) in the drinking water increases susceptibility to UV-induced skin tumors
6 in hairless mice. *Toxicol Appl Pharmacol* 196: 431-437.
7 <http://dx.doi.org/10.1016/j.taap.2004.01.006>
- 8 [Day, CP; James, OF.](#) (1998). Hepatic steatosis: Innocent bystander or guilty party? [Review].
9 *Hepatology* 27: 1463-1466. <http://dx.doi.org/10.1002/hep.510270601>
- 10 [De Flora, S; Badolati, GS; Serra, D; Picciotto, A; Magnolia, MR; Savarino, V.](#) (1987). Circadian
11 reduction of chromium in the gastric environment. *Mutat Res Lett* 192: 169-174.
12 [http://dx.doi.org/10.1016/0165-7992\(87\)90051-0](http://dx.doi.org/10.1016/0165-7992(87)90051-0)
- 13 [De Flora, S; Camoirano, A; Bagnasco, M; Bennicelli, C; Corbett, GE; Kerger, BD.](#) (1997). Estimates of
14 the chromium(VI) reducing capacity in human body compartments as a mechanism for
15 attenuating its potential toxicity and carcinogenicity. *Carcinogenesis* 18: 531-537.
- 16 [De Flora, S; Camoirano, A; Micale, RT; La Maestra, S; Savarino, V; Zentilin, P; Marabotto, E; Suh, M;
17 Proctor, DM.](#) (2016). Reduction of hexavalent chromium by fasted and fed human gastric
18 fluid. I. Chemical reduction and mitigation of mutagenicity. *Toxicol Appl Pharmacol* 306:
19 113-119. <http://dx.doi.org/10.1016/j.taap.2016.07.004>
- 20 [De Flora, S; D'Agostini, F; Balansky, R; Micale, R; Baluce, B; Izzotti, A.](#) (2008). Lack of genotoxic
21 effects in hematopoietic and gastrointestinal cells of mice receiving chromium(VI) with the
22 drinking water [Review]. *Mutat Res* 659: 60-67.
23 <http://dx.doi.org/10.1016/j.mrrev.2007.11.005>
- 24 [De Flora, S; Iltcheva, M; Balansky, RM.](#) (2006). Oral chromium(VI) does not affect the frequency of
25 micronuclei in hematopoietic cells of adult mice and of transplacentally exposed fetuses.
26 *Mutat Res* 610: 38-47. <http://dx.doi.org/10.1016/j.mrgentox.2006.06.011>
- 27 [De Mattia, G; Bravi, MC; Laurenti, O; De Luca, O; Palmeri, A; Sabatucci, A; Mendico, G; Ghiselli, A.](#)
28 (2004). Impairment of cell and plasma redox state in subjects professionally exposed to
29 chromium. *Am J Ind Med* 46: 120-125. <http://dx.doi.org/10.1002/ajim.20044>
- 30 [Delshad, SD; Almario, CV; Chey, WD; Spiegel, BMR.](#) (2020). Prevalence of gastroesophageal reflux
31 disease and proton pump inhibitor-refractory symptoms. *Gastroenterology* 158: 1250.
32 <http://dx.doi.org/10.1053/j.gastro.2019.12.014>
- 33 [Deng, C; Lee, HH; Xian, H; Yao, M; Huang, J; Ou, B.](#) (1988). Chromosomal aberrations and sister
34 chromatid exchanges of peripheral blood lymphocytes in Chinese electroplating workers:
35 Effect of nickel and chromium. *J Trace Elem Exp Med* 1: 57-62.
- 36 [Deng, G; Wu, K; Cruce, AA; Bowman, MK; Vincent, JB.](#) (2015). Binding of trivalent chromium to
37 serum transferrin is sufficiently rapid to be physiologically relevant. *J Inorg Biochem* 143:
38 48-55. <http://dx.doi.org/10.1016/j.jinorgbio.2014.12.004>
- 39 [Deng, Y; Wang, M; Tian, T; Lin, S; Xu, P; Zhou, L; Dai, C; Hao, Q; Wu, Y; Zhai, Z; Zhu, Y; Zhuang, G; Dai,
40 Z.](#) (2019). The Effect of Hexavalent Chromium on the Incidence and Mortality of Human
41 Cancers: A Meta-Analysis Based on Published Epidemiological Cohort Studies. 9: 24.
42 <http://dx.doi.org/10.3389/fonc.2019.00024>
- 43 [Dertinger, SD; Torous, DK; Hayashi, M; Macgregor, JT.](#) (2011). Flow cytometric scoring of
44 micronucleated erythrocytes: an efficient platform for assessing in vivo cytogenetic damage
45 [Review]. *Mutagenesis* 26: 139-145. <http://dx.doi.org/10.1093/mutage/geq055>
- 46 [Devoy, J; Géhin, A; Müller, S; Melczer, M; Remy, A; Antoine, G; Sponne, I.](#) (2016). Evaluation of
47 chromium in red blood cells as an indicator of exposure to hexavalent chromium: An in
48 vitro study. *Toxicol Lett* 255: 63-70. <http://dx.doi.org/10.1016/j.toxlet.2016.05.008>

- 1 [Dobrovolsky, VN; Heflich, RH.](#) (2018). Chapter eleven: Detecting mutations in vivo. In Mutagenicity:
2 Assays and applications. Cambridge, MA: Academic Press. [http://dx.doi.org/10.1016/B978-](http://dx.doi.org/10.1016/B978-0-12-809252-1.00011-0)
3 [0-12-809252-1.00011-0](#)
- 4 [Doki, K; Darwich, AS; Patel, N; Rostami-Hodjegan, A.](#) (2017). Virtual bioequivalence for achlorhydric
5 subjects: The use of PBPK modelling to assess the formulation-dependent effect of
6 achlorhydria. Eur J Pharm Sci 109. <http://dx.doi.org/10.1016/j.ejps.2017.07.035>
- 7 [Dornan, JD.](#) (1981). Occupational dermatoses amongst chrome platers in the Sheffield area 1977--
8 80. Contact Derm 7: 354-355. <http://dx.doi.org/10.1111/j.1600-0536.1981.tb04116.x>
- 9 [Dressman, JB; Berardi, RR; Dermontzoglou, LC; Russell, TL; Schmaltz, SP; Barnett, JL; Jarvenpaa, KM.](#)
10 (1990). Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 7:
11 756-761.
- 12 [Eastmond, DA; Hartwig, A; Anderson, D; Anwar, WA; Cimino, MC; Dobrev, I; Douglas, GR; Nohmi, T;](#)
13 [Phillips, DH; Vickers, C.](#) (2009). Mutagenicity testing for chemical risk assessment: Update of
14 the WHO/IPCS harmonized scheme. Mutagenesis 24: 341-349.
15 <http://dx.doi.org/10.1093/mutage/geb014>
- 16 [Eastmond, DA; Macgregor, JT; Slesinski, RS.](#) (2008). Trivalent chromium: Assessing the genotoxic
17 risk of an essential trace element and widely used human and animal nutritional
18 supplement. Crit Rev Toxicol 38: 173-190.
19 <http://dx.doi.org/10.1080/10408440701845401>
- 20 [Eferl, R; Wagner, EF.](#) (2003). AP-1: a double-edged sword in tumorigenesis [Review]. Nat Rev
21 Cancer 3: 859-868. <http://dx.doi.org/10.1038/nrc1209>
- 22 [EFSA CONTAM Panel](#) (EFSA Panel on Contaminants in the Food Chain). (2014). Scientific Opinion
23 on the risks to public health related to the presence of chromium in food and drinking
24 water. EFSA J 12: 3595. <http://dx.doi.org/10.2903/j.efsa.2014.3595>
- 25 [Egger, M; Smith, GD; Schneider, M; Minder, C.](#) (1997). Bias in meta-analysis detected by a simple,
26 graphical test. Br Med J 315: 629-634. <http://dx.doi.org/10.1136/bmj.315.7109.629>
- 27 [Eizaguirre-García, D; Rodríguez-Andrés, C; Watt, G.](#) (2000). Congenital anomalies in Glasgow
28 between 1982 and 1989 and chromium waste. J Public Health (Oxf) 22: 54-58.
29 <http://dx.doi.org/10.1093/pubmed/22.1.54>
- 30 [El-Demerdash, FM; Jebur, AB; Nasr, HM; Hamid, HM.](#) (2019). Modulatory effect of *Turnera diffusa*
31 against testicular toxicity induced by fenitrothion and/or hexavalent chromium in rats.
32 Environ Toxicol 34: 330-339. <http://dx.doi.org/10.1002/tox.22688>
- 33 [El-Demerdash, FM; Yousef, MI; Elaswad, FA.](#) (2006). Biochemical study on the protective role of
34 folic acid in rabbits treated with chromium (VI). J Environ Sci Health B 41: 731-746.
35 <http://dx.doi.org/10.1080/03601230600704282>
- 36 [El Safty, AMK; Samir, AM; Mekki, MK; Fouad, MM.](#) (2018). Genotoxic effects due to exposure to
37 chromium and nickel among electroplating workers. Int J Toxicol 37: 234-240.
38 <http://dx.doi.org/10.1177/1091581818764084>
- 39 [Elbetieha, A; Al-Hamood, MH.](#) (1997). Long-term exposure of male and female mice to trivalent and
40 hexavalent chromium compounds: effect on fertility. Toxicology 116: 39-47.
41 [http://dx.doi.org/10.1016/S0300-483X\(96\)03516-0](http://dx.doi.org/10.1016/S0300-483X(96)03516-0)
- 42 [Elhosary, N; Maklad, A; Soliman, E; El-Ashmawy, N; Oreby, M.](#) (2014). Evaluation of oxidative stress
43 and DNA damage in cement and tannery workers in Egypt. Inhal Toxicol 26: 289-298.
44 <http://dx.doi.org/10.3109/08958378.2014.885100>
- 45 [Elsaieed, EM; Nada, SA.](#) (2002). Teratogenicity of hexavalent chromium in rats and the beneficial
46 role of ginseng. Bull Environ Contam Toxicol 68: 361-368.
47 <http://dx.doi.org/10.1007/s00128-001-0262-0>
- 48 [Elshazly, MO; Morgan, AM; Ali, ME; Abdel-Mawla, E; Abd El-Rahman, SS.](#) (2016). The mitigative
49 effect of *Raphanus sativus* oil on chromium-induced geno- and hepatotoxicity in male rats.
50 JAR 7: 413-421. <http://dx.doi.org/10.1016/j.jare.2016.02.008>

- 1 [EMEA](#) (European Medicines Agency). (2008). Non-clinical guideline on drug induced hepatotoxicity.
2 (Doc. Ref. EMEA/CHMP/SWP/150115/2006). London, UK.
3 [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/
4 WC500003355.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003355.pdf)
- 5 [EMEA](#) (European Medicines Agency). (2010). Reflection paper on non-clinical evaluation of drug-
6 induced liver injury (DILI). (EMEA/CHMP/SWP/150115/2006). London, UK.
7 [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/
8 WC500094591.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094591.pdf)
- 9 [Engström, G; Hedblad, B; Berglund, G; Janzon, L; Lindgärde, F.](#) (2007a). Plasma levels of
10 complement C3 is associated with development of hypertension: a longitudinal cohort
11 study. *J Hum Hypertens* 21: 276-282. <http://dx.doi.org/10.1038/sj.jhh.1002129>
- 12 [Engström, G; Hedblad, B; Eriksson, KF; Janzon, L; Lindgärde, F.](#) (2005). Complement C3 is a risk
13 factor for the development of diabetes: a population-based cohort study. *Diabetes* 54: 570-
14 575. <http://dx.doi.org/10.2337/diabetes.54.2.570>
- 15 [Engström, G; Hedblad, B; Janzon, L; Lindgärde, F.](#) (2007b). Complement C3 and C4 in plasma and
16 incidence of myocardial infarction and stroke: a population-based cohort study. *Eur J*
17 *Cardiovasc Prev Rehabil* 14: 392-397.
18 <http://dx.doi.org/10.1097/01.hjr.0000244582.30421.b2>
- 19 [Evans, TJ; Ganjam, VK.](#) (2011). Chapter 2 - Reproductive anatomy and physiology. In RC Gupta (Ed.),
20 *Reproductive and Developmental Toxicology* (1st ed., pp. 7-32). San Diego, CA: Academic
21 Press. <http://dx.doi.org/10.1016/B978-0-12-382032-7.10002-5>
- 22 [Fagliano, JA; Savrin, J; Udasin, I; Gochfeld, M.](#) (1997). Community exposure and medical screening
23 near chromium waste sites in New Jersey. *Regul Toxicol Pharmacol* 26: S13-S22.
24 <http://dx.doi.org/10.1006/rtph.1997.1134>
- 25 [Faux, SP; Gao, M; Aw, TC; Braithwaite, RA; Levy, LS.](#) (1994). Molecular epidemiological studies in
26 workers exposed to chromium-containing compounds. *Clin Chem* 40: 1454-1456.
- 27 [Fébel, H; Szegedi, B; Huszár, S.](#) (2001). Absorption of inorganic, trivalent and hexavalent chromium
28 following oral and intrajejunal doses in rats. *Acta Vet Hung* 49: 203-209.
- 29 [Feldman, M; Barnett, C.](#) (1991). Fasting gastric pH and its relationship to true hypochlorhydria in
30 humans. *Dig Dis Sci* 36: 866-869. <http://dx.doi.org/10.1007/BF01297133>
- 31 [Fendorf, S; Wielinga, BW; Hansel, CM.](#) (2000). Chromium transformations in natural environments:
32 The role of biological and abiological. processes in chromium(VI) reduction. *International*
33 *Geology Review* 42: 691-701. <http://dx.doi.org/10.1080/00206810009465107>
- 34 [Fendorf, SE.](#) (1995). Surface reactions of chromium in soils and waters. *Geoderma* 67: 55-71.
35 [http://dx.doi.org/10.1016/0016-7061\(94\)00062-F](http://dx.doi.org/10.1016/0016-7061(94)00062-F)
- 36 [Fendorf, SE; Li, G.](#) (1996). Kinetics of Chromate Reduction by Ferrous Iron. *Environ Sci Technol* 30:
37 1614-1617. <http://dx.doi.org/10.1021/es950618m>
- 38 [Fernandes, MA; Mota, IM; Silva, MT; Oliveira, CR; Geraldés, CF; Alpoim, MC.](#) (1999). Human
39 erythrocytes are protected against chromate-induced peroxidation. *Ecotoxicol Environ Saf*
40 43: 38-46. <http://dx.doi.org/10.1006/eesa.1998.1755>
- 41 [Fernández-Nieto, M; Quirce, S; Carnés, J; Sastre, J.](#) (2006). Occupational asthma due to chromium
42 and nickel salts. *Int Arch Occup Environ Health* 79: 483-486.
43 <http://dx.doi.org/10.1007/s00420-005-0078-z>
- 44 [Figgitt, M; Newson, R; Leslie, IJ; Fisher, J; Ingham, E; Case, CP.](#) (2010). The genotoxicity of
45 physiological concentrations of chromium (Cr(III) and Cr(VI)) and cobalt (Co(II)): an in
46 vitro study. *Mutat Res* 688: 53-61. <http://dx.doi.org/10.1016/j.mrfmmm.2010.03.008>
- 47 [Figoni, RA; Treagan, L.](#) (1975). Inhibitory effect of nickel and chromium upon antibody response of
48 rats to immunization with T-1 phage. *Res Commun Mol Pathol Pharmacol* 11: 335-338.

- 1 [Figueiredo, ACM, G; Gomes-Filho, IS; Silva, RB; Pereira, PPS; Mata, FAF, D; Lyrio, AO; Souza, ES; Cruz,](#)
2 [SS; Pereira, MG.](#) (2018). Maternal anemia and low birth weight: A systematic review and
3 meta-analysis [Review]. *Nutrients* 10: 601. <http://dx.doi.org/10.3390/nu10050601>
4 [Finley, BL; Kerger, BD; Katona, MW; Gargas, ML; Corbett, GC; Paustenbach, DJ.](#) (1997). Human
5 ingestion of chromium (VI) in drinking water: pharmacokinetics following repeated
6 exposure. *Toxicol Appl Pharmacol* 142: 151-159.
7 <http://dx.doi.org/10.1006/taap.1996.7993>
8 [Foley, GL.](#) (2001). Overview of male reproductive pathology [Review]. *Toxicol Pathol* 29: 49-63.
9 <http://dx.doi.org/10.1080/019262301301418856>
10 [Foster, P; Gray, LE, Jr.](#) (2013). Toxic responses of the reproductive system. In CD Klaassen (Ed.),
11 Casarett & Doull's toxicology: The basic science of poisons (8th ed., pp. 861-906). New York,
12 NY: McGraw-Hill Education. [https://www.mheducation.com/highered/product/casarett-](https://www.mheducation.com/highered/product/casarett-doull-s-toxicology-basic-science-poisons-9th-edition-klaassen/9781259863745.html)
13 [doubl-s-toxicology-basic-science-poisons-9th-edition-klaassen/9781259863745.html](#)
14 [Fox, JG; Wang, TC.](#) (2007). Inflammation, atrophy, and gastric cancer [Review]. *J Clin Invest* 117: 60-
15 69. <http://dx.doi.org/10.1172/JCI30111>
16 [Fox, JG; Wang, TC.](#) (2014). Dietary factors modulate Helicobacter-associated gastric cancer in
17 rodent models. *Toxicol Pathol* 42: 162-181. <http://dx.doi.org/10.1177/0192623313512564>
18 [Francke, S; Mog, S.](#) (2021). Pathology review of hexavalent chromium mode of action evidence. U.S.
19 Department of Health and Human Services, Food and Drug Administration.
20 [Fresquez, MR; Pappas, RS; Watson, CH.](#) (2013). Establishment of toxic metal reference range in
21 tobacco from US cigarettes. *J Anal Toxicol* 37: 298-304.
22 <http://dx.doi.org/10.1093/jat/bkt021>
23 [Frey, M; Seidel, C; Edwards, M.](#) (2004). Occurrence survey of boron and hexavalent chromium. (No.
24 91044F). Denver, CO: American Water Works Association Research Foundation.
25 <http://www.waterrf.org/PublicReportLibrary/91044F.pdf>
26 [Fryzek, JP; Mumma, MT; Mclaughlin, JK; Henderson, BE; Blot, WJ.](#) (2001). Cancer mortality in
27 relation to environmental chromium exposure. *J Occup Environ Med* 43: 635-640.
28 [Furman, D; Campisi, J; Verdin, E; Carrera-Bastos, P; Targ, S; Franceschi, C; Ferrucci, L; Gilroy, DW;](#)
29 [Fasano, A; Miller, GW; Miller, AH; Mantovani, A; Weyand, CM; Barzilai, N; Goronzy, JJ; Rando,](#)
30 [TA; Effros, RB; Lucia, A; Kleinstreuer, N; Slavich, GM.](#) (2019). Chronic inflammation in the
31 etiology of disease across the life span. *Nat Med* 25: 1822-1832.
32 <http://dx.doi.org/10.1038/s41591-019-0675-0>
33 [Gabay, M; Li, Y; Felsher, DW.](#) (2014). MYC activation is a hallmark of cancer initiation and
34 maintenance [Review]. *Cold Spring Harb Perspect Med* 4.
35 <http://dx.doi.org/10.1101/cshperspect.a014241>
36 [Gambelungho, A; Piccinini, R; Abbritti, G; Ambrogi, M; Ugolini, B; Marchetti, C; Migliorati, G;](#)
37 [Balducci, C; Muzi, G.](#) (2006). Chromium VI-induced apoptosis in a human bronchial
38 epithelial cell line (BEAS-2B) and a lymphoblastic leukemia cell line (MOLT-4). *J Occup*
39 *Environ Med* 48: 319-325. <http://dx.doi.org/10.1097/01.jom.0000197859.46894.7d>
40 [Gambelungho, A; Piccinini, R; Ambrogi, M; Villarini, M; Moretti, M; Marchetti, C; Abbritti, G; Muzi, G.](#)
41 (2003). Primary DNA damage in chrome-plating workers. *Toxicology* 188: 187-195.
42 [Gandhi, M; Aweeka, F; Greenblatt, RM; Blaschke, TF.](#) (2004). Sex differences in pharmacokinetics
43 and pharmacodynamics [Review]. *Annu Rev Pharmacol Toxicol* 44: 499-523.
44 <http://dx.doi.org/10.1146/annurev.pharmtox.44.101802.121453>
45 [Gao, M; Levy, LS; Faux, SP; Aw, TC; Braithwaite, RA; Brown, SS.](#) (1994). Use of molecular
46 epidemiological techniques in a pilot study on workers exposed to chromium. *Occup*
47 *Environ Med* 51: 663-668. <http://dx.doi.org/10.1136/oem.51.10.663>
48 [Gatto, NM; Kelsh, MA; Mai, DH; Suh, M; Proctor, DM.](#) (2010). Occupational exposure to hexavalent
49 chromium and cancers of the gastrointestinal tract: a meta-analysis. *Cancer Detect Prev* 34:
50 388-399. <http://dx.doi.org/10.1016/j.canep.2010.03.013>

- 1 [Gazon, H; Barbeau, B; Mesnard, JM; Peloponese, JM.](#) (2017). Hijacking of the AP-1 Signaling Pathway
2 during Development of ATL [Review]. *FMICB* 8: 2686.
3 <http://dx.doi.org/10.3389/fmicb.2017.02686>
- 4 [GBD 2017](#) (GBD 2017 Gastro-oesophageal Reflux Disease Collaborators). (2020). The global,
5 regional, and national burden of gastro-oesophageal reflux disease in 195 countries and
6 territories, 1990–2017: Aa systematic analysis for the Global Burden of Disease Study 2017.
7 *Lancet Gastroenterology and Hepatology* 5: 561-581. <http://dx.doi.org/10.1016/S2468->
8 [1253\(19\)30408-X](http://dx.doi.org/10.1016/S2468-1253(19)30408-X)
- 9 [Geetha, S; Sai Ram, M; Mongia, SS; Singh, V; Ilavazhagan, G; Sawhney, RC.](#) (2003). Evaluation of
10 antioxidant activity of leaf extract of Seabuckthorn (*Hippophae rhamnoides* L.) on
11 chromium(VI) induced oxidative stress in albino rats. *J Ethnopharmacol* 87: 247-251.
12 [http://dx.doi.org/10.1016/S0378-8741\(03\)00154-5](http://dx.doi.org/10.1016/S0378-8741(03)00154-5)
- 13 [Gehlhaus, MW, III; Gift, JS; Hogan, KA; Kopylev, L; Schlosser, PM; Kadry, AR.](#) (2011). Approaches to
14 cancer assessment in EPA's Integrated Risk Information System [Review]. *Toxicol Appl*
15 *Pharmacol* 254: 170-180. <http://dx.doi.org/10.1016/j.taap.2010.10.019>
- 16 [Gelberg, H.](#) (2018). Pathophysiological mechanisms of gastrointestinal toxicity. In CA McQueen
17 (Ed.), *Comprehensive toxicology*, vol 3 (3rd ed., pp. 139-178). Amsterdam, Netherlands:
18 Elsevier. <http://dx.doi.org/10.1016/B978-0-12-801238-3.10923-7>
- 19 [Geoffroy-Siraudin, C; Perrard, MH; Chaspoul, F; Lanteaume, A; Gallice, P; Durand, P; Guichaoua, MR.](#)
20 (2010). Validation of a rat seminiferous tubule culture model as a suitable system for
21 studying toxicant impact on meiosis effect of hexavalent chromium. *Toxicol Sci* 116: 286-
22 296. <http://dx.doi.org/10.1093/toxsci/kfq099>
- 23 [Gerin, M; Fletcher, AC; Gray, C; Winkelmann, R; Boffetta, P; Simonato, L.](#) (1993). Development and
24 use of a welding process exposure matrix in a historical prospective study of lung cancer
25 risk in European welders. *Int J Epidemiol* 22: S22-S28.
- 26 [Gibb, H; Wang, J; O'Leary, K; Chen, C; Bateson, TF; Kopylev, L.](#) (2020). The effect of age on the
27 relative risk of lung cancer mortality in a cohort of chromium production workers. *Am J Ind*
28 *Med* 63: 774-778. <http://dx.doi.org/10.1002/ajim.23152>
- 29 [Gibb, HJ; Lees, PS; Pinsky, PF; Rooney, BC.](#) (2000a). Clinical findings of irritation among chromium
30 chemical production workers. *Am J Ind Med* 38: 127-131.
- 31 [Gibb, HJ; Lees, PS; Pinsky, PF; Rooney, BC.](#) (2000b). Lung cancer among workers in chromium
32 chemical production. *Am J Ind Med* 38: 115-126.
- 33 [Gibb, HJ; Lees, PS; Wang, J; Grace O'Leary, K.](#) (2015). Extended followup of a cohort of chromium
34 production workers. *Am J Ind Med* 58: 905-913. <http://dx.doi.org/10.1002/ajim.22479>
- 35 [Glaser, U; Hochrainer, D; Klöppel, H; Kuhnen, H.](#) (1985). Low level chromium (VI) inhalation
36 effects on alveolar macrophages and immune functions in Wistar rats. *Arch Toxicol* 57: 250-
37 256. <http://dx.doi.org/10.1007/BF00324787>
- 38 [Glaser, U; Hochrainer, D; Kloepfel, H; Oldiges, H.](#) (1986). Carcinogenicity of sodium dichromate and
39 chromium (VI/III)oxide aerosols inhaled by male Wistar rats. *Toxicology* 42: 219-232.
40 [http://dx.doi.org/10.1016/0300-483X\(86\)90011-9](http://dx.doi.org/10.1016/0300-483X(86)90011-9)
- 41 [Glaser, U; Hochrainer, D; Steinhoff, D.](#) (1990). Investigation of irritating properties of inhaled Cr(VI)
42 with possible influence on its carcinogenic action. In NH Seemayer; W Hadnagy (Eds.),
43 *Environmental hygiene II* (pp. 239-245). Berlin, Germany: Springer-Verlag.
- 44 [Glaviano, A; Nayak, V; Cabuy, E; Baird, DM; Yin, Z; Newson, R; Ladon, D; Rubio, MA; Slijepcevic, P;](#)
45 [Lyng, F; Mothersill, C; Case, CP.](#) (2006). Effects of hTERT on metal ion-induced genomic
46 instability. *Oncogene* 25: 3424-3435. <http://dx.doi.org/10.1038/sj.onc.1209399>
- 47 [Go'ldina, IR; Saichenko, SP; Nadeenko, VG; Diachenko, OZ.](#) (1989). [Changes in the occurrence of
48 sister chromatid exchange and chromosome aberrations in bone marrow cells of mice after
49 administration of chromium with drinking water]. *Gig Sanit* 7-9.

- 1 [Gochfeld, M.](#) (2007). Framework for gender differences in human and animal toxicology [Review].
2 Environ Res 104: 4-21. <http://dx.doi.org/10.1016/j.envres.2005.12.005>
- 3 [Goldberg, MT; Blakey, DH; Bruce, WR.](#) (1983). Comparison of the effects of 1,2-dimethylhydrazine
4 and cyclophosphamide on micronucleus incidence in bone marrow and colon. Mutat Res
5 Fundam Mol Mech Mutagen 109: 91-98. [http://dx.doi.org/10.1016/0027-5107\(83\)90098-2](http://dx.doi.org/10.1016/0027-5107(83)90098-2)
- 6 [Gomes, ER.](#) (1972). Incidence of chromium-induced lesions among electroplating workers in Brazil.
7 Ind Med Surg 41: 21-25.
- 8 [Gonda, TA; Tu, SP; Wang, TC.](#) (2009). Chronic inflammation, the tumor microenvironment and
9 carcinogenesis [Review]. Cell Cycle 8: 2005-2013. <http://dx.doi.org/10.4161/cc.8.13.8985>
- 10 [Goulart, M; Batoréu, MC; Rodrigues, AS; Laires, A; Rueff, J.](#) (2005). Lipoperoxidation products and
11 thiol antioxidants in chromium exposed workers. Mutagenesis 20: 311-315.
12 <http://dx.doi.org/10.1093/mutage/gei043>
- 13 [Goullé, JP; Sausseureau, E; Grosjean, J; Doche, C; Mahieu, L; Thouret, JM; Guerbet, M; Lacroix, C.](#)
14 (2012). Accidental potassium dichromate poisoning. Toxicokinetics of chromium by ICP-
15 MS-CRC in biological fluids and in hair. Forensic Sci Int 217: e8-12.
16 <http://dx.doi.org/10.1016/j.forsciint.2011.10.020>
- 17 [Greenspan, LC; Lee, MM.](#) (2018). Endocrine disrupters and pubertal timing [Review]. Curr Opin
18 Endocrinol Diabetes Obes 25: 49-54. <http://dx.doi.org/10.1097/MED.0000000000000377>
- 19 [Gromadzińska, J; Wasowicz, W; Sklodowska, M; Bulikowski, W; Rydzyński, K.](#) (1996). The influence
20 of atmospheric chromium on selenium content and glutathione peroxidase activity in blood
21 of tannery workers. Environ Health Perspect 104: 1312-1316.
22 <http://dx.doi.org/10.1289/ehp.104-1469531>
- 23 [Group, FW.](#) (2000). Nonclinical assessment of potential hepatotoxicity in man (a concept paper
24 meant to provide a framework for discussion at a February 12&13 Workshop. FDA Working
25 Group.
- 26 [Güerci, A; Seoane, A; Dulout, FN.](#) (2000). Aneugenic effects of some metal compounds assessed by
27 chromosome counting in MRC-5 human cells. Mutat Res 469: 35-40.
- 28 [Guo, X; Feng, L; Lemos, B; Lou, J.](#) (2019). DNA methylation modifications induced by hexavalent
29 chromium. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 37: 133-145.
30 <http://dx.doi.org/10.1080/10590501.2019.1592640>
- 31 [Guo, YJ; Pan, WW; Liu, SB; Shen, ZF; Xu, Y; Hu, LL.](#) (2020). ERK/MAPK signalling pathway and
32 tumorigenesis [Review]. Exp Ther Med 19: 1997-2007.
33 <http://dx.doi.org/10.3892/etm.2020.8454>
- 34 [Halasova, E; Adamkov, M; Matakova, T; Kavcova, E; Poliacek, I; Singliar, A.](#) (2010). Lung cancer
35 incidence and survival in chromium exposed individuals with respect to expression of anti-
36 apoptotic protein survivin and tumor suppressor P53 protein. Eur J Med Res 15: 55-59.
- 37 [Halasova, E; Matakova, T; Musak, L; Polakova, V; Letkova, L; Dobrota, D; Vodicka, P.](#) (2012).
38 Evaluating chromosomal damage in workers exposed to hexavalent chromium and the
39 modulating role of polymorphisms of DNA repair genes. Int Arch Occup Environ Health 85:
40 473. <http://dx.doi.org/10.1007/s00420-011-0684-x>
- 41 [Halasova, E; Matakova, T; Musak, L; Polakova, V; Vodicka, P.](#) (2008). Chromosomal damage and
42 polymorphisms of DNA repair genes XRCC1 and XRCC3 in workers exposed to chromium.
43 Neuro Endocrinol Lett 29: 658-662.
- 44 [Hamilton, EM; Young, SD; Bailey, EH; Watts, MJ.](#) (2018). Chromium speciation in foodstuffs: A
45 review [Review]. Food Chem 250. <http://dx.doi.org/10.1016/j.foodchem.2018.01.016>
- 46 [Hanahan, D.](#) (2022). Hallmarks of cancer: New dimensions [Review]. Cancer Discovery 12: 31-46.
47 <http://dx.doi.org/10.1158/2159-8290.CD-21-1059>
- 48 [Hanahan, D; Weinberg, RA.](#) (2011). Hallmarks of cancer: The next generation [Review]. Cell 144:
49 646-674. <http://dx.doi.org/10.1016/j.cell.2011.02.013>

- 1 [Hanaoka, T; Yamano, Y; Katsuno, N; Kagawa, J; Ishizu, S.](#) (1997). Elevated serum levels of pantropic
2 p53 proteins in chromium workers. *Scand J Work Environ Health* 23: 37-40.
3 <http://dx.doi.org/10.5271/sjweh.176>
- 4 [Hanslian, L; Navratil, J; Jurak, J.](#) (1967). [Damage to the upper respiratory tract by a chromic acid
5 aerosol]. *Czech J Occup Med* 19: 294-298.
- 6 [Hantson, P; Van Caenegem, O; Decordier, I; Haufroid, V; Lison, D.](#) (2005). Hexavalent chromium
7 ingestion: Biological markers of nephrotoxicity and genotoxicity. *Clin Toxicol* 43: 111-112.
8 <http://dx.doi.org/10.1081/CLT-50414>
- 9 [Harris, HH; Levina, A; Dillon, CT; Mulyani, I; Lai, B; Cai, Z; Lay, PA.](#) (2005). Time-dependent uptake,
10 distribution and biotransformation of chromium(VI) in individual and bulk human lung
11 cells: application of synchrotron radiation techniques. *J Biol Inorg Chem* 10: 105-118.
12 <http://dx.doi.org/10.1007/s00775-004-0617-1>
- 13 [Haschek, WM; Rousseaux, CG; Wallig, MA.](#) (2009). Male reproductive system. In *Fundamentals of*
14 *toxicologic pathology* (2nd ed.). Cambridge, MA: Academic Press.
15 <http://dx.doi.org/10.1016/B978-0-12-370469-6.00018-0>
- 16 [Haseman, JK; Bailer, AJ; Kodell, RL; Morris, R; Portier, K.](#) (2001). Statistical issues in the analysis of
17 low-dose endocrine disruptor data. *Toxicol Sci* 61: 201-210.
- 18 [Hausladen, DM; Alexander-Ozinskas, A; McClain, CN; Fendorf, S.](#) (2018). Hexavalent chromium
19 sources and distribution in California groundwater. *Environ Sci Technol* 52: 8242-8251.
20 <http://dx.doi.org/10.1021/acs.est.7b06627>
- 21 [Hausladen, DM; Fendorf, S.](#) (2017). Hexavalent chromium generation within naturally structured
22 soils and sediments. *Environ Sci Technol* 51: 2058-2067.
23 <http://dx.doi.org/10.1021/acs.est.6b04039>
- 24 [Hayakawa, Y; Fox, JG; Gonda, T; Worthley, DL; Muthupalani, S; Wang, TC.](#) (2013). Mouse models of
25 gastric cancer. *Cancers* 5: 92-130. <http://dx.doi.org/10.3390/cancers5010092>
- 26 [Hayashi, M.](#) (2016). The micronucleus test-most widely used in vivo genotoxicity test [Review].
27 *Genes Environ* 38: 18. <http://dx.doi.org/10.1186/s41021-016-0044-x>
- 28 [Hayes, RB; Lilienfeld, AM; Snell, LM.](#) (1979). Mortality in chromium chemical production workers: A
29 prospective study. *Int J Epidemiol* 8: 365-374. <http://dx.doi.org/10.1093/ije/8.4.365>
- 30 [He, F; Ru, X; Wen, T.](#) (2020). NRF2, a transcription factor for stress response and beyond [Review].
31 *International Journal of Molecular Sciences* 21: 4777.
32 <http://dx.doi.org/10.3390/ijms21134777>
- 33 [He, J; Qian, X; Carpenter, R; Xu, Q; Wang, L; Qi, Y; Wang, ZX; Liu, LZ; Jiang, BH.](#) (2013). Repression of
34 miR-143 Mediates Cr (VI)-Induced Tumor Angiogenesis via IGF-IR/IRS1/ERK/IL-8
35 Pathway. *Toxicol Sci* 134: 26-38. <http://dx.doi.org/10.1093/toxsci/kft101>
- 36 [Hedberg, YS.](#) (2018). Metal allergy: Chromium. In J Chen; J Thyssen (Eds.), *Metal allergy* (pp. 349-
37 364). Cham, Switzerland: Springer. http://dx.doi.org/10.1007/978-3-319-58503-1_27
- 38 [Helmbold, P; Rytter, M; Ziegler, V; Hausteiner, UF.](#) (1993). Induction of type IV hypersensitivity to
39 contact allergens in guinea pigs by in vitro haptenized allogenic peritoneal exudate cells.
40 *Acta Derm Venereol* 73: 365-369. <http://dx.doi.org/10.2340/0001555573365369>
- 41 [Henderson, RE.](#) (1984). Use of bronchoalveolar lavage to detect lung damage [Review]. *Environ*
42 *Health Perspect* 56: 115-129.
- 43 [Henderson, RE; Benson, JM; Hahn, FF; Hobbs, CH; Jones, RK; Mauderly, JL; McClellan, RO; Pickrell,](#)
44 [JA.](#) (1985). New approaches for the evaluation of pulmonary toxicity: Bronchoalveolar
45 lavage fluid analysis [Review]. *Toxicol Sci* 5: 451-458.
- 46 [Hens, B; Brouwers, J; Anneveld, B; Corsetti, M; Symillides, M; Vertzoni, M; Reppas, C; Turner, DB;](#)
47 [Augustijns, P.](#) (2014). Gastrointestinal transfer: In vivo evaluation and implementation in
48 vitro and in silico predictive tools. *Eur J Pharm Sci* 63: 233-242.
49 <http://dx.doi.org/10.1016/j.ejps.2014.07.008>

- 1 [Hertle, E; van Greevenbroek, MM; Stehouwer, CD.](#) (2012). Complement C3: an emerging risk factor
2 in cardiometabolic disease. *Diabetologia* 55: 881-884. [http://dx.doi.org/10.1007/s00125-](http://dx.doi.org/10.1007/s00125-012-2462-z)
3 [012-2462-z](#)
- 4 [Hfaiedh, M; Brahmi, D; Zourgui, L.](#) (2014). Protective role of cactus cladodes extract on sodium
5 dichromate-induced testicular injury and oxidative stress in rats. *Biol Trace Elem Res* 159:
6 304-311. <http://dx.doi.org/10.1007/s12011-014-9969-8>
- 7 [Hilali, A; Anane, R; Jaaouani, N; Creppy, EE; Verschaeve, L.](#) (2008). Cytogenetic analysis of tannery
8 workers in Morocco. *J Appl Toxicol* 28: 439-442. <http://dx.doi.org/10.1002/jat.1291>
- 9 [Hill, AB.](#) (1965). The environment and disease: Association or causation? *Proc R Soc Med* 58: 295-
10 300.
- 11 [Hiller, MM; Leggett, RW.](#) (2020). A biokinetic model for trivalent or hexavalent chromium in adult
12 humans. *J Radiol Prot* 40: 19-39. <http://dx.doi.org/10.1088/1361-6498/ab4286>
- 13 [Hinds, WC.](#) (1999). 11: Respiratory Deposition. In *Aerosol Technology: Properties, Behavior, and*
14 *Measurement of Airborne Particles* (2 ed.). New York, NY: Wiley- Interscience.
- 15 [Hirose, T; Kondo, K; Takahashi, Y; Ishikura, H; Fujino, H; Tsuyuguchi, M; Hashimoto, M; Yokose, T;](#)
16 [Mukai, K; Kodama, T; Monden, Y.](#) (2002). Frequent microsatellite instability in lung cancer
17 from chromate-exposed workers. *Mol Carcinog* 33: 172-180.
- 18 [Hjollund, NH; Bonde, JP; Ernst, E; Lindenberg, S; Andersen, AN; Olsen, J.](#) (2005). Spontaneous
19 abortion in IVF couples--a role of male welding exposure. *Hum Reprod* 20: 1793-1797.
20 <http://dx.doi.org/10.1093/humrep/deh680>
- 21 [Hjollund, NH; Bonde, JP; Hansen, KS.](#) (1995). Male-mediated risk of spontaneous abortion with
22 reference to stainless steel welding. *Scand J Work Environ Health* 21: 272-276.
23 <http://dx.doi.org/10.5271/sjweh.37>
- 24 [Hjollund, NH; Bonde, JP; Jensen, TK; Ernst, E; Henriksen, TB; Kolstad, HA; Giwercman, A;](#)
25 [Skakkebaek, NE; Olsen, J.](#) (1998). Semen quality and sex hormones with reference to metal
26 welding. *Reprod Toxicol* 12: 91-95.
- 27 [Hjollund, NH; Bonde, JP; Jensen, TK; Henriksen, TB; Andersson, AM; Kolstad, HA; Ernst, E;](#)
28 [Giwercman, A; Skakkebaek, NE; Olsen, J.](#) (2000). Male-mediated spontaneous abortion
29 among spouses of stainless steel welders. *Scand J Work Environ Health* 26: 187-192.
- 30 [Holmes, AL; Wise, SS; Sandwick, SJ; Lingle, WL; Negron, VC; Thompson, WD; Wise, JP, Sr.](#) (2006).
31 Chronic exposure to lead chromate causes centrosome abnormalities and aneuploidy in
32 human lung cells. *Cancer Res* 66: 4041-4048. [http://dx.doi.org/10.1158/0008-5472.can-](http://dx.doi.org/10.1158/0008-5472.can-05-3312)
33 [05-3312](#)
- 34 [Hooftman, RN; Arkesteyn, CWM; Roza, P.](#) (1988). Cytotoxicity of some types of welding fume
35 particles to bovine alveolar macrophages. *Ann Occup Hyg* 32: 95-102.
36 <http://dx.doi.org/10.1093/annhyg/32.1.95>
- 37 [Horiguchi, S; Morinaga, K; Endo, G.](#) (1990). Epidemiological study of mortality from cancer among
38 chromium platers. *Asia Pac J Public Health* 4: 169-174.
39 <http://dx.doi.org/10.1177/101053959000400316>
- 40 [Houghton, J; Stoicov, C; Nomura, S; Rogers, AB; Carlson, J; Li, H; Cai, X; Fox, JG; Goldenring, JR; Wang,](#)
41 [TC.](#) (2004). Gastric cancer originating from bone marrow-derived cells. *Science* 306: 1568-
42 1571. <http://dx.doi.org/10.1126/science.1099513>
- 43 [Hu, G; Li, P; Cui, X; Li, Y; Zhang, J; Zhai, X; Yu, S; Tang, S; Zhao, Z; Wang, J; Jia, G.](#) (2018). Cr(VI)-
44 induced methylation and down-regulation of DNA repair genes and its association with
45 markers of genetic damage in workers and 16HBE cells. *Environ Pollut* 238: 833-843.
46 <http://dx.doi.org/10.1016/j.envpol.2018.03.046>
- 47 [Hu, G; Li, P; Li, Y; Wang, T; Gao, X, in; Zhang, W; Jia, G.](#) (2016). Methylation levels of P16 and TP53
48 that are involved in DNA strand breakage of 16HBE cells treated by hexavalent chromium.
49 *Toxicol Lett* 249: 15-21. <http://dx.doi.org/10.1016/j.toxlet.2016.03.003>

- 1 [Hu, G; Long, C; Hu, L; Zhang, Y; Hong, S; Zhang, Q; Zheng, P; Su, Z; Xu, J; Wang, L; Gao, X; Zhu, X; Yuan,](#)
2 [F; Wang, T; Yu, S; Jia, G.](#) (2022). Blood chromium exposure, immune inflammation and
3 genetic damage: Exploring associations and mediation effects in chromate exposed
4 population. *J Hazard Mater* 425: 127769. <http://dx.doi.org/10.1016/j.jhazmat.2021.127769>
5 [Huang, L; Yu, CH; Hopke, PK; Liroy, PJ; Buckley, BT; Shin, JY; Fan, ZT.](#) (2014). Measurement of soluble
6 and total hexavalent chromium in the ambient airborne particles in New Jersey. *Aerosol Air*
7 *Qual Res* 14: 1939-1949. <http://dx.doi.org/10.4209/aaqr.2013.10.0312>
8 [Huang, YL; Chen, CY; Sheu, JY; Chuang, IC; Pan, JH; Lin, TH.](#) (1999). Lipid peroxidation in workers
9 exposed to hexavalent chromium. *J Toxicol Environ Health A* 56: 235-247.
10 <http://dx.doi.org/10.1080/009841099158088>
11 [Husgafvel-Pursiainen, K; Kalliomaki, PL; Sorsa, M.](#) (1982). A chromosome study among stainless
12 steel welders. *J Occup Environ Med* 24: 762-766.
13 [Huvinen, M; Mäkitie, A; Järventaus, H; Wolff, H; Stjernvall, T; Hovi, A; Hirvonen, A; Ranta, R;](#)
14 [Nurminen, M; Norppa, H.](#) (2002a). Nasal cell micronuclei, cytology and clinical symptoms in
15 stainless steel production workers exposed to chromium. *Mutagenesis* 17: 425-429.
16 <http://dx.doi.org/10.1093/mutage/17.5.425>
17 [Huvinen, M; Uitti, J; Oksa, P; Palmroos, P; Laippala, P.](#) (2002b). Respiratory health effects of long-
18 term exposure to different chromium species in stainless steel production. *Occup Med*
19 (Lond) 52: 203-212.
20 [Huvinen, M; Uitti, J; Zitting, A; Roto, P; Virkola, K; Kuikka, P; Laippala, P; Aitio, A.](#) (1996).
21 Respiratory health of workers exposed to low levels of chromium in stainless steel
22 production. *Occup Environ Med* 53: 741-747.
23 [Hydrometrics.](#) (2013). Project report background concentrations of inorganic constituents in
24 Montana surface soils. Helena, MT: Hydrometrics, Inc.
25 [https://deq.mt.gov/Portals/112/Land/StateSuperfund/Documents/InorganicBackground/](https://deq.mt.gov/Portals/112/Land/StateSuperfund/Documents/InorganicBackground/BkgdInorganicsReport.pdf)
26 [BkgdInorganicsReport.pdf](#)
27 [IARC](#) (International Agency for Research on Cancer). (2012). A review of human carcinogens. Part
28 C: Arsenic, metals, fibres, and dusts [IARC Monograph]. In *Arsenic, Metals, Fibres and Dusts*.
29 Lyon, France: World Health Organization.
30 <http://monographs.iarc.fr/ENG/Monographs/vol100C/mono100C.pdf>
31 [Iarmarcovai, G; Sari-Minodier, I; Chaspoul, F; Botta, C; De Meo, M; Orsiere, T; Berge-Lefranc, JL;](#)
32 [Gallice, P; Botta, A.](#) (2005). Risk assessment of welders using analysis of eight metals by ICP-
33 MS in blood and urine and DNA damage evaluation by the comet and micronucleus assays;
34 influence of XRCC1 and XRCC3 polymorphisms. *Mutagenesis* 20: 425-432.
35 <http://dx.doi.org/10.1093/mutage/gei058>
36 [Ibrahim, R; Brix, A; Malarkey, DE; Nyska, A; Asif, M; Ramot, Y.](#) (2021). Chemical-induced oral
37 squamous cell neoplasms in rodents: An overview of NTP 2-year cancer studies. *Toxicol*
38 *Pathol.* <http://dx.doi.org/10.1177/0192623321989956>
39 [ICRP](#) (International Commission on Radiological Protection). (1994). Human respiratory tract
40 model for radiological protection. *Ann ICRP* 24.
41 [ICRP](#) (International Commission on Radiological Protection). (2006). Human alimentary tract
42 model for radiological protection. *ICRP Publication* 100. A report of The International
43 Commission on Radiological Protection. *Ann ICRP* 36: 25-327, iii.
44 [Iijima, S; Spindle, A; Pedersen, RA.](#) (1983). Developmental and cytogenetic effects of potassium
45 dichromate on mouse embryos in vitro. *Teratology* 27: 109-115.
46 <http://dx.doi.org/10.1002/tera.1420270116>
47 [Ikarashi, Y; Momma, J; Tsuchiya, T; Nakamura, A.](#) (1996). Evaluation of skin sensitization potential
48 of nickel, chromium, titanium and zirconium salts using guinea-pigs and mice. *Biomaterials*
49 17: 2103-2108. [http://dx.doi.org/10.1016/0142-9612\(96\)00038-5](http://dx.doi.org/10.1016/0142-9612(96)00038-5)

- 1 [Ikarashi, Y; Tsuchiya, T; Nakamura, A.](#) (1992). Detection of contact sensitivity of metal salts using
2 the murine local lymph node assay. *Toxicol Lett* 62: 53-61.
3 [http://dx.doi.org/10.1016/0378-4274\(92\)90078-x](http://dx.doi.org/10.1016/0378-4274(92)90078-x)
- 4 [IOM](#) (Institute of Medicine). (2011). Dietary reference intakes for calcium and vitamin D. In AC
5 Ross; CL Taylor; AL Yaktine; HB Del Valle (Eds.). Washington, DC: National Academies Press.
6 <http://dx.doi.org/10.17226/13050>
- 7 [IPCS](#) (International Programme on Chemical Safety). (2012). Harmonization project document no.
8 10: Guidance for immunotoxicity risk assessment for chemicals. (Harmonization Project
9 Document No. 10). Geneva, Switzerland: World Health Organization.
10 <http://www.inchem.org/documents/harmproj/harmproj/harmproj10.pdf>
- 11 [IPCS](#) (International Programme on Chemical Safety). (2013). Inorganic chromium(VI) compounds.
12 (78). Geneva, Switzerland: World Health Organization.
13 http://www.who.int/ipcs/publications/cicad/cicad_78.pdf
- 14 [Ishikawa, Y; Nakagawa, K; Satoh, Y; Kitagawa, T; Sugano, H; Hirano, T; Tsuchiya, E.](#) (1994a).
15 Characteristics of chromate workers' cancers, chromium lung deposition and precancerous
16 bronchial lesions: an autopsy study. *Br J Cancer* 70: 160-166.
- 17 [Ishikawa, Y; Nakagawa, K; Satoh, Y; Kitagawa, T; Sugano, H; Hirano, T; Tsuchiya, E.](#) (1994b). Hot
18 spots of chromium accumulation at bifurcations of chromate workers' bronchi. *Cancer Res*
19 54: 2342-2346.
- 20 [Islam, LN; Rahman, F; Hossain, A.](#) (2019). Serum Immunoglobulin Levels and Complement Function
21 of Tannery Workers in Bangladesh. 9: 190308. [http://dx.doi.org/10.5696/2156-9614-](http://dx.doi.org/10.5696/2156-9614-9.21.190308)
22 [9.21.190308](http://dx.doi.org/10.5696/2156-9614-9.21.190308)
- 23 [Izzotti, A; Bagnasco, M; Camoirano, A; Orlando, M; De Flora, S.](#) (1998). DNA fragmentation, DNA-
24 protein crosslinks, 32P postlabeled nucleotidic modifications, and 8-hydroxy-2'-
25 deoxyguanosine in the lung but not in the liver of rats receiving intratracheal instillations of
26 chromium(VI). Chemoprevention by oral N-acetylcysteine. *Mutat Res Fundam Mol Mech*
27 *Mutagen* 400: 233-244. [http://dx.doi.org/10.1016/S0027-5107\(98\)00028-1](http://dx.doi.org/10.1016/S0027-5107(98)00028-1)
- 28 [Jacquet, P; Draye, JP.](#) (1982). Toxicity of chromium salts to cultured mouse embryos. *Toxicol Lett*
29 12: 53-57. [http://dx.doi.org/10.1016/0378-4274\(82\)90198-9](http://dx.doi.org/10.1016/0378-4274(82)90198-9)
- 30 [Jardine, PM; Mehlhorn, TL; Bailey, WB; Brooks, SC; Fendorf, S; Gentry, RW; Phelps, TJ; Saiers, JE.](#)
31 (2011). Geochemical processes governing the fate and transport of chromium(III) and
32 chromium(VI) in soils. *Vadose Zone J* 10: 1058-1070.
33 <http://dx.doi.org/10.2136/vzj2010.0102>
- 34 [Jasperson, KW; Patel, SG; Ahnen, DJ.](#) (2017). APC-Associated Polyposis Conditions. In MP Adam; HH
35 Ardinger; RA Pagon; SE Wallace; LJH Bean; G Mirzaa; A Amemiya (Eds.), *GeneReviews*
36 [Internet]. Seattle, WA: University of Washington, Seattle.
- 37 [Jelnes, JE; Knudsen, LE.](#) (1988). Stainless steel welding and semen quality. *Reprod Toxicol* 2: 213-
38 215. [http://dx.doi.org/10.1016/0890-6238\(88\)90025-1](http://dx.doi.org/10.1016/0890-6238(88)90025-1)
- 39 [Jia, G.](#) (2021). [Request sent to Professor Guang Jia for information from publication with reply,
40 response to request, and follow-up attached]. Available online
- 41 [Jin, Y; Liu, L; Zhang, S; Tao, B; Tao, R; He, X; Qu, L; Huang, J; Wang, X; Fu, Z.](#) (2016). Chromium alters
42 lipopolysaccharide-induced inflammatory responses both in vivo and in vitro. *Chemosphere*
43 148: 436-443. <http://dx.doi.org/10.1016/j.chemosphere.2016.01.057>
- 44 [Jin, Y; Zhang, S; Tao, R; Huang, J; He, X; Qu, L; Fu, Z.](#) (2014). Oral exposure of mice to cadmium (II),
45 chromium (VI) and their mixture induce oxidative- and endoplasmic reticulum-stress
46 mediated apoptosis in the livers. *Environ Toxicol* 31: 693-705.
47 <http://dx.doi.org/10.1002/tox.22082>
- 48 [Jirova, D; Janeckovo, V; Znojemska, S; Pekarek, J.](#) (1983). Adjuvant Activity Of Muramyldipeptide In
49 A Guinea Pig Model Of Contact Allergy To Chromium. *J Hyg* 27: 395-402.

- 1 [Johansson, A; Robertson, B; Curstedt, T; Camner, P.](#) (1986a). Rabbit lung after inhalation of hexa-
2 and trivalent chromium. *Environ Res* 41: 110-119.
- 3 [Johansson, A; Wiernik, A; Jarstrand, C; Camner, P.](#) (1986b). Rabbit alveolar macrophages after
4 inhalation of hexa- and trivalent chromium. *Environ Res* 39: 372-385.
5 [http://dx.doi.org/10.1016/S0013-9351\(86\)80063-9](http://dx.doi.org/10.1016/S0013-9351(86)80063-9)
- 6 [Johnson, J; Schewel, L; Graedel, TE.](#) (2006). The contemporary anthropogenic chromium cycle.
7 *Environ Sci Technol* 40: 7060-7069. <http://dx.doi.org/10.1021/es060061i>
- 8 [Jones, KB; Klein, OD.](#) (2013). Oral epithelial stem cells in tissue maintenance and disease: the first
9 steps in a long journey [Review]. *International Journal of Oral Science* 5: 121-129.
10 <http://dx.doi.org/10.1038/ijos.2013.46>
- 11 [Jones, RP; Sutton, PA; Evans, JP; Clifford, R; Mcavoy, A; Lewis, J; Rousseau, A; Mountford, R;
12 Mcwhirter, D; Malik, HZ.](#) (2017). Specific mutations in KRAS codon 12 are associated with
13 worse overall survival in patients with advanced and recurrent colorectal cancer. *Br J*
14 *Cancer* 116: 923-929. <http://dx.doi.org/10.1038/bjc.2017.37>
- 15 [JP, B; Olsen, JH; Hansen, KS.](#) (1992). Adverse pregnancy outcome and childhood malignancy with
16 reference to paternal welding exposure. *Scand J Work Environ Health* 18: 169-177.
- 17 [Juanes, MA.](#) (2020). Cytoskeletal control and Wnt signaling-APC's dual contributions in stem cell
18 division and colorectal cancer [Review]. *Cancers* 12: 3811.
19 <http://dx.doi.org/10.3390/cancers12123811>
- 20 [Junaid, M; Murthy, RC; Saxena, DK.](#) (1995). Chromium fetotoxicity in mice during late pregnancy.
21 *Vet Hum Toxicol* 37: 320-323.
- 22 [Junaid, M; Murthy, RC; Saxena, DK.](#) (1996a). Embryo and fetotoxicity of chromium in
23 pregestationally exposed mice. *Bull Environ Contam Toxicol* 57: 327-334.
- 24 [Junaid, M; Murthy, RC; Saxena, DK.](#) (1996b). Embryotoxicity of orally administered chromium in
25 mice: exposure during the period of organogenesis. *Toxicol Lett* 84: 143-148.
- 26 [Kaiser, JP; Lipscomb, JC; Wesselkamper, SC.](#) (2012). Putative mechanisms of environmental
27 chemical-induced steatosis. *Int J Toxicol* 31: 551-563.
28 <http://dx.doi.org/10.1177/1091581812466418>
- 29 [Kalahasthi, RB; Rao, RH; Murthy, RB; Kumar, MK.](#) (2006). Effect of chromium(VI) on the status of
30 plasma lipid peroxidation and erythrocyte antioxidant enzymes in chromium plating
31 workers. *Chem Biol Interact* 164: 192-199. <http://dx.doi.org/10.1016/j.cbi.2006.09.012>
- 32 [Kalantzi, L; Goumas, K; Kalioras, V; Abrahamsson, B; Dressman, JB; Reppas, C.](#) (2006).
33 Characterization of the human upper gastrointestinal contents under conditions simulating
34 bioavailability/bioequivalence studies. *Pharm Res* 23: 165-176.
35 <http://dx.doi.org/10.1007/s11095-005-8476-1>
- 36 [Kaltreider, RC; Pesce, CA; Ihnat, MA; Lariviere, JP; Hamilton, JW.](#) (1999). Differential effects of
37 arsenic(III) and chromium(VI) on nuclear transcription factor binding. *Mol Carcinog* 25:
38 219-229. [http://dx.doi.org/10.1002/\(SICI\)1098-2744\(199907\)25:3<219::AID-
MC8>3.0.CO;2-X](http://dx.doi.org/10.1002/(SICI)1098-2744(199907)25:3<219::AID-
39 MC8>3.0.CO;2-X)
- 40 [Kanojia, RK; Junaid, M; Murthy, RC.](#) (1996). Chromium induced teratogenicity in female rat. *Toxicol*
41 *Lett* 89: 207-213. [http://dx.doi.org/10.1016/S0378-4274\(96\)03812-X](http://dx.doi.org/10.1016/S0378-4274(96)03812-X)
- 42 [Kanojia, RK; Junaid, M; Murthy, RC.](#) (1998). Embryo and fetotoxicity of hexavalent chromium: a
43 long-term study. *Toxicol Lett* 95: 165-172. [http://dx.doi.org/10.1016/S0378-
4274\(98\)00034-4](http://dx.doi.org/10.1016/S0378-
44 4274(98)00034-4)
- 45 [Kararli, TT.](#) (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of
46 humans and commonly used laboratory animals [Review]. *Biopharm Drug Dispos* 16: 351-
47 380. <http://dx.doi.org/10.1002/bdd.2510160502>
- 48 [Karaulov, AV; Renieri, EA; Smolyagin, AI; Mikhaylova, IV; Stadnikov, AA; Begun, DN; Tsarouhas, K;
49 Buha Djordjevic, A; Hartung, T; Tsatsakis, A.](#) (2019). Long-term effects of chromium on

- 1 morphological and immunological parameters of Wistar rats. Food Chem Toxicol 133:
2 110748. <http://dx.doi.org/10.1016/j.fct.2019.110748>
- 3 [Katabami, M; Dosaka-Akita, H; Mishina, T; Honma, K; Kimura, K; Uchida, Y; Morikawa, K; Mikami, H;](#)
4 [Fukuda, S; Inuyama, Y; Ohsaki, Y; Kawakami, Y.](#) (2000). Frequent cyclin D1 expression in
5 chromate-induced lung cancers. Hum Pathol 31: 973-979.
6 <http://dx.doi.org/10.1053/hupa.2000.9081>
- 7 [Katiyar, S; Awasthi, SK; Sahu, RK.](#) (2008). Suppression of IL-6 level in human peripheral blood
8 mononuclear cells stimulated with PHA/LPS after occupational exposure to chromium. Sci
9 Total Environ 390: 355-361. <http://dx.doi.org/10.1016/j.scitotenv.2007.10.031>
- 10 [Kempe, DS; Lang, PA; Durantou, C; Akel, A; Lang, KS; Huber, SM; Wieder, T; Lang, F.](#) (2006).
11 Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J 20: 368-370.
12 <http://dx.doi.org/10.1096/fj.05-4872fje>
- 13 [Kerger, BD; Butler, WJ; Paustenbach, DJ; Zhang, J; Li, S.](#) (2009). Cancer mortality in chinese
14 populations surrounding an alloy plant with chromium smelting operations. J Toxicol
15 Environ Health A 72: 329-344. <http://dx.doi.org/10.1080/15287390802529898>
- 16 [Kerger, BD; Finley, BL; Corbett, GE; Dodge, DG; Paustenbach, DJ.](#) (1997). Ingestion of chromium (VI)
17 in drinking water by human volunteers: absorption, distribution, and excretion of single and
18 repeated doses. J Toxicol Environ Health 50: 67-95.
- 19 [Kerger, BD; Paustenbach, DJ; Corbett, GE; Finley, BL.](#) (1996). Absorption and elimination of trivalent
20 and hexavalent chromium in humans following ingestion of a bolus dose in drinking water.
21 Toxicol Appl Pharmacol 141: 145-158. <http://dx.doi.org/10.1006/taap.1996.0271>
- 22 [Khan, DA; Mushtaq, S; Khan, FA; Khan, MQA.](#) (2013). Toxic effects of chromium on tannery workers
23 at Sialkot (Pakistan). Toxicol Ind Health 29: 209-215.
24 <http://dx.doi.org/10.1177/0748233711430974>
- 25 [Kim, H; Cho, SH; Chung, MH.](#) (1999). Exposure to hexavalent chromium does not increase 8-
26 hydroxydeoxyguanosine levels in Korean chromate pigment workers. Ind Health 37: 335-
27 341.
- 28 [Kim, HY; Lee, SB; Jang, BS.](#) (2004). Subchronic inhalation toxicity of soluble hexavalent chromium
29 trioxide in rats. Arch Toxicol 78: 363-368. <http://dx.doi.org/10.1007/s00204-004-0553-4>
- 30 [Kim, JG; Dixon, JB.](#) (2002). Oxidation and fate of chromium in soils. Soil Sci Plant Nutr 48: 483-490.
31 <http://dx.doi.org/10.1080/00380768.2002.10409230>
- 32 [Kim, SH; Lee, I, nC; Baek, HS; Moon, C; Kang, SS, oo; Bae, CS, ik; Kim, SH, o; Shin, DH, o; Kim, JC.](#)
33 (2012). Pycnogenol (R) prevents hexavalent chromium-induced spermatotoxicity in rats.
34 Mol Cell Toxicol 8: 249-256. <http://dx.doi.org/10.1007/s13273-012-0030-8>
- 35 [Kim, WR; Flamm, SL; Di Bisceglie, AM; Bodenheimer, HC.](#) (2008). Serum activity of alanine
36 aminotransferase (ALT) as an indicator of health and disease. Hepatology 47: 1363-1370.
37 <http://dx.doi.org/10.1002/hep.22109>
- 38 [Kim, YD; An, SC; Oyama, T; Kawamoto, T; Kim, H.](#) (2003). Oxidative stress, hogg1 expression and
39 NF-kappaB activity in cells exposed to low level chromium. J Occup Health 45: 271-277.
40 <http://dx.doi.org/10.1539/joh.45.271>
- 41 [Kimber, I; Bentley, AN; Hilton, J.](#) (1990). Contact sensitization of mice to nickel sulphate and
42 potassium dichromate. Contact Derm 23: 325-330. <http://dx.doi.org/10.1111/j.1600-0536.1990.tb05166.x>
- 43 [Kimbrough, DE; Cohen, Y; Winer, A; Creelman, L; Mabuni, C.](#) (1999). A critical assessment of
44 chromium in the environment. Crit Rev Environ Sci Tech 29: 1-46.
45 <http://dx.doi.org/10.1080/10643389991259164>
- 46 [Kirman, CR; Aylward, LL; Suh, M; Harris, MA; Thompson, CM; Haws, LC; Proctor, DM; Lin, SS; Parker,](#)
47 [W; Hays, SM.](#) (2013). Physiologically based pharmacokinetic model for humans orally
48 exposed to chromium. Chem Biol Interact 204: 13-27.
49 <http://dx.doi.org/10.1016/j.cbi.2013.04.003>

- 1 [Kirman, CR; Hays, SM; Aylward, LL; Suh, M; Harris, MA; Thompson, CM; Haws, LC; Proctor, DM.](#)
2 (2012). Physiologically based pharmacokinetic model for rats and mice orally exposed to
3 chromium. *Chem Biol Interact* 200: 45-64. <http://dx.doi.org/10.1016/j.cbi.2012.08.016>
- 4 [Kirman, CR; Suh, M; Hays, SM; Gürleyük, H; Gerads, R; De Flora, S; Parker, W; Lin, S; Haws, LC;](#)
5 [Harris, MA; Proctor, DM.](#) (2016). Reduction of hexavalent chromium by fasted and fed
6 human gastric fluid. II. Ex vivo gastric reduction modeling. *Toxicol Appl Pharmacol* 306:
7 120-133. <http://dx.doi.org/10.1016/j.taap.2016.07.002>
- 8 [Kirman, CR; Suh, M; Proctor, DM; Hays, SM.](#) (2017). Improved physiologically based
9 pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to
10 address temporal variation and sensitive populations. *Toxicol Appl Pharmacol* 325: 9-17.
11 <http://dx.doi.org/10.1016/j.taap.2017.03.023>
- 12 [Kirpnick-Sobol, Z; Reliene, R; Schiestl, RH.](#) (2006). Carcinogenic Cr(VI) and the nutritional
13 supplement Cr(III) induce DNA deletions in yeast and mice. *Cancer Res* 66: 3480-3484.
14 <http://dx.doi.org/10.1158/0008-5472.CAN-05-3944>
- 15 [Kitamura, F; Yokoyama, K; Araki, S; Nishikitani, M; Choi, JW; Yum, YT; Park, HC; Park, SH; Sato, H.](#)
16 (2003). Increase of olfactory threshold in plating factory workers exposed to chromium in
17 Korea. *Ind Health* 41: 279-285. <http://dx.doi.org/10.2486/indhealth.41.279>
- 18 [Kleinfeld, M; Rosso, A.](#) (1965). Ulcerations of the nasal septum due to inhalation of chromic acid
19 mist. *Indian J Med Surg* 34: 242-243.
- 20 [Kleinstreuer, C; Zhang, Z; Donohue, JF.](#) (2008). Targeted drug-aerosol delivery in the human
21 respiratory system. *Annu Rev Biomed Eng* 10: 195-220.
22 <http://dx.doi.org/10.1146/annurev.bioeng.10.061807.160544>
- 23 [Kodavanti, U.](#) (2014). Respiratory toxicity biomarkers. In R Gupta (Ed.), *Biomarkers in toxicology*
24 (pp. 217-239). San Diego, CA: Academic Press. [http://dx.doi.org/10.1016/B978-0-12-](http://dx.doi.org/10.1016/B978-0-12-404630-6.00012-9)
25 [404630-6.00012-9](http://dx.doi.org/10.1016/B978-0-12-404630-6.00012-9)
- 26 [Kohl, KD; Stengel, A; Samuni-Blank, M; Dearing, MD.](#) (2013). Effects of anatomy and diet on
27 gastrointestinal pH in rodents. *J Exp Zool A Ecol Genet Physiol* 319: 225-229.
28 <http://dx.doi.org/10.1002/jez.1786>
- 29 [Kołański, Z; Kostrzewski, P; Kruszewska, S; Raźniewska, G; Mielczarska, J.](#) (1999). Acute
30 potassium dichromate poisoning: a toxicokinetic case study. *J Toxicol Clin Toxicol* 37: 785-
31 791.
- 32 [Kolacinski, Z; Kruszewska, S; Winnicka, R; Razniewska, G; Kolacinska, M.](#) (2004). Toxicokinetics of
33 Chromium Elimination in Hemodialysis and Forced Diuresis Based on a Case of Potassium
34 Dichromate Intoxication. *J Toxicol Clin Toxicol* 42.
- 35 [Kondo, K; Hino, N; Sasa, M; Kamamura, Y; Sakiyama, S; Tsuyuguchi, M; Hashimoto, M; Uyama, T;](#)
36 [Monden, Y.](#) (1997). Mutations of the p53 gene in human lung cancer from chromate-
37 exposed workers. *Biochem Biophys Res Commun* 239: 95-100.
38 <http://dx.doi.org/10.1006/bbrc.1997.7425>
- 39 [Kondo, K; Takahashi, Y; Hirose, Y; Nagao, T; Tsuyuguchi, M; Hashimoto, M; Ochiai, A; Monden, Y;](#)
40 [Tangoku, A.](#) (2006). The reduced expression and aberrant methylation of p16(INK4a) in
41 chromate workers with lung cancer. *Lung Cancer* 53: 295-302.
42 <http://dx.doi.org/10.1016/j.lungcan.2006.05.022>
- 43 [Kondo, K; Takahashi, Y; Ishikawa, S; Uchihara, H; Hirose, Y; Yoshizawa, K; Tsuyuguchi, M; Takizawa,](#)
44 [H; Miyoshi, T; Sakiyama, S; Monden, Y.](#) (2003). Microscopic analysis of chromium
45 accumulation in the bronchi and lung of chromate workers. *Cancer* 98: 2420-2429.
46 <http://dx.doi.org/10.1002/cncr.11818>
- 47 [Kopec, AK; Kim, S; Forgacs, AL; Zacharewski, TR; Proctor, DM; Harris, MA; Haws, LC; Thompson,](#)
48 [CM.](#) (2012a). Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia
49 following 7 and 90days of exposure to hexavalent chromium in drinking water. *Toxicol Appl*
50 *Pharmacol* 259: 13-26. <http://dx.doi.org/10.1016/j.taap.2011.11.012>

- 1 [Kopec, AK; Thompson, CM; Kim, S; Forgacs, AL; Zacharewski, TR.](#) (2012b). Comparative
2 toxicogenomic analysis of oral Cr(VI) exposure effects in rat and mouse small intestinal
3 epithelia. *Toxicol Appl Pharmacol* 262: 124-138.
4 <http://dx.doi.org/10.1016/j.taap.2012.04.026>
- 5 [Korallus, U; H-J, L; Neiss, A; Zwingers, T.](#) (1982). [Relationships between hygienic measures and the
6 bronchial carcinoma mortality in the chromate producing industry]. *Arbeitsmed Sozialmed*
7 *Praventivmed* 17: 159-167.
- 8 [Korotzer, B; Ong, S; Hansen, JE.](#) (2000). Ethnic differences in pulmonary function in healthy
9 nonsmoking Asian-Americans and European-Americans. *Am J Respir Crit Care Med* 161:
10 1101-1108. <http://dx.doi.org/10.1164/ajrccm.161.4.9902063>
- 11 [Koshi, K; Yagami, T; Nakanishi, Y.](#) (1984). Cytogenetic analysis of peripheral blood lymphocytes
12 from stainless steel welders. *Ind Health* 22: 305-318.
13 <http://dx.doi.org/10.2486/indhealth.22.305>
- 14 [Koutras, GA; Hattori, M; Schneider, AS; Ebaugh, FG; Valentine, WN.](#) (1964). STUDIES ON
15 CHROMATED ERYTHROCYTES. EFFECT OF SODIUM CHROMATE ON ERYTHROCYTE
16 GLUTATHIONE REDUCTASE. *J Clin Invest* 43: 323-331.
17 <http://dx.doi.org/10.1172/JCI104917>
- 18 [Koyama, Y; Brenner, DA.](#) (2017). Liver inflammation and fibrosis [Review]. *J Clin Invest* 127: 55-64.
19 <http://dx.doi.org/10.1172/JCI88881>
- 20 [Krause, DS; Theise, ND; Collector, MI; Henegariu, O; Hwang, S; Gardner, R; Neutzel, S; Sharkis, SJ.](#)
21 (2001). Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell.
22 *Cell* 105: 369-377. [http://dx.doi.org/10.1016/S0092-8674\(01\)00328-2](http://dx.doi.org/10.1016/S0092-8674(01)00328-2)
- 23 [Krawic, A; Luczak, M; Zhitkovich, A.](#) (2017). Variation in extracellular detoxification is a link to
24 different carcinogenicity among chromates in rodent and human lungs. *Chem Res Toxicol*
25 30: 1720-1729. <http://dx.doi.org/10.1021/acs.chemrestox.7b00172>
- 26 [Krim, M; Messaadia, A; Maida, I; Aouacheri, O; Saka, S.](#) (2013). Protective effect of ginger against
27 toxicity induced by chromate in rats. *Ann Biol Clin (Paris)* 71: 165-173.
28 <http://dx.doi.org/10.1684/abc.2013.0806>
- 29 [Kumar, A; Barthwal, R.](#) (1991). Hexavalent chromium effects on hematological indices in rats. *Bull*
30 *Environ Contam Toxicol* 46: 761-768. <http://dx.doi.org/10.1007/BF01689965>
- 31 [Kumar, A; Rana, SVS.](#) (1982). Lipid accumulation in chromium poisoned rats. *Int J Tissue React* 4:
32 291-295.
- 33 [Kumar, KM; Aruldas, MM; Banu, SL; Sadasivam, B; Vengatesh, G; Ganesh, KM;](#)
34 [Navaneethabalakrishnan, S; Navin, AK; Michael, FM; Venkatachalam, S; Stanley, JA;](#)
35 [Ramachandran, I; Banu, SK; Akbarsha, MA.](#) (2017). Male reproductive toxicity of CrVI: In-
36 utero exposure to CrVI at the critical window of testis differentiation represses the
37 expression of Sertoli cell tight junction proteins and hormone receptors in adult F1 progeny
38 rats. *Reprod Toxicol* 69: 84-98. <http://dx.doi.org/10.1016/j.reprotox.2017.02.007>
- 39 [Kumar, S; Sathwara, NG; Gautam, AK; Agarwal, K; Shah, B; Kulkarni, PK; Patel, K; Patel, A; Dave, LM;](#)
40 [Parikh, DJ; Saiyed, HN.](#) (2005). Semen quality of industrial workers occupationally exposed
41 to chromium. *J Occup Health* 47: 424-430.
- 42 [Kunstyr, J; Peters, K; Gärtner, K.](#) (1976). Investigations on the function of the rat forestomach. *Lab*
43 *Anim Sci* 26: 166-170.
- 44 [Kuo, HW; Chang, SF; Wu, KY; Wu, FY.](#) (2003). Chromium (VI) induced oxidative damage to DNA:
45 increase of urinary 8-hydroxydeoxyguanosine concentrations (8-OHdG) among
46 electroplating workers. *Occup Environ Med* 60: 590-594.
- 47 [Kuo, HW; Lai, JS; Lin, TI.](#) (1997a). Concentration and size distribution of airborne hexavalent
48 chromium in electroplating factories. *Am Ind Hyg Assoc J* 58: 29-32.
49 <http://dx.doi.org/10.1080/15428119791013044>

- 1 [Kuo, HW; Lai, JS; Lin, TI.](#) (1997b). Nasal septum lesions and lung function in workers exposed to
2 chromic acid in electroplating factories. *Int Arch Occup Environ Health* 70: 272-276.
- 3 [Kuo, HW; Wu, ML.](#) (2002). Effects of chromic acid exposure on immunological parameters among
4 electroplating workers. *Int Arch Occup Environ Health* 75: 186-190.
- 5 [Kurosaki, K; Nakamura, T; Mukai, T; Endo, T.](#) (1995). Unusual findings in a fatal case of poisoning
6 with chromate compounds. *Forensic Sci Int* 75: 57-65.
- 7 [Lacerda, LM; Garcia, SC; da Silva, LB; de Ávila Dornelles, M; Presotto, AT; Lourenço, ED; de](#)
8 [Franceschi, ID; Fernandes, E; Wannmacher, CMD; Brucker, N; Sauer, E; Gioda, A; Machado,](#)
9 [AB; Oliveira, E; Trombini, TL; Feksa, LR.](#) (2019). Evaluation of hematological, biochemical
10 parameters and thiol enzyme activity in chrome plating workers. *Environ Sci Pollut Res Int*
11 26: 1892-1901. <http://dx.doi.org/10.1007/s11356-018-3755-7>
- 12 [Laskin, DL; Malaviya, R; Laskin, JD.](#) (2019). Role of Macrophages in Acute Lung Injury and Chronic
13 Fibrosis Induced by Pulmonary Toxicants [Review]. *Toxicol Sci* 168: 287-301.
14 <http://dx.doi.org/10.1093/toxsci/kfy309>
- 15 [Lee, HS; Goh, CL.](#) (1988). Occupational dermatosis among chrome platers. *Contact Derm* 18: 89-93.
16 <http://dx.doi.org/10.1111/j.1600-0536.1988.tb02746.x>
- 17 [Lee, YH; Su, SB; Huang, CC; Sheu, HM; Tsai, JC; Lin, CH; Wang, YJ; Wang, BJ.](#) (2014). N-acetylcysteine
18 attenuates hexavalent chromium-induced hypersensitivity through inhibition of cell death,
19 ROS-related signaling and cytokine expression. *PLoS ONE* 9: e108317.
20 <http://dx.doi.org/10.1371/journal.pone.0108317>
- 21 [Leininger, JR; Schutten, M.](#) (2018). Chapter 4 - Oral cavity, teeth and gingiva. In AW Suttie (Ed.),
22 *Boorman's pathology of the rat* (2nd ed., pp. 15-21). Cambridge, MA: Academic Press.
23 <http://dx.doi.org/10.1016/B978-0-12-391448-4.00004-6>
- 24 [Leoz, ML; Carballal, S; Moreira, L; Ocaña, T; Balaguer, F.](#) (2015). The genetic basis of familial
25 adenomatous polyposis and its implications for clinical practice and risk management
26 [Review]. *The Application of Clinical Genetics* 8: 95-107.
27 <http://dx.doi.org/10.2147/TACG.S51484>
- 28 [Levina, A; Lay, PA.](#) (2005). Mechanistic studies of relevance to the biological activities of chromium.
29 *Coord Chem Rev* 249: 281-298. <http://dx.doi.org/10.1016/j.ccr.2004.02.017>
- 30 [Levina, A; Pham, TH; Lay, PA.](#) (2016). Binding of chromium(III) to transferrin could be involved in
31 detoxification of dietary chromium(III) rather than transport of an essential trace element.
32 *Angew Chem Int Ed Engl* 55: 8104-8107. <http://dx.doi.org/10.1002/anie.201602996>
- 33 [Lewis, RJ, Sr; Hawley, GG.](#) (2007). Chromium. In RJ Lewis, Sr.; GG Hawley (Eds.), *Hawley's*
34 *condensed chemical dictionary* (15th ed., pp. 298-299). Hoboken, NJ: John Wiley & Sons.
35 <http://dx.doi.org/10.1002/9780470114735.hawley03760>
- 36 [Li, C; Park, S; Zhang, X; Eisenberg, LM; Zhao, H; Darzynkiewicz, Z; Xu, D.](#) (2017). Nuclear Gene
37 33/Mig6 regulates the DNA damage response through an ATM serine/threonine kinase-
38 dependent mechanism. *J Biol Chem* 292: 16746-16759.
39 <http://dx.doi.org/10.1074/jbc.M117.803338>
- 40 [Li, H; Chen, Q; Li, S; Yao, W; Li, L; Shi, X; Wang, L; Castranova, V; Vallyathan, V; Ernst, E; Chen, C.](#)
41 (2001). Effect of Cr(VI) exposure on sperm quality: human and animal studies. *Ann Occup*
42 *Hyg* 45: 505-511.
- 43 [Li, HC; Stoicov, C; Rogers, AB; Houghton, J.](#) (2006). Stem cells and cancer: Evidence for bone marrow
44 stem cells in epithelial cancers [Review]. *World J Gastroenterol* 12: 363-371.
45 <http://dx.doi.org/10.3748/wjg.v12.i3.363>
- 46 [Li, LT; Jiang, G; Chen, Q; Zheng, JN.](#) (2015a). Ki67 is a promising molecular target in the diagnosis of
47 cancer [Review]. *Mol Med Rep* 11: 1566-1572. <http://dx.doi.org/10.3892/mmr.2014.2914>
- 48 [Li, P; Gu, Y; Yu, S; Li, Y; Yang, J; Jia, G.](#) (2014a). Assessing the suitability of 8-OHdG and micronuclei
49 as genotoxic biomarkers in chromate-exposed workers: a cross-sectional study. *BMJ Open*
50 4: e005979. <http://dx.doi.org/10.1136/bmjopen-2014-005979>

- 1 [Li, P; Li, Y; Zhang, J, i; Yu, SF, a; Tong, W, ei; Hu, X; Jia, G.](#) (2015b). Biomarkers for Lung Epithelium
2 Injury in Occupational Hexavalent Chromium-Exposed Workers. *J Occup Environ Med* 57:
3 E45-E50. <http://dx.doi.org/10.1097/JOM.0000000000000436>
- 4 [Li, Y; Hu, G; Li, P; Tang, S; Zhang, J; Jia, G.](#) (2016). miR-3940-5p enhances homologous
5 recombination after DSB in Cr(VI) exposed 16HBE cell. *Toxicology* 344-346: 1-6.
6 <http://dx.doi.org/10.1016/j.tox.2016.02.003>
- 7 [Li, Y; Li, P; Yu, S; Zhang, J; Wang, T; Jia, G.](#) (2014b). miR-3940-5p associated with genetic damage in
8 workers exposed to hexavalent chromium. *Toxicol Lett* 229: 319-326.
9 <http://dx.doi.org/10.1016/j.toxlet.2014.06.033>
- 10 [Liang, Q; Xiao, Y; Liu, K; Zhong, C; Zeng, M; Xiao, F.](#) (2018a). Cr(VI)-induced autophagy protects L-02
11 hepatocytes from apoptosis through the ROS-AKT-mTOR pathway. *Cell Physiol Biochem* 51:
12 1863-1878. <http://dx.doi.org/10.1159/000495713>
- 13 [Liang, Q; Zhang, Y; Huang, M; Xiao, Y; Xiao, F.](#) (2019). Role of mitochondrial damage in
14 Cr(VI)-induced endoplasmic reticulum stress in L-02 hepatocytes. *Mol Med Rep* 19: 1256-
15 1265. <http://dx.doi.org/10.3892/mmr.2018.9704>
- 16 [Liang, Q; Zhang, Y; Zeng, M; Guan, L; Xiao, Y; Xiao, F.](#) (2018b). The role of IP3R-SOCs in Cr(VI)-
17 induced cytosolic Ca²⁺ overload and apoptosis in L-02 hepatocytes. *Toxicology Research* 7:
18 521-528. <http://dx.doi.org/10.1039/c8tx00029h>
- 19 [Lide, D.](#) (2008). Chromium and compounds. In *CRC handbook of chemistry and physics*. Boca Raton,
20 FL: CRC Press.
- 21 [Lin, D; Triadafilopoulos, G.](#) (2015). Dual ambulatory pH monitoring in patients with
22 gastroesophageal reflux rendered asymptomatic with proton pump inhibitor therapy. *Dig*
23 *Dis Sci* 60: 1343–1349. <http://dx.doi.org/10.1007/s10620-014-3324-y>
- 24 [Lin, SC; Tai, CC; Chan, CC; Wang, JD.](#) (1994). Nasal septum lesions caused by chromium exposure
25 among chromium electroplating workers. *Am J Ind Med* 26: 221-228.
26 <http://dx.doi.org/10.1002/ajim.4700260207>
- 27 [Lindberg, E; Hedenstierna, G.](#) (1983). Chrome plating: Symptoms, findings in the upper airways, and
28 effects on lung function. *Arch Environ Occup Health* 38: 367-374.
- 29 [Lindberg, M; Forslind, B; Wahlberg, JE.](#) (1982). Reactions of epidermal keratinocytes in sensitized
30 and non-sensitized guinea pigs after dichromate exposure: an electron microscopic study.
31 *Acta Derm Venereol* 62: 389-396.
- 32 [Lindemann, M; Rietschel, F; Zabel, M; Grosse-Wilde, H.](#) (2008). Detection of chromium allergy by
33 cellular in vitro methods. *Clin Exp Allergy* 38: 1468-1475.
34 <http://dx.doi.org/10.1111/j.1365-2222.2008.02970.x>
- 35 [Linos, A; Petralias, A; Christophi, CA; Christoforidou, E; Kouroutou, P; Stolidis, M; Veloudaki, A;
36 Tzala, E; Makris, KC; Karagas, MR.](#) (2011). Oral ingestion of hexavalent chromium through
37 drinking water and cancer mortality in an industrial area of Greece--an ecological study.
38 *Environ Health* 10: 50. <http://dx.doi.org/10.1186/1476-069X-10-50>
- 39 [Linqing, Y; Bo, X; Xueqin, Y; Hong, D; Desheng, W; Huimin, Z; Gaofeng, J; Jianjun, L; Zhixiong, Z.](#)
40 (2016). Mitochondrial DNA hypomethylation in chrome plating workers. *Toxicol Lett* 243:
41 1-6. <http://dx.doi.org/10.1016/j.toxlet.2015.11.031>
- 42 [Lischka, G.](#) (1971). [Lymphocyte transformation test in chromium-hypersensitivity]. 240: 212-218.
- 43 [Littorin, M; Hogstedt, B; Stromback, B; Karlsson, A; Welinder, H; Mitelman, F; Skerfving, S.](#) (1983).
44 No cytogenetic effects in lymphocytes of stainless steel welders. *Scand J Work Environ*
45 *Health* 9: 259-264.
- 46 [Locke, WJ; Guanzon, D; Ma, C; Liew, YJ; Duesing, KR; Fung, K; Ross, JP.](#) (2019). DNA methylation
47 cancer biomarkers: Translation to the clinic [Review]. *Front Genet* 10: 1150.
48 <http://dx.doi.org/10.3389/fgene.2019.01150>
- 49 [Long, C; Liu, J; Hu, G; Feng, H; Zhou, D; Wang, J; Zhai, X; Zhao, Z; Yu, S; Wang, T; Jia, G.](#) (2019).
50 Modulation of homologous recombination repair gene polymorphisms on genetic damage in

- 1 chromate exposed workers. Environ Toxicol Pharmacol 66: 126-132.
2 <http://dx.doi.org/10.1016/j.etap.2019.01.004>
- 3 [Losi, ME; Amrhein, C; Frankenberger, WT.](#) (1994). Environmental biochemistry of chromium
4 [Review]. Rev Environ Contam Toxicol 136: 91-121. [http://dx.doi.org/10.1007/978-1-](http://dx.doi.org/10.1007/978-1-4612-2656-7_3)
5 [4612-2656-7 3](http://dx.doi.org/10.1007/978-1-4612-2656-7_3)
- 6 [Loubières, Y; de Lassence, A; Bernier, M; Vieillard-Baron, A; Schmitt, JM; Page, B; Jardin, F.](#) (1999).
7 Acute, fatal, oral chromic acid poisoning. J Toxicol Clin Toxicol 37: 333-336.
- 8 [Lu, J; Tang, M; Liu, Y; Wang, J; Wu, Z.](#) (2018). Comparative Proteomics of Chromium-Transformed
9 Beas-2B Cells by 2D-DIGE and MALDI-TOF/TOF MS. Biol Trace Elem Res.
10 <http://dx.doi.org/10.1007/s12011-017-1222-9>
- 11 [Lucas, JB.](#) (1976). Health Hazard Evaluation Determination, Report No. HHE-74-111-283, Cook
12 Paint and Varnish Company, North Kansas City, Missouri, April 1976 (pp. 74-111).
13 (NIOSH/00099446). Lucas, JB.
- 14 [Lucas, JB; Kramkowski, RS.](#) (1975). Health Hazard Evaluation Report No. HHE-74-87-221, Industrial
15 Platers, Inc., Columbus, Ohio (pp. 74-87). (NIOSH/00049983). Cincinnati, OH: National Inst.
16 for Occupational Safety and Health.
- 17 [Luczak, MW; Green, SE; Zhitkovich, A.](#) (2016). Different ATM Signaling in Response to
18 Chromium(VI) Metabolism via Ascorbate and Nonascorbate Reduction: Implications for in
19 Vitro Models and Toxicogenomics. Environ Health Perspect 124: 61-66.
20 <http://dx.doi.org/10.1289/ehp.1409434>
- 21 [Luippold, RS; Mundt, KA; Dell, LD; Birk, T.](#) (2005). Low-level hexavalent chromium exposure and
22 rate of mortality among US chromate production employees. J Occup Environ Med 47: 381-
23 385. <http://dx.doi.org/10.1097/01.jom.0000158703.32263.0d>
- 24 [Lum, G.](#) (1995). Significance of low serum alkaline phosphatase activity in a predominantly adult
25 male population. Clin Chem 41: 515-518.
- 26 [Luo, D; Xu, Z; Hu, X; Zhang, F; Bian, H; Li, N; Wang, Q; Lu, Y; Zheng, Q; Gu, J.](#) (2016). URI prevents
27 potassium dichromate-induced oxidative stress and cell death in gastric cancer cells. 8:
28 5399-5409.
- 29 [Lupescu, A; Jilani, K; Zelenak, C; Zbidah, M; Qadri, SM; Lang, F.](#) (2012). Hexavalent chromium-
30 induced erythrocyte membrane phospholipid asymmetry. Biometals 25: 309-318.
31 <http://dx.doi.org/10.1007/s10534-011-9507-5>
- 32 [Luster, MI; Portier, C; Pait, DG; Rosenthal, GJ; Germolec, DR; Corsini, E; Blaylock, BL; Pollock, P;
33 Kouchi, Y; Craig, W.](#) (1993). Risk assessment in immunotoxicology. II. Relationships
34 between immune and host resistance tests. Fundam Appl Toxicol 21: 71-82.
- 35 [Luster, MI; Portier, C; Pait, DG; White, KL, Jr; Gennings, C; Munson, AE; Rosenthal, GJ.](#) (1992). Risk
36 assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. Fundam
37 Appl Toxicol 18: 200-210. [http://dx.doi.org/10.1016/0272-0590\(92\)90047-L](http://dx.doi.org/10.1016/0272-0590(92)90047-L)
- 38 [Lv, Y; Zhang, P; Guo, J; Zhu, Z; Li, X; Xu, D; Zeng, W.](#) (2018). Melatonin protects mouse
39 spermatogonial stem cells against hexavalent chromium-induced apoptosis and epigenetic
40 histone modification. Toxicol Appl Pharmacol 340: 30-38.
41 <http://dx.doi.org/10.1016/j.taap.2017.12.017>
- 42 [Macgregor, JT; Wehr, CM; Henika, PR; Shelby, MD.](#) (1990). The in vivo erythrocyte micronucleus
43 test: Measurement at steady state increases assay efficiency and permits integration with
44 toxicity studies. Fundam Appl Toxicol 14: 513-522. [http://dx.doi.org/10.1016/0272-](http://dx.doi.org/10.1016/0272-0590(90)90255-I)
45 [0590\(90\)90255-I](http://dx.doi.org/10.1016/0272-0590(90)90255-I)
- 46 [Machle, W; Gregorius, F.](#) (1948). Cancer of the respiratory system in the United States chromate-
47 producing industry. Public Health Rep 63: 1114-1127. <http://dx.doi.org/10.2307/4586677>
- 48 [MacKenzie, RD; Byerrum, RU; Decker, CF; Hoppert, CA; Langham, RF.](#) (1958). Chronic toxicity
49 studies. II. Hexavalent and trivalent chromium administered in drinking water to rats. AMA
50 Arch Ind Health 18: 232-234.

- 1 [Maeng, SH; Chung, HW; Kim, KI; Lee, BM; Shin YC Kim, SJ; Yu, IJ.](#) (2004). Chromosome aberration
2 and lipid peroxidation in chromium-exposed workers. *Biomarkers* 9: 418-434.
3 <http://dx.doi.org/10.1080/13547500400022200>
- 4 [Maeng, SH; Chung, HW; Yu, IJ; Kim, HY; Lim, CH; Kim, KI; Kim, SJ; Ootsuyama, Y; Kasai, H.](#) (2003).
5 Changes of 8-OH-dG levels in DNA and its base excision repair activity in rat lungs after
6 inhalation exposure to hexavalent chromium. *Mutat Res* 539: 109-116.
7 [http://dx.doi.org/10.1016/S1383-5718\(03\)00154-2](http://dx.doi.org/10.1016/S1383-5718(03)00154-2)
- 8 [Malsch, PA; Proctor, DM; Finley, BL.](#) (1994). Estimation of a chromium inhalation reference
9 concentration using the benchmark dose method: A case study [Review]. *Regul Toxicol*
10 *Pharmacol* 20: 58-82. <http://dx.doi.org/10.1006/rtph.1994.1036>
- 11 [Mancuso, TF.](#) (1951). Occupational cancer and other health hazards in a chromate plant: A medical
12 appraisal. II. Clinical and toxicologic aspects. *Ind Med Surg* 20: 393-407.
- 13 [Mancuso, TF.](#) (1975). Consideration of chromium as an industrial carcinogen. In International
14 conference on heavy metals in the environment: v III, health; October. Toronto, ON, Canada:
15 Institute for Environmental Studies.
- 16 [Mancuso, TF.](#) (1997). Chromium as an industrial carcinogen: Part I. *Am J Ind Med* 31: 129-139.
17 [http://dx.doi.org/10.1002/\(SICI\)1097-0274\(199702\)31:2<129::AID-AJIM1>3.0.CO;2-V](http://dx.doi.org/10.1002/(SICI)1097-0274(199702)31:2<129::AID-AJIM1>3.0.CO;2-V)
- 18 [Mandervelt, C; Clottens, FL; Demedts, M; Nemery, B.](#) (1997). Assessment of the sensitization
19 potential of five metal salts in the murine local lymph node assay. *Toxicology* 120: 65-73.
- 20 [Marat, I; Arstan, M; Galymzhan, Y; Timur, J; Yerbolat, I; Almasbek, Y.](#) (2018). Impact of chromium
21 and boron compounds on the reproductive function in rats. *Toxicol Ind Health* 34: 365-374.
22 <http://dx.doi.org/10.1177/0748233718759162>
- 23 [Margonis, GA; Kim, Y; Spolverato, G; Ejaz, A; Gupta, R; Cosgrove, D; Anders, R; Karagkounis, G; Choti,](#)
24 [MA; Pawlik, TM.](#) (2015). Association between specific mutations in KRAS codon 12 and
25 colorectal liver metastasis. *JAMA Surgery* 150: 722-729.
26 <http://dx.doi.org/10.1001/jamasurg.2015.0313>
- 27 [Marin, RA; Bose, R; Dabrowski, B; Kolesnik, S.](#) (2018). Magnetic Characterization of Chromium
28 Intermediates in the Reduction of Chromium (VI) by Glutathione in Acidic Solutions. 4.
29 <http://dx.doi.org/10.3390/magnetochemistry4020023>
- 30 [Marouani, N; Tebourbi, O; Hallègue, D; Mokni, M; Yacoubi, MT; Sakly, M; Benkhalifa, M; Rhouma, KB.](#)
31 (2015a). Mechanisms of chromium hexavalent-induced apoptosis in rat testes. *Toxicol Ind*
32 *Health* 33: 97-106. <http://dx.doi.org/10.1177/0748233715600333>
- 33 [Marouani, N; Tebourbi, O; Mahjoub, S; Yacoubi, MT; Sakly, M; Benkhalifa, M; Rhouma, KB.](#) (2012).
34 Effects of hexavalent chromium on reproductive functions of male adult rats. *Reprod Biol*
35 *12*: 119-133.
- 36 [Marouani, N; Tebourbi, O; Mokni, M; Yacoubi, MT; Sakly, M; Benkhalifa, M; Ben Rhouma, K.](#) (2015b).
37 Hexavalent chromium-induced apoptosis in rat uterus: Involvement of oxidative stress.
38 *Arch Environ Occup Health* 70: 189-195.
39 <http://dx.doi.org/10.1080/19338244.2013.828673>
- 40 [Martin, BD; Schoenhard, JA; Hwang, JM; Sugden, KD.](#) (2006). Ascorbate is a pro-oxidant in
41 chromium-treated human lung cells. *Mutat Res* 610: 74-84.
42 <http://dx.doi.org/10.1016/j.mrgentox.2006.06.014>
- 43 [Martino, J; Holmes, AL; Xie, H; Wise, SS; Wise, JP.](#) (2015). Chronic Exposure to Particulate Chromate
44 Induces Premature Centrosome Separation and Centriole Disengagement in Human Lung
45 Cells. *Toxicol Sci* 147: 490-499. <http://dx.doi.org/10.1093/toxsci/kfv146>
- 46 [Marynka-Kalmani, K; Treves, S; Yafee, M; Rachima, H; Gafni, Y; Cohen, MA; Pitaru, S.](#) (2010). The
47 lamina propria of adult human oral mucosa harbors a novel stem cell population. *Stem Cells*
48 *28*: 984-995. <http://dx.doi.org/10.1002/stem.425>
- 49 [Mathebula, MW; Mandiwana, K; Panichev, N.](#) (2017). Speciation of chromium in bread and breakfast
50 cereals. *Food Chem* 217: 655-659. <http://dx.doi.org/10.1016/j.foodchem.2016.09.020>

- 1 [McClain, CN; Fendorf, S; Webb, SM; Maher, K.](#) (2017). Quantifying Cr(VI) production and export
2 from serpentine soil of the California coast range. *Environ Sci Technol* 51: 141-149.
3 <http://dx.doi.org/10.1021/acs.est.6b03484>
- 4 [McConnell, EL; Basit, AW; Murdan, S.](#) (2008). Measurements of rat and mouse gastrointestinal pH,
5 fluid and lymphoid tissue, and implications for in-vivo experiments. *J Pharm Pharmacol* 60:
6 63-70. <http://dx.doi.org/10.1211/jpp.60.1.0008>
- 7 [Mckinzie, PB; Parsons, BL.](#) (2002). Detection of rare K-ras codon 12 mutations using allele-specific
8 competitive blocker PCR. *Mutat Res* 517: 209-220. <http://dx.doi.org/10.1016/s1383->
9 [5718\(02\)00077-3](http://dx.doi.org/10.1016/s1383-5718(02)00077-3)
- 10 [Mckinzie, PB; Parsons, BL.](#) (2011). Accumulation of K-Ras codon 12 mutations in the F344 rat distal
11 colon following azoxymethane exposure. *Environ Mol Mutagen* 52: 409-418.
12 <http://dx.doi.org/10.1002/em.20644>
- 13 [Medeiros, MG; Rodrigues, AS; Batoréu, MC; Laires, A; Rueff, J; Zhitkovich, A.](#) (2003). Elevated levels
14 of DNA-protein crosslinks and micronuclei in peripheral lymphocytes of tannery workers
15 exposed to trivalent chromium. *Mutagenesis* 18: 19-24.
- 16 [Meenakshi, CE; Padmini, E; Motlag, DB.](#) (1989). Comparative toxicity of trivalent and hexavalent
17 chromium in rats. *Indian J Environ Health* 31: 250-256.
- 18 [Meng, F; Knapp, GW; Green, T; Ross, JA; Parsons, BL.](#) (2010). K-Ras mutant fraction in A/J mouse
19 lung increases as a function of benzo[a]pyrene dose. *Environ Mol Mutagen* 51: 146-155.
20 <http://dx.doi.org/10.1002/em.20513>
- 21 [Mezencev, R; Auerbach, SS.](#) (2021). Inferred inactivation of the Cftr gene in the duodena of mice
22 exposed to hexavalent chromium (Cr(VI)) in drinking water supports its tumor-suppressor
23 status and implies its potential role in Cr(VI)-induced carcinogenesis of the small intestines.
24 *Toxicol Appl Pharmacol* 433: 115773. <http://dx.doi.org/10.1016/j.taap.2021.115773>
- 25 [Migliore, L; Parrini, M; Sbrana, I; Biagini, C; A; Loprieno, N.](#) (1991). Micronucleated lymphocytes in
26 people occupationally exposed to potential environmental contaminants: The age effect.
27 *Mutat Res* 256: 13-20. [http://dx.doi.org/doi:10.1016/0921-8734\(91\)90028-A](http://dx.doi.org/doi:10.1016/0921-8734(91)90028-A)
- 28 [Mignini, F; Streccioni, V; Baldo, M; Vitali, M; Indraccolo, U; Bernacchia, G; Cocchioni, M.](#) (2004).
29 Individual susceptibility to hexavalent chromium of workers of shoe, hide, and leather
30 industries. Immunological pattern of HLA-B8, DR3-positive subjects. *Prev Med* 39: 767-775.
31 <http://dx.doi.org/10.1016/j.ypmed.2004.02.048>
- 32 [Mignini, F; Tomassoni, D; Traini, E; Vitali, M; Scuri, S; Baldoni, E; Grappasonni, I; Cocchioni, M.](#)
33 (2009). Immunological pattern alteration in shoe, hide, and leather industry workers
34 exposed to hexavalent chromium. *Environ Toxicol* 24: 594-602.
35 <http://dx.doi.org/10.1002/tox.20464>
- 36 [Miksche, LW; Lewalter, J.](#) (1997). Health surveillance and biological effect monitoring for
37 chromium-exposed workers [Review]. *Regul Toxicol Pharmacol* 26: S94-S99.
38 <http://dx.doi.org/10.1006/rtph.1997.1146>
- 39 [Miller, AC; Comellas, AP; Hornick, DB; Stoltz, DA; Cavanaugh, JE; Gerke, AK; Welsh, MJ; Zabner, J;
40 \[Polgreen, PM.\]\(#\) \(2020\). Cystic fibrosis carriers are at increased risk for a wide range of cystic
41 fibrosis-related conditions. *Proc Natl Acad Sci USA* 117: 1621-1627.
42 <http://dx.doi.org/10.1073/pnas.1914912117>](#)
- 43 [Mills, JC; Shivdasani, RA.](#) (2011). Gastric epithelial stem cells [Review]. *Gastroenterology* 140: 412-
44 424. <http://dx.doi.org/10.1053/j.gastro.2010.12.001>
- 45 [Mirsalis, JC; Hamilton, CM; O'Loughlin, KG; Paustenbach, DJ; Kerger, BD; Patierno, S.](#) (1996).
46 Chromium (VI) at plausible drinking water concentrations is not genotoxic in the in vivo
47 bone marrow micronucleus or liver unscheduled DNA synthesis assays. *Environ Mol*
48 *Mutagen* 28: 60-63. [http://dx.doi.org/10.1002/\(SICI\)1098-2280\(1996\)28:1<60::AID-](http://dx.doi.org/10.1002/(SICI)1098-2280(1996)28:1<60::AID-)
49 [EM9>3.0.CO;2-I](http://dx.doi.org/10.1002/(SICI)1098-2280(1996)28:1<60::AID-EM9>3.0.CO;2-I)

- 1 [Mitrov, D; Hadzi-Petrushev, N; Stojkovski, V; Gjorgievska, E; Gagov, H; Mladenov, M.](#) (2014).
2 Influence of chronic chromium exposition on the processes of lipid peroxidation
3 inflammation and platelet activation in rats [Letter]. *J Biol Regul Homeost Agents* 28: 531-
4 535.
- 5 [Miyamoto, T; Ichikawa, K; Kabe, J; Horiuchi, Y.](#) (1975). Delayed-type hypersensitivity reaction in the
6 lungs of guinea pigs due to potassium dichromate. *J Allergy Clin Immunol* 56: 464-472.
- 7 [Mo, J; Tang, C; Wang, X; Lu, W; Tong, H, ui; Zhang, C; Zhang, G.](#) (2018). Histopathological analysis of
8 ductular reaction in rabbit liver after chronic exposure of chromium (VI). *Acta med*
9 *Mediterr* 34: 1213-1219. http://dx.doi.org/10.19193/0393-6384_2018_5_186
- 10 [Monserrat-Mesquida, M; Quetglas-Llabrés, M; Abbate, M; Montemayor, S; Mascaró, CM; Casares, M;](#)
11 [Tejada, S; Abete, I; Zulet, MA; Tur, JA; Martínez, JA; Sureda, A.](#) (2020). Oxidative stress and
12 pro-inflammatory status in patients with non-alcoholic fatty liver disease. *Antioxidants* 9:
13 759. <http://dx.doi.org/10.3390/antiox9080759>
- 14 [Mor, S; Ben-Efraim, S; Leibovici, J; Ben-David, A.](#) (1988). Successful contact sensitization to
15 chromate in mice. *International Arch Allergy Appl Immunol* 85: 452-457.
16 <http://dx.doi.org/10.1159/000234550>
- 17 [Moriyama, M; Aoyagi, N; Kaniwa, N; Kojima, S; Ogata, H.](#) (2001). Assessment of gastric acidity of
18 Japanese subjects over the last 15 years. *Biol Pharm Bull* 24: 313-315.
19 <http://dx.doi.org/10.1248/bpb.24.313>
- 20 [Moschandreas, DJ; Karuchit, S; Berry, MR; O'Rourke, MK; Lo, D; Lebowitz, MD; Robertson, G.](#) (2002).
21 Exposure apportionment: ranking food items by their contribution to dietary exposure. *J*
22 *Expo Anal Environ Epidemiol* 12: 233-243. <http://dx.doi.org/10.1038/sj.jea.7500230>
- 23 [Moulin, JJ; Clavel, T; Roy, D; Dananché, B; Marquis, N; Févotte, J; Fontana, JM.](#) (2000). Risk of lung
24 cancer in workers producing stainless steel and metallic alloys. *Int Arch Occup Environ*
25 *Health* 73: 171-180. <http://dx.doi.org/10.1007/s004200050024>
- 26 [Moulin, JJ; Portefaix, P; Wild, P; Mur, JM; Smagghe, G; Mantout, B.](#) (1990). Mortality study among
27 workers producing ferroalloys and stainless steel in France. *Br J Ind Med* 47: 537-543.
28 <http://dx.doi.org/10.1136/oem.47.8.537>
- 29 [Moulin, JJ; Wild, P; Haguenoer, JM; Faucon, D; De Gaudemaris, R; Mur, JM; Mereau, M; Gary, Y;](#)
30 [Toamain, JP; Birembaut, Y.](#) (1993a). A mortality study among mild steel and stainless steel
31 welders. *Br J Ind Med* 50: 234-243. <http://dx.doi.org/10.1136/oem.50.3.234>
- 32 [Moulin, JJ; Wild, P; Mantout, B; Fournier-Betz, M; Mur, JM; Smagghe, G.](#) (1993b). Mortality from lung
33 cancer and cardiovascular diseases among stainless-steel producing workers. *Cancer*
34 *Causes Control* 4: 75-81. <http://dx.doi.org/10.1007/BF00053147>
- 35 [Mozafari, P; Rezazadeh Azari, M; Shokoohi, Y; Sayadi, M.](#) (2016). Feasibility of biological effective
36 monitoring of chrome electroplaters to chromium through analysis of serum
37 malondialdehyde. *Int J Occup Environ Med* 7: 199-206.
38 <http://dx.doi.org/10.15171/ijoem.2016.782>
- 39 [Mudie, DM; Amidon, GL; Amidon, GE.](#) (2010). Physiological parameters for oral delivery and in vitro
40 testing [Review]. *Mol Pharm* 7: 1388-1405. <http://dx.doi.org/10.1021/mp100149j>
- 41 [Mukherjee, P; Poddar, S; Talukder, G; Sharma, A.](#) (1999). Protection by black tea extract against
42 chromosome damage induced by two heavy metals in mice. *Pharmaceutical Biology* 37:
43 243-247. <http://dx.doi.org/10.1076/phbi.37.3.243.6309>
- 44 [Mukherjee, P; Sarkar, D; Sharma, A.](#) (1997). Effects of dietary consumption of black tea infusion
45 alone and in combination with known clastogens on mouse bone marrow chromosomes in
46 vivo. *Food Chem Toxicol* 35: 657-661. [http://dx.doi.org/10.1016/S0278-6915\(97\)00044-6](http://dx.doi.org/10.1016/S0278-6915(97)00044-6)
- 47 [Murphy, K; Weaver, C.](#) (2016). *Janeway's immunobiology* (9th ed.). New York, NY: Garland Science.
- 48 [Murthy, RC; Junaid, M; Saxena, DK.](#) (1996). Ovarian dysfunction in mice following chromium (VI)
49 exposure. *Toxicol Lett* 89: 147-154. [http://dx.doi.org/10.1016/S0378-4274\(96\)03803-9](http://dx.doi.org/10.1016/S0378-4274(96)03803-9)

- 1 [Murthy, RC; Saxena, DK; Gupta, SK; Chandra, SV.](#) (1991). Ultrastructural observations in testicular
2 tissue of chromium-treated rats. *Reprod Toxicol* 5: 443-447.
3 [http://dx.doi.org/10.1016/0890-6238\(91\)90008-4](http://dx.doi.org/10.1016/0890-6238(91)90008-4)
- 4 [Myers, CR; Antholine, WE; Myers, JM.](#) (2010). The pro-oxidant chromium(VI) inhibits mitochondrial
5 complex I, complex II, and aconitase in the bronchial epithelium: EPR markers for Fe-S
6 proteins. *Free Radic Biol Med* 49: 1903-1915.
7 <http://dx.doi.org/10.1016/j.freeradbiomed.2010.09.020>
- 8 [Myers, JM; Antholine, WE; Myers, CR.](#) (2008). Hexavalent Chromium Causes the Oxidation of
9 Thioredoxin in Human Bronchial Epithelial Cells. *Toxicology* 246(2-3): 222-233.
10 <http://dx.doi.org/10.1016/j.tox.2008.01.017>
- 11 [Myers, JM; Antholine, WE; Myers, CR.](#) (2011). The intracellular redox stress caused by hexavalent
12 chromium is selective for proteins that have key roles in cell survival and thiol redox
13 control. *Toxicology* 281: 37-47. <http://dx.doi.org/10.1016/j.tox.2011.01.001>
- 14 [Myers, JM; Myers, CR.](#) (2009). The effects of hexavalent chromium on thioredoxin reductase and
15 peroxiredoxins in human bronchial epithelial cells. *Free Radic Biol Med* 47: 1477-1485.
16 <http://dx.doi.org/10.1016/j.freeradbiomed.2009.08.015>
- 17 [Nature.](#) (2019). Cytokines in the balance [Editorial]. *Nat Immunol* 20: 1557.
18 <http://dx.doi.org/10.1038/s41590-019-0557-0>
- 19 [Navin, AK; Aruldas, MM; Navaneethabalakrishnan, S; Mani, K; Michael, FM; Srinivasan, N; Banu, SK.](#)
20 (2021). Prenatal exposure to hexavalent chromium disrupts testicular steroidogenic
21 pathway in peripubertal F1 rats. *Reprod Toxicol* 101: 63-73.
22 <http://dx.doi.org/10.1016/j.reprotox.2021.01.014>
- 23 [Navya, K; Kumar, GP; Anilakumar, KR.](#) (2017a). Ameliorating effect of Curculigo orchoides on
24 chromium(VI) induced oxidative stress via, modulation of cytokines, transcription factors
25 and apoptotic genes. *J Appl Biomed* 15: 299-306.
26 <http://dx.doi.org/10.1016/j.jab.2017.03.003>
- 27 [Navya, K; Phani Kumar, G; Chandrasekhar, Y; Anilakumar, KR.](#) (2017b). Evaluation of potassium
28 dichromate (K₂Cr₂O₇)-induced liver oxidative stress and ameliorative effect of Picrorhiza
29 kurroa extract in Wistar albino rats. *Biol Trace Elem Res* 184: 154-164.
30 <http://dx.doi.org/10.1007/s12011-017-1172-2>
- 31 [Neal-Kluever, A; Fisher, J; Grylack, L; Kakiuchi-Kiyota, S; Halpern, W.](#) (2019). Physiology of the
32 Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered
33 Medications. *Drug Metab Dispos* 47: 296-313. <http://dx.doi.org/10.1124/dmd.118.084418>
- 34 [Negrini, S; Gorgoulis, VG; Halazonetis, TD.](#) (2010). Genomic instability — an evolving hallmark of
35 cancer [Review]. *Nat Rev Mol Cell Biol* 11: 220-228. <http://dx.doi.org/10.1038/nrm2858>
- 36 [Nettesheim, P; Hanna, MG, Jr; Doherty, DG; Newell, RF; Hellman, A.](#) (1971). Effect of calcium
37 chromate dust, influenza virus, and 100 R whole-body X radiation on lung tumor incidence
38 in mice. *J Natl Cancer Inst* 47: 1129-1144.
- 39 [Nettesheim, P; Hanna, MG, Jr; Doherty, DG; Newell, RF; Hellman, A.](#) (1970). Effect of chronic
40 exposure to air pollutants on the respiratory tracts of mice: Histopathological findings. In P
41 Nettesheim; MG Hanna, Jr.; JW Deatherage, Jr. (Eds.), *Morphology of experimental*
42 *respiratory carcinogenesis: proceedings of a biology division, Oak Ridge National*
43 *Laboratory conference; May; Gatlinburg, TN. Oak Ridge, TN: U.S. Atomic Energy*
44 *Commission.*
- 45 [Ng, AW; Bidani, A; Heming, TA.](#) (2004). Innate host defense of the lung: effects of lung-lining fluid
46 pH [Review]. *Lung* 182: 297-317. <http://dx.doi.org/10.1007/s00408-004-2511-6>
- 47 [Nguyen, HT; Duong, HQ.](#) (2018). The molecular characteristics of colorectal cancer: Implications for
48 diagnosis and therapy [Review]. *Oncol Lett* 16: 9-18.
49 <http://dx.doi.org/10.3892/ol.2018.8679>

- 1 [Nickens, KP; Patierno, SR; Ceryak, S.](#) (2010). Chromium genotoxicity: A double-edged sword
2 [Review]. Chem Biol Interact xx: xxx. <http://dx.doi.org/10.1016/j.cbi.2010.04.018>
- 3 [Nielsen, J; Dahlvist, M; Welinder, H; Thomassen, Y; Alexandersson, R; Skerfving, S.](#) (1993). Small
4 airways function in aluminium and stainless steel welders. Int Arch Occup Environ Health
5 65: 101-105. <http://dx.doi.org/10.1007/BF00405727>
- 6 [NIH](#) (National Institutes of Health). (2017). Dietary supplement fact sheet: Chromium — health
7 professional fact sheet. Available online at [https://ods.od.nih.gov/factsheets/Chromium-](https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/)
8 [HealthProfessional/](https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/) (accessed June 12, 2017).
- 9 [Nijs, M; Kirsch-Volders, M.](#) (1986). Induction of spindle inhibition and abnormal mitotic figures by
10 Cr(II), Cr(III) and Cr(VI) ions. Mutagenesis 1: 247-252.
11 <http://dx.doi.org/10.1093/mutage/1.4.247>
- 12 [Nikula, KJ; Mccartney, JE; MCGovern, T; Miller, GK; Odin, M; Pino, MV; Reed, MD.](#) (2014). STP
13 Position Paper: Interpreting the Significance of Increased Alveolar Macrophages in Rodents
14 Following Inhalation of Pharmaceutical Materials. Toxicol Pathol 42: 472-486.
15 <http://dx.doi.org/10.1177/0192623313507003>
- 16 [Ning, J; Grant, MH.](#) (1999). Chromium (VI)-induced cytotoxicity to osteoblast-derived cells. Toxicol
17 In Vitro 13: 879-887.
- 18 [Ning, J; Grant, MH.](#) (2000). The role of reduced glutathione and glutathione reductase in the
19 cytotoxicity of chromium (VI) in osteoblasts. Toxicol In Vitro 14: 329-335.
- 20 [Ning, J; Henderson, C; Grant, MH.](#) (2002). The cytotoxicity of chromium in osteoblasts: Effects on
21 macromolecular synthesis. J Mater Sci Mater Med 13: 47-52.
22 <http://dx.doi.org/10.1023/A:1013630401959>
- 23 [NIOSH](#) (National Institute for Occupational Safety and Health). (1972). Chromic acid mist in air. In
24 Physical and Chemical Analysis Branch. (NIOSH/00051221). Rockville, MD.
- 25 [NIOSH](#) (National Institute for Occupational Safety and Health). (2013). Criteria for a recommended
26 standard: Occupational exposure to hexavalent chromium. (NIOSH Publication Number
27 2013-128). Centers for Disease Control and Prevention.
28 [https://www.cdc.gov/niosh/docs/2013-](https://www.cdc.gov/niosh/docs/2013-128/pdfs/2013_128.pdf?id=10.26616/NIOSH PUB2013128)
29 [128/pdfs/2013_128.pdf?id=10.26616/NIOSH PUB2013128](https://www.cdc.gov/niosh/docs/2013-128/pdfs/2013_128.pdf?id=10.26616/NIOSH PUB2013128)
- 30 [Nohmi, T; Katoh, M; Suzuki, H; Matsui, M; Yamada, M; Watanabe, M; Suzuki, M; Horiya, N; Ueda, O;](#)
31 [Shibuya, T; Ikeda, H; Sofuni, T.](#) (1996). A new transgenic mouse mutagenesis test system
32 using Spi- and 6-thioguanine selections. Environ Mol Mutagen 28: 465-470.
33 [http://dx.doi.org/10.1002/\(SICI\)1098-2280\(1996\)28:4<465::AID-EM24>3.0.CO;2-C](http://dx.doi.org/10.1002/(SICI)1098-2280(1996)28:4<465::AID-EM24>3.0.CO;2-C)
- 34 [Nolte, T; Brander-Weber, P; Dangler, C; Deschl, U; Elwell, MR; Greaves, P; Hailey, R; Leach, MW;](#)
35 [Pandiri, AR; Rogers, A; Shackelford, CC; Spencer, A; Tanaka, T; Ward, JM.](#) (2016).
36 Nonproliferative and proliferative lesions of the gastrointestinal tract, pancreas and salivary
37 glands of the rat and mouse [Review]. J Toxicol Pathol 29(1 Suppl.): 1S-125S.
38 <http://dx.doi.org/10.1293/tox.29.1S>
- 39 [Nordberg, GF; Fowler, BA; Nordberg, M.](#) (2015). Handbook on the toxicology of metals. In GF
40 Nordberg; BA Fowler; M Nordberg (Eds.), (4th ed.). Burlington, MA: Elsevier Science.
41 <http://dx.doi.org/10.1016/C2011-0-07884-5>
- 42 [Norppa, H; Bonassi, S; Hansteen, IL; Hagmar, L; Strömberg, U; Rössner, P; Boffetta, P; Lindholm, C;](#)
43 [Gundy, S; Lazutka, J; Cebulska-Wasilewska, A; Fabiánová, E; Srám, RJ; Knudsen, LE; Barale,](#)
44 [R; Fucic, A.](#) (2006). Chromosomal aberrations and SCEs as biomarkers of cancer risk
45 [Review]. Mutat Res 600: 37-45. <http://dx.doi.org/10.1016/j.mrfmmm.2006.05.030>
- 46 [NRC](#) (National Research Council). (1988). Health risks of radon and other internally deposited
47 alpha emitters: BEIR IV. Washington, DC.
48 http://books.nap.edu/openbook.php?record_id=1026&page=R1

- 1 [NRC](#) (National Research Council). (2001). Standing operating procedures for developing acute
2 exposure guideline levels (AEGs) for hazardous chemicals. Washington, DC: National
3 Academies Press. <http://dx.doi.org/10.17226/10122>
- 4 [NRC](#) (National Research Council). (2011). Review of the Environmental Protection Agency's draft
5 IRIS assessment of formaldehyde (pp. 1-194). Washington, DC: The National Academies
6 Press. <http://dx.doi.org/10.17226/13142>
- 7 [Nriagu, JO.](#) (1989). A global assessment of natural sources of atmospheric trace metals. *Nature* 338:
8 47-49. <http://dx.doi.org/10.1038/338047a0>
- 9 [Nriagu, JO; Pacyna, JM.](#) (1988). Quantitative assessment of worldwide contamination of air, water
10 and soils by trace metals. *Nature* 333: 134-139. <http://dx.doi.org/10.1038/333134a0>
- 11 [NTP](#) (National Toxicology Program). (1996a). Final report on the reproductive toxicity of potassium
12 dichromate (hexavalent) (CAS No. 7778-50-9) administered in diet to BALB/c mice [NTP].
13 Research Triangle Park: U.S. Department of Health and Human Services, Public Health
14 Service.
15 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB97125363.xhtml>
- 16 [NTP](#) (National Toxicology Program). (1996b). Final report on the reproductive toxicity of
17 potassium dichromate (hexavalent) (CAS No. 7778-50-9) administered in diet to SD rats
18 [NTP]. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public
19 Health Service.
20 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB97125355.xhtml>
- 21 [NTP](#) (National Toxicology Program). (1997). Final report on the reproductive toxicity of potassium
22 dichromate (CAS No. 7778-50-9) administered in diet to BALB/c mice [NTP]. Research
23 Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service.
24 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB97144919.xhtml>
- 25 [NTP.](#) (2005). Immunotoxicity of hexavalent chromium in female B6C3F1 mice. Protocol: RF-HCR-
26 28-1 M-DW. RTP: NIEHS.
- 27 [NTP.](#) (2006a). Immunotoxicity of hexavalent chromium in female Fischer 344 rats. Protocol: RF-
28 HCR-28-2R-DW. RTP: NIEHS.
- 29 [NTP.](#) (2006b). Immunotoxicity of hexavalent chromium in female Sprague Dawley rats. Protocol:
30 RF-HCR-28-1R-DW. RTP: NIEHS.
- 31 [NTP](#) (National Toxicology Program). (2007). NTP technical report on the toxicity studies of sodium
32 dichromate dihydrate (CAS No. 7789-12-0) administered in drinking water to male and
33 female F344/N rats and B6C3F1 mice and male BALB/c and am3-C57BL/6 mice [NTP].
34 (Toxicity Report Series 72). Research Triangle Park, NC.
35 https://ntp.niehs.nih.gov/ntp/htdocs/st_rpts/tox072.pdf
- 36 [NTP](#) (National Toxicology Program). (2008). Toxicology and carcinogenesis studies of sodium
37 dichromate dihydrate (Cas No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking
38 water studies) (pp. 1-192). (NTP TR 546; NIH Publication No. 08-5887).
- 39 [NTP](#) (National Toxicology Program). (2010). NTP toxicology and carcinogenesis studies of
40 chromium picolinate monohydrate (CAS No. 27882-76-4) in F344/N rats and B6C3F1 mice
41 (feed studies). (NTP TR 556; NIH Publication No. 10-5897). Research Triangle Park, NC: U.S.
42 Department of Health and Human Services, Public Health Service, National Institutes of
43 Health, National Toxicology Program. <https://ntp.niehs.nih.gov/go/tr556abs>
- 44 [NTP](#) (National Toxicology Program). (2011). Report on carcinogens. Twelfth Edition, 2011 (12th
45 ed., pp. 507). Research Triangle Park, NC: U.S. Department of Health and Human Services,
46 Public Health Service, National Institutes of Health.
47 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB2011111646.xhtml>
- 48 [NTP](#) (National Toxicology Program). (2020). Organ sites with neoplasia: number of test articles
49 associated with site-specific neoplasia that produced positive, clear or some evidence of
50 carcinogenicity. Available online at <https://manticore.niehs.nih.gov/organsites/>

- 1 [Nudler, SI; Quinteros, FA; Miler, EA; Cabilla, JP; Ronchetti, SA; Duvilanski, BH.](#) (2009). Chromium VI
2 administration induces oxidative stress in hypothalamus and anterior pituitary gland from
3 male rats. *Toxicol Lett* 185: 187-192. <http://dx.doi.org/10.1016/j.toxlet.2009.01.003>
- 4 [O'Brien, KO; Ru, Y.](#) (2017). Iron status of North American pregnant women: An update on
5 longitudinal data and gaps in knowledge from the United States and Canada [Review]. *Am J*
6 *Clin Nutr* 106: 1647S-1654S. <http://dx.doi.org/10.3945/ajcn.117.155986>
- 7 [O'Brien, TJ; Ceryak, S; Patierno, S. R.](#) (2003). Complexities of chromium carcinogenesis: role of
8 cellular response, repair and recovery mechanisms [Review]. *Mutat Res* 533: 3-36.
9 <http://dx.doi.org/10.1016/j.mrfmmm.2003.09.006>
- 10 [O'Brien, TJ; Ding, H; Suh, M; Thompson, CM; Parsons, BL; Harris, MA; Winkelman, WA; Wolf, JC;](#)
11 [Hixon, JG; Schwartz, AM; Myers, MB; Haws, LC; Proctor, DM.](#) (2013). Assessment of K-Ras
12 mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of
13 exposure to Cr(VI) in drinking water. *Mutat Res* 754: 15-21.
14 <http://dx.doi.org/10.1016/j.mrgentox.2013.03.008>
- 15 [O'Flaherty, EJ.](#) (1993). A pharmacokinetic model for chromium. *Toxicol Lett* 68: 145-158.
16 [http://dx.doi.org/10.1016/0378-4274\(93\)90127-J](http://dx.doi.org/10.1016/0378-4274(93)90127-J)
- 17 [O'Flaherty, EJ.](#) (1996). A physiologically based model of chromium kinetics in the rat. *Toxicol Appl*
18 *Pharmacol* 138: 54-64. <http://dx.doi.org/10.1006/taap.1996.0097>
- 19 [O'Flaherty, EJ; Kerger, BD; Hays, SM; Paustenbach, DJ.](#) (2001). A physiologically based model for the
20 ingestion of chromium(III) and chromium(VI) by humans. *Toxicol Sci* 60: 196-213.
21 <http://dx.doi.org/10.1093/toxsci/60.2.196>
- 22 [O'Flaherty, EJ; Radike, MJ.](#) (1991). Pharmacokinetic modeling of trivalent and hexavalent chromium
23 based on ingestion and inhalation of soluble chromium compounds. (AL-TR-1991-0162).
24 Wright-Patterson AFB, Ohio: Armstrong Laboratory.
25 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults.xhtml?searchQuery=ADA256238>
- 26 [O'Neil, M; Heckelman, P; Koch, C.](#) (2006). Chromium and compounds. In *The Merck index*.
27 Whitehouse Station, NJ: Merck & Co. Inc.
- 28 [O'Hara, KA; Klei, LR; Vaghjiani, RJ; Barchowsky, A.](#) (2004). Selective signaling pathways for
29 chromium(VI) induced patterns of transcription factor binding in exposed airway epithelial
30 cells [Abstract]. *Toxicologist* 78: 239.
- 31 [OAQPS](#) (EPA Office of Air Quality Planning and Standards). (2012). Residual risk assessment for the
32 chromic acid anodizing, decorative chromium electroplating, and hard chromium
33 electroplating source categories. Research Triangle Park, NC: U.S. Environmental Protection
34 Agency.
- 35 [Ochieng, J; Chaudhuri, G.](#) (2010). Cystatin superfamily [Review]. *J Health Care Poor Underserved* 21:
36 51-70. <http://dx.doi.org/10.1353/hpu.0.0257>
- 37 [OECD](#) (Organisation for Economic Co-operation and Development). (2016a). Test no. 474:
38 Mammalian erythrocyte micronucleus test [Standard]. In *OECD guidelines for the testing of*
39 *chemicals Section 4, health effects*. Paris, France: OECD Publishing.
40 <http://dx.doi.org/10.1787/9789264264762-en>
- 41 [OECD](#) (Organisation for Economic Co-operation and Development). (2016b). Test no. 478: Rodent
42 dominant lethal test. In *OECD guidelines for the testing of chemicals, Section 4: Health*
43 *effects*. Paris, France. <http://dx.doi.org/10.1787/9789264264823-en>
- 44 [OECD](#) (Organisation for Economic Co-operation and Development). (2020). Test no. 488:
45 Transgenic rodent somatic and germ cell gene mutation assays. In *OECD Guidelines for the*
46 *Testing of Chemicals, Section 4: Health Effects*. Paris, France.
47 <http://dx.doi.org/10.1787/9789264203907-en>
- 48 [Ohyama, W; Gonda, M; Miyajima, H; Kondo, K; Noguchi, T; Yoshida, J; Hatakeyama, S; Watabe, E;](#)
49 [Ueno, Y; Hayashi, M; Tokumitsu, T.](#) (2002). Collaborative validation study of the in vivo

- 1 micronucleus test using mouse colonic epithelial cells. *Mutat Res* 518: 39-45.
2 [http://dx.doi.org/10.1016/s1383-5718\(02\)00061-x](http://dx.doi.org/10.1016/s1383-5718(02)00061-x)
- 3 **Okada, E; Fujishi, Y; Narumi, K; Kado, S; Ohyama, W.** (2019). Evaluation of a 28-day repeated-dose
4 micronucleus test in rat glandular stomach, colon, and liver using gastrointestinal tract-
5 targeted genotoxic-carcinogens and non-carcinogens. *Mutat Res* 844: 62-68.
6 <http://dx.doi.org/10.1016/j.mrgentox.2019.05.008>
- 7 **Olaguibel, JM; Basomba, A.** (1989). Occupational asthma induced by chromium salts [Review].
8 *Allergol Immunopathol* 17: 133-136.
- 9 **Oregon DEQ** (Oregon Department of Environmental Quality). (2014). Update: Former Ken Foster
10 Farm cleanup in Sherwood [Fact Sheet]. Portland, OR.
11 <http://www.deq.state.or.us/lq/cu/nwr/kenfoster/KenFosterFarmsFactSheet.pdf>
- 12 **Oregon DEQ** (Oregon Department of Environmental Quality). (2016a). Bullseye Glass area-wide soil
13 sampling report. Portland, OR.
- 14 **Oregon DEQ** (Oregon Department of Environmental Quality). (2016b). Portland Metals air
15 monitoring data. Portland, OR.
- 16 **Oregon DEQ** (Oregon Department of Environmental Quality). (2016c). Uroboros Glass area-wide
17 soil sampling report. Portland, OR.
18 <http://www.oregon.gov/deq/FilterDocs/soilsamplingUro.pdf>
- 19 **OSHA** (Occupational Safety & Health Administration). (2006). Occupational exposure to hexavalent
20 chromium. Final rule. *Fed Reg* 71: 10099-10385.
- 21 **Ottenwaelder, H; Wiegand, HJ; Bolt, HM.** (1988). Uptake of ⁵¹Cr(VI) by human erythrocytes:
22 Evidence for a carrier-mediated transport mechanism. *Sci Total Environ* 71: 561-566.
23 [http://dx.doi.org/10.1016/0048-9697\(88\)90237-9](http://dx.doi.org/10.1016/0048-9697(88)90237-9)
- 24 **Oze, C; Bird, DK; Fendorf, S.** (2007). Genesis of hexavalent chromium from natural sources in soil
25 and groundwater. *Proc Natl Acad Sci USA* 104: 6544-6549.
26 <http://dx.doi.org/10.1073/pnas.0701085104>
- 27 **Oze, C; Fendorf, S; Bird, DK; Coleman, RG.** (2004). Chromium geochemistry of serpentine soils.
28 *International Geology Review* 46: 97-126. <http://dx.doi.org/10.2747/0020-6814.46.2.97>
- 29 **Pacyna, J; Nriagu, J.** (1988). Atmospheric emissions of chromium from natural and anthropogenic
30 sources. In JO Nriagu; E Nieboer (Eds.), *Chromium in the natural and human environments*
31 (pp. 105-123). New York, NY: Wiley. [https://www.wiley.com/en-](https://www.wiley.com/en-us/Chromium+in+the+Natural+and+Human+Environments+-p-9780471856436)
32 [us/Chromium+in+the+Natural+and+Human+Environments+-p-9780471856436](https://www.wiley.com/en-us/Chromium+in+the+Natural+and+Human+Environments+-p-9780471856436)
- 33 **Page, BJ; Loar, GW.** (2004). Chromium compounds. In Kirk-Othmer encyclopedia of chemical
34 technology. New York, NY: John Wiley & Sons.
- 35 **Paixão, P; Bermejo, M; Hens, B; Tsume, Y; Dickens, J; Shedden, K; Salehi, N; Koenigsnecht, MJ;**
36 **Baker, JR; Hasler, WL; Lionberger, R; Fan, J; Wysocki, J; Wen, B; Lee, A; Frances, A; Amidon,**
37 **GE; Yu, A; Benninghoff, G; Löbenberg, R; Talattof, A; Sun, D; Amidon, GL.** (2018). Gastric
38 emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin
39 in human subjects: A multi-compartment stomach approach. *Eur J Pharm Biopharm* 129:
40 162-174. <http://dx.doi.org/10.1016/j.ejpb.2018.05.033>
- 41 **Pan, CH; Jeng, HA; Lai, CH.** (2017). Biomarkers of oxidative stress in electroplating workers exposed
42 to hexavalent chromium. *J Expo Sci Environ Epidemiol* 28: 76-83.
43 <http://dx.doi.org/10.1038/jes.2016.85>
- 44 **Park, S; Zhang, X; Li, C; Yin, C; Li, J; Fallon, JT; Huang, W; Xu, D.** (2017). Single-cell RNA sequencing
45 reveals an altered gene expression pattern as a result of CRISPR/cas9-mediated deletion of
46 Gene 33/Mig6 and chronic exposure to hexavalent chromium in human lung epithelial cells.
47 *Toxicol Appl Pharmacol* 330: 30-39. <http://dx.doi.org/10.1016/j.taap.2017.07.003>
- 48 **Parker, D; Turk, JL; Drossler, K.** (1984). Comparison of DNFB and K₂Cr₂O₇ 'flare-up' reactions in
49 the guinea pig. *International Arch Allergy Appl Immunol* 73: 123-128.
50 <http://dx.doi.org/10.1159/000233451>

- 1 [Parrott, N; Lukacova, V; Fraczekiewicz, G; Bolger, MB.](#) (2009). Predicting pharmacokinetics of drugs
2 using physiologically based modeling--application to food effects [Review]. *AAPS J* 11: 45-
3 53. <http://dx.doi.org/10.1208/s12248-008-9079-7>
- 4 [Parsons, BL; Marchant-Miros, KE; Delongchamp, RR; Verkler, TL; Patterson, TA; Mckinzie, PB; Kim,
5 LT.](#) (2010). ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in
6 colon tumor and non-tumor tissue. *Cancer Invest* 28: 364-375.
7 <http://dx.doi.org/10.3109/07357901003630975>
- 8 [Pascal, LE; Tessier, DM.](#) (2004). Cytotoxicity of chromium and manganese to lung epithelial cells in
9 vitro. *Toxicol Lett* 147: 143-151. <http://dx.doi.org/10.1016/j.toxlet.2003.11.004>
- 10 [Patlolla, AK; Barnes, C; Hackett, D; Tchounwou, PB.](#) (2009). Potassium dichromate induced
11 cytotoxicity, genotoxicity and oxidative stress in human liver carcinoma (HepG2) cells. *Int J*
12 *Environ Res Public Health* 6: 643-653. <http://dx.doi.org/10.3390/ijerph6020643>
- 13 [Paustenbach, DJ; Hays, SM; Brien, BA; Dodge, DG; Kerger, BD.](#) (1996). Observation of steady state in
14 blood and urine following human ingestion of hexavalent chromium in drinking water. *J*
15 *Toxicol Environ Health* 49: 453-461. <http://dx.doi.org/10.1080/009841096160682>
- 16 [Pellerin, C; Booker, SM.](#) (2000). Reflections on hexavalent chromium: Health hazards of an
17 industrial heavyweight. *Environ Health Perspect* 108: a402-a407.
18 <http://dx.doi.org/10.1289/ehp.108-a402>
- 19 [Peng, N; Zhao, X.](#) (2014). Comparison of K-ras mutations in lung, colorectal and gastric cancer.
20 *Oncol Lett* 8: 561-565. <http://dx.doi.org/10.3892/ol.2014.2205>
- 21 [Peng, Y; Hu, J; Li, Y; Zhang, B; Liu, W; Li, H; Zhang, H; Hu, C; Chen, X; Xia, W; Lu, S; Xu, S.](#) (2018).
22 Exposure to chromium during pregnancy and longitudinally assessed fetal growth: Findings
23 from a prospective cohort. *Environ Int* 121: 375-382.
24 <http://dx.doi.org/10.1016/j.envint.2018.09.003>
- 25 [Peterson-Roth, E; Reynolds, M; Quievryn, G; Zhitkovich, A.](#) (2005). Mismatch repair proteins are
26 activators of toxic responses to chromium-DNA damage. *Mol Cell Biol* 25: 3596-3607.
27 <http://dx.doi.org/10.1128/MCB.25.9.3596-3607.2005>
- 28 [Petrilli, FL; De Flora, S.](#) (1982). Interpretations on chromium mutagenicity and carcinogenicity. In M
29 Sorsa; H Vainio (Eds.), *Mutagens in our environment: Proceedings of the twelfth annual*
30 *meeting of the European Environmental Mutagen Society* (pp. 453-464). New York, NY: A. R.
31 Liss.
- 32 [Petrilli, FL; Rossi, GA; Camoirano, A; Romano, M; Serra, D; Bennicelli, C; De Flora, A; De Flora, S.](#)
33 (1986). Metabolic reduction of chromium by alveolar macrophages and its relationships to
34 cigarette smoke. *J Clin Invest* 77: 1917-1924. <http://dx.doi.org/10.1172/JCI112520>
- 35 [PHS](#) (U.S. Public Health Service). (1953). *Health of workers in chromate producing industry.* (No.
36 192). Washington, DC.
- 37 [Poljsak, B; Gazdag, Z; Jenko-Brinovec, S; Fujs, S; Pesti, M; Bélagyi, J; Plesnicar, S; Raspor, P.](#) (2005).
38 Pro-oxidative vs antioxidative properties of ascorbic acid in chromium(VI)-induced
39 damage: an in vivo and in vitro approach. *J Appl Toxicol* 25: 535-548.
40 <http://dx.doi.org/10.1002/jat.1093>
- 41 [Pool-Zobel, BL; Lotzmann, N; Knoll, M; Kuchenmeister, F; Lambertz, R; Leucht, U; Schröder, HG;
42 Schmezer, P.](#) (1994). Detection of genotoxic effects in human gastric and nasal mucosa cells
43 isolated from biopsy samples. *Environ Mol Mutagen* 24: 23-45.
44 <http://dx.doi.org/10.1002/em.2850240105>
- 45 [Popper, HH; Grygar, E; Ingolic, E; Wawschinek, O.](#) (1993). Cytotoxicity of chromium-III and
46 chromium-VI compounds. I. In vitro studies using different cell culture systems. *Inhal*
47 *Toxicol* 5: 345-369. <http://dx.doi.org/10.3109/08958379308998392>
- 48 [Potten, CS; Booth, C; Pritchard, DM.](#) (1997). The intestinal epithelial stem cell: the mucosal governor
49 [Review]. *Int J Exp Pathol* 78: 219-243. [2613.1997.280362.x](http://dx.doi.org/10.1046/j.1365-
50 2613.1997.280362.x)

- 1 [Potten, CS; Gandara, R; Mahida, YR; Loeffler, M; Wright, NA.](#) (2009). The stem cells of small
2 intestinal crypts: where are they? *Cell Prolif* 42: 731-750.
3 <http://dx.doi.org/10.1111/j.1365-2184.2009.00642.x>
- 4 [Pournourmohammadi, S; Khazaelp, P; Eslamizad, S; Tajvar, A; Mohammadirad, A; Abdollahi, M.](#)
5 (2008). Study on the oxidative stress status among cement plant workers. *Hum Exp Toxicol*
6 27: 463-469. <http://dx.doi.org/10.1177/0960327108094956>
- 7 [Proctor, DM; Panko, JP; Liebig, EW; Paustenbach, DJ.](#) (2004). Estimating historical occupational
8 exposure to airborne hexavalent chromium in a chromate production plant: 1940--1972. *J*
9 *Occup Environ Hyg* 1: 752-767. <http://dx.doi.org/10.1080/15459620490523294>
- 10 [Proctor, DM; Suh, M; Aylward, LL; Kirman, CR; Harris, MA; Thompson, CM; Gürleyük, H; Gerads, R;](#)
11 [Haws, LC; Hays, SM.](#) (2012). Hexavalent chromium reduction kinetics in rodent stomach
12 contents. *Chemosphere* 89: 487-493.
13 <http://dx.doi.org/10.1016/j.chemosphere.2012.04.065>
- 14 [Proctor, DM; Suh, M; Mittal, L, iz; Hirsch, S; Salgado, RV; Bartlett, C; Van Landingham, C; Rohr, A;](#)
15 [Crumpp, K.](#) (2016). Inhalation cancer risk assessment of hexavalent chromium based on
16 updated mortality for Painesville chromate production workers. *J Expo Sci Environ*
17 *Epidemiol* 26: 224-231. <http://dx.doi.org/10.1038/jes.2015.77>
- 18 [Pukkala, E; Martinsen, J; Lynge, E; Gunnarsdottir, H; Sparén, P; Tryggvadottir, L; Weiderpass, E;](#)
19 [Kjaerheim, K.](#) (2009). Occupation and cancer - follow-up of 15 million people in five Nordic
20 countries. *Acta Oncol* 48: 646-790. <http://dx.doi.org/10.1080/02841860902913546>
- 21 [Qayyum, S; Ara, A; Usmani, JA.](#) (2012). Effect of nickel and chromium exposure on buccal cells of
22 electroplaters. *Toxicol Ind Health* 28: 74-82.
23 <http://dx.doi.org/10.1177/0748233711407237>
- 24 [Qian, Q, in; Li, P; Wang, T; Zhang, J, i; Yu, S; Chen, T; Yan, L, ei; Song, Y; Liu, X; Gu, Y; Wang, Y, un; Jia,](#)
25 [G.](#) (2013). Alteration of Th1/Th2/Th17 cytokine profile and humoral immune responses
26 associated with chromate exposure. *Occup Environ Med* 70: 697-702.
27 <http://dx.doi.org/10.1136/oemed-2013-101421>
- 28 [Qin, Q; Xie, H; Wise, SS; Browning, CL; Thompson, KN; Holmes, AL; Wise, JP.](#) (2014). Homologous
29 recombination repair signaling in chemical carcinogenesis: prolonged particulate
30 hexavalent chromium exposure suppresses the rad51 response in human lung cells. *Toxicol*
31 *Sci* 142: 117-125. <http://dx.doi.org/10.1093/toxsci/kfu175>
- 32 [Quansah, R; Jaakkola, JJ.](#) (2009). Paternal and maternal exposure to welding fumes and metal dusts
33 or fumes and adverse pregnancy outcomes. *Int Arch Occup Environ Health* 82: 529-537.
34 <http://dx.doi.org/10.1007/s00420-008-0349-6>
- 35 [Quante, M; Tu, SP; Tomita, H; Gonda, T; Wang, SS; Takashi, S; Baik, GH; Shibata, W; Diprete, B; Betz,](#)
36 [KS; Friedman, R; Varro, A; Tycko, B; Wang, TC.](#) (2011). Bone marrow-derived
37 myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth.
38 *Cancer Cell* 19: 257-272. <http://dx.doi.org/10.1016/j.ccr.2011.01.020>
- 39 [Quante, M; Varga, J; Wang, TC; Greten, FR.](#) (2013). The gastrointestinal tumor microenvironment
40 [Review]. *Gastroenterology* 145: 63-78. <http://dx.doi.org/10.1053/j.gastro.2013.03.052>
- 41 [Quante, M; Wang, TC.](#) (2008). Inflammation and stem cells in gastrointestinal carcinogenesis
42 [Review]. *Physiology (Bethesda)* 23: 350-359.
43 <http://dx.doi.org/10.1152/physiol.00031.2008>
- 44 [Quante, M; Wang, TC.](#) (2009). Stem cells in gastroenterology and hepatology. *Nat Rev Gastroenterol*
45 *Hepatol* 6: 724-737. <http://dx.doi.org/10.1038/nrgastro.2009.195>
- 46 [Quievryn, G; Goulart, M; Messer, J; Zhitkovich, A.](#) (2001). Reduction of Cr (VI) by cysteine:
47 Significance in human lymphocytes and formation of DNA damage in reactions with variable
48 reduction rates. *Mol Cell Biochem* 222: 107-118.
49 <http://dx.doi.org/10.1023/A:1017923609175>

- 1 [Quievryn, G; Messer, J; Zhitkovich, A.](#) (2002). Carcinogenic chromium(VI) induces cross-linking of
2 vitamin C to DNA in vitro and in human lung A549 cells. *Biochemistry* 41: 3156-3167.
3 <http://dx.doi.org/10.1021/bi011942z>
- 4 [Quievryn, G; Peterson, E; Messer, J; Zhitkovich, A.](#) (2003). Genotoxicity and mutagenicity of
5 chromium(VI)/ascorbate-generated DNA adducts in human and bacterial cells.
6 *Biochemistry* 42: 1062-1070. <http://dx.doi.org/10.1021/bi0271547>
- 7 [Quinteros, FA; Machiavelli, LI; Miler, EA; Cabilla, JP; Duvilanski, BH.](#) (2008). Mechanisms of
8 chromium (VI)-induced apoptosis in anterior pituitary cells. *Toxicology* 249: 109-115.
9 <http://dx.doi.org/10.1016/j.tox.2008.04.012>
- 10 [Quinteros, FA; Poliandri, AH; Machiavelli, LI; Cabilla, JP; Duvilanski, BH.](#) (2007). In vivo and in vitro
11 effects of chromium VI on anterior pituitary hormone release and cell viability. *Toxicol Appl*
12 *Pharmacol* 218: 79-87. <http://dx.doi.org/10.1016/j.taap.2006.10.017>
- 13 [Qureshi, IZ; Mahmood, T.](#) (2010). Prospective role of ascorbic acid (vitamin C) in attenuating
14 hexavalent chromium-induced functional and cellular damage in rat thyroid. *Toxicol Ind*
15 *Health* 26: 349-359. <http://dx.doi.org/10.1177/0748233710371109>
- 16 [Radke, EG; Glenn, B; Galizia, A; Persad, A; Nachman, R; Bateson, T; Wright, JM; Navas-Acien, A;](#)
17 [Arroyave, WD; Puett, RC; Harville, EW; Pollack, AZ; Burns, JS; Lynch, CD; Sagiv, SK; Stein, C;](#)
18 [Cooper, GS.](#) (2019). Development of outcome-specific criteria for study evaluation in
19 systematic reviews of epidemiology studies. *Environ Int* 130: 104884.
20 <http://dx.doi.org/10.1016/j.envint.2019.05.078>
- 21 [Radtke, F; Clevers, H.](#) (2005). Self-renewal and cancer of the gut: two sides of a coin [Review].
22 *Science* 307: 1904-1909. <http://dx.doi.org/10.1126/science.1104815>
- 23 [Rafael, AI; Almeida, A; Santos, P; Parreira, I; Madeira, VM; Alves, R; Cabrita, AM; Alpoim, MC.](#) (2007).
24 A role for transforming growth factor-beta apoptotic signaling pathway in liver injury
25 induced by ingestion of water contaminated with high levels of Cr(VI). *Toxicol Appl*
26 *Pharmacol* 224: 163-173. <http://dx.doi.org/10.1016/j.taap.2007.07.004>
- 27 [Rager, JE; Ring, CL; Fry, RC; Suh, M; Proctor, DM; Haws, LC; Harris, MA; Thompson, CM.](#) (2017).
28 High-throughput screening data interpretation in the context of in vivo transcriptomic
29 responses to oral Cr(VI) exposure. *Toxicol Sci* 158: 199-212.
30 <http://dx.doi.org/10.1093/toxsci/kfx085>
- 31 [Rager, JE; Suh, M; Chappell, GA; Thompson, CM; Proctor, DM.](#) (2019). Review of transcriptomic
32 responses to hexavalent chromium exposure in lung cells supports a role of epigenetic
33 mediators in carcinogenesis [Review]. *Toxicol Lett* 305: 40-50.
34 <http://dx.doi.org/10.1016/j.toxlet.2019.01.011>
- 35 [Rahman, MM; Abe, SK; Rahman, MS; Kanda, M; Narita, S; Bilano, V; Ota, E; Gilmour, S; Shibuya, K.](#)
36 (2016). Maternal anemia and risk of adverse birth and health outcomes in low- and middle-
37 income countries: Systematic review and meta-analysis [Review]. *Am J Clin Nutr* 103: 495-
38 504. <http://dx.doi.org/10.3945/ajcn.115.107896>
- 39 [Rao, MV; Chawla, SL; Sharma, SR.](#) (2009). Protective role of vitamin E on nickel and/or chromium
40 induced oxidative stress in the mouse ovary. *Food Chem Toxicol* 47: 1368-1371.
41 <http://dx.doi.org/10.1016/j.fct.2009.03.018>
- 42 [Rasool, M; Zaigham, K; Malik, A; Naseer, MI; Umm-E-Habiba, MI; Manan, A; Qazi, MH; Asif, M.](#)
43 (2014). Potential reproductive health effects and oxidative stress associated with exposure
44 to potassium dichromate (K₂Cr₂O₇) and magnesium sulphate (MgSO₄) in male mice.
45 *Pakistan Journal of Medical Sciences online* 30: 819-823.
- 46 [Rawla, P; Barsouk, A.](#) (2019). Epidemiology of gastric cancer: Global trends, risk factors and
47 prevention [Review]. *Prz Gastroenterol* 14: 26-38.
48 <http://dx.doi.org/10.5114/pg.2018.80001>

- 1 [Remy, LL; Byers, V; Clay, T.](#) (2017). Reproductive outcomes after non-occupational exposure to
2 hexavalent chromium, Willits California, 1983-2014. *Environ Health* 16: 18.
3 <http://dx.doi.org/10.1186/s12940-017-0222-8>
- 4 [Ren, K; Li, Y; Lu, H; Li, Z; Han, X.](#) (2017). miR-3940-5p Functions as a Tumor Suppressor in Non-
5 Small Cell Lung Cancer Cells by Targeting Cyclin D1 and Ubiquitin Specific Peptidase-28.
6 *Translational Oncology* 10: 80-89. <http://dx.doi.org/10.1016/j.tranon.2016.11.004>
- 7 [Ren, R; Li, Z; Zhang, Z.](#) (2003). [Investigation on the effect of occupational chromium on workers'
8 fertility]. *Zhongguo Gonggong Weisheng Guanli/Chinese Journal of Public Health*
9 *Management* (1): 82-83.
- 10 [Reynolds, M; Armknecht, S; Johnston, T; Zhitkovich, A.](#) (2012). Undetectable role of oxidative DNA
11 damage in cell cycle, cytotoxic and clastogenic effects of Cr(VI) in human lung cells with
12 restored ascorbate levels. *Mutagenesis* 27: 437-443.
13 <http://dx.doi.org/10.1093/mutage/ger095>
- 14 [Reynolds, M; Zhitkovich, A.](#) (2007). Cellular vitamin C increases chromate toxicity via a death
15 program requiring mismatch repair but not p53. *Carcinogenesis* 28: 1613-1620.
16 <http://dx.doi.org/10.1093/carcin/bgm031>
- 17 [Richardson, DB; Langholz, B.](#) (2012). Background stratified Poisson regression analysis of cohort
18 data. *Radiat Environ Biophys* 51: 15-22. <http://dx.doi.org/10.1007/s00411-011-0394-5>
- 19 [Ritchie, RF; Palomaki, GE; Neveux, LM; Navolotskaia, O; Ledue, TB; Craig, WY.](#) (2004). Reference
20 distributions for complement proteins C3 and C4: A practical, simple and clinically relevant
21 approach in a large cohort. *J Clin Lab Anal* 18: 1-8. <http://dx.doi.org/10.1002/jcla.10100>
- 22 [Riva, L; Pandiri, AR; Li, YR; Droop, A; Hewinson, J; Quail, MA; Iyer, V; Shepherd, R; Herbert, RA;
23 Campbell, PJ; Sills, RC; Alexandrov, LB; Balmain, A; Adams, DJ.](#) (2020). The mutational
24 signature profile of known and suspected human carcinogens in mice. *Nat Genet* 52: 1189-
25 1197. <http://dx.doi.org/10.1038/s41588-020-0692-4>
- 26 [Royle, H.](#) (1975). Toxicity of chromic acid in the chromium plating industry(2). *Environ Res* 10:
27 141-163. [http://dx.doi.org/10.1016/0013-9351\(75\)90079-1](http://dx.doi.org/10.1016/0013-9351(75)90079-1)
- 28 [Rudnykh, AA; Zasukhina, GD.](#) (1985). DNA repair synthesis in lymphocytes of people contacting
29 chromium compounds in industry. *Cytology and Genetics* 19: 68-69.
- 30 [Russell, TL; Berardi, RR; Barnett, JL; Dermentzoglou, LC; Jarvenpaa, KM; Schmaltz, SP; Dressman, JB.](#)
31 (1993). Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men
32 and women. *Pharm Res* 10: 187-196. <http://dx.doi.org/10.1023/A:1018970323716>
- 33 [Russo, P; Catassi, A; Cesario, A; Imperatori, A; Rotolo, N; Fini, M; Granone, P; Dominioni, L.](#) (2005).
34 Molecular mechanisms of hexavalent chromium-induced apoptosis in human
35 bronchoalveolar cells. *Am J Respir Cell Mol Biol* 33: 589-600.
36 <http://dx.doi.org/10.1165/rcmb.2005-02130C>
- 37 [Saleh, FY; Parkerton, TF; Lewis, RV; Huang, JH; Dickson, KL.](#) (1989). Kinetics of chromium
38 transformations in the environment. *Sci Total Environ* 86: 25-41.
- 39 [Saloga, J; Knop, J; Kolde, G.](#) (1988). Ultrastructural cytochemical visualization of chromium in the
40 skin of sensitized guinea pigs. *Arch Dermatol Res* 280: 214-219.
- 41 [Samuel, JB; Stanley, JA; Roopha, DP; Vengatesh, G; Anbalagan, J; Banu, SK; Aruldas, MM.](#) (2011).
42 Lactational hexavalent chromium exposure-induced oxidative stress in rat uterus is
43 associated with delayed puberty and impaired gonadotropin levels. *Hum Exp Toxicol* 30:
44 91-101. <http://dx.doi.org/10.1177/09603271110364638>
- 45 [Samuel, JB; Stanley, JA; Sekar, P; Princess, RA; Sebastian, MS; Aruldas, MM.](#) (2012a). Persistent
46 hexavalent chromium exposure impaired the pubertal development and ovarian
47 histoarchitecture in wistar rat offspring. *Environ Toxicol* 29: 814-828.
48 <http://dx.doi.org/10.1002/tox.21810>
- 49 [Samuel, JB; Stanley, JA; Vengatesh, G; Princess, RA; Muthusami, S; Roopha, DP; Suthagar, E; Kumar,
50 KM; Sebastian, MS; Aruldas, MM.](#) (2012b). Ameliorative effect of vitamin C on hexavalent

- 1 chromium-induced delay in sexual maturation and oxidative stress in developing Wistar rat
2 ovary and uterus. *Toxicol Ind Health* 28: 720-733.
3 <http://dx.doi.org/10.1177/0748233711422728>
- 4 [Sánchez-Martín, FJ; Fan, Y; Carreira, V; Ovesen, JL; Vonhandorf, A; Xia, Y; Puga, A.](#) (2015). Long-term
5 coexposure to hexavalent chromium and B[a]P causes tissue-specific differential biological
6 effects in liver and gastrointestinal tract of mice. *Toxicol Sci* 146: 52-64.
7 <http://dx.doi.org/10.1093/toxsci/kfv070>
- 8 [Sánchez, LM; Lewicki, M; De Lucca, RC; Ubios, ÁM.](#) (2015). Impairment of bony crypt development
9 associated with hexavalent chromium exposure during tooth eruption. *Acta Odontol*
10 *Latinoam* 28: 203-209.
- 11 [Sánchez, LM; Ubios, ÁM.](#) (2020). Alterations in odontogenesis and tooth eruption resulting from
12 exposure to hexavalent chromium in suckling animals. *Int J Paediatr Dent* 30: 35-41.
13 <http://dx.doi.org/10.1111/ipd.12573>
- 14 [Sánchez, LM; Ubios, ÁM.](#) (2021). Hexavalent chromium exposure alters bone remodeling in the
15 developing tooth alveolus and delays tooth eruption. 34: 91-97.
16 <http://dx.doi.org/10.54589/aol.34/2/091>
- 17 [Saraswathy, CP; Usharani, MV.](#) (2007). Monitoring of cellular enzymes in the serum of
18 electroplating workers at Coimbatore. *J Environ Biol* 28: 287-290.
- 19 [Sarkar, D; Sharma, A; Talukder, G.](#) (1993). Differential protection of chlorophyllin against
20 clastogenic effects of chromium and chlordane in mouse bone marrow in vivo. *Mutat Res*
21 301: 33-38. [http://dx.doi.org/10.1016/0165-7992\(93\)90053-X](http://dx.doi.org/10.1016/0165-7992(93)90053-X)
- 22 [Sarkar, D; Sharma, A; Talukder, G.](#) (1996). Protection afforded by crude spinach-beet leaf extract
23 and equivalent amounts of chlorophyll and chlorophyllin against clastogenic effects of
24 potassium dichromate in mice in vivo. *Int J Pharmacogn* 34: 58-63.
25 <http://dx.doi.org/10.1076/phbi.34.1.58.13174>
- 26 [Sarto, F; Cominato, I; Bianchi, V; Levis, AG.](#) (1982). Increased incidence of chromosomal aberrations
27 and sister chromatid exchanges in workers exposed to chromic acid (CrO₃) in electroplating
28 factories. *Carcinogenesis* 3: 1011-1016. <http://dx.doi.org/10.1093/carcin/3.9.1011>
- 29 [Sarto, F; Tomanin, R; Giacomelli, L; Iannini, G; Cupiraggi, AR.](#) (1990). The micronucleus assay in
30 human exfoliated cells of the nose and mouth: Application to occupational exposures to
31 chromic acid and ethylene oxide. *Mutat Res* 244: 345-351. [http://dx.doi.org/10.1016/0165-7992\(90\)90083-V](http://dx.doi.org/10.1016/0165-7992(90)90083-V)
- 32
- 33 [Sasso, AF; Schlosser, PM.](#) (2015). An evaluation of in vivo models for toxicokinetics of hexavalent
34 chromium in the stomach. *Toxicol Appl Pharmacol* 287: 293-298.
35 <http://dx.doi.org/10.1016/j.taap.2015.06.016>
- 36 [Sawicka, E; Długosz, A.](#) (2017). The role of 17 β -estradiol metabolites in chromium-induced
37 oxidative stress. *Advances in Clinical and Experimental Medicine* 26: 215-221.
38 <http://dx.doi.org/10.17219/acem/62217>
- 39 [Sazakli, E; Villanueva, CM; Kogevinas, M; Maltezis, K; Mouzaki, A; Leotsinidis, M.](#) (2014). Chromium
40 in Drinking Water: Association with Biomarkers of Exposure and Effect. *Int J Environ Res*
41 *Public Health* 11: 10125-10145. <http://dx.doi.org/10.3390/ijerph111010125>
- 42 [SCAQMD](#) (South Coast Air Quality Management District). (2016). Summary of efforts in paramount:
43 significant improvements since October 2016.
- 44 [Schiestl, RH; Aubrecht, J; Khogali, F; Carls, N.](#) (1997). Carcinogens induce reversion of the mouse
45 pink-eyed unstable mutation. *Proc Natl Acad Sci USA* 94: 4576-4581.
46 <http://dx.doi.org/10.1073/pnas.94.9.4576>
- 47 [Schlesinger, RB; Lippmann, M.](#) (1978). Selective particle deposition and bronchogenic carcinoma.
48 *Environ Res* 15: 424-431.

- 1 [Schlosser, PM; Sasso, AF.](#) (2014). A revised model of ex-vivo reduction of hexavalent chromium in
2 human and rodent gastric juices. *Toxicol Appl Pharmacol* 280: 352-361.
3 <http://dx.doi.org/10.1016/j.taap.2014.08.010>
- 4 [Schneeberger, HW; Forck, G.](#) (1974). Experimental chromium allergy of animals: The influence of
5 valences and chemical properties of chromium ions. 249: 71-81.
- 6 [Schroeder, WH; Dobson, M; Kane, DM; Johnson, ND.](#) (1987). Toxic trace elements associated with
7 airborne particulate matter: A review [Review]. *J Air Waste Manag Assoc* 37: 1267-1285.
8 <http://dx.doi.org/10.1080/08940630.1987.10466321>
- 9 [Schwitalla, S; Fingerle, AA; Cammareri, P; Nebelsiek, T; Göktuna, SI; Ziegler, PK; Canli, O; Heijmans,](#)
10 [J; Huels, DJ; Moreaux, G; Rupec, RA; Gerhard, M; Schmid, R; Barker, N; Clevers, H; Lang, R;](#)
11 [Neumann, J; Kirchner, T; Taketo, MM; van den Brink, GR; Sansom, OJ; Arkan, MC; Greten, FR.](#)
12 (2013). Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-
13 like properties. *Cell* 152: 25-38. <http://dx.doi.org/10.1016/j.cell.2012.12.012>
- 14 [Scott, P; Anderson, K; Singhanian, M; Cormier, R.](#) (2020). Cystic Fibrosis, CFTR, and Colorectal Cancer
15 [Review]. *International Journal of Molecular Sciences* 21.
16 <http://dx.doi.org/10.3390/ijms21082891>
- 17 [Sedman, RM; Beaumont, J; Mcdonald, TA; Reynolds, S; Krowech, G; Howd, R.](#) (2006). Review of the
18 evidence regarding the carcinogenicity of hexavalent chromium in drinking water [Review].
19 *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 24: 155-182.
20 <http://dx.doi.org/10.1080/10590500600614337>
- 21 [Sellappa, S; Prathyumn, S; Keyan, KS; Joseph, S; Vasudevan, BS; Sasikala, K.](#) (2010). Evaluation of
22 DNA damage induction and repair inhibition in welders exposed to hexavalent chromium.
23 *Asian Pac J Cancer Prev* 11: 95-100.
- 24 [Sengupta, T; Chattopadhyay, D; Ghosh, N; Das, M; Chatterjee, GC.](#) (1990). Effect of chromium
25 administration on glutathione cycle of rat intestinal epithelial cells. *Indian J Exp Biol* 28:
26 1132-1135.
- 27 [Seoane, AI; Dulout, FN.](#) (1999). Contribution to the validation of the anaphase-telophase test:
28 Aneugenic and clastogenic effects of cadmium sulfate, potassium dichromate and nickel
29 chloride in Chinese hamster ovary cells. *Genet Mol Biol* 22: 551-555.
- 30 [Seoane, AI; Dulout, FN.](#) (2001). Genotoxic ability of cadmium, chromium and nickel salts studied by
31 kinetochore staining in the cytokinesis-blocked micronucleus assay. *Mutat Res* 490: 99-106.
32 [http://dx.doi.org/10.1016/S1383-5718\(00\)00145-5](http://dx.doi.org/10.1016/S1383-5718(00)00145-5)
- 33 [Seoane, AI; Güerci, AM; Dulout, FN.](#) (2002). Malsegregation as a possible mechanism of aneuploidy
34 induction by metal salts in MRC-5 human cells. *Environ Mol Mutagen* 40: 200-206.
35 <http://dx.doi.org/10.1002/em.10110>
- 36 [Sharma, N; Chauhan, S; Varma, S.](#) (2003). Fatal potassium dichromate ingestion [Letter]. *J Postgrad*
37 *Med* 49: 286-287.
- 38 [Sharma, P; Bihari, V; Agarwal, SK; Verma, V; Kesavachandran, CN; Pangtey, BS; Mathur, N; Singh, KP;](#)
39 [Srivastava, M; Goel, SK.](#) (2012). Groundwater contaminated with hexavalent chromium [Cr
40 (VI)]: a health survey and clinical examination of community inhabitants (Kanpur, India).
41 *PLoS ONE* 7: e47877. <http://dx.doi.org/10.1371/journal.pone.0047877>
- 42 [Sharma, S; Kelly, TK; Jones, PA.](#) (2010). Epigenetics in cancer [Review]. *Carcinogenesis* 31: 27-36.
43 <http://dx.doi.org/10.1093/carcin/bgp220>
- 44 [Shaw Environmental](#) (Shaw Environmental, Inc). (2006). Final report. Industry profile, exposure
45 profile, technological feasibility evaluation, and environmental impact for industries
46 affected by a revised OSHA standard for hexavalent chromium (General industry,
47 construction, and maritime sectors). (OSHA-H054A-2006-0064-2537). Washington, DC: U.S.
48 Department of Labor, Occupational Safety and Health Administration.
49 <https://www.regulations.gov/document?D=OSHA-H054A-2006-0064-2537>

- 1 [Shi, H; Hudson, LG; Liu, KJ.](#) (2004). Oxidative stress and apoptosis in metal ion-induced
2 carcinogenesis [Review]. *Free Radic Biol Med* 37: 582-593.
3 <http://dx.doi.org/10.1016/j.freeradbiomed.2004.03.012>
- 4 [Shih, GL; Brensinger, C; Katzka, DA; Metz, DC.](#) (2003). Influence of age and gender on gastric acid
5 secretion as estimated by integrated acidity in patients referred for 24-hour ambulatory pH
6 monitoring. *Am J Gastroenterol* 98: 1713-1718. [http://dx.doi.org/10.1016/S0002-](http://dx.doi.org/10.1016/S0002-9270(03)00435-0)
7 [9270\(03\)00435-0](http://dx.doi.org/10.1016/S0002-9270(03)00435-0)
- 8 [Shih, IM; Wang, TL; Traverso, G; Romans, K; Hamilton, SR; Ben-Sasson, S; Kinzler, KW; Vogelstein, B.](#)
9 (2001). Top-down morphogenesis of colorectal tumors. *Proc Natl Acad Sci USA* 98: 2640-
10 2645. <http://dx.doi.org/10.1073/pnas.051629398>
- 11 [Shindo, Y; Toyoda, Y; Kawamura, K; Kurebe, M; Shimada, H; Hattori, C; Satake, S.](#) (1989).
12 Micronucleus test with potassium chromate(VI) administered intraperitoneally and orally
13 to mice. *Mutat Res* 223: 403-406.
- 14 [Shobana, N; Aruldas, MM; Tochowang, L; Loganathan, A; Balaji, S; Kumar, MK; Banu, LAS; Navin,](#)
15 [AK; Mayilvanan, C; Ilangovan, R; Balasubramanian, K.](#) (2017). Transient gestational
16 exposure to drinking water containing excess hexavalent chromium modifies insulin
17 signaling in liver and skeletal muscle of rat progeny. *Chem Biol Interact* 277: 119-128.
18 <http://dx.doi.org/10.1016/j.cbi.2017.09.003>
- 19 [Shobana, N; Kumar, MK; Navin, AK; Akbarsha, MA; Aruldas, MM.](#) (2020). Prenatal exposure to
20 excess chromium attenuates transcription factors regulating expression of androgen and
21 follicle stimulating hormone receptors in Sertoli cells of prepuberal rats. *Chem Biol Interact*
22 328: 109188. <http://dx.doi.org/10.1016/j.cbi.2020.109188>
- 23 [Shoeb, M; Kodali, VK; Farris, BY; Bishop, LM; Meighan, TG; Salmen, R; Eye, T; Friend, S; Schwegler-](#)
24 [Berry, D; Roberts, JR; Zeidler-Erdely, PC; Erdely, A; Antonini, JM.](#) (2017). Oxidative stress,
25 DNA methylation, and telomere length changes in peripheral blood mononuclear cells after
26 pulmonary exposure to metal-rich welding nanoparticles. *NanoImpact* 5: 61-69.
27 <http://dx.doi.org/10.1016/j.impact.2017.01.001>
- 28 [Shrivastava, R; Srivastava, S; Upreti, RK; Chaturvedi, UC.](#) (2005a). Effects of dengue virus infection
29 on peripheral blood cells of mice exposed to hexavalent chromium with drinking water.
30 *Indian J Med Res* 122: 111-119.
- 31 [Shrivastava, R; Upreti, RK; Chaturvedi, UC.](#) (2003). Various cells of the immune system and intestine
32 differ in their capacity to reduce hexavalent chromium. *FEMS Immunol Med Microbiol* 38:
33 65-70.
- 34 [Shrivastava, R; Upreti, RK; Chaturvedi, UC.](#) (2005b). Effects of dengue virus infection on the spleen
35 of male mice given hexavalent chromium with drinking water. *Toxicol Mech Meth* 15: 323-
36 329. <http://dx.doi.org/10.1080/153765291009732>
- 37 [Shubin, AV; Demidyuk, IV; Komissarov, AA; Rafieva, LM; Kostrov, SV.](#) (2016). Cytoplasmic
38 vacuolization in cell death and survival [Review]. *Onct* 7: 55863-55889.
39 <http://dx.doi.org/10.18632/oncotarget.10150>
- 40 [Shumilla, JA; Barchowsky, A.](#) (1999). Inhibition of protein synthesis by chromium(VI) differentially
41 affects expression of urokinase and its receptor in human type II pneumocytes. *Toxicol Appl*
42 *Pharmacol* 158: 288-295. <http://dx.doi.org/10.1006/taap.1999.8704>
- 43 [Siegenthaler, U; Laine, A; Polak, L.](#) (1983). Studies on contact sensitivity to chromium in the guinea
44 pig The role of valence in the formation of the antigenic determinant. *J Invest Dermatol* 80:
45 44-47.
- 46 [Singh, CBP; Sharma, A; Talukder, G.](#) (1990). Effects of chromium on cellular systems in animals.
47 *Nucleus* 33: 84-106.
- 48 [Singhal, VK; Deswal, BS; Singh, BN.](#) (2015). Study of skin and mucous membrane disorders among
49 workers engaged in the sodium dichromate manufacturing industry and chrome plating

- 1 industry. *Indian J Occup Environ Med* 19: 129-133. <http://dx.doi.org/10.4103/0019-5278.173994>
- 2
- 3 [Sitalakshmi, R; Saikumar, P; Jeyachandran, P; Manoharan, P; Thangavel, P; Thomas, J.](#) (2016). Civil
4 construction work: The unseen contributor to the occupational and global disease burden.
5 *Indian J Occup Environ Med* 20: 103-108. <http://dx.doi.org/10.4103/0019-5278.197542>
- 6 [Sivakumar, KK; Stanley, JA; Arosh, JA; Pepling, ME; Burghardt, RC; Banu, SK.](#) (2014). Prenatal
7 exposure to chromium induces early reproductive senescence by increasing germ cell
8 apoptosis and advancing germ cell cyst breakdown in the F1 offspring. *Dev Biol* 388: 22-34.
9 <http://dx.doi.org/10.1016/j.ydbio.2014.02.003>
- 10 [Sivakumar, KK; Stanley, JA; Behlen, JC; Wuri, L; Dutta, S; Wu, J; Arosh, JA; Banu, SK.](#) (2022).
11 Inhibition of Sirtuin-1 hyperacetylates p53 and abrogates Sirtuin-1-p53 interaction in
12 Cr(VI)-induced apoptosis in the ovary. *Reprod Toxicol* 109: 121-134.
13 <http://dx.doi.org/10.1016/j.reprotox.2022.03.007>
- 14 [Smith, AH.](#) (2008). Hexavalent chromium, yellow water, and cancer: a convoluted saga.[comment]
15 [Letter]. *Epidemiology* 19: 24-26.
- 16 [Smith, DB; Cannon, WF; Woodruff, LG; Solano, F; Kilburn, JE; Fey, DL.](#) (2013). Geochemical and
17 mineralogical data for soils of the conterminous United States. (Data Series 801). Reston,
18 VA: U.S. Department of the Interior, U.S. Geological Survey. <http://pubs.usgs.gov/ds/801/>
- 19 [Smith, MT; Guyton, KZ; Gibbons, CF; Fritz, JM; Portier, CJ; Rusyn, I; DeMarini, DM; Caldwell, JC;
20 Kavlock, RJ; Lambert, PF; Hecht, SS; Bucher, JR; Stewart, BW; Baan, RA; Coglian, VJ; Straif,
21 K.](#) (2016). Key characteristics of carcinogens as a basis for organizing data on mechanisms
22 of carcinogenesis [Review]. *Environ Health Perspect* 124: 713-721.
23 <http://dx.doi.org/10.1289/ehp.1509912>
- 24 [Snyder, CA; Udasin, I; Waterman, SJ; Toioli, E; Gochfeld, M.](#) (1996). Reduced IL-6 levels among
25 individuals in Hudson County, New Jersey, an area contaminated with chromium. *Arch*
26 *Environ Health* 51: 26-28. <http://dx.doi.org/10.1080/00039896.1996.9935989>
- 27 [Snyder, CA; Valle, CD.](#) (1991). Immune function assays as indicators of chromate exposure. *Environ*
28 *Health Perspect* 92: 83-86. <http://dx.doi.org/10.1289/ehp.919283>
- 29 [Soares, ME; Vieira, E; Bastos, M.](#) (2010). Chromium speciation analysis in bread samples. *J Agric*
30 *Food Chem* 58: 1366-1370. <http://dx.doi.org/10.1021/jf903118v>
- 31 [Sobaszek, A; Edme, JL; Boulenguez, C; Shirali, P; Mereau, M; Robin, H; Haguenoer, JM.](#) (1998).
32 Respiratory symptoms and pulmonary function among stainless steel welders. *J Occup*
33 *Environ Med* 40: 223-229.
- 34 [Song, Y; Zhang, J; Yu, S; Wang, T; Cui, X; Du, X; Jia, G.](#) (2012). Effects of chronic chromium(vi)
35 exposure on blood element homeostasis: an epidemiological study. *Metallomics* 4: 463-472.
36 <http://dx.doi.org/10.1039/c2mt20051a>
- 37 [Sorahan, T; Burges, DC; Hamilton, L; Harrington, JM.](#) (1998). Lung cancer mortality in
38 nickel/chromium platers, 1946-95. *Occup Environ Med* 55: 236-242.
39 <http://dx.doi.org/10.1136/oem.55.4.236>
- 40 [Sorahan, T; Burges, DCL; Waterhouse, JAH.](#) (1987). A mortality study of nickel/chromium platers.
41 *Br J Ind Med* 44: 250-258.
- 42 [Soudani, N; Bouaziz, H; Sefi, M; Chtourou, Y; Boudawara, T; Zeghal, N.](#) (2013). Toxic effects of
43 chromium (VI) by maternal ingestion on liver function of female rats and their suckling
44 pups. *Environ Toxicol* 28: 11-20. <http://dx.doi.org/10.1002/tox.20692>
- 45 [Soudani, N; Ibtissem Ben Amara, N; Troudi, A; Bouaziz, H; Boudawara, T; Zeghal, N.](#) (2011a).
46 Oxidative stress induced by chromium (VI) in bone of suckling rats. *Toxicol Ind Health* 27:
47 724-734. <http://dx.doi.org/10.1177/0748233710395992>
- 48 [Soudani, N; Sefi, M; Bouaziz, H; Chtourou, Y; Boudawara, T; Zeghal, N.](#) (2011b). Nephrotoxicity
49 induced by chromium (VI) in adult rats and their progeny. *Hum Exp Toxicol* 30: 1233-1245.
50 <http://dx.doi.org/10.1177/0960327110387454>

- 1 [Speer, RM; Toyoda, JH; Croom-Perez, TJ; Liu, KJ; Wise, JP.](#) (2021). Particulate hexavalent chromium
2 inhibits E2F1 leading to reduced RAD51 nuclear foci formation in human lung cells. *Toxicol*
3 *Sci* 181: 35-46. <http://dx.doi.org/10.1093/toxsci/kfab019>
- 4 [Spiteri, NJ.](#) (1982). Circadian patterning of feeding, drinking and activity during diurnal food access
5 in rats. *Physiol Behav* 28: 139-147. [http://dx.doi.org/10.1016/0031-9384\(82\)90115-9](http://dx.doi.org/10.1016/0031-9384(82)90115-9)
- 6 [Squier, CA; Kremer, MJ.](#) (2001). Biology of oral mucosa and esophagus [Review]. *J Natl Cancer Inst*
7 *Monogr* 29: 7-15.
- 8 [Standeven, AM; Wetterhahn, KE.](#) (1989). Chromium-vi toxicity uptake reduction and dna damage. *J*
9 *Am Coll Toxicol* 8: 1275-1284. <http://dx.doi.org/10.3109/10915818909009118>
- 10 [Standeven, AM; Wetterhahn, KE.](#) (1991). Ascorbate is the principal reductant of chromium (VI) in
11 rat liver and kidney ultrafiltrates. *Carcinogenesis* 12: 1733-1737.
12 <http://dx.doi.org/10.1093/carcin/12.9.1733>
- 13 [Standeven, AM; Wetterhahn, KE.](#) (1992). Ascorbate is the principal reductant of chromium(VI) in
14 rat lung ultrafiltrates and cytosols, and mediates chromium-DNA binding in vitro.
15 *Carcinogenesis* 13: 1319-1324. <http://dx.doi.org/10.1093/carcin/13.8.1319>
- 16 [Stanley, JA; Lee, J; Nithy, TK; Arosh, JA; Burghardt, RC; Banu, SK.](#) (2011). Chromium-VI arrests cell
17 cycle and decreases granulosa cell proliferation by down-regulating cyclin-dependent
18 kinases (CDK) and cyclins and up-regulating CDK-inhibitors. *Reprod Toxicol* 32: 112-123.
19 <http://dx.doi.org/10.1016/j.reprotox.2011.05.007>
- 20 [Stanley, JA; Sivakumar, KK; Arosh, JA; Burghardt, RC; Banu, SK.](#) (2014). Edaravone mitigates
21 hexavalent chromium-induced oxidative stress and depletion of antioxidant enzymes while
22 estrogen restores antioxidant enzymes in the rat ovary in F1 offspring. *Biol Reprod* 91: 12.
23 <http://dx.doi.org/10.1095/biolreprod.113.113332>
- 24 [Stanley, JA; Sivakumar, KK; Nithy, TK; Arosh, JA; Hoyer, PB; Burghardt, RC; Banu, SK.](#) (2013).
25 Postnatal exposure to chromium through mother's milk accelerates follicular atresia in F1
26 offspring through increased oxidative stress and depletion of antioxidant enzymes. *Free*
27 *Radic Biol Med* 61: 179-196. <http://dx.doi.org/10.1016/j.freeradbiomed.2013.02.006>
- 28 [Stearns, DM.](#) (2000). Is chromium a trace essential metal? [Review]. *BioFactors* 11: 149-162.
29 <http://dx.doi.org/10.1002/biof.5520110301>
- 30 [Stearns, DM; Kennedy, LJ; Courtney, KD; Giangrande, PH; Phieffer, LS; Wetterhahn, KE.](#) (1995).
31 Reduction of chromium(VI) by ascorbate leads to chromium-DNA binding and DNA strand
32 breaks in vitro. *Biochemistry* 34: 910-919. <http://dx.doi.org/10.1021/bi00003a025>
- 33 [Stearns, DM; Wetterhahn, KE.](#) (1994). Reaction of chromium(VI) with ascorbate produces
34 chromium(V), chromium(IV), and carbon-based radicals. *Chem Res Toxicol* 7: 219-230.
35 <http://dx.doi.org/10.1021/tx00038a016>
- 36 [Stearns, DM; Wetterhahn, KE.](#) (1997). Intermediates Produced in the Reaction of Chromium(VI)
37 with Dehydroascorbate Cause Single-Strand Breaks in Plasmid DNA. *Chem Res Toxicol* 10:
38 271-278. <http://dx.doi.org/10.1021/tx9601521>
- 39 [Steinhoff, D; ShC, G; Hatfield, GK; Mohr, U.](#) (1986). Carcinogenicity study with sodium dichromate in
40 rats. *Exp Toxicol Pathol* 30: 129-141. [http://dx.doi.org/10.1016/S0232-1513\(86\)80085-8](http://dx.doi.org/10.1016/S0232-1513(86)80085-8)
- 41 [Stern, AH; Yu, CH; Black, K; Lin, L; Liroy, PJ; Gochfeld, M; Fan, ZH.](#) (2010). Hexavalent chromium in
42 house dust--a comparison between an area with historic contamination from chromate
43 production and background locations. *Sci Total Environ* 408: 4993-4998.
44 <http://dx.doi.org/10.1016/j.scitotenv.2010.07.035>
- 45 [Stift, A; Friedl, J; Laengle, F.](#) (1998). Liver transplantation for potassium dichromate poisoning
46 [Letter]. *N Engl J Med* 338: 766-767. <http://dx.doi.org/10.1056/NEJM199803123381115>
- 47 [Stift, A; Friedl, J; Längle, F; Berlakovich, G; Steininger, R; Mühlbacher, F.](#) (2000). Successful
48 treatment of a patient suffering from severe acute potassium dichromate poisoning with
49 liver transplantation. *Transplantation* 69: 2454-2455.

- 1 [Stout, MD; Nyska, A; Collins, BJ; Witt, KL; Kissling, GE; Malarkey, DE; Hooth, MJ.](#) (2009). Chronic
2 toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in
3 feed to F344/N rats and B6C3F1 mice for 2 years. *Food Chem Toxicol* 47: 729-733.
4 <http://dx.doi.org/10.1016/j.fct.2009.01.006>
- 5 [Subramanian, S; Rajendiran, G; Sekhar, P; Gowri, C; Govindarajulu, P; Aruldas, MM.](#) (2006).
6 Reproductive toxicity of chromium in adult bonnet monkeys (*Macaca radiata* Geoffrey).
7 Reversible oxidative stress in the semen. *Toxicol Appl Pharmacol* 215: 237-249.
8 <http://dx.doi.org/10.1016/j.taap.2006.03.004>
- 9 [Sudha, S; Kripa, SK; Shibily, P; Joseph, S; Balachandar, V.](#) (2011). Biomonitoring of genotoxic effects
10 among shielded manual metal arc welders. *Asian Pac J Cancer Prev* 12: 1041-1044.
- 11 [Sugden, KD; Campo, CK; Martin, BD.](#) (2001). Direct oxidation of guanine and 7,8-dihydro-8-
12 oxoguanine in DNA by a high-valent chromium complex: a possible mechanism for
13 chromate genotoxicity. *Chem Res Toxicol* 14: 1315-1322.
- 14 [Sugden, KD; Stearns, DM.](#) (2000). The role of chromium(V) in the mechanism of chromate-induced
15 oxidative DNA damage and cancer [Review]. *J Environ Pathol Toxicol Oncol* 19: 215-230.
- 16 [Sugiyama, M; Tsuzuki, K; Ogura, R.](#) (1991). Effect of ascorbic acid on DNA damage, cytotoxicity,
17 glutathione reductase, and formation of paramagnetic chromium in Chinese hamster V-79
18 cells treated with sodium chromate(VI). *J Biol Chem* 266: 3383-3386.
- 19 [Suh, M; Thompson, CM; Kirman, CR; Carakostas, MC; Haws, LC; Harris, MA; Proctor, DM.](#) (2014).
20 High concentrations of hexavalent chromium in drinking water alter iron homeostasis in
21 F344 rats and B6C3F1 mice. *Food Chem Toxicol* 65: 381-388.
22 <http://dx.doi.org/10.1016/j.fct.2014.01.009>
- 23 [Suh, M; Wikoff, D; Lipworth, L; Goodman, M; Fitch, S; Mittal, L; Ring, C; Proctor, D.](#) (2019).
24 Hexavalent chromium and stomach cancer: a systematic review and meta-analysis. *Crit Rev*
25 *Toxicol* 49: 140-159. <http://dx.doi.org/10.1080/10408444.2019.1578730>
- 26 [Suzuki, Y.](#) (1990). Synergism of ascorbic acid and glutathione in the reduction of hexavalent
27 chromium in vitro. *Ind Health* 28: 9-19.
- 28 [Suzuki, Y; Fukuda, K.](#) (1990). Reduction of hexavalent chromium by ascorbic acid and glutathione
29 with special reference to the rat lung. *Arch Toxicol* 64: 169-176.
30 <http://dx.doi.org/10.1007/BF02010721>
- 31 [Takahashi, Y; Kondo, K; Hirose, T; Nakagawa, H; Tsuyuguchi, M; Hashimoto, M; Sano, T; Ochiai, A;](#)
32 [Monden, Y.](#) (2005). Microsatellite instability and protein expression of the DNA mismatch
33 repair gene, hMLH1, of lung cancer in chromate-exposed workers. *Mol Carcinog* 42: 150-
34 158. <http://dx.doi.org/10.1002/mc.20073>
- 35 [Talattof, A; Amidon, GL.](#) (2018). Pulse packet stochastic model for gastric emptying in the fasted
36 state: A physiological approach. *Mol Pharm* 15: 2107-2115.
37 <http://dx.doi.org/10.1021/acs.molpharmaceut.7b01077>
- 38 [Tanigawa, T; Araki, S; Sata, F; Nakata, A; Araki, T.](#) (1998). Effects of smoking, aromatic amines, and
39 chromates on CD4+ and CD8+ T lymphocytes in male workers [Comment]. *Environ Res* 78:
40 59-63. <http://dx.doi.org/10.1006/enrs.1997.3827>
- 41 [Taniguchi, K; Karin, M.](#) (2018). NF- κ B, inflammation, immunity and cancer: coming of age. *Nat Rev*
42 *Immunol* 309-324. <http://dx.doi.org/10.1038/nri.2017.142>
- 43 [Tarrant, JM.](#) (2010). Blood cytokines as biomarkers of in vivo toxicity in preclinical safety
44 assessment: Considerations for their use [Review]. *Toxicol Sci* 117: 4-16.
45 <http://dx.doi.org/10.1093/toxsci/kfq134>
- 46 [TCEQ](#) (Texas Commission on Environmental Quality). (2014). Development support document for
47 hexavalent chromium (particulate compounds). Austin, TX.
- 48 [Than, BL; Linnekamp, JF; Starr, TK; Largaespada, DA; Rod, A; Zhang, Y; Bruner, V; Abrahante, J;](#)
49 [Schumann, A; Luczak, T; Walter, Niemczyk, A; O'Sullivan, MG; Medema, JP; Fijneman, RJ;](#)
50 [Meijer, GA; Van Den Broek, E; Hodges, CA; Scott, PM; Vermeulen, L; Cormier, RT.](#) (2016).

1 CFTR is a tumor suppressor gene in murine and human intestinal cancer. *Oncogene* 35:
2 4179-4187. <http://dx.doi.org/10.1038/onc.2015.483>

3 [Thermo Fisher](#) (Thermo Fisher Scientific Inc.). (2009). Safety data sheet: Potassium dichromate.
4 [Thomann, RV; Snyder, CA; Squibb, KS.](#) (1994). Development of a pharmacokinetic model for
5 chromium in the rat following subchronic exposure: I. The importance of incorporating
6 long-term storage compartment. *Toxicol Appl Pharmacol* 128: 189-198.
7 <http://dx.doi.org/10.1006/taap.1994.1197>

8 [Thompson, CM; Donahue, DA; Hobbs, C; Costecalde, Y; Franzen, A; Suh, M; Proctor, DM; Harris, MA.](#)
9 (2020). Exposure to environmentally-relevant concentrations of hexavalent chromium does
10 not induce ovarian toxicity in mice. *Regul Toxicol Pharmacol* 116: 104729.
11 <http://dx.doi.org/10.1016/j.yrtph.2020.104729>

12 [Thompson, CM; Fedorov, Y; Brown, DD; Suh, M; Proctor, DM; Kuriakose, L; Haws, LC; Harris, MA.](#)
13 (2012a). Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content
14 analysis. *PLoS ONE* 7: e42720. <http://dx.doi.org/10.1371/journal.pone.0042720>

15 [Thompson, CM; Kirman, CR; Proctor, DM; Haws, LC; Suh, M; Hays, SM; Hixon, JG; Harris, MA.](#) (2014).
16 A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. *J Appl*
17 *Toxicol* 34: 525-536. <http://dx.doi.org/10.1002/jat.2907>

18 [Thompson, CM; Proctor, DM; Haws, LC; Hébert, CD; Grimes, SD; Shertzer, HG; Kopec, AK; Hixon, JG;](#)
19 [Zacharewski, TR; Harris, MA.](#) (2011). Investigation of the mode of action underlying the
20 tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium.
21 *Toxicol Sci* 123: 58-70. <http://dx.doi.org/10.1093/toxsci/kfr164>

22 [Thompson, CM; Proctor, DM; Suh, M; Haws, LC; Hébert, CD; Mann, JF; Shertzer, HG; Hixon, JG;](#)
23 [Harris, MA.](#) (2012b). Comparison of the effects of hexavalent chromium in the alimentary
24 canal of F344 rats and B6C3F1 mice following exposure in drinking water: implications for
25 carcinogenic modes of action. *Toxicol Sci* 125: 79-90.
26 <http://dx.doi.org/10.1093/toxsci/kfr280>

27 [Thompson, CM; Proctor, DM; Suh, M; Haws, LC; Kirman, CR; Harris, MA.](#) (2013). Assessment of the
28 mode of action underlying development of rodent small intestinal tumors following oral
29 exposure to hexavalent chromium and relevance to humans [Review]. *Crit Rev Toxicol* 43:
30 244-274. <http://dx.doi.org/10.3109/10408444.2013.768596>

31 [Thompson, CM; Seiter, J; Chappell, MA; Tappero, RV; Proctor, DM; Suh, M; Wolf, JC; Haws, LC; Vitale,](#)
32 [R; Mittal, L; Kirman, CR; Hays, SM; Harris, MA.](#) (2015a). Synchrotron-based imaging of
33 chromium and γ -H2AX immunostaining in the duodenum following repeated exposure to
34 Cr(VI) in drinking water. *Toxicol Sci* 143: 16-25. <http://dx.doi.org/10.1093/toxsci/kfu206>

35 [Thompson, CM; Wolf, JC; Elbekai, RH; Paranipe, MG; Seiter, JM; Chappell, MA; Tappero, RV; Suh, M;](#)
36 [Proctor, DM; Bichteler, A; Haws, LC; Harris, MA.](#) (2015b). Duodenal crypt health following
37 exposure to Cr(VI): Micronucleus scoring, γ -H2AX immunostaining, and synchrotron X-ray
38 fluorescence microscopy. *Mutat Res Genet Toxicol Environ Mutagen* 789-790: 61-66.
39 <http://dx.doi.org/10.1016/j.mrgentox.2015.05.004>

40 [Thompson, CM; Young, RR; Dinesdurance, H; Suh, M; Harris, MA; Rohr, AC; Proctor, DM.](#) (2017).
41 Assessment of the mutagenic potential of hexavalent chromium in the duodenum of big
42 blue® rats. *Toxicol Appl Pharmacol* 330: 48-52.
43 <http://dx.doi.org/10.1016/j.taap.2017.07.002>

44 [Thompson, CM; Young, RR; Suh, M; Dinesdurance, HR; Elbekai, RH; Harris, MA; Rohr, AC; Proctor,](#)
45 [DM.](#) (2015c). Assessment of the mutagenic potential of Cr(VI) in the oral mucosa of Big
46 Blue((R)) transgenic F344 rats. *Environ Mol Mutagen* 56: 621-628.
47 <http://dx.doi.org/10.1002/em.21952>

48 [Tian, M; Guo, F; Sun, Y; Zhang, W; Miao, F; Liu, Y; Song, G; Ho, CL; Yu, X; Sun, JZ; Wong, WY.](#) (2014). A
49 fluorescent probe for intracellular cysteine overcoming the interference by glutathione. *Org*
50 *Biomol Chem* 12: 6128-6133. <http://dx.doi.org/10.1039/c4ob00382a>

- 1 [Tielemans, E; Burdorf, A; Te Velde, ER; Weber, RFA; Van Kooij, RJ; Veulemans, H; Heederik, DJJ.](#)
2 (1999). Occupationally related exposures and reduced semen quality: A case-control study.
3 *Fertil Steril* 71: 690-696.
- 4 [Toebak, MJ; Pohlmann, PR; Sampat-Sardjoepersad, SC; von Blomberg, BM; Bruynzeel, DP; Scheper,](#)
5 [RJ; Rustemeyer, T; Gibbs, S.](#) (2006). CXCL8 secretion by dendritic cells predicts contact
6 allergens from irritants. *Toxicol In Vitro* 20: 117-124.
7 <http://dx.doi.org/10.1016/j.tiv.2005.06.039>
- 8 [Tong, Z; Zhang, C.](#) (2003). [Study on liver toxic damage of occupational chromium exposure].
9 *Anquan Jiankang he Huanjing/Safety Health and Environment* (3): 21.
- 10 [Travlos, GS; Mirris, RW; Elwell, MR; Duke, A; Rosenblum, S; Thompson, MB.](#) (1996). Frequency and
11 relationships of clinical chemistry and liver and kidney histopathology findings in 13-week
12 toxicity studies in rats. *Toxicology* 107: 17-29. [http://dx.doi.org/10.1016/0300-](http://dx.doi.org/10.1016/0300-483X(95)03197-N)
13 [483X\(95\)03197-N](http://dx.doi.org/10.1016/0300-483X(95)03197-N)
- 14 [Trivedi, B; Saxena, DK; Murthy, RC; Chandra, SV.](#) (1989). Embryotoxicity and fetotoxicity of orally
15 administered hexavalent chromium in mice. *Reprod Toxicol* 3: 275-278.
16 [http://dx.doi.org/10.1016/0890-6238\(89\)90022-1](http://dx.doi.org/10.1016/0890-6238(89)90022-1)
- 17 [Tsao, DA; Tseng, WC; Chang, HR.](#) (2011). The expression of RKIP, RhoGDI, galectin, c-Myc and p53
18 in gastrointestinal system of Cr(VI)-exposed rats. *J Appl Toxicol* 31: 730-740.
19 <http://dx.doi.org/10.1002/jat.1621>
- 20 [Tsukamoto, T; Mizoshita, T; Tatematsu, M.](#) (2007). Animal models of stomach carcinogenesis
21 [Review]. *Toxicol Pathol* 35: 636-648. <http://dx.doi.org/10.1080/01926230701420632>
- 22 [Tully, DB; Collins, BJ; Overstreet, JD; Smith, CS; Dinse, GE; Mumtaz, MM; Chapin, RE.](#) (2000). Effects
23 of arsenic, cadmium, chromium, and lead on gene expression regulated by a battery of 13
24 different promoters in recombinant HepG2 cells. *Toxicol Appl Pharmacol* 168: 79-90.
25 <http://dx.doi.org/10.1006/taap.2000.9014>
- 26 [Turk, JL; Parker, D.](#) (1977). Sensitization with Cr, Ni, and Zr salts and allergic type granuloma
27 formation in the guinea pig. *J Invest Dermatol* 68: 341-345.
- 28 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1986a). Effect of chlorine on chromium
29 speciation in tap water [EPA Report]. (EPA/600/M-86/015). Washington, D.C.: U.S.
30 Environmental Protection Agency.
- 31 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1986b). Guidelines for carcinogen risk
32 assessment [EPA Report] (pp. 33993-34003). (EPA/630/R-00/004). Washington, DC: U.S.
33 Environmental Protection Agency, Risk Assessment Forum.
34 [https://www.epa.gov/iris/basic-information-about-integrated-risk-information-](https://www.epa.gov/iris/basic-information-about-integrated-risk-information-system#risk)
35 [system#risk](https://www.epa.gov/iris/basic-information-about-integrated-risk-information-system#risk)
- 36 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1986c). Guidelines for mutagenicity risk
37 assessment (pp. 1-17). (ISSN 0097-6326
38 EISSN 2167-2520
39 EPA/630/R-98/003). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment
40 Forum. <https://www.epa.gov/risk/guidelines-mutagenicity-risk-assessment>
- 41 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1988). Recommendations for and documentation
42 of biological values for use in risk assessment [EPA Report]. (EPA600687008). Cincinnati,
43 OH. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855>
- 44 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1991). Guidelines for developmental toxicity risk
45 assessment. *Fed Reg* 56: 63798-63826.
- 46 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1994). Methods for derivation of inhalation
47 reference concentrations and application of inhalation dosimetry [EPA Report].
48 (EPA600890066F). Research Triangle Park, NC.

- 1 <https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=71993&CFID=51174829&CFTOKEN=25006317>
- 2
- 3 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1996a). Guidelines for reproductive toxicity risk
4 assessment (pp. 1-143). (EPA/630/R-96/009). Washington, DC: U.S. Environmental
5 Protection Agency, Risk Assessment Forum.
- 6 [https://www.epa.gov/sites/production/files/2014-
7 11/documents/guidelines_repro_toxicity.pdf](https://www.epa.gov/sites/production/files/2014-11/documents/guidelines_repro_toxicity.pdf)
- 8 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1996b). Guidelines for reproductive toxicity risk
9 assessment. Fed Reg 61: 56274-56322.
- 10 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1996c). Proposed guidelines for carcinogen risk
11 assessment: notice of availability and opportunity to comment. Fed Reg 61: 17960-18011.
- 12 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1998a). Guidelines for neurotoxicity risk
13 assessment [EPA Report] (pp. 1-89). (ISSN 0097-6326
14 EISSN 2167-2520
15 EPA/630/R-95/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment
16 Forum. <http://www.epa.gov/risk/guidelines-neurotoxicity-risk-assessment>
- 17 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1998b). Health effects test guidelines OPPTS
18 870.7800 immunotoxicity. (EPA 712-C-98-351). Washington, DC: Prevention, Pesticides and
19 Toxic Substances, U.S. Environmental Protection Agency.
- 20 http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series870.htm
- 21 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1998c). Toxicological review of hexavalent
22 chromium [EPA Report] (pp. 80). (630R98009). Washington, DC.
23 https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0144tr.pdf
- 24 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2002). A review of the reference dose and
25 reference concentration processes. (EPA630P02002F). Washington, DC.
26 <https://www.epa.gov/sites/production/files/2014-12/documents/rfd-final.pdf>
- 27 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2005a). Guidelines for carcinogen risk
28 assessment [EPA Report]. (EPA630P03001F). Washington, DC.
29 [https://www.epa.gov/sites/production/files/2013-
30 09/documents/cancer_guidelines_final_3-25-05.pdf](https://www.epa.gov/sites/production/files/2013-09/documents/cancer_guidelines_final_3-25-05.pdf)
- 31 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2005b). Supplemental guidance for assessing
32 susceptibility from early-life exposure to carcinogens [EPA Report]. (EPA/630/R-03/003F).
33 Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum.
34 [https://www.epa.gov/risk/supplemental-guidance-assessing-susceptibility-early-life-
35 exposure-carcinogens](https://www.epa.gov/risk/supplemental-guidance-assessing-susceptibility-early-life-exposure-carcinogens)
- 36 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2006a). 2006 community water system survey -
37 Volume I: Overview [EPA Report]. (EPA 815-R-09-001). Washington, DC: U.S.
38 Environmental Protection Agency, Office of Water.
39 <https://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=P1009JJI.txt>
- 40 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2006b). 2006 community water system survey -
41 Volume II: Detailed tables and survey methodology [EPA Report]. (EPA 815-R-09-002).
42 Washington, DC: U.S. Environmental Protection Agency, Office of Water.
43 <https://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=P1009USA.txt>
- 44 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2006c). Approaches for the application of
45 physiologically based pharmacokinetic (PBPK) models and supporting data in risk
46 assessment (Final Report) [EPA Report] (pp. 1-123). (EPA/600/R-05/043F). Washington,
47 DC: U.S. Environmental Protection Agency, Office of Research and Development, National
48 Center for Environmental Assessment.
49 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=157668>

Toxicological Review of Hexavalent Chromium

- 1 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2006d). A framework for assessing health risk of
2 environmental exposures to children (pp. 1-145). (EPA/600/R-05/093F). Washington, DC:
3 U.S. Environmental Protection Agency, Office of Research and Development, National Center
4 for Environmental Assessment.
5 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=158363>
- 6 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2008). Reregistration eligibility decision for
7 chromated arsenicals. (EPA 739-R-08-006). Office of Prevention, Pesticides And Toxic
8 Substances; U.S. Environmental Protection Agency.
- 9 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2009). Risk assessment guidance for superfund
10 volume I: Human health evaluation manual (Part F, supplemental guidance for inhalation
11 risk assessment): Final [EPA Report]. (EPA/540/-R-070/002). Washington, DC.
12 <https://www.epa.gov/risk/risk-assessment-guidance-superfund-rags-part-f>
- 13 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2011a). Exposure factors handbook: 2011
14 edition [EPA Report]. (EPA/600/R-090/052F). Washington, DC: U.S. Environmental
15 Protection Agency, Office of Research and Development, National Center for Environmental
16 Assessment. <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100F2OS.txt>
- 17 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2011b). (Fourth) Five-year review report for
18 United Chrome Products ORD 009043001 Corvallis, Benton County, Oregon Draft August
19 2011 revision 5. Seattle, WA: U.S. Environmental Protection Agency Region 10.
- 20 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2011c). Recommended use of body weight 3/4
21 as the default method in derivation of the oral reference dose. (EPA100R110001).
22 Washington, DC. [https://www.epa.gov/sites/production/files/2013-
23 09/documents/recommended-use-of-bw34.pdf](https://www.epa.gov/sites/production/files/2013-09/documents/recommended-use-of-bw34.pdf)
- 24 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2011d). Toxicological review of
25 trichloroethylene (CAS No. 79-01-6) in support of summary Information on the Integrated
26 Risk Information System (IRIS) [EPA Report]. (EPA635R09011F). Washington, DC.
27 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100CB6V.txt>
- 28 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012a). Benchmark Dose Software (BMDS).
29 Version 2.2. Retrieved from <http://www.epa.gov/NCEA/bmids/index.html>
- 30 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012b). Benchmark dose technical guidance
31 [EPA Report]. (EPA100R12001). Washington, DC: U.S. Environmental Protection Agency,
32 Risk Assessment Forum. <https://www.epa.gov/risk/benchmark-dose-technical-guidance>
- 33 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012c). The third Unregulated Contaminant
34 Monitoring Rule (UCMR 3). Presentation presented at US EPA Webinar, September, 2012,
35 OGWDW, SRMD Technical Support Center Cincinnati Ohio.
- 36 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012d). Toxicological review of
37 tetrachloroethylene (Perchloroethylene) (CASRN 127-18-4) in support of summary
38 information on the Integrated Risk Information System (IRIS) [EPA Report].
39 (EPA635R08011F). Washington, DC: National Center for Environmental Assessment.
40 https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0106tr.pdf
- 41 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014a). Discharge monitoring report (DMR)
42 pollutant loading tool. Washington, DC. Retrieved from
43 <https://cfpub.epa.gov/dmr/index.cfm>
- 44 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014b). Preliminary materials for the Integrated
45 Risk Information System (IRIS) toxicological review of hexavalent chromium part 1:
46 Experimental animal studies [CASRN] 18540-29-9 [EPA Report]. (EPA/635/R-14/094).
47 Research Triangle Park, NC. [https://www.epa.gov/iris/iris-bimonthly-public-meeting-jun-
48 2014](https://www.epa.gov/iris/iris-bimonthly-public-meeting-jun-2014)
- 49 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014c). Preliminary materials for the Integrated
50 Risk Information System (IRIS) toxicological review of hexavalent chromium part 2: Human,

- 1 toxicokinetic, and mechanistic Studies [CASRN] 18540-29-9] [EPA Report]. (EPA/635/R-
2 14/218). Research Triangle Park, NC. [https://www.epa.gov/iris/iris-bimonthly-public-](https://www.epa.gov/iris/iris-bimonthly-public-meeting-oct-2014)
3 [meeting-oct-2014](https://www.epa.gov/iris/iris-bimonthly-public-meeting-oct-2014)
- 4 U.S. EPA (U.S. Environmental Protection Agency). (2014d). The third Unregulated Contaminant
5 Monitoring Rule (UCMR 3) occurrence data. Retrieved from
6 <http://water.epa.gov/lawsregs/rulesregs/sdwa/ucmr/data.cfm#ucmr2013>
- 7 U.S. EPA (U.S. Environmental Protection Agency). (2014e). Toxicological review of libby amphibole
8 asbestos: In support of summary information on the Integrated Risk Information System
9 (IRIS) [EPA Report]. (EPA/635/R-11/002F). Washington, DC: Integrated Risk Information
10 System, National Center for Environmental Assessment, Office of Research and
11 Development.
12 https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/1026tr.pdf
- 13 U.S. EPA (U.S. Environmental Protection Agency). (2016a). 2014 National Emissions Inventory
14 (NEI) data (Version 2). Washington, DC. Retrieved from [https://www.epa.gov/air-](https://www.epa.gov/air-emissions-inventories/2014-national-emissions-inventory-nei-data)
15 [emissions-inventories/2014-national-emissions-inventory-nei-data](https://www.epa.gov/air-emissions-inventories/2014-national-emissions-inventory-nei-data)
- 16 U.S. EPA (U.S. Environmental Protection Agency). (2016b). Evaluation of the inhalation
17 carcinogenicity of ethylene oxide (CASRN 75-21-8): In support of summary information on
18 the Integrated Risk Information System (IRIS) [EPA Report]. (EPA635R16350Fa).
19 Washington, DC: U.S. Environmental Protection Agency, Office of Research and
20 Development, National Center for Environmental Assessment.
21 https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/1025tr.pdf
- 22 U.S. EPA (U.S. Environmental Protection Agency). (2016c). US EPA's report on the environment
23 (ROE). Available online at <https://cfpub.epa.gov/roe/index.cfm>
- 24 U.S. EPA (U.S. Environmental Protection Agency). (2018). Toxic Release Inventory (TRI). Retrieved
25 from <https://www.epa.gov/enviro/tri-search>
- 26 U.S. EPA (U.S. Environmental Protection Agency). (2019). Systematic Review Protocol for the
27 Hexavalent Chromium IRIS Assessment (Preliminary Assessment Materials) [EPA Report].
28 (EPA/635/R-18/155).
- 29 U.S. EPA (U.S. Environmental Protection Agency). (2020a). Benchmark Dose Software (BMDS).
30 Version 3.2: User guide [EPA Report]. (EPA/600/R-20/216). Washington, DC: U.S.
31 Environmental Protection Agency, Office of Research and Development.
32 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockkey=P10103T2.txt>
- 33 U.S. EPA (U.S. Environmental Protection Agency). (2020b). ORD staff handbook for developing IRIS
34 assessments (public comment draft) [EPA Report]. (EPA/600/R-20/137). Washington, DC:
35 U.S. Environmental Protection Agency, Office of Research and Development, Center for
36 Public Health and Environmental Assessment.
37 https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=350086
- 38 U.S. EPA (U.S. Environmental Protection Agency). (2021a). Model log files for the IRIS toxicological
39 review of hexavalent chromium.
- 40 U.S. EPA (U.S. Environmental Protection Agency). (2021b). National Emissions Inventory (NEI).
41 Available online at [https://www.epa.gov/air-emissions-inventories/national-emissions-](https://www.epa.gov/air-emissions-inventories/national-emissions-inventory-nei)
42 [inventory-nei](https://www.epa.gov/air-emissions-inventories/national-emissions-inventory-nei) (accessed February 10, 2021).
- 43 U.S. EPA (U.S. Environmental Protection Agency). (2021c). TRI Toxics Tracker. Available online at
44 <https://edap.epa.gov/public/extensions/TRIToxicsTracker/TRIToxicsTracker.html>
- 45 Uddin, AN; Burns, FJ; Rossman, TG; Chen, H; Kluz, T; Costa, M. (2007). Dietary chromium and nickel
46 enhance UV-carcinogenesis in skin of hairless mice. *Toxicol Appl Pharmacol* 221: 329-338.
47 <http://dx.doi.org/10.1016/j.taap.2007.03.030>
- 48 Urbano, AM; Ferreira, LMR; Alpoim, MC. (2012). Molecular and cellular mechanisms of hexavalent
49 chromium-induced lung cancer: An updated perspective [Review]. *Curr Drug Metab* 13:
50 284-305.

- 1 [USGS](#) (U.S. Geological Survey). (1995). Chromium life cycle study. (IC 9411). Washington, D.C.: U.S.
2 Department of the Interior, Bureau of Mines.
- 3 [Vaglenov, A; Nosko, M; Georgieva, R; Carbonell, E; Creus, A; Marcos, R.](#) (1999). Genotoxicity and
4 radioresistance in electroplating workers exposed to chromium. *Mutat Res* 446: 23-34.
- 5 [Valentine, CC; Young, RR; Fielden, MR; Kulkarni, R; Williams, LN; Li, T; Minocherhomji, S; Salk, JJ.](#)
6 (2020). Direct quantification of in vivo mutagenesis and carcinogenesis using duplex
7 sequencing. *Proc Natl Acad Sci USA* 117: 33414-33425.
8 <http://dx.doi.org/10.1073/pnas.2013724117>
- 9 [van Heerden, PV; Jenkins, IR; Woods, WP; Rossi, E; Cameron, PD.](#) (1994). Death by tanning--a case
10 of fatal basic chromium sulphate poisoning [Review]. *Intensive Care Med* 20: 145-147.
- 11 [van Oud Alblas, AB; van Furth, R.](#) (1979). Origin, Kinetics, and characteristics of pulmonary
12 macrophages in the normal steady state. *J Exp Med* 149: 1504-1518.
- 13 [Vandamme, D; Herrero, A; Al-Mulla, F; Kolch, W.](#) (2014). Regulation of the MAPK pathway by Raf
14 kinase inhibitory protein [Review]. *Crit Rev Oncog* 19: 405-415.
15 <http://dx.doi.org/10.1615/critrevoncog.2014011922>
- 16 [Vanhouwaert, A; Vanparys, P; Kirsch-Volders, M.](#) (2001). The in vivo gut micronucleus test detects
17 clastogens and aneugens given by gavage. *Mutagenesis* 16: 39-50.
18 <http://dx.doi.org/10.1093/mutage/16.1.39>
- 19 [Vengosh, A; Coyte, R; Karr, J; Harkness, JS; Kondash, AJ; Ruhl, LS; Merola, RB; Dywer, GS.](#) (2016).
20 Origin of hexavalent chromium in drinking water wells from the piedmont aquifers of North
21 Carolina. *Environ Sci Technol Lett* 3: 409-414.
22 <http://dx.doi.org/10.1021/acs.estlett.6b00342>
- 23 [Verschoor, MA; Bragt, PC; Herber, RFM; Zielhuis, RL; Zwennis, WCM.](#) (1988). Renal function of
24 chrome-plating workers and welders. *Int Arch Occup Environ Health* 60: 67-70.
25 <http://dx.doi.org/10.1007/BF00409381>
- 26 [Videla, LA; Rodrigo, R; Orellana, M; Fernandez, V; Tapia, G; Quiñones, L; Varela, N; Contreras, J;
27 Lazarte, R; Csendes, A; Rojas, J; Maluenda, F; Burdiles, P; Diaz, JC; Smok, G; Thielemann, L;
28 Poniachik, J.](#) (2004). Oxidative stress-related parameters in the liver of non-alcoholic fatty
29 liver disease patients. *Clin Sci (Lond)* 106: 261-268.
30 <http://dx.doi.org/10.1042/CS20030285>
- 31 [Viechtbauer, W.](#) (2010). Conducting meta-analyses in R with the metafor package. *J Stat Softw* 36: 1-
32 48.
- 33 [Vigliani, EC; Zurlo, N.](#) (1955). Erfahrungen der Clinica del Lavoro mit einigen maximalen
34 Arbeitsplatzkonzentrationen (MAK) von Industriegiften. *Int Arch Occup Environ Health* 13:
35 528-534. <http://dx.doi.org/10.1007/BF00312756>
- 36 [Vincent, J.](#) (2013). Chromium: is it essential, pharmacologically relevant, or toxic? In *Interrelations*
37 *between Essential Metal Ions and Human Diseases*: Springer.
38 http://dx.doi.org/10.1007/978-94-007-7500-8_6
- 39 [Vincent, JB.](#) (2017). New evidence against chromium as an essential trace element. *J Nutr* 147:
40 2212-2219. <http://dx.doi.org/10.3945/jn.117.255901>
- 41 [Vreeburg, KJ; de Groot, K; van Hoogstraten, IM; von Blomberg, BM; Scheper, RJ.](#) (1991). Successful
42 induction of allergic contact dermatitis to mercury and chromium in mice. *International*
43 *Arch Allergy Appl Immunol* 96: 179-183. <http://dx.doi.org/10.1159/000235491>
- 44 [Wang, BJ; Guo, YL; Chang, HY; Sheu, HM; Pan, MH; Lee, YH; Wang, YJ.](#) (2010a). N-acetylcysteine
45 inhibits chromium hypersensitivity in adjuvant chromium-sensitized albino guinea pigs
46 by suppressing the effects of reactive oxygen species. *Exp Dermatol* 19: e191-e200.
47 <http://dx.doi.org/10.1111/j.1600-0625.2009.01045.x>
- 48 [Wang, BJ; Sheu, HM; Guo, YL; Lee, YH; Lai, CS; Pan, MH; Wang, YJ.](#) (2010b). Hexavalent chromium
49 induced ROS formation, Akt, NF-kappaB, and MAPK activation, and TNF-alpha and IL-1alpha

- 1 production in keratinocytes. *Toxicol Lett* 198: 216-224.
2 <http://dx.doi.org/10.1016/j.toxlet.2010.06.024>
- 3 [Wang, L; Qiu, JG; He, J; Liu, WJ; Ge, X; Zhou, FM; Huang, YX; Jiang, BH; Liu, LZ.](#) (2019). Suppression of
4 miR-143 contributes to overexpression of IL-6, HIF-1 α and NF- κ B p65 in Cr(VI)-induced
5 human exposure and tumor growth. *Toxicol Appl Pharmacol* 378: 114603.
6 <http://dx.doi.org/10.1016/j.taap.2019.114603>
- 7 [Wang, TC; Jia, G; Song, Y, anS; Zhang, J, i; Ma, Y, anHui; Feng, W, eiYue; Leu, L, anZ; Zhang, N; Zhou,](#)
8 [JW, en; Yan, L, ei; Zhen, S, en; Qian, Q, in.](#) (2012a). Effects of chronic chromate exposure on
9 human serum prostate specific antigen: A cross sectional study. *Ind Health* 50: 95-102.
10 <http://dx.doi.org/10.2486/indhealth.MS1278>
- 11 [Wang, TC; Song, YS; Wang, H; Zhang, J; Yu, SF; Gu, YE; Chen, T; Wang, Y; Shen, HQ; Jia, G.](#) (2012b).
12 Oxidative DNA damage and global DNA hypomethylation are related to folate deficiency in
13 chromate manufacturing workers. *J Hazard Mater* 213-214: 440-446.
14 <http://dx.doi.org/10.1016/j.jhazmat.2012.02.024>
- 15 [Wang, X; Qin, Q; Xu, X; Xu, J; Wang, J; Zhou, J; Huang, S; Zhai, W; Zhou, H; Chen, J.](#) (1994). Chromium-
16 Induced Early Changes in Renal Function among Ferrochromium-Producing Workers.
17 *Toxicology* 90: 93-101. [http://dx.doi.org/10.1016/0300-483X\(94\)90208-9](http://dx.doi.org/10.1016/0300-483X(94)90208-9)
- 18 [Wang, XF; Lou, XM; Shen, Y; Xing, ML; Xu, LH.](#) (2010c). Apoptotic-related protein changes induced
19 by hexavalent chromium in mice liver. *Environ Toxicol* 25: 77-82.
20 <http://dx.doi.org/10.1002/tox.20478>
- 21 [Wang, Y; Wu, W; Yao, C; Lou, J; Chen, R; Jin, L; Wu, N; Gao, M; Song, P; Tan, Y; Liu, K.](#) (2015). Elevated
22 tissue Cr levels, increased plasma oxidative markers, and global hypomethylation of blood
23 DNA in male Sprague-Dawley rats exposed to potassium dichromate in drinking water.
24 *Environ Toxicol.* <http://dx.doi.org/10.1002/tox.22117>
- 25 [Wang, Z; Peng, H; Zhang, R; Jiang, X; Chen, S; Guo, P; Xiao, Y; Zeng, X; Wang, Q; Aschner, M; Chou,](#)
26 [WC; Li, D; Chen, W; Chen, L.](#) (2022). Assessment of intestinal injury of hexavalent chromium
27 using a modified in vitro gastrointestinal digestion model. *Toxicol Appl Pharmacol* 436:
28 115880. <http://dx.doi.org/10.1016/j.taap.2022.115880>
- 29 [Wang, Z; Yang, C.](#) (2019). Metal carcinogen exposure induces cancer stem cell-like property through
30 epigenetic reprogramming: A novel mechanism of metal carcinogenesis [Review]. *Semin*
31 *Cancer Biol* 57: 95-104. <http://dx.doi.org/10.1016/j.semcancer.2019.01.002>
- 32 [Ward, FW; Coates, ME.](#) (1987). Gastrointestinal pH measurement in rats: Influence of the microbial
33 flora, diet and fasting. *Lab Anim* 21: 216-222.
34 <http://dx.doi.org/10.1258/002367787781268693>
- 35 [Wear, HM; Mcpike, MJ; Watanabe, KH.](#) (2016). From primordial germ cells to primordial follicles: A
36 review and visual representation of early ovarian development in mice [Review]. *Journal of*
37 *Ovarian Research* 9: 36. <http://dx.doi.org/10.1186/s13048-016-0246-7>
- 38 [Welling, R; Beaumont, JJ; Petersen, SJ; Alexeeff, GV; Steinmaus, C.](#) (2015). Chromium VI and stomach
39 cancer: a meta-analysis of the current epidemiological evidence [Review]. *Occup Environ*
40 *Med* 72: 151-159. <http://dx.doi.org/10.1136/oemed-2014-102178>
- 41 [Westbrook, A, yaM; Szakmary, A; Schiestl, RH.](#) (2010). Mechanisms of intestinal inflammation and
42 development of associated cancers: Lessons learned from mouse models [Review]. *Mutat*
43 *Res Rev Mutat Res* 705: 40-59. <http://dx.doi.org/10.1016/j.mrrev.2010.03.001>
- 44 [Whalan, JE.](#) (2000). A guide to clinical pathology in animals. Whalan, JE.
45 [Whalan, JE.](#) (2015). *Clinical Chemistry.* 67-94. http://dx.doi.org/10.1007/978-3-319-15853-2_6
- 46 [WHO](#) (World Health Organization). (2003). Chromium in drinking water.
47 (WHO/SDE/WSH/03.04/04). Geneva, Switzerland.
48 http://www.who.int/water_sanitation_health/dwq/chemicals/chromium.pdf

- 1 [WHO](#) (World Health Organization). (2010). WHO laboratory manual for the examination and
2 processing of human semen. In WHO laboratory manual for the examination and processing
3 of human semen (5th ed.). Geneva, Switzerland.
- 4 [Wiegand, HJ; Ottenwalder, H; Bolt, HM.](#) (1985). Fast uptake kinetics in vitro of 51Cr (VI) by red
5 blood cells of man and rat. Arch Toxicol 57: 31-34. <http://dx.doi.org/10.1007/BF00286571>
- 6 [Wiegand, HJ; Ottenwalder, H; Bolt, HM.](#) (1986). Disposition of a soluble chromate in the isolated
7 perfused rat liver. Xenobiotica 16: 839-844.
8 <http://dx.doi.org/10.3109/00498258609038965>
- 9 [Williams, AB; Schumacher, B.](#) (2016). p53 in the DNA-Damage-Repair Process [Review]. Cold Spring
10 Harb Perspect Med 6. <http://dx.doi.org/10.1101/cshperspect.a026070>
- 11 [Wisconsin DHS](#) (Wisconsin Department of Health Services). (2010). Chromium. Available online at
12 <http://www.dhs.wisconsin.gov/eh/ChemFS/fs/chromium.htm>
- 13 [Wise, JP; Young, JL; Cai, J; Cai, L.](#) (2022). Current understanding of hexavalent chromium [Cr(VI)]
14 neurotoxicity and new perspectives [Review]. Environ Int 158: 106877.
15 <http://dx.doi.org/10.1016/j.envint.2021.106877>
- 16 [Wise, SS; Aboueissa, AE; Martino, J; Wise, JP.](#) (2018). Hexavalent chromium-induced chromosome
17 instability drives permanent and heritable numerical and structural changes and a dna
18 repair-deficient phenotype. Cancer Res 78: 4203-4214. <http://dx.doi.org/10.1158/0008-5472.CAN-18-0531>
- 19 [Wise, SS; Holmes, AL; Liou, L; Adam, RM; Wise, JP.](#) (2016). Hexavalent chromium induces
20 chromosome instability in human urothelial cells. Toxicol Appl Pharmacol 296: 54-60.
21 <http://dx.doi.org/10.1016/j.taap.2016.02.015>
- 22 [Wise, SS; Wise, JP, Sr.](#) (2010). Aneuploidy as an early mechanistic event in metal carcinogenesis
23 [Review]. Biochem Soc Trans 38: 1650-1654. <http://dx.doi.org/10.1042/BST0381650>
- 24 [Witt, KL; Stout, MD; Herbert, RA; Travlos, GS; Kissling, GE; Collins, BJ; Hooth, MJ.](#) (2013).
25 Mechanistic Insights from the NTP Studies of Chromium. Toxicol Pathol 41: 326-342.
26 <http://dx.doi.org/10.1177/0192623312469856>
- 27 [Wong, V; Armknecht, S; Zhitkovich, A.](#) (2012). Metabolism of Cr(VI) by ascorbate but not
28 glutathione is a low oxidant-generating process. 26: 192-196.
29 <http://dx.doi.org/10.1016/j.jtemb.2012.04.016>
- 30 [Wu, FY; Wu, WY; Kuo, HW; Liu, CS; Wang, RY; Lai, JS.](#) (2001). Effect of genotoxic exposure to
31 chromium among electroplating workers in Taiwan. Sci Total Environ 279: 21-28.
- 32 [Wultsch, G; Nersesyan, A; Kundi, M; Jakse, R; Beham, A; Wagner, KH; Knasmueller, S.](#) (2014). The
33 sensitivity of biomarkers for genotoxicity and acute cytotoxicity in nasal and buccal cells of
34 welders. Int J Hyg Environ Health 217: 492-498.
35 <http://dx.doi.org/10.1016/j.ijheh.2013.09.005>
- 36 [Wultsch, G; Nersesyan, A; Kundi, M; Miřik, M; Setayesh, T; Waldherr, M; Vodicka, P; Vodickova, L;
37 Knasmueller, S.](#) (2017). Genotoxic and cytotoxic effects in exfoliated buccal and nasal cells of
38 chromium and cobalt exposed electroplaters. J Toxicol Environ Health A 80: 1-10.
39 <http://dx.doi.org/10.1080/15287394.2017.1286918>
- 40 [Xia, W; Hu, J; Zhang, B; Li, Y; Wise, JP; Bassig, BA; Zhou, A; Savitz, DA; Xiong, C; Zhao, J; Du, X; Zhou,
41 Y; Pan, X; Yang, J; Wu, C; Jiang, M; Peng, Y; Qian, Z; Zheng, T; Xu, S.](#) (2016). A case-control
42 study of maternal exposure to chromium and infant low birth weight in China.
43 Chemosphere 144: 1484-1489. <http://dx.doi.org/10.1016/j.chemosphere.2015.10.006>
- 44 [Xiao, F; Feng, X; Zeng, M; Guan, L; Hu, Q; Zhong, C.](#) (2012a). Hexavalent chromium induces energy
45 metabolism disturbance and p53-dependent cell cycle arrest via reactive oxygen species in
46 L-02 hepatocytes. Mol Cell Biochem 371: 65-76. <http://dx.doi.org/10.1007/s11010-012-1423-7>
- 47 [Xiao, F; Li, Y; Dai, L; Deng, Y; Zou, Y; Li, P; Yang, Y; Zhong, C.](#) (2012b). Hexavalent chromium targets
48 mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent
49

- 1 caspase-3 activation in L-02 hepatocytes. *Int J Mol Med* 30: 629-635.
2 <http://dx.doi.org/10.3892/ijmm.2012.1031>
- 3 [Xiao, F; Li, Y; Luo, L; Xie, Y; Zeng, M; Wang, A; Chen, H; Zhong, C.](#) (2014). Role of mitochondrial
4 electron transport chain dysfunction in Cr(VI)-induced cytotoxicity in L-02 hepatocytes. *Cell*
5 *Physiol Biochem* 33: 1013-1025. <http://dx.doi.org/10.1159/000358672>
- 6 [Xiao, Y; Zeng, M; Yin, L; Li, N; Xiao, F.](#) (2019). Clusterin increases mitochondrial respiratory chain
7 complex I activity and protects against hexavalent chromium-induced cytotoxicity in L-02
8 hepatocytes. *Toxicology Research* 8: 15-24. <http://dx.doi.org/10.1039/c8tx00231b>
- 9 [Xiaohua, L; Yanshuang, S; Li, W; Yuhui, L; Ji, Z; Yanhui, M; Yun, W; Wenjun, M; Lei, Y; Guang, J.](#)
10 (2012). Evaluation of the correlation between genetic damage and occupational chromate
11 exposure through BNMN frequencies. *J Occup Environ Med* 54: 166-170.
12 <http://dx.doi.org/10.1097/JOM.0b013e31823d86b4>
- 13 [Xie, Y; Xiao, F; Luo, L; Zhong, C.](#) (2014). Activation of autophagy protects against ROS-mediated
14 mitochondria-dependent apoptosis in L-02 hepatocytes induced by Cr(VI). *Cell Physiol*
15 *Biochem* 33: 705-716. <http://dx.doi.org/10.1159/000358646>
- 16 [Xu, J; Zhao, M; Pei, L; Zhang, R; Liu, X; Wei, L; Yang, M; Xu, Q.](#) (2018). Oxidative stress and DNA
17 damage in a long-term hexavalent chromium-exposed population in North China: a cross-
18 sectional study. *BMJ Open* 8: e021470. <http://dx.doi.org/10.1136/bmjopen-2017-021470>
- 19 [Yamate, J; Izawa, T; Kuwamura, M.](#) (2016). Histopathological analysis of rat hepatotoxicity based on
20 macrophage functions: In particular, an analysis for thioacetamide-induced hepatic lesions
21 [Review]. *Food Saf* 4: 61-73. <http://dx.doi.org/10.14252/foodsafetyfscj.2016012>
- 22 [Yang, F; Zhao, L; Mei, D; Jiang, L; Geng, C; Li, Q; Yao, X; Liu, Y; Kong, Y; Cao, J.](#) (2017). HMG2 plays
23 an important role in Cr (VI)-induced autophagy. *Int J Cancer* 141: 986-997.
24 <http://dx.doi.org/10.1002/ijc.30789>
- 25 [Yang, L.](#) (2006). Incidence and mortality of gastric cancer in China [Review]. *World J Gastroenterol*
26 12: 17-20. <http://dx.doi.org/10.3748/wjg.v12.i1.17>
- 27 [Yazar, S; Yildirim, IY.](#) (2018). Oxidative DNA damage in electroplaters co-exposed to chromium and
28 nickel. *Fresen Environ Bull* 27: 6831-6836.
- 29 [Yi, X; Xiao, F; Zhong, X; Duan, Y; Liu, K; Zhong, C.](#) (2017). A Ca(2+) chelator ameliorates chromium
30 (VI)-induced hepatocyte L-02 injury via down-regulation of voltage-Dependent anion
31 channel 1 (VDAC1) expression. *Environ Toxicol Pharmacol* 49: 27-33.
32 <http://dx.doi.org/10.1016/j.etap.2016.11.007>
- 33 [Yi, X; Zhang, Y; Zhong, C; Zhong, X; Xiao, F.](#) (2016). The role of STIM1 in the Cr(vi)-induced [Ca(2+)]i
34 increase and cell injury in L-02 hepatocytes. *Metallomics* 8: 1273-1282.
35 <http://dx.doi.org/10.1039/c6mt00204h>
- 36 [Yoisungnern, T; Das, J; Choi, YJ; Parnpai, R; Kim, JH.](#) (2015). Effect of hexavalent chromium-treated
37 sperm on in vitro fertilization and embryo development. *Toxicol Ind Health*.
38 <http://dx.doi.org/10.1177/0748233715579805>
- 39 [Younan, S; Sakita, GZ; Coluna, JGY; Rufino, MN; Keller, R; Bremer-Neto, H.](#) (2019). Probiotic
40 mitigates the toxic effects of potassium dichromate in a preclinical study: A randomized
41 controlled trial. *J Sci Food Agric* 99: 183-190. <http://dx.doi.org/10.1002/jsfa.9159>
- 42 [Younossi, ZM.](#) (2019). Non-alcoholic fatty liver disease – A global public health perspective
43 [Review]. *J Hepatol* 70: 531-544. <http://dx.doi.org/10.1016/j.jhep.2018.10.033>
- 44 [Yousef, MI; El-Demerdash, FM; Kamil, KI; Elasad, FA.](#) (2006). Ameliorating effect of folic acid on
45 chromium(VI)-induced changes in reproductive performance and seminal plasma
46 biochemistry in male rabbits. *Reprod Toxicol* 21: 322-328.
47 <http://dx.doi.org/10.1016/j.reprotox.2005.09.005>
- 48 [Yu, A; Jackson, T; Tsume, Y; Koenigsnecht, M; Wysocki, J; Marciani, L; Amidon, GL; Frances, A;](#)
49 [Baker, JR; Hasler, W; Wen, B; Pai, A; Sun, D.](#) (2017). Mechanistic Fluid Transport Model to

- 1 Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time. AAPS J 19:
2 1682-1690. <http://dx.doi.org/10.1208/s12248-017-0145-x>
- 3 [Yuan, JH.](#) (1993). Modeling blood/plasma concentrations in dosed feed and dosed drinking water
4 toxicology studies. *Toxicol Appl Pharmacol* 119: 131-141.
- 5 [Yuan, WM; Lu, YQ; Wei, Z; Chen, M; He, SL; Mai, WY; Zhang, MB.](#) (2016). An epistaxis emergency
6 associated with multiple pollutants in elementary students. *Biomed Environ Sci* 29: 893-
7 897. <http://dx.doi.org/10.3967/bes2016.119>
- 8 [Yuan, Y; Ming, Z; Gong-Hua, H; Lan, G; Lu, D; Peng, L; Feng, J; Cai-Gao, Z.](#) (2012a). Cr(VI) induces the
9 decrease of ATP level and the increase of apoptosis rate mediated by ROS or VDAC1 in L-02
10 hepatocytes. *Environ Toxicol Pharmacol* 34: 579-587.
11 <http://dx.doi.org/10.1016/j.etap.2012.06.016>
- 12 [Yuan, Y; Peng, L; Gong-Hua, H; Lu, D; Xia-Li, Z; Yu, Z; Cai-Gao, Z.](#) (2012b). Chi-square analysis of the
13 reduction of ATP levels in L-02 hepatocytes by hexavalent chromium. 45: 482-487.
14 <http://dx.doi.org/10.1590/S0100-879X2012007500040>
- 15 [Zabulyte, D; Uleckiene, S; Drebigkas, V; Semaska, V; Jonauskiene, I.](#) (2009). Investigation of
16 combined effect of chromium (VI) and sodium fluoride in experiments on rats. *Trace Elem*
17 *Electroly* 26: 67-71.
- 18 [Zabulyte, D; Uleckiene, S; Kalibatas, J; Paltanaviciene, A; Juozulynas, A; Gocentas, A.](#) (2006).
19 Investigation of combined effect of chromium (VI) and nitrate in experiments on rats. *Trace*
20 *Elem Electroly* 23: 287-291.
- 21 [Zahid, ZR; Al-hakkak, ZS; Kadhim, AHH; Elias, EA; Al-jumaily, IS.](#) (1990). Comparative effects of
22 trivalent and hexavalent chromium on spermatogenesis of the mouse. *Toxicol Environ*
23 *Chem* 25: 131-136. <http://dx.doi.org/10.1080/02772249009357512>
- 24 [Zendehdel, R; Shetab-Boushehri, SV; Azari, MR; Hosseini, V; Mohammadi, H.](#) (2014). Chemometrics
25 models for assessment of oxidative stress risk in chrome-electroplating workers. *Drug*
26 *Chem Toxicol* 38: 1-6. <http://dx.doi.org/10.3109/01480545.2014.922096>
- 27 [Zeng, M; Xiao, F; Zhong, X; Jin, F; Guan, L; Wang, A; Liu, X; Zhong, C.](#) (2013). Reactive oxygen species
28 play a central role in hexavalent chromium-induced apoptosis in Hep3B cells without the
29 functional roles of p53 and caspase-3. *Cell Physiol Biochem* 32: 279-290.
30 <http://dx.doi.org/10.1159/000354436>
- 31 [Zey, JN; Lucas, C.](#) (1985). Health hazard evaluation report no. HETA-82-358-1558, United Catalysts,
32 Inc. South Plant, Louisville, Kentucky. (HETA-82-358-1558). Cincinnati, OH: National
33 Institute for Occupational Safety and Health.
34 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults.xhtml?searchQuery=PB86116951>
- 35 [Zhang, B; Zhou, Y; Lin, N; Lowdon, RF; Hong, C; Nagarajan, RP; Cheng, JB; Li, D; Stevens, M; Lee, HJ;](#)
36 [Xing, X; Zhou, J; Sundaram, V; Elliott, G; Gu, J; Shi, T; Gascard, P; Sigaroudinia, M; Tlsty, TD;](#)
37 [Kadlecek, T; Weiss, A; O'Geen, H; Farnham, PJ; Maire, CL; Ligon, KL; Madden, PA; Tam, A;](#)
38 [Moore, R; Hirst, M; Marra, MA; Zhang, B; Costello, IF; Wang, T.](#) (2013). Functional DNA
39 methylation differences between tissues, cell types, and across individuals discovered using
40 the M&M algorithm. *Genome Res* 23: 1522-1540. <http://dx.doi.org/10.1101/gr.156539.113>
- 41 [Zhang, JD; Li, S.](#) (1997). RETRACTED: Cancer mortality in a Chinese population exposed to
42 hexavalent chromium in water. *J Occup Environ Med* 39: 315-319.
43 <http://dx.doi.org/10.1097/00043764-199704000-00008>
- 44 [Zhang, JD; Li, XL.](#) (1987a). [Chromium pollution of soil and water in Jinzhou]. *Zhonghua Yufang*
45 *Yixue Zazhi* 21: 262-264.
- 46 [Zhang, JD; Li, XL.](#) (1987b). Investigation and Study of Chromium Pollution in Jinzhou. *Zhonghua*
47 *Yufang Yixue Zazhi* 21.
- 48 [Zhang, R; Xiang, Y; Ran, Q; Deng, X; Xiao, Y; Xiang, L; Li, Z.](#) (2014). Involvement of calcium, reactive
49 oxygen species, and ATP in hexavalent chromium-induced damage in red blood cells. *Cell*
50 *Physiol Biochem* 34: 1780-1791. <http://dx.doi.org/10.1159/000366378>

- 1 [Zhang, XH; Zhang, X; Wang, XC; Jin, LF; Yang, ZP; Jiang, CX; Chen, Q; Ren, XB; Cao, JZ; Wang, Q; Zhu,](#)
2 [YM.](#) (2011). Chronic occupational exposure to hexavalent chromium causes DNA damage in
3 electroplating workers. *BMC Public Health* 11: 224. [http://dx.doi.org/10.1186/1471-2458-](http://dx.doi.org/10.1186/1471-2458-11-224)
4 [11-224](#)
- 5 [Zhang, Y; Su, Z; Hu, G; Hong, S; Long, C; Zhang, Q; Zheng, P; Wang, T; Yu, S; Yuan, F; Zhu, X; Jia, G.](#)
6 (2022). Lung function assessment and its association with blood chromium in a chromate
7 exposed population. *Sci Total Environ* 818: 151741.
8 <http://dx.doi.org/10.1016/j.scitotenv.2021.151741>
- 9 [Zhang, Y; Xiao, F; Liu, X; Liu, K; Zhou, X; Zhong, C.](#) (2017). Cr(VI) induces cytotoxicity in vitro
10 through activation of ROS-mediated endoplasmic reticulum stress and mitochondrial
11 dysfunction via the PI3K/Akt signaling pathway. *Toxicol In Vitro* 41: 232-244.
12 <http://dx.doi.org/10.1016/j.tiv.2017.03.003>
- 13 [Zhang, Y; Zhang, Y; Xiao, Y; Zhong, C; Xiao, F.](#) (2019). Expression of Clusterin suppresses Cr(VI)-
14 induced premature senescence through activation of PI3K/AKT pathway. *Ecotoxicol*
15 *Environ Saf* 183: 109465. <http://dx.doi.org/10.1016/j.ecoenv.2019.109465>
- 16 [Zhang, Y; Zhang, Y; Zhong, C; Xiao, F.](#) (2016). Cr(VI) induces premature senescence through ROS-
17 mediated p53 pathway in L-02 hepatocytes. *Sci Rep* 6(34578): 1-10.
18 <http://dx.doi.org/10.1038/srep34578>
- 19 [Zhao, L; Song, Y; Pu, J; Guo, J; Wang, Y; Chen, Z; Chen, T; Gu, Y; Jia, G.](#) (2014). Effects of repeated
20 Cr(VI) intratracheal instillation on club (Clara) cells and activation of nuclear factor-kappa B
21 pathway via oxidative stress. *Toxicol Lett* 231: 72-81.
22 <http://dx.doi.org/10.1016/j.toxlet.2014.09.011>
- 23 [Zheng, W; Ge, F; Wu, K; Chen, X; Li, X; Chen, Y; Lv, Y; Lian, Q; Ge, RS.](#) (2018). In utero exposure to
24 hexavalent chromium disrupts rat fetal testis development. *Toxicol Lett* 299: 201-209.
25 <http://dx.doi.org/10.1016/j.toxlet.2018.10.010>
- 26 [Zhitkovich, A.](#) (2005). Importance of chromium-DNA adducts in mutagenicity and toxicity of
27 chromium(VI) [Review]. *Chem Res Toxicol* 18: 3-11. <http://dx.doi.org/10.1021/tx049774+>
28 [Zhitkovich, A.](#) (2011). Chromium in drinking water: sources, metabolism, and cancer risks [Review].
29 *Chem Res Toxicol* 24: 1617-1629. <http://dx.doi.org/10.1021/tx200251t>
- 30 [Zhitkovich, A; Voitkun, V; Costa, M.](#) (1996). Formation of the amino acid-DNA complexes by
31 hexavalent and trivalent chromium in vitro: importance of trivalent chromium and the
32 phosphate group. *Biochemistry* 35: 7275-7282.
- 33 [Zhong, X; de Cássia da Silveira E Sá, R; Zhong, C.](#) (2017a). Mitochondrial biogenesis in response to
34 chromium (VI) toxicity in human liver cells. *International Journal of Molecular Sciences* 18.
35 <http://dx.doi.org/10.3390/ijms18091877>
- 36 [Zhong, X; Yi, X; da Silveira E Sá, RC; Zhang, Y; Liu, K; Xiao, F; Zhong, C.](#) (2017b). CoQ10 Deficiency
37 May Indicate Mitochondrial Dysfunction in Cr(VI) Toxicity. *International Journal of*
38 *Molecular Sciences* 18. <http://dx.doi.org/10.3390/ijms18040816>
- 39 [Zhong, X; Zeng, M; Bian, H; Zhong, C; Xiao, F.](#) (2017c). An evaluation of the protective role of vitamin
40 C in reactive oxygen species-induced hepatotoxicity due to hexavalent chromium in vitro
41 and in vivo. *J Occup Med Toxicol* 12: 12. <http://dx.doi.org/10.1186/s12995-017-0161-x>
- 42 [Zhu, L; Li, X; Yuan, Y; Dong, C; Yang, M.](#) (2021). APC promoter methylation in gastrointestinal cancer
43 [Review]. *Front Oncol* 11: 653222. <http://dx.doi.org/10.3389/fonc.2021.653222>
- 44 [Zuo, Z; Cai, T; Li, J; Zhang, D; Yu, Y; Huang, C.](#) (2012). Hexavalent chromium Cr(VI) up-regulates
45 COX-2 expression through an NFκB/c-Jun/AP-1-dependent pathway. *Environ Health*
46 *Perspect* 120: 547-553. <http://dx.doi.org/10.1289/ehp.1104179>

47